Patent Publication Number: US-2004048256-A1

Title: Novel proteins and nucleic acids encoding same

Description:
RELATED APPLICATIONS  
     [0001] This application claims priority to provisional patent applications U.S. Ser. No. 60/318120, filed Sep. 7, 2001; U.S. Ser. No. 60/318430, filed Sep. 10, 2001; U.S. Ser. No. 60/322781, filed Sep. 17, 2001; U.S. Ser. No. 60/318184, filed Sep. 7, 2001; U.S. Ser. No. 60/361663, filed Mar. 5, 2002; U.S. Ser. No. 60/396412, filed Jul. 17, 2002; U.S. Ser. No. 60/322636, filed Sep. 17, 2001; U.S. Ser. No. 60/322817, filed Sep. 17, 2001; U.S. Ser. No. 60/322816, filed Sep. 17, 2001; U.S. Ser. No. 60/323519, filed Sep. 19, 2001; U.S. Ser. No. 60/323631, filed Sep. 20, 2001; U.S. Ser. No. 60/377908, filed May 3, 2002; U.S. Ser. No. 60/381483, filed May 17, 2002; U.S. Ser. No. 60/323636, filed Sep. 20, 2001; U.S. Ser. No. 60/324969, filed Sep. 25, 2001; U.S. Ser. No. 60/383863, filed May 29, 2002; U.S. Ser. No. 60/325091, filed Sep. 25, 2001; U.S. Ser. No. 60/324990, filed Sep. 26, 2001; U.S. Ser. No. 60/341144, filed Dec. 14, 2001; U.S. Ser. No. 60/359599, filed Feb. 26, 2002; U.S. Ser. No. 60/393332, filed Jul. 2, 2002; and U.S. Ser. No. 60/403517, filed Aug. 13, 2002; each of which is incorporated herein by reference in its entirety. 
    
    
     
       FIELD OF THE INVENTION  
       [0002] The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.  
       BACKGROUND  
       [0003] Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.  
       [0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.  
       [0005] Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.  
       [0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest.  
       [0007] Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions.  
       [0008] In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds.  
       [0009] In many cases the objective of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds.  
       SUMMARY OF THE INVENTION  
       [0010] The invention includes nucleic acid sequences and the novel polypeptides they encode. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110.  
       [0011] In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.  
       [0012] Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0013] In a further embodiment, the invention includes a method of identifying an agent that binds to a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector.  
       [0014] In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.  
       [0015] The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence.  
       [0016] In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.  
       [0017] In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed. In another embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence.  
       [0018] In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof.  
       [0019] In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.  
       [0020] In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.  
       [0022] Other features and advantages of the invention will be apparent from the following detailed description and claims. 
     
    
    
     BRIEF DESCRIPTION OF THE FIGURES  
     [0023]FIG. 1 shows the x-ray crystal structure of trypsin 1 at a 2.2 Å resolution (Gaboriaud, C. et. al, Jol. Mol. Biol., 1996, 259:995-1010)(PDB code 1TRN). The sequences absent in the CG59482-02 splice variant are denoted by short arrows. The view in FIG. 1 shows the active site facing outward with a diisopropyl-phosphofluoridate inhibitor in the active site (indicated by long arrows).  
     [0024]FIG. 2 shows the three residues which form the catalytic triad of the active site.  
     [0025]FIG. 3 depicts a proposed mechanism for catalytic triad formation. The pK a  for the serine hydroxyl is usually about 13, which makes it a poor nucleophile. The aspartate, histidine and serine are arranged in a charge relay system of hydrogen bonds that helps to lower this pK a , which makes the sidechain more reactive. The carboxyl side chain on aspartate attracts a proton from histidine, which in turn abstracts a proton from the hydroxyl of serine allowing it to react with and then cleave the polypeptide substrate. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION  
     [0026] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.  
               TABLE A                          Sequences and Corresponding SEQ ID Numbers                                         SEQ   SEQ                   ID NO   ID NO       NOVX   Internal   (nucleic   (amino       Assignment   Identification   acid)   acid)   Homology                                         1a   CG105324-01   1   2   Nuclear Orphan receptor LXR alpha protein       1b   212779039   3   4   Human nuclear orphan receptor LXR-alpha-                       like Proteins       1c   CG105324-01   5   6   Human nuclear orphan receptor LXR-alpha-                       like Proteins       1d   209829541   7   8   Human nuclear orphan receptor LXR-alpha-                       like Proteins       2a   CG105355-01   9   10   Nuclear Aryl Hydrocarbon receptor protein       2b   245279626   11   12   Aryl hydrocarbon receptor- like Proteins       2c   CG105355-02   13   14   Aryl hydrocarbon receptor- like Proteins       2d   CG105355-03   15   16   Aryl hydrocarbon receptor- like Proteins       3a   CG105521-01   17   18   stearoyl CoA desaturase protein       3b   CG105521-02   19   20   stearoyl CoA desaturase protein       3c   301113881   21   22   stearoyl CoA desaturase protein       3d   CG105521-01   23   24   Stearoyl CoA desaturase protein       3e   309330043   25   26   Stearoyl CoA desaturase protein       3f   309330069   27   28   Stearoyl CoA desaturase protein       3g   CG105521-01   29   30   Stearoyl CoA desaturase -like protein       3h   212779051   31   32   Stearoyl CoA desaturase -like protein       3i   CG105521-01   33   34   Stearoyl CoA desaturase- like protein       3j   308782133   35   36   Stearoyl CoA desaturase- like protein       3k   CG105521-03   37   38   Stearoyl CoA desaturase- like protein       3l   CG105521-04   39   40   Stearoyl CoA desaturase- like protein       3m   CG105521-05   41   42   Stearoyl CoA desaturase- like protein       3n   CG105521-06   43   44   Stearoyl CoA desaturase- like protein       4a   CG107234-01   45   46   HYDROLASE like protein       4b   CG107234-03   47   48   HYDROLASE like protein       4c   CG107234-02   49   50   HYDROLASE like protein       5a   CG113144-01   51   52   CtBP like protein       5b   CG113144-02   53   54   CtBP like protein       5c   CG113144-03   55   56   CtBP like protein       6a   CG122634-01   57   58   Neuronal kinesin heavy chain protein       7a   CG125197-01   59   60   LYSOPHOSPHOLIPASE like protein       7b   CG125197-03   61   62   LYSOPHOSPHOLIPASE like protein       7c   CG125197-02   63   64   LYSOPHOSPHOLIPASE like protein       8a   CG125312-01   65   66   Myosin IF (Myosin IE) protein       9a   CG134439-01   67   68   Cation Efflux domain containing Protein                       like protein       10a   CG137109-01   69   70   phospholipid-transporting                       ATPase like protein       11a   CG137330-01   71   72   TGF-BETA Receptor Type I                       Precursor like protein       12a   CG137339-01   73   74   Epidermal Growth Factor Receptor                       Precursor like protein       12b   CG137339-02   75   76   Epidermal Growth Factor Receptor                       Precursor like protein       13a   CG138130-01   77   78   cGMP-stimulated 3′, 5′-cyclic                       nucleotide phosphodiesterase-like Proteins       14a   CG138372-01   79   80   Maleylacetoacetate Isomerase-                       like Proteins       14b   CG138372-02   81   82   Maleylacetoacetate Isomerase-                       like Proteins       14c   CG138372-01   83   84   Maleylacetoacetate Isomerase-                       like Proteins       14d   277582121   85   86   Maleylacetoacetate Isomerase-                       like Proteins       14e   CG138372-03   87   88   Maleylacetoacetate Isomerase-                       like Proteins       15a   CG138461-01   89   90   Intracellular Protein                       belonging to Nitroreductase                       family-like Proteins       16a   CG138529-01   91   92   Novel SA protein-like Proteins       17a   CG138563-01   93   94   Novel CHOLINE/ETHANOLAMINE KINASE-                       like protein       17b   CG138563-02   95   96   Novel CHOLINE/ETHANOLAMINE KINASE-                       like protein       18a   CG138848-01   97   98   Novel protein-tyrosine kinase ryk -                       Like-like Proteins       19a   CG139990-01   99   100   transferase HTFS-18 like protein       20a   CG140041-01   101   102   Pyridoxal-dependent decarboxylase                       like protein       21a   CG140061-01   103   104   IMP dehydrogenase like protein       22a   CG140335-01   105   106   urea transporter isoform UTA-3 like                       protein       23a   CG140355-01   107   108   PEPTIDYLPROLYL ISOMERASE                       A like protein       23b   CG140612-01   109   110   PEPTIDYLPROLYL ISOMERASE                       A like protein       24a   CG140612-02   111   112   ATP SYNTHASE B CHAIN, MITOCHONDRIAL                       like protein       25a   CG140696-01   113   114   AAA ATPase like protein       25b   CG140696-02   115   116   AAA ATPase like protein       25c   CG140696-03   117   118   AAA ATPase like protein       26a   CG140747-01   119   120   Dual specificity phosphatase                       like protein       27a   CG141137-01   121   122   long-chain acyl-coA thioesterase                       2 like protein       28a   CG141240-01   123   124   ATP synthase F chain, mitochondrial                       like protein       29a   CG141355-01   125   126   GTPASE RAB37 like protein       29b   CG141355-02   127   128   Novel GTPASE RAB37 -like Proteins       30a   CG142072-01   129   130   CATHEPSIN L PRECURSOR like protein       30b   CG142072-02   131   132   CATHEPSIN L PRECURSOR like protein       31a   CG142102-01   133   134   PEPTIDYLPROLYL ISOMERASE A                       (CYCLOPHILIN A) like protein       32a   CG57760-01   135   136   Prostaglandin-H2 D-isomerase                       precursor like protein       32b   CG57760-02   137   138   Prostaglandin-H2 D-isomerase                       precursor like protein       33a   CG59361-01   139   140   POTENTIAL PHOSPHOLIPID-TRANSPORTING                       ATPASE VA like protein       34a   CG59444-01   141   142   SA protein like protein       34b   CG59444-02   143   144   SA protein like protein       35a   CG59482-01   145   146   Trypsin I precursor like protein       35b   CG59482-02   147   148   Trypsin I precursor like protein       35c   CG59482-03   149   150   Trypsin I precursor like protein       36a   CG59522-01   151   152   Myosin I protein       36b   CG59522-02   153   154   Myosin I protein       37a   CG89709-01   155   156   Serine/threonine Protein kinase                       like protein       37b   CG89709-02   157   158   Serine/threonine Protein kinase                       like protein       37c   CG89709-03   159   160   novel ser/thr kinase protein       37d   CG89709-04   161   162   Serine/threonine Protein kinase                       like protein       37e   CG89709-01   163   164   Serine/threonine Protein kinase                       like protein       38a   CG90879-01   165   166   Protein kinase D2 like protein       39a   CG96334-01   167   168   DUAL-SPECIFICITY TYROSINE-                       PHOSPHORYLATION REGULATED                       KINASE 1A like protein       39b   CG96334-02   169   170   DUAL-SPECIFICITY TYROSINE-                       PHOSPHORYLATION REGULATED                       KINASE 1A like protein       40a   CG96714-01   171   172   UDP-galactose transporter related                       isozyme 1 protein       40b   212778987   173   174   UDP-galactose transporter related                       isozyme 1-like Proteins       40c   CG96714-02   175   176   UDP-galactose transporter related                       isozyme 1-like Proteins       40d   190235426   177   178   UDP-galactose transporter related                       isozyme 1-like Proteins       40e   CG96714-03   179   180   UDP-galactose transporter related                       isozyme 1-like Proteins       41a   CG97025-01   181   182   3-Hydroxy-3methylglutaryl coenzyme                       A synthase protein       41b   CG97025-01   183   184   Cytosolic HMG-CoA Synthase-like                       protein       41c   CG97025-01   185   186   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41d   254869578   187   188   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41e   CG97025-01   189   190   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41f   253174237   191   192   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41g   CG97025-01   193   194   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41h   256420363   195   196   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41i   CG97025-01   197   198   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41j   255667064   199   200   HYDROXYMETHYLGLUTARYL-COA SYNTHASE,                       CYTOPLASMIC- like Proteins       41k   CG97025-01   201   202   Cytosolic HMG-CoA Synthase-                       like protein       41l   228832739   203   204   Cytosolic HMG-CoA Synthase-                       like protein       41m   CG97025-02   205   206   Cytosolic HMG-CoA Synthase-                       like protein       41n   CG97025-03   207   208   Cytosolic HMG-CoA Synthase-                       like protein       41o   CG97025-04   209   210   Cytosolic HMG-CoA Synthase-                       like protein       41p   CG97025-05   211   212   Cytosolic HMG-CoA Synthase-                       like protein       42a   CG97955-01   213   214   Carboxypeptidase A1 like protein       42b   CG97955-03   215   216   Carboxypeptidase A1 like protein       42c   308559628   217   218   Carboxypeptidase A1 like protein       42d   CG97955-02   219   220   Carboxypeptidase A1 like protein                  
 
     [0027] Table A indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A.  
     [0028] Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to: cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn&#39;s disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias,] the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility.  
     [0029] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
     [0030] Consistent with other known members of the family of proteins, identified in column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.  
     [0031] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table A.  
     [0032] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g. detection of a variety of cancers.  
     [0033] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.  
     [0034] NOVX Clones  
     [0035] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
     [0036] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.  
     [0037] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon.  
     [0038] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO 2n, wherein n is an integer between 1 and 110 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).  
     [0039] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 110; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 110 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.  
     [0040] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.  
     [0041] NOVX Nucleic Acids and Polypeptides  
     [0042] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.  
     [0043] A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.  
     [0044] The term “probe”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single-stranded or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.  
     [0045] The term “isolated” nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals.  
     [0046] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2 nd  Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, New York, N.Y., 1993.)  
     [0047] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.  
     [0048] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.  
     [0049] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, thereby forming a stable duplex.  
     [0050] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.  
     [0051] A “fragment” provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.  
     [0052] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.  
     [0053] A “derivative” is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An “analog” is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g. they differs from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A “homolog” is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species.  
     [0054] Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, New York, N.Y., 1993, and below.  
     [0055] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.  
     [0056] A NOVX polypeptide is encoded by the open reading frame (“ORF”) of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.  
     [0057] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110; or an anti-sense strand nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110; or of a naturally occurring mutant of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110.  
     [0058] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.  
     [0059] “A polypeptide having a biologically-active portion of a NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.  
     [0060] NOVX Nucleic Acid and Polypeptide Variants  
     [0061] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110.  
     [0062] In addition to the human NOVX nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.  
     [0063] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.  
     [0064] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.  
     [0065] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.  
     [0066] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.  
     [0067] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2×SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).  
     [0068] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6×SSC, 5× Reinhardt&#39;s solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1×SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.  
     [0069] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization onditions are hybridization in 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2×SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1 % SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981.  Proc Natl Acad Sci USA  78: 6789-6792.  
     [0070] Conservative Mutations  
     [0071] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.  
     [0072] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO: 2n, wherein n is an integer between 1 and 110. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110; more preferably at least about 70% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110; still more preferably at least about 80% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110; even more preferably at least about 90% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110; and most preferably at least about 95% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110.  
     [0073] An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.  
     [0074] Mutations can be introduced any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.  
     [0075] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.  
     [0076] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).  
     [0077] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).  
     [0078] Interfering RNA  
     [0079] In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including the 5′ untranslated (UT) region, the ORF, or the 3′ UT region. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, WO02/16620, and WO02/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway.  
     [0080] According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e.g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes &amp; Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.  
     [0081] The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3′ overhang. The sequence of the 2-nt 3′ overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3′ overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3′ overhang are deoxyribonucleotides. Using 2′-deoxyribonucleotides in the 3′ overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize and are most likely more nuclease resistant.  
     [0082] A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3′ of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5′ of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner.  
     [0083] In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H1. One example of a vector system is the GeneSuppressor™ RNA Interference kit (commercially available from Imgenex). The U6 and H1 promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. Cleavage at this position generates a 3′ UU overhang in the expressed siRNA, which is similar to the 3′ overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript.  
     [0084] A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy.  
     [0085] In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands.  
     [0086] A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to 100 nt downstream of the start codon. Alternatively, 5′ or 3′ UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene.  
     [0087] In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene.  
     [0088] Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility.  
     [0089] A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(N19)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to (N19)TT or N21, respectively. In the latter case, conversion of the 3′ end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3′ overhangs. Symmetric 3′ overhangs may help to ensure that the siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes &amp; Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition.  
     [0090] Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5′ (N19)TT, as it is believed that the sequence of the 3′-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 4557-4565, incorporated by reference in its entirety.  
     [0091] Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 μg of the siRNA duplex is generally sufficient. Cells are typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g. inversion versus vortexing) are also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as within the scope of the present invention.  
     [0092] For a control experiment, transfection of 0.84 μg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 μg antisense siRNA has a weak silencing effect when compared to 0.84 μg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for, example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g. commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology.  
     [0093] Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If he NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting.  
     [0094] An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues.  
     [0095] The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment.  
     [0096] Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA&#39;s to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX − ) phenotype in the treated subject sample. The NOVX −  phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment.  
     [0097] In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below.  
     [0098] Production of RNAs  
     [0099] Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 μM) in 10 mM Tris-HCl (pH 7.5) with 20 mM NaCl were heated to 95° C. for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989).  
     [0100] Lysate Preparation  
     [0101] Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer&#39;s directions. dsRNA is incubated in the lysate at 30° C. for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis.  
     [0102] In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a  32 P-ATP. Reactions are stopped by the addition of 2× proteinase K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined.  
     [0103] The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques.  
     [0104] RNA Preparation  
     [0105] 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, &amp; Tuschl, Genes &amp; Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)).  
     [0106] These RNAs (20 μM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C. followed by 1 h at 37° C.  
     [0107] Cell Culture  
     [0108] A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3×105 cells/ml) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3′ ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.  
     [0109] The above method provides a way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in vivo transfection or gene therapy transfection techniques.  
     [0110] Antisense Nucleic Acids  
     [0111] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, are additionally provided.  
     [0112] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding a NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).  
     [0113] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).  
     [0114] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, pseudouracil, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 2-thiouracil, 4-thiouracil, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, queosine, 2-thiocytosine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-methylthio-N6-isopentenyladenine, beta-D-mannosylqueosine, 5-methyl-2-thiouracil, 5′-methoxycarboxymethyluracil, uracil-5-oxyacetic acid (v), wybutoxosine, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).  
     [0115] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.  
     [0116] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987.  Nucl. Acids Res.  15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987.  Nucl. Acids Res.  15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987.  FEBS Lett.  215: 327-330.  
     [0117] Ribozymes and PNA Moieties  
     [0118] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.  
     [0119] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988.  Nature  334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993)  Science  261:1411-1418.  
     [0120] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991.  Anticancer Drug Des.  6: 569-84; Helene, et al. 1992.  Ann. N.Y Acad. Sci.  660: 27-36; Maher, 1992.  Bioassays  14: 807-15.  
     [0121] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996.  Bioorg Med Chem  4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O&#39;Keefe, et al., 1996.  Proc. Natl. Acad. Sci. USA  93: 14670-14675.  
     [0122] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S 1  nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O&#39;Keefe, et al., 1996. supra).  
     [0123] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996.  Nucl Acids Res  24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989.  Nucl Acid Res  17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975.  Bioorg. Med. Chem. Lett.  5: 1119-11124.  
     [0124] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989.  Proc. Natl. Acad. Sci. U.S.A.  86: 6553-6556; Lemaitre, et al., 1987.  Proc. Natl. Acad. Sci.  84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988.  BioTechniques  6:958-976) or intercalating agents (see, e.g., Zon, 1988.  Pharm. Res.  5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.  
     [0125] NOVX Polypeptides  
     [0126] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO: 2n, wherein n is an integer between 1 and 110. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.  
     [0127] In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.  
     [0128] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.  
     [0129] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.  
     [0130] The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.  
     [0131] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.  
     [0132] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.  
     [0133] In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 110, and retains the functional activity of the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, and retains the functional activity of the NOVX proteins of SEQ ID NO: 2n, wherein n is an integer between 1 and 110.  
     [0134] Determining Homology Between Two or More Sequences  
     [0135] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).  
     [0136] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970.  J Mol Biol  48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110.  
     [0137] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.  
     [0138] Chimeric and Fusion Proteins  
     [0139] The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX “chimeric protein” or “fusion protein” comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.  
     [0140] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.  
     [0141] In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.  
     [0142] In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.  
     [0143] A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCP amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.  
     [0144] NOVX Agonists and Antagonists  
     [0145] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.  
     [0146] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983.  Tetrahedron  39: 3; Itakura, et al., 1984.  Annu. Rev. Biochem.  53: 323; Itakura, et al., 1984.  Science  198: 1056; Ike, et al., 1983.  Nucl. Acids Res.  11: 477.  
     [0147] Polypeptide Libraries  
     [0148] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.  
     [0149] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992.  Proc. Natl. Acad. Sci. USA  89: 7811-7815; Delgrave, et al., 1993.  Protein Engineering  6:327-331.  
     [0150] Anti-NOVX Antibodies  
     [0151] Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F ab , F ab ′ and F( ab ′) 2  fragments, and an F ab  expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.  
     [0152] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 110, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.  
     [0153] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981,  Proc. Nat. Acad. Sci. USA  78: 3824-3828; Kyte and Doolittle 1982,  J. Mol. Biol.  157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
     [0154] The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (K D ) is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.  
     [0155] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.  
     [0156] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.  
     [0157] Polyclonal Antibodies  
     [0158] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund&#39;s (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
     [0159] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).  
     [0160] Monoclonal Antibodies  
     [0161] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.  
     [0162] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.  
     [0163] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding,  Monoclonal Antibodies: Principles and Practice,  Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.  
     [0164] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).  
     [0165] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.  
     [0166] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding,1986). Suitable culture media for this purpose include, for example, Dulbecco&#39;s Modified Eagle&#39;s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.  
     [0167] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. I The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.  
     [0168] Humanized Antibodies  
     [0169] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2  or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No.5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).  
     [0170] Human Antibodies  
     [0171] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANMBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).  
     [0172] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al,( Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).  
     [0173] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal&#39;s endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host&#39;s genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.  
     [0174] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.  
     [0175] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.  
     [0176] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.  
     [0177] F ab  Fragments and Single Chain Antibodies  
     [0178] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of F ab  expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F ab  fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F( ab ′) 2  fragment produced by pepsin digestion of an antibody molecule; (ii) an F ab  fragment generated by reducing the disulfide bridges of an F( ab ′) 2  fragment; (iii) an F ab  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v  fragments.  
     [0179] Bispecific Antibodies  
     [0180] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.  
     [0181] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).  
     [0182] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).  
     [0183] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.  
     [0184] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab′) 2  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thioritrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.  
     [0185] Additionally, Fab′ fragments can be directly recovered from  E. coli  and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′) 2  molecule. Each Fab′ fragment was separately secreted from  E. coli  and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.  
     [0186] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H  and V L  domains of one fragment are forced to pair with the complementary V L  and V H  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).  
     [0187] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).  
     [0188] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcdγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).  
     [0189] Heteroconjugate Antibodies  
     [0190] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.  
     [0191] Effector Function Engineering  
     [0192] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).  
     [0193] Immunoconjugates  
     [0194] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).  
     [0195] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from  Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin,  Aleurites fordii  proteins, dianthin proteins,  Phytolaca americana  proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  212  Bi,  131 I,  131 In,  90 Y, and  186 Re.  
     [0196] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al.,  Science  238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.  
     [0197] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.  
     [0198] Immunoliposomes  
     [0199] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.  
     [0200] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).  
     [0201] Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention  
     [0202] In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
     [0203] Antibodies directed against a NOVX protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of a NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).  
     [0204] An antibody specific for a NOVX protein of the invention (e.g., a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  125 I,  131 I,  35 S or  3 H.  
     [0205] Antibody Therapeutics  
     [0206] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.  
     [0207] Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.  
     [0208] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.  
     [0209] Pharmaceutical Compositions of Antibodies  
     [0210] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, N.Y.  
     [0211] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.  
     [0212] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.  
     [0213] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.  
     [0214] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.  
     [0215] ELISA Assay  
     [0216] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., F ab  or F (ab)2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Thory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
     [0217] NOVX Recombinant Expression Vectors and Host Cells  
     [0218] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably, as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.  
     [0219] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).  
     [0220] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).  
     [0221] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as  Escherichia coli,  insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE ExPRESSION TECHNOLOGY: METHODS n. ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.  
     [0222] Expression of proteins in prokaryotes is most often carried out in  Escherichia coli  with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988.  Gene  67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.  
     [0223] Examples of suitable inducible non-fusion  E. coli  expression vectors include pTrc (Amrann et al., (1988)  Gene  69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).  
     [0224] One strategy to maximize recombinant protein expression in  E. coli  is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in  E. coli  (see, e.g., Wada, et al., 1992.  Nucl. Acids Res.  20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.  
     [0225] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast  Saccharomyces cerivisae  include pYepSec1 (Baldari, et al., 1987.  EMBO J.  6: 229-234), pMFa (Kurjan and Herskowitz, 1982.  Cell  30: 933-943), pJRY88 (Schultz et al., 1987.  Gene  54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).  
     [0226] Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983.  Mol. Cell. Biol.  3: 2156-2165) and the pVL series (Lucklow and Summers, 1989.  Virology  170: 31-39).  
     [0227] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987.  Nature  329: 840) and pMT2PC (Kaufman, et al., 1987.  EMBO J.  6: 187-195). When used in mammalian cells, the expression vector&#39;s control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.  
     [0228] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987.  Genes Dev.  1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988.  Adv. Immunol.  43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989.  EMBO J.  8: 729-733) and immunoglobulins (Banerji, et al., 1983.  Cell  33: 729-740; Queen and Baltimore, 1983.  Cell  33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989.  Proc. Natl. Acad. Sci. USA  86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985.  Science  230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990.  Science  249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989.  Genes Dev.  3: 537-546).  
     [0229] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,”  Reviews - Trends in Genetics,  Vol. 1(1) 1986.  
     [0230] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.  
     [0231] A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as  E. coli,  insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.  
     [0232] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.  
     [0233] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).  
     [0234] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.  
     [0235] Transgenic NOVX Animals  
     [0236] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.  
     [0237] A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.  
     [0238] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).  
     [0239] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987.  Cell  51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992.  Cell  69: 915.  
     [0240] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991.  Curr. Opin. Biotechnol.  2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.  
     [0241] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992.  Proc. Natl. Acad. Sci. USA  89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of  Saccharomyces cerevisiae.  See, O&#39;Gorman, et al., 1991.  Science  251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.  
     [0242] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997.  Nature  385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G 0  phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.  
     [0243] Pharmaceutical Compositions The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington&#39;s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger&#39;s solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.  
     [0244] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.  
     [0245] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.  
     [0246] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.  
     [0247] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.  
     [0248] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.  
     [0249] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.  
     [0250] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.  
     [0251] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.  
     [0252] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.  
     [0253] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994.  Proc. Natl. Acad. Sci. USA  91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.  
     [0254] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.  
     [0255] Screening and Detection Methods  
     [0256] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease(possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.  
     [0257] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.  
     [0258] Screening Assays  
     [0259] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.  
     [0260] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997.  Anticancer Drug Design  12: 145.  
     [0261] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.  
     [0262] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993.  Proc. Natl. Acad. Sci. U.S.A.  90: 6909; Erb, et al., 1994.  Proc. Natl. Acad. Sci. U.S.A.  91: 11422; Zuckermann, et al., 1994.  J. Med. Chem.  37: 2678; Cho, et al., 1993.  Science  261: 1303; Carrell, et al., 1994.  Angew. Chem. Int. Ed. Engl.  33: 2059; Carell, et al., 1994.  Angew. Chem. Int. Ed. Engl.  33: 2061; and Gallop, et al., 1994.  J. Med. Chem.  37: 1233.  
     [0263] Libraries of compounds may be presented in solution (e.g., Houghten, 1992.  Biotechniques  13: 412-421), or on beads (Lam, 1991.  Nature  354: 82-84), on chips (Fodor, 1993.  Nature  364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992.  Proc. Natl. Acad. Sci. USA  89: 1865-1869) or on phage (Scott and Smith, 1990.  Science  249: 386-390; Devlin, 1990.  Science  249: 404-406; Cwirla, et al., 1990.  Proc. Natl. Acad. Sci. U.S.A.  87: 6378-6382; Felici, 1991.  J. Mol. Biol.  222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).  
     [0264] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  125 I,  35 S,  14 C, or  3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.  
     [0265] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a “target molecule” is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.  
     [0266] Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca 2+ , diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.  
     [0267] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.  
     [0268] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.  
     [0269] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.  
     [0270] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether) n , N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).  
     [0271] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.  
     [0272] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.  
     [0273] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.  
     [0274] In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993.  Cell  72: 223-232; Madura, et al., 1993.  J. Biol. Chem.  268: 12046-12054; Bartel, et al., 1993.  Biotechniques  14: 920-924; Iwabuchi, et al., 1993.  Oncogene  8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.  
     [0275] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.  
     [0276] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.  
     [0277] Detection Assays  
     [0278] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.  
     [0279] Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.  
     [0280] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.  
     [0281] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D&#39;Eustachio, et al., 1983.  Science  220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.  
     [0282] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.  
     [0283] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).  
     [0284] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.  
     [0285] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987.  Nature,  325: 783-787.  
     [0286] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.  
     [0287] Tissue Typing  
     [0288] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual&#39;s genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).  
     [0289] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual&#39;s genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual&#39;s DNA and subsequently sequence it.  
     [0290] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).  
     [0291] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.  
     [0292] Predictive Medicine  
     [0293] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.  
     [0294] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of ag nts (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)  
     [0295] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.  
     [0296] These and other agents are described in further detail in the following sections.  
     [0297] Diagnostic Assays  
     [0298] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 110, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.  
     [0299] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′) 2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
     [0300] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.  
     [0301] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.  
     [0302] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.  
     [0303] Prognostic Assays  
     [0304] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.  
     [0305] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).  
     [0306] The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
     [0307] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988.  Science  241: 1077-1080; and Nakazawa, et al., 1994.  Proc. Natl. Acad. Sci. USA  91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995.  Nucl. Acids Res.  23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.  
     [0308] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990.  Proc. Natl. Acad. Sci. USA  87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989.  Proc. Natl. Acad. Sci. USA  86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988.  BioTechnology  6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.  
     [0309] In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.  
     [0310] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996.  Human Mutation  7: 244-255; Kozal, et al., 1996.  Nat. Med.  2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.  
     [0311] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977.  Proc. Natl. Acad. Sci. USA  74: 560 or Sanger, 1977.  Proc. Natl. Acad. Sci. USA  74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995.  Biotechniques  19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996.  Adv. Chromatography  36: 127-162; and Griffin, et al., 1993.  Appl. Biochem. Biotechnol.  38: 147-159).  
     [0312] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985.  Science  230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1  nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988.  Proc. Natl. Acad. Sci. USA  85: 4397; Saleeba, et al., 1992.  Methods Enzymol.  217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.  
     [0313] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of  E. coli  cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994.  Carcinogenesis  15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.  
     [0314] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989.  Proc. Natl. Acad. Sci. USA:  86: 2766; Cotton, 1993.  Mutat. Res.  285: 125-144; Hayashi,, 1992.  Genet. Anal. Tech. Appl.  9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991.  Trends Genet.  7: 5.  
     [0315] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985.  Nature  313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987.  Biophys. Chem.  265: 12753.  
     [0316] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986.  Nature  324: 163; Saiki, et al., 1989.  Proc. Natl. Acad. Sci. USA  86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.  
     [0317] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989.  Nucl. Acids Res.  17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993.  Tibtech.  11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992.  Mol. Cell Probes  6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991.  Proc. Natl. Acad. Sci. USA  88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.  
     [0318] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.  
     [0319] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
     [0320] Pharmacogenomics  
     [0321] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
     [0322] In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual&#39;s genotype and that individual&#39;s response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual&#39;s genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.  
     [0323] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996.  Clin. Exp. Pharmacol. Physiol.,  23: 983-985; Linder, 1997.  Clin. Chem.,  43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.  
     [0324] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.  
     [0325] Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual&#39;s drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.  
     [0326] Monitoring of Effects During Clinical Trials  
     [0327] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.  
     [0328] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.  
     [0329] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.  
     [0330] Methods of Treatment  
     [0331] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
     [0332] These methods of treatment will be discussed more fully, below.  
     [0333] Diseases and Disorders  
     [0334] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989.  Science  244:1288-1292); or (v) modulators ( i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.  
     [0335] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.  
     [0336] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).  
     [0337] Prophylactic Methods  
     [0338] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.  
     [0339] Therapeutic Methods  
     [0340] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.  
     [0341] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).  
     [0342] Determination of the Biological Effect of the Therapeutic  
     [0343] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.  
     [0344] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient&#39;s disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.  
     [0345] Prophylactic and Therapeutic Uses of the Compositions of the Invention  
     [0346] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
     [0347] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein.  
     [0348] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.  
     [0349] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.  
     EXAMPLES  
     Example A  
     [0350] Polynucleotide and Polypeptide Sequences, and Homology Data  
     Example 1  
     [0351] The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A.  
               TABLE 1A                       NOV1 Sequence Analysis                                                    SEQ ID NO: 1   1808 bp                             NOV1a,     CGATCGCAGAGAGGCTGGAGTGTGCTACCGACGTCGAATATCCATGCAGACTAGAAGAGTATAATCTG             CG105324-01       DNA Sequence     GGTCCTTCCTGCAGGACAGTGCCTTGGTAATGACCACGGCTCCAGGAAGAG   ATG TCCTTGTGGCTGGG                           GGCCCCTGTGCCTGACATTCCTCCTGACTCTCGGAAGGAGCTGTGGAAGCCAGGCGCACAGGATGCAA                   CCAGCCACGCCCAGGGAGGCAGCAGCTGCATCCTCAGAGACGAAGCCAGGATGCCCCACTCTGCTGGG                   GGTACTGCAGCGGTGGGGCTGGAGGCTGCAGACCCCACAGCCCTCCTCACCAGGGCAGAGCCCCCTTC                   AGAACCCACAGAGATCCGTCCACAAAAGCGGAAAAAGGGGCCAGCCCCCAAAATGCTGGGGAACGAGC                   TATGCAGCGTGTGTGGGGACAAGGCCTCGGGCTTCCACTACAATGTTCTGAGCTGCGAGGGCTCCAAC                   GCATTCTTCCGCCGCAGCGTCATCAAGGGAGCGCACTACATCTGCCACAGTGGCGGCCACTGCCCCAT                   GGACACCTACATGCGTCGCAAGTGCCAGGAGTGTCGGCTTCGCAAATGCCGTCAGGCTGGCATGCGGG                   AGGAGTGTGTCCTGTCAGAAGAACAGATCCGCCTGAAGAAACTGAAGCGGCAAGAGGAGGAACAGGCT                   CATGCCACATCCTTGCCCCCCAGGCGTTCCTCACCCCCCCAAATCCTGCCCCAGCTCAGCCCGGAACA                   ACTGGGCATGATCGAGAAGCTCGTCGCTGCCCAGCAACAGTCTAACCGGCGCTCCTTTTCTGACCGGC                   TTCGAGTCACGCCTTGGCCCATGGCACCAGATCCCCATAGCCGGGACGCCCGTCAGCAGCGCTTTGCC                   CACTTCACTGAGCTGGCCATCGTCTCTGTGCAGGAGATAGTTGACTTTGCTAAACAGCTACCCGGCTT                   CCTGCAGCTCAGCCGGGAGGACCAGATTGCCCTGCTGAAGACCTCTGCGATCGAGGTGATGCTTCTGG                   AGACATCTCGGAGGTACAACCCTCGGAGTGAGAGTATCACCTTCCTCAAGGATTTCAGTTATAACCGG                   GAAGACTTTGCCAAAGCAGGGCTGCAAGTGGAATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCAT                   GAATGAGCTGCAACTCAATGATGCCGAGTTTGCCTTGCTCATTGCTATCAGCATCTTCTCTGCAGACC                   GGCCCAACGTGCAGGACCAGCTCCAGGTAGAGAGGCTGCAGCACACATATGTGGAAGCCCTGCATGCC                   TACGTCTCCATCCACCATCCCCATGACCGACTGATGTTCCCACCGATGCTAATGAAACTGGTGAGCCT                   CCGGACCCTGAGCAGCGTCCACTCAGAGCAAGTGTTTGCACTGCGTCTGCAGGACAAAAAGCTCCCAC                   CGCTGCTCTCTGAGATCTGCGATGTGCACGAA TGA   CTGTTCTGTCCCCATATTTTCTGTTTTCTTGGC                       CGGATGGCTGAGOCCTGGTGGCTGCCTCCTAGAAGTGGAACAGACTGAGAAGGGCAAACATTCCTGGG                       AGCTGGGCAAGGAGATCCTCCCGTGGCATTAAAAGAGAGTCAAAGGGTTGCGAGTTTTGTGGCTACTG                       AGCAGTGGAGCCCTCGCTAACACTGTGCTGTGTCTGAAGATCATGCTGACCCCACAAACGGATGGGCC                       TGGGGGCCACTTTGCACACGGTTCTCCAGAGCCCTCCCCATCCTGCCTCCACCACTTCCTGTTTTTCC                       CACACGGCCCCAAGAAAAATTCTCCACTGTCAAAAAAAAA                                               ORF Start: ATG at 120       ORF Stop: TGA at 1461               SEQ ID NO: 2   447 aa   MW at 50480.3kD                         NOV1a,   MSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMFHSAGGTAGVGLEAAEPTALLT           CG105324-O1       Protein   RAEPPSEPTETRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGAHYICHS       Sequence           GGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRRSSPPQILP                   QLSPEQLGMIERLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFA                   KQLPGFLQLSREDQIALLKTSAILTMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIF                   EFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRML                   MXLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE                                         SEQ ID NO:3   1461 bp                             NOV1b,     CCCCCAAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAG             212779039       DNA Sequence     GTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATA                       CGACTCACTATAG   GGA GACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCC                   ACCATGTCCTTGTGGCTGGGGGCCCCTGTGCCTGACATTCCTCCTGACTCTGCGGTGGAGCTGTGGA                   AGCCAGGCGCACAGGATGCAAGCAGCCAGGCCCACGGAGGCAGCAGCTGCATCCTCAGAGAGGAAGC                   CAGGATGCCCCACTCTGCTGGGGGTACTGCAGGGGTGOGGCTGGAGGCTGCAGAGCCCACAGCCCTG                   CTCACCACGGCACAGCCCCCTTCAGAACCCACAGGTGTCCTGTCAGAAGAACAGATCCGCCTGAAGA                   AACTGAAGCGGCAAGAGGAGGAACAGGCTCATGCCACATCCTTGCCCCCCACGGCTTCCTCACCCCC                   CCAAATCCTGCCCCAGCTCAGCCOGGAACAACTGGGCATGATCCAGAAGCTCGTCGCTGCCCAGCAA                   CAGTCTAACCGGCGCTCCTTTTCTGACCGGCTTCCAGTCACGCCTTGGCCCATCGCACCAGATCCCC                   ATAGCCGGGAGGCCCGTCAGCAGCGCTTTGCCCACTTCACTGAGCTGGCCATCGTCTCTGTGCAGGA                   GATAGTTGACTTTGCTAAACAGCTACCCGGCTTCCTCCACCTCAGCCGGGAGGACCAGATTCCCCTG                   CTGAAGACCTCTGCGATCGACGTGATGCTTCTGGAGACATCTCGGAGGTACAACCCTGGGAGTGAGA                   GTATCACCTTCCTCAAGGATTTCAGTTATAACCGGGAAGACTTTGCCAAAGCAGGGCTGCAAGTGGA                   ATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCATGAATGAGCTGCAACTCAATGATGCCGAGTTT                   GCCTTGCTCATTGCTATCAGCATCTTCTCTGCAGACCGGCCCAACGTGCAGGACCAGCTCCAGGTAG                   AGAGGCTGCAGCACACATATGTGGAAGCCCTCCATGCCTACGTCTCCATCCACCATCCCCATGACCG                   ACTGATGTTCCCACGGATGCTAATGAAACTGGTGAGCCTCCCGACCCTGAGCAGCGTCCACTCAGAG                   CAAGTGTTTGCACTGCGTCTGCAGGACAAAAAGCTCCCACCGCTGCTCTCTGAGATCTGGGATGTGC                   ACGAA TGA   GCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTCATCAGCCTCGACTGTGCCTT                       CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCC                       CACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTTAGGA                                               ORF Start: at 148       ORF Stop: TGA at 1279               SEQ ID NO: 4   377 aa   MW at 42216.6kD                         NOV1b,   GDPSWLAFKLKLGTELGSTMSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGOSSCILREEARMPH           212779039       Protein   SAGGTAGVGLEAAEPTALLTRAEPPSEPTGVLSEEQIRLKKLKRQEEEQAHATSLPPRASSPPQILP       Sequence           QLSPEQLGMIEKLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDF                   AKQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINP                   IFEFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSTHHPHDRLMFP                                         SEQ ID NO:5   1808 bp                             NOV1c,     CGATCGGAGAGAGGCTGGAGTGTGCTACCGACGTCGAATATCCATGCAGACTAGAGTATAATCTG             CG105324-01       DNA Sequence     GGTCCTTCCTGCAGGACAGTGCCTTGGTAATGACCAGGCCTCCAGCAAGAG   ATG TCCTTGTGGCTGGG                   GGCCCCTGTGCCTGACATTCCTCCTGACTCTGCGGTGGAGCTGTGGAAGCCAGGCGCACAGGATGCAA                   GCAGCCAGGCCCAGGGAGGCAGCAGCTGCATCCTCAGAGAGGAAGCCAGGATGCCCCACTCTGCTGGG                   GGTACTGCAGGGGTGGGGCTGGAGGCTGCAGAGCCCACAGCCCTCCTCACCAGGGCAGAGCCCCCTTC                   AGAACCCACAGAGATCCGTCCACAAAAGCGGAAAAAGGGGCCAGCCCCCAAAATGCTGGGGAACGAGC                   TATGCAGCGTGTGTGGGGACAAGGCCTCGGGCTTCCACTACGTGTTCTGAGCTGCGAGGGCTGCATGC                   GGATTCTTCCGCCGCAGCGTCATCAAGGGAGCGCACTACATCTGCCACAGTGGCGGCCACTGCCCCAT                   GGACACCThCATGCGTCGCAAGTGCCAGGGAGTGTCGGCTTCCCGATGCCGTCAGGCTGGCATCCGGG                   AGGAGTGTGTCCTGTCAGAAGAACAGATCCGCCTGAAGAAACTGAAGCGGCAAGAGGAGGAACAGGCT                   CATGCCACATCCTTGCCCCCCAGGCGTTCCTCACCCCCCCTTCCTCCCCCAGCTCAGCCCGGAACACA                   ACTGGGCATGATCGAGAGGCTCGTCGCTGCCCAGCAACAGTGTAACCGGCGCTCCTTTTCTGACCGGC                   TTCGAGTCACGCCTTGGCCCATGGCACCAGATCCCCATAGCCGGGAGGCCCGTCAGCAGCGCTTTGCC                   CACTTCACTGAGCTGGCCATCGTCTCTGTGCAGGAGATAGTTGACTTTGCTAAACAGCTACCCGGCTT                   CCTGCAGCTCAGCCGGGACGACCAGATTGCCCTGCTGAAGACCTCTGCGATCGAGGTGATGCTTCTGG                   AGACATCTCGGAGGTACAACCCTGGGAGTGAGAGTATCACCTTCCTCAAGGATTTCAGTTATGCCCGG                   GAAGACTTTGCCAAAGCAGGGCTGCAAGTGGAATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCAT                   GAATGAGCTGCAACTCAATGATGCCGAGTTTGCCTTCCTCATTCCTATCAGCATCTTCTCTGCAGACC                   GGCCCAACGTGCAGGACCAGCTCCAGGTAGAGAGGCTGCAGCACACATATGTGGTCGCCCTGCATGCC                   TACGTCTCCATCCACCATCCCCATGACCGACTGATGTTCCCACGGATGCTAATGAAACTGGTGAGCCT                   CCGGACCCTGAGCAGCGTCCACTCAGAGCAAGTGTTTGCACTGCGTCTGCAGCACGCTAHGCTCCCAC                   CGCTGCTCTCTGAGATCTGGGATGTGCACGAA TGA   CTGTTCTGTCCCCATATTTTCTGTTTTCTTGCC                       GGATGGCTGAGGCCTGGTGGCTGCCTCCTAGAAGTGGAACAGACTGAGATTGGGCGCACATTCCTGGC                       AGCTGGGCAAGGAGATCCTCCCGTGGCATTAGAGAGAGTCGTAAGGGTTGCGAGTTTTGTGGCTACTG                       AGCAGTGGAGCCCTCGCTAACACTGTGCTGTGTCTGAAGATCATGCTGACCCCACGCTCGGATGGGCC                       TGGGGGCCACTTTGCACAGGGTTCTCCAGAGCCCTGCCCATCCTGCCTCCACCACTTCCTGTTTTTCC                       CACAGGGCCCCAAGAAAATTCTCCACTGTCAAAAAAAAAA                                               ORF Start: ATG at 120       RF Stop: TGA at 1461               SEQ ID NO: 6   447 aa   MW at 50480.3kD                         NOV1c,   MSLMLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAGVGLEAAEPTALLT           CG105324-01       Protein   RAEPPSEPTEIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGAHYICHS       Sequence           GGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRRSSPPQILP                   QLSPEQLGMIEKLVAAQQQCNRRSFSDRLRVTPWPMAPDPHSREQQRFAHFTELHFAIVSVQEIVDFA                   KQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIF                   EFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRML                   MKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE                                         SEQ ID NO:7   1374bp                             NOV1d,   CGCGGATCCACCATGTCCTTGTGGCTGGGGGCCCCTGTGCCTGACATTCCTCCTGACTCTGCGGTGG           209829541       DNA Sequence   AGCTGTGGAAGCCAGCCGCACAGGATGCAAGCAGCCAGGCCCAGGGAGGCAGCAGCTGCATCCTCAG                   AGAGGAAGCCAGGATGCCCCACTCTGCTGGGGGTACTGCAGGGGTGGGGCTGGAGGCTGCAGAGCCC                   ACAGCCCTGCTCACCAGGGCAGAGCCCCCTTCAGTACCCACAGAGATCCGTCCACAAAAGCGGAAAA                   AGGGGCCAGCCCCCAAAATGCTGGGGAACGAGCTATGCAGTGTGTGTGGGGACAAGGCCTCGGGCTT                   CCACTACAATGTTCTGAGCTGCGAGGGCTGCATCGGGATTCTTCCGCCGCAGCGTCATCGGATAGCG                   CACTACATCTGCCACAGTGGCGGCCACTGCCCCATGGACACCTACATGCGTCGCAAGTGCCAGAAGT                   GTCGGCTTCGCAAATGCCGTCAGGCTGGCATGCGGACGAGTGTGTCCTGTCAGTCGAGTCAGATCCG                   CCTGAAGAAACTGAGCGCAAGAGGAGGAACAAATGCTCATGCCACATCCTTGCCCCCCAAGCATTCC                   TCACCCCCCCAATCCTGCCCCAGCTCAGCCCGGAACAACTGGGCATGATCGAGAAGCATCGTCGCTG                   CCCAGCAACAGTGTAACCGGCGCTCCTTTTCTGACCGGCTTCGAGTCACGCCTTGGCCCATGGCACC                   AGATCCCCATAGCCGGGAGGCCCGTCACCAGCGCTTTGCCCACTTCACTGACCTGCCCATCGTCTCT                   GTGCAGGAGATAGTTGACTTTGCTAAACAGCTACCCGGCTTCCTGCAGCTCAGCCGTAGGAGCCAGA                   TTGCCCTGCTGATGACCTCTOCCATCCAGGTGATGCTTCTGGAGACATCTCGGAGGTACATCCCTGA                   GAGTGAGAGTATCACCTTCCTCAAGGATTTCAGTTATAACCGGGAAGACTTTGCCAAAGCAGGGCTG                   CAAGTGGAATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCATGAATGAGCTGCAACTCAATGATG                   CCGAGTTTGCCTTGCTCATTGCTATCAGCATCTTCTCTGCAGACCGGCCCAACGTGCAGGACCAGCT                   CCAGGTAGAGAGGCTGCAGCACACATATGTGGAAGCCCTGCATGCCTACGTCTCCATCCACCATCCC                   CATGACCGACTGATGTTCCCACGGATGCTAATGAAACTGGTGAGCCTCCCGACCCTGAGCAGCCTCC                   ACTCACAGCAAGTGTTTGCACTGCGTCTGCAGGACAAAAAGCTCCCACCGCTGCTCTCTGAGATCTG                   GGATGGGCACGAA TGA   GCGGCCGCTTTTTTCCTT                                               ORF Start: at 1       ORF Stop: TGA at 1354               SEQ ID NO: 8   451 aa   MW at 50796.6kD                         NOV1d,   RGSTMSLWLGAPVPDIPPDSAVELWKPGAQDASSQAQGGSSCILREEARMPHSAGCTAGVGLEAAEP           209829541       Protein   TALLTRAEPPSEPTEIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCEGCKGFFRRSVIKGA       Sequence           HYICHSGGHCPMDTYNRRKCQECRLRKCRQAGMREECVLSEEQIRLKKLKRQEEEQAHATSLPPRAS                   SPPQILPQLSPEQLGMIEKLVAAQQQCNRRSTSDRLRVTPWPMAPDPHSREARQQRFAHFTELAIVS                   VQEIVDFAXQLPGFLQLSREDQIALLKTSAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGL                   QVEFINPIFEFSRAMNELQLNDAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHP                   HDRLMFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE                  
 
     [0352] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 1B.  
               TABLE 1B                          Comparison of NOV1a against NOV1b through NOVld.                                         Identities/                   Similarities           Protein   NOV1a Residues/   for the           Sequence   Match Residues   Matched Region                       NOV1b   168 . . . 447    264/280 (94%)               98 . . . 377    264/280 (94%)           NOV1c   1 . . . 447   418/447 (93%)               1 . . . 447   418/447 (93%)           NOV1d   1 . . . 447   417/447 (93%)               5 . . . 451   417/447 (93%)                      
 
     [0353] Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.  
               TABLE 1C                       Protein Sequence Properties NOV1a                                                 PSort analysis:   0.3000 probability located in nucleus;               0.1000 probability located in mitochondrial               matrix space; 0.1000 probability located in               lysosome (lumen); 0.0000 probability located               in endoplasmic reticulum (membrane)           SignalP analysis:   No Known Signal Sequence Predicted                      
 
     [0354] A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.  
               TABLE 1D                          Geneseq Results for NOVla                                         NOV1a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAW03326   LXR-alpha, orphan member   1 . . . 447    447/447 (100%)   0.0           of nuclear hormone receptor   1 . . . 447    447/447 (100%)           superfamily -  Homo sapiens ,           447 aa.[WO9621726-A1,           18 JUL. 1996]       AAR33744   XR2 -  Homo sapiens , 440 aa.   1 . . . 447   436/447 (97%)   0.0           [WO9306215-A,   1 . . . 440   437/447 (97%)           01 APR. 1993]       AAR88452   Retinoic acid receptor   1 . . . 447   422/447 (94%)   0.0           epsilon - Homo sapiens , 433   1 . . . 433   425/447 (94%)           aa.[WO9600242-A1,           04 JAN. 1996]       AAY32374   Mouse CNREB-1 -  Mus     1 . . . 447   409/447 (91%)   0.0             musculus , 445 aa.   1 . . . 445   421/447 (93%)           [WO9955343-A1,           04 NOV. 1999]       AAR74738   Human ubiquitous nuclear   14 . . . 447    287/460 (62%)   e−154           receptor protein -  Homo     4 . . . 460   338/460 (73%)             sapiens , 460 aa.           [WO9513373-A1,           18 MAY. 1995]                  
 
     [0355] In a BLAST search of public sequence datbases, the NOV1a protein was found to  
               TABLE 1E                          Public BLASTP Results for NOV1a                                         NOV1a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q13133   Oxysterols receptor LXR-alpha   1 . . . 447    447/447 (100%)   0.0           (Liver X receptor alpha) (Nuclear   1 . . . 447    447/447 (100%)           orphan receptor LXR-alpha) -             Homo sapiens  (Human), 447 aa.       Q9Z0Y9   Oxysterols receptor LXR-alpha   1 . . . 447   410/447 (91%)   0.0           (Liver X receptor alpha) (Nuclear   1 . . . 445   422/447 (93%)           orphan receptor LXR-alpha) -             Mus musculus  (Mouse), 445 aa.       Q91X41   Similar to nuclear receptor   1 . . . 447   409/447 (91%)   0.0           subfamily 1, group H, member 3 -   1 . . . 445   421/447 (93%)             Mus musculus  (Mouse), 445 aa.       Q62685   Oxysterols receptor LXR-alpha   1 . . . 447   408/447 (91%)   0.0           (Liver X receptor alpha) (Nuclear   1 . . . 445   420/447 (93%)           orphan receptor LXR-alpha) (RLD-1) -             Rattus norvegicus  (Rat), 445 aa.       AAM90897   Liver X receptor -  Gallus gallus     62 . . . 447    310/386 (80%)   0.0           (Chicken), 409 aa.   24 . . . 409    341/386 (88%)                  
 
     [0356] PFam analysis predicts that the NOV1a protein contains the domains shown in the Table 1F.  
               TABLE 1F                          Domain Analysis of NOV1a                                     Identities/               NOV1a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               zf-C4   96 . . . 171   43/77 (56%)   3.4e−41               64/77 (83%)       hormone_rec   262 . . . 443    63/207 (30%)    1.7e−53               148/207 (71%)                   
 
     Example 2  
     [0357] The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.  
               TABLE 2A                       NOV2 Sequence Analysis                                                    SEQ ID NO:9   5864 bp                             NOV2a,     CACTCGCTGGGGAGTCCCGTCGACGCTCTGTTCCGAGAGCGTGCCCCGGACCGCCAGCTCAGAACAGC             CG105355-01       DNA Sequence     GGCAGCCGTGTAGCCGAACGGAAGCTGGGAGCAGCCGGGACTGGTGGCCCGCGCCCGGAGCTCCGCAGG                       CGGGAACCACCCTGGATTTGGGAAGTCCCGGGACCAGCGCGGCGGCACCTCCCTCACCCAAGGGGCCG                       CGGCGACGGTCACGGGGCGCGGCGCCACCGTGAGCGACCCAGGCCAGGATTCTAAATACACGGCCCAG                       GCTCCTCCTCCGCCCGGGCCGCCTCACCTGCGGGCATTGCCGCGCCGCCTCCGCCGGTGTAGACGCCA                       CCTGCGCCGCCTTGCTCGCGOGTCTCCGCCCCTCGCCCACCCTCACTGCGCCAGGCCCAGGCAGCTCA                       CCTGTGCTGGCGCGGGCTGCGGAAGCCTGCGTGAGCCGAGGCGTTGAGGCGCGGCGCCCACGCCACTG                       TCCCGAGAGGACGCAGGTGGAGCGGGCGCGGCTTCGCGGAACCCGGCGCCGGCCGCCGCAGTGGTCCC                       AGCCTACACCGGGTTCCGGGGACCCGGCCGCCAGTGCCCGGGGAGTAGCCGCCGCCGTCGGCTGGGCA                       CC   ATG AACAGCAGCAOCGCCAACATCACCTACGCCAGTCGCAAGCGGCGGAAGCCGGTGCAGAAAACA                   GTAAAGCCAATCCCAGCTGAAGGAATCAAGTCAAATCCTTCCAAGCGGCATAGA~ACCGACTTAATAC                   AGAGTTGGACCGTTTGGCTAGCCTGCTGCCTTTCCCACAAGATGTTATTAATAAGTTGGACAAACTTT                   CAGTTCTTAGGCTCAGCGTCAGTTACCTGAGAGCCAAGAGCTTCTTTGATGTTGCATTAAAATCCTCC                   CCTACTGAAAGAAACGGAGGCCAGGATAACTGTAGAGCAGCAAATTTCAGAGAAGGCCTGAACTTACA                   AGAAGGAGAATTCTTATTACAGGCTCTGAATGGCTTTGTATTAGTTGTCACTACAGATGCTTTGGTCT                   TTTATGCTTCTTCTACTATACAAGATTATCTAGGGTTTCAGCAGTCTGATGTCATACATCAGAGTGTA                   TATGAACTTATCCATACCGAAGACCGAGCTGAATTTCAGCGTCAGCTACACTGGGCATTAAATCCTTC                   TCAGTGTACAGAGTCTGGACAAGGAATTGAAGAAGCCACTGGTCTCCCCCAGACAGTAGTCTGTTATA                   ACCCAGACCAGATTCCTCCAGAAAACTCTCCTTTAATGGAGAGGTGCTTCATATGTCGTCTAATGTGT                   CTGCTGGATAATTCATCTGGTTTTCTGGCAATGAATTTCCAAGGGAAGTTAAAGTATCTTCATCGACA                   GAAAAAGAAAGGGAAAGATGGATCAATACTTCCACCTCAGTTGGCTTTGTTTGCGATAGCTACTCCAC                   TTCAGCCACCATCCATACTTGAAATCCGGACCAAAAATTTTATCTTTAGAACCAGACACAAACTAGAC                   TTCACACCTATTGGTTGTGATGCCAAAGGAAGAATTGTTTTACGATATACTGAAGCAGAGCTGTGCAC                   GAGAGGCTCAGGTTATCAGTTTATTCATGCAGCTGATATGCTTTATTGTGCCGAGTCCCATATCCGAA                   TGATTAAGACTGGAGAGGAGTGGCATGATAGTTTTCCGGCTTCTTACAAAAACAACCGATGGACTTGG                   GTCCAGTCTAATGCACGCCTGCTTTATAAAAATGGAAGACCAGATTATATCATTGTAACTCAGAGACC                   ACTAACAGATGAGGAAGGAACAGAGCATTTACGAAAACGAAATACGAAGTTGCCTTTTATGTTTACCA                   CTGGAGAAGCTGTGTTGTATGAGGCACCAACCCTTTTCCTGCCATAATGGATCCCTTACCACTAGGGG                   ACTAAAAATGGCACTAGTGGAAAAGACTCTGCTACCACATCCACTCTAAGCAAGGACTCTCTCGATCC                   TAGTTCCCTCCTGGCTGCCATCATGCAACAAGATGAGTCTATTTATCTCTATCCTGCTTCAAGTACTT                   CAAGTACTGCACCTTTTGAAAACAACTTTTTCAACGAATCTATGAATGAATGCAGATTGATTGGATAT                   AATACTGCACCGATGGGAAATGATACTATCCTGAAACATGAGCAAATTGACCAGCCTGAGGATGTGAT                   CTCATTTGCTGGAGGTCACCCAGGGCTCTTTCAAGATAGTAAAACAGTGACTTGTACAGCATGATTGA                   AAAACCTAGGCATTGATTTTGAAGACATCAGACACATGCAGAATGAAAAATTTTTCAGAATGAGTTTT                   TCTGGTGAGGTTGACTTCAGAGACATTGACTTAACGGATGAAATCCTGACGTATGTGATGATTCTTTT                   AAGTAAGTCTCCCTTCATACCTTCAGATTATCAACAGCAACAGTCCTTGGCTCTGAACTCAAGCTGTA                   TGGTACAGGAACACCTACTATCTAGAACAGCAACAGCAACATCACCAAAGCAAGTAGTAGTGGAGCCA                   CAGCAACAGCTGTGTCAGAAGATGAAGCACATGCAAGTTAATGGCATGTTGAAAATTGGAACATCTAA                   CCAATTCGTGCCTTTCAATTGTCCACAGCAAGACCCACAACAATATAATGTCTTTACAGACTTACATG                   GGATCAGTCAAGAGTTCCCCTACAAATCTGAAATGGATTCTATGCCTTATACACAGAGCTTTATTTCC                   TGTAATCAGCCTGTATTACCACAACATTCCAAATGTACAGAGCTGGACTACCCTATGGGGAGTTTTGA                   ACCATCCCCCATACCCCACTACTTCTAGTTTAGAAGATTTGTCACTTGTTTACAACTTCCTGAAAACC                   AAAAGCATGGATTAAATCCACAGTCAGCCATAATAACTCCTCAGACATGTTATGCTGGGGCCGTGTCG                   ATGTATCAGTGCCAGCCAGAACCTCAGCACACCCACGTGGGTCAGATGCAGTACAATCCAGTACTGCC                   AGCCCAACAGCCATTTTTAAACAAGTTTCAGAATGGAGTTTTAATGAACATATCCAGCTGAAATTTAA                   ATAACATAAATAACACTCAGACTACCACACATCTTCAGCCACTTCATCATCCGTCAGAGCCAGACACT                   TTTCCTGATTTGACATCCAGTGGATTCCTG TAA   TTCCAAGCCCAATTTTGACCCTGGTTTTTGGATTA                       AATTAGTTTGTGAAGGATTATGCAAAAATAAAACTGTCACTGTTGGACGTCAGCAAGTTCACATGGAG                       GCATTGATGCATGCTATTCACAATTATTCCAAACCAATTTTAATTTTTCCTTTTAAGAAAAGGGAGTT                       TAAAAATGGTATCAAAATTACATATACTACAGTCAAGATAGATAGGGTGCTCCCACGGAGTGGTGAGG                       TACCGTCTACATTTCACATTATTCTGGGCACCACAAAATATACATACTTTATCAGGGAACTAAGCGAT                       TCTTTTAAATTAGAAAATATTCTCTATTTGAATTATTTCTGTCACAGTAAAAAGATTATACTTTGAGT                       TTTGAGCTACTGGATTCTTATTAGTTCCCCAAATACAAAGTTAGAGAACTATGCTAGTTTTTCCTATC                       ATGTTAACCTCTGCTTTTATCTCAGATGTTAAAATAAATGGTTTGGTGCTTTTTATAAAAAGATAATC                       TCAGTGCTTTCCTCCTTCACTGTTTCATCTAAGTGCCTCACATTTTTTTCTACCTATAACACTCTAGC                       ATGTATATTTTATATAAAGTATTCTTTTTCTTTTTTAAATTAATATCTTTCTGCACACAGTTATTATT                       TGTGTTTCCTAAATCCAACCATTTTCATTAATTCAGGCATATTTTAACTCCACTGCTTACCTACTTTC                       TTCAGGTAAAGGGCAAATAATCATCGAAAAAATAATTATTTATTACATAATTTAGTTGTTTCTAGACT                       ATAATGTTGCTATGTCCCTTATGTTGAAAAAATTTAAAAGTAAATGTCTTTCCAAAGCTTATTTCTTA                       ATTATTATAAAAATATTAAGACAATAGCACTTAAATTCCTCAACAGTGTTTTCAGAAGAAATAAATAT                       ACCACTCTTTACCTTTATTGATATCTCCATGATGATAGTTGAATGTTCCAATGTG~.AATCTGCTGT                       ATTTCAATGTCTATAAATTGTCTTTAAAAACTGTTTTAGACCTATAATCCTTGATAATATATTGTGTT                       GACGTTATAAATTTCGCTTCTTAGAACAGTGCAATCTATGTGTTTTTCTCATATTTGAGGAGTGTTTT                       GATTGCAGATAGCAAGGTTTCGTGCAAGTATTATAATGAGTGAATTGATGGTGCATTGTATAGATATA                       TAATGAACAAATTATTTGTAAGATATTTGCAGTTTTTCATTTTAAAAAGTCCATACCTTATAGTATGC                       ACTTAATTTGTTGGGGCTTTACATACTTTATCAATGTGTCTTTCTAAGAAATCAAGTAATGAATCCAA                       CTGCTTAAAGTTGGTATTAATAAAAAGACAACCACATACTTCGTTTACCTTCAAACTTTAGGTTTTTT                       TAATGATATACTGATCTTCATTACCAATAGGCAAATTAATCACCCTACCAACTTTACTGTCCTAACAT                       GGTTTAAAAGAAAAAATGACACCATCTTTTATTCTTTTTTTTTTTTTTTTTGAGAGAGAGTCTTACTC                       TGCCGCCCAACTGGAGTGCAGTCGCACAATCTTGGCTCACTGCAACCTCTACGCTCCTCGGTTCAAGT                       GATTCTCTTGCCTCAGCCTCCCGAGTTGCTGOGATTGCGGGCATGGTGGCGTGAGCCTGTAGTCCTAG                       CTACTCGGGAGGCTGAGGCAGGAGAATAGCCTGAACCTGGGAATCGGAGCTTCCAGGGcCAACATCGC                       CCCACTGCACTCCAGCCTGGCAATAGACCGAGACTCCGTCTCCAAAAAAAAAAAAAATACAATTTTTA                       TTTCTTTTACTTTTTTTAGTAAGTTAATGTATATAAAAATGGCTTCCGACAAAATATCTCTGAGTTCT                       GTGTATTTTCAGTCAAAACTTTAAACCTGTAGAATCAATTTAAGTGTTGGAAAAAATTTGTCTGAAAC                       ATTTCATAATTTGTTTCCAGCATGAGTATCTAAGGATTTAAAACCAGAGGTCTAGATTAATACTCTAT                       TTTTACATTTAAACCTTTTATTATAAGTCTTACATAAACCATTTTTGTTACTCTCTTCCACATGTTAC                       TGGATAAATTGTTTAGTGGAA~ATAGGCTTTTTAATCATGAATATGATGACAATCAGTTATACAGTTA                       TAAAATTAAAAGTTTGAAAAGCAATATTGTATATTTTTATCTATATAAAATAACTAAAATGTATCTAA                       GAATAATAAAATCACGTTAAACCAAATACACGTTTGTCTGTATTGTTAAGTGCCAAACAAAGGATACT                       TAGTGCACTGCTACATTGTGGGATTTATTTCTAGATGATGTGCACATCTAAGGATATGGATGTGTCTA                       ATTTTAGTCTTTTCCTGTACCAGGTTTTTCTTACAATACCTGAAGACTTACCAGTATTCTAGTGTATT                       ATGAAGCTTTCAACATTACTATGCACAAACTAGTGTTTTTCGATGTTACTAAATTTTAGGTAAATGCT                       TTCATGGCTTTTTTCTTCAAAATGTTACTGCTTACATATATCATGCATAGATTTTTGCTTAAAGTATG                       ATTTATAATATCCTCATTATCAAAGTTGTATACAATAATATATAATAAAATAACAAATATGAATAATA                       AAAAAAAAAAAAAAAA                                               ORF Start: ATG at 615       ORF Stop: TAA at 3159               SEQ ID NO: 10   848 aa   MW at 96146.5kD                         NOV2a,   NNSSSANITYASRXRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDKLS           CG105355-01       Protein   VLRLSVSYLRAKSFFDVALKSSPTERNGGQDNCRAANFREGLNLQEGEFLLQALNGFVLVVTTDALVF       Sequence           YASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATGLPQTVVCYN                   PDQIPPENSPLMERCFICRLRCLLDNSSGFLAMNFQGKLKYLHGQKKKGKDGSILPPQLALFAIATPL                   QPPSILEIRTKNFIFRTKHKLDFTPIGCDAKGRIVLGYTEAELCTRGSGYQFIHAADMLYCAESHIRM                   IKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYIIVTQRPLTDEEGTEHLRKRNTKLPFMFTT                   GEAVLYEATNPFPAIMDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAAMMQQDESIYLYPASSTS                   STAPFENNFFNESMNECRNWQDNTAPMGNDTILKHEQIDQPQDVNSFAGGHPGLFQDSKNSDLYSIMK                   NLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPFIPSDYQQQQSLALNSSCM                   VOEHLHLEOOOOHHOKOVVVEPOOOLCOKMKHMOVNGMFENWNSNOFVPFNCPOODPOOYNVFTDLHG                   ISQEFPYKSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLEDFVTCLQLPENQ                   KHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPVLPGQQAFLNKFQNGVLNETYFAELN                   NINNTQTTTHLQPLHHPSEARPFPDLTSSGFL                                         SEQ ID NO:11   2551 bp                             NOV2b,   CACCATGAACAGCAGCAGCGCCAACATCACCTACGCCAGTCGCAAGCGGCGGAAGCCGGTGCAGAAA           245279626       DNA Sequence   ACAGTAAAGCCAATCCCAGCTGAAGGAATCAAGTCAAATCCTTCCAAGCGGCATAGAGACCGACTTA                   ATACAGAGTTGGACCGTTTGGCTAGCCTGCTGCCTTTCCCACAAGATGTTATTAATAAGTTGGACAA                   ACTTTCAGTTCTTAGGCTCAGCGTCAGTTACCTGAGAGCCAAGAGCTTCTTTGATGTTGCATTAAAA                   TCCTCCCCTACTGAAAGAAACGGAGGCCAGGATAACTGTAGAGCAGCAAATTTCAGAGAAGGCCTGA                   ACTTACAAGAAGGAGAATTCTTATTACAGGCTCTGAATGGCTTTGTATTAGTTGTCACTACAGATCC                   TTTGGTCTTTTATGCTTCTTCTACTATACAAGATTATCTAGGGTTTCAGCAGTCTGATGTCATACAT                   CAGAGTGTATATGAACTTATCCATACCGAAGACCGACCTGAATTTCAGCGTCAGCTACACTGCGCAT                   TAAATCCTTCTCAGTGTACAGAGTCTGGACAAGGAATTGAAGAAGCCACTGGTCTCCCCCAGACAGT                   AGTCTGTTATAACCCAGACCAGATTCCTCCAGAAAACTCTCCTTTAATGGAGAGGTGCTTCATATGT                   CGTCTAAGGTGTCTGCTGGATAATTCATCTGGTTTTCTGGCAATGAATTTCCAAGGGAAGTTAAAGT                   ATCTTCATGGACAGAAAAAGAAAGGGAAAGATGGATCAATACTTCCACCTCAGTTGGCTTTGTTTGC                   GATAGCTACTCCACTTCAGCCACCATCCATACTTGAAATCCGGACCAAAAATTTTATCTTTAGAACC                   AAACACAAACTAGACTTCACACCTATTGGTTGTGATGCCAAAGGAAGAATTGTTTTAGGATATACTG                   AAGCAGAGCTGTGCACGAGAGGCTCAGGTTATCAGTTTATTCATGCAGCTGATATGCTTTATTGTGC                   CGAGTCCCATATCCGAATGATTAAGACTGGAGAAAGTGGCATGATAGTTTTCCGGCTTCTTACAAAA                   AACAACCGATGGACTTGGGTCCAGTCTAATGCACGCCTGCTTTATAAAAATGGAAGACCAGATTATA                   TCATTGTAACTCAGAGACCACTAACAGATGAGGAAGGAACAGAGCATTTACGAAAACGAAATACGAA                   GTTGCCTTTTATGTTTACCACTGGAGAAGCTGTGTTGTATGAGGCAACCAACCCTTTTCCTGCCATA                   ATGGATCCCTTACCACTAAGGACTAAAAATGCCACTAGTGGAAAAGACTCTGCTACCACATCCACTC                   TAAGCAAGGACTCTCTCAATCCTAGTTCCCTCCTGGCTGCCATGATGCAACGAGATGAGTCTATTTA                   TCTCTATCCTGCTTCAAGTACTTCAAGTACTGCACCTTTTGAAACAACTTTTGTCAACGAATCTATG                   AATGAATGCAGAAATTGGCAAGATAATACTGCACCGATCGGAAATGATACTATCCTGAGCCATGAGC                   AAATTGACCAGCCTCAGGATGTGAACTCATTTGCTGGAGGTCACCCAGGGCTCTTTCAAGATAGTAA                   AAACAGTGACTTGTACAGCATAATGAAAAACCTAGGCATTGATTTTGAAGACATCAGACACATGCAG                   AATGAAAAATTTTTCAGAAATGATTTTTCTGGTGAGGTTGACTTCAGAGACATTGACTTAACGGATG                   AATCCTGACGTATGTCCAAGATTCTTTAAGTAAGTCTCCCTTCATACCTTCAGATTATCAAACAGCA                   ACAGTCCTTGGCTCTGAACTCAAGCTGTATGGTACAGGAACACCTACATCTAGAACAGCAACAGCAA                   CATCACCAAAAGCAAGTAGTAGTGGAGCCACAGCAACAGCTGTGTCAGAAGATGAACCACATGCAAG                   TTAATGGCATGTTTGAAAATTGGAACTCTAACCAATTCGTGCCTTTCAATTGTCCACAGCAAGACCC                   ACAACAATATAATGTCTTTACAGACTTACATGGGATCAGTCAAGAGTTCCCCTACAAATCTGAAATG                   GATTCTATGCCTTATACACAGAACTTTATTTCCTGTAATCAGCCTGTATTACCACAACATTCCAAAT                   GTACAGAGCTGGACTACCCTATGGGGAGTTTTGAACCATCCCCATACCCCACTACTTCTAGTTTAGA                   AGATTTTGTCACTTGTTTACAACTTCCTGAAACCAAAAGCATGGATTAAATCCACAGGTCAGCCATA                   ATAACTCCTCAGACATGTTATGCTGGGGCCGTGTCGATGTATCAGTGCCAGCCAGAACCTCAGCACA                   CCCACGTGGGTCACATGCAGTACAATCCAGTACTGCCAGGCCAAACAGGCATTTTTAACAAGTTTCA                   GAATGGAGTTTTAAATGAAACATATCCAGCTGAATTAAATAACATAAATAACACTCAGACTACCACA                   CATCTTCAGCCACTTCATCATCCGTCAGAAGCCAGACCTTTTCCTGATTTGACATCCAGTGGATTCC                   TG TAA                                               ORF Start: at 2       ORF Stop: TAA at 2549               SEQ ID NO: 12   849 aa   MW at 96247.6kD                     NOV2b,   TMNSSSANITYASRKRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDK       245279626       Protein   LSVLRLSVSYLRAKSFFDVALKSSPTERNCOQDNCRAANFREGLNLQEGEFLLQALNGFVLVVTTDA       Sequence           LVFYASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATGLPQTV                   VCYNPDQTPPENSPLMERCFICRLRCLLDNSSGFLAMNFQGKLKYLHGQKKKGKDGSILPPQLALFA                   IATPLQPPSILEIRTKNFIFRTKHKLDFTPTGCDAKGRIVLGYTEAELCTRGSGYQFIHAADMLYCA                   ESHIRMIKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYIIVTQRPLTDEEGTEHLRKRNTK                   LPFMFTTGEAVLYEATNPFPAIMDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAKUMQQDESIY                   LYPASSTSSTAPFENNFFNESMNECRNWQDNTAPMGNDTILKHEQIDQPQDVNSFAGGHPGLFQDSK                   NSDLYSIMKNLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPFIPSDYQQQ                   QSLALNSSCMVQEHLHLEQQQQHHQKQVVVEPQQQLCQKMXHMQVNGMFENWNSNQFVPFNCPQQDP                   QQYNVFTDLNGISQEFPYKSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLE                   DFVTCLQLPENQKHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPvLPGQQAFLNKFQ                   NGVLNETYPAELNNINNTQTTTHLQPLHHPSEARPFPDLTSSGFL                                         SEQ ID NO: 13   2677 bp                             NOV2c,     CCAGTGCCCGGGGAGTAGCCGCCGCCGTCGGCTGGGCACC   ATG AACAGCAGCACCGCCAACATCACCT           CG105355-02       DNA Sequence   ACGCCAGTCGCAAGCGGCGGAAGCCGTGCAGAAAACAGTAAAGCCAATCCCAGCTGAAGGAAATCAAG                   TCAAATCCTTCCAAGCGGCATAGAGACCGACTTAATACACAGTTGGACCGTTTGGCTAGCCTGCTGCC                   TTTCCCACAAGATGTTATTAATAAGTTGGACAAACTTTCAGTTCTTAGGCTCAGCGTCAGTTACCTGA                   GAGCCAAGAGCTTCTTTGATGTTGCATTAAAATCCTCCCCTACTGAAAGAAACGGAGGCCAGGATAAC                   TGTAGAGCAGCAAATTTCAGAGAAGGCCTGAACTTACAAGAGGACAATTCTTATTACAGGCTCTGAAA                   TGGCTTTGTATTAGTTGTCACTACAGATGCTTTGGTCTTTTATGCTTCTTCTACTATACAAGATTATC                   TAGGGTTTCAGCAGTCTGATGTCATA&amp;ATCAGAGTCTATATGAACTTATCCATACCGAAGACCGAGCT                   GAATTTCAOCGTCAGCTACACTGGGCATTAAATCCTTCTCAGTGTACAGAGTcTGGAcAAGGAATTGA                   AGAAGCCACTGGTCTCCCCCAGACAGTAGTCTGTTATAACCCAGACCAGATTCCTCCAGAAAACTCTC                   CTTTAATGGAGAGGTGCTTCATATGTCGTCTAWGTGTCTGCTGGATAATTCATCTGGTTTTCTAAACA                   ATGAATTTCCAAGGGAAGTTTAAAGTATCTTCATGGACAGAAGAAAGGGAGGATGGATCAAAAATACT                   TCCACCTCAGTTGGCTTTGTTTGCGATAGCTACTCCACTTCAGCCACCATCCATACTTGAAATCCGGA                   CCAAAAATTTTATCTTTAGAACCAAACACAAACTAGACTTCACACCTATTGGTTGTGATGCCAAAGGA                   AGAATTGTTTTAGGATATACTGAAGCAGAGCTGTGCACGAGAGGCTCAGGTTATCAGTTTATTCATGC                   AGCTGATATGCTTTATTGTGCCGACTCCCATATCCGAATGATTAAGACTGGAGAAAGTGGCATGATAG                   TTTTCCGGCTTCTTACAAAAAACAACCGATGGACTTGGGTCCAGTCTAATGCACGCCTGCTTTATAAA                   AATGGAAGACCAGATTATATCATTGTAACTCAGAGACCACTAACAGATGAGGAAGCAACAGAGCATTT                   ACGAAAACGAAATACGAAGTTGCCTTTTATGTTTACCACTGGAGAAGCTGTGTTGTATGAGGCAACCA                   ACCCTTTTCCTGCCATAATGGATCCCTTACCACTAAGGACTGAAAATGGCACTAGTGGAAAAGACTCT                   GCTACCACATCCACTCTAAGCAAGGACTCTCTCAATCCTAGTTCCCTCCTGGCTGCCATGATGCAACA                   AGATGAGTCTATTTATCTCTATCCTGCTTCAAGTACTTCAAGTACTGCACCTTTTGAAAACAACTTTT                   TCAACGAATCTATGAATGAATGCAGAAATTGGCAAGATAATACTGCACCGATGGGAAATGATACTATC                   CTGAAACATGAGCAAATTGACCAGCCTCAGGATGTGAACTCATTTGCTGGAGGTCACCCAGGGCTCTT                   TCAAGATAGTAAAAACAGTGACTTGTACAGCATAATGAAAAACCTAGGCATTGATTTTGAAGACATCA                   GACACATGCAGAATGAAAAATTTTTCAGAAATGATTTTTCTGGTGAGGTTGACTTCAGAGACATTGAC                   TTAACGGATGAAATCCTGACGTATGTCCAAGATTCTTTAAGTAAGTCTCCCTTCATACCTTCAGATTA                   TCAACAGCAACAGTCCTTGGCTCTGAACTCAAGCTGTATGGTACAGGAACACCTACATCTAGAACAGC                   AACAGCAACATCACCAAAAGCAAGTAGTAGTGGAGCCACAGCAACAGCTGTGTCAGAAGATGAAGCAC                   ATGCAAGTTAATGGCATGTTTGAAAATTGGAACTCTAACCAATTCGTGCCTTTCAATTGTCCACAGCA                   AGACCCACAACAATATAATGTCTTTACAGACTTACATGGGATCAGTCAAGAGTTCCCCTACAAATCTG                   AAATGGATTCTATGCCTTATACACAGAACTTTATTTCCTGTAATCAGCCTGTATTACCACAACATTCC                   AAATGTACAGAGCTGGACTACCCTATGGGGAGTTTTGAACCATCCCCATACCCCACTACTTCTACTTT                   AGAAGATTTTGTCACTTGTTTACAACTTCCTGAAAACCAAAAGCATGGATTAAATCCACAGTCAGCCA                   TAATAACTCCTCAGACATGTTATGCTGGGGCCGTGTCGATGTATCAGTGCCAGCCAGAACCTCAGCAC                   ACCCACGTGGGTCAGATGCAGTACAATCCAGTACTGCCAGGCCAACAGOCATTTTTAAACAAGTTTCA                   GAATGGAGTTTTAAATGAAACATATCCAGCTGAATTAAATAACATAAATAACACTCAGACTACCACAC                   ATCTTCAGCCACTTCATCATCCGTCAGAAGCCAGACCTTTTCCTGATTTGACATCCAGTGGATTCCTG                     TAA   TTCCAAGCCCAATTTTGAGCCTGGTTTTTGGATTAAATTAGTTTGTGAAGGATTATGGAAAAATA                       AAACTGTCACTGTTGGACGTCAGCA                                               ORF Start: ATG at 41       ORF Stop: TAA at 2585               SEQ ID NO: 14   848 aa   MW at 96146.5kD                         NOV2c,   MNSSSANITYASRKRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDKLS           CG105355-02       Protein   VLRLSVSYLRAKSFFDVALKSSPTERNGGQDNCRAANFREGLNLQEGEFLLQALNGFVLVVTTDALVF       Sequence           YASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATGLPQTVVCYN                   PDQIPPENSPLMERCFICRLRCLLDNSSGFLAMNFQGKLKYLHGQKKKGKDGSILPPQLALFAIATPL                   QPPSILEIRTKNFTERTKHKLDFTPIGCDAXGRIVLGYTEAELCTRGSGYQFHAADMLYCAESHITPL                   IKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYTIVTQRPLTDEEGTEHLRKRNTKLPFMFTT                   GEAVLYEATNPFPAIMDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAAMMQQDESIYLYPASSTS                   STAPFENNFFNESMNECRNWQDNTAPMGNDTILKHEQTDQPQDVNSFAGGHPGLFQDSKNSDLYSINK                   NLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPFIPSDYQQQQSLALNSSCM                   VQEMLHLEQQQQHHQKQVVVEPQQQLCQKMKHMQVNGMFENWNSNQFVPFNCFQQDPQQYNVFTDLHG                   ISQEFPYXSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLEDFVTCLQLPENQ                   KHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPVLPGQQAFLNKFQNGVLNETYPAELN                   NINNTQTTTHLQPLHHPSEARPFPDLTSSGFL                                             SEQ ID NO:15   2551 bp                                 NOV2d,     C   ACC ATGAACAGCAGCAGCGCCAACATCACCTACGCCAGTCGCAAGCGGCGGAAGCCGGTGCAGAAA           CG105355-03       DNA Sequence   ACAGTAAAGCCAATCCCAGCTGAAGGAATCAAGTCAAATCCTTCCAAGCGGCATAGAGACCGACTTA                   ATACAGAGTTGGACCGTTTGGCTAGCCTGCTGCCTTTCCCACAAGATGTTATTAATAAGTTGGACAA                   ACTTTCAGTTCTTAGGCTCAGCGTCAGTTACCTGAGAGCCAAGAGCTTCTTTGATGTTGCATTAAAA                   TCCTCCCCTACTGAAAGAAACGGAGGCCAGGATAACTGTAGAGCAGCAAATTTCAGAGAAGGCCTGA                   ACTTACAAGAAGGAGAATTCTTATTACAGGCTCTGAATGGCTTTGTATTAGTTGTCACTACAGATGC                   TTTGGTCTTTTATGCTTCTTCTACTATACAAGATTATCTAGGGTTTCAGCAGTCTGATGTCATACAT                   CAGAGTGTATATGAACTTATCCATACCGAAGACCGAGCTGAATTTCAGCGTCAGCTACACTGGGCAT                   TAAATCCTTCTCAGTGTACAGAGTCTGGACAAGGAATTGAAGAAGCCACTGGTCTCCCCCAGACAGT                   AGTCTGTTATAACCCAGACCAGATTCCTCCAGAAAACTCTCCTTTAATGGAGAGGTGCTTCATATGT                   CGTCTAAGGTGTCTGCTGGATAATTCATCTGGTTTTCTCGCAATGAATTTCCAAGGGAAGTTAAAGT                   ATCTTCATGGACAGAAAAAGAAAGGGAAAGATGGATCAATACTTCCACCTCAGTTCGCTTTGTTTGC                   GATAGCTACTCCACTTCAGCCACCATCCATACTTGAAATCCCGACCAAAAATTTTATCTTTAGAACC                   AAACACAAACTAGACTTCACACCTATTGGTTGTGATGCCAAAGGAAGAATTGTTTTAGCATATACTG                   AAGCAGAGCTGTCCACGAGAGGCTCAGGTTATCAGTTTATTCATGCAGCTGATATGCTTTATTGTGC                   CGAGTCCCATATCCGAATGATTAAGACTGGAGAAAGTGGCATGATAGTTTTCCGGCTTCTTACAAAA                   AACAACCGATGGACTTGCGTCCAGTCTAATGCACGCCTGCTTTATAAAAATGGAAGACCAGATTATA                   TCATTGTAACTCAGAGACCACTAACAGATGAGGAAGGAACAGAGCATTTACGAAAACGAAATACGAA                   GTTGCCTTTTATGTTTACCACTGGAGAAGCTGTGTTGTATGAGGCAACCAACCCTTTTCCTGCCATA                   ATGGATCCCTTACCACTAAGGACTAAAAATGGCACTAGTCGAAAAGACTCTGCTACCACATCCACTC                   TAAGCAAGGACTCTCTCAATCCTAGTTCCCTCCTGGCTGCCATGATGCAACAAGATGAGTCTATTTA                   TCTCTATCCTGCTTCAAGTACTTCAAGTACTGCACCTTTTGAAAACAACTTTTTCAACGAATCTATG                   AATGAATGCAGAAATTGGCAAGATAATACTGCACCGATGGGAAATGATACTATCCTGAAACATGAGC                   AAATTGACCAGCCTCAGGATGTGAACTCATTTGCTGGAGGTCACCCAGGGCTCTTTCAAGATAGTAA                   AAACAGTGACTTGTACAGCATAATGAAAAACCTAGGCATTGATTTTGAAGACATCAGACACATGCAG                   AATGAAAAATTTTTCAGAAATGATTTTTCTGGTGAGGTTGACTTCAGAGACATTGACTTAACGGATG                   AAATCCTGACGTATGTCCAAGATTCTTTAAGTAAGTCTCCCTTCATACCTTCAGATTATCAACAGCA                   ACAGTCCTTGGCTCTGAACTCAAGCTGTATGGTACAGGAACACCTACATCTAGAACAGCAACAGCAA                   CATCACCAAAAGCAAGTAGTAGTGGAGCCACAGCAACAGCTGTGTCAGAAGATGAAGCACATGCAAG                   TTAATGGCATGTTTGAAAAGTGGAACTCTAACCAATTCGTGCCTTTCAATTGTCCACAGCAAGACCC                   ACAACAATATAATGTCTTTACAGACTTACATGGGATCAGTCAACAGTTCCCCTACAAATCTGAAGTG                   GATTCTATGCCTTATACACAGAACTTTATTTCCTGTAATCAGCCTGTATTACCACAACATTCCAAAT                   GTACAGAGCTGGACTACCCTATGGGGAGTTTTGAACCATCCCCATACCCCACTACTTCTAGTTTAGA                   AGATTTTGTCACTTGTTTACAACTTCCTGAAAACCAAAAGCATCGATTAAATCCACAGTCAGCCATA                   ATAACTCCTCAGACATGTTATGCTGGGGCCGTGTCGATGTATCAGTGCCAGCCAGAACCTCAGCACA                   CCCACGTGGGTCAGATGCAGTACAATCCAGTACTGCCAGGCCAACAGGCATTTTTAAACAAGTTTCA                   GAATGGAGTTTTAAATGAAACATATCCAGCTGAATTAAATAACATAAATAACACTCAGACTACCACA                   CATCTTCAGCCACTTCATCATCCGTCAGAAGCCAGACCTTTTCCTATTTGACATCCCAGTGGATTCC                   TG TAA                                               ORF Start: at 2       ORF Stop: TAA at 2549               SEQ ID NO: 16   849 aa   MW at 96247.6kD                         NOV2d,   TMNSSSANITYASRKRRKPVQKTVKPIPAEGIKSNPSKRHRDRLNTELDRLASLLPFPQDVINKLDK           CG105355-03       Protein   LSVLRLSVSYLRAKSFFDVALKSSPTERNGGQDNCRAANFREGLNLQEGEPLLQALNGFVLVVTTDA       Sequence           LVFYASSTIQDYLGFQQSDVIHQSVYELIHTEDRAEFQRQLHWALNPSQCTESGQGIEEATOLPQTV                   VCYMPDQIPPENSPLMERCFICRLRCLLDNSSGFLANNFQGKLKYLhGQKKKGKDGSILPPQLALFA                   IATPLQPPSILEIRDTKNFIFRTKHKLDFTPIGCDAKGRIVLGYTEAELCTRGSGYQFIHADMLYCA                   SHIRMIKTGESGMIVFRLLTKNNRWTWVQSNARLLYKNGRPDYIHIVTQRPLTDEEGTEHLRKRNTK                   LPFMFTTGEAVLYEATNPFPAIHDPLPLRTKNGTSGKDSATTSTLSKDSLNPSSLLAAMMQQDESIY                   LYPASSTSSTAPFENNFFNESNNECRNWQDNTAPMGNDTILKHEQIDQPQDVNSFAGGHPGLFQDSK                   NSDLYSIMKNLGIDFEDIRHMQNEKFFRNDFSGEVDFRDIDLTDEILTYVQDSLSKSPSIPSDYQQQ                   QSLLWSSCMVQEHLHLEQQQQHHQKQVVVEPQQQLCQKHTKHMQVNGMFENWNSNQFVPFNcPQQDP                   QQYNVFTDLHGISQEFPYKSEMDSMPYTQNFISCNQPVLPQHSKCTELDYPMGSFEPSPYPTTSSLE                   DFVTCLQLPENQKHGLNPQSAIITPQTCYAGAVSMYQCQPEPQHTHVGQMQYNPvLPGQQAFLNKFQ                   NGVLNETYPAELNNINNTQTTTHLQPLHHPSEARPFPDLTSSGFL                  
 
     [0358] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B.  
               TABLE 2B                          Comparison of NOV2a against NOV2b through NOV2d.                                     NOV2a   Identities/               Residues/   Similarities           Protein   Match   for the           Sequence   Residues   Matched Region                       NOV2b   1 . . . 848   783/848 (92%)               2 . . . 849   783/848 (92%)           NOV2c   1 . . . 848   783/848 (92%)               1 . . . 848   783/848 (92%)           NOV2d   1 . . . 848   783/848 (92%)               2 . . . 849   783/848 (92%)                      
 
     [0359] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.  
               TABLE 2C                       Protein Sequence Properties NOV2a                                        PSort analysis:   0.5452 probability located in mitochondrial           matrix space; 0.4900 probability located in           nucleus; 0.3000 probability located in microbody           (peroxisome); 0.2672 probability located in           mitochondrial inner membrane       SignalP analysis:   No Known Signal Sequence Predicted                  
 
     [0360] search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.  
               TABLE 2D                          Geneseq Results for NOV2a                                         NOV2a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/   Match   for the   Expect       Identifier   Length [Patent #, Date]   Residues   Matched Region   Value                                         AAW25668   Human Ah-receptor -  Homo     1 . . . 848   847/848 (99%)   0.0             sapiens , 848 aa.   1 . . . 848   847/848 (99%)           [US5650283-A, 22 JUL. 1997]       AAR80551   Human Ah receptor protein -   1 . . . 848   847/848 (99%)   0.0             Homo sapiens , 848 aa.   1 . . . 848   847/848 (99%)           [US5378822-A, 03 JAN. 1995]       AAB73957   Guinea pig dioxin receptor -   1 . . . 848   661/852 (77%)   0.0             Cavia porcellus , 846 aa.   1 . . . 846   734/852 (85%)           [JP2000354494-A, 26 DEC. 2000]       AAR80561   Murine Ah receptor protein -   3 . . . 804   590/814 (72%)   0.0             Mus musculus , 805 aa.   2 . . . 805   675/814 (82%)           [US5378822-A, 03 JAN. 1995]       ABB08868     Cricetulus griseus  dioxin   3 . . . 848   573/960 (59%)   0.0           receptor SEQ ID NO 1 -   2 . . . 941   663/960 (68%)             Cricetulus griseus , 941 aa.           [JP2002045188-A, 12 FEB. 2002]                  
 
     [0361] In a BLAST search of public sequence datbases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.  
               TABLE 2E                          Public BLASTP Results for NOV2a                                         NOV2a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                         P35869   Ah receptor (Aryl hydrocarbon   1 . . . 848    848/848 (100%)   0.0           receptor) (AhR)-  Homo     1 . . . 848    848/848 (100%)             sapiens  (Human), 848 aa.       Q95LD9   Aryl hydrocarbon receptor -   1 . . . 848   713/854 (83%)   0.0             Delphinapterus leucas     1 . . . 845   767/854 (89%)           (Beluga whale), 845 aa.       BAB88683   Aryl hydrocarbon receptor -   1 . . . 848   679/851 (79%)   0.0             Phoca sibirica  (Baikal seal),   1 . . . 843   740/851 (86%)           843 aa.       O02747   AH receptor (Aryl hydrocarbon   1 . . . 848   669/852 (78%)   0.0           receptor) -  Oryctolagus cuniculus     1 . . . 847   734/852 (85%)           (Rabbit), 847 aa.       Q95M15   Aryl hydrocarbon receptor -   1 . . . 848   676/851 (79%)   0.0             Phoca vitulina  (Harbor seal),   1 . . . 843   740/851 (86%)           843 aa.                  
 
     [0362] PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F.  
               TABLE 2F                          Domain Analysis of NOV2a                                             Identities/                       Similarities for           Pfam   NOV2a   the Matched   Expect           Domain   Match Region   Region   Value                       PAS   113 . . . 177   20/69 (29%)   1.6e−13                   54/69 (78%)           PAC   348 . . . 389   10/43 (23%)   1.3e−08                   37/43 (86%)                      
 
     Example 3  
     [0363] The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.  
               TABLE 3A                       NOV3 Sequence Analysis                                                    SEQ NO: 17   5221 bp                             NOV3a,     ATAAAAGGGCGCTGAGGAAATACCGGACACGGTCACCCGTTGCCAGCTCTAGCCTTTAAATTCCCGGC             CG105521-01       DNA Sequence     TCGGGGACCTCCACGCACCGCGGCTAGCGCCGACAACCAGCTAGCGTGCAAGGCGCCGCGGCTCAGCG                       CGTACCGGCGGGCTTCGAAACCGCAGTCCTCCGGCGACCCCGAACTCCGCTCCGGAGCCTCAGCCCCC                       TGGAAAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCAGGACGATATCTCTAGCT                   CCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTG                   GAGACGATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCAC                   CTACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTC                   TCCTACACTTGCGACCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGG                   GGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCACCG                   CTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATG                   ATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCAT                   AATTCCCGACGTGGCTTTTTCTTCTCTCACCTGGGTTGGCTCCTTGTGCGCAAACACCCAGCTGTCAA                   AGAGAAGCGGAGTACGCTACACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGT                   ACTACAAACCTGGCTTGCTGCTGATGTGCTTCATCCTCCCCACGCTTGTGCCCTGGTATTTCTGGGGT                   CAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTCTCGTGCTTAATGCCACCTG                   GCTGGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCCGGGAGA                   ATATCCTGTTTTCACTTGGAGCTGTGGGTGACGGCTTCCACAACTACCACCACTCCTTTCCCTATGAC                   TACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCT                   CGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGAG                   ATGCAAACTACAAGAGTCGC TGA GTTTGGGGTCCCTCAGGTTTCCTTTTTCAAAAACCAGCCACGCAG                     AGGTTTTAATGTCTGTTTATTAACTACTGAATAATGCTACCAGGATGCT~GATGATGATGTT~CC                       CATTCCAGTACAGTATTCTTTTAAAATTCAAAAGTATTGAAAGCCAAC~CTCTGCCTTTATGATGCT                       AAGCTGATATTATTTCTTCTCTTATCCTCTCTCTCTTCTAGGCCCATTGTCCTCCTTTTCACTTTATT                       GCTATCGCCCTCCTTTCCCTTATTGCCTCCCAGGCAAGCAGCTGGTCAGTCTTTGCTCAGTGTCCAGC                       TTCCAAAGCCTAGACAACCTTTCTGTAGCCTAAAACGAATGGTCTTTGCTCCAGATAACTCTCTTTCC                       TTGAGCTGTTGTGAGCTTTGAAGTAGGTGGCTTGAGCTAGAGATAAAACAGAATCTTCTGGGTAGTCC                       CCTGTTGATTATCTTCAGCCCAGGCTTTTGCTAGATGGA~ATGGAA~GC~CTTCATTTGACAC~G                       CTTCTAAGCAGGTAAATTGTCGGGGGAGAGAGTTAGCATGTATGAATGTAAGGATOAGG~AGCG~                       GCAAGAGGAACCTCTCGCCATGATCAGACATACAGCTGCCTACCTAATGAGGACTTC~GCCCCACCP                       CATAGCATGCTTCCTTTCTCTCCTGGCTCGGGGTAAAAAGTGGCTGCGGTCTTTGGC~TGCT~TTC                       AATCCCGCAACATATAGTTGAGGCCGAGGATAAAGAAAAGACATTTTAAGTTTGTAGT~~GTGGTC                       TCTGCTGGGGAAGGGTTTTCTTTTCTTTTTTTCTTTAATAACAAGGAGATTTCTTAGTTCATATATC~                       AGAAGTCTTGAAGTTGGGTGTTTCCAGAATTGGTAAAAACAGCAGCTCATGGAATTTTGAGTATTCCA                       TGAGCTGCTCATTACAGTTCTTTCCTCTTTCTGCTCTGCCATCTTCAGGATATTGGTTCTTCCCCTCA                       TAGTAATAAGATGGCTGTGGCATTTCCAAACATCCAAAAAAAGGGAAGGATTTAAGGAGGTGAAGTCG                       GGTCAAAAATAAAATATATATACATATATACATTGCTTAGAACGTTAAACTATTAGAGTATTTCCCTT                       CCAAAGAGGGATGTTTGGAAAAAACTCTGAAGGAGAGGAGAAATTAGTTCGGATGCCAATTTCCTCTC                       CACTGCTGGACATGAGATCGAGAGGCTGAGGGACAGGATCTATAGGCAGCTTCTAAGAGCGCACTTCA                       CATAGGAAGGGATCTGAGAACACGTTGCCAGGGGCTTGAGAAGGTTACTGAGTGAGTTATTGGGAGTC                       TTAATAAAATAAACTAGATATTAGGTCCATTCATTAATTAGTTCCAGTTTCTCCTTGAAATGAGTAAA                       AACTAGAAGGCTTCTCTCCACAGTGTTGTGCCCCTTCACTCATTTTTTTTTGAGGAGAAGGGGGTCTC                       TGTTAACATCTAGCCTAAAGTATACAACTGCCTGGGGGGCACGGTTAGGAATCTCTTCACTACCCTGA                       TTCTTGATTCCTGGCTCTACCCTGTCTGTCCCTTTTCTTTGACCAGATCTTTCTCTTCCCTGAGCGTT                       TTCTTCTTTCCCTGGACAGGCAGCCTCCTTTGTGTGTATTCAGAGGCAGTGATGACTTGCTGTCCAGT                       CAGCTCCCTPCCTGCACACAGAATGCTCAGGGTCACTGAACCACTGCTTCTCTTTTGAAAGTACAGCTA                       GCTGCCACTTTCACGTGGCCTCCGCAGTGTCTCCACCTACACCCCTGTGCTCCCCTGCCACACTGATC                       GCTCAAGACAAGGCTGGCAAACCCTCCCAGAAACATCTCTGGCCCAGAAAGCCTCTCTCTCCCTCCCT                       CTCTCATGAGGCACAGCCAAGCCAAGCGCTCATGTTGAGCCAGTGGGCCAGCCACAGAGCAAAAGAGG                       GTPTATTTTCAGTCCCCTCTCTCTGGGTCAGAACCAGAGGGCATGCTGAATGCCCCCTGCTTACTTGG                       TGAGGGTGCCCCGCCTGAGTCAGTGCTCTCAGCTGGCAGTGCAATGCTTGTAGTATATAGAAGTCTGG                       GTTCTCACTGGGAAGAAGCAAGGGCAAGAACCCAAGTGCCTCACCTCCAAAGGAGGCCCTGTTCCCTG                       GAGTCAGGGTGAACTGCAAGCTTTGGCTGAGACCTQGGATTTGAGATACCACAACCCTGCTGACATTT                       CAGTGTCTGTTCAGCAAACTAACCAGCATTCCCTACAGCCTAGGGCAGACAATAGTATAGAACTCTGC                       AAAAAAACAAAAACAGAATTTGAGAACCTTGGACCACTCCTGTCCCTGTAGCTCAGTCATCAAAGCAG                       AAGTCTCGCTTTGCTCTATTAAGATTGGAAATGTACACTACCAAACACTCAGTCCACTGTTGACCCCC                       AGTGCTGGAAGGGAGGAAGGCCTTTCTTCTGTGTTAATTGCGTAGAGGCTACAGGGGTTAGCCTGGAC                       TAAAGGCATCCTTGTCTTTTTGAGCTATTCACCTCAGTAGAAAAGGATCTAAGGGAGATCACTGTAGT                       TTAGTTCTGTTGACCTGTGCACCTACCCCTTGGAAATGTCTGCTGGTATTTCTAATTCCACAGGTCAT                       CAGATGCCTGCTTGATAATATATAAACAATAAAAACAACTTTCACTTCTTCCTATTGTAATCGTGTGC                       CATGGATCTGATCTGTACCATGACCCTACATAAGGCTGGATGGCACCTCAGGCTGAGGGCCCCAATGT                       ATGTGTGGCTGTGGGTGTGGGTGGGAGTGTGTCTGCTGAGTAAGGAACACGATTTTCAAGATTCTAAA                       GCTCAATTCAAGTGACACATTAATGATAAACTCAGATCTGATCAAGAGTCCGGATTTCTAACAGTCCC                       TGCTTTGGGGGGTGTGCTGACAACTTAGCTCAGGTGCCTTACATCTTTTCTAATCACAGTGTTGCATA                       TGAGCCTGCCCTCACTCCCTCTGCAGAATCCCTTTGCACCTGAGACCCTACTGAAGTAACTGGTAGAA                       AAAGGGGCCTGAGTGGAGGATTATCAGTATCACGATTTGCAGGATTCCCTTCTGGGCTTCATTCTGGA                       AACTTTTGTTAGGGCTGCTTTTCTTAAGTGCCCACATTTGATGGAGGGTGGAAATAATTTGAATGTAT                       TTGATTTATAAGTTTTTTTTTTTTTTTGGGTTAAAAGATGGTTGTAGCATTTAAAATGGAAAATTTTC                       TCCTTGGTTTGCTAGTATCTTGGGTGTATTCTCTGTAAGTGTAGCTCAAATACGTCATCATGAGGTAA                       TAAAAAAGCGAGGTGGCCATGTTATGCTGGTGGTTAAGGCCAGACCTCTCCACCACTGTGCCACTCAA                       ACTTGCTGTGTGACCCTGGGCAAGTCACTTAACTATAAGGTGCCTCAGTTTTCCTTCTGTTAAAATGG                       GGATAATAATACTGACCTACCTCAAAGGGCAGTTTTGAGGCATGACTAATGCTTTTTAGAAAGCATTT                       TGGGATCCTTCAGCACAGGAATTCTCAAGACCTGAGTATTTTTTATAATAGGAATGTCCACCATGAAC                       TTGATACGTCCGTGTGTCCCAGATGCTGTCATTAGTCTATATGGTTCTCCAAGAAACTGAATGAATCC                       ATTGGAGAAGCGGTGGATAACTAGCCAGACAAAATTTGAGAATACATAAACAACGCATTGCCACGGAA                       ACATACAGAGGATGCCTTTTCTGTGATTGGGTGGGATTTTTTCCCTTTTTATGTGGGATATAGTAGTT                       ACTTGTGACAAAAATAATTTTGGAATAATTTCTATTAATATCAACTCTGAAGCTAATTGTACTAATCT                       GAGATTGTGTTTGTTCATAATAAAAGTGAAGTGAATCTAAAAAAAAAAAAAAA                                               ORF Start: ATG at 236       ORF Stop: TGA at 1313               SEQ ID NO:18   359 aa   MW at 41504.1kD                         NOV3a,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPK           CG105521-01       Protein   VEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRL       Sequence           FLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSD                   LEAEKLVMFQRRYYKPGLLLMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFG                   YRPYDKNISPRENTLVSLGAVGEGFHNYHHSFPYDYSASEYRWHIMFTTFFIDCMAALGLAYDRKKVS                                         SEQ ID NO: 19   1988 bp                             NOV3b,     GGGCTGAGCAAATACCGGACACGCTCACCCGTTGCCAGCTCTAGCCTTTAAATTCCCGGCTCGGGG             CG105521-02       DNA Sequence     ACCTCCACGCACCGCGGCTAGCGCCGACAACCAGCTAGCGTGCCAACGCCGCGGCTCAGCGCGTAC                       CGCCGGGCTTCGAAACCGCAGTCCTCCGGCGACCCCGAACTCCGCTCCGGAGCCTCAGCCCCTGGA                       AAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCAGGCGATATCTCTAGCTCCT                   ATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGTCCTGCAGAATGGAGGAGATAAGTTTGGA                   GACGATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCACC                   TACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTC                   TGCTACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTG                   GGGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCAC                   CGCTCTTACAAGCTCGGCTGCCCCTACCGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAA                   ATGATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCC                   TCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCCCAAACACCCAGCT                   GTCAAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGA                   GGAGGTACTACAAACCTGGCTTGCTGATGATGTCCTTCATCCTGCCCACGCTTGTGCCCTAATATTT                   CTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAAT                   GCCACCTGGCTGGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCC                   CCCGGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTT                   TCCCTATGACTACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCATTGATTGC                   ATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAACGCCGCCATCTTGGCCAGGATTA                   AAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GTTTGGGGTCCCTCAGGTTCCTTTTTCAAAAA                       CCAGCCAGGCAGAGGTTTTAATGTCTGTTTATTAACTACTGAATAATGCTACCAGGATGCTAAAGAT                       GATGATGTTAACCCATTCCAGTACACTATTCTTTTAAAATTCAAAAGTATTGAAAGCCAACAACTCT                       GCCTTTATGATGCTAAGCTGATATTATTTCTTCTCTTATCCTCTCTCTCTTCTAGGCCCATTGTCCT                       CCTTTTCACTTTATTGCTATCGCCCTCCTTTCCCTTATTGCCTCCCACGCAAGCAGCTGGTCAGTCT                       TTGCTCAGTGTCCAGCTTCCAAGCCTAGACAACCTTTCTGTAGCCTAAAACGAATTGGTCTTTGCTC                       CAGATAACTCTCTTTCCTTGAGCTGTTGTGAGCTTTGAAGTAGGTGGCTTGAGCTAGAGATAAAACA                       GAATCTTCTGGGTAGTCCCCTGTTGATTATCTTCAGCCCAGGCTTTTGCTAGATGGAATGGAAAAGC                       AACTTCATTTGACACAAAGCTTCTAAAGCAGGTAAATTGTCGGGGGAGAGAGTTAGCATGTATGAAT                       GTAAGGATGAGGGAAGCGAAGCAACAGGAACCTCTCGCCATGATCAGACATACAGCTGCCTACCTAA                       TGAGGACTTCAAGCCCCACCACATAGCATGCTTCCTTTCTCTCCT                                               ORF Start: ATG at 229       ORF Stop: TGA at 1306               SEQ ID NO:20   359 aa   MW at 41522.2kD                         NOV3b,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSP           CG105521-02       Protein   KVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPL       Sequence           RLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLD                   LSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAA                   HLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYD                   RKKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO:21   1104 bp                             NOV3c,   CACCGGATCCACCATGCCGGCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATACCACCACCACCA           301113881       DNA Sequence   CCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGACGATGCCCCTCTAC                   TTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAAGGAAGG                   CCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTAGAGACCC                   TGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGAATATTCTACTATTTT                   GTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCACCGCTCTTACAAAGCTCGGCT                   GCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATGATGTCTATGAATGGGCTC                   GTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCCGACGTGGCTTT                   TTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAAGGGGAGTACGCT                   AGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGTACTACAAACCTAACTTGC                   TGATGATGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGTGAAACTTTTCAAAACAGT                   GTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTGGCTGGTGAACAGTGCTGC                   CCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCCAAGAGAATATCCTGGTTTCACTTG                   GAGCTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGACTACTCTGCCAGTGAGTAC                   CGCTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCG                   GAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGAGATGGAACTACAAACAGTG                   GC TGA   GCGGCCGCTAT                                               ORF Start: at 2       ORF Stop: TGA at 1091               SEQ ID NO: 22   363 aa   MW at 41868.5kD                         NOV3c,   TGSTMPAHLLQDDISSSYTTTTTTTAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEG           301113881       Protein   PSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGARRLWSHRSYKARL       Sequence           PLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTL                   DLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAA                   ELFGYRPYDKNISPRENILVSLGAVGEGFHYHHSFPYDYSASEYRWHINFTTFFIDCMAAKLGLAYDR                   KKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO:23   5221 bp                             NOV3d,     ATAAAAGGGGGCTGACGAATACCGGACACGGTCACCCGTTGCCAGCTCTAGCCTTTTAAATTCCCGG             CG105521-01       DNA Sequence     CTCGGGGACCTCCACGCACCGCGGCTAGCGCCGACAACCAGCTAGCGTCCAAGGCGCCGCGGCTCAG                       CGCGTACCGGCGGGCTTCGAAACCGCAGTCCTCCGGCGACCCCGAACTCCGCTCCGGAGCCTCAGCC                       CCCTGGAAAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCAGGACGATATCTCT                   AGCTCCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATAAAGGAGATA                   AGTTGGAGACGATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGA                   CCCCACCTACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTT                   ATGTCTCTGCTACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCT                   GGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTG                   GAGCCACCGCTCTTACAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAAACACAATGGCA                   TTCCAGAATGATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATG                   CTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACA                   CCCAGCTGTCAAAGAGAAGCGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATG                   TTCCAGAGGAGGTACTACAAACCTGGCTTGCTGCTGATGTGCTTCATCCTGCCCACGCTTGTGCCCT                   GGTATTTCTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGT                   GCTTATGCCACCTGGCTGGTGACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAAGCC                   ATTAGCCCCCGGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACC                   ACTCCTTTCCCTATGACTACTCTGCCAGTGACTACCGCTGCCACATCAACTTCACCACATTCTTCAT                   TGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCC                   AGGATTAAAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GTTTGGGGTCCCTCAGGTTTCCTTT                       TTCAAAAACCAGCCAGGCAGAGGTTTTAATGTCTGTTTATTAACTACTGAATAATGCTACCAGGATG                       CTAAAGATGATGATGTTAACCCATTCCAGTACAGTATTCTTTTAAAATTCAAAAGTATTGAAAGCCA                       ACAACTCTGCCTTTATGATGCTAACCTGATATTATTTCTTCTCTTATCCTCTCTCTCTTCTAGGCCC                       ATTGTCCTCCTTTTCACTTTATTGCTATCGCCCTCCTTTCCCTTATTGCCTCCCAGGCAAGCAGCTG                       GTCAGTCTTTGCTCAGTGTCCAGCTTCCAAAGCCTAGACAACCTTTCTGTAGCCTAAAACGAATGGT                       CTTTGCTCCAGATAACTCTCTTTCCTTGAGCTGTTGTGAGCTTTGAAGTAGGTGGCTTGAGCTAGAG                       ATAAAACAGAATCTTCTGGGTAGTCCCCTGTTGATTATCTTCAGCCCAGGCTTTTGCTAGATGGAAT                       GGAAAAGCAACTTCATTTGACACAAAGCTTCTAAAGCAGGTAAATTGTCGGGGGAGAGAGTTAGCAT                       GTATGAATGTAAGGATGAGGGAAGCGAAGCAAGAGGAACCTCTCGCCATGATCAGACATACAGCTCC                       CTACCTAATGAGGACTTCAAGCCCCACCACATAGCATGCTTCCTTTCTCTCCTGGCTCGGGGTAAAA                       AGTGGCTGCGGTGTTTGGCAATGCTAATTCAATGCCGCAACATATAGTTGAGGCCGAGGATAAAGAA                       AAGACATTTTAAGTTTGTAGTAAAAGTGGTCTCTGCTGGGGAAGGGTTTTCTTTTCTTTTTTTCTTT                       AATAACAAGGAGATTTCTTAGTTCATATATCAAGAAGTCTTGAAGTTGGGTGTTTCCAGAATTGGTA                       AAAACAGCAACTCATGGAATTTTGAGTATTCCATGAGCTGCTCATTACAGTTCTTTCCTCTTTCTGC                       TCTGCCATCTTCAGGATATTGGTTCTTCCCCTCATAGTAATAAGATGGCTGTGGCATTTCCAAACAT                       CCAAAAAAAGGGAAGGATTTAAGGAGGTGAAGTCGGGTCAAAAATAAAATATATATACATATATACA                       TTGCTTAGAACGTTAAACTATTAGAGTATTTCCCTTCCAAAGACGGATGTTTGGAAAAAACTCTGAA                       AGAGAGGAGGAATTAGTTGGGATGCCAATTTCCTCTCCACTGCTGGACATGAGATGGAGAGGCTGAG                       GGACAGGATCTATAGGCAGCTTCTAAGAGCGAACTTCACATAGGAAGGGATCTGAGAACACGTTGCC                       AGGGGCTTGAGAAGGTTACTGAGTGAGTTATTGGGAGTCTTAATAAAATAAACTAGATATThGGTCC                       ATTCATTAATTAGTTCCAGTTTCTCCTTGAAATGAGTAAAAACTAGAACGCTTCTCTCCACAGTGTT                       GTGCCCCTTCACTCATTTTTTTTTGAGGAGAAGCGGGTCTCTGTTAACATCTAGCCTAAAGTATACA                       ACTGCCTGGGGGGCAGGGTTACGAATCTCTTCACTACCCTGATTCTTCATTCCTGGCTCTACCCTGT                       CTGTCCCTTTTCTTTGACCAGATCTTTCTCTTCCCTGAACGTTTTCTTCTTTCCCTGGACAGGCAGC                       CTCCTTTGTGTGTATTCAGAGGCAGTGATGACTTGCTGTCCAGGCAGCTCCCTCCTGCACACAGAAT                       GCTCAGGGTCACTGAACCACTGCTTCTCTTTTGAAAGTAGAGCTAGCTGCCACTTTCACGTGCCCTC                       CGCAGTGTCTCCACCTACACCCCTGTGCTCCCCTGCCACACTGATGGCTCAAGACAAGGCTGGCAAA                       CCCTCCCAGAAACATCTCTGGCCCAGAAAGCCTCTCTCTCCCTCCCTCTCTCATGAGGCACAGCCAA                       GCCAAGCGCTCATGTTGAGCCAGTGGGCCAGCCACAGAGCAAAAGAGGGTTTATTTTCAGTCCCCTC                       TCTCTGGGTCAGAACCAGAGGGCATGCTGAATGCCCCCTGCTTACTTGGTGAGGGTGCCCCGCCTGA                       GTCAGTGCTCTCAGCTGGCAGTGCAATGCTTGTAGAAGTACGAGGAAACAGTTCTCACTGGGAAGAA                       GCAACGGCAAGAACCCAAGTGCCTCACCTCGAAAGGAGGCCCTGTTCCCTGGAGTCAGCGTGAACTG                       CAAAGCTTTGGCTGACACCTGGGATTTGAGATACCACAAACCCTGCTGAACACAGTGTCTGTTCAGC                       AAACTAACCAGCATTCCCTACAGCCTAGGGCAGACAATAGTATAGAAGTCTGGAAAAAAACAAAAAC                       AGAATTTGAGAACCTTGGACCACTCCTGTCCCTGTAGCTCAGTCATCAAAGCAGAAGTCTGGCTTTG                       CTCTATTAAGATTGGAAATGTACACTACCAAACACTCAGTCCACTGTTGAGCCCCAGTGCTCGAAGG                       GAGGAAGGCCTTTCTTCTGTGTTAATTGCGTAGAGGCTACAGGGGTTAGCCTGGACTAAAGGCATCC                       TTGTCTTTTGAGCTATTCACCTCAGTAGAAAAGGATCTAAGGGAAGATCACTGTAGTTTAGTTCTGT                       TGACCTGTGCACCTACCCCTTGGAAATGTCTGCTGGTATTTCTAATTCCACAGGTCATCAGATGCCT                       CCTTGATAATATATAAACAATAAAAACAACTTTCACTTCTTCCTATTGTAATCGTGTGCCATGGATC                       TGATCTGTACCATGACCCTACATAAGGCTGGATGGCACCTCAGGCTGAGCGCCCCAATGTATGTGTG                       GCTGTGGGTGTGGGTGGGAGTGTGTCTGCTGAGTAAGGAACACGATTTTCAAGATTCTAAAGCTCAA                       TTCAAGTGACACATTAATGATAAACTCAGATCTGATCAAGAGTCCGGATTTCTAACAGTCCCTGCTT                       TGGGGGGTGTGCTGACAACTTAGCTCAGGTGCCTTACATCTTTTCTAATCACAGTGTTGCATATGAG                       CTCTGCCTCACTCCCTCTGCAGAATCCCTTTGCACCTGAGACCCTACTGAAGTGGCTGGTAGAAAAA                       GGGGCCTGAGTGGAGGATTATCAGTATCACGATTTGCAGGATTCCCTTCTGGGCTTCATTCTGGAAA                       CTTTTGTTAGGGCTGCTTTTCTTAAGTGCCCACATTTGATGGAGGGTGGAAATAATTTGAATGTATT                       TGATTTATAAGTTTTTTTTTTTTTTTGGGTTAAAAGATGGTTGTAGCATTTAAAATGGAAAATTTTC                       TCCTTGGTTTGCTAGTATCTTGGGTTTATTCTCTGTAAGTGTAGCTCAAATAGGTCATCATGAAAGG                       TTAAAAAAGCGAGGTGGCCATGTTATGCTGGTGGTTAAGGCCAGGGCCTCTCCAACCACTGTGCCAC                       TGACTTGCTGTGTGACCCTGGGCAAGTCACTTAACTATAAGGTGCCTCAGTTTTCCTTCTGTTAAAA                       TGGGGATAATAATACTGACCTACCTCAAAGGGCAGTTTTGAGGCATGACTAATGCTTTTTAGAAAGC                       ATTTTGCGATCCTTCAGCACAGGAATTCTCAAGACCTGAGTATTTTTTATAATAGGAATGTCCACCA                       TGAACTTGATACGTCCGTGTGTCCCAGATGCTGTCATTAGTCTATATGGTTCTCCAAGAAACTGAAT                       GAATCCATTGGAGAAGCCGTGGATAACTAGCCAGACAAAATTTGACAATACATAAACAACGCATTGC                       TACGGAAACATACAGAGGATGCCTTTTCTGTGATTGGGTGGGATTTTTTCCCTTTTTATGTGGGATA                       TAGTAGTTACTTGTGACAAAAATAATTTTGGAATAATTTCTATTAATATCAACTCTGAAGCTAATTG                       TACTAATCTGAGATTGTGTTTGTTCATAATAAAAGTGAAGTGAATCTAAAAAAAAAAAAAAA                                               ORF Start: ATG at 236       ORF Stop: TGA at 1313               SEQ ID NO: 24   359 aa   MW at 41504.1kD                         NOV3d,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSP           CG105521-01       Protein   KVEYVWRNIILMSLLHLGALYGITLTPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPL       Sequence           RLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLD                   LSDLEAEKLVMFQRRYYXPGLLLMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAA                   HLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWUINFTTFFIDCMAALGLAYD                   RKKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO:25   1116 bp                             NOV3e,     CCG GCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATACCACCACCACCACCATTACAGCGCCTCC           309330043       DNA Sequence   CTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGACCATGCCCCTCTACTTGCAAGACGACATTC                   GCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAACGAAGGCCCAAGCCCCAAGGTT                   GAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTGGGAGCCCTGTATGGGATCACTTT                   GATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCCTGGCCA                   TAACAGCAGGAGCTCATCGTCTGTGGAGCCACCGCTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTT                   CTCATCATTGCCAACACAATGGCATTCCAGAATGATGTCTATGAATGGGCTCGTGACCACCGTGCCCA                   CCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGG                   GTTGCCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTA                   GAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGTACTACAAACCTG~CTTGCTGATGATGTGCTTCAT                   CCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTT                   TCTTGCGATATGCTGTGGTGCTTAATGCCACCTGGCTGGTGAACAGTGCTGCCCACCTCTTCGGATAT                   CGTCCTTATGACAAGAACATTAGCCCCCGGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGG                   CTTCCACAACTACCACCACTCCTTTCCCTATGACTACTCTGCCAGTGAGTACCGCTGGCACATCAACT                   TCACCACATTCTTCATTGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAG                   GCCGCCATCTTGGCCAGGATTAAAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GCAGGTGCGGC                       CGCACTCGAGCACCACCACCACCACCAC                                               ORF Start: at 1       ORF Stop: TGA at 1075               SEQ ID NO:26   358 aa   MW at 41391.0kD                         NOV3e,   PAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPKV           309330043       Protein   EYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRLF       Sequence           LIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFESHVCWLLVRKHPAVKEKGSTLDLSDL                   EAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFGY                   RPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSK                   AAILARIKRTGDGNYKSG                                         SEQ ID NO:27   1129 bp                             NOV3f,     A CAT CATCACCACCATCACCCGGCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATACCACCACCA             309330069       DNA Sequence   CCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGACGATGCCCCTC                   TACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAAGGA                   ACGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTGGGAG                   CCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGGGTATTCTACTAT                   TTTGTCAGTGCCCTGGGCATAACAGCACGAGCTCATCGTCTGTGGAGCCACCGCTCTTACAAAGCTCG                   GCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATGATGTCTATGAATGGG                   CTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCCGACGTGGC                   TTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAAGGGGAGTAC                   GCTAGACTTGTCTGACCTAGAAGCTGAGAAACTCGTGATGTTCCAGAGGACGTACTACAAACCTGGCT                   TGCTGATGATGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGTGAAACTTTTCAAAAC                   AGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTGCCTGGTGAACAGTGC                   TGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCCGGGAGAATATCCTGGTTTCAC                   TTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGACTACTCTGCCAGTGAG                   TACCGCTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCTCGOTCTGGCCTATGA                   CCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGAGATGGAAACTACAAGA                   GTGGC TGA   GCGGCCGCACTCGAGCACCACCACCACCACCAC                                               ORF Start: at 2       ORF Stop: TGA at 1094               SEQ ID NO: 28   364 aa   MW at 42213.9kD                         NOV3f,   HHHHHHPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKE           309330069       Protein   GPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAOAHRLWSHRSYKAR       Sequence           LPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGST                   LDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSA                   AHLFGYRPYDKNISPRENTLVSLGAVGEOFHNYHHSFPYDYSASEYRWHINFTTFEIDCHAALGLAYD                   RKKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO:29   5221 bp                             NOV3g,     ATAAAAGGGGGCTGAGGAAATACCGGACACGGTCACCCGTTGCCAGCTCTAGCCTTTAAATTCCCGG             CG105521-01       DNA Sequence     CTCGGGGACCTCCACGCACCGCGGCTAGCGCCGACAACCAGCTAGCGTGCAAGGCGCCGCGGCTCAG                       CGCGTACCGGCCGOCTTCGAAACCGCAGTCCTCCGGCGACCCCGAACTCCGCTCCGGAGCCTCAGCC                       CCCTGGAAAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCAGGACGATATCTCT                   AGCTCCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTCCAGAATGGAGGAGATA                   AGTTGGAGACGATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGA                   CCCCACCTACAAGGATAAGGAAGGCCCAAGCCCCAACGTTGAATATGTCTGGAGAAACATCATCCTT                   ATGTCTCTGCTACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCT                   GGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTG                   GAGCCACCGCTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCA                   TTCCAGAATGATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCACAAACACATG                   CTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACA                   CCCAGCTGTCAAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTCATG                   TTCCAGAGGAGGTACTACAAACCTGGCTTGCTGCTGATGTGCTTCATCCTGCCCACGCTTGTGCCCT                   GGTATTTCTGGGOTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGT                   GCTTAATGCCACCTGGCTGGTCAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAAc                   ATTAGCCCCCGGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACC                   ACTCCTTTCCCTATGACTACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCAT                   TGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCC                   AGGATTAAAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GTTTGGGGTCCCTCAGGTTTCCTTT                       TTCAAAAACCAGCCAGGCAGAGGTTTTAATGTCTGTTTATTAACTACTGAATAATGCTACCAGGATG                       CTAAAGATGATGATGTTAACCCATTCCAGTACAGTATTCTTTTAAAATTCAAAAGTATTGAAAGCCA                       ACAACTCTGCCTTTATGATGCTAAGCTGATATTATTTCTTCTCTTATCCTCTCTCTCTTCTAGGCCC                       ATTGTCCTCCTTTTCACTTTATTGCTATCGCCCTCCTTTCCCTTATTGCCTCCCAGGCAAGCAGCTG                       GTCAGTCTTTGCTCAGTGTCCAGCTTCCAAAGCCTAGACAACCTTTCTGTAGCCTAAAACGAATGGT                       CTTTGCTCCAGATAACTC~CTTTCCTTGAGCTGTTGTGAGCTTTGAAGTAGGTGGCTTGAGCTAGAG                       ATAAAACAGAATCTTCTGGGTAGTCCCCTGTTGATTATCTTCAGCCCAGGCTTTTGCTAGATGGAAT                       GGAAAAGCAACTTCATTTGACACAAAGCTTCTAAAGCAGGTAAATTGTCGGGGGAGAGAGTTAGCAT                       GTATGAATGTAAGGATGAGGGAAGCGAAGCAAGACGAACCTCTCGCCATGATCAGACATACAGCTGC                       CTACCTAATGAGGACTTCAAGCCCCACCACATAGCATGCTTCCTTTCTCTCCTGGCTCGGGGTAAAA                       AGTGGCTGCGGTGTTTGGCAATGCTAATTCAATGCCGCAACATATAGTTGAGGCCGAGGATAAAGAA                       AAGACATTTTAAGTTTGTAGTAAAAGTGGTCTCTGCTGGGGAAGGGTTTTCTTTTCTTTTTTTCTTT                       AATAACAAGGAGATTTCTTAGTTCATATATCAAGAAGTCTTGAAGTTGGGTGTTTCCAGAATTGGTA                       AAAACAGCAGCTCATGGAATTTTGAGTATTCCATGAGCTGCTCATTACAGTTCTTTCCTCTTTCTGC                       TCTGCCATCTTCAGGATATTGGTTCTTCCCCTCATAGTAATAAGATGGCTGTGGCATTTCCAAACAT                       ACAAAAAAAGGGAAGGATTTAAGGAGGTGAAGTCGGGTCAAAAATAAAATATATATACATATATACA                       TTGCTTAGAACGTTAAACTATTAGAGTATTTCCCTTCCAAAGAGGGATGTTTGGAAAAAACTCTGAA                       GGAGAGGAGGAATTAGTTGGGATGCCAATTTCCTCTCCACTGCTGGACATGAGATGGAGAGGCTGAG                       GGACAGGATCTATAGGCAGCTTCTAAGAGCGAACTTCACATAGGAAGGGATCTGAGAACACGTTGCC                       AGGGGCTTGAGAAGGTTACTGAGTGAGTTATTGGGAGTCTTAATAAAATAAACTAGATATTAGGTCC                       ATTCATTAATTAGTTCCAGTTTCTCCTTGAAATGAGTAAAAACTAGAAGGCTTCTCTCCACAGTGTT                       GTGCCCCTTCACTCATTTTTTTTTGAGGAGAAGGGGGTCTCTGTTAACATCTAGCCTAAAGTATACA                       ACTGCCTGGGGGGCAGGGTTAGGAATCTCTTCACTACCCTGATTCTTGATTCCTGGCTCTACCCTGT                       CTGTCCCTTTTCTTTGACCAGATCTTTCTCTTCCCTGAACGTTTTCTTCTTTCCCTGGACAGGCAGC                       CTCCTTTGTGTGTATTCAGAGGCAGTGATGACTTGCTGTCCAGGCAGCTCCCTCCTGCACACAGAAT                       ACTCAGCGTCACTGAACCACTGCTTCTCTTTTGAAAGTAGAGCTAGCTGCCACTTTCACGTGGCCTC                       CGCAGTGTCTCCACCTACACCCCTGTGCTCCCCTGCCACACTGATGGCTCAAGACAAGGCTGGCAAA                       CCCTCCCAGAAACATCTCTGGCCCAGAAAGCCTCTCTCTCCCTCCCTCTCTCATGAGGCACAGCCAA                       GCCAAGCGCTCATGTTGAGCCAGTGCGCCAGCCACAGAGCAAAAGAGGGTTTATTTTCAGTCCCCTC                       TCTCTGGGTCAGAACCAGAGGGCATGCTGAATGCCCCCTGCTTACTTGGTGAGGGTGCCCCGCCTGA                       GTCAGTGCTCTCAGCTGGCAGTGCAATGCTTGTAGAAGTAGGAGGAAACAGTTCTCACTGGGAAGAA                       ACAAGGGCAAGAACCCAAGTGCCTCACCTCGAAAGGAGGCCCTGTTCCCTGGAGTCAGGGTGAACTG                       CAAAGCTTTGCCTGAGACCTGGGATTTGAGATACCACAAACCCTGCTGAACACAGTGTCTGTTCAGC                       AAACTAACCAGCATTCCCTACAGCCTAGGGCAGACAATAGTATAGAAGTCTGGAAAAAAACAAAAAC                       AGAATTTGAGAACCTTGGACCACTCCTGTCCCTGTAGCTCAGTCATCAAAGCAGAAGTCTGGCTTTG                       CTCTATTAAGATTGGAAATGTACACTACCAAACACTCAGTCCACTGTTGAGCCCCAGTGCTGGAAGG                       CAGGAAGGCCTTTCTTCTGTGTTAATTGCGTAGAGGCTACAGGGGTTAGCCTGGACTAAAGGCATCC                       TTGTCTTTTGAGCTATTCACCTCAGTAGAAAAGGATCTAAGGGAAGATCACTGTAGTTTAGTTCTGT                       TGACCTGTGCACCTACCCCTTGGAAATGTCTGCTGGTATTTCTAATTCCACAGGTCATCAGATGCCT                       GCTTGATAATATATAAACAATAAAAACAACTTTCACTTCTTCCTATTGTAATCGTGTGCCATGGATC                       TGATCTGTACCATGACCCTACATAAGGCTGGATGGCACCTCAGGCTGACGGCCCCAATGTATGTGTG                       GCTGTGGGTGTGGGTGGGAGTGTGTCTGCTGAGTAAGGAACACGATTTTCAAGATTCTAAAGCTCAA                       TTCAAGTGACACATTAATGATAAACTCAGATCTGATCAAGAGTCCGGATTTCTAACAGTCCCTGCTT                       TGGGGGGTGTGCTGACAACTTAGCTCAGGTGCCTTACATCTTTTCTAATCACAGTGTTGCATATGAG                       CCTGCCCTCACTCCCTCTGCAGAATCCCTTTGCACCTGAGACCCTACTGAAGTGGCTGGTAGAAAAA                       GGGGCCTGAGTGGAGGATTATCAGTATCACGATTTGCAGGATTCCCTTCTGGGCTTCATTCTGGAAA                       CTTTTGTTAGGGCTGCTTTTCTTAAGTGCCCACATTTGATGGAGGGTGGAAATAATTTGAATGTATT                       TGATTTATAAGTTTTTTTTTTTTTTTGGGTTAAAAGATGGTTGTACCATTTAAAATGGAAAATTTTC                       TCCTTGGTTTGCTAGTATCTTGGGTGTATTCTCTGTAAGTGTAGCTCAAATAGGTCATCATGAAAGG                       TTAAAAAAGCGAGGTGGCCATGTTATGCTGGTGGTTAAGGCCAGGGCCTCTCCAACCACTGTGCCAC                       TGACTTGCTGTGTGACCCTGGGCAAGTCACTTAACTATAAGGTGCCTCAGTTTTCCTTCTGTTAAAA                       TGGGGATAATAATACTGACCTACCTCAAAGGGCAGTTTTGAGGCATGACTAATGCTTTTTAGAAAGC                                               ORF Start: ATG at 236       ORF Stop: TGA at 1313               SEQ ID NO: 30   359 aa   MW at 41504.1kD                         NOV3g,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDFTYKDKEGPSP           CG105521-01       Protein   KVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPL       Sequence           RLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLD                   LSDLEAEKLVMFQRRYYKPGLLLMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAA                   HLFGYRPYDKNISPREUILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYD                   RKKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO: 31   1420bp                             NOV3h,     ATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCACAGCTCTCTGGCTAACTAGAGAACCCA             212779051       DNA Sequence     CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAG   GGA GACCCAAGCTGGCTAGCGTTTAAA                   CTTAAGCTTGGTACCGAGCTCGGATCCACCATGCCGGCCCACTTGCTGCAGGACGATATCTCTAGCT                   CCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTT                   GGAGACGAPGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCC                   ACCTACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGT                   CTCTGCTACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCT                   TTGGGGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGC                   CACCGCTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCC                   AGAATGATGTCTATGAATGGGCTCGTGACCACCGGGCCCACCACAAGTTTTCAGAAACACATGCTGA                   TCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACACCCA                   GCTGTCAAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCC                   AGAGGAGGTACTACAAACCTGGCTTGCTGCTGATGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTA                   TTTCTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTT                   AATGCCACCTGGCTGGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTA                   GCCCCCGGGAGAATATCCTGGTTTCACTTGGAGCTCTGGGTGAGGGCTTCCACAACTACCACCACTC                   CTTTCCCTATGACTACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCATTGAT                   TGCATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGA                   TTAAAAGAACCGGAGATGGAAACTACAAGAGTGGCTGAGCGGCCGCTCGAGTCTAGAGGGCCCGTTT                   AAACCCGCTGATCAGCCTCCACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGT                   GCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCG                   CATTGTCTGAGTT                                             ORF Start: at 108       ORF Stop: TGA at 1242               SEQ ID NO:32   378 aa   MW at 43506.4kD                         NOV3h,   GDPSWLAFKLKLGTELGSTMPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRP           212779051       Protein   DIKDDIYDPTYKDKEGPSPKVEYVWRNTILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGI       Sequence           TAGAHRLWSHRSYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHV                   GWLLVRKHPAVKEKGSTLDLSDLEAEKLVMFQRRYYKPGLLLMCFILPTLVPWYFWGETFQNSVFVA                   TFLRYAVVLNATWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHIYHHSFPYDYSASEYRWH                   INFTTFFIDCMAALGLAYDRKKVSKAAILARIKRTGDGNYXSG                                         SEQ ID NO:33   5221 bp                             NOV3i,     ATAAAAGGGGGCTGAGGAAATACCGGACACGGTCACCCGTTGCCAGCTCTAGCCTTTAAATTCCCGGC             CG105521-01       DNA Sequence     TCGGGGACCTCCACGCACCGCGGCTAGCGCCGACAACCAGCTAGCGTGCAAGGCGCCGCGGCTCAGCC                       CGTACCGGCGGGCTTCGAAACCGCAGTCCTCCGGCGACCCCGAACTCCGCTCCGGAGCCTCAGCCCCC                       TGGAAAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCAGGACGATATCTCTAGCT                   CCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTG                   GAGACGATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCAC                   CTACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTC                   TGCTACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGG                   CGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTc~GAGCCACCG                   CTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATG                   ATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCAT                   AATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGCCTGCTTGTGCGCAAACACCCAGCTGTCAA                   AGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGT                   ACTACAAACCTGGCTTGCTGCTGATGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGT                   GAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTG                   GCTGGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCCGGGAGA                   ATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGAC                   TACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCT                   CGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCGTCTTGGCCAGGATTAAAAGAACCGGAG                   ATGGAAACTACAAGAGTGGC TGA   GTTTGGGGTCCCTCAGGTTTCCTTTTTCAAAAACCAGCCAGGCAG                       AGGTTTTAATGTCTGTTTATTAACTACTGAATAATGCTACCAGGATGCTAAAGATGATGATGTTAACC                       CATTCCAGTACAGTATTCTTTTAAAATTCAAAAGTATTGAAAGCCAACAACTCTGCCTTTATGATGCT                       AAGCTGATATTATTTCTTCTCTTATCCTCTCTCTCTTCTAGQCCCATTGTCCTCCTTTTCACTTTATT                       CCTATCGCCCTCCTTTCCCTTATTGCCTCCCAGGCAAGCAGCTGGTCAGTCTTTGCTCAGTGTCCAGC                       TTCCAAAGCCTAGACAACCTTTCTGTAGCCTAAAACGAATGGTCTTTGCTCCAGATAACTCTCTTTCC                       TTGAGCTGTTGTGAGCTTTGAAGTAGGTGGCTTGAGCTAGAGATAAAACAGAATCTTCTGGGTAGTCC                       CCTGTTGATTATCTTCAGCCCACGCTTTTGCTAGATGGAATGGAAAAGCAACTTCATTTCACACAAAC                       CTTCTAAAGCAGGTAAATTGTCGGGGGAGAGAGTTAGCATGTATGAATGTAAGGATGAGGGAAGCGAA                       CCAAGAGGAACCTCTCGCCATGATCAGACATACAGCTGCCTACCTAATGAGGACTTCAAGCCCCACCA                       CATAGCATGCTTCCTTTCTCTCCTGGCTCGGGGTAAAAAGTGGCTGCGGTGTTTGGCAATGCTAATTC                       AATGCCGCAACATATAGTTGAGGCCGAGGATAAAGAAAAGACATTTTAAGTTTGTAGTAAAAGTCGTC                       TCTGCTGGGGAAGGGTTTTCTTTTCTTTTTTTCTTTAATAACAAGGAGATTTCTTAGTTCATATATCA                       AGAAGTCTTGAAGTTGGGTGTTTCCAGAATTGGTAAAAACAGCAGCTCATGGAATTTTGAGTATTCCA                       TGAGCTGCTCATTACAGTTCTTTCCTCTTTCTGCTCTGCCATCTTCAGGATATTGGTTCTTCCCCTCA                       TAGTAATAAGATGGCTGTGGCATTTCCAAACATCCAAAAAAAGGGAAGGATTTAAGGAGGTGAAGTCG                       GGTCAAAAATAAAATATATATACATATATACATTGCTTAGAACGTTAAACTATTAGAGTATTTCCCTT                       CCAAAGAGGGATGTTTGCAAAAAACTCTGAAGGAGAGGAGGAATTAGTTGGGATGCCAATTTCCTCTC                       CACTGCTGGACATGAGATGGAGAGGCTGAGGGACAGGATCTATAGGCAGCTTCTAAGAGCGAACTTCA                       CATACGAAAGGATCTGAGAACACGTTCCCAGGGGCTTGAGAAGGTTACTGACTGAGTTATTGGGAGTC                       TTAATAAAATAAACTAGATATTAGGTCCATTCATTAATTAGTTCCAGTTTCTCCTTGAAATGAGTAAA                       AACTAGAAGGCTTCTCTCCACAGTGTTGTGCCCCTTCACTCATTTTTTTTTGAGGAGAAGGGGGTCTC                       TGTTAACATCTAGCCTAAAGTATACAACTGCCTGGGGGGCAGGGTTAGGAATCTCTTCACTACCCTGA                       TTCTTGATTCCTGGCTCTACCCTGTCTGTCCCTTTTCTTTGACCATATCTTTCTCTTCCCTGAACGTT                       TTCTTCTTTCCCTGGACAGGCAGCCTCCTTTGTGTGTATTCAGAGGCAGTGATGACTTGCTGTCCAGG                       CAGCTCCCTCCTGCACACAGAATGCTCAGGGTCACTGAACCACTGCTTCTCTTTTGAAAGTAGAGCTA                       GCTGCCACTTTCACGTGGCCTCCGCAGTGTCTCCACCTACACCCCTGTGCTCCCCTGCCACACTGATG                       GCTCAAGACAACGCTGGCAAACCCTCCCAGAAACATCTCTGGCCCAGAAAGCCTCTCTCTCCCTCCCT                       CTCTCATGAGGCACAGCCAAGCCAAGCGCTCATGTTGAGCCAGTGGGCCAGCCACAGAGCAAAAGAGG                     GTTTATTTTCAGTCCCCTCTCTCTGGGTCAGAACCAGAGGGCATGCTGAATGCCCCCTGCTTACTTGG                     TGAGGGTGCCCCGCCTGAGTCAGTGCTCTCAGCTGGCAGTGCAATGCTTCTAGAAGTAGGAGGAAACA                       GTTCTCACTGGGAAGAAGCAACGGCAAGAACCCAAGTGCCTCACCTCGAAAGGAGGCCCTGTTCCCTG                       GAGTCAGGGTGAACTGCAAAGCTTTGGCTGAGACCTGGGATTTGAGATACCACAAACCCTGCTGAACA                       CAGTGTCTGTTCAGCAAACThACCAGCATTCCCTACAGCCTAGGGCAGACAATAGTATAAAAGTCTGG                       AAAAAAACAAAAACAGAATTTGAGAACCTTGGACCACTCCTGTCCCTGTAGCTCAGTCATCAAAGCAG                       AAGTCTGGCTTTGCTCTATTAAGATTGGAAATGTACACTACCAAACACTCAGTCCACTGTTGAGCCCC                       AGTGCTGGAAGGGAGGAAGGCCTTTCTTCTGTGTTAATTGCGTAGAGGCTACAGGGGTTAGCCTGGAC                       TAAAGGCATCCTTGTCTTTTGAGCTATTCACCTCAGTAGAAAAGGATCTAAGGGAAGATCACTGTAGT                       TTAGTTCTOTTGACCTGTGCACCTACCCCTTGGAAATCTCTCCTGGTATTTCTAATTCCACAGGTCAT                       CAGATGCCTGCTTGATAATATATAAACAATAAAAACAACTTTCACTTCTTCCTATTGTAATCCTGTGC                       CATGGATCTGATCTGTACCATGACCCTACATAAGGCTGGATGGCACCTCAGGCTGAGGGCCCCAATGT                       ATGTGTGGCTGTGGGTGTGGGTGGGAGTGTGTCTGCTGAGTAAGGAACACGATTTTCAAGATTCTAAA                       GCTCAATTCAAGTGACACATTAATGATAAACTCAGATCTGATCAAGAGTCCGGATTTCTAACAGTCCC                       TGCTTTGGGGGGTGTGCTGACAACTTAGCTCAGGTGCCTTACATCTTTTCTAATCACAGTGTTGCATA                       TGAGCCTGCCCTCACTCCCTCTGCAGAATCCCTTTGCACCTGAGACCCTACTGAAGTGGCTGGTAGAA                       AAAGGGGCCTGAGTGGAGGATTATCAGTATCACGATTTCCAGGATTCCCTTCTGGGCTTCATTCTGGA                       AACTTTTGTTAGGGCTGCTTTTCTTAAGTGCCCACATTTGATGGAGGGTGGAAATAATTTGAATGTAT                       TTGATTTATAAGTTTTTTTTTTTTTTTGCGTTAAAAGATGGTTGTAGCATTTAAAATGGAAAATTTTC                       TCCTTGGTTTGCTAGTATCTTGGGTGTATTCTCTGTAAGTGTAGCTCAAATAGGTCATCATGAAAGGT                       TAAAAAAGCGAGGTGGCCATGTTATGCTGGTGGTTAAGGCCAGGGCCTCTCCAACCACTGTGCCACTG                       ACTTGCTGTGTGACCCTGGGCAAGTCACTTAACTATAAGGTGCCTCAGTTTTCCTTCTGTTAAAATGG                       GGATAATAATACTGACCTACCTCAAAGGGCAGTTTTGAGGCATGACTAATGCTTTTTAGAAAGCATTT                       TGGGATCCTTCAGCACAGGAATTCTCAAGACCTGAGTATTTTTTATAATAGGAATGTCCACCATGAAC                       TTGATACGTCCGTGTGTCCCAGATGCTGTCATTAGTCTATATGGTTCTCCAAGAAACTGAATGAATCC                       ATTGGAGAAGCCGTGGATAACTAGCCAGACAAAATTTGAGAATACATAAACAACGCATTGCCACGGAA                       ACATACAGACGATGCCTTTTCTGTGATTGGGTGGGATTTTTTCCCTTTTTATGTGGGATATAGTAGTT                       ACTTGTGACAAAAATAATTTTGGAATAATTTCTATTAATATCAACTCTGAAGCTAATTGTACTAATCT                       GAGATTGTGTTTGTTCATAATAAAGTGAAGTGAATCTAAAAAAAAAAAAAAAA                                               ORF Start: ATG at 236       ORF Stop: TGA at 1313               SEQ ID NO: 34   359 aa   MW at 41504.1kD                         NOV3i,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSPK           CG105521-01       Protein   VEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRL       Sequence           FLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSD                   LEAEKLVMFQRRYYKPGLLLMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFG                   YRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRXKVS                   KAAILARIRRTGDGNYKSG                                         SEQ ID NO:35   1089 bp                             NOV3j,     ACC ATGCCGGCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATACCACCACCACCACCATTACAGC           308782133       DNA Sequence   GCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGACGATGCCCCTCTACTTGGAAGACG                   ACATTCGCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAAGGAAGGCCCAAGCCCC                   AAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTGGGAGCCCTGTATGGGAT                   CACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCC                   TGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCACCGCTCTPACAAAGCTCGGCTGCCCCTACGG                   CTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATCATGTCTATGAATGGGCTCGTGACCACCG                   TGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTC                   ACGTGGGTTCGCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAAGCGGAGTACGCTAGACTTGTCT                   GACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGTACTACAAACCTGGCTTGCTGATGATGTG                   CTTCATCCTCCCCACGCTTGTGCCCTCGTATTTCTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTG                   CCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTGGCTGGTGAACAGTGCTGCCCACCTCTTC                   GCATATCGTCCTTATGACAAGAACATTAGCCCCCGGGAGAATATCCTCGTTTCACTTCGAGCTGTGGG                   TGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGACTACTCTGCCAGTGAGTACCGCTGGCACA                   TCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCCGAAGAAAGTC                   TCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GCAGG                       T                                               ORF Start: at 1       ORF Stop: TGA at 1081               SEQ ID NO:36   360 aa   MW at 41623.3kD                         NOV3j,   TMPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDKEGPSP           308782133       Protein   KVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLR       Sequence           LFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLS                   DLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLF                   GYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKV                   SKAAILARIKRTGDGNYKSG                                         SEQ ID NO:37   1104 bp                             NOV3k,     ACC ATGGGACATCATCACCACCATCACCCGGCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATA           CG105521-03       DNA Sequence   CCACCACCACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGAC                   GATGCCCCTCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCACCTAC                   AAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGC                   TACACTTGGGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGG                   CGTATTCTACTATTTTGTCAGTCCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCACCGC                   TCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATG                   ATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCA                   TAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACACCCAGCTGTC                   AAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGA                   GGTACTACAAACCTGGCTTGCTGATGATGTGCTTCATCCTCCCCACGCTTGTGCCCTGGTATTTCTG                   GGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCC                   ACCTGGCTGGTGAACAGTGCTCCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCC                   GGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCcACAAcTACCACCACTccTTTcc                   CTATGACTACTCTCCCAGTGAGTACCGCTCGCACATCAACTTCACCACATTCTTCATTGATGCATG                   GCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAA                   GAACCGOACATGGAAACTACAAGACTGGC TGA                                               ORF Start: at 1       ORF Stop: TGA at 1102               SEQ ID NO: 38   367 aa   MW at 42503.2kD                         NOV3k,   TMGHHHHHHPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMFLYLEDDIRPDIKDDIYDPTY           CG105521-03       Protein   KDKEGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGABRLWSHR       Sequence           SYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAV                   KEKGSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNA                   TWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCM                   AALGLAYDRKKVSKAAILARIKRTGDGNYKSG                                         SEQ ID NO:39   1138 bp                             NOV31,     GCCGAATTCTCAGCCCCTGGAAAGTGATCCCGGCATCCGAGAGCCAAG   ATG CCGGCCCACTTGCTGCA           CG105521-04       DNA Sequence   GGACGATATCTCTAGCTCCTATACCACCACCACCACCATTACAGCGCCTCCCTCCAGGCTCCTGCAGA                   ATGGAGGAGATAAGTTGGAGACGATGCCCCTCTACTTCGAAGACGACATTCGCCCTGATATAAAAGAT                   GATATATATGACCCCACCTACAAGGATAAGGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAA                   CATCATCCTTATGTCTCTGCTACACTTGGGAGCCCTGTATGCGATCACTTTGATTCCTACCTGCAAGT                   TCTACACCTGGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCAT                   CGTCTGTGGAGCCACCGCTCTTACAAAGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACAC                   AATCGCATTCCAGAATGATGTCTATGAATGGGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAC                   CACATGCTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTCCGC                   AAACACCCAGCTGTCAAAGAGAAGGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGT                   GATGTTCCAGAGGAGGTACTACAAACCTGGCTTGCTGATGATGTGCTTCATCCTGCCCACGCTTGTGC                   CCTGGTATTTCTGGGGTGAAACTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTG                   GTGCTTAATGCCACCTGGCTGGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAA                   CATTAGCCCCCGGGAGAATATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACC                   ACTCCTTTCCCTATGACTACTCTGCCAGTGAGTACCGCTGCCACATCAACTTCACCACATTCTTCATT                   GATTGCATGGCCGCCCTCGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAG                   GATTAAAAGAACCGGAGATGGAAACTACAAGAGTGGC TGA   GGATCCGGTG                                               ORF Start: ATG at 49       ORF Stop: TGA at 1126               SEQ ID NO: 40   359 aa   MW at 41522.2kD                         NOV31,   MPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDTYDPTYKDKEGPSPK           CG105521-04       Protein   VEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRL       Sequence           FLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSD                   LEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFG                   YRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVS                   KAAILARIKRTGDGNYKSG                                         SEQ ID NO:41   1129 bp                             NOV3m,   ACATCATCACCACCATCACCCGGCCCACTTGCTGCAGGACGATATCTCTAGCTCCTATACCACCACC           CG105521-05       DNA Sequence   ACCACCATTACAGCGCCTCCCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTGGAGACGATGCCCC                   TCTACTTGGAAGACGACATTCGCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAA                   GGAAGGCCCAAGCCCCAAGGTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTG                   GGAGCCCTGTATGGGATCACTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGGGTATTCT                   ACTATTTTGTCAGTGCCCTGGGCATAACAGCAGGAGCTCATCGTCTGTGGAGCCACCGCTCTTACAA                   AGCTCGGCTGCCCCTACGGCTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATGATGTCTAT                   GAATGCGCTCGTGACCACCGTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCC                   GACGTGGCTTTTTCTTCTCTCACGTGGGTTGGCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAA                   GGGGAGTACGCTAGACTTGTCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGOAGGTACTAC                   AAACCTGGCTTGCTGATGATGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGTGAAA                   CTTTTCAAAACAGTGTGTTCGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTGGCT                   GGTGAACAGTGCTGCCCACCTCTTCGGATATCGTCCTTATGACAAGAACATTAGCCCCCGGGAGAAT                   ATCCTGGTTTCACTTGGAGCTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGACT                   ACTCTGCCAGTGAGTACCGCTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCT                   CGGTCTGGCCTATGACCGGAAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGA                   GATGGAAACTACAAGAGTGGC TGA   GCCGCCGCACTCGAGCACCACCACCACCACCAC                                               ORF Start: at 2       ORF Stop: TGA at 1094               SEQ ID NO: 42   364 aa   MW at 42213.9W                         NOV3m,   HHHHHHPAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDIKDDIYDPTYKDK           CG105521-05       Protein   EGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGARRLWSHRSYK       Sequence           ARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEK                   GSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWL                   VNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAAL                   GLAYDRKKVSKAAILARIKRTGDGNYXSG                                         SEQ ID NO:43   1116 bp                             NOV3n,   CCGGCCCACTTGCTGCAGGACGATATCTCTACCTCCTATACCACCACCACCACCATTACAGCGCCTC           CG105521-06       DNA Sequence   CCTCCAGGGTCCTGCAGAATGGAGGAGATAAGTTOGAGACGATGCCCCTCTACTTGGAAGACGACAT                   TCGCCCTGATATAAAAGATGATATATATGACCCCACCTACAAGGATAAGGAAGGCCCAAGCCCCAAG                   GTTGAATATGTCTGGAGAAACATCATCCTTATGTCTCTGCTACACTTGGGAGCCCTGTATGGGATCA                   CTTTGATTCCTACCTGCAAGTTCTACACCTGGCTTTGGGGGGTATTCTACTATTTTGTCAGTGCCCT                   GGGCATAACAGCAGGAGCTCATCGTCTGTCGAGCCACCGCTCTTACAAAGCTCCGCTGCCCCTACCG                   CTCTTTCTGATCATTGCCAACACAATGGCATTCCAGAATGATGTCTATGAATGGGCTCGTGACCACC                   GTGCCCACCACAAGTTTTCAGAAACACATGCTGATCCTCATAATTCCCGACGTGGCTTTTTCTTCTC                   TCACGTGGGTTGGCTGCTTGTGCGCAAACACCCAGCTGTCAAAGAGAAGGGGAGTACGCTAGACTTG                   TCTGACCTAGAAGCTGAGAAACTGGTGATGTTCCAGAGGAGGTACTACAAACCTGGCTTGCTGATGA                   TGTGCTTCATCCTGCCCACGCTTGTGCCCTGGTATTTCTGGGGTGAAACTTTTCAAAACAGTGTGTT                   CGTTGCCACTTTCTTGCGATATGCTGTGGTGCTTAATGCCACCTGGCTGGTGAACAGTGCTGCCCAC                   CTCTTCCGATATCGTCCTTATGACAAGAACATTAGCCCCCCGGAGAATATCCTGGTTTCACTTGGAG                   CTGTGGGTGAGGGCTTCCACAACTACCACCACTCCTTTCCCTATGACTACTCTCCCAGTGAGTACCG                   CTGGCACATCAACTTCACCACATTCTTCATTGATTGCATGGCCGCCCTCGGTCTGGCCTATGACCGG                   AAGAAAGTCTCCAAGGCCGCCATCTTGGCCAGGATTAAAAGAACCGGAGATGGAAACTACAAGAGTG                   GCTGAGCAGGTGCGGCCGCACTCGAGCACCACCACCACCACCAC                                             ORF Start: at 1       ORF Stop: TGA at 1075               SEQ ID NO:44   358 aa   MW at 41391.0kD                         NOV3n,   PAHLLQDDISSSYTTTTTITAPPSRVLQNGGDKLETMPLYLEDDIRPDTKDDIYDPTYKDKEGPSPK           CG105521-06       Protein   VEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLR       Sequence           LFLIIANTMAEQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDL                   SDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAH                   LFGYRPYDKNISPRENTLVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDR                   KKVSKAAILARIKRTGDGNYKSG                  
 
     [0364] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 3B.  
               TABLE 3B                          Comparison of NOV3a against NOV3b through NOV3n.                                         Identities/                   Similarities for           Protein   NOV3a Residues/   the Matched           Sequence   Match Residues   Region                       NOV3b   1 . . . 359   346/359 (96%)               1 . . . 359   347/359 (96%)           NOV3c   1 . . . 359   346/359 (96%)               5 . . . 363   347/359 (96%)           NOV3d   1 . . . 359   347/359 (96%)               1 . . . 359   347/359 (96%)           NOV3e   2 . . . 359   345/358 (96%)               1 . . . 358   346/358 (96%)           NOV3f   2 . . . 359   345/358 (96%)               7 . . . 364   346/358 (96%)           NOV3g   1 . . . 359   347/359 (96%)               1 . . . 359   347/359 (96%)           NOV3h   1 . . . 359   347/359 (96%)               20 . . . 378    347/359 (96%)           NOV3i   1 . . . 359   347/359 (96%)               1 . . . 359   347/359 (96%)           NOV3j   1 . . . 359   346/359 (96%)               2 . . . 360   347/359 (96%)           NOV3k   2 . . . 359   345/358 (96%)               10 . . . 367    346/358 (96%)           NOV3l   1 . . . 359   346/359 (96%)               1 . . . 359   347/359 (96%)           NOV3m   2 . . . 359   345/358 (96%)               7 . . . 364   346/358 (96%)           NOV3n   2 . . . 359   345/358 (96%)               1 . . . 358   346/358 (96%)                      
 
     [0365] Further analysis of the NOV3a protein yielded the following properties shown in Table 3C.  
               TABLE 3C                       Protein Sequence Properties NOV3a                                                PSort   0.6000 probability located in plasma membrane;           analysis:   0.4000 probability located in Golgi body;               0.3000 probability located in endoplasmic               reticulum (membrane); 0.3000 probability located               in microbody (peroxisome)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0366] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3D.  
               TABLE 3D                          Geneseq Results for NOV3a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV3a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               ABB44583   Human wound healing   1 . . . 359    359/359 (100%)   0.0           related polypeptide SEQ ID   1 . . . 359    359/359 (100%)           NO 40 -  Homo sapiens , 359           aa. [CA2325226-A1,           17 MAY 2001]       AAY69378   Amino acid sequence of   1 . . . 359    359/359 (100%)   0.0           human skin stearoyl-CoA   1 . . . 359    359/359 (100%)           desaturase -  Homo sapiens ,           359 aa. [WO200009754-A2,           24 FEB. 2000]       AAY69377   Amino acid sequence of   1 . . . 359   298/359 (83%)   0.0           murine skin stearoyl-CoA   1 . . . 359   334/359 (93%)           desaturase (M-SCD4v1) -           Mus sp, 359 aa.           [WO200009754-A2,           24 FEB. 2000]       ABB44582   Mouse wound healing related   1 . . . 359   297/359 (82%)   0.0           polypeptide SEQ ID NO 39 -   1 . . . 358   327/359 (90%)             Mus musculus , 358 aa.           [CA2325226-A1,           17 MAY 2001]       AAR25853   MSH-dependent protein obtd.   1 . . . 359   290/360 (80%)   e−179           from hamster flank organ -   1 . . . 354   324/360 (89%)             Mesocricetus auratus , 354 aa.           [JP04179481-A,           26 JUN. 1992]                  
 
     [0367] In a BLAST search of public sequence datbases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3E.  
               TABLE 3E                          Public BLASTP Results for NOV3a                                             Identities/           Protein           Similarities for       Accession       NOV3a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         O00767   Acyl-CoA desaturase (EC   1 . . . 359   358/359 (99%)   0.0           1.14.99.5) (Stearoyl-CoA   1 . . . 359   359/359 (99%)           desaturase) (Fatty acid           desaturase)           (Delta(9)-desaturase) -  Homo               sapiens  (Human), 359 aa.       Q9P1L1   Acyl-CoA desaturase (EC   38 . . . 359    321/322 (99%)   0.0           1.14.99.5) (Stearoyl-CoA   1 . . . 322   322/322 (99%)           desaturase) (Fatty acid           desaturase)           (Delta(9)-desaturase) -  Homo               sapiens  (Human), 322 aa.       O62849   Acyl-CoA desaturase (EC   1 . . . 359   312/359 (86%)   0.0           1.14.99.5) (Stearoyl-CoA   1 . . . 359   342/359 (94%)           desaturase) (Fatty acid           desaturase)           (Delta(9)-desaturase) -  Ovis               aries  (Sheep), 359 aa.       Q9BG81   Acyl-CoA desaturase (EC   1 . . . 359   312/359 (86%)   0.0           1.14.99.5) (Stearoyl-CoA   1 . . . 359   342/359 (94%)           desaturase) (Fatty acid           desaturase)           (Delta(9)-desaturase) -  Capra               hircus  (Goat), 359 aa.       Q95MI7   Stearoyl coenzyme A   1 . . . 359   312/359 (86%)   0.0           desaturase (EC 1.14.99.5) -   1 . . . 359   341/359 (94%)             Capra hircus  (Goat), 359 aa.                  
 
     [0368] PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3F.  
               TABLE 3F                          Domain Analysis of NOV3a                                             Identities/                       Similarities for           Pfam   NOV3a   the Matched   Expect           Domain   Match Region   Region   Value                       Desaturase   77 . . . 321   154/248 (62%)   2.9e−164                   231/248 (93%)                      
 
     Example 4  
     [0369]               TABLE 4A                       NOV4 Sequence Analysis                                                    SEQ ID NO: 45   1346 bp                             NOV4a,     TGGAACTCCAGGATACACTCCCCTCCTGCTACCTAGGCAGGCGTGAGGGTGTGACGGCCGCGCATTCG             CG107234-01       DNA Sequence     CCAGACGAGAGCG   ATG CTGACAACGCCGCACCAGGTCTGATCTCAGAGCTGGGCTGGCTGTGCCCT                   GGGGCCACATCGCAGCCAAAGCCTGGGGCTCCCTGCACGGCCCTCCAGTTCTCTGCCTGCACGGCTGG                   CTGGACAATGCCAGCTCCTTCGACAGACTCATCCCTCTTCTCCCGCAAGACTTTTATTACGTTGCCAT                   GGATTTCGGAGGTCATGGGCTCTCGTCCCATTACAGCCCAGGTGTCCCATATTACCTCCAGACTTTTG                   TGAGTGAGATCCGAAGAGTTGTGGCAGCCTTGAAATGGAATCGATTCTCCATTCTGGGCCACAGCTTC                   GGTGGCGTCGTGGGCGGAATGTTTTTCTGTACCTTCCCCGAGATGGTGGATCCGATCTTATCTTGCTA                   CACGCCGCTCTTTCTCCTCGAATCAGATGAAATGGAGAACTTGCTGACCTACAGGCGGAGAGCCATAG                   AGCACGTCCTCCAGGTAGAGGCCTCCCAGGAGCCCTCGCACGTGTTCAGCCTGAAGCAGCTGCTGCAG                   AGGCAGAGAACAGCATTGACTTCGTCAGCAGGGAGCTGTGTGCGCATTCCATCATAGAGCTGCAGGCC                   CATGTCCTGTTGATCAAAGCAGTCCACGGATATTTTGATCCAAGAGAGAGATTACTCTGACGGGAGTC                   CCTGTCGTTCATGATAGACACAATGAATCCACCCTCAAGAGGACTACTTCGTAATACGTTCACAGCAA                   ACCCTGGCCTCGGCCCTGCCCTGTCCCTGCCATGCAACTTCACAACTCAGCTGGCCTAGACCCCTGGC                   AGGCCTCCAAGTCCCTAAGCGGTTCCAGTTTGTGGAAGTCCCAGGCAATCACTGTGTCCACATGAGCG                   AACCCCAGCACGTGGCCAGTATCATCAGCTCCTTCTTACAGTGCACACACACGCTCCCAGCCCAGCTG                   TAGCTCTGGGCCTGGAACTATGAAGACCTAGTGCTCCCAGACTCGACACTGGGACTCTGAGTGCCTGA                   GCCCCACAACAAGGCCAGGGATGGTGTGGACAGGCCTCACTAGTCTTGAGGCCCAGCCTAGGATGGTG                   GTCAGGGGAAGGAGCGAGATTCCAACTTCAACATCTGTGACCTCAAGGGGGAGACAGAGTCTGGGTTC                   CAGGGCTGCTGTCTCCTGGCTAATAATCTCCAGCCAGCTGGAGGAAGGAAGGGCGGGCTGGGCCCACC                                             ORF Start: ATG at 82       ORF Stop: TGA at 691               SEQ ID NO: 46   203 aa   MW at 22470.7kD                         NOV4a,   MAENAAPGLISELKLAVPWGHIAAKAWGSLQGPPVLCLHGWLDNASSFDRLIPLLPQDFYYVAMDFGG           CG107234-01       Protein   HGLSSHYSPGVPYYLQTFVSEIRRVVAALKWNRFSILGHSFGGVVGGMFFCTFPEMVDKLILLDTPLF       Sequence           LLESDEMENLLTYKRRAIEHVLQVEASQEPSHVFSLKQLLQRQRTALTSSAGSCVRIPSGSCRPMSC                                         SEQ ID NO:47   937 bp                             NOV4b,   CGGGACGAGAGCGATGAGTGAGAACGCCGCACCAGGTCTGATCTCAGAGCTGAAGCTGGCTGTGCCC           CG107234-03       DNA Sequence   TGGGGCCACATCGCAGCCAAAGCCTGGGGCTCCCTGCAGGGCCCTCCAGTTCTCTGCCTGCACGGCT                   GGCTGGACAATGCCAGCTCCTTCGACAGACTCATCCCTCTTCTCCCGCATGACTTTTATTACGTTGC                   CATGGATTTCGGAGGTCATGGGCTCTCGTCCCATTACAGCCCAGGTGTCCCATATTACCTCCAGACT                   TTTGTGAGTCACATCCGAAGAGTTGTGGCAGGTGGCGTCGTGGGCGGAGTGTTTTTCTGTACCTTCC                   CCGAGATGGTGGATAAACTTATCTTGCTGGACACGCCGCTCTTTCTCCTGGAATCAGATGAAATGGA                   GAATTGCTGACCTACAAGCGAGAGCCATAGAGCACGTGCTGCACGTAGAGTCCTCCCATTAGAGCCC                   TCGCACGTGTTCAGCCTGAAGCAGCTGCTGCAGAGGTTACTGAAGAGCAATAGCCACTTGAGTGAGG                   AGTGCGGGAGCTTCTCCTGCAAGAGAACCACGAAGGTGGCCACAGGTCTGGTTCTGTCGATCAGAGA                   CCAGAGGCTCGCCTGGGCAGAGAACACCATTGACTTCATCACCAGGGAGCTGTGTGCGCATTCCATC                   AGGAAGCTGCAGGCCCATGTCCTGTTGATCAAAGCAGTCCACGGATATTTTGATTCAAGACAGAATT                   ACTCTGAGAAGGAGTCCCTGTCGTTCATGATAGACACGATGAAATCCACCCTCAAAGAGCAGTTCCA                   GTTTGTGGAAGTCCCAGGCAATCACTGTGTCCACATGAGCGAACCCCAGCACGTGGCCAGTATCATC                     AGCTCCTTCTTACAGCGCACACACATGCTCCCAGCCCAGCTGTAGCTCTGGGCCTGGAACTATGAA                                               ORF Start: ATG at 14       ORF Stop: TAG at 914               SEQ ID NO: 48   300 aa   MW at 33777.6kD                         NOV4b,   MSENAAPGLISELKLAVPWGHIAAKAWGSLQGPPVLCLHGWLDNASSFDRLIPLLPQDFYYVAMDFG           CG107234-03       Protein   GHGLSSHYSPGVPYYLQTFVSEIRRVVAGGVVGGMEFCTFPEMVDKLILLDTPLFLLESDEMEKLLT       Sequence           YKRRAIEHVLQVEASQEPSHVFSLKQLLQRLLKSNSHLSEECGELLLQRGTTKVATGLVLNRDQRLA                   WAENSIDFISRELCAHSIRKLQAHVLLIKAVHGYFDSRQNYSEKESLSFMIDTMKSTLKEQFQFVEV                   PGNHCVHMSEPQHVASIISSFLQRTHMLPAQL                                         SEQ ID NO: 49   1058 bp                             NOV4c,     CGGGACGAGAGCG   ATG AGTGAGAACGCCGCACCAGGTCTGATCTCAGAGCTGAAGCTGGCTGTGCCCT           CG107234-02       DNA Sequence   GGGGCCACATCGCAGCCAAAGCCTGGGGCTCCCTGCAGGGCCCTCCAGTTCTCTGCCTGCACGGCTGG                   CTGGACAATGCCAACTCCTTCGACAGACTCATCCCTCTTCTCCCGCAAGACTTTTATTACGTTGCCAT                   GGATTTCGGAGGTCATGGGCTCTCGTCCCATTACAGCCCAGGTGTCCCATATTACCTCCAGACTTTTG                   TGAGTGAGATCCGAAGAGTTGTGGCAGCCTTGAAATGGAATCGATTCTCCATTCTGGGCCACAGCTTC                   GGTGGCGTCCTGGGCGGAATGTTTTTCTGTACCTTCCCCGAGATGGTGGATAAACTTATCTTGCTGGA                   CACGCCGCTCTTTCTCCTGGAATCAGATGAAATGGAGAACTTGCTGACCTACAAGCGGAGAGCCATAG                   AGCACGTGCTGCAGGTAGAGGCCTCCCAGOAGCCCTCGCACGTGTTCAGCCTGAAGCAGCTGCTGCAG                   AGGTTACTGAAGAGCAATAGCCACTTGAGTGAGGAGTGCGGGGAGCTTCTCCTGCAAAGAGGAACCAC                   GAAGGTGGCCACAGAGATGGAGTTTCGCCATGTTGCCCAGGCTGGTCTCGAACTCCTGAACTCAAGCG                   ATCCTACTGACTCGACCTCCCAAAATGGTCTGGTTCTGAACAGAGACCAGAGGCTCGCCTGGGCAGAG                   AACAGCATTGACTTCATCAGCAGGGAGCTGTGTGCGCATTCCATCAGGAAGCTGCAGGCCCATGTCCT                   GTTGATCAAAGCAGTCCACGGATATTTTGATTCAAGACAGAATTACTCTGAGAAGGAGTCCCTGTCGT                   TCATGATAGACACGATGAAATCCACCCTCAAAGAGCAGTTCCAGTTTGTGGAAGTCCCAGGCAATCAC                   TGTGTCCACATGAGCGAACCCCAGCACGTGGCCAGTATCATCAGCTCCTTCTTACAGCGCACACACAT                   GCTCCCAGCCCAGCTGTAGCTCTGGGCCTGGAACTATG                                             ORF Start: ATG at 14       ORF Stop: TAG at 1037               SEQ ID NO: 50   341 aa   MW at 38407.6kD                         NOV4c,   MSENAAPGLISELKLAVPWGHIAAKAWGSLQGPPVLCLHGWLDNANSFDRLIPLLPQDFYYVAMDFGG           CG107234-02       Protein   HGLSSHYSPGVPYYLQTFVSEIRRVVAALKWNRFSILGHSFGGVVGGMFFCTFPEMVDKLILLDTPLF       Sequence           LLESDEMENLLTYKRRAIEHVLQVEASQEPSHVFSLKQLLQRLLKSNSHLSEECGELLLQRGTTKVAT                   EMEERHVAQAGLELLNSSDPTDSTSQNGLVLNRDQRLAWAENSIDFISRELCAHSIRKLQAHVLLIKA                   VHGYFDSRQNYSEKESLSFMIDTMKSTLKEQEQFVEVPGNHCVHMSEPQHXTASHSSFLQRTHMLPAQ                   L                    
     [0370] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 4B.  
               TABLE 4B                          Comparison of NOV4a against NOV4b and NOV4c.                                         Identities/                   Similarities for           Protein   NOV4a Residues/   the Matched           Sequence   Match Residues   Region                       NOV4b   1 . . . 170   145/170 (85%)               1 . . . 156   146/170 (85%)           NOV4c   1 . . . 170   168/170 (98%)               1 . . . 170   170/170 (99%)                      
 
     [0371] Further analysis of the NOV4a protein yielded the following properties shown in Table 4C.  
               TABLE 4C                       Protein Sequence Properties NOV4a                                                PSort   0.6072 probability located in microbody           analysis:   (peroxisome); 0.4500 probability located               in cytoplasm; 0.1930 probability located               in lysosome (lumen); 0.1000 probability               located in mitochondrial matrix space           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0372] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D.  
               TABLE 4D                          Geneseq Results for NOV4a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV4a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAY71117   Human Hydrolase protein-15   1 . . . 178   177/178 (99%)    e−102           (HYDRL-15) -  Homo     1 . . . 178   178/178 (99%)             sapiens , 314 aa.           [WO200028045-A2,           18 MAY 2000]       AAU23386   Novel human enzyme   1 . . . 178   175/178 (98%)    e−100           polypeptide #472 -  Homo     10 . . . 187    176/178 (98%)             sapiens , 323 aa.           [WO200155301-A2,           02 AUG. 2001]       AAM39135   Human polypeptide SEQ ID   1 . . . 98     94/98 (95%)   1e−51           NO 2280 -  Homo sapiens ,   1 . . . 98     96/98 (97%)           150 aa. [WO200153312-A1,           26 JUL. 2001]       ABB60261     Drosophila melanogaster     12 . . . 132     58/122 (47%)   4e−28           polypeptide SEQ ID NO 7575 -   41 . . . 162     77/122 (62%)             Drosophila melanogaster ,           331 aa. [WO200171042-A2,           27 SEP. 2001]       ABB68618     Drosophila melanogaster     12 . . . 177     61/171 (35%)   2e−27           polypeptide SEQ ID NO   8 . . . 176    98/171 (56%)           32646 -  Drosophila               melanogaster , 342 aa.           [WO200171042-A2,           27 SEP. 2001]                  
 
     [0373] In a BLAST search of public sequence datbases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E.  
               TABLE 4E                          Public BLASTP Results for NOV4a                                             Identities/           Protein           Similarities for       Accession       NOV4a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               Q9NQF3   Putative serine hydrolase-like   1 . . . 203    203/203 (100%)    e−117           protein (EC 3.1.-.-) -  Homo     1 . . . 203    203/203 (100%)             sapiens  (Human), 203 aa.       Q9H4I8   Serine hydrolase-like protein   1 . . . 178   177/178 (99%)    e−101           (EC 3.1.-.-) -  Homo sapiens     1 . . . 178   178/178 (99%)           (Human), 314 aa.       Q9EPB5   Serine hydrolase-like protein   8 . . . 177   127/171 (74%)   1e−71           (EC 3.1.-.-) (SHL) -  Mus     2 . . . 172   145/171 (84%)             musculus  (Mouse), 311 aa.       BAC04444   CDNA FLJ37553 fis, clone   1 . . . 114   111/114 (97%)   2e−61           BRCAN2028338, moderately   1 . . . 114   111/114 (97%)           similar to  Mus musculus             serine hydrolase protein,           isoform 2 -  Homo sapiens             (Human), 146 aa.       O18391   Probable serine hydrolase   12 . . . 132     58/122 (47%)   1e−27           (EC 3.1.-.-) (Kraken protein) -   41 . . . 162     77/122 (62%)             Drosophila melanogaster             (Fruit fly), 331 aa.                  
 
     [0374] PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4F.  
               TABLE 4F                          Domain Analysis of NOV4a                                     Identities/                   Similarities for       Pfam   NOV4a   the Matched   Expect       Domain   Match Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 5  
     [0375] The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.  
               TABLE 5A                       NOV5 Sequence Analysis                                                    SEQ ID NO:51   2109 bp                             NOV5a,     CGCGCAGCCCGCCGGAGTGGTCGGGGCCCGCGGCCGCTCGCGCCTCTCG   ATG GGCAGCTCGCACTTGC           CG113144-01       DNA Sequence   TCAACAAGGGCCTGCCGCTTCGCGTCCGACCTCCGATCATGAACGGGCCCCTGCACCCGCGGCCCCTG                   GTGGCATTGCTGGATGGCCGGGACTGCACAGTGGAGATGCCCATCCTGAAGGACGTCCCCACTGTGGC                   CTTCTGCGACGCGCAGTCCACGCAGGAGATCCATGAGAAGGTCCTGAACGAGGCTGTGGGGGCCCTGA                   TGTACCACACCATCACTCTCACCACGGAGGACCTGGAGAAGTTCAAAGCCCTCCGCATCATCGTCCGG                   ATTCGCAGTGGTTTTGACAACATCGACATCAAGTCGGCCGGGGATTTAGGCATTGCCGTCTGCAACGT                   GCCCGCGGCGTCTGTGGAGGAGACGGCCGACTCGACCCTGTGCCACATCCTGAACCTGTACCGGCGGG                   CCACCTCGCTGCACCAGGCGCTGCGGGAGGGCACACGAGTCCAGAGCGTCGAGCAGATCCGCGAGGTG                   GCGTCCGGCGCTGCCAGGATCCGCGGGGAGACCTTGGGCATCATCCGACTTGGTCGCGTGGGGCAGGC                   AGTGGCGCTGCGGGCCAAGGCCTTCGGCTTCAACGTGCTCTTCTACGACCCTTACTTGTCGGATGGCG                   TGGAGCGGGCGCTGGGGCTGCAGCGTGTCAGCACCCTGCAGGACCTGCTCTTCCACAGCGACTGCGTG                   ACCCTGCACTGCGCCCTCAACGAGCACAACCACCACCTCATCAACGACTTCACCGTCAAGCAGATGAG                   ACAAGGGGCCTTCCTGGTGAACACAGCCCGGGGTGGCCTGGTGGATGAGAAGGCGCTGGCCCAGGCCC                   TGAAGGAGGGCCGGATCCCCGGCGCGGCCCTGGATGTGCACGAGTCCGAACCCTTCAGCTTTAGCCAG                   GGCCCTCTGAAGGATGCACCCAACCTCATCTGCACCCCCCATGCTGCATGGTACAGCGAGCAGGCATC                   CATCGAGATGCGAGAGGAGGCGGCACGGGAGATCCGCAGAGCCATCACAGGCCGGATCCCAGACAGCC                   TGAAGAACTGTGTCAACAAGGACCATCTGACAGCCGCCACCCACTGGGCCAGCATGGACCCCGCCGTC                   GTGCACCCTGAGCTCAATGGGGCTGCCTATAGGTACCCTCCGGGCGTGGTGGGCGTGGCCCCCACTGG                   CATCCCAGCTGCTGTGGAAGGTATCGTCCCCAGCGCCATGTCCCTGTCCCACGGCCTGCCCCCTGTGG                   CCCACCCGCCCCACGCCCCTTCTCCTGGCCAAACCGTCAAGCCCGAGGCGGATAGAGACCACGCCAGT                   GACCAGTTG TAG   CCCGGGACGAGCTCTCCAGCCTCGGCGCCTGGGGCAGCGGGCCCGGAAACCCTCGA                       CCAGAGTGTGTGAGAGCATGTGTGTGGTGGCCCCTGTACACTGCAGAACTGGTCCGGGCTGTCAGGAG                       GGCGGGAGGGCGCAGCGCTGGGCCTCGTGTCGCTTGTCGTCCGTCCTGTGGGCGCTCTGCCCTGTGTC                       CTTCGCGTTCCTCGTTAAGCAGAAGAAGTCAGTAGTTATTCTCCCATGAACGTTCTTGTCTGTGTACA                       GTTTTTAGAACATTACAAAGGATCTGTTTGCTTAGCTGTCAACAAAAAGAAAACCTGAAGGAGCATTT                       GGAAGTCAATTTGAGGTTTTTTTTTTTGGTTTTTTTTTTTTTOTATTTTGGAACGTGCCCCAGAATGA                       GGCAGTTGGCAAACTTCTCAGGACAATGAATCTTCCCGTTTTTCTTTTTATGCCACACACTGCATTGT                       TTTTTCTACCTGCTTGTCTTATTTTTAGCATAATTTAGAAAAACAAAACAAAGGCTGTTTTTCCTAAT                       TTTGGCATCAACCCCCCCTTGTTCCAAAATGAAGACGGCATCATCACGAACCAGCTCCAAAAGGAAAA                       GCTTGGCAGGTGCCCTCGTCCTGGGGACGTGGAGGGTGGCACGCTCCCCGCCTGCACCAGTGCCGTCC                       TGCTGATGTGGTAGGCTAGCAATATTTTGGTTAAAATCATGTTTGTGGCCGAACGGGCCCCTGCACCC                       G                                               ORF Start: ATG at 50       ORF Stop: TAG at 1370               SEQ ID NO: 52   440 aa   MW at 47534.7kD                         NOV5a,   MGSSHLLNXGLPLGVRPPINNGPLHPRPLVALLDGRDCTVEMPILKDVATVAFCDAQSTQEIHEKVLN           CG113144-01       Protein   EAVGALMYHTITLTREDLEKFKALRIIVRIGSGFDNIDIKSAGDLGIAVCNVPAASVEETADSTLCHI       Sequence           LNLYRRATWLHQALREGTRVQSVEQIREVASGAARIRGETLGIIGLGRVGQAVALRAKAFGFNVLFYD                   PYLSDGVERALGLQRVSTLQDLLFHSDCVTLHCGLNEHNHHLINDFTVKQMRQGAFLVNTARGGLVDE                   KALAQALKEGRIRGAALDVHESEPFSFSQGPLKDAPNLICTPHAAWYSEQASIEMREEAAREIRRAIT                   GRIPDSLKNCVNKDHLTAATHWASMDPAVVHPELNGAAYRYPPGVVGVAPTGIPAAVEGIVPSAMSLS                   HGLPPVAHPPHAPSPGQTVKPEADRDHASDQL                                         SEQ ID NO:53   2125 bp                             NOV5b,   TATTAAGAGATGTCAGGCGTCCGACCTCCGATCATGAACGGGCCCCTGCACCCGCGGCCCCTGGTCG           CG113144-02       DNA Sequence   CATTGCTGGATGGCCGGGACTGCACAGTGGAGATGCCCATCCTGAAGGACGTGGCCACTGTGGCCTT                   CTGCGACGCGCAGTCCACGCAGCAGATCCATGAGAAGGTCCTGAACGAGGCTGTGGGGGCCCTGATG                   TACCACACCATCACTCTCACCAGGGAGGACCTGGACAAGTTCAAACCCCTCCGCATCATCGTCCGGA                   TTGGCAGTCGTTTTGACAACATCGACATCAAGTCGGCCGGGGATTTAGGCATTGCCGTCTGCAACGT                   GCCCGCGGCGTCTGTGGAGGAGACGGCCGACTCGACGCTGTGCCACATCCTGAACCTGTACCGGCGG                   GCCACCTCGCTGCACCAGCCGCTGCGGGAGGGCACACGAGTCCAGAGCGTCGAGCAGATCCGCGAGG                   TGGCCTCCGGCGCTGCCAGGATCCGCGGGGAGACCTTGCGCATCATCGGACTTCGTCCCGTGGCGCA                   GCCAGTGGCGCTGCGCGCCAAGGCCTTCGGCTTCAACGTGCTCTTCTACGACCCTTACTTGTCGGAT                   GGCGTGGAGCGGGCGCTGGGGCTGCAGCGTGTCAGCACCCTGCAGCACCTCCTCTTCCACACCGACT                   GCGTGACCCTGCACTCCGGCCTCAACGAGCACAACCACCACCTCATCAACGACTTCACCGTCAACCA                   GATGAGACAAGGGGCCTTCCTGGTGAACACAGCCCGGGGTGGCCTCGTCGATCAGAACCCGCTGGCC                   CAGGCCCTGAAGGAGGGCCGCATCCGCGGCGCGGCCCTGGATGTGCACGAGTCGGAACCCTTCAGCT                   TTAGCCAGGGCCCTCTGAAGGATGCACCCAACCTCATCTGCACCCCCCATCCTCCATCGTACACCGA                   GCAGCCATCCATCGAGATGCGAGAGGAGGCGGCACGGGAGATCCGCAGAGCCATCACAGGCCGGATC                   CCAGACAGCCTGAAGAACTGTGTCAACAAGGACCATCTGACAGCCGCCACCCACTCCGCCAGCATGC                   ACCCCCCCGTCGTGCACCCTGAGCTCAATGGCGCTGCCTATAGCAGGTACCCTCCGGGCGTGGTGGG                   CGTGGCCCCCACTGGCATCCCAGCTGCTGTGGAAGOTATCGTCCCCAGCGCCATGTCCCTCTCCCAC                   GGCCTGCCCCCTGTCGCCCACCCCCCCCACGCCCCTTCTCCTGCCCAAACCGTCAAGCCCGACGCGG                   ATAGAGACCACGCCAGTGACCAGTTG TAG   CCCGGGAGGACCTCTCCAGCCTCGGCGCCTGGGCAGAG                       GGCCCGGAAACCCTCGGACCAGACTGTCTGCAGGAGGCATCTGTGTCCTGGCCCTGGCACTGCAGAC                       ACTCGTCCGGGCTGTCAGGAGGCGGGAGGGGGCAGCGCTGGGCCTCGTGTCGCTTGTCGTCGTCCGT                       CCTGTGGGCGCTCTGCCCTGTGTCCTTCGCGTTCCTCGTTAAGCACAAGAAGTCAGTAGTTATTCTC                       ACATGAACGTTCTTGTCTGTGTACACTTTTTAGAACATTACAAAGGATCTGTTTGCTTAGCTGTCAA                       CAAAAAGAAAACCTCAAGGAGCATTTGGAACTCAATTTCAGGTTTTTTTTTTTCGTTTTTTTTTTTT                       TGTATGTTGGAACCTCCCCCAGAATGAGGCAGTTGGCAAACTTCTCACCACAATCAATCCTTCCCGT                       TTTTCTTTTTATGCCACACAGTGCATTGTTTTTTCTACCTGCTTGTCTTATTTTTAGAATAATTTAC                       AAAAACAAAACAAAGGCTGTTTTTCCTAATTTTCGCATGAACCCCCCCTTGTTCCAAATGAAGACCG                       CATCATCACGAACCACCTCCAAAAGGAAAAGCTTGCGCGGTGCCCAGCGTGCCCGCTGCCCATCGAC                       GTCTGTCCTGGGGACGTGGAGGGTGGCAGCGTCCCCGCCTGCACCAGTGCCGTCCTCCTGATGTGGT                       AGGCTAGCAATATTTTCGTTAAAATCATGTTTGTCACTGTAACCATTTGTATGAATTATTTTAAAGA                       AATAAAAATCCTCGAAAGAGCCAGCGTGCCCACCAAAAAAAAAACCTC                                               ORF Start: ATG at 10       ORF Stop: TAG at 1300               SEQ ID NO: 54   430 aa   MW at 46491.5kD                         NOV5b,   MSGVRPPIMNGPLHPRPLVALLDGRDCTVEMPILKDVATVAFCDAQSTQEIHEKVLNEAVGALMYHT           CG113144-02       Protein   ITLTREDLEKFKALRIIVRIGSGFDNIDIKSAGDLGIAVCNVPAASVEETADSTLCHILNLYRRATW       Sequence           LHQALREGTRVQSVEQIREVASGAARIRGETLGITGLGRVGQAVALRAKAFGFNVLFYDPYLSDGVE                   RALGLQRVSTLQDLLFHSDCVTLHCGLNEHNHHLINDFTVKQMRQGAFLVNTARGGLVDEKALAQAL                   KEGRIRGAALDVHESEPFSFSQGPLKDAPNLICTPHAAWYSEQASIENREEAAREIRRAITGRIPDS                   PVAHPPHAPSPGQTVKPEADRDHASDQL                                         SEQ ID NO:55   2085 bp                             NOV5c,     GCGCAGGCCGCCGAGGGTCGGGGCCCGCGCCGGCTCGCGCCTCTCG   ATG GGCAGCTCGCACTTGCTCA           CG113144-03       DNA Sequence   ACAAGGGCCTGCCGCTTCGCGTCCGACCTCCGATCATGAACGGGCCCCTGCACCCGCGGCCCCTGGTG                   GCATTGCTGGATGGCCGGGACTGCACAGTGGAGATGCCCATCCTGAAGGACGTGGCCACTGTGGCCTT                   CTGCGACGCGCAGTCCACGCAGGAGATCCATGAGAAGGTCCTGAACGAGGCTGTGGGGGCCCTGATGT                   ACCACACCATCACTCTCACCAGGGAGGACCTGGAGAAGTTCAAAGCCCTCCGCATCATCGTCCGGATT                   GGCAGTGGTTTTGACAACATCGACATCAAGTCGGCCGGGGATTTAGGCATTGCCGTCTGCAACGTGCC                   CGCGGCGTCTGTGGAGGAGACGGCCGACTCGACGCTGTGCCACATCCTGAACCTGTACCGGCGGGCCA                   CTGGCTGCACCAGGCGCTGCGGGAGGGCACACGAGTCCAGAGCGTCGAGCAGATCCGCGAGGTGGCGT                   CCGCGCTGCCAGGATCCGCGGGGAGACCTTGGGCATCATCGGACTTGOTCGCGTGGGGCAGGCAGTGG                   CGCTGCGGGCCAACGTGTCGGCTTCAACCTGCTCTTCTACGACCCTTACTTGTCGGATGGCGTGGAGC                   GGGCGCTGGGGCTGCAGCGTGTCAGCACCCTGCAGGACCTGCTCTTCCACAGCGACTGCGTGACCCTG                   CACTGCGGCCTCAACGAGCACAACCACCACCTCATCAACGACTTCACCGTCAAGCAGATGAGACAAGG                   GGCCTTCCTGGTGAACACAGCCCGGGGTGGCCTGGTGGATGAGAAGGCGCTCCCCCAGGCCCTGAAGG                   AGGGCCGGATCCGCGGCGCGGCCCTGGATGTGCACGAGTCGGAACCCTTCAGCTTTAGCCAGGGCCCT                   CTGAAGGATGCACCCAACCTCATCTGCACCCCCCATGCTGCATGGTACAGCGAGCAGGCATCCATCGA                   GATGCGAGAGGAGGCGGCACGGGAGATCCGCAGAGCCATCACAGGCCGGATCCCAGACAGCCTGAAGA                   ACTGTGTCAACAAGGACCATCTGACAGCCGCCACCCACTGGGCCAGCATGGACCCCGCCGTCGTGCAC                   CCTGAGCTCAATGGGGCTCCCTATAGGTACCCTCCGGGCGTGGTGGGCGTGGCCCCCACTGGCATCCC                   AGCTGCTGTGGAAGGTATCGTCCCCAGCGCCATGTCCCTGTCCCACGGCCTGCCCCCTGTGGCCCACC                   CGCCCCACGCCCCTTCTCCTGGCCAAACCGTCAAGCCCGAGGCGGATAGAGACCACGCCAGTGACCAG                   TTG TAG   CCCGGGAGGAGCTCTCCAGCCTCGGCGCCTGGGGCACCGGGCCCGGAAACCCTCCACCAGAG                       TGTGTGAGAGCATGTGTGTGGTGGCCCCTGGCACTGCAGAGACTGGTCCGGCCTGTCAGGAGGGCGGC                       AGGGCGCAGCGCTGGGCCTCGTGTCGCTTGTCGTCCGTCCTGTGGGCGCTCTGCCCTGTGTCCTTCGC                       GTTCCTCGTTAAGCAGAAGAAGTCAGTAGTTATTCTCCCATGAACGTTCTTGTCTGTGTACAGTTTTT                       ACAACATTACAAAGGATCTGTTTGCTTAGCTGTCAACAAAAAGAAAACCTGAAGGAGCATTTGGAAGT                       CAATTTGAGCTTTTTTTTTTTGGTTTTTTTTTTTTTGTATTTTGGAACGTGCCCCAGAATGAOGCAGT                       TGGCAAACTTCTCAGGACAATGAATCTTCCCGTTTTTCTTTTTATGCCACACAGTGCATTGTTTTTTC                       TACCTGCTTGTCTTATTTTTAGCATAATTTAGAAAAACAAAACAAAGGCTGTTTTTCCTAATTTTGGC                       ATGAACCCCCCCTTGTTCCAAAATGAAGACGGCATCATCACGAAGCAGCTCCAAAAGGAAAAGCTTGG                       CAGCTGCUCCTCGTCCTGGGGACGTGGAGGGTGGCACGGTCCCCGCCTGCACCAGTGCCGTCCTGCTG                       ATGTGGTAGGCTAGCAATATTTTGGTTAAAATCATGTTTGTGCCC                                               ORF Start: ATG at 47       ORF Stop TAG at 1364               SEQ ID NO: 56   439 aa   MW at 47552.4kD                         NOV5c,   MGSSHLLNKGLPLGVRPPIMNGPLHPRPLVALLDGRDCTVEMPILKDVATVAFCDAQSTQEIHEKVLN           CG113144-03       Protein   EAVGALMYHTITLTREDLEKFKALRIIVRIGSGFDNIDIKSAGDLGIAVCNVPAASVEETADSTLCHI       Sequence           LNLYRRATGCTRRCGRAHESRASSRSARWRPRCQDPRGDLGHBRTWSRGAGSGAAGQRVGFNVLFYDP                   YLSDGVERALGLQRVSTLQDLLFHSDCVTLHCGLNEHNUHLINDFTVKQMRQGAFLVNTARGGLVDEK                   ALAQALKEGRIRGAALDVHESEPFSFSQGPLKDAPNLICTPHAAWYSEQASIEHREEAAHEIRRAITG                   RIPDSLKNCVNKDHLTAATHWASHDFAVVHPELNGAAYRYPPGVVGVAPTGIPAAVEGIVPSAMSLSH                   GLPPVAHPPHAPSPGQTVKPEADRDHASDQL                  
 
     [0376] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 5B.  
               TABLE 5B                          Comparison of NOV5a against NOV5b and NOV5c.                                         Identities/                   Similarities for           Protein   NOV5a Residues/   the Matched           Sequence   Match Residues   Region                       NOV5b   14 . . . 440    394/428 (92%)               3 . . . 430   394/428 (92%)           NOV5c   1 . . . 440   355/440 (80%)               1 . . . 439   357/440 (80%)                      
 
     [0377] Further analysis of the NOV5a protein yielded the following properties shown in Table 5C.  
               TABLE 5C                       Protein Sequence Properties NOV5a                                                PSort   0.4500 probability located in cytoplasm; 0.3000           analysis:   probability located in microbody (peroxisome);               0.2559 probability located in lysosome (lumen);               0.1000 probability located in mitochondrial               matrix space           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0378] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D.  
               TABLE 5D                          Geneseq Results for NOV5a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV5a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAB12879   Murine JNK3 binding protein   14 . . . 440    421/428 (98%)   0.0           amino acid sequence #5 -   3 . . . 430   424/428 (98%)           Mus sp, 430 aa.           [WO200031132-A1,           02 JUN. 2000]       AAW42104   Amino acid sequence of the   1 . . . 440   396/447 (88%)   0.0           Adenovirus E1A binding   1 . . . 439   403/447 (89%)           protein (CtBP) -  Homo               sapiens , 439 aa.           [US5773599-A,           30 JUN. 1998]       AAB95805   Human protein sequence SEQ   74 . . . 439    288/366 (78%)   e−175           ID NO: 18790 -  Homo     1 . . . 366   329/366 (89%)             sapiens , 366 aa.           [EP1074617-A2,           07 FEB. 2001]       ABB12442   Human bone marrow   99 . . . 439    252/342 (73%)   e−150           expressed protein SEQ ID   1011 . . . 1352    292/342 (84%)           NO: 281 -  Homo sapiens ,           1352 aa. [WO200174836-A1,           11 OCT. 2001]       ABB71579     Drosophila melanogaster     1 . . . 373   262/375 (69%)   e−150           polypeptide SEQ ID NO   1 . . . 375   307/375 (81%)           41529 -  Drosophila               melanogaster , 386 aa.           [WO200171042-A2           27 SEP. 2001]                  
 
     [0379] In a BLAST search of public sequence datbases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E.  
               TABLE 5E                          Public BLASTP Results for NOV5a                                             Identities/           Protein           Similarities for       Accession       NOV5a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         Q13363   C-terminal binding protein 1   1 . . . 440    440/440 (100%)   0.0           (CtBP1) -  Homo sapiens     1 . . . 440    440/440 (100%)           (Human), 440 aa.       O88712   C-terminal binding protein 1   1 . . . 440   435/440 (98%)   0.0           (CtBP1) -  Mus musculus     1 . . . 440   437/440 (98%)           (Mouse), 440 aa.       Q91WI6   C-terminal binding protein 1 -   1 . . . 440   435/441 (98%)   0.0             Mus musculus  (Mouse), 441   1 . . . 441   437/441 (98%)           aa.       Q9YHU0   C-terminal binding protein   1 . . . 440   420/440 (95%)   0.0           (CtBP) -  Xenopus laevis     1 . . . 440   428/440 (96%)           (African clawed frog), 440 aa.       Q91YX3   C-terminal binding protein 1 -   14 . . . 440    422/428 (98%)   0.0             Mus musculus  (Mouse), 430   3 . . . 430   424/428 (98%)           aa.                  
 
     [0380] PFam analysis predicts that the NOV5a protein contains the domains shown in the Table 5F.  
               TABLE 5F                          Domain Analysis of NOV5a                                     Identities/                   Similarities for       Pfam   NOV5a   the Matched   Expect       Domain   Match Region   Region   Value               2-Hacid_DH   28 . . . 122   28/104 (27%)   0.011               65/104 (62%)       2-Hacid_DH_C   124 . . . 315    83/207 (40%)   3.6e−54               145/207 (70%)                   
 
     Example 6  
     [0381] The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A.  
               TABLE 6A                       NOV6 Sequence Analysis                                                    SEQ ID NO:57   3657 bp                             NOV6a,     GAGTCCCAGCCCCACGCCGGCTACCACC   ATG GCGGAGACCAACAACGAATGTAGCATCAAGGTGCTCT           CG122634-01       DNA Sequence   GCCGATTCCGGCCCCTGAACCAGGCTGAGATTCTGCGGGGAGACAAGTTCATCCCCATTTTCCAAGGG                   GACGACAGCGTCGTTATTGGGGGGAAGCCATATGTTTTTGACCGTGTATTCCCCCCAAACACGACTCA                   ACAAGCAAGTTTATCATGCATGTGCCATGCAGATTGTCAAAGATGTCCTTGTGGCTACAATGGCACCA                   TTTTTGCTTATGGACAGACATCCTCAGGGAAAACACATACCATGGAGGGAAAGCTGCACGACCCTCAG                   CTGATGGGAATCATTCCTCGAATTGCCCGAGACATCTTCAACCACATCTACTCCATGGATCACAACCT                   TGAGTTCCACATCAAGGTTTCTTACTTTGAAATTTACCTGGACAAAATTCCTGACCTTCTGCATGTGA                   CCAAGACAAATCTGTCCGTGCACGAGGACAAGAACCGGGTGCCATTTGTCAAGGGTTGTACTGAACGC                   TTTGTGTCCAGCCCGGAGGAGATTCTGGATGTGATTGATGAAGGGAAATCAAATCGTCATGTGGCTGT                   CACCAACATGAATGAACACAGCTCTCGGAGCCACAGCATCTTCCTCATCAACATCAAGCAGGAGAACA                   TGGAAACGGAGCAGAAGCTCAGTGGGAAGCTGTATCTGGTGGACCTGGCAGGGAGTGAGAAGGTCAGC                   AAGACTGGAGCACAGGGAGCCGTGCTGGACGAGGCAAAGAATATCAACAAGTCACTGTCAGCTCTGGG                   CAATGTGATCTCCGCACTGGCTGAGCGCACTAAAAGCTATGTTCCATATCGTGACAGCAAAATGACAA                   GGATTCTCCAGGACTCTCTCGCGGGAAACTGCCGGACGACTATGTTCATCTGTTGCTCACCATCCAGT                   TATAATGATGCAGAGACCAAGTCCACCCTGATGTTTGGGCAGCGGGCAAAGACCATTAAGAACACTGC                   CTCAGTAAATTTCGAGTTGACTGCTGAGCAGTGGAAGAAGAAATATGAGAAGGAGAAGGAGAAGACAA                   AGGCCCAGAAGGAGACGATTGCGAAGCTGGAGGCTGAGCTGAGCCGGTGGCGCAATGOAGAGAATGTG                   CCTGAGACAGAGCGCCTGGCTGGGGAGGAGGCAGCCCTGGGAGCCGAGCTCTGTGAGGAGACCCCTGT                   GAATGACAACTCATCCATCGTGGTGCGCATCGCGCCCGAGGAGCGGCAGAAATACGAGGAGGAGATCC                   GCCGTCTCTATAAGCAGCTTGACGACAAGGATGATGAAATCAACCAACAAAGCCAACTCATAGAGAAG                   CTCAAGCAGCAAATGCTGGACCAGGAAGAGCTGCTGGTGTCCACCCGAGGAGACAACGAGAAGGTCCA                   GCGGGAGCTGAGCCACCTGCAATCAGAGAACGATGCCGCTAAGGATGAGGTGAAGGAAGTGCTGCAGG                   CCCTGGAGGAGCTGGCTGTGAACTATGACCAGAAGTCCCAGGAGGTGGAGGAGAAGAGCCAGCAGAAC                   CAGCTTCTCGTGGATGAGCTGTCTCAGAAGGTGGCCACCATGCTGTCCCTGGAGTCTGAGTTGCAGCG                   GCTACAGGAGGTCAGTGGACACCAGCGAAAACGAATTGCTGAGGTGCTGAACGGGCTGATGAAGGATC                   TGAGCGAGTTCAGTGTCATTGTGGGCAACGGGGAGATTAAGCTGCCAGTGGAGATCAGTGGGGCCATC                   GAGGAGGAGTTCACTGTGGCCCGACTCTACATCAGCAAAATCAAATCAGAAGTCAAGTCTGTGGTCAA                   GCGGTGCCGGCAGCTGGAGAACCTCCAGGTGGAGTGTCACCGCAAGATGGAAGTGACCGGGCGGGAGC                   TCTCATCCTGCCAGCTCCTCATCTCTCAGCATGAGGCCAAGATCCCCTCGCTTACGGAATACATGCAG                   AGCGTGGAGCTAAAGAAGCGGCACCTGGAAGAGTCCTATGACTCCTTGAGCGATGACCTGGCCAAGCT                   CCAGGCCCAGGAAACTGTGCATGAAGTGGCCCTGAAGGACAAGGAGCCTGACACTCAGGATGCAGATG                   AAGTGAAGAAGGCTCTGGAGCTGCAGATGGAGAGTCACCGGGAGGCCCATCACCGGCAGCTGGCCCGG                   CTCCGGGACGAGATCAACGAGAAGCAGAAGACCATTGATGAGCTCAAAGACCTAAATCAGAAGCTCCA                   GTTAGAGCTAGAGAAGCTTCAGGCTGACTACGAGAAGCTGAAGAGCGAAGAACACGAGAAGAGCACCA                   AGCTGCAGGAGCTGACATTTCTGTACGAGCGACATGAGCAGTCCAAGCAGGACCTCAAGGGTCTGGAG                   GAGACAGTTGCCCGGGAACTCCAGACCCTCCACAACCTTCGCAAGCTGTTCGTTCAAGACGTCACGAC                   TCGAGTCAAGAAAAGTGCAGAAATGGAGCCCGAAGACAGTGGGGGGATTCACTCCCAAAAGCAGAACA                   TTTCCTTTCTTGAGAACAACCTGGAACAGCTTACAAAGGTTCACAAACAGCTGGTACGTGACAATGCA                   GATCTGCGTTGTCAGCTTCCTAAATTGGAAAAACGACTTAGGGCTACGGCTGAGAGAGTTAAGGCCCT                   GGAGGGTGCACTGAAGGAGGCCGTTCGCTACAAGAGCTCGGGCAAACGGGGCCATTCTGCCCAGATTG                   CCAAACCCGTCCGGCCTGGCCACTACCCAGCATCCTCACCCACCAACCCCTATGGCACCCGGAGCCCT                   GAGTGCATCAGTTACACCAACAGCCTCTTCCAGAACTACCAGAATCTCTACCTGCAGGCCACACCCAG                   CTCCACCTCAGATATGTACTTTGCAAACTCCTGTACCAGCACTGGAGCCACATCTTCTGGCGGCCCCT                   TGGCTTCCTACCAGAAGGCCAACATGGACAATGGAAATGCCACAGATATCAATGACAATAGGAGTGAC                   CTGCCGTGTCGCTATGAGGCTGAGGACCAGGCCAAGCTTTTCCCTCTCCACCAAGAGACAGCAGCCAG                   C TAA   TCTCCCACACCCACGGCTGCATACCTGCACTTTCAGTTTCTAAGAGGGACTGAGGCCTCTTCTC                       AGCATGCTGCAAACCTGTGGTCTCTGATACTAACTCCCTCCCCAACCCCTGTTGTTGGACTGTACTAT                       GTTTGATGTCTTCTCTTACTTACTCTGTATCTCTTTGTACTCTGTATCTATATATCAAAAGCTGCTGC                       TATGTCTCTCTTCTGTCTTATTCTCAAGTATCTACTGATGTATTTAGCAATTTCAAAGCATAGTCTAC                       CTTCCTTATTTGGGGCAATAGGGAGGAGGGTGAATGTTTCTTCTTTCTCATCTACTCGTCTCACACTG                       AGTGGTGTTAGTCACTGAGTAGAGGTCACAGAGATGACAAAAGGAAAAATGGGAGCTAGAGGGTTGTG                       ACCCTTCATACACACACGCACACACGCACACAAACATGCACACACGCATGCACACACACAAAGCCTTA                       AGCAGAAGAATGTCTTAGCATCATGAGACGAGAAATATACTCTTCCTCCCTCCTCTTTCACATATAGC                       ACAGAAGGTAAAATGGAACGGCTCCTAATTGAGACATATAATTTTCGCAATTC                                               ORF Start: ATG at 29       ORF Stop: TAA at 3062               SEQ ID NO:58   1011 aa   MW at 114816.1kD                         NOV6a,   MAETNNECSIKVLCRFRPLNQAEILRGDKFTPIFQGDDSVVIGGKPYVFDRVFPPNTTQEQVYHACAM           CG122634-01       Protein   QIVKDVLAGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIARDIFNHIYSHDENLEFHIKVSYF       Sequence           EIYLDKIRDLLDVTKTNLSVHEDKNRVPFVKGCTERFVSSPEEILDVIDEGKSURHVAVTNNNEHSSR                   SHSIFLINIKQENMETEQKLSGKLYLVDLACSEKVSKTGAEGAVLDFAKNINKSLSALGNVISALAEG                   TKSYVPYRDSKHTRILQDSLGGNCRTTMFICCSPSSYNDAETKSTLHFGQRAKTIKNTASVNLELTAE                   QWKKKYEKEKEKTKAQKETIAXLEAELSRWRNGENVPETERLAGEEAALGAELCEETPVNDNSSIVVR                   IAPEERQKYEEEIRRLYKQLDDKDDEINQQSQLIEKLKQQMLDQEELLVSTRGDNEKVQRELSHLQSE                   NDAAKDEVKEVLQALEELAVNYDQKSQEVEEKSQQNQLLVDELSQKVATMLSLESELQRLQEVSGHQR                   KRIAEVLNGLHKDLSEFSVIVGNGEIKLPVEISGAIEEEFTVARLYISKHISEVKSVVKRCRQLENLQ                   VECHRKMEVTGRELSSCQLLISQHEAKIRSLTEYMQSVELKKRHLEESYDSLSDELAKLQAQETVHEV                   ALKDKEPDTQDADEXTKKALELQMESHREAHHRQLARLRDEINEKQKTIDELKDLNQKLQLLEKLQAD                   YEKLKSEEHEKSTKLQELTFLYERHEQSKQDLKGLEETVARELQTLHNLRKLFVQDVTTRVKKSAEME                   PEDSGGTHSQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAVR                   YKSSGKRGHSAOIAKPVRPGHYPASSPTNPYGTRSPECISYTNSLFONYONLYLOATPSSTSDMYFAN                   SCTSSGATSSGGPLASYQKANMDNGNATDINDNRSDLPCGYEAEDQAKLFPLHQETAAS                  
 
     [0382] Further analysis of the NOV6a protein yielded the following properties shown in Table 6B.  
               TABLE 6B                       Protein Sequence Properties NOV6a                                                PSort   0.4379 probability located in mitochondrial           analysis:   matrix space; 0.3000 probability located in               microbody (peroxisome); 0.3000 probability               located in nucleus; 0.1217 probability located               in mitochondrial inner membrane           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0383] A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6C.  
               TABLE 6C                          Geneseq Results for NOV6a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV6a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAM78880   Human protein SEQ ID NO   7 . . . 918   661/939 (70%)   0.0           1542 -  Homo sapiens , 963 aa.   6 . . . 941   787/939 (83%)           [WO200157190-A2,           09 AUG. 2001]       AAM79864   Human protein SEQ ID NO   7 . . . 918   654/940 (69%)   0.0           3510 -  Homo sapiens , 979 aa.   21 . . . 957    780/940 (82%)           [WO200157190-A2,           09 AUG. 2001]       ABB63485     Drosophila melanogaster     7 . . . 904   551/946 (58%)   0.0           polypeptide SEQ ID NO   10 . . . 949    699/946 (73%)           17247 -  Drosophila               melanogaster , 975 aa.           [WO200171042-A2,           27 SEP. 2001]       AAW72746   Drosophila kinesin -   7 . . . 904   550/946 (58%)   0.0           Drosophila sp, 975 aa.   10 . . . 949    698/946 (73%)           [US5830659-A,           03-NOV-1998]       AAW72745   Drosophila kinesin   7 . . . 386   273/383 (71%)   e−159           N-terminal 411 amino acid   10 . . . 392    322/383 (83%)           residues - Drosophila sp, 411           aa. [US5830659-A,           03 NOV. 1998]                  
 
     [0384] In a BLAST search of public sequence datbases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6D.  
               TABLE 6D                          Public BLASTP Results for NOV6a                                             Identities/           Protein           Similarities for       Accession       NOV6a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         Q12840   Neuronal kinesin heavy chain   1 . . . 1011   1010/1032 (97%)    0.0           (NKHC) (Kinesin heavy chain   1 . . . 1032   1010/1032 (97%)            isoform 5A) (Kinesin heavy chain           neuron-specific 1) -             Homo sapiens  (Human), 1032           aa.       P33175   Neuronal kinesin heavy chain   1 . . . 1011   983/1032 (95%)   0.0           (NKHC) (Kinesin heavy chain   1 . . . 1027   999/1032 (96%)           isoform 5A) (Kinesin heavy           chain neuron-specific 1) -             Mus musculus  (Mouse), 1027           aa.       S37711   kinesin heavy chain - mouse,   7 . . . 1011   956/1027 (93%)   0.0           1027 aa.   6 . . . 1027   987/1027 (96%)       O60282   Kinesin heavy chain isoform   7 . . . 918     699/939 (74%)   0.0           5C (Kinesin heavy chain   6 . . . 943     806/939 (85%)           neuron-specific 2) -  Homo               sapiens  (Human), 957 aa.       P28738   Kinesin heavy chain isoform   7 . . . 918     695/938 (74%)   0.0           5C (Kinesin heavy chain   6 . . . 942     803/938 (85%)           neuron-specific 2) -  Mus               musculus  (Mouse), 956 aa.                  
 
     [0385] PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6E.  
               TABLE 6E                          Domain Analysis of NOV6a                                     Identities/                   Similarities for       Pfam   NOV6a   the Matched   Expect       Domain   Match Region   Region   Value               kinesin   15 . . . 357   178/417 (43%)   8.4e−174               299/417 (72%)       Phosphoprotein   482 . . . 507      7/26 (27%)   0.77                20/26 (77%)                  
 
     Example 7  
     [0386] The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.  
               TABLE 7A                       NOV7 Sequence Analysis                                                    SEQ ID NO: 59   701 bp                             NOV7a,      GCGGTGT ATGTGCGGCAATAACATGTCAACCCCOCTGCCCACCATCGTGCCCGCCCCCCGGAAGGCCA           CG125197-01        DNA Sequence    CCACTGAGGTGATTTTCCTGCATGGATTGGGAGATACTGGGCACGGATGGGCAGAAGccTTTGCCGGT                   ATCATAAGTTCACATATCAAATATATCTGCCCGCATGCGCCTGTTAGGCCTGTTACATTAAATATGAA                   CATAGCTATGCCTTCATGGTTTGATATTATTGGGCTTTCACCAGATTCACAGGAGGATGAATCTGGGA                   TTAAACAGGCAGCACAAAATATAAAAGCTTTGATTGATCAAGAAGTGAAGAATGGCATTCCTTCTAAC                   AGAATTATTTTGGGAGGGTTTTCTCAGGGAGGAGCTTTATCTTTATATACTGCCCTTACCACGCACCA                   GAAACTGGCAGGTGTCACTGCACTCAATTGCTGGCTTCCACTTTGGGCTTCCTTTCCACAGGGTCCTA                   TCGGTGGTGCTAATAGAGATATTTCTATTCTCCAGTGCCACGGGGATTGTGACCCTTTGGTTCCCCTG                   ATGTTTGGTTCTCTTACGGTTGAAAAACTAAAAACATTGGTGAATCCACCCAATGTGACCTTTAAAAC                   CTATGAAGGTATGATGCACAGTTCGTGTCAACAGGAAATGATGAATGTCAAGCAATTCATTGATAAAC                   TCCTACCTCCAATTGATTGA C                                           ORF Start: ATG at 8   ORF Stop: TGA at 698                                         SEQ ID NO: 60   230 aa   MW at 24848.5kD                             NOV7a,    MCGNNMSTPLPTIVPAPRKATTEVIFLHGLGDTGHGWAEAFAGIISSHIKYICPHAPVRPVTLNMNIA           CG125197-01        Protein    MPSWFDIIGLSPDSQEDESGIKQAAQNIKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTHQKL               Sequence    AGVTALNCWLPLWASFPQGPIGGANRDISILQCHGDCDPLVPLMFGSLTVEKLKTLVNPANVTFKTYE                   GMMHSSCQQEMNVKQFIDKLLPPID                                         SEQ ID NO: 61   616 bp                             NOV7b,      TGTGAGCTGAGGCGGTG TATGTGCGGCAATAACATGTCAACCCCGCTGCCCGCCATCGTGCCCGCCG           CG125197-03        DNA Sequence    CCCGGAAGGCCACCGCTCCGGTGATTTTCCTGCATGGGTTGGGAGATACTGGGCACGGATOGGCAGA                   AGCCTTTGCAGGTATCAGAAGTTCACATATCAAATATATCTGCCCGCATGCGCCTGTTAGGCCTGTT                   ACATTAAATATGAACGTGGCTATGCCTTCATGGTTTGATATTATTGGGCTTTCACCAGATTCACAGG                   AGGATGAATCTGGGATTAAACAGGCAGCAGAAAATATAAAAGCTTTGATTGATCAAGAAGTGAAGAA                   TGGCATTCCTTCTAACAGAATTATTTTGGCAGGGTTTTCTCAGTGCCACGGGGATTGTGACCCTTTG                   GTTCCCCTGATGTTTGGTCCTCTTACGGTGGAAAAACTAAAAACATTGGTGAATCCAGCCAATGTGA                   CCTTTAAAACCTATGAAGGTATGATGCACAGTTCGTGTCAACACGAAATGATGGATGTCAAGCAATT                   CATTGATAAACTCCTACCTCCAATTGATTGA CGTCACTAAGAGGCCTTGTGTAGAAGTACACCAGCA                       TCATTGTAGTAGA                                           ORF Start: ATG at 19   ORF Stop: TGA at 565                                         SEQ ID NO: 62   182 aa   MW at 19740.7kD                             NOV7b,    MCGNNMSTPLPAIVPAARKATAAVIFLHGLGDTGHGWAEAFAGIRSSHIKYICPHAPVRPVTLNMNV           CG125197-03        Protein    AMPSWFDIIGLSPDSQEDESGIKQAAENIKALIDQEVKNGIPSNRIILGGFSQCHGDCDPLVPLMFG       Sequence           PLTVEKLKTLVNPANVTFKTYEGMMHSSCQQEMMDVKQFIDKLLPPID                                         SEQ ID NO: 63   1486 bp                             NOV7c,      AGCCGCTCGCACGCCCTTGGGCCGCGGCCGGGCGCCCGCTCTTCCTTCCGCTTGCGCTGTGAGCTGAG             CG125197-02        DNA Sequence      GCGGTGT ATGTGCGGCAATAACATGTCAACCCCGCTGCCCGCCATCGTGCCCGCCGCCCGGAAGGCCA                   CCGCTGCGGTGATTTTCCTGCATGGATTGGGAGATACTGGGCACGGATGGGCAGAAGCCTTTGCAGGT                   ATCAGAAGTTCACATATCAAATATATCTGCCCGCATGCGCCTGTTACGCCTGTTACATTAAATATGAA                   CGTGGCTATGCCTTCATGGTTTGATATTATTGGGCTTTCACCAGATTCACAGGAGGATGAATCTGGGA                   TTAAACAGGCAGCAGAAAATATAAAAGCTTTGATTGATCAAGAAGTGAAGAATGGCATTCCTTCTAAC                   AGAATTATTTTGGGAGGGTTTTCTCAGGGAGGAGCTTTATCTTTATATACTGCCCTTACCACACAGCA                   GAAACTCGCAGGTGTCACTGCACTCAGTTGCTGGCTTCCACTTCGGGCTTCCTTTCCACAGGGTCCTA                   TCGGTGGTGCTAATAGAGATATTTCTATTCTCCAGTGCCACGCGGATTGTGACCCTTTGGTTCCCCTG                   ATGTTTGGTTCTCTTACGGTCGAAAAACTAAAAACATTGGTGAATCCAGCCAATGTGACCTTTAAAAC                   CTATGAAGGTATGATGCACAGTTCGTGTCAACAGGAAATGATGGATGTCAAGCAATTCATTGATAAAC                   TCCTACCTCCAATTGATTGA CGTCACTAAGAGGCCTTGTGTAGAAGTACACCAGCATCATTGTAGTAG                       AGTGTAAACCTTTTCCCATGCCCAGTCTTCAAATTTCTAATGTTTTGCAGTGTTAAAATGTTTTGCAA                       ATACATGCCAATAACACAGATCAAATAATATCTCCTCATGAGAAATTTATGATCTTTTAAGTTTCTAT                       ACATGTATTCTTATAAGACGACCCAGGATCTACTATATTAGAATAGATGAAGCAGGTAGCTTCTTTTT                       TCTCAAATGTAATTCAGCAAAATAATACAGTACTGCCACCAGATTTTTTATTACATCATTTGAAAATT                       AGCAGTATCCTTAATGAAAATTTGTTCAGGTATAAATGAGCAGTTAAGATATAAACAATTTATGCATG                       CTGTGACTTAGTCTATGGATTTATTCCAAAATTGCTTAGTCACCATGCAGTGTCTGTATTTTTATATA                       TGTGTTCATATATACATAATGATTATAATACATAATAAGAATGACGTGGTATTACATTATCCCTAATA                     ATAGGGATAATGCTGNTTATTGTCCAGGAAAAAGTAAAATCGGTCCCCTTCAATTAATGGCCCTTTTA                   ATNTNGGGACCAGGCTTTTAATTTTCCCCGGATATTAATTTCCAATTTAATACCCCTTTCCNCNCCAG                   AAAAAAAAAAAAAGTTTGTTTTTTCCTTAATTGTCTTCATAGCAGGCCAAGTATTGCC                                         ORF Start: ATG at 76   ORF Stop: TGA at 766                                         SEQ ID NO: 64   230 aa   MW at 24669.3kD                             NOV7c,    MCGNNMSTPLPAIVPAARKATAAVIFLHGLGDTGHGWAEAFAGIRSSHIKYICPHAPVRPVTLNMNVA           CG125197-02        Protein    MPSWFDIIGLSPDSQEDESGIKQAAENIKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTQQKL       Sequence            AGVTALSCWLPLRASFPQGPIGGANRDISILQCHGDCDPLVPLMFGSLTVEKLKTLVNPANVTFKTYE                   GMMHSSCQQEMMDVKQFIDKLLPPID                  
 
     [0387] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 7B.  
               TABLE 7B                          Comparison of NOV7a against NOV7b and NOV7c.                                         Identities/               NOV7a Residues/   Similarities for           Protein Sequence   Match Residues   the Matched Region                       NOV7b   1 . . . 230   173/230 (75%)               1 . . . 182   176/230 (76%)           NOV7c   1 . . . 230   219/230 (95%)               1 . . . 230   223/230 (96%)                      
 
     [0388] Further analysis of the NOV7a protein yielded the following properties shown in Table 7C.  
               TABLE 7C                       Protein Sequence Properties NOV7a                                        PSort analysis:   0.6500 probability located in cytoplasm; 0.2605           probability located in lysosome (lumen); 0.1000           probability located in mitochondrial matrix space;           0.0000 probability located in endoplasmic reticulum           (membrane)       SignalP analysis:   No Known Signal Sequence Predicted                  
 
     [0389] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7D.  
               TABLE 7D                          Geneseq Results for NOV7a                                         NOV7a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAU85134   Human lysophospholipase I   1 . . . 230   219/230 (95%)   e−128           #2 -  Homo sapiens , 230 aa.   1 . . . 230   223/230 (96%)           [WO200210185-A1,           07 FEB. 2002]       AAU85132   Human lysophospholipase I   1 . . . 230   219/230 (95%)   e−128           #1 -  Homo sapiens , 230 aa.   1 . . . 230   223/230 (96%)           [WO200210185-A1,           07 FEB. 2002]       ABG07277   Novel human diagnostic   1 . . . 230   219/230 (95%)   e−128           protein #7268 -  Homo     46 . . . 275    223/230 (96%)             sapiens , 275 aa.           [WO200175067-A2,           11 OCT. 2001]       AAB53451   Human colon cancer antigen   1 . . . 230   219/230 (95%)   e−128           protein sequence SEQ ID   34 . . . 263    223/230 (96%)           NO: 991 -  Homo sapiens , 263           aa. [WO200055351-A1,           21 SEP. 2000]       AAY09531   Human lysophospholipase   1 . . . 230   219/230 (95%)   e−128           extended NHLP -  Homo     1 . . . 230   223/230 (96%)             sapiens , 230 aa.           [WO9849319-A1,           05 NOV. 1998]                  
 
     [0390] In a BLAST search of public sequence datbases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7E.  
               TABLE 7E                          Public BLASTP Results for NOV7a                                         NOV7a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               O75608   Lysophospholipase   1 . . . 230   219/230 (95%)   e−127           (Acyl-protein thioesterase-1)   1 . . . 230   223/230 (96%)           (Lysophospholipase I) -  Homo               sapiens  (Human), 230 aa.       O77821   Calcium-independent   1 . . . 230   202/230 (87%)   e−119           phospholipase A2 isoform 2 -   1 . . . 230   213/230 (91%)             Oryctolagus cuniculus             (Rabbit), 230 aa.       P70470   LYSOPHOSPHOLIPASE -   1 . . . 230   203/230 (88%)   e−118             Rattus norvegicus (Rat), 230   1 . . . 230   213/230 (92%)           aa.       O77820   Calcium-independent   14 . . . 230    202/217 (93%)   e−116           phospholipase A2 isoform 1 -   3 . . . 219   207/217 (95%)             Oryctolagus cuniculus             (Rabbit), 219 aa (fragment).       Q9UQF9   Lysophospholipase isoform -   1 . . . 230   204/230 (88%)   e−114             Homo sapiens  (Human), 214   1 . . . 214   207/230 (89%)           aa.                  
 
     [0391] PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7F.  
               TABLE 7F                          Domain Analysis of NOV7a                                     Identities/               NOV7a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               abhydrolase_2   10 . . . 226   123/236 (52%)   1.3e−108               193/236 (82%)                  
 
     Example 8  
     [0392] The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.  
               TABLE 8A                       NOV8 Sequence Analysis                                                    SEQ ID NO: 65   3515 bp                             NOV8a,      AAAGGGGAGTCCGGTGAACGGGCAGAAGCAGGGCCATGCCCAAGCCACCCCCAAGATCCCCCTGAACC             CG125312-01        DNA Sequence      TGCACCTCCATCACGACCCATTCAGGAGCCTCCAGGAGCCCAGACACCAGCCCCCCACC ATGGGCAGC                   AAGGAGCGCTTCCACTGGCAGAGCCACAACGTGAAGCAGAGCGGCGTGGATGACATGGTGCTTCTTCC                   CCAGATCACCGAAGACGCCATTGCCGCCAACCTCCGGAAGCGCTTCATGGACGACTACATCTTCACCT                   ACATCGGCTCTGTGCTCATCTCTGTAAACCCCTTCAAGCAGATGCCCTACTTCACCGACCGTGAGATC                   GACCTCTATCAGGGCGCGGTGCAGTATGAGAATCCCCCGCACATCTACGCCCTCACGGACAACATGTA                   CCGGAACATGCTTATCGACTGTGAGAACCAGTGTGTCATCATTAGTCGAGAGAGTGGAGCTGGGAAGA                   CAGTGGCAGCCAAATATATCATGGGCTACATCTCCAAGGTGTCTGGCGGAGGCGAGAAGGTCCAGCAC                   GTCAAAGATATCATCCTGCAGTCCAACCCGCTGCTCGAGGCCTTCGGCAACGCCAAGACTGTGCGCAA                   CAACAATTCCAGCCGCTTTGGCAAGTACTTTGAGATCCAGTTCAGCCGAGGTGGGGAGCCAGATGGGG                   GCAAGATCTCCAACTTCTTGCTGGAGAAGTCCCGCGTGGTCATCCAAAATGAAAATGAGAGGAACTTC                   CACATCTACTACCAGCTGCTGGAAGGGGCCTCCCAGGAGCAAAGGCAGAACCTGGGCCTCATGACACC                   GGACTACTATTACTACCTCAACCAATCGGACACCTACCAGGTGGACGGCACGGACGACAGAAGCGACT                   TTGGTGAGACTCTGAGTGCTATGCAGGTTATTGGGATCCCGCCCAGCATCCAGCAGCTGGTCCTGCAG                   CTCGTGGCCGGCATCTTGCACCTGGGGAACATCAGTTTCTGTGAAGACGGGAATTACGCCCGAGTGGA                   GAGTGTGGACCTGGCCTTTCCCGCCTACCTGCTGGGCATTGACAGCGGGCGACTGCAGGAGAAGCTGA                   CCAGCCGCAAGATGGACAGCCCCTCGGGCCGGCGCAGCGAGTCCATCAATGTGACCCTCAACGTGGAG                   CAGGCAGCCTACACCCGTGATGCCCTGGCCAAGGGGCTCTATGCCCGCCTCTTCGACTTCCTCGTGGA                   GGCGATCAACCGTGCTATGCAGAAACCCCAGGAAGAGTACAGCATCGGTGTGCTGGACATTTACGGCT                   TCGAGATCTTCCAGAAAAATGGCTTCGAGCAGTTTTGCATCAACTTCGTCAATGAGAAGCTGCAGCAA                   ATCTTTATCGAACTTACCCTGAAGGCCGAGCAGGAGGAGTATGTGCAGGAAGGCATCCGCTGGACTCC                   AATCCAGTACTTCAACAACAAGGTCGTCTGTGACCTCATCGAAAACAAGCTGAGCCCCCCAGGCATCA                   TGAGCGTCTTGGACGACGTGTGCGCCACCATCCACGCCACGCGCCGGGGAGCAGACCAGACACTGCTG                   CAGAAGCTGCAGGCGGCTGTGGGGACCCACGAGCATTTCAACAGCTGGAGCGCCGGCTTCGTCATCCA                   CCACTACGCTGGCAAGGTGTCCTACGACGTCAGCGGCTTCTGCCAGAGGAACCGAGACGTTCTCTTCT                   CCGACCTCATAGAGCTGATGCAGACCAGTGAGCAGTTCCTCCGGATGCTCTTCCCCGAGAAGCTGGAT                   GGAGACAAGAAGGGGCGCCCCAGCACCGCCGGCTCCAAGATCAAGAAACAAGCCAACGACCTGGTGGC                   CACACTGATGACGTGCACACCCCACTACATCCGCTGCATCAAACCCAACGAGACCAAGAGGCCCCGAG                   ACTGGGAGGAGAACAGGGTCAAGCACCAGGTGGAATACCTGGGCCTGAAGGAGAACATCAGGGTGCGC                   AGAGCCGGCTTCGCCTACCGCCGCCAGTTCGCCAAATTCCTGCAGACGTATGCCATTCTGACCCCCGA                   GACGTGGCCGCGGTGGCGTGGGGACGAACCCCAGGGCGTCCAGCACCAGCTTCGGGCGGTCAACATGG                   AGCCCGACCAGTACCAGATGGGGAGCACCAAGGTCTTTGTCAAGAACCCAGAGTCGCTTTTCCTCCTG                   GAGGAGGTGCGACAGCGAAAGTTCGATCGCTTTGCCCGAACCATCCAGAAGGCCTGGCGGCGCCACGT                   GGCTGTCCGOAAGTACGAGGAGATGCGGGAGGAAGCTTCCAACATCCTGCTGAACAAGAAGGAGCGGA                   GGCGCAACAGCATCAATCGGAACTTCGTCCGGGACTACCTGGGGCTGGACGAGCGGCCCGAGCTGCGT                   CAGTTCCTGGGCAAGAGGGAGCGGGTGGACTTCGCCGATTCGGTCACCAAGTACGACCGCCGCTTCAA                   GCCCATCAAGCGGGACTTGATCCTGACGCCCAAGTGTGTGTATGTGATTGGGCGAGAGAAAGTGAAGA                   AGGGACCTGACAAGGGCCAGGTGTGTGAAGTCTTGAAGAAGAAAGTGGACATCCAGGCTCTGCGGGGA                   GTCTCCCTCAGCACGCGACAGGACGACTTCTTCATCCTCCAAGAGGATGCCGCCGACAGCTTCCTGGA                   GAGCGTCTTCAAGACCGAGTTTGTCAGCCTTCTGTGCAAGCGCTTCGAGGAGGCGACGCGGAGGCCCC                   TGCCCCTCACCTTCAGCGACAGACTACAGTTTCGGGTGAAGAAGGAGGCCTGGGGCGGTGGCGGCACC                   CGCAGCGTCACCTTCTCCCGCGGCTTCGGCGACTTGGCAGTGCTCAAGGTTGGCGGTCGGACCCTCAC                   GGTCAGCGTGGGCCATGGGCTGCCCAAGAGCTCAGAGCCTACGCGGAAGCGAATCGCCAAGGGAAAAC                   CTCGGAGGTCGTCCCAAGCCCCTACCCGGGCGGCCCCTGCGCCCCCCAGAGGTATGGATCGCAATGGG                   GTGCCCCCCTCTGCCAGAGGGGGCCCCCTGCCCCTGGAGATCATGTCTGGAGGGGGCACCCACAGGCC                   TCCCCGGGGCCCTCCGTCCACATCCCTGGGAGCCAGCAGACGACCCCGGGCACGTCCGCCCTCAGAGC                   ACAACACAGAATTCCTCAACGTGCCTGACCAGGGCATGGCCGGGATGCAGAGGAACCCCACCGTGGGG                   CAACGGCCAGTGCCTGGTGTGGGCCGACCCAAGCCCCACCCTCGGACACATGGTCCCAGGTGCCGGGC                   CCTATACCAGTACGTGGGCCAAGATGTGGACGAGCTGAGCTTCAACGTGAACCAGGTCATTGAGATCC                   TCATGGAAGATCCCTCGGGCTGGTGGAAGGGCCGGCTTCACGGCCAGGAGGGCCTTTTCCCAGGAAAC                   TACGTGGAGAACATCTGA GCTGGGCCCTCGGATACTGCCTTCTCTPTCGCCCGCCTATCTGCCTGCCG                       GCCTGGTGCGGAGCCAGGCCCTGCCAATGAGAGCCTCGTTTACCTGG                                           ORF Start: ATG at 128   ORF Stop: TGA at 3416                                         SEQ ID NO: 66   1096 aa   MW at 124743.0kD                             NOV8a,    MGSKERFHWQSHNVKQSGVDDMVLLPQITEDAIAANLRKRFHDDYTFTYIGSVLISVNPFKQMPYPTD           CG125312-01        Protein    REIDLYQGAVQYENPPHIYALTDNMYRNMLIDCENQCVIISGESGAGKTVAAKYIMGYISKVSGGGEK       Sequence            VQHVKDIILQSNPLLEAFGNAKTVRNNNSSRFGKYFEIQFSRGGEPDGGKISNFLLEKSRVVMQNENE                   RNFHIYYQLLEGASQEQRQNLGLMTPDYYYYLNQSDTYQVDGTDDRSDFGETLSAMQVIGIPPSIQQL                   VLQLVAGILHLGNISFCEDGNYARVESVDLAFPAYLLGIDSGRLQEKLTSRKNDSRWGGRSESINVTL                   NVEQAAYTRDALAKGLYARLFDFLVEAINRAMQKPQEEYSIGVLDIYGFEIFQKNGFEQFCINFVNEK                   LQQIFIELTLKAEQEEYVQEGIRWTPIQYFNNKVVCDLIENKLSPPGIMSVLDDVCATNHATGGGADQ                   TLLQKLQAAVGTHEHFNSWSAGFVIHHYAGKVSYDVSGFCERNRDVLFSDLIELMQTSEQFLRMLFPE                   KLDGDKKGRPSTAGSKIKKQANDLVATLNRCTPHYIRCIKPNETKRPRDWEENRVKHQVEYLGLKENI                   RVRRAGFAYRRQFAKFLQRYAILTPETWPRWRGDERQGVQHLLRAVNMEPDQYQMGSTKVFVKNPESL                   FLLEEVRERKFDGFARTIQKAWRRHVAVRKYEEMREEASNILLNKKERRRNSINRNFVGDYLGLEERP                   ELRQFLGKRERVDFADSVTKYDRRFKPIKRDLILTPKCVYVIGREKVKKGPEKGQVCEVLKKKVDTQA                   LRGVSLSTRQDDFFILQEDAADSFLESVFKTEFVSLLCKRFEEATRRPLPLTFSDRLQFRVKKEGWGG                   GGTRSVTFSRGFGDLAVLKVGGRTLTVSVGDGLPKSSEPTRKGMAXGKPRRSSQAPTRAAPAPPRGMD                   RNGVPPSARGGPLPLEIMSGGGTHRPPRGPPSTSLGASRRPRARPPSEUNTEFLNVPDQGMAGMQRKR                   SVGQRPVPGVGRPKPQPRTHGPRCRALYQYVGQDVDELSFNVNEVIEILMEDPSGWWKGRLHGQEGLF                   PGNYVEKI                  
 
     [0393] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.  
               TABLE 8B                       Protein Sequence Properties NOV8a                                        PSort analysis:   0.9800 probability located in nucleus; 0.4008           probability located in microbody (peroxisome);           0.1619 probability located in lysosome (lumen);           0.1000 probability located in mitochondrial           matrix space       SignalP analysis:   No Known Signal Sequence Predicted                  
 
     [0394] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.  
               TABLE 8C                          Geneseq Results for NOV8a                                         NOV8a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAU97544   Human Myosin-1F protein    1 . . . 1096   1089/1098 (99%)    0.0           MYO1F -  Homo sapiens ,    1 . . . 1098   1092/1098 (99%)            1098 aa.           [WO200218946-A2,           07 MAR. 2002]       ABB97258   Novel human protein SEQ    63 . . . 1096   994/1097 (90%)    0.0           ID NO: 526 -  Homo sapiens ,    1 . . . 1089   1006/1097 (91%)            1089 aa.           [WO200222660-A2,           21 MAR. 2002]       AAM39991   Human polypeptide SEQ ID   18 . . . 718   327/724 (45%)   e−173           NO 3136 -  Homo sapiens ,   47 . . . 761   453/724 (62%)           1063 aa.           [WO200153312-A1,           26 JUL. 2001]       ABG10171   Novel human diagnostic   18 . . . 718   327/724 (45%)   e−173           protein #10162 -  Homo     33 . . . 747   453/724 (62%)             sapiens , 1050 aa.           [WO200175067-A2,           11 OCT. 2001]       AAB64616   Human secreted protein   18 . . . 686   319/701 (45%)   e−169           BLAST search protein SEQ   16 . . . 697   438/701 (61%)           ID NO: 126 -  Homo sapiens ,           697 aa. [WO200077197-A1,           21 DEC. 2000]                  
 
     [0395] In a BLAST search of public sequence datbases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.  
               TABLE 8D                          Public BLASTP Results for NOV8a                                         NOV8a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               AAH28071   Hypothetical 124.8 kDa   1 . . . 1096   1093/1098 (99%)   0.0           protein -  Homo sapiens     1 . . . 1098   1094/1098 (99%)           (Human), 1098 aa.       Q8WWN7   Myosin-1F -  Homo sapiens     1 . . . 1096   1089/1098 (99%)   0.0           (Human), 1098 aa.   1 . . . 1098   1092/1098 (99%)       BAC03995   CDNA FLJ35558 fis, clone   1 . . . 1087   1083/1089 (99%)   0.0           SPLEN2004984, highly   1 . . . 1089   1084/1089 (99%)           similar to  M. musculus             myosin I -  Homo sapiens             (Human), 1098 aa.       P70248   Myosin If -  Mus musculus     1 . . . 1096    993/1107 (89%)   0.0           (Mouse), 1099 aa.   1 . . . 1099   1042/1107 (93%)       Q90748   Brush border myosin IB -   1 . . . 1096    917/1102 (83%)   0.0             Gallus gallus  (Chicken),   1 . . . 1099    996/1102 (90%)           1099 aa.                  
 
     [0396] PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E.  
               TABLE 8E                          Domain Analysis of NOV8a                                     Identities/               NOV8a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                     myosin_head   19 . . . 675   336/736 (46%)    0               549/736 (75%)        IQ   692 . . . 712     8/21 (38%)   0.96               16/21 (76%)       SH3   1042 . . . 1096    28/58 (48%)   2.2e−20               49/58 (84%)                  
 
     Example 9  
     [0397] The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.  
               TABLE 9A                       NOV9 Sequence Analysis                                                    SEQ ID NO: 67   1364 bp                             NOV9a,      AGATCTTAGTCGAAGCTTGTGTGGAATTATTCCGGGACTTAGCAGTATCTTCCTTCCCCGA ATGAATC           CG134439-01        DNA Sequence    CATTTGTTTTGATTGATCTTGCTGGAGCATTTGCTCTTTGTATTACATATATGCTCATTGAAATTAAT                   AATTATTTTGCCGTAGACACTGCCTCTGCTATAGCTATTGCCTTGATGACATTTGGCACTATGTATCC                   CATGAGTGTGTACAGTGGGAAAGTCTTACTCCAGACAACACCACCCCATGTTATTGGTCAGTTGGACA                   AACTCATCAGAGAGGTATCTACCTTAGATGGAGTTTTAGAAGTCCGAAATGAACATTTTTCGACCCTA                   GGTTTTGGCTCATTGGCTGGATCAGTGCATGTAAGAATTCGACGAGATGCCAATGAACAAATGGTTCT                   TGCTCATGTGACCAACAGGCTGTACACTCTAGTGTCTACTCTAACTGTTCAAATTTTCAAGGATGACT                   GGATTAGGCCTGGCTTATTGTCTGGGCCTCTTGCAGCCAATGTCCTAAACTTTTCAGATCATCACGTA                   ATCCCAATGCCTCTTTTAAAGGGTACTGATGGTTTGAACCCGTATGTTCATTTCCTTTGGAAGATTAA                   TTTTTTCCTTTTTTTTGACATGGAGTCTCTCTCTGTCGCCCAGGCTGGAGTGCAGTGGCACGATCTTG                   GCTCACTGCAACCCCACCTCCCAGGTTCAAGCAATTCTGCCTGCCTCAGCCTCCCGAGTAGCTGCGAT                   TACAGGCATGCACCACCACACTTGCCTAATTTTTGTATTATTAGTAAAGATGGGGTTCTGCCATGTTG                   GCCATCCTGGTCTTGA ACTCGTGACCTAAGGTGATCTGCCTGCCTTGGCCTCCCAAACTGCTGGGATT                       ACAGGTGTGAGCCACTACACCCGGCCTGATTAATTTCTTTTACTTGCTTCAAGTGTCTCCTTTATTCC                       AGCCTACACATACAGGTAAATATTCCTAGGAAACTTTCAGCAAGTTAAATCCTATTATAAAATCCCAG                       AGTCAGTTGTCTAATTPTTATTTTATTTTATTATTATTATTTTTTTTGAGACAGGGTCTTGCTTTGTC                       ACCCAGGCTGGAGTGCAGTGGCGTGAACACAGCTCACCACAGCCTTCACCTCCCAGGCTCAAGTGATC                       GTTCCAGTTCAGCCTCCTTAGTAGCTGGGATCACAGGTGCAGACCACCACACCCGACTAATTTTCTTT                       TTTTTTTTTTTAAGACAAGGTCTCACTCTGTCGTCCAGGCTGGAGTACAGTGAGCTGAGATTGTGCCA                       CTACTCCAGCCTGGGTGACAGAGCAAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA                       AAAA                                           ORF Start: ATG at 62   ORF Stop: TGA at 830                                         SEQ ID NO: 68   256 aa   MW at 28494.7kD                             NOV9a,    MNPFVLIDLAGAFALCITYMLIEINNYFAVDTASAIAIALMTFGTMYPMSVYSGKVLLQTTPPHVIGQ           CG134439-01        Protein    LDKLIREVSTLDGVLEVRNEHFWTLGFGSLAGSVHVRIRRDANEQMVLAHVTNRLYTLVSTLTVQIFK       Sequence            DDWIRPGLLSGPVAANVLNFSDHHVIPMPLLKGTDGLNPYVHFLWXINFFLFFDMESLSVAQAGVQWH                   DLGSLQPHLPGSSNSACLSLPSSWDYRHAPPHLPNFCIISKDGVLPCWPCWS                  
 
     [0398] Further analysis of the NOV9a protein yielded the following properties shown in Table 9B.  
               TABLE 9B                       Protein Sequence Properties NOV9a                                        PSort analysis:   0.7762 probability located in outside; 0.2165           probability located in microbody (peroxisome);           0.1000 probability located in endoplasmic           reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP analysis:   Cleavage site between residues 54 and 55                  
 
     [0399] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9C.  
               TABLE 9C                          Geneseq Results for NOV9a                                         NOV9a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               ABG08221   Novel human diagnostic   26 . . . 175   148/150 (98%)    5e−81           protein #8212 -  Homo     239 . . . 388    148/150 (98%)              sapiens , 477 aa.           [WO200175067-A2,           11 OCT. 2001]       AAM05878   Peptide #4560 encoded by   99 . . . 175   75/77 (97%)   4e−37           probe for measuring breast   1 . . . 77   75/77 (97%)           gene expression -  Homo               sapiens , 166 aa.           [WO200157270-A2,           09 AUG. 2001]       AAM02915   Peptide #1597 encoded by   99 . . . 175   75/77 (97%)   4e−37           probe for measuring breast   1 . . . 77   75/77 (97%)           gene expression -  Homo               sapiens , 166 aa.           [WO200157270-A2,           09 AUG. 2001]       AAM30756   Peptide #4793 encoded by   99 . . . 175   75/77 (97%)   4e−37           probe for measuring placental   1 . . . 77   75/77 (97%)           gene expression -  Homo               sapiens , 166 aa.           [WO200157272-A2,           09 AUG. 2001]       AAM27634   Peptide #1671 encoded by   99 . . . 175   75/77 (97%)   4e−37           probe for measuring placental   1 . . . 77   75/77 (97%)           gene expression -  Homo               sapiens , 166 aa.           [WO200157272-A2,           09 AUG. 2001]                  
 
     [0400] In a BLAST search of public sequence datbases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9D.  
               TABLE 9D                          Public BLASTP Results for NOV9a                                         NOV9a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9NWI4   CDNA FLJ20837 fis, clone   49 . . . 256    207/208 (99%)    e−123           ADKA02602 -  Homo sapiens     1 . . . 208   207/208 (99%)           (Human), 208 aa.       Q96NC3   CDNA FLJ31101 fis, clone   1 . . . 175   173/175 (98%)   2e−95           IMR321000266, weakly   198 . . . 372    173/175 (98%)           similar to zinc/cadmium           resistance protein -  Homo               sapiens  (Human), 461 aa.       AAM27917   Zinc transporter 6 -  Mus     1 . . . 175   164/175 (93%)   4e−89             musculus  (Mouse), 460 aa.   198 . . . 372    165/175 (93%)       Q8R4Z2   Zinc transporter-like 3   1 . . . 175   161/175 (92%)   1e−87           protein -  Mus musculus     198 . . . 372    163/175 (93%)           (Mouse), 460 aa.       AAH32525   Similar to hypothetical   49 . . . 175    125/127 (98%)   5e−67           protein MGC11963 -  Homo     1 . . . 127   125/127 (98%)             sapiens  (Human), 216 aa.                  
 
     [0401] PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9E.  
               TABLE 9E                          Domain Analysis of NOV9a                                     Identities/                   Similarities           NOV9a   for the Matched   Expect       Pfam Domain   Match Region   Region   Value               Cation_efflux   30 . . . 123   24/97 (25%)   6e−14               74/97 (76%)                  
 
     Example 10  
     [0402] The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.  
               TABLE 10A                       NOV10 Sequence Analysis                                                    SEQ ID NO: 69   3450 bp                             NOV10a,      CGCCCCGCGGGACCCGGACGGCGACGACGGGGGA ATGTCCCGCTGGATCCGGCAGCAGCTGCGTTTT           CG137109.01        DNA Sequence    GACCCACCACATCAGAGTGACACAAGAACCATCTACGTAGCCAACAGGTTTCCTCAGAATGGCCTTT                   ACACACCTCAGAAATTTATAGATAACACGATCATTTCATCTAAGTACACTGTGTGCAATTTTCTTCC                   AAAAAATTTATTTGAACAGTTCAGAAOAGTGGCAAACTTTTATTTTCTTATTATATTTTTGGTTCAG                   CTTATGATTGATACACCTACCAGTCCAGTTACCAGTGGACTTCCATTATTCTTTGTGATAACACTAA                   CTGCCATAAAGCAGGGATATGAAGATTGGTTACGGCATAACTCAGATAATGAACTAAATGGACCTCC                   TGTTTATGTTGTTCGAAGTGGTGGCCTTGTAAAAACTACATCAAAAAACATTCGGGTGGGTGATATT                   GTTCGAATAGCCAAACATGAAATTTTTCCTGCAGACTTGGTGCTTCTGTCCTCAGATCGACTGGATG                   GTTCCTGTCACGTTACAACTCCTAGTTTGCACCGACAAACTAACCTGAAGACACATGTGGCAGTTCC                   AGAAACAGCATTATTACAAACACTTGCCAATTTCGACACTCTAGTAGCTGTAATAGAATGCCAGCAA                   CCAGAAGCAGACTTATACAGATTCATGGGACGAATGATCATAACCCAACAAATGGAACAAATTGTAA                   GGCCTCTGGGGCCCGAGAGTCTCCTGCTTCGTCGACCCACATTAAAAAACACAAAAGAAATTTTTGG                   TTTGTACATATTTAAACATTTTAAATTAGGTGTTGCGGTATACACTGGAATGCAAACTAAGATGGCA                   TTAAATTACAACAGCAAATCACAGAAACGATCTGCACTAGAAAAGTCAATGAATACATTTTTGATAA                   TTTATCTAGTAATTCTTATATCTCAAGCTGTCATCAGCACTATCTTGAAGTATACATGGCAAGCTGA                   AGAAAAATGGGATGAACCTTCCTATAACCAAAAAACACAACATCAAAGAAATAOCAGTAAGGTAGAG                   TACCTGTTTACAGATAAAACTGGTACACTGACAGAAAATGAGATGCAGTTTCCCCAATGTTCAATTA                   ATGGCATGAAATACCAAGAAATTAATGGTAGACTTGTACCCGAACGACCAACACCAGACTCTTCAGA                   AGGAAACTTATCTTATCTTAGTACTTTATCCCATCTTAACAACTTATCCCATCTTACAACCAGTTCC                   TCTTTCAGAACCAGTCCTGAAAATGAAACTGAACTAGTAAAAGAACATGATCTCTTCTTTAAAGCAG                   TCAGTCTCTGTCACACTGTACAGATTAGCAATGTTCAAACTGACTGCACTGGTGATGGTCCCTGGCA                   ATCCAACCTGGCACCATCGCAGTTGGAGTACTATGCATCTTCACCAGATGAAAAGGCTCTAGTAGAA                   GCTGCTGCAAGGATTCGTATTGTGTTTATTCCCAATTCTCAAGAAACTATGGAGGTTAAAACTCTTG                   GAAAACTGGAACGGTACAAACTGCTTCATATTCTGGAATTTGATTCACATCGTAGCACAATGAGTGT                   AATTGTTCAGGCACCTTCAGGTGACAAGTTATTATTTGCTAAAGGACCTGAGTCATCAATTCTCCCT                   AAATGTATAGGTGCAGAAATAGAAAAAACCACAATTCATGTAGATGAATTTGCTTTGAAAGGGCTAA                   GAACTCTGTGTATAGCATATAGAAAATTTACATCAAAAGAGTATCAGCAAATACATAAACGCATATT                   TGAAGCCAGGACTGCCTTGCACCAGCGGGAAGAGAAATTCGCACCTGTTTTCCAGTTCATAGAGAAA                   GACCTGATATTACTTGGAGCCACAGCAGTAGAAGACAGACTACAAGATAAACTTCCACAAACTATTG                   AAGCATTGAGAATGGCTGGTATCAAAGTATGGGTACTTACTGGGGATAAACATGAAACAGCTGTTAG                   TGTGAGTTTATCATGTGGCCATTTTCATAGAACCATGAACATCCTTGAACTTATAAACCAGAAATCA                   GACAGCGAGTCTCCTGAACAATTGAGCCAGCTTGCCAGAAGAATTACAGAGGATCATGTGATTCAGC                   ATGGGCTGGTAGTGGATGGGACCAGCCTATCTCTTGCACTCAGGGAGCATCAAAAACTATTTATGGA                   ACTTTGCACAAATTCTTCAGCTGTATTATGCTGTCGTATGGCTCCACTCCAGAAAGCAAAAGTAATA                   AGACTAATAAAAATATCACCTGAGAAACCTATAACATTCGCTGTTGCTGATGCTCCTAATGACGTAA                   GCATGATACAAGAAGCCCATGTTGGCATAGGAATCATGGGTAAAGAAGGAAGACACGCTGCAAGAAA                   CAGTGACTATGCAATAGCCACATTTAAGTTCCTCTCCAAATTGCTTTTTGTTCATGGTCATTTTTAT                   TATATTAGAATAGCTACCCTTGTACAGTATTTTTTTTATAAGAATGTGTGCTTTATCACACCCCAGT                   TTTTATATCAGTTCTACTGTTTGTTTTCTCACCAAACATTGTATGACACCGTCTACCTGACTTTATA                   CAATATTTGTTTTACTTCCCTACCTATTCTCATATATACTCTTTTCGAACAGCATGTAGACCCTCAT                   GTGTTACAAAATAAGCCCACCCTTTATCGAGACATTAGTAAAAACCGCCTCTTAAGTATTAAAACAT                   TTCTTTATTGCACCATCCTGGGCTTCAGTCATCCCTTTATTTTCTTTTTTGGATCCTATTTACTAAT                   AGGGAAAGATACATCTCTGCTTCGAAATCGCCAGATGTTTGCAAACTCCACATTTGGCACTTTGGTC                   TTCACAGTCATGGTTATTACAGTCACAGTAAACATGGCTCTGGAAACTCATTTTTGGACTTGGATCA                   ACCATCTCGTTACCTGGGGATCTATTATATTTTATTTTGTATTTTCCTTGTTTTATGGAGCGATTCT                   CTGGCCATTTTTGGGCTCCCAGAATATGTATTTTGTGTTTATTCAGCTCCTGTCAAGTGGTTCTGCT                   TGGTTTGCCATAATCCTCATGGTTGTTACATGTCTATTTCTTGATATCATAAAGAAGGTCTTTGACC                   GACACCTCCACCCTACAAGTACTGAAAAGCCACAGCTTACTGAAACAAATGCAGGTATCAACTGCTT                   GGACTCCATGTGCTCTTTCCCCGAAGGAGAAGCAGCGTGTGCATCTGTTGGAAGAATGCTGGAACGA                   GTTATAGGAAGATCTAGTCCAACCCACATCACCAGATCATGGAGTGCATCGGATCCTTTCTATACCA                   ACGACAGGAGCATCTTGACTCTCTCCACAATGGACTCATCTACTTGTTAA AGGGGCAGTAGTACTTT                       GTGGCAGCCAGTTCACCTCCTTTCCTAAAATTC                                           ORF Start: ATG at 35   ORF Stop: TAA at 3398                                         SEQ ID NO: 70   1121 aa   MW at 127704.1kD                             NOV10a,    MWRWIRQQLGFDPPHQSDTRTIYVANRFPQNGLYTPQKFIDNRIISSKYTVWNFVPKNLFEQFRRVA           CS137109-01        Protein Sequence   NFYFLIIFLVQLMIDTFTSPVTSGLPLFFVITVTAIKQGYEDWLRHNSDNEVNCAPVYVVRSGGLVK                   TRSKNIRVGDIVRIAKDEIFPADLVLLSSDRLDGSCHVTTASLDCETNLKTHVAVPETALLQTVANL                   DTLVAVIECQQFEADLYRFMGRMIITQQMEEIVRPLCPESLLLRGARLKNTKEIFCLYIFKHFKLGV                   AVYTCMETKMALNYKSKSQKRSAVEKSMNTFLIIYLVILISEAVISTILKYTWQAEEKWDEPWYNQK                   TEHQRNSSKVEYVFTDKTGTLTENEMQFRECSINGMXYQEINGRLVPEGPTPDSSEGNLSYLSSLSH                   LNNLSHLTTSSSFRTSPENETELVKEHDLFFKAVSLCHTVQISNVQTDCTGDGPWQSNLAFSQLEYY                   ASSPDEKALVEAAARIGIVFICNSEETMEVKTLGKLERYKLLHILEFDSDRRRMSVIVQAFSGEKLL                   FAKGAESSILPKCIGGEIEKTRIHVDEFALKCLRTLCIAYRKFTSKEYEEIDKRIFEARTALQQREE                   KLAAVFQFIEKDLILLCATAVEDRLQDKVRETIEALRMAGIKVWVLTGDKHETAVSVSLSCCHFHRT                   MNILELINQKSDSECAEQLRQLARRITEDHVIQNGLVVDCTSLSLALREHEKLFMEVCRNCSAVLCC                   RMAPLQKAKVIRLIKISPEKPITLAVGDCANDVSMIQEAHVGIGIMCKEGRQAARNSDYAIARFKFL                   SKLLFVHGHFYYIRTATLVQYFFYKNVCFITPQFLYQFYCLFSQQTLYDSVYLTLYNICFTSLPILI                   YSLLEQHVDPHVLQNKPTLYRDISKNRLLSIKTFLYWTILGFSHAFIFFFGSYLLIGKDTSLLGNGQ                   NFGNWTFGTLVFTVMVITVTVKMALETHFWTWINHLVTWCSIIFYFVFSLFYCCILWPFLGSQNMYF                   VFTQLLSSCSAWFAIILMVVTCLFLDIIKKVFDRULHFTSTEKAQLTETUAGIKCLDSMCCFPEGEA                   ACASVGRMLERVIGRCSPTHISRSWSASDPFYTNDRSTLTLSTMDSSTC                  
 
     [0403] Further analysis of the NOV10a protein yielded the following properties shown in Table 10B.  
               TABLE 10B                       Protein Sequence Properties NOV10a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane); 0.3000           probability located in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0404] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10C.  
               TABLE 10C                          Geneseq Results for NOV10a                                         NOV10a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAO14203   Human transporter and ion   1 . . . 1095   1084/1095 (98%)   0.0           channel TRICH-20 -  Homo     1 . . . 1085   1085/1095 (98%)             sapiens , 1096 aa.           [WO200204520-A2,           17 JAN. 2002]       AAG67546   Amino acid sequence of a   1 . . . 1121   1064/1187 (89%)   0.0           human transporter protein -   1 . . . 1177   1081/1187 (90%)             Homo sapiens , 1177 aa.           [WO200164878-A2,           07 SEP. 2001]       AAM39290   Human polypeptide SEQ ID   327 . . . 1121     780/804 (97%)   0.0           NO 2435 -  Homo sapiens ,   12 . . . 815     789/804 (98%)           815 aa. [WO200153312-A1,           26 JUL. 2001]       AAM41076   Human polypeptide SEQ ID   344 . . . 1121     775/778 (99%)   0.0           NO 6007 -  Homo sapiens ,   5 . . . 782     778/778 (99%)           782 aa. [WO200153312-A1,           26 JUL. 2001]       AAO14200   Human transporter and ion   18 . . . 1050     591/1129 (52%)   0.0           channel TRICH-17 -  Homo     22 . . . 1109     759/1129 (66%)             sapiens , 1192 aa.           [WO200204520-A2,           17 JAN. 2002]                  
 
     [0405] In a BLAST search of public sequence datbases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 10D.  
               TABLE 10D                          Public BLASTP Results for NOV10a                                         NOV10a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9N0Z4   RING-finger binding   9 . . . 1121   1047/1117 (93%)    0.0           protein -  Oryctolagus     1 . . . 1107   1080/1117 (95%)              cuniculus  (Rabbit), 1107           aa (fragment).       Q9Y2G3   Potential   450 . . . 1121     672/672 (100%)   0.0           phospholipid-transporting   1 . . . 672     672/672 (100%)           ATPase IR (EC 3.6.3.1) -             Homo sapiens  (Human), 672           aa (fragment).       Q8R0F1   Hypothetical 69.8 kDa   508 . . . 1121    573/614 (93%)   0.0           protein -  Mus musculus     1 . . . 613    596/614 (96%)           (Mouse), 613 aa (fragment).       T42662   hypothetical protein   698 . . . 1121     424/424 (100%)   0.0           DKFZp434N1615.1 - human,   1 . . . 424     424/424 (100%)           424 aa (fragment).       P98196   Potential   299 . . . 1050    407/789 (51%)   0.0           phospholipid-transporting   15 . . . 772    537/789 (67%)           ATPase IS (EC 3.6.3.1) -             Homo sapiens  (Human), 797           aa (fragment).                  
 
     [0406] PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10E.  
     [0407] PFam analysis predicts that the NOV10a protein contained the domains shown in the Table 10E.  
               TABLE 10E                          Domain Analysis of NOV10a                                     Identities/                   Similarities           NOV10a   for the Matched   Expect       Pfam Domain   Match Region   Region   Value               E1-E2_ATPase   126 . . . 164   10/39 (26%)   0.13               32/39 (82%)       Hydrolase   345 . . . 786   48/453 (11%)    6.6e−09               277/453 (61%)                   
 
     Example 11  
     [0408] The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.  
               TABLE 11A                       NOV11 Sequence Analysis                                                    SEQ ID NO: 71   2077 bp                             NOV11a,      GGCGAGGCGAGGTTTGCTGGOGTGAGGCAGCGGCGCGGCCGGGCCGGGCCGOGCCACAGGCGGTGGC             CG137330-01        DNA Sequence      GGCGGGACC ATGGACGCGGCGGTCGCTGCTCCGCGTCCCCGGCTGCTCCTCCTCGTGCTGGCGGCGG                   CGGCGGCGGCGGCGGCCGCGCTGCTCCCGGGGGCGACGGCGTTACAGTGTTTCTGCCACCTCTGTAC                   AAAAGACAATTTTACTTGTGTGACAGATGGGCTCTGCTTTGTCTCTGTCACAGAGACCACAGACAAA                   GTTATACACAACAGCATGTGTATAGCTGAAATTGACTTAATTCCTCGAGATAGGCCGTTTGTATGTG                   CACCCTCTTCAAAAACTGGGTCTGTGACTACAACATATTCCTGCAATCAGGACCATTGCAATAAAAT                   AGAACTTCCAACTACTGGTTTACCATTGCTTGTTCAGAGAACAATTGCGAGAACTATTGTGTTACAA                   GAAAGCATTGGCAAAGGTCGATTTGGAGAAGTTTGGAGAGGAAAGTCGCGGGGAGAAGAAGTTGCTG                   TTAAGATATTCTCCTCTACAGAAGAACGTTCGTGGTTCCGTGAGGCAGAGATTTATCAAACTGTAAT                   GTTACGTCATGAAAACATCCTGGGATTTATAGCAGCAGACAATAAAGACAATGGTACTTGGACTCAG                   CTCTGGTTGGTGTCAGATTATCATGAGCATGGATCCCTTTTTGATTACTTAAACAGATACACAGTTA                   CTGTGGAAGGAATGATAAAACTTGCTCTGTCCACGGCCAGCGGTCTTGCCCATCTTCACATGGAGAT                   TGTTGGTACCCAAGGAAAGCCAGCCATTGCTCATAGAGATTTGAAATCAAAGAATATCTTGGTAAAG                   AAGAATGGAACTTGCTGTATTGCAGACTTAGGACTGGCAGTAAGACATGATTCAGCCACAGATACCA                   TTGATATTGCTCCAAACCACAGAGTGGGAACAAAAAGGTACATGGCCCCTGAAGTTCTCGATGATTC                   CATAAATATGAAACATTTTGAATCCTTCAAACGTGCTGACATCTATGCAATGGGCTTAGTATTCTGG                   GAAATTGCTCGACGATGTTCCATTGGTGGAATTCATGAAGATTACCAACTGCCTTATTATGATCTTG                   TACCTTCTGACCCATCAGTTGAAGAAATGAGAAAAGTTGTTTGTGAACAGAAGTTAAGGCCAAATAT                   CCCAAACAGATGGCAGAGCTGTGAAGCCTTGAGAGTAATGGCTAAAATTATGAGAGAATGTTGGTAT                   GCCAATGGAGCAGCTAGGCTTACAGCATTGCGGATTAAGAAAACATTATCGCAACTCAGTCAACAGG                   AAGGCATCAAAATGTAA TTCTACAGCTTTGCCTGAACTCTCCTTTTTTCTTCAGATCTGCTCCTGGG                       TTTTAATTTGGGAGGTCAGTTGTTCTACCTCACTGAGAGGGAACAGAAGGATATTGCTTCCTTTTGC                       AGCAGTGTAATAAAGTCAATTAAAAACTTCCCAGGATTTCTTTGGACCCAGGAAACAGCCATGTGGG                       TCCTTTCTGTGCACTATGAACGCTTCTTTCCCAGGACAGAAAATGTGTAGTCTACCTTTATTTTTTA                       TTAACAAAACTTGTTTTTTAAAAAGATGATTGCTGGTCTTAACTTTAGGTAACTCTGCTGTGCTGGA                       GATCATCTTTAAGGGCAAAGGAGTTGGATTCCTGAATTACAATGAAACATGTCTTATTACTAAAGAA                       AGTGATTTACTCCTGGTTAGTACATTCTCAGAGGATTCTGAACCACTAGAGTTTCCTTGATTCAGAC                       TTTGAATGTACTGTTCTATAGTTTTTCAGGATCTTAAAACTAACACTTATAAAACTCTTATCTTGAG                       TCTAAAAATCACCTCATATAGTAGTGAGGAACATAATTCATGCAATTGTATTTTGTATACTATTATT                       GTTCTTTCACTTATTCAGAACATTACATGCCTTCAAAATGGGATTGTACTATACCAGTAAGTGCCAC                       TTCTGTGTCTTTCTAATGGAAATGAGTAGAATTGCTGAAAGTCTCTATGTTAAAACCTATAGTGTTT                                           ORF Start: ATG at 77   ORF Stop: TAA at 1355                                         SEQ ID NO: 72   426 aa   MW at 47689.6kD                             NOV11a,    MEAAVAAPRPRLLLLVLAAAAAAAAALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIH           CG137330-01        Protein Sequence   NSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTGLPLLVQRTIARTIVLQESI                   GKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWL                   VSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHNEIVGTQGKPAIARRDLKSKNILVKKNG                   TCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIA                   RRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANG                   AARLTALRIKKTLSQLSQQEGIKM                  
 
     [0409] Further analysis of the NOV11a protein yielded the following properties shown in Table 11B.  
               TABLE 11B                       Protein Sequence Properties NOV11a                                        PSort   0.8200 probability located in outside; 0.1900       analysis:   probability located in lysosome (lumen); 0.1038           probability located in microbody (peroxisome); 0.1000           probability located in endoplasmic reticulum (membrane)       SignalP   Cleavage site between residues 34 and 35       analysis:                  
 
     [0410] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11C.  
               TABLE 11C                          Geneseq Results for NOV11a                                         NOV11a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAY59452   Human Transforming growth   114 . . . 426   312/313 (99%)   0.0           factor-beta protein sequence -   191 . . . 503   313/313 (99%)             Homo sapiens , 503 aa.           [JP11326328-A,           26 NOV. 1999]       AAY33303   Human hALK-5 clone   114 . . . 426   312/313 (99%)   0.0           EMBLA protein -  Homo     191 . . . 503   313/313 (99%)             sapiens , 503 aa.           [WO9946386-A1,           16 SEP. 1999]       AAW03758   Mullerian inhibiting   114 . . . 426   312/313 (99%)   0.0           substance receptor MISR4 -   189 . . . 501   313/313 (99%)           Rattus sp, 501 aa.           [US5538892-A,           23 JUL. 1996]       AAR70241   Serine/threonine kinase   114 . . . 426   312/313 (99%)   0.0           receptor W120 -  Mus     191 . . . 503   313/313 (99%)             musculus , 503 aa.           [WO9507982-A,           23 MAR. 1995]       AAR41923   MISR4 -  Rattus rattus , 501   114 . . . 426   312/313 (99%)   0.0           aa. [WO9319177-A,   189 . . . 501   313/313 (99%)           30 SEP. 1993]                  
 
     [0411] In a BLAST search of public sequence datbases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11D.  
               TABLE 11D                          Public BLASTP Results for NOV11a                                         NOV11a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               JC2062   transforming growth factor   114 . . . 426   312/313 (99%)   0.0           beta receptor type I   187 . . . 499   313/313 (99%)           precursor - mouse, 499 aa.       Q9D5H8   Transforming growth factor,   114 . . . 426   312/313 (99%)   0.0           beta receptor I -  Mus     108 . . . 420   313/313 (99%)             musculus  (Mouse), 420 aa.       P80204   TGF-beta receptor type I   114 . . . 426   312/313 (99%)   0.0           precursor (EC 2.7.1.37)   189 . . . 501   313/313 (99%)           (TGFR-1) (TGF-beta type I           receptor)           (Serine/threonine-protein           kinase receptor R4) (SKR4) -             Rattus norvegicus  (Rat), 501           aa.       Q64729   TGF-beta receptor type I   114 . . . 426   312/313 (99%)   0.0           precursor (EC 2.7.1.37)   191 . . . 503   313/313 (99%)           (TGFR-1) (TGF-beta type I           receptor) (ESK2) -  Mus               musculus  (Mouse), 503 aa.       P36897   TGF-beta receptor type I   114 . . . 426   312/313 (99%)   0.0           precursor (EC 2.7.1.37)   191 . . . 503   313/313 (99%)           (TGFR-1) (TGF-beta type I           receptor)           (Serine/threonine-protein           kinase receptor R4) (SKR4)           (Activin receptor-like kinase           5) (ALK-5) -  Homo sapiens             (Human), 503 aa.                  
 
     [0412] PFam analysis predicts that the NOV11a protein contains the domains shown in the Table 11E.  
               TABLE 11E                          Domain Analysis of NOV11a                                     Identities/                   Similarities           NOV11a   for the Matched   Expect       Pfam Domain   Match Region   Region   Value               Activin_recp   21 . . . 114   40/118 (34%)   9.4e−30               77/118 (65%)       pkinase   128 . . . 415    85/312 (27%)   6.1e−61               222/312 (71%)                   
 
     Example 12  
     [0413] The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.  
               TABLE 12A                       NOV12 Sequence Analysis                                                    SEQ ID NO: 73   5367 bp                             NOV12a,      GCCGCGCTGCGCCGGAGTCCCGAGCTAGCCCCGGCGCCGCCGCCGCCCAGACCGGACGACAGGCCAC             CS137339-01        DNA Sequence      CTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCCCGCACGGCCCCCTGA                       CTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCG ATGCGACCCTCCGGG                   ACGGCCCGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAA                   AGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACOCAGTTCGGCACTTTTGAAGATCATTTTCTCAG                   CCTCCACACGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGG                   AATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACA                   CAGTGGAGCCAATTCCTTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTA                   TGCCTTAGCAGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAAT                   TTACAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAGAGCA                   TCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTCCAGAACCACCT                   GGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGACCTGCTGGGGTGCAGGAGAGCAGAAC                   TGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCCGGGCGCTGCCGTGGCAAGTCCCCCA                   GTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGCACAGGCCCCCGGGAGAGCGACTGCCTGGTCTG                   CCGCAAATTCCGAGACGAAGCCACGTGCAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACC                   ACGTACCAGATGGATGTGAACCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCCTGAAGAAGTGTC                   CCCGTAATTATGTGGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGAT                   GGAGGAAGACGGCGTCCGCAAGTGTAAGAACTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA                   GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCA                   CCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGCTCAGTTTTCTCTTGCAGT                   CGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGATGTGATA                   ATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTGTTTGGGACCTCCG                   GTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCA                   TGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCGGAATGTC                   AGCCGACGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGGGAGCCAAGGGAGTTTGTGGAGA                   ACTCTGAGTGCATACAGTGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACG                   GGGACCAGACAACTGTATCCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCG                   GCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACC                   TGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCC                   TAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTCGTGGCCCTGGGG                   ATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGGAGGCTGCTGCAGGAGA                   GGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCTTGAA                   GGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCCGGTGCGTTCGGCACGGTGTATAAGGGACTC                   TGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTC                   CGAAAGCCAACAAGGAAATCCTCGATGAAGCCTACGTGATCGCCAGCGTGGACAACCCCCACGTGTG                   CCGCCTGCTGGGCATCTGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCCGCTGC                   CTCCTGGACTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGC                   AGATCGCAAAGGGCATGAACTACTTCGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAA                   CGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCG                   GAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGGATGGCATTGGAATCAATTT                   TACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTACGGGGTGACCGTTTGGGAGTTGATGAC                   CTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAA                   CGCCTCCCTCAGCCACCCATATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAG                   ACGCAGATAGTCGCCCAAAGTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCA                   GCGCTACCTTGTCATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTAC                   CGTGCCCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGC                   AGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAA                   CAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTC                   TTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCC                   CAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTA                   TCACAATCAGCCTCTGAACCCCGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGCACTGCA                   GTGGGCAACCCCGAGTATCTCAACACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTG                   CCCACTGGGCCCAGAAAGGCAGCCACCAAATTAGCCTCGACAACCCTGACTACCAGCAGGACTTCTT                   TCCCAAGGAACCCAAGCCAAATCGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGG                   GTCGCGCCACAAAGCAGTGAATTTATTGGAGCATGA CCACGGAGGATAGTATGAGCCCTAAAAATCC                       AGACTCTTTCGATACCCAGGACCAAGCCACAGCAGGTCCTCCATCCCAACAGCCATGCCCGCATTAG                       CTCTTAGACCCACAGACTGGTTTTGCAACGTTTACACCGACTAGCCAGGAAGTACTTCCACCTCGGG                       CACATTTTGGGAAGTTGCATTCCTTTGTCTTCAAACTGTGAAGCATTTACAGAAACCCATCCAGCAA                       GAATATTGTCCCTTTGAGCAGAAATTTATCTTTCAAAGAGGTATATTTCAAAAAAAAAAAAAAAGTA                       TATGTGAGGATTTTTATTGATTGGGGATCTTGGAGTTTTTCATTGTCGCTATTGATTTTTACTTCAA                       TGGGCTCTTCCAACAAGGAAGAAGCTTGCTCGTAGCACTTGCTACCCTGAGTTCATCCAGGCCCAAC                       TGTGAGCAAGGAGCACAAGCCACAAGTCTTCCAGAGGATGCTTGATTCCAGTGGTTCTGCTTCAAGG                       CTTCCACTGCAAAACACTAAAGATCCAAGAAGGCCTTCATGGCCCCAGCAGGCCGGATCGGTACTGT                       ATCAAGTCATGCCAGGTACAGTAGGATAAGCCACTCTGTCCCTTCCTGGGCAAAGAAGAAACGGAGG                       GGATGAATTCTTCCTTAGACTTACTTTTGTAAAAATGTCCCCACGGTACTTACTCCCCACTGATGGA                       CCAGTGGTTTCCAGTCATGAGCGTTAGACTGACTTGTTTGTCTTCCATTCCATTGTTTTGAAACTCA                       GTATGCCGCCCCTGTCTTGCTGTCATGAAATCAGCAAGAGAGGATGACACATCAAATAATAACTCGG                       ATTCCAGCCCACATTGGATTCATCAGCATTTGGACCAATAGCCCACAGCTGAGAATGTGGAATACCT                       AAGGATAACACCGCTTTTGTTCTCGCAAAAACGTATCTCCTAATTTGAGGCTCAGATGAAATGCATC                       AGGTCCTTTGGGGCATAGATCAGAAGACTACAAAAATCAACCTGCTCTGAAATCTCCTTTAGCCATC                       ACCCCAACCCCCCAAAATTAGTTTGTGTTACTTATGGAAGATAGTTTTCTCCTTTTACTTCACTTCA                       AAAGCTTTTTACTCAAAGAGTATATGTTCCCTCCAGGTCAGCTGCCCCCAAACCCCCTCCTTACGCT                       TTGTCACACAAAAAGTGTCTCTGCCTTGAGTCATCTATTCAAGCACTTACAGCTCTGGCCACAACAG                       GGCATTTTACAGGTGCGAATGACAGTAGCATTATGAGTAGTGTGAATTCAGGTAGTAAATATGAAAC                       TAGGGTTTGAAATTGATAATGCTTTCACAACATTTGCAGATGTTTTAGAAGGAAAAAAGTTCCTTCC                       TAAAATAATTTCTCTACAATTGGAAGATTGGAAGATTCAGCTAGTTAGGAGCCCATTTTTTCCTAAT                       CTGTGTGTGCCCTGTAACCTGACTGGTTAACAGCAGTCCTTTGTAAACAGTGTTTTAAACTCTCCTA                       GTCAATATCCACCCCATCCAATTTATCAAGGAACAAATGGTTCAGAAAATATTTTCAGCCTACAGTT                       ATGTTCAGTCACACACACATACAAAATGTTCCTTTTGCTTTTAAAGTAATTTTTGACTCCCAGATCA                       GTCAGAGCCCCTACAGCATTGTTAAGAAAGTATTTGATTTTTGTCTCAATGAAAATAAAACTATATT                       CATTTCC                                           ORF Start: ATG at 187   ORF Stop: TGA at 3652                                         SEQ ID NO: 74   1155 aa   MW at 127869.7kD                             NOV12a,    MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTPEDHFLSLQRMFNNCEVVLGNLEI           CG137339-01        Protein Sequence   TYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANXTGLKE                   LPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWG                   AGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLM                   LYNPTTYQMDVNPEGKYSEGATCVKKCPRNYVVTDHCSCVRACGADSYEMEEDGVRKCKKCEGPCRK                   VCNGTGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGGQFSLAVVSLNITSLGLRSLKEIS                   DGDVIISGNXNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCV                   SCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNTTCTGRGPDNCIQCAHYIDGPHC                   VKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGNVGALLLLL                   VVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGT                   VYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQL                   NPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGNNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLA                   KLLGAEEKEYHAEGGKVPIKWMALESILHRIYThQSDVWSYGVTVWELMTFGSKPYDGIPASEISSI                   LEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVXQGDERMHLPSPT                   DSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPI                   KEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQD                   PHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAEN                   AEYLRVAPQSSEFIGA                                         SEQ ID NO: 75   3633 bp                             NOV12b,    ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTC           CG137339-02        DNA Sequence    GGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCACTTGGGCACTTTTGA                   AGATCATTTTCTCAGCCTCCAOAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATT                   ACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTGGCTGGTTATGTCC                   TCATTGCCCTCAACACAGTGGAGCGAATTCCTTTGGAAAACCTGCAGATCATCAGAGGAAATATGTA                   CTACGAAAATTCCTATGCCTTAGCAGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAACGAG                   CTGCCCATGAGAAATTTACAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGT                   GCAACGTGGAGAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATCGA                   CTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGGCGT                   GCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCCGGGCGCTGCC                   GTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGCACAGGCCCCCGGGAGAG                   CGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGCAAGGACACCTGCCCCCCACTCATG                   CTCTACAACCCCACCACGTACCAGATGGATGTGAACCCCGAGGGCAAATACAGCTTTGGTGCCACCT                   GCGTGAAGAAGTGTCCCCGTAATTATGTGOTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGC                   CGACAGCTATGAGATGGAGGAAGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAA                   GTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAAC                   ACTTCAAAAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTC                   CTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCACA                   GGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAGAAA                   TCATACGCGGCAGGACCAAGCAACATGGTCAGTTTPCTCTTGCAGTCGTCAGCCTGAACATAACATC                   CTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTG                   TGCTATGCAAATACAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATAA                   GCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGG                   CTGCTGGGGCCCOGAGCCCAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTG                   GACAAGTGCAAGCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCC                   ACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATCCA                   GTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATGGGAGAAAAC                   AACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAAACTGCACCT                   ACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCAC                   TGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGCGAAGG                   CGCCACATCGTTCGGAAGCGCACGCTGCGGAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTA                   CACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGAT                   CAAAGTGCTCGGCTCCGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAA                   GTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCC                   TCGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATCTGCCT                   CACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGACTATGTCCGGGAA                   CACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAGGGCATGAACT                   ACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCA                   GCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTCCTGGGTGCGGAAGAGAAAGAATACCATGCA                   GAAGGAGGCAAAGTGCCTATCAAGTGGATGGCATTGGAATCAATTTTACACAGAATCTATACCCACC                   AGAGTGATGTCTGGAGCTACGGGGTGACCGTTTCGGAGTTGATGACCTTTGGATCCAAGCCATATGA                   CGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATA                   TGTACCATCCATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAGT                   TCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTCATTCAGGG                   GGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCCCTGATGGATGAAGAA                   GACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAGCAGCCCCT                   CCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCAT                   TGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGAC                   CCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACC                   AGTCCGTTCCCAAAAGGCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCC                   CGCGCCCAGCAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTC                   AACACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAAGGCA                   GCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAA                   TGGCATCTTTAAGGCCTCCACAGCTGAAAATGCAGAATACCTAAGGGTCGCGCCACAAAGCAGTGAA                   TTTATTGGAGCATGA                                         ORF Start: ATG at 1   ORF Stop: TGA at 3631                                         SEQ ID NO: 76   1210 aa   MW at 134289.9kD                             NOV12b,    MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEI           CG137339-02        Protein Sequence   TYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKE                   LPNRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNCSCWG                   AGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLM                   LYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRK                   VCNGIGIGEFKDSLSTNATNIKHFKNCTSISGDLHILPVAFRGDSFThTPPLDPQELDILKTVKEIT                   GFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISCNKNL                   CYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECV                   DKCKLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGEN                   NTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRR                   RHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEK                   VKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVRE                   HKDNIGSQYLLNWCVQIAXGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHA                   EGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPI                   CTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVTQGDERMHLPSPTDSNFYRALMDEE                   DMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSD                   PTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYL                   NTVQFTCVNSTFDSPAHWAQKGSMQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSE                   FIGA                  
 
     [0414] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 12B.  
               TABLE 12B                          Comparison of NOV12a against NOV12b.                                 Protein   NOV12a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV12b   1 . . . 1155   1049/1210 (86%)               1 . . . 1210   1051/1210 (86%)                      
 
     [0415] Further analysis of the NOV12a protein yielded the following properties shown in Table 12C.  
               TABLE 12C                       Protein Sequence Properties NOV12a                                                PSort   0.8834 probability located in plasma membrane;           analysis:   0.1000 probability located in endoplasmic               reticulum (membrane); 0.1000 probability located               in endoplasmic reticulum (lumen);               0.1000 probability located in outside           SignalP   Cleavage site between residues 25 and 26           analysis:                      
 
     [0416] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D.  
               TABLE 12D                          Geneseq Results for NOV12a                                         NOV12a                       Residues/   Identities/       Geneseq   Protein/Organism/Length   Match   Similarities for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                         AAB68420   Amino acid sequence of   1 . . . 1155   1149/1210 (94%)   0.0           wild type EGFR1 -  Homo     1 . . . 1210   1149/1210 (94%)             sapiens , 1210 aa.           [WO200136659-A2,           25 MAY 2001]       AAE23019   Human Her-1 protein #1 -   1 . . . 1155   1148/1210 (94%)   0.0             Homo sapiens , 1210 aa.   1 . . . 1210   1148/1210 (94%)           [WO200226758-A1,           04 APR. 2002]       AAM50768   Human epidermal growth   1 . . . 1155   1148/1210 (94%)   0.0           factor receptor precursor -   1 . . . 1210   1148/1210 (94%)             Homo sapiens , 1210 aa.           [WO200198321-A1,           27 DEC. 2001]       AAY50616   Human EGF receptor protein -   1 . . . 1155   1148/1210 (94%)   0.0             Homo sapiens , 1210 aa.   1 . . . 1210   1148/1210 (94%)           [US5985553-A,           16 NOV. 1999]       AAB19259   Amino acid sequence of an   1 . . . 1155   1148/1210 (94%)   0.0           epidermal growth factor   1 . . . 1210   1148/1210 (94%)           receptor -  Homo sapiens ,           1210 aa. [US6127126-A,           03 OCT. 2000]                  
 
     [0417] In a BLAST search of public sequence datbases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E.  
               TABLE 12E                          Public BLASTP Results for NOV12a                                         NOV12a               Protein       Residues/   Identities/       Accession       Match   Similarities for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                         P00533   Epidermal growth factor   1 . . . 1155   1149/1210 (94%)   0.0           receptor precursor (EC   1 . . . 1210   1149/1210 (94%)           2.7.1.112) (Receptor           protein-tyrosine kinase           ErbB-1) -  Homo sapiens             (Human), 1210 aa.       GQHUE   epidermal growth factor   1 . . . 1155   1148/1210 (94%)   0.0           receptor precursor - human,   1 . . . 1210   1148/1210 (94%)           1210 aa.       Q01279   Epidermal growth factor   1 . . . 1155   1040/1212 (85%)   0.0           receptor precursor (EC   1 . . . 1210   1091/1212 (89%)           2.7.1.112) - Mus musculus             (Mouse), 1210 aa.       A53183   epidermal growth factor   1 . . . 1155   1039/1212 (85%)   0.0           receptor precursor - mouse,   1 . . . 1210   1091/1212 (89%)           1210 aa.       Q9EP98   Epidermal growth factor   1 . . . 1155   1039/1212 (85%)   0.0           receptor isoform 1 -  Mus     1 . . . 1210   1090/1212 (89%)             musculus  (Mouse), 1210 aa.                  
 
     [0418] PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12F.  
               TABLE 12F                          Domain Analysis of NOV12a                                     Identities/                   Similarities           NOV12a   for the           Match   Matched   Expect       Pfam Domain   Region   Region   Value               Recep_L_domain    57 . . . 180   54/133 (41%)   5.1e−59               116/133 (87%)        Furin-like   184 . . . 338   93/183 (51%)     2e−99               150/183 (82%)        Recep_L_domain   341 . . . 437   32/132 (24%)   2.8e−11               74/132 (56%)       pkinase   657 . . . 910   80/294 (27%)     1e−74               210/294 (71%)                   
 
     Example 13  
     [0419] The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.  
               TABLE 13A                       NOV13 Sequence Analysis                                                    SEQ ID NO: 77   4145 bp                             NOV13a,      GGCGGGCGGGCGGGCGGCTGCGAGCATGGTCCTGGTGCTGCACCACATCCTCATCGCTGTTGTCCAA             CG138130-01        DNA Sequence      TTCCTCACGCGGGGCCAGCACGTCTTCCTCAAGCCGGACGAGCCGCCGCCCCCGCCGCAGCC ATGCG                   CCGACAGCCTGCAGCCAGCCTGGACCCCCTTGCAAAGGAGCCAGGACCCCCACGGAGTAGACACGAC                   CGACTGGAGGACGCCTTGCTGAGTCTGGGCTCTGTCATCGACATTTCAGGCCTGCAACGTGCTGTCA                   AGGAGGCCCTGTCAGCTGTGCTCCCCCGAGTGGAAACTGTCTACACCTACCTACTGGATGGTGAGTC                   CCAGCTGGTGTGTGAGGACCCCCCACATGAGCTGCCCCAGGAGGGGAAAGTCCGGGAGGCTATCATC                   TCCCAGAAGCGGCTGGGCTGCAATGGGCTGGGCTTCTCAGACCTGCCACGGAAGCCCTTGGCCAGGC                   TGGTGGCTCCACTGGCTCCTGATACCCAAGTGCTGGTCATGCCGCTACCGGACAAGGAGGCTGGCGC                   CGTGGCAGCTGTCATCTTGGTGCACTGTGGCCAGCTGAGTGATAATGAGGAATGGAGCCTGCAGGCG                   GTGGAGAAGCATACCCTGGTCGCCCTGCGGAGGGTGCAGGTCCTGCAGCAGCGCGGGCCCAGGGAGG                   CTCCCCGAGCCGTCCAOAACCCCCCGGAGGGGACGGCGGAAGACCAGAAGGGCGGGGCGGCGTACAC                   CGACCGCGACCGCAAGATCCTCCAACTGTGCGGGGAACTCTACGACCTGGATGCCTCTTCCCTGCAG                   CTCAAAGTGCTCCAATACCTGCAGCAGGAGACCCGGGCATCCCGCTGCTGCCTCCTGCTGGTGTCGG                   AGGACAATCTCCAGCTTTCTTGCAAGGTCATCGGAGACAAAGTGCTCGGGGAAGAGGTCAGCTTTCC                   CTTGACAGGATGCCTGGGCCAGGTGGTGGAAGACAAGAAGTCCATCCAGCTGAAGGACCTCACCTCC                   GAGGATGTACAACAGCTGCAGAGCATGTTGGGCTGTGAGCTGCAGGCCATGCTCTGTGTCCCTGTCA                   TCAGCCGGGCCACTGACCAGGTGGTGGCCTTGGCCTGCGCCTTCAACAAGCTAGAAGGAGACTTGTT                   CACCGACGAGGACGAGCATGTGATCCAGCACTGCTTCCACTACACCAGCACCGTGCTCACCAGCACC                   CTGGCCTTCCAGAAGGAACAGAAACTCAAGTGTGAGTGCCAGGCTCTTCTCCAAGTGGCAAAGAACC                   TCTTCACCCACCTGGATGACGTCTCTGTCCTGCTCCAGGAGATCATCACGGAGGCCAGAAACCTCAG                   CAACGCAGAGATCTGCTCTGTGTTCCTGCTGGATCAGAATGAGCTGGTGGCCAAGGTGTTCGACGGG                   GGCGTGGTGGATGATGAGAGCTATGAGATCCGCATCCCGGCCGATCAGGGCATCGCGGGACACGTGG                   CGACCACGGGCCACATCCTGAACATCCCTOACGCATATGCCCATCCGCTTTTCTACCGCGGCGTGGA                   CGACAGCACCGGCTTCCCCACGCGCAACATCCTCTGCTTCCCCATCAAGAACGAGAACCAGGAGGTC                   ATCGGTGTGGCCGAGCTGGTGAACAAGATCAATGGGCCATGGTTCAGCAAGTTCGACGAGGACCTGG                   CGACGGCCTTCTCCATCTACTGCGGCATCAGCATCGCCCATTCTCTCCTATACAAAAAAGTGAATGA                   GGCTCAGTATCGCAGCCACCTGGCCAATGAGATGATGATGTACCACATGAAGGTCTCCGACGATGAG                   TATACCAAACTTCTCCATGATGGGATCCAGCCTGTGGCTGCCATTGACTCCAATTTTGCAAGTTTCA                   CCTATACCCCTCCTTCCCTGCCCGAGGATGACACGTCCATGGCCATCCTGAGCATGCTCCAGGACAT                   GAATTTCATCAACAACTACAAAATTGACTGCCCGACCCTCGCCCGGTTCTGTTTOATGGTGAAGAAG                   GGCTACCGGGATCCCCCCTACCACAACTGGATGCACGCCTTTTCTGTCTCCCACTTCTGCTACCTGC                   TCTACAAGAACCTGGAGCTCACCAACTACCTCCAGGACATCGAGATCTTTGCCTTGTTTATTTCCTG                   CATGTGTCATGACCTGGACCACAGAGGCACAAACAACTCTTPCCAGGTGGCCTCGAAATCTGTGCTG                   GCTGCGCTCTACAGCTCTGAGGGCTCCGTCATGGAGAGGCACCACTTTGCTCAGGCCATCGCCATCC                   TCAACACCCACGGCTGCAACATCTTTGATCATTTCTCCCGGAAGGACTATCAGCGCATGCTGGATCT                   GATGCGGGACATCATCTTGGCCACAGACCTGGCCCACCATCTCCGCATCTTCAAGGACCTCCAGAAG                   ATGGCTGAGGTGGGCTACGACCGAAACAACAAGCAGCACCACAGACTTCTCCTCTGCCTCCTCATGA                   CCTCCTGTGACCTCTCTGACCAGACCAAGCGCTGGAAGACTACGAGAAAGATCGCGGAGCTGATCTA                   CAAAGAATTCTTCTCCCAGGGAGACCTGGAGAAGGCCATGGGCAACAGGCCGATGGAGATGATGGAC                   CGGGAGAAGGCCTATATCCCTGAGCTGCAAATCAGCTTCATGGAGCACATTGCAATGCCCATCTACA                   AGCTGTTGCAGGACCTGTTCCCCAAAGCGGCAGAGCTGTACGAGCGCGTGGCCTCCAACCGTGAGCA                   CTGGACCAAGGTGTCCCACAAGTTCACCATCCGCGGCCTCCCAAGTAACAACTCGCTGGACTTCCTG                   GATGAGGAGTACGAGGTGCCTGATCTGGATGGCACTAGGGCCCCCATCAATGGCTGCTGCAGCCTTG                   ATGCTGAGTGA TCCCCTCCAGGACACTTCCCTGCCCAGGCCACCTCCCACAGCCCTCCACTGGTCTG                       GCCAGATGCACTCGGAACAGAGCCACGGGTCCTGGGTCCTAGACCAGGACTTCCTGTGTGACCCTGG                       ACAAGTACTACCTTCCTGGGCCTCAGCTTTCTCCTCTGTATAATGGAAGCAAGACTTCCAACCTCAC                       GGAGACTTTGTAATTTCCTTCTCTGAGAGCACAGGGGTGACCAATGAGCAGTGGGCCCTACTCTGCA                       CCTCTGACCACACCTTGGCAAGTCTTTCCCAAGCCATTCTTTGTCTGAGCAGCTTGATGGTTTCTCC                       TTGCCCCATTTCTGCCCCACCAGATCTTTGCTCCTTTCCCTTTGAGGACTCCCACCCTTTGGGTCTC                       CAGGATCCTCATGGAAGGGGAAGCTGAGACATCTGAGTGAGCAGAGTGTGGCATCTTGGAAACAGTC                       CTTAGTTCTGTGGGAGGACTAGAAACAGCCGCGGCGAAGGCCCCCTGAGGACCACTACTATACTGAT                       GGTGGGATTGGGACCTGGGGGATACAGGGGCCCCAGGAAGAAGCTGGCCAGAGGCGCAGCTCAGTGC                       TCTGCAGAGAGGGGCCCTGGGGAGAACCAGGATGGGATTGATGGCCAGGAGGGATCCCCGCACTGGG                       AGACAGGCCCAGGTATGAATGAGCCAGCCATGCTTCCTCCTGCCTGTGTGACGCTGGGCGAGTCTCT                       TCCCCTGTCTGGGCCAAACAGGGAGCGGGPAAGACAATCCATGCTCTAAGATCCATTTTAGATCAAT                       GTCTAAAATAGCTCTATGGCTCTGCGGAGTCCCAGCAGAGGCTATGGAATGTTTCTGCAACCCTAAG                       GCACAGAGAGCCAACCCTGAGTGTCTCAGAGGCCCCCTGAGTGTTCCCCTTGGCCTGAGCCCCTTAC                       CCATTCCTGCAGCCAGTGAGAGACCTGGCCTCAGCCTGGCAGCGCTCTCTTCAAGGCCATATCCACC                       TGTGCCCTGGGGCTTGGGAGACCCCATAGGCCGGCACTCTTGGGTCAGCCCGCCACTGGCTTCTCTC                       TTTTTCTCCGTTTCATTCTGTGTGCGTTGTGGGGTGGGGGAGGGGGTCCACCTGCCTTACCTTTCTG                       AGTTGCCTTTAGAGAGATGCGTTTTTCTAGGACTCTCTGCAACTGTCGTATATGGTCCCGTGGGCTG                       ACCGCTTTGTACATGAGAATAAATCTATTTCTTTCTACCAAAAAAAAAAAAAAAAAAA                                           ORF Start: ATG at 130   ORF Stop: TGA at 2890                                         SEQ ID NO: 78   920aa   MW at 103477.0kD                             NOV13a,    MRRQPAASLDPLAKEPGPPOSRDDRLEDALLSLGSVIDISGLQRAVKEALSAVLPRVETVYTYLLDG           CG138130-01        Protein Sequence   ESQLVCEDPPHELPQEGKVREAIISQKRLGCNGLGESDLPGKPLARLVAPLAPDTQVLVMPLADKEA                   GAVAAVILVHCGQLSDNEEWSLQAVEKHTLVALRRVQVLQQRGPREAPRAVQNPPEGTAEDQKGGAA                   YTDRDRKILQLCGELYDLDASSLQLKVLQYLQQETRASRCCLLLVSEDMLQLSCKVIGDKVLGEEVS                   FPLTGCLGQVVEDKKSIQLKDLTSEDVQQLQSMLGCELQAMLCVPVISRATDQVVALACAFNKLEGD                   LFTDEDEBVIQHCFHYTSTVLTSTLAFQKEQKLKCECQALLQVAKNLFTHLDDVSVLLQEIITEARN                   LSNAEICSVFLLDQNELVAXVFDGGVVDDESYEIRIPADQGIAGHVATTGQILNIPDAYAHPLFYRG                   VDDSTGFRTRNILCFPIKNENQEVIGVAELVNKINGPWFSKFDEDLATAFSIYCGISIAHSLLYKKV                   NEAQYRSHLANEMMMYHMKVSDDEYTKLLHDGIQPVAAIDSNFASFTYTPRSLPEDDTSMAILSMLQ                   DMNFINNYKIDCPTLARFCLMVKKGYRDPPYHNWMHAFSVSHFCYLLYKNLELTNYLEDIEIFALFI                   SCMCHDLDHRGTNNSFQVASKSVLAALYSSEGSVMERHHFAQAIAILNTHGCNIFDHFSRKDYQRML                   DLMRDIILATDLAHHLRIFKDLQKMAEVGYDRNNKQHHRLLLCLLMTSCDLSDQTKGWKTTRKIAEL                   IYKEFFSQGDLEKAMGNRPMEMMDREKAYIPELQISFMEHIAMPIYKLLQDLFPKAAELYERVASNR                   EHWTKVSHKFTIRGLPSNNSLDFLDEEYEVPDLDGTRAPINGCCSLDAE                  
 
     [0420] Further analysis of the NOV13a protein yielded the following properties shown in Table 13B.  
               TABLE 13B                       Protein Sequence Properties NOV13a                                        PSort   0.4500 probability located in cytoplasm; 0.3000       analysis:   probability located in microbody (peroxisome);           0.1000 probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0421] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C.  
               TABLE 13C                          Geneseq Results for NOV13a                                         NOV13a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                         AAB85117   Human cGMP-stimulated   16 . . . 920   898/905 (99%)   0.0           PDE2A3 -  Homo sapiens ,   37 . . . 941   899/905 (99%)           941 aa. [EP1097707-A1,           09 MAY 2001]       AAB85106   Human cGMP-stimulated   16 . . . 920   898/905 (99%)   0.0           PDE2A3 sequence -  Homo     37 . . . 941   899/905 (99%)             sapiens , 941 aa.           [EP1097706-A1,           09 MAY 2001]       AAG66539   Human interferon-alpha   16 . . . 920   898/905 (99%)   0.0           induced polypeptide, PDE2A -   37 . . . 941   899/905 (99%)             Homo sapiens , 941 aa.           [WO200159155-A2,           16 AUG. 2001]       AAE07954   Human phosphodiesterase   16 . . . 920   898/905 (99%)   0.0           (PDE) type 2 protein -  Homo     37 . . . 941   899/905 (99%)             sapiens , 941 aa.           [EP1097719-A1,           09 MAY 2001]       AAE07918   Human phosphodiesterase   16 . . . 920   898/905 (99%)   0.0           (PDE) type 2 protein -  Homo     37 . . . 941   899/905 (99%)             sapiens , 941 aa.           [EP1097718-A1,           09 MAY 2001]                  
 
     [0422] In a BLAST search of public sequence datbases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13D.  
               TABLE 13D                          Public BLASTP Results for NOV13a                                         NOV13a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         O00408   cGMP-dependent 3′,5′-cyclic   16 . . . 920    898/905 (99%)   0.0           phosphodiesterase (EC   37 . . . 941    899/905 (99%)           3.1.4.17) (Cyclic GMP           stimulated           phosphodiesterase)           (CGS-PDE) (cGSPDE) -             Homo sapiens  (Human),           941 aa.       P14099   cGMP-dependent 3′,5′-cyclic   1 . . . 920   873/921 (94%)   0.0           phosphodiesterase (EC   1 . . . 921   894/921 (96%)           3.1.4.17) (Cyclic GMP           stimulated           phosphodiesterase)           (CGS-PDE) (cGSPDE) -  Bos               taurus  (Bovine), 921 aa.       Q01062   cGMP-dependent 3′,5′-cyclic   1 . . . 918   835/919 (90%)   0.0           phosphodiesterase (EC   16 . . . 927    866/919 (93%)           3.1.4.17) (Cyclic GMP           stimulated           phosphodiesterase)           (CGS-PDE) (cGSPDE) -             Rattus norvegicus  (Rat), 928           aa.       AAH29810   Similar to cyclic GMP   407 . . . 918    507/512 (99%)   0.0           stimulated phosphodiesterase -   1 . . . 512   512/512 (99%)             Mus musculus  (Mouse),           513 aa (fragment).       Q922S4   cGMP-dependent 3′,5′-cyclic   555 . . . 918    359/364 (98%)   0.0           phosphodiesterase (EC   1 . . . 364   364/364 (99%)           3.1.4.17) (Cyclic GMP           stimulated           phosphodiesterase)           (CGS-PDE) (cGSPDE) -  Mus               musculus  (Mouse), 365 aa           (fragment).                  
 
     [0423] PFam analysis predicts that the NOV13a protein contains the domains shown in the Table 13E.  
               TABLE 13E                          Domain Analysis of NOV13a                                             Identities/                   NOV13a   Similarities           Pfam   Match   for the   Expect           Domain   Region   Matched Region   Value                       GAF   220 . . . 361    28/148 (19%)   3.8e−16                   104/148 (70%)           GAF   388 . . . 532    45/150 (30%)   2.6e−36                   125/150 (83%)           PDEase   634 . . . 871   119/279 (43%)    1.6e−181                   236/279 (85%)                      
 
     Example 14  
     [0424] The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.  
               TABLE 14A                       NOV14 Sequence Analysis                                                    SEQ ID NO: 79   1216 bp                             NOV14a,      AAGACACGGGCCTGATTCGTCGAGTCTCACTGAGCCTTAGTCGTCGGCAGGTCCCAGGCCCGAAGTT             CG138372-01        DNA Sequence      TCTCGGCCTGGAGGAGGGGGTCGCGCGAAGTGCCAG ATGCAGGCGGGGAAGCCCATCCTCTATTCCT                   ATTTCCGAAGCTCCTGCTCATGGAGAGTTCGAATTGCTCTGGCCTTGAAAGGCATCGACTACAAGAC                   GGTGCCCATCAATCTCATAAAGGATGGGGGCCAACAGTTTTCTAAGGACTTCCAGGCACTGAATCCT                   ATGAAGCAGGTGCCAACCCTGAAGATTGATGGAATCACCATTCACCAGTCACTGGCCATCATTGAGT                   ATCTAGAGGAGACGCGTCCCACTCCGCGACTTCTGCCTCAGGACCCAAAGAAGAGOGCCAGCGTGCG                   TATGATTTCTGACCTCATCGCTGGTGGCATCCAGCCCCTGCAGAACCTGTCTGTCCTGAAGCAAGTG                   GGAGAGGAGATGCAGCTGACCTGGGCCCAGAACGCCATCACTTGTGGCTTTAACGCCCTGGAGCAGA                   TCCTACAGAGCACAGCGGGCATATACTGTGTAGGAGACGAGGTGACCATGGCTGATCTGTGCTTGGT                   GCCTCAGGTGGCAAATGCTGAAAGATTCAAGGTGGATCTCACCCCCTACCCTACCATCAGCTCCATC                   AACAAGAGGCTGCTGGTCTTGGAGGCCTTCCAGGTGTCTCACCCCTGCCGGCAGCCAGATACACCCA                   CTGAGCTGAGGGCCTAG CTCCCAAATCCTGCCCCGTTGGCACAGGGCCACAGGAGCAGAAGCTGGGT                       GGGCTGAAGAGGCCTGGAAACGAGAGTCTTAATTGAGGAGATGGGAGACTCGAACTCTAGCCCTGGA                       TCTGCCTTCCTGCTGAAACTTGTTCCACCTCAGTCCCCTCATCTGTCACACGCATGTGGGGTGGAGT                       AGGGAGATGCGGGGAGCAGGGTGGGCAGGAATACTGTTATCTATGTGACGGGGCAGTCGTGAGGCTG                       AGATGAGAATGCGGATTAAAATGCCTGGCGTGCTCACCGTAACACCACGGGGAAGGCTGTGTGCCTT                       TTCTCATCCGCTTTTGTTGTGTGTGACTCCAAAGAATGCCCGCGCTGAAATTTGGCGTGAATTAAAC                       TGAAGCCCAGGCCTCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA                       AAAAAAAAAA                                           ORF Start ATG at 104   ORF Stop: TAG at 752                                         SEQ ID NO: 80   216 aa   MW at 24082.7kD                             NOV14a,    MQAGKPILYSYFRSSCSWRVRIALALKGIDYKTVPINLIKDGGQQFSKDFQALNPMKQVPTLKIDGI           CG138372-01        Protein Sequence   TIHQSLAIIEYLEETRPTPRLLPQDPKKRASVRMTSDLIAGGIQPLQNLSVLKQVGEEMQLTWAQNA                   ITCGFNALEQILQSTAGIYCVGDEVTMADLCLVPQVANAERFKVDLTPYPTISSINKRLLVLEAFQV                   SHPCRQPDTPTELRA                                         SEQ ID NO: 81   579 bp                             NOV14b,      GTCGCGCGAAGTGCCAG ATGCAGGCGGGGAAGCCCATCCTCTATTCCTATTTCCGAAGCTCCTGCTC           CG138372-01        DNA Sequence    ATGGAGAGTTCGAATTGCTCTGGCCTTGAAAGGCATCGACTACGACACGGTGCCCATCAATCTCATA                   AAGGATGGGGGCCAACAGTTTTCTAAGGACTTCCAGGCACTGAATCCTATGAAGCAGGTGCCAACCC                   TGAAGATTGATGGAATCACCATTCACCAGTCAAACCTGTCTGTCCTGAAGCAAGTGGGAGAGGAGAT                   GCAGCTGACCTGGGCCCAGAACGCCATCACTTGTCGCTTTAACGCCCTGGAGCAGATCCTACAGAGC                   ACAGCGGGCATATACTGTGTAGGAGACGAGGTGACCATGGCTGATCTGTGCTTGGTCCCTCAGGTGG                   CAAATGCTGAAAGATTCAAGGTGGATCTCACCCCCTACCCTACCATCAGCTCCATCAACAAGAGGCT                   GCTGGTCTTGGAGGCCTTCCACGTGTCTCACCCCTGCCGGCAGCCAGATACACCCACTGAGCTGAGG                   GCCTAG CTCCCAAATCCTGCCCCGTTGGCACAGGGCCACAGGA                                           ORF Start: ATG at 18   ORF Stop: TAG at 540                                         SEQ ID NO: 82   174 aa   MW at 19382.2kD                             NOV14b,    MQAGKPILYSYFRSSCSWRVRIALALKGIDYETVPINLIKDCGQQFSKDFQALNPMKQVPTLKIDGI           CG138372-02        Protein Sequence   TIHQSNLSVLKQVGEEMQLTWAQNAITCGFNALEQILQSTAGIYCVGDEVTMADLCLVPQVANAERF                   KVDLTPYPTISSINKRLLVLEAFHVSHPCRQPDTPTELRA                                         SEQ ID NO: 83   1216 bp                             NOV14c,      AAGACACGGGCCTGATTCGTCGAGTCTCACTGAGCCTTAGTCGTCGGCAGGTCCCAGGCGCGAACTT             CG138372-01        DNA Sequence      TCTCGGCCTGGAGGAGGGGGTCGCGCGAAGTGCCAG ATGCAGGCGGGGAAGCCCATCCTCTATTCCT                   ATTTCCGAAGCTCCTGCTCATGGAGAGTTCGAATTGCTCTGGCCTTGAAAGGCATCGACTACAAGAC                   GGTGCCCATCAATCTCATAAAGGATGGGGCCCAACAGTTTTCTAAGGACTTCCACGCACTGAATCCT                   ATGAAGCAGGTGCCAACCCTOAAGATTGATGGAATCACCATTCACCAGTCACTGGCCATCATTGAGT                   ATCTAGAGGAGACGCGTCCCACTCCGCGACTTCTGCCTCAGGACCCAAAGAAGAGGGCCAGCGTGCG                   TATGATTTCTGACCTCATCGCTGGTGGCATCCAGCCCCTGCAGAACCTGTCTGTCCTGAAGCAAGTG                   GGAGAGGAGATGCAGCTGACCTGGGCCCAGAACGCCATCACTTGTGGCTTTAACGCCCTGGAGCAGA                   TCCTACAGAGCACAGCGGGCATATACTGTGTAGGAGACGAGGTGACCATGGCTGATCTGTGCTTGGT                   GCCTCAGGTGGCAAATGCTGAAAGATTCAAGGTGGATCTCACCCCCTACCCTACCATCAGCTCCATC                   AACAAGAGGCTGCTGGTCTTGCAGGCCTTCCAGGTGTCTCACCCCTGCCGGCAGCCAGATACACCCA                   CTGAGCTGAGGGCCTAG CTCCCAAATCCTGCCCCGTTGGCACAGGGCCACAGGAGCAGAAGCTGGGT                     GGGCTGAAGAGGCCTGGAAACGAGAGTCTTAATTGAGGAGATGGGAGACTCGAACTCTAGCCCTGGA                   TCTGCCTTCCTGCTGAAACTTGTTCCACCTCAGTCCCCTCATCTGTCACACGCATGTGGGGTGGAGT                   AGGGAGATGCGGGCAGCAGGGTGGCCACGAATACTGTTATCTATGTGACGGGGCAGTCGTGAGGCTG                   AGATGAGAATGCGGATTAAAATGCCTGGCGTGCTCACCGTAACACCACGGGGAAGGCTGTGTGCCTT                   TTCTCATCCGCTTTTGTTGTGTGTCACTCCAAAGAATGCCCGCGCTGAAATTTGGCGTGAATTAAAC                   TGAAGCCCAGGCCTCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA                   AAAAAAAAAA                                         ORF Start: ATG at 104   ORF Stop: TAG at 752                                         SEQ ID NO: 84   216 aa   MW at 24082.7kD                             NOV14c,    MQAGKPILYSYFRSSCSWRVRIALALKGIDYKTVPINLIKDGGQQFSKDFQALNPMKQVPTLKIDGI           CG138372-01        Protein Sequence   TIHQSLAITEYLEETRPTPRLLPQDPKKRASVEMISDLIAGGIQPLQNLSVLKQVGEEMQLTWAQNA                   ITCGFNALEQILQSTAGIYCVGDEVTMADLCLVPQVANAERFKVDLTPYPTISSINKRLLVLEAFQV                   SHPCRQPDTPTELRA                                         SEQ ID NO: 85   159 bp                             NOV14d,      C ACCGGATCCACCATGCAGGCGGGGAAGCCCATCCTCTATTCCTATTTCCGAAGCTCCTGCTCATGG           277582121 DNA        Sequence    AGAGTTCGAATTGCTCTGGCCTTGAAAGGCATCGACTACGAGACGGTGCCCATCAATCTCATAAAGG                   ATGGGGGCCAACAGTTTTCTAAGGACTTCCAGCCACTGAATCCTATGAAGCACGTGCCAACCCTGAA                   GATTGATGGAATCACCATTCACCAGTCAAACCTGTCTGTCCTGAAGCAAGTGGGAGAGGAGATGCAG                   CTGACCTGGGCCCAGAACGCCATCACTTGTGGCTTTAACGCCCTGGAGCAGATCCTACAGAGCACAG                   CGGGCATATACTGTGTAGGAGACOAGGTGACCATCGCTGATCTGTGCTTGGTGCCTCAGGTGGCAAA                   TGCTGAAAGATTCAAGGTGGATCTCACCCCCTACCCTACCATCAGCTCCATCAACAAGAGGCTGCTG                   GTCTTGGAGGCCTTCCAGGTGTCTCACCCCTGCCGGCAGCCAGATACACCCACTGAGCTGAGGGCCC                   TCGAGGGC                                         ORF Start: at 2   ORF Stop: end of sequence                                         SEQ ID NO: 86   181 aa   MW at 20018.8kD                             NOV14d,    TGSTMQAGKPILYSYFRSSCSWRVRIALALKGIDYETVPINLIKDGGQQFSKDFQALNPMKQVPTLK           277582121        Protein Sequence   IDGITIHQSNLSVLKQVGEEMQLTWAQNAITCGFNALEQILQSTAGIYCVGDEVTMADLCLVPQVAN                   AERFKVDLTPYPTISSINKRLLVLEAFQVSHPCRQPDTPTELRALEG                                         SEQ ID NO: 87   720 bp                             NOV14e,      GTCGCGCGAAGTGCCAG ATGCAGGCGGGGAAGCCCATCCTCTATTCCTATTTCCGAAGCTCCTGCTC           CG138372-03        DNA Sequence    ATGGAGAGTTCGAATTGCTCTGGCCTTGAAAGGCATCGACTACGAGACGGTGCCCATCAATCTCATA                   AAGGATGGGGGCCAACAGTTTTCTAAGGACTTCCAGGCACTGAATCCTATGAAGCAGGTGCCAACCC                   TGAAGATTGATGGAATCACCATTCACCAGTCACTGGCCATCATTGAGTATCTAGAGGAGACGCGTCC                   CACTCCGCGACTTCTGCCTCAGGACCCAAAGAAGAGGGCCAGCGTGCGTATGATTTCTGACCTCATC                   GCTGGTGGCATCCAGCCCCTGCAGAACCTGTCTGTCCTGAAGCAAGTGGGAGAGGAGATGCAGCTGA                   CCTGGGCCCAGAACGCCATCACTTGTGGCTTTAACGCCCTGGAGCAGATCCTACAGAGCACAGCGGG                   CATATACTGTGTAGGAGACGAGGTGACCATCGCTGATCTGTGCTTGGTGCCTCAGGTGGCAAATGCT                   GAAAGATTCAAGGTGGATCTCACCCCCTACCCTACCATCAGCTCCATCAACAAGAGGCTGCTGGTCT                   TGGAGCCCTTCCAGGTGTCTCACCCCTGCCGGCAGCCAGATACACCCACTGAGCTGAGGGCCTAG CT                       CCCAAATCCTGCCCCGTTGGCACACGGCCACAGGAGCAGAAGAAGGGCGA                                           ORF Start: ATG at 18   ORF Stop: TAG at 666                                         SEQ ID NO: 88   216 aa   MW at 24083.7kD                             NOV14e,    MQAGKPILYSYFRSSCSWRVRIALALKGIDYETVPINLIKDGGQQFSKDFQALNPMKQVPTLKIDGI           CG138372-03        Protein Sequence   TIHQSLAIIEYLEETRPTPRLLPQDPKKRASVRMISDLIAGGIQPLQNLSVLKQVGEEMQLTWAQNA                   ITCGFNALEQILQSTAGIYCVGDEVTMADLCLVPQVANAERFKVDLTPYPTISSINKRLLVLEAFQV                   SHPCRQPDTPTELRA                  
 
     [0425] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 14B.  
               TABLE 14B                          Comparison of NOV14a against NOV14b through NOV14e.                                         Identities/                   Similarities           Protein   NOV14a Residues/   for the           Sequence   Match Residues   Matched Region                       NOV14b   1 . . . 216   172/216 (79%)               1 . . . 174   173/216 (79%)           NOV14c   1 . . . 216    216/216 (100%)               1 . . . 216    216/216 (100%)           NOV14d   1 . . . 216   173/216 (80%)               5 . . . 178   174/216 (80%)           NOV14e   1 . . . 216   215/216 (99%)               1 . . . 216   216/216 (99%)                      
 
     [0426] Further analysis of the NOV14a protein yielded the following properties shown in Table 14C.  
               TABLE 14C                       Protein Sequence Properties NOV14a                                                PSort   0.4856 probability located in mitochondrial           analysis:   matrix space; 0.3000 probability located in               nucleus; 0.2246 probability located in               lysosome (lumen); 0.1962 probability located in               mitochondrial inner membrane           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0427] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D.  
               TABLE 14D                          Geneseq Results for NOV14a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV14a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               ABB64377     Drosophila melanogaster     3 . . . 213   123/212 (58%)   3e−68           polypeptide SEQ ID NO   31 . . . 242    160/212 (75%)           19923 -  Drosophila               melanogaster , 246 aa.           [WO200171042-A2,           27 SEP. 2001]       ABB64379     Drosophila melanogaster     5 . . . 214   126/210 (60%)   2e−66           polypeptide SEQ ID NO   15 . . . 224    155/210 (73%)           19929 -  Drosophila               melanogaster , 227 aa.           [WO200171042-A2,           27 SEP. 2001]       AAG43196     Arabidopsis thaliana  protein   8 . . . 212   100/210 (47%)   2e−47           fragment SEQ ID NO: 53962 -   11 . . . 218    137/210 (64%)             Arabidopsis thaliana , 221           aa. [EP1033405-A2,           06 SEP. 2000]       AAG43195     Arabidopsis thaliana  protein   8 . . . 212   100/210 (47%)   2e−47           fragment SEQ ID NO: 53961 -   27 . . . 234    137/210 (64%)             Arabidopsis thaliana , 237           aa. [EP1033405-A2,           06 SEP. 2000]       AAG10203   Arabidopsis thaliana protein   8 . . . 212    98/210 (46%)   4e−46           fragment SEQ ID NO: 8428 -   11 . . . 218    134/210 (63%)             Arabidopsis thaliana , 221 aa.           [EP1033405-A2,           06 SEP. 2000]                  
 
     [0428] In a BLAST search of public sequence datbases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E.  
               TABLE 14E                          Public BLASTP Results for NOV14a                                             Identities/           Protein           Similarities for       Accession       NOV14a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               O43708   Maleylacetoacetate isomerase   1 . . . 216   215/216 (99%)    e−120           (EC 5.2.1.2) (MAAI)   1 . . . 216   215/216 (99%)           (Glutathione S- transferase           zeta 1) (EC 2.5.1.18)           (GSTZ1-1) -  Homo sapiens             (Human), 216 aa.       Q9WVL0   Maleylacetoacetate isomerase   1 . . . 215   184/215 (85%)    e−102           (EC 5.2.1.2) (MAAI)   1 . . . 215   196/215 (90%)           (Glutathione S- transferase           zeta 1) (EC 2.5.1.18)           (GSTZ1-1) -  Mus musculus             (Mouse), 216 aa.       Q9VHD3   Probable maleylacetoacetate   3 . . . 213   123/212 (58%)   8e−68           isomerase 1 (EC 5.2.1.2)   31 . . . 242    160/212 (75%)           (MAAI 1) -  Drosophila               melanogaster  (Fruit fly), 246           aa.       Q9VHD2   Probable maleylacetoacetate   5 . . . 214   126/210 (60%)   6e−66           isomerase 2 (EC 5.2.1.2)   15 . . . 224    155/210 (73%)           (MAAI 2) -  Drosophila               melanogaster  (Fruit fly), 227           aa.       AAM61889   Glutathione S-transferase -   5 . . . 213   123/209 (58%)   4e−65             Anopheles gambiae  (African   11 . . . 219    156/209 (73%)           malaria mosquito), 222 aa.                  
 
     [0429] PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14F.  
               TABLE 14F                          Domain Analysis of NOV14a                                             Identities/                   NOV14a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       GST_N   3 . . . 81   27/88 (31%)   1.5e−20                   65/88 (74%)           GST_C   90 . . . 197   29/121 (24%)    1.1e−05                   75/121 (62%)                       
 
     Example 15  
     [0430] The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A.  
               TABLE 15A                       NOV15 Sequence Analysis                                                    SEQ ID NO: 89   891 bp                             NOV15a,      ACC ATGTATTTCCTGACTCCCATCTTGGTAGCCATTCTCTGCATTTTGGTTGTGTGGATCTTTAAAA           CG138461-01        DNA Sequence    ATGCCGACAGAAGCATGGAGAAAAAGAAGGGGGAGCCTAGAACCAGGGCCGAAGCTCGCCCCTGGGT                   GGATGAAGACTTAAAAGACAGCAGTOACCTGCACCAAGCAGAAGAAGATGCTGATGAATGGCAAGAA                   TCAGAAGAAAATGTTGAACACATCCCCTTCTCTCATAACCACTATCCTGAGAAGGAAATGGTTAAGA                   GGTCTCAGGAATTTTATGAACTTCTCAATAAGAGACGGTCAGTCAGGTTCATAAGTAATGAGCAAGT                   CCCAATGGAAGTCATTGATAATGTCATCAGAACGGCAGGTACAGCCCCGAGTGGGGCTCACACAGAG                   CCCTGGACCTTCGTGGTTGTGAAGGACCCAGACGTGAAGCACAAGATTCGAAAGATCATTGAGGAGG                   AAGAGGAGATCAACTACATGAAAAGGATGGGACATCGCTGGGTCACAGACCTCAAGAAACTGAGAAC                   CAACTGGATTAAAGAGTACTTGGATACTGCCCCTATTTTGATTCTCATTTTCAAACAAGTACATGGT                   TTCGCCGCAAATGGCAAGAAAAAAGTCCACTACTACAATGAGATCAGTGTTTCCATCGCTTGTGGCA                   TCCTGCTAGCTGCCCTGCAGAATGCAGGTCTGGTGACTGTCACTACCACTCCTCTCAACTGTGGCCC                   TCGACTGAGGGTGCTCCTGGGCCGCCCCGCACATGAAAAGCTGCTGATGCTGCTCCCCGTGGGGTAC                   CCCAGCAAGGAGGCCACGGTGCCTGACCTCAAGCGCAAACCTCTGGACCAGATCATGGTGACAGTGT                   AG GCACGGCCCCCCAAGGGA                                           ORF Start: ATG at 4   ORF Stop: TAG at 871                                         SEQ ID NO: 90   289 aa   MW at 33359.3kD                             NOV15a,    MYFLTPILVAILCILVVWIFKNADRSMEKKKGEPRTRAEARPWVDEDLKDSSDLHQAEEDADEWQES           CG138461-01        Protein Sequence   EENVEHIPFSHNHYPEKEMVKRSQEFYELLNKRRSVRFISNEQVPMEVIDNVIRTAGTAPSGAUTEP                   WTFVVVKDPDVKHKIRKIIEEEEEINYNKRMGHRWVTDLKKLRTNWIKEYLDTAPILILIFKQVHGF                   AANGKKKVHYYNETSVSIACGILLAALQNAGLVTVTTTPLNCGPRLRVLLGRPAHEKLLMLLPVGYP                   SKEATVPDLKRKPLDQIMVTV                  
 
     [0431] Further analysis of the NOV15a protein yielded the following properties shown in Table 15B.  
               TABLE 15B                       Protein Sequence Properties NOV15a                                                PSort   0.8200 probability located in endoplasmic reticulum           analysis:   (membrane); 0.1900 probability located in plasma               membrane; 0.1080 probability located in nucleus;               0.1000 probability located in endoplasmic reticulum               (lumen)           SignalP   Cleavage site between residues 24 and 25           analysis:                      
 
     [0432] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C.  
               TABLE 15C                          Geneseq Results for NOV15a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV15a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAM39746   Human polypeptide SEQ ID   1 . . . 289    289/289 (100%)   e−169           NO 2891 -  Homo sapiens ,   1 . . . 289    289/289 (100%)           289 aa. [WO200153312-A1,           26 JUL. 2001]       ABG27497   Novel human diagnostic   42 . . . 289    236/259 (91%)   e−134           protein #27488 -  Homo     146 . . . 404    240/259 (92%)             sapiens , 404 aa.           [WO200175067-A2,           11 OCT. 2001]       ABG26409   Novel human diagnostic   45 . . . 287    224/243 (92%)   e−128           protein #26400 -  Homo     166 . . . 404    227/243 (93%)             sapiens , 404 aa.           [WO200175067-A2,           11 OCT. 2001]       ABG26408   Novel human diagnostic   1 . . . 167    167/167 (100%)   2e−95            protein #26399 -  Homo     2 . . . 168    167/167 (100%)             sapiens , 168 aa.           [WO200175067-A2,           11 OCT. 2001]       ABG27496   Novel human diagnostic   1 . . . 156   155/156 (99%)   6e−88            protein #27487 -  Homo     2 . . . 157   156/156 (99%)             sapiens , 157 aa.           [WO200175067-A2,           11 OCT. 2001]                  
 
     [0433] In a BLAST search of public sequence datbases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D.  
               TABLE 15D                          Public BLASTP Results for NOV15a                                             Identities/           Protein           Similarities for       Accession       NOV15a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               Q9DCX8   0610009AO7Rik protein    1 . . . 289   245/289 (84%)    e−144           (RIKEN cDNA 0610009A07    1 . . . 285   271/289 (92%)           gene) -  Mus musculus             (Mouse), 285 aa.       O75989   DJ422F24.1 (Putative novel   74 . . . 257    184/184 (100%)    e−105           protein similar to  C. elegans      1 . . . 184    184/184 (100%)           C02C2.5) -  Homo sapiens             (Human), 184 aa (fragment).       Q8T3Q0   AT19107p -  Drosophila     44 . . . 288   137/247 (55%)   3e−68             melanogaster  (Fruit fly), 287   49 . . . 286   173/247 (69%)           aa.       Q9VTE7   CG6279 protein -  Drosophila     44 . . . 288   137/247 (55%)   5e−68             melanogaster  (Fruit fly), 748   510 . . . 747    174/247 (69%)           aa.       Q9XAG5   Putative oxidoreductase -   74 . . . 282    87/210 (41%)   2e−40           Streptomyces coelicolor, 226    9 . . . 217   124/210 (58%)           aa.                  
 
     [0434] PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15E.  
               TABLE 15E                          Domain Analysis of NOV15a                                             Identities/                   NOV15a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       Nitroreductase   92 . . . 254   39/182 (21%)   1.3e−13                   113/182 (62%)                       
 
     Example 16  
     [0435] The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.  
               TABLE 16A                       NOV16 Sequence Analysis                                                    SEQ ID NO: 91   1787 bp                             NOV16a,      TTCATTCTCAGCACTACAATCTCAGTCATTATCCCTCTGAGCTGCTCAATTACTCCCTGTCTTTTCC             CG138529-01        DNA Sequence      TCAATTTACCTAGGTGGTTCCCTGTCTGACCCAA ATGCTAGGCCGATTTCPACCCTTCTCCTTGGTC                   CGGAGTTTCAGACTGCGATTTGGAGCCTGCTGCTATCCAAACCAAAAATGTGCTACTCAGACCATCA                   GACCCCCTGACTCCAGGTGCCTAGTCCAAGCAGTTTCTCAGAACTTTAATTTTGCAAAGGATGTGTT                   GGATCAGTGGTCCCAGCTGGAAAAGGTAGACGGACTCAGAGGGCCTTACCCCGCCCTCTGGAAGGTT                   AGTGCCAAAGGAGAAGAGGACAAATGGAGCTTTGAAAGGATGACTCAACTCTCCAAGAAGGCCGCCA                   GCATCCTCTCACACACCTGTGCCCTTAGCCATGGAGACCGGCTGATGATAATCTTGCCCCCAACACC                   TCAACCCTACTGGATCTGCCTGGCCTGTGTGCGCTTGGGTATCACCTTTGTGCCTGGGAGCCCCCAG                   CTGACTGCCAAGAAAATTCGCTATCAATTACGCATGTCTAAGGCCCAGTGCATTGTGGCTAATGAAG                   CTATGGCCCCAGTTGTAAACTCTGCCGTGTCCGACTGCCCCACCTTGAAAACCAAGCTCCTGGTGTC                   AGATAAGAGCTATCATGGGTGGTTGGATTTCAAGAAGTTGATTCAGGTTGCCCCTCCAAAGCAGACC                   TACATGAGGACCAAAAGCCAAGATCCAATCGCCATATTCTTCACCAAGGGTACAACAGCAGCTCCCA                   AAATGGTCGAGTATTCCCAGTATGGTTTGGGAATGGGATTCAGCCACGCTTCCAGGTACTGGATGGA                   TCTCCAGCCAACAGATGTCTTGTGGAGTCTGGGTGATGCCTTTGGTGGATCTTTATCCCTGAGCGCT                   GTCTTGGGAACTTGGTTCCAAGGAGCCTGTGTGTTTCTGTGTCACATGCCAACCTTCTGCCCTGAGA                   CTGTTCTAAATGTAAGATCAATTCCTAGTGTGGAATGTGTGGGACAAAGGCCAGAGAGAGGCATTAG                   CAATGACCCAGTGACTAGCTACAGATTCAAGAGTCTGAAGCAGTGTGTGGCTGCAGGAGCACCCATC                   AGCCCTGGGGTGATTGAGGACTGGAAACGCATCACTAAGTTGGACATCTATGAAGGCTATGGGCAGA                   CGCAAACTGTAGGTCTCTGTGCCACTTCCAAAACAATAAAATTGAAGCCAAGCTCTCTGGGGAAGCC                   ATTGCCACCTTATATTGTCCAGCAGATTGTGGATGAAAACTCAAATCTCCTGCCTCCAGGGGAAGAA                   GGAAATATTGCAATCCGCATAAAACTAAACCAACCTGCTTCTCTGTACTGTCCACACATGGTAAGAA                   AATTTTCTGCTTCAGCAAGAGGCCACATGCTTTACCTCACAGGTGACAGAGGGATCATGGATGAAGA                   CGGCTACTTCTGGTGGTCTGGTAGAGTTGATGATGTTGCCAATGCATTGGGTCAGAGATTGAATGCC                   AACCAACACCCCAGCTTATCTGAGGTCAGCATAGTTACACACCTAGTTTGTACTCCCATTCTGCAGG                   TGGTGAAGCCCCCTAATGTCCTGACTCCACAGTTCCTGTCCCATGACCAGGGCCAGCTCACCAAAGA                   GCTATAG CAGCACATAAAGTCAGTGACAGGCCCATGCAAGTACCAAAGGAAGGTGGAGTTTGTCCCA                       GAGCTGCCAAAAACCGTCACTCGCAAGATTAAACGGGAACTTCAA                                           ORF Start: ATG at 102   ORF Stop: TAG at 1680                                         SEQ ID NO: 92   526 aa   MW at 58238.8kD                             NOV16a,    MLGRFQPFSLVRSFRLGFCACCYPWQKCATQTIRPPDSRCLVQAVSQNFNFAKDVLDQWSQLEKVDG           CG138529-01        Protein Sequence   LRGPYPALWKVSAKGEEDKWSFERMTQLSKKAASILSDTCALSHGDRLMIILPPTPEAYWICLACVR                   LGITFVPGSPQLTAKKIRYQLRMSKAQCIVANEANAPVVNSAVSDCPTLKTKLLVSDKSYDGWLDFK                   KLIQVAPPKQTYMRTKSQDPMAIFFTKGTTGAPKMVEYSQYGLGMGFSQASRYWMDLQPTDVLWSLG                   DAFGGSLSLSAVLGTWFQGACVFLCHMPTFCPETVLNVRSIPSVECVGQRPERCISNDPVTSYREKS                   LKQCVAAGGPISPGVIEDWKRITKLDIYEGYGQTETVGLCATSKTIKLKPSSLGKPLPPYIVQQIVD                   ENSNLLPPGEEGNIAIRIKLNQPASLYCPHMVRKFSASARGHHLYLTGDRGIMDEDGYFWWSGRVDD                   VANALGQRLNANQHPSLSEVSIVTHLVCTPILQVVKPPNVLTPQFLSHDQGQLTKEL                  
 
     [0436] Further analysis of the NOV16a protein yielded the following properties shown in Table 16B.  
               TABLE 16B                       Protein Sequence Properties NOV16a                                                PSort   0.4993 probability located in mitochondrial           analysis:   matrix space; 0.2177 probability located in               mitochondrial inner membrane; 0.2177               probability located in mitochondrial               intermembrane space; 0.2177 probability               located in mitochondrial outer membrane           SignalP   Cleavage site between residues 22 and 23           analysis:                      
 
     [0437] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C.  
               TABLE 16C                           Geneseq Results for NOV16a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV16a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               ABB53263   Human polypeptide #3 -   1 . . . 526   480/539 (89%)   0.0             Homo sapiens , 583 aa.   1 . . . 534   489/539 (90%)           [WO200181363-A1,           01 NOV. 2001]       ABB53262   Human polypeptide #2 -   1 . . . 478   450/482 (93%)   0.0             Homo sapiens , 480 aa.   1 . . . 480   455/482 (94%)           [WO200181363-A1,           01 NOV. 2001]       AAE22093   Human kidney specific renal   43 . . . 526    204/496 (41%)         e−103           cell carcinoma (KSRCC)   38 . . . 527    304/496 (61%)           protein -  Homo sapiens , 577           aa. [WO200216595-A2,           28 FEB. 2002]       AAB43245   Human ORFX ORF3009   49 . . . 526    203/490 (41%)         e−102           polypeptide sequence SEQ   4 . . . 487   302/490 (61%)           ID NO: 6018 -  Homo sapiens ,           537 aa. [WO200058473-A2,           05 OCT. 2000]       AAM41894   Human polypeptide SEQ ID   258 . . . 526    107/281 (38%)        6e−45           NO 6825 -  Homo sapiens ,   7 . . . 283   163/281 (57%)           390 aa. [WO200153312-A1,           26 JUL. 2001]                  
 
     [0438] In a BLAST search of public sequence datbases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16D.  
               TABLE 16D                          Public BLASTP Results for NOV16a                                             Identities/           Protein           Similarities for       Accession       NOV16a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               O60363   SA gene -  Homo sapiens     45 . . . 526   225/494 (45%)   e−120           (Human), 578 aa.   46 . . . 534   318/494 (63%)       Q13732   SA SA gene product precursor -   45 . . . 526   222/494 (44%)   e−118             Homo sapiens  (Human), 578   46 . . . 534   315/494 (62%)           aa.       Q91WI1   SA rat hypertension-associated   45 . . . 526   215/494 (43%)   e−113           homolog (SA protein) -  Mus     46 . . . 534   314/494 (63%)             musculus  (Mouse), 578 aa.       Q9Z2F3   SA protein -  Mus musculus     45 . . . 526   215/494 (43%)   e−113           (Mouse), 578 aa.   46 . . . 534   314/494 (63%)       Q9Z2X0   SA -  Mus musculus  (Mouse),   45 . . . 526   214/495 (43%)   e−111           578 aa.   46 . . . 534   312/495 (62%)                  
 
     [0439] PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16E.  
               TABLE 16E                          Domain Analysis of NOV16a                                     Identities/               NOV16a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               AMP-binding    88 . . . 297   41/212 (19%)    9.9e−25               136/212 (64%)        AMP-binding   334 . . . 419   25/89 (28%)     5e−13               62/89 (70%)       AMP-binding   447 . . . 477   14/31 (45%)   0.0025               23/31 (74%)                  
 
     Example 17  
     [0440] The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.  
               TABLE 17A                       NOV17 Sequence Analysis                                                    SEQ ID NO:93   1574 bp                             NOV 17a,     TCGGCCTTCCGAAACACCCCCGGGCCGGGGCACGGAGAGAGCCGAGCGCCGCAGCCGTGAGCCGAAT             CG138563-01       DNA Sequence     AGAGCCGGAGAGACCCGAGT   ATG ACCGGAGAAGCCCAGGCCGGCCCGAAGAGGAGCCGAGCGCGGCC                   GGAAGGAACCGAGCCCGTCCGAAGGGAGCGGACGCAGCCTGGCCTGGGGCCCGGTCGAGCCCGCGCC                   ATGGCGGCCGAGGCGACAGCTGTGGCCGGAAGCGGGGCTGTTCGCGGCTGCCTGGCCAAAGACGGCT                   TGCAGCAGTCTAAGTGCCCGGACACTACCCCAAAACGGCCGCGCGCCTCGTCGCTGTCGCGTGACGC                   CGAGCGCCGAGCCTACCAATGGTGCCGGGAGTACTTGGGCGGGGCCTGGCGCCGAGTGCAGCCCGAG                   GAGCTGAGGGTTTACCCCGTGAGCGGAGGCCTCAGCAACCTGCTCTTCCGCTGCTCGCTCCCGGACC                   ACCTGCCCAGCGTTGGCGAGGAGCCCCGGGAGGTGCTTCTGCGGCTGTACGGAGCCATCTTGCAGGG                   CGTGGACTCCCTGGTGCTAGAAAGCGTGATGTTCGCCATACTTGCGGAGCGGTCGCTGGCCCCCCAG                   CTGTACGGAGTCTTCCCAGAGGGCCGGCTGGAACAGTACATCCCAAGTCGGCCATTGAAAACTCAAG                   AGCTTCGAGAGCCAGTGTTGTCAGCAGCCATTGCCACGAAGATGGCGCAATTTCATGGCATGGAGAT                   GCCTTTCACCAAGGAGCCCCACTGGCTGTTTGGGACCATGGAGCGGTACCTAAAACAGATCCAGGAC                   CTGCCCCCAACTGGCCTCCCTGAGATGAACCTGCTGGAGATGTACAGCCTGAAGGATGAGATGGGCA                   ACCTCAGGAAGTTACTAGAGTCTACCCCATCGCCAGTCGTCTTCTGCCACAATGACATCCAGGAAGG                   TAGGAGAAGGCATCTGAGTCTCCTAACCCAAGATGGAAGAGCCAGAGGGCTCTGGAGTGAGCAGAAC                   CTCACCCCATTCCCCCAGGGAACATCTTGCTGCTCTCAGAGCCAGAAAATGCTGACAGCCTCATGCT                   GGTGGACTTCGAGTACAGCAGTTATAACTATAGTTGCATTTTATTCGTCATTACCTGGCAGAGGCAA                   AGAAACG TGA   GACCCTCTCCCAAGAGGAGCAGAGAAAACTGGAAGAAGATTTGCTGGTAGAAGTCAG                       TCGGTATGCTCTGGCATCCCATTTCTTCTGGGGTCTGTGGTCCATCCTCCAGGCATCCATGTCCACC                       ATAGAATTTGGTTACTTCGACTATGCCCAGTCTCGGTTCCAGTTCTACTTCCAGCAGAAGGGGCAGC                       TGACCAGTGTCCACTCCTCATCCTGACTCCACCCTCCCACTCCTTGGATTTCTCCTGGAGCCTCCAG                       GGCAGGACCTTGGAGGGAGGAACAACGAGCAGAAGGCCCTGGCGACTGGGCTGAGCCCCCAAGTGAA                       ACTGAGGTTCAGGAGACCGGCCTGTTCCTGAGTTTGAGTAGGTCCCCATGGCTGGCAGGCCAGAGCC                       CCGTGCTGTGTATGTAACACAATAAACAAGCTG                                               ORE Start: ATG at 88       ORE Stop: TGA at 1147               SEQ ID NO: 94   353 aa   MW at 39344.7 kD                         NOV 17a,   MTGEAQAGRXRSRARPEGTEPVRRERTQPGLGPGRARANAAEATAVAGSGAVGGCLAKDGLQQSKCP           CG138563-01       Protein Sequence   DTTPKRRRASSLSRDAERRAYQWCREYLGGAWRRVQPEELRVYPVSGGLSNLLFRCSLPDHLPSVGE                   EPREVLLRLYGAILOGVDSLVLESVMFAILAERSLGPOLYGVFPEGRLEOYIPSRPLKTOELREPVL                   SAAIATKMAQFHGMEMPFTKEPHWLFGTMERYLKQIQDLPPTGLPEMMLLEMYSLKDEMGNLRKLLE                   STPSPVVFCHNDIQEGRRRHLSLLTQDGRARGLWSEQNLTPFPQGTSCCSQSQKMLTASCWWTSSTA                   VITIVAFYSSLPGRGKER                                         SEQ ID NO:95   1540 bp                             NOV 17b,     AGCCGAATAGAGCCGGAGAGACCCGAGTATGACCGGAGAAGCCCAGGCCGGCCGGAAGAGGAGCCGA             CG138563-02       DNA Sequence     GCGCGGCCGGAAGGAACCGAGCCCGTCCGAAGGGAGCGGAGCGCAGCCTGGCCTGGGGCCCGGTCGA                       GCCCGCGCC   ATG GCGGCCGAGGCGACAGCTGTGGCCGGAAGCGGGGCTGTTGGCGGCTGCCTGGCCA                   AAGACGGCTTGCAGCAGTCTAAGTGCCCGGACACTACCCCAAAACGGCGGCGCGCCTCGTCGCTGTC                   GCGTGACGCCGAGCGCCGAGCCTACCAATGGTGCCGGGAGTACTTGGGCGGGGCCTGGCGCCGAGTG                   CAGCCCGAGGAGCTGAGGGTTTACCCCGTGAGCGGAGGCCTCAGCAACCTGCTCTTCCGCTGCTCGC                   TCCCGGACCACCTGCCCAGCGTTGGCGAGGAGCCCCGGGAGGTGCTTCTGCGGCTGTACGGAGCCAT                   CTTGCAGGGCGTGGACTCCCTGGTGCTAGAAAGCGTGATGTTCGCCATACTTGCGGAGCGGTCGCTG                   GGGCCCCAGCTGTACGGAGTCTTCCCAGAGGGCCGGCTGGAACAGTACATCCCAAGTCGGCCATTGA                   AAACTCAAGAGCTTCGAGAGCCAGTGTTGTCAGCAGCCATTGCCACGAAGATGGCGCAATTTCATGG                   CATGGAGATGCCTTTCACCAAGGAGCCCCACTGGCTGTTTGGGACCATGGAGCGGTACCTAAAACAG                   ATCCAGGACCTGCCCCCAACTGGCCTCCCTGAGATGAACCTGCTGGAGATGTACAGCCTGAAGGATG                   ACATGGGCAACCTCAGGAAGTTACTAGAGTCTACCCCATCGCCAGTCGTCTTCTGCCACAATGACAT                   CCAGGAAGGGAACATCTTGCTGCTCTCAGAGCCAGAAAATGCTGACAGCCTCATGCTGCTGGACTTC                   GAGTACAGCAGTTATAACTATAGGGGCTTTGACATTGGGAACCATTTTTGTGAGPGGGTTTATGATT                   ATACTCACGAGGAATGGCCTTTCTACAAAGCAAGGCCCACAGACTACCCCACTCAAGAACAGCAGTT                   GCATTTTATTCGTCATTACCTGGCAGAGGCAAAGAAAGGTGAGACCCTCTCCCAAGAGGAGCAGAGA                   AAACTGGAAGAAGATTTGCTGGTAGAAGTCAGTCGGTATGCTCTGGCATCCCATTTCTTCTGGGGTC                   TGTGGTCCATCCTCCAGGCATCCATGTCCACCATAGAATTTGGTTACTTGGACTATGCCCAGTCTCG                   GTTCCAGTTCTACTTCCAGCAGAAGGGGCAGCTGACCAGTGTCCACTCCTCATCC TGA   CTCCACCCT                       CCCACTCCTTGGATTTCTCCTGGAGCCTCCAGGGCAGGACCTTGGAGGGAGGAACAACGAGCAGAAC                       GCCCTGGCGACTGGGCTGAGCCCCCAAGTGAAACTGAGGTTCAGGAGACCGGCCTGTTCCTGAGTTT                       GAGTAGGTCCCCATGGCTGGCACGCCAGAGCCCCGTGCTGTGTATGTAACACAATAAACAAGCTTC                                               ORF Start: ATG at 144       ORF Stop: TGA at 1329               SEQ ID NO:96   395 aa   MW at 45270.9 kD                         NOV 17b,   MAAEATAVAGSGAVCGCLAKDGLQQSKCPDTTPKRRRASSLSRDAERRAYQWCREYLGGAURRVQPE           CG138563-02       Protein Sequence   ELRVYPVSGGLSNLLFRCSLPDHLPSVGEEPREVLLRLYGAILQGVDSLVLESVMFAILAERSLGPQ                   LYGVFPEGRLEQYIPSRPLKTQELREPVLSAAIATKMAQFHGMEMPFTKEPHWLFGTMERYLKQIQD                   LPPTGLPEMNLLEMYSLKDEMGNLRKLLESTPSPVVFCHNDIQEGNILLLSEPENADSLMLVDFEYS                   SYNYRGFDIGNHFCEWVYDYTHEEWPFYKARPTDYPTQEQQLHFIRHYLAEAKKGETLSQEEQRKLE                   EDLLVEVSRYALASHFFWGLWSILQASMSTIEFGYLDYAQSRFQFYFQQKGQLTSVHSSS                  
 
     [0441] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 17B.  
               TABLE 17B                          Comparison of NOV17a against NOV17b.                                     NOV17a   Identities/               Residues/   Similarities           Protein   Match   for the           Sequence   Residues   Matched Region                       NOV17b   58 . . . 317   236/266 (88%)               20 . . . 282   241/266 (89%)                      
 
     [0442] Further analysis of the NOV17a protein yielded the following properties shown in Table 17C.  
               TABLE 17C                       Protein Sequence Properties NOV17a                                        PSort analysis:   0.9600 probability located in nucleus; 0.1629 probability           located in lysosome (lumen); 0.1000 probability located           in mitochondrial matrix space; 0.0000 probability located           in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0443] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17D.  
               TABLE 17D                          Geneseq Results for NOV17a                                         NOV17a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAY68787   Amino acid sequence of a   1 . . . 317   293/323 (90%)    e−166           human phosphorylation   1 . . . 320   298/323 (91%)           effector PHSP-19 -  Homo               sapiens , 433 aa.           [WO200006728-A2,           10 FEB. 2000]       AAU30777   Novel human secreted   7 . . . 329   258/335 (77%)    e−137           protein #1268 -  Homo     7 . . . 337   271/335 (80%)             sapiens , 483 aa.           [WO200179449-A2,           25 OCT. 2001]       AAR32999   Rat choline kinase -  Rattus     85 . . . 284    125/204 (61%)   5e−67             rattus , 435 aa.   85 . . . 288    158/204 (77%)           [JP05015367-A,           26 JAN. 1993]       ABB58945     Drosophila melanogaster     123 . . . 284     67/174 (38%)   3e−32           polypeptide SEQ ID NO   137 . . . 310    107/174 (60%)           3627 -  Drosophila               melanogaster , 495 aa.           [W0200171042-A2,           27 SEP. 2001]       AAB87672   Bovine mammary tissue   188 . . . 247     55/60 (91%)   1e−26           derived protein #63 -  Bos     9 . . . 68     58/60 (96%)             taurus , 69 aa.           [WO200114553-A1,           01 MAR. 2001]                  
 
     [0444] In a BLAST search of public sequence datbases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E.  
               TABLE 17E                          Public BLASTP Results for NOV17a                                         NOV17a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9Y259   Choline/ethanolamine kinase   39 . . . 317   255/285 (89%)   e−142           [Includes: Choline kinase (EC    1 . . . 282   260/285 (90%)           2.7.1.32) (CK); Ethanolamine           kinase (EC 2.7.1.82)(EK)] -  Homo               sapiens  (Human), 395 aa.       O55229   Choline/ethanolamine kinase   39 . . . 284   211/246 (85%)   e−122           [Includes: Choline kinase (EC    1 . . . 246   226/246 (91%)           2.7.1.32) (CK); Ethanolamine           kinase (EC 2.7.1.82)(EK)] -  Mus               musculus  (Mouse), 394 aa.       O54783   Choline/ethanolamine kinase   39 . . . 284   208/246 (84%)   e−120           [Includes: Choline kinase (EC    1 . . . 246   226/246 (91%)           2.7.1.32) (CK); Ethanolamine           kinase (EC 2.7.1.82)(EK)] -  Rattus               norvegicus  (Rat), 394 aa.       AAH36471   Similar to choline kinase -  Homo     85 . . . 297   133/217 (61%)   7e−70              sapiens  (Human), 439 aa.   89 . . . 300   169/217 (77%)       P35790   Choline kinase (EC 2.7.1.32) (CK)   29 . . . 297   145/292 (49%)   2e−68            (CHETK-alpha) -  Homo sapiens     31 . . . 317   187/292 (63%)           (Human), 456 aa.                  
 
     [0445] PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17F.  
               TABLE 17F                          Domain Analysis of NOV17a                                     Identities/               NOV17a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               Choline_kinase   125 . . . 352   88/349 (25%)   1.6e−41               192/349 (55%)                   
 
     Example 18  
     [0446] The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A.  
               TABLE 18A                       NOV18 Sequence Analysis                                                    SEQ ID NO:97   3705 bp                             NOV18a,     CGGCTCGGGGCTGTGAGCGCCTCGGGGCCGGGGGTGGGCGGCGGTGCGGCGGGCGGCCGACGCTCCT             CG138848-01       DNA Sequence     CTTCGGCGGCCGCGGCGGCGGCC   ATG CGTGGGGCGGCGCGGCTGGCGCGGCCGGGCCGGAGTTGCCT                   CCCGGGGGCCCGCGGCCTGAGGGCCCCGCCGCCGCCGCCGCTGCTGCTTCTGCTTGCGCTGTTGCCG                   CTGCTGCCCGCGCCTGGCGCTGCCGCCGCCCCCGCCCCGCGGCCCCCGGAGCTGCAGTCGGCTTCCG                   CGGGGCCCAGCGTGAGTCTCTACCTGAGCGAGGACGAGGTGCGCCGGCTGATCGGTCTTGATGCAGA                   ACTTTATTATGTGAGAAATGACCTTATTAGTCACTACGCTCTATCCTTTAGTCTCTTAGTACCCAGT                   GAGACAAATTTCCTGCACTTCACCTGGCATGCGAAGTCCAAGGTTGAATATAAGCTGGGATTCCAAG                   TGGACAATGTTTTGGCAATGGATATGCCCCAGGTCAACATTTCTGTTCAGGCGGAAGTTCCACGCAC                   TTTATCAGTGTTTCGGGTAGAGCTTTCCTGTACTCGCAAAGTAGATTCTGAAGTTATGATACTAATG                   CAGCTCAACTTGACAGTAAATTCTTCAAAAAATTTTACCGTCTTAAATTTTAAACGAAGGAAAATGT                   GCTACAAAAAACTTGAAGAAGTAAAAACTTCAGCCTTGGACAAAAACACTAGCAGAACTATTTATGA                   TCCTGTACATGCAGCTCCAACCACTTCTACGCGTGTGTTTTATATTAGTGTAGGGGTTTGTTGTGCA                   GTAATATTTCTCGTAGCAATAATATTAGCTGTTTTGCACCTTCATAGTATGAAAAGGATTGAACTGG                   ATGACAGCATTAGTGCCAGCAGTAGTTCCCAAGGGCTGTCTCAGCCATCCACCCAGACGACTCAGTA                   TCTGAGAGCAGACACGCCCAACAAPGCAACTCCTATCACCAGCTCCTTAGGTTATCCTACCTTGCGG                   ATAGAGAAGAACGACTTGAGAAGTGTCACTCTTTTGGAGGCCAAAGGCAAGGTGAAGGATATAGCAA                   TATCCAGAGAGAGGATAACTCTAAAAGATGTACTCCAAGAAGGTACTTTTGGGCGTATTTTCCATGG                   GATTTTAATAGATGAAAAAGATCCAAATAAAGAAAAACAAGCATTTGTCAAAACAGTTAAAGATCAA                   GCTTCTGAAATTCAGGTGACAATGATGCTCACTGAAAGTTGTAAGCTGCGAGGTCTTCATCACAGAA                   ATCTTCTTCCTATTACTCATGTGTGTATAGAAGAAGGAGAAAAGCCCATGGTGATATTGCCTTACAT                   GAATTGGGGGAATCTTAAATTGTTTTTACGACAGTGCAAGTTAGTAGAGGCCAATAATCCACAGGCA                   ATTTCTCAGCAAGACCTGGTACACATGGCTATTCAGATTGCCTGTGGAATGAGCTACCTGGCCAGAA                   GGGAAGTCATCCACAAAGACCTGGCTGCCAGGAACTGTGTCATTGATGACACACTTCAAGTTAAGAT                   CACAGACAATGCCCTCTCCAGAGACTTGTTCCCCATGGACTATCACTGTCTGGGGGACAATGAAAAC                   ACGCCAGTTCGTTGGATGGCTCTTGAAAGTCTGGTTAATAACGAGTTCTCTAGCGCTAGTGATGTGT                   GGGCCTTTGGAGTGACGCTGTGGGAACTCATGACTCTGGGCCAGACTCCCTACGTGGACATTGACCC                   CTTCGAGATGGCCGCATACCTGAAAGATGGTTACCGAATAGCCCAGCCAATCAACTGTCCTGATGAA                   TTATTTGCTGTGATGGCCTGTTGCTGGGCCTTAGATCCAGAGGAGAGGCCCAAGTTTCAGCAGCTGG                   TACAGTGCCTAACAGAGTTTCATGCACCCCTCGGGGCCTACGTC TGA   CTCCTCTCCAATCCCACACC                       ATCAGGAAGAAGGTGCCTGTCGGGGCTCACTTGAAGCCTGTCAGGGATGCTTTGTATCTAACACAAC                       GCCAACAGAAGCACATTTGTCTTCCAGAACACCGTGCCTTAGAAATGCTTTAGAATCTGAACTTTTT                       AAGACAGACTTAATAATGTGGCATATTTTCTAGATATCACTTTTATTAGGTTGAACTGAAAGGGTTT                       TTGTAAATTTTTTGGCCAAAATTTTTTAAAACATACTTACTTTGGACTAGGGGTACATTCTTACAAA                       ATAAATAAACAGTTTTTAAAATTGTTTAGACACAGATATTTGGAATTAGCTATCTTAGTGCCAACTG                       CTTTTTATTTTTTTACTTCATCAAGGTGATGTAAGTGACTCACCTTTAAAGTTTTTTTAGTGTTATT                       TTTTATCACTACTCTGGGAAATGGTTTGTCTTCAAGATGCAATACTTTTCTTAGTAAAGGAAAAACA                       GCATAAAAAGATACCTGGTCTGCCTTGTACAAGAAAAGGCAATATTAGAGGAAGAAAATTTAAAGAA                       AAGCTAGAGGAAAAAAAAATTTTTTTAAAAATACTTATTAGAAGCAAACTGCCCTTGCATGGAAAAC                       TGTTTATTTTTTTCAGTGAAAAGGAATTCTGCTTTCGTGTTTTTGGGAAAGCAGGAACTGAGTTCAT                       TACATCTTTAATTTGGCAGAAATTAGCCTTTCTGTGAACCAGATGTGGTTTGGGGCAGATCTGTTGT                       AAACAATGGTGATTTTATTTATTTTTACTCTCTGGAAAAGGAGATAATACAATTCCAGAAAGTGAAC                       TCATATTTCTAAGGTTAAGATTCCCTTTTATTGCACCTAGAATAGTGCTATGCACAGAGCGGGTGCT                       TGAGTTGTTGTCGTTTTTTGTTTGTTTTTTAAATGTAAACTGGTAAATTTTGTGCTTATCTTCAAGG                       CTGGCTTAAGTATAAAATTGTTTTTTAAACACTTGAAAAATTAAAGGATTTGTTTTATATTATGACA                       GTATTGAAATTATTTTTCATAATGAATGATTGGTTATTGTGTCTGGTAAGTCTTTGAACATTCAACA                       GCCAGACATTTGTGTTTTATTTCATGATGTTCCAGTCAAGTTCCAAAGCCCTAACACAGTTAAACTG                       GCTCAGACTCCAGGTTCTAGTAAAAAGTTGGAATTAATGTTATAAGGAAGTATTAAAACACTGAAAC                       ATTTCTCCAGAACCAGCAAGTAAGGGATATGTATGTATTTATGCTCAGTTTTAGTTGGCCTAAAGCA                       GAGTTGAATGGGCTTTCTAAATAGCTAGCCCTGCAGGTACCTGCCACTACTCCCATCTTCAGAGGTA                       TATAAGGGAGAATGTGTAGCAGTTTGACGCTTTTGCTGTTTTTAAAAAAGCCTTATGAATCAGCAGC                       ACACCGGGAAAAATAGCTCACATAGTACCTGGTTTTCCACAAGTAAGCCAAGGGCATGATTTTCTGT                       GTACATTTATTAACAGTTCTTTGGTTTTATGAAATACTCATATGAAGCCAGTCCCTGGAGTACTGTT                       TTTTAAAAGGTCCCTTTGAACCATTTGTAAATTATATTTTCATTCATAACCTGCATTCTTAGAAGGC                       ATTCAGTCAACATTTACAGCACTTACTGTGTATTTTCCACATGGAGTGGTTCAACTCAAGCGTCCCT                       TCCAGTATTCAGGGCATTCTTATTTCATGTTCAAGTGAGTGCATTGTTTAGAAATCACAGTTTATTA                       ACATGTACATGATCTATTTT                                               ORF Start: ATG at 91       ORF Stop: TGA at 1921               SEQ ID NO:98   610 aa   MW at 68071.0 kD                         NOV18a,   MRGAARLGRPGRSCLPGARGLRAPPPPPLLLLLALLPLLPAPGAAAAPAPRPPELQSASAGPSVSLY           CG138848-011       Protein Sequence   LSEDEVRRLIGLDAELYYVRNDLISHYALSFSLLVPSETNFLHFTWHAXSKVEYKLGFQVDNVLAMD                   MPQVNTSVQGEVPRTLSVFRVELSCTGKVDSEVMILMQLNLTVNSSKNFTVLNFKRRKMCYKKLEEV                   KTSALDKNTSRTIYDPVHAAPTTSTRVFYISVGVCCAVIFLVAITLAVLHLHSMKRIELDDSISASS                   SSQGLSQPSTQTTQYLRADTPNNATPITSSLGYPTLRIEKNDLRSVTLLEAKGKVKDIAISRERITL                   KDVLQEGTFGRIFHGILIDEKDPNKEKQAFVKTVKDQASEIQVTMMLTESCKLRGLHHRNLLPITHV                   CIEEGEKPMVILPYMNWGNLKLFLRQCKLVEANNPQAISQQDLVHMAIQIACGMSYLARREVIHKDL                   AARNCVIDDTLQVKITDNALSRDLFPMDYHCLGDNENRPVRWMALESLVNNEFSSASDVWAFGVTLW                   ELMTLGQTPYVDIDPFEMAAYLKDGYRIAQPINCPDELFAVMACCWALDPEERPKFQQLVQCLTEFH                   AALGAYV                  
 
     [0447] Further analysis of the NOV18a protein yielded the following properties shown in Table 18B.  
               TABLE 18B                       Protein Sequence Properties NOV18a                                                PSort   0.6000 probability located in plasma membrane;           analysis:   0.4000 probability located in Golgi body; 0.3000               probability located in endoplasmic reticulum               (membrane); 0.3000 probability located in               microbody (peroxisome)           SignalP   Cleavage site between residues 47 and 48           analysis:                      
 
     [0448] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18C.  
               TABLE 18C                          Geneseq Results for NOV18a                                         NOV18a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAG66030   Amino acid sequence of seq   1 . . . 610   604/610 (99%)   0.0           Id No. 6 -  Homo sapiens , 607   1 . . . 607   606/610 (99%)           aa. [WO200185789-A2,           15 NOV. 2001]       AAR42480   Human RYK cDNA -  Homo     1 . . . 610   581/612 (94%)   0.0             sapiens , 606 aa.   1 . . . 606   587/612 (94%)           [WO9323429-A,           25 NOV. 1993]       AAR42479   Mouse RYK -  Mus musculus ,   46 . . . 610    539/565 (95%)   0.0           593 aa. [WO9323429-A,   32 . . . 593    548/565 (96%)           25 NOV. 1993]       ABB57333   Mouse ischaemic condition   9 . . . 331   291/323 (90%)   e−158           related protein sequence SEQ   2 . . . 314   298/323 (92%)           ID NO: 928 -  Mus musculus ,           317 aa. [WO200188188-A2,           22 NOV. 2001]       AAG66025   Ryk protein extracellular   47 . . . 237    190/191 (99%)   e−105           domain -  Homo sapiens , 191   1 . . . 191   191/191 (99%)           aa. [WO200185789-A2,           15 NOV. 2001]                  
 
     [0449] In a BLAST search of public sequence datbases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18D.  
               TABLE 18D                          Public BLASTP Results for NOV18a                                         NOV18a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                         I37560   protein-tyrosine kinase (EC   1 . . . 610   603/610 (98%)   0.0           2.7.1.112) ryk - human, 607   1 . . . 607   605/610 (98%)           aa.       P34925   Tyrosine-protein kinase RYK   1 . . . 610   585/610 (95%)   0.0           precursor (EC 2.7.1.112) -   1 . . . 604   588/610 (95%)             Homo sapiens  (Human), 604           aa.       Q01887   Tyrosine-protein kinase RYK   9 . . . 610   566/602 (94%)   0.0           precursor (EC 2.7.1.112)   2 . . . 594   577/602 (95%)           (Kinase VIK) (NYK-R)           (Met-related kinase) -  Mus               musculus  (Mouse), 594 aa.       I58386   receptor tyrosine kinase -   9 . . . 610   565/602 (93%)   0.0           mouse, 594 aa.   2 . . . 594   576/602 (94%)       A47186   receptor protein tyrosine   9 . . . 610   550/602 (91%)   0.0           kinase homolog RYK - mouse,   2 . . . 593   562/602 (92%)           593 aa.                  
 
     [0450] PFam analysis predicts that the NOV18a protein contains the domains shown in the Table 18E.  
               TABLE 18E                          Domain Analysis of NOV18a                                     Identities/               NOV18a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               WIF   66 . . . 194   64/147 (44%)   1.7e−69               125/147 (85%)        pkinase   333 . . . 599    78/302 (26%)   1.8e−76               216/302 (72%)                   
 
     Example 19  
     [0451] The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.  
               TABLE 19A                       NOV19 Sequence Analysis                                                    SEQ ID NO:99   1983bp                             NOV 19a,     GGTAGAGCGGAGACGACGCTCCCAGACTCCTCCGGTCTCCCCGGGCAGC   ATG AAGACCGCCGAGAAC           CG139990-01       DNA Sequence   ATCAGAGGAACCCGCAGCGACGGGCCGCGGAAACGAGGCCTCTGCGTCCTCTGTGGCCTCCCCGCGG                   CAGGAAAATCGACTTTCGCGCGCGCCCTCGCCCACCGOCTGCAGCAGGAGCAGGGTTGGGCCATCGG                   TGTTGTCGCGTATGATGACGTCATGCCCGACGCGTTTCTCGCCGGGGCAAGAGCGCGACCGGCGCCA                   TCCCAATGGAAATTGCTTCGACAGGAACTGTTGAAGTACCTGGAATACTTCTTGATGGCTGTCATTA                   ATGGGTGTCAGATGTCTGTCCCACCCAACAGGACTGAAGCCATGTGGGAAGATTTTATAACCTGCTT                   AAAGGATCAAGATCTGATATTTTCTGCAGCATTTGAGGCCCAGTCTTGCTACCTCTTAACAAAAACT                   GCTGTTTCTAGACCTTTGTTTTTGGTTTTGGATGACAATTTTTATTATCAGAGTATGAGATATGAAG                   TCTACCAGCTGGCTCGGAAATATTCATTGGGCTTTTGCCAGCTCTTTTTAGATTGTCCTCTTGAGAC                   CTGTTTACAGACGAATGGCCAGAGGCCACAGGCACTGCCTCCTGAGACCATCCACCTGATGCGAAGA                   AAGCTAGAAAAGCCCAACCCTGAGAAAAATGCTTGGGAACACAACAGCCTCACAATTCCGAGTCCAG                   CATGTGCTTCGGAGGCCAGA TGA   ACAAGTGCTTCCTCACAACTTGAAGCTTCTAGCAGAAGAACTTA                       ACCAGCTCAAAGCAGAGTTTTTGOAAGACCTAAAACAAGGAAACAAAAAATATCTGTGCTTTCAGCA                       AACCATTGACATACCAGATGTCATTTCTTTTTTTCATTATGAGAAAGATAATAPTGTACAGAAGTAT                       TTTTCAAAGCAGCATTAAAATTTCTGAACTGCCAAAAAAAAAAAA                                               ORF Start: ATG at 50       ORF Stop: TGA at 758               SEQ ID NO:100   1236 aa   MW at 26728.5 kD                         NOV19a,   MKTAENIRGTGSDGPRKRGLCVLCGLPAAGKSTFARALAHRLQQEQGWAIGVVAYDDVMPDAFLAGA           CG139990-01       Protein Sequence   RARPAPSQWKLLRQELLKYLEYFLMAVINGCQNSVPPNRTEAMWEDFITCLKDQDLIFSAAFEAQSC                   YLLTKTAVSRPLFLVLDDNFYYQSMRYEVYQLARKYSLGFCQLFLDCPLETCLQRNGQRPQALPPET                       IHLMRRKLEKPNPEKNAWEHNSLTIPSPACASEAR                  
 
     [0452] Further analysis of the NOV19a protein yielded the following properties shown in Table 19B.  
               TABLE 19B                       Protein Sequence Properties NOV19a                                                PSort   0.3700 probability located in outside; 0.1000           analysis:   probability located in endoplasmic reticulum               (membrane); 0.1000 probability located in               endoplasmic reticulum (lumen); 0.1000               probability located in lysosome (lumen)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0453] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C.  
               TABLE 19C                          Geneseq Results for NOV19a                                         NOV19a                       Residues/   Identities/       Geneseq   Protein/Organism/Length   Match   Similarities for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAB73511   Human transferase HTFS-18,    1 . . . 235    235/235 (100%)    e−138           SEQ ID NO: 18 -  Homo      1 . . . 235    235/235 (100%)             sapiens , 358 aa.           [WO200132888-A2,           10 MAY 2001]       AAB47957   Homo zinc finger protein   95 . . . 220   123/126 (97%)   1e−69           18.04 -  Homo sapiens , 164   21 . . . 146   124/126 (97%)           aa. [WO200220595-A1,           14 MAR. 2002]       AAU14714   Novel bone marrow   121 . . . 235     115/115 (100%)   7e−64           polypeptide #113 -  Homo      1 . . . 115    115/115 (100%)             sapiens , 238 aa.           [WO200157187-A2,           9 AUG. 2001]       AAG74560   Human colon cancer antigen   21 . . . 107    86/87 (98%)   1e−44           protein SEQ ID NO: 5324 -   12 . . . 98     86/87 (98%)             Homo sapiens , 98 aa.           [WO200122920-A2,           5 APR. 2001]       ABB65970     Drosophila melanogaster     16 . . . 226    62/216 (28%)   2e−12           polypeptide SEQ ID NO    2 . . . 178    94/216 (42%)           24702 -  Drosophila               melanogaster , 292 aa.           [WO200171042-A2,           27 SEP. 2001]                  
 
     [0454] In a BLAST search of public sequence datbases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D.  
               TABLE 19D                          Public BLASTP Results for NOV19a                                         NOV19a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9VWF7   CG12788 protein (SD05444P) -   16 . . . 226   62/216 (28%)    5e−12             Drosophila melanogaster      2 . . . 178   94/216 (42%)            (Fruit fly), 292 aa.       Q8TUS5   Predicted nucletide kinase -   20 . . . 234   57/219 (26%)    6e−08             Methanopyrus kandleri , 255    3 . . . 160   90/219 (41%)            aa.       Q58933   Hypothetical protein MJ1538 -   129 . . . 226    30/98 (30%)   4e−07             Methanococcus jannaschii ,   57 . . . 152   55/98 (55%)           252 aa.       Q9XTU1   Y49E10.22 protein -   134 . . . 213    24/82 (29%)   0.015             Caenorhabditis elegans , 259   58 . . . 139   44/82 (53%)           aa.       P34253   KTI12 protein -   139 . . . 229    24/92 (26%)   0.015             Saccharomyces cerevisiae     73 . . . 163   44/92 (47%)           (Baker&#39;s yeast), 313 aa.                  
 
     [0455] PFam analysis predicts that the NOV19a protein contains the domains shown in the Table 19E.  
               TABLE 19E                          Domain Analysis of NOV19a                                     Identities/               NOV19a   Similarities       Pfam   Match   for the Matched   Expect       Domain   Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 20  
     [0456] The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.  
               TABLE 20A                       NOV20 Sequence Analysis                                                    SEQ ID NO:101   3875 bp                             NOV2Oa,     CGGGGGACGTCAGCGCTGCCAGCGTGGAAGGAGCTGCGGGGCGCGGGAGGAGGAAGTAGAGCCCCGC             CG140041-01       DNA Sequence     ACCGCCAGGCCACCACCGGCCGCCTCAGCC   ATG GACGCGTCCCTGGAGAAGATAGCAGACCCCACGT                   TAGCTGAAATGGGAAAAAACTTGAAGGAGGCAGTGAAGATGCTGGAGGACAGTCAGAGAAGAACAGA                   AGAGGAAAATGGAAAGAAGCTCATATCCGGAGATATTCCAGGCCCACTCCAGGGCAGTGGGCAAGAT                   ATGGTGAGCATCCTCCAGTTAGTTCAGAATCTCATGCATGGAGATGAAGATGAGGAGCCCCAGAGCC                   CCAGAATCCAAAATATTGGAGAACAAGGTCATATGGCTTTGTTGGGACATAGTCTCGGAGCTTATAT                   TTCAACTCTGGACAAAGAGAAGCTGAGAAAACTTACAACTAGGATACTTTCAGATACCACCTTATGG                   CTATGCAGAATTTTCAGATATGAAAATGGGTGTGCTTATTTCCACGAAGAGGAAAGAGAAGGACTTG                   CAAAGATATGTAGGCTTGCCATTCATTCTCGATATGAAGACTTCGTAGTGGATGGCTTCAATGTGTT                   ATATAACAAGAAGCCTGTCATATATCTTAGTGCTGCTGCTAGACCTGGCCTGGGCCAATACCTTTGT                   AATCAGCTCGGCTTGCCCTTCCCCTGCTTGTGCCGTGTACCCTGTAACACTGTGTTTGGATCCCAGC                   ATCAGATGGATGTTGCCTTCCTGGAGAAACTGATTAAAGATGATATAGAGCGAGGAAGACTGCCCCT                   GTTGCTTGTCGCAAATGCAGGAACGGCAGCAGTAGGACACACAGACAAGATTGGGAGATTGAAAGAA                   CTCTGTGAGCAGTATGGCATATGGCTTCATGTGGAGGGTGTGAATCTGGCAACATTGGCTCTGGGTT                   ATGTCTCCTCATCAGTGCTGGCTGCAGCCAAATGTGATAGCATGACGATGACTCCTGGCCCGTGGCT                   GGGTTTGCCAGCTGTTCCTGCGGTGACACTGTATAAACACGATGACCCTGCCTTGACTTTAGTTGCT                   GGTCTTACATCAAATAAGCCCACAGACAAACTCCGTGCCCTGCCTCTGTGGTTATCTTTACAATACT                   TGGGACTTGATGGGTTTGTGGAGAGGATCAAGCATGCCTGTCAACTGAGTCAACGGTTGCAGGAAAG                   TTTGAAGAAAGTGAATTACATCAAAATCTTGGTGGAAGATGAGCTCAGCTCCCCAGTGGTGGTGTTC                   AGATTTTTCCAGGAATTACCAGGCTCAGATCCGGTGTTTAAAGCCGTCCCAGTGCCCAACATGACAC                   CTTCAGGAGTCGGCCGGGAGAGGCACTCGTGTGACGCGCTGAATCGCTGGCTGGGAGAACAGCTGAA                   GCAGCTGGTGCCTGCAAGCGGCCTCACAGTCATGGATCTGGAAGCTGAGGGCACGTGTTTGCGGTTC                   AGCCCTTTGATGACCGCAGCAGTTTTAGGAACTCGGCGAGAGGATGTGGATCAGCTCGTAGCCTGCA                   TAGAAAGCAAACTGCCAGTGCTGTGCTGTACGCTCCAGTTGCGTGAAGAGTTCAAGCAGGAAGTGGA                   AGCAACAGCAGGTCTCCTATATGTTGATGACCCTAACTGGTCTGGAATAGGGGTTGTCAGGTATGAA                   CATGCTAATGATGATAAGAGCAGTTTGAAATCAGATCCCGAAGGGGAAAACATCCATGCTGGACTCC                   TGAAGAAGTTAAATGAACTGGAATCTGACCTAACCTTTAAAATAGGCCCTGAGTATAAGAGCATGAA                   GAGCTGCCTTTATGTCGGCATCGCGAGCGACAACGTCGATGCTGCTGAGCTCGTGGAGACCATTGCG                   GCCACAGCCCGGGAGATAGAGGAGAACTCGAGGCTTCTGGAAAACATGACAGAAGTGGTTCGGAAAG                   GCATTCAGGAAGCTCAAGTGGAGCTGCAGAAGGCAAGTGAAGAACGGCTTCTGGAAGAGGGGGTGTT                   GCGGCAGATCCCTGTAGTGGGCTCCGTGCTGAATTCGTTTTCTCCGGTCCAGGCTTTACAGAAGGGA                   AGAACTTTTAACTTGACAGCAGGCTCTCTGGAGTCCACAGAACCCATATATGTCTACAAAGCACAAG                   GTGCAGGAGTCACGCTGCCTCCAACGCCCTCCGGCAGTCGCACCAAGCAGAGGCTTCCAGGCCAGAA                   GCCTTTTAAAAGGTCCCTGCGAGGTTCAGATGCTTTGAGTGAGACCAGCTCAGTCAGTCACATTGAA                   GACTTAGAAAAGGTGGAGCGCCTATCCAGTGCGCCGGAGCAGATCACCCTCOAGGCCAGCAGCACTG                   AGGGACACCCAGGGGCTCCCAGCCCTCAGCACACCGACCAGACCGAGGCCTTCCAGAAAGGGGTCCC                   ACACCCAGAAGATGACCACTCACAGGTAGAAGGACCGGAGAGCTTAAGATGAGACTCATTGTGTGGT                   TTGAGACTGTACTGAGTATTGTTTCAGGGAAGATGAAGTTCTATTGGAA ATG   TGAACTGTGCCACAT                       ACTAATATAAATTACTGTTGTTTGTGCTTCACTGGGATTTTGGCACAAATATGTGCCTGAAAGGTAC                       GCTTTCTAGGAGGGGAGTCAGCTTGTCTAACTTCATGTACATGTAGAACCACGTTTGCTGTCCTACT                       ACGACTTTTCCCTAAGTTACCATAAACACATTTTATTCACAAAAAACACTTCGAATTTCAAGTGTCT                       ACCAGTAGCACCCTTGCTCTTTCTAAACATAAGCCTAAGTATATGAGGTTGCCCGTGGCAACTTTTT                       GGTAAAACAGCTTTTCATTAGCACTCTCCAGGTTCTCTGCAACACTTCACAGAGGCGAGACTGGCTG                       TATCCTTTGCTGTCGGTCTTTAGTACGATCAAGTTGCAATATACAGTGGGACTGCTAGACTTGAAGG                       AGAGCAGTGATTGTGGGATTGTAAATAAGAGCATCAGAAGCCCTCCCCAGCTACTGCTCTTCGTGGA                       GACTTAGTAAGGACTGTGTCTACTTGAGCTGTGGCAAGGCTGCTGTCTGGGACTGTCCTCTGCCACA                       AGGCCATTTCTCCCATTATATACCGTTTGTAAAGAGAAACTGTAAAGTCTCCTCCTGACCATATATT                       TTTAAATACTGGCAAAGCTTTTAAAATTGGCACACAAGTACAGACTGTGCTCATTTCTGTTTAGTAT                       CTGAAAACCTGATAGATGCTACCCTPAAGAGCTTGCTCTTCCGTGTGCTACGTAGCACCCACCTGGT                       TAAAATCTGAAAACAAGTACCCCTTTGACCTGTCTCCCACTGAAGCTTCTACTGCCCTGGCAGCTCC                       CCTGGGCCCAACTCAGAAACAGGAGCCAGCAGAGCACTCTCTCACGCTGATCCAGCCGGGCACCCTC                       CTTAAGTCAGTAGAAGCTCGCTGGCACTGCCCGTTCCTACTTTTCCGAAGTACTGCGTCACTTTGTC                       GTAAGTAATGGCCCCTGTGCCTTCTTAATCCAGCAGTCAAGCTTTTGGGAGACCTGAAAATGGGAAA                       ATTCACACTGGGTTTCTGGACTGTAGTATTGGAAGCCTTAGTTATAGTATATTAAGCCTATAATTAT                       ACTCTGATTTGATGGGATTTTTGACATTTACACTTCTCAAAATGCAGGGGGTTTTTTTTCGTGCAGA                       TGATTAAACAGTCTTCCCTATTTGGTGCAATCAAGTATAGCAGATAAAATGGGGGAGGGGTAAATTA                       TCACCTTCAAGAAAATTACATGTTTTTATATATATTTGGAATTGTTAAATTGGTTTTGCTGAAACAT                       TTCACCCTTGAGATATTATTTGAATGTTGCTTTCAATAAAGGTTCTTGAAATTGTT                                               ORE Start: ATG at 98       ORF Stop: TGA at 2462               SEQ ID NO:102   788 aa   MW at 86705.9 kD                         NOV2Oa,   MDASLEKIADPTLAEMGKNLKEAVKMLEDSQRRTEEENGKKLISGDIPGPLQGSGQDMVSILQLVQN           CG14004101       Protein Sequence   LMHGDEDEEPQSPRIQNIGEQGHIMLLGHSLGAYISTLDKEKLRKLTTRILSDTTLWLCRIFRYENG                   CAYFHEEEREGLAKICRLAIHSRYEDFVVDGFNVLYNXKPVIYLSAAARPGLGQYLCNQLGLPFPCL                   CRVPCNTVFGSOHQMDVAFLEKLIKDDIERGRLPLLLVANAGTAAVGHTDKIGRLKELCEOYGIWLH                   VEGVNLATLALGYVSSSVLAAAKCDSMTMTPGPWLGLPAVPAVTLYKHDDPALTLVAGLTSNKPTDK                   LRALPLWLSLQYLGLDGFVERIKHACQLSQRLQESLKKVNYIKILVEDELSSPVVVFRFFQELPGSD                   PVFKAVPVPNMTPSGVGRERHSCDALNRWLGEQLKQLVPASGLTVMDLEAEGTCLRFSPLMTAAVLG                   TRGEDVDQLVACIESKLPVLCCTLQLREEFKQEVEATAGLLYVDDPNWSGIGVVRYEHANDDKSSLK                   SDPEGENIHAGLLKKLNELESDLTFKIGPEYKSMKSCLYVGMASDNVDAAELVETIAATAREIEENS                   RLLENMTEVVRKGIQEAQVELQKASEERLLEEGVLRQIPVVGSVLNWFSPVQALQKGRTFNLTAGSL                   ESTEPIYVYKAQGAGVTLFPTPSGSRTKQRLPGQKPFKRSLRGSDALSETSSVSHIEDLEKVERLSS                   GPEQITLEASSTEGHPGAPSPQHTDQTEAFQKGVPHPEDDHSQVEGPESLR                  
 
     [0457] Further analysis of the NOV20a protein yielded the following properties shown in Table 20B.  
               TABLE 20B                       Protein Sequence Properties NOV20a                                        PSort   0.4500 probability located in cytoplasm; 0.3000       analysis:   probability located in microbody (peroxisome);           0.1000 probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0458] A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20C.  
               TABLE 20C                          Geneseq Results for NOV20a                                         NOV20a                       Residues/   Identities/       Geneseq   Protcin/Organism/Length   Match   Similarities for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                         AAM39095   Human polypeptide SEQ ID   1 . . . 788   788/788 (100%)   0.0           NO 2240 -  Homo sapiens ,   1 . . . 788   788/788 (100%)           788 aa. [WO200153312-A1,           26 JUL. 2001]       AAM40881   Human polypeptide SEQ ID   1 . . . 788   784/788 (99%)    0.0           NO 5812 -  Homo sapiens ,   33 . . . 820    786/788 (99%)            820 aa. [WO200153312-A1,           26 JUL. 2001]       AAM25938   Human protein sequence   1 . . . 466   466/466 (100%)   0.0           SEQ ID NO: 1453 -  Homo     36 . . . 501    466/466 (100%)             sapiens , 518 aa.           [WO200153455-A2,           26 JUL. 2001]       AAG75454   Human colon cancer antigen   381 . . . 788    408/408 (100%)   0.0           protein SEQ ID NO: 6218 -   18 . . . 425    408/408 (100%)             Homo sapiens , 425 aa.           [WO200122920-A2,           5 APR. 2001]       AAB57103   Human prostate cancer   432 . . . 788    357/357 (100%)   0.0           antigen protein sequence   15 . . . 371    357/357 (100%)           SEQ ID NO: 1681 -  Homo               sapiens , 371 aa.           [WO200055174-A1,           21 SEP. 2000]                  
 
     [0459] In a BLAST search of public sequence datbases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20D.  
               TABLE 20D                          Public BLASTP Results for NOV20a                                         NOV20a               Protein       Residues/   Identities/       Accession       Match   Similarities for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                         O00236   KIAA0251 protein -  Homo     1 . . . 788    788/788 (100%)   0.0             sapiens  (Human), 820 aa   33 . . . 820     788/788 (100%)           (fragment).       Q99K01   Hypothetical 87.3 kDa   1 . . . 788   697/788 (88%)   0.0           protein -  Mus musculus     1 . . . 787   726/788 (91%)           (Mouse), 787 aa.       Q9DC25   Adult male lung cDNA,   1 . . . 702   638/702 (90%)   0.0           RIKEN full-length enriched   1 . . . 702   664/702 (93%)           library, clone: 1200006G13,           full insert sequence -  Mus               musculus  (Mouse), 710 aa.       Q8TBS5   Similar to KIAA0251   193 . . . 788    595/596 (99%)   0.0           hypothetical protein -  Homo     3 . . . 598   596/596 (99%)             sapiens  (Human), 598 aa           (fragment).       AAH33748   Similar to expressed   1 . . . 369   345/369 (93%)   0.0           sequence AA415817 -  Homo     1 . . . 346   346/369 (93%)             sapiens  (Human), 347 aa.                  
 
     [0460] PFam analysis predicts that the NOV20a protein contains the domains shown in the Table 20E.  
               TABLE 20E                          Domain Analysis of NOV20a                                             Identities/                   NOV20a   Similarities               Match   for the Matched   Expect           Pfam Domain   Region   Region   Value                       pyridoxal_deC   214 . . . 269   22/62 (35%)   1.6e−12                   44/62 (71%)                      
 
     Example 21  
     [0461] The NOV21 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 21A.  
               TABLE 21A                       NOV21 Sequence Analysis                                                    SEQ ID NO:103   1683 bp                             NOV21a,     TTATGTCGGGTCGCGGGGTGTC   ATG ACAGCATGGCAGACTACCTGATCAGCAGCGGCACCAGCTACG           CG14006101       DNA Sequence   TGCCCGAGGACGGGCTCACCGCGCAGCAGCTCTTCACCAGCACCAACGGCCTCACCTACAATGACTT                   CCTGATTCTCCCAOGATTCATAGACTTCATAGCTGATGATGAGGTGGACCTCACCTCAGCCCTGACC                   CACAAGGGCCTGAAGACGCCGCTGATCTCCTCCCCTATGGACACTTCTCCTCCCCTGTGGACACTGA                   CAGAGGCTGACATGGCAATCGGGATGGCTCTGATGGGAGGTATTGGTTTCATTCACCACAACTGCAC                   CCCAGAGTTCGAGGCCAATGAGGTGCTGAAGGTCAAGAAGTTTGAACAGGGCTTCATCACGGACCCT                   GTGGTGCTGAGCCCCTTGCACACCGTGGGTGATGTGCTTCTGAAGACGCCGCTGATCTCCTCCCCTG                   TGGACACTGAGGCCAAGATGCTGCATCGCTTCTCTGGTATCCCCCTCACTGAGACGGGCACCATGGG                   CAGCAAGCTGGTGGGCATCATCACCTCCCGAGACGTCGACTTTCTTGCTAAGAAGGAGCACGCCACC                   TTCATCAGTGAGGTGATGACCCCAAGCATGGAACTGGTGGTGGCTGACAAAGGTGTGACGTTGAAAG                   AGGCAAATGAGATCCTGCAGCGTAACAAGAAAGGGAAGCTGCCTATCGTCAGTGATCGCGATGAGCT                   GGTGGCCATCATTGCCCGCACTGACCTGAAGAAGAATCGAGACTACCCTCTGGCCTCCAAGGATTCC                   CACAAACAGCTGCTGTGCAGGGCAGCTGTGGGCACCCGTGAGGATGACGAATGCCACCTGGACCTGC                   TCACCCAGGCGGGTGTCAATGTTGTAGTCTTGGACTCATCCCAAGGGAGCTCGGTGTATCAGATCAC                   CATGGTGCATTACATCAAACAGAAGTACCCCCACCTCCAGGTGATTGGGGGGAACGTGGTGACAGCA                   GCCCAGGCCAAGAACCTGATGGACGCTCGTGTGGACGGGCTGCATGTGGGCATGGGCTACGGCTCCA                   TCTGCATTACCCAGAAAGTGATGGCCTGCGGTTGGCCCCAGGGCACTGCTGTGTACAAGGTCGCCAA                   GTATGCCCAGTGCTTTGGTGTGCCCATCATAGTCGATGGTGGCATCCAGACTGTGGGGCACGTGGTC                   AAGGCCCTGGCCCTTGGAGCCTCCACAGTGATGATGGCCTCCCTGCTGGCCACCACCACGGAGGCAC                   CTGGTGAGTACTTCTTCTTAGAAAGGGTGCAGCTCAAGAAGTACCAGGGCATGGGCTCACTGGATGC                   CATGGAGAAGAGCAGCAGCAGCCAGAAACGATACTTCAGCAAGCGGGATAAGGTGAAGATCGCACAG                   GGTGTCTCGGGCTCCATCCAGGACAAAGGGTCCATTCAGAAGTTCGTGCCCTACCTCATAGCGGGCA                   TCCAGCACAGCTGCCAGGATATCGGGGCCCGCAGCCTGTCTGTCCTTTGGTCCATGATGTACTCAGG                   GGAGCTCAAGTTTGAGAAGCAGACCATGTCGGCCCAGATCAAGGGTGGTGTCCATGGCCTGCACTCG                   TATGAGAAGCAGCTG TGA   TGAGGACAGCGGTGGAGGCTCAGGTCGTGCAGCGGGTGCACCCTGAAGA                       CGCCGCTG                                               ORF Start: ATG at 31       ORE Stop: TGA at 1624               SEQ ID NO:104   531 aa   MW at 57605.0 kD                         NOV21a,   MADYLISSGTSYVPEDGLTAQQLFTSTNGLTYNDFLILPGFIDFIADDEVDLTSALTHKGLKTPLIS           CG140061-01       Protein Sequence   SPMDTSPPLWTLTEADMAIGMALMGGIGFIHHNCTPEFEANEVLKVKKFEQGFITDPVVLSPLHTVG                   DVLLKTPLISSPVDTEAKMLHGFSGIPLTETGTMGSKLVGIITSRDVDFLAKKEHATFISEVMTPRM                   ELVVADKGVTLKEANEILQRNKKGKLPIVSDRDELVAIIARTDLKKNRDYPLASKDSHKQLLCRAAV                   GTREDDECHLDLLTQAGVNVVVLDSSQGSSVYQITMVHYIKQKYPHLQVIGGNVVTAAQAKNLMDAR                   VDGLHVGMGYGSICITQKVMACGWPQGTAVYKVAKYAQCFGVPIIVDGGIQTVGHVVKALALGASTV                   MMGSLLATTTEAPGEYFFLERVQLKKYQGMGSLDAMEKSSSSQKRYFSKGDKVKIAQGVSCSIQDKG                   SIQKFVPYLIAGIQHSCQDIGARSLSVLWSMMYSGELKFEKQTMSAQIKGGVHGLHSYEKQL                  
 
     [0462] Further analysis of the NOV21a protein yielded the following properties shown in Table 21B.  
               TABLE 21B                       Protein Sequence Properties NOV21a                                                PSort   0.4500 probability located in cytoplasm;           analysis:   0.3785 probability located in microbody               (peroxisome); 0.1507 probability located               in lysosome (lumen); 0.1000 probability               located in mitochondrial matrix space           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0463] A search of the NOV21 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21C.  
               TABLE 21C                          Geneseq Results for NOV21a                                         NOV21a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                         AAE18188   Human wild-type inosine   1 . . . 531   454/532 (85%)   0.0           5′-monophosphate   1 . . . 513   481/532 (90%)           dehydrogenase (IMPDH) -             Homo sapiens , 514 aa.           [WO200185952-A2,           15 NOV. 2001]       AAE18257   Human type I inosine   1 . . . 531   453/532 (85%)   0.0           5′-monophosphate   1 . . . 513   480/532 (90%)           dehydrogenase (IMPDH)           mutant, D29G -  Homo               sapiens , 514 aa.           [WO200185952-A2,           15 NOV. 2001]       AAE18258   Human type I IMPDH   1 . . . 531   453/532 (85%)   0.0           mutant, N109K -  Homo     1 . . . 513   480/532 (90%)             sapiens , 514 aa.           [WO200185952-A2,           15 NOV. 2001]       AAE18185   Human wild-type, type I   1 . . . 531   452/532 (84%)   0.0           IMPDH #1 -  Homo sapiens ,   1 . . . 513   479/532 (89%)           514 aa. [WO200185952-A2,           15 NOV. 2001]       AAE18190   Human wild-type, type I   1 . . . 531   448/532 (84%)   0.0           IMPDH #2 -  Homo sapiens ,   1 . . . 513   475/532 (89%)           514 aa. [WO200185952-A2,           15 NOV. 2001]                  
 
     [0464] In a BLAST search of public sequence datbases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21D.  
               TABLE 21D                          Public BLASTP Results for NOV21a                                         NOV21a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         AAH33622   IMP (inosine monophosphate)   1 . . . 531   454/532 (85%)   0.0           dehydrogenase 1 -  Homo sapiens     1 . . . 513   481/532 (90%)           (Human), 514 aa.       P20839   Inosine-5′-monophosphate   1 . . . 531   452/532 (84%)   0.0           dehydrogenase 1 (EC 1.1.1.205)   1 . . . 513   479/532 (89%)           (IMP dehydrogenase 1) (IMPDH-I)           (IMPD 1) -  Homo sapiens  (Human),           514aa.       P50096   Inosine-5′-monophosphate   1 . . . 531   445/532 (83%)   0.0           dehydrogenase 1 (EC 1.1.1.205)   1 . . . 513   479/532 (89%)           (IMP dehydrogenase 1) (IMPDH-I)           (IMPD 1) -  Mus musculus  (Mouse),           514aa.       Q96NU2   CDNA FLJ30078 fis, clone   1 . . . 531   431/532 (81%)   0.0           BGGI12000533, highly similar to   1 . . . 488   457/532 (85%)           inosine-5′-monophosphate           dehydrogenase 2 (EC 1.1.1.205) -             Homo sapiens  (Human), 489 aa.       P12268   Inosine-5′-monophosphate   1 . . . 531   395/532 (74%)   0.0           dehydrogenase 2(EC 1.1.1.205)   1 . . . 513   452/532 (84%)           (IMP dehydrogenase 2) (IMPDH-II)           (IMPD 2) -  Homo sapiens  (Human),           514aa.                  
 
     [0465] PFam analysis predicts that the NOV21a protein contains the domains shown in the Table 21E.  
               TABLE 21E                          Domain Analysis of NOV21a                                     Identities/                   Similarities for       Pfam   NOV21a   the Matched   Expect       Domain   Match Region   Region   Value               IMPDH_N    21 . . . 116   49/97 (51%)   6.7e−40               81/97 (84%)       CBS   118 . . . 186   16/69 (23%)   0.33               50/69 (72%)       CBS   197 . . . 250   16/54 (30%)     1e−08               43/54 (80%)       IMPDH_C   280 . . . 501   113/232 (49%)     6.7e−134               202/232 (87%)                   
 
     Example 22  
     [0466] The NOV22 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 22A.  
               TABLE 22A                       NOV22 Sequence Analysis                                                    SEQ ID NO:105   1387 bp                             NOV22a,     GA   ATG TCTGACCCCCACAGCAGTCCTCTCCTGCCAGAGCCACTTTCCAGCAGATACAAACTCTACGA           CG140335-01       DNA Sequence   GGCAGAGTTTACCAGCCCGAGCTGGCCCTCGACATCCCCGGATACTCACCCAGCTCTGCCCCTCCTG                   GAAATGCCTGAAGAAAAGGATCTCCGGTCTTCCAATGAAGACAGTCACATTGTGAAGATCGAAAAGC                   TCAATGAAAGGAGTAAAAGGAAAGACGACGGGGTGGCCCATCGGGACTCAGCAGGCCAAAGGTGCAT                   CTGCCTCTCCAAAGCAGTGGGCTACCTCACGGGCGACATGAAGGAGTACAGGATCTGGCTTCCAGAC                   AAACCCGTGGTCCTCCAGTTCATTGACTGGATTCTCCGGCGCATATCCCAAGTCGTGTTCGTCAACA                   ACCCCGTCAGTGGAATCCTGATTCTGGTAGGACTTCTTGTTCAGAACCCCTGGTGGGCTCTCACTCG                   CTGGCTGGGAACAGTGGTCTCCACTCTGATGGCCCTCTTGCTCAGCCAGGACAGGTCTGCCATTGCC                   TCAGGACTCCATGGGTACAACGGGATGCTGGTGGGACTGCTGATGGCCGTGTTCTCGGAGAAGTTAG                   ACTACTACTGGTGCCTTCTGTTTCCTGTGACCTTCACAGCCATGTCCGGACCAGTTCTTTCTAGTGC                   CTTGAATTCCATCTTCAGCAAGTGGGACCTCCCCGTCTTCACTCTGCCCTTCAACATTGCAGTCACC                   TTGTACCTTGCAGCCACAGGCCACTACAACCTCTTCTTCCCCACAACACTGGTAGAGCCTGTGTCTT                   CAGTGCCCAATATCACCTGGACAGAGATGGAAATGCCCCTGCTGTTACAAGCCATCCCTGTTGGGGT                   CCGCCAGGTGTATGGCTGTGACAATCCCTGGACAGGCGGCGTGTTCCTGGTGGCTCTGTTCATCTCC                   TCGCCACTCATCTGCTTGCATGCAGCCATTGGCTCAATCGTGGGGCTGCTAGCAGCCCTGTCAGTGG                   CCACACCCTTCGAGACCATCTACACAGGCCTCTGGAGCTACAACTGCGTCCTCTCCTGCAPCGCCAT                   CGGAGGCATGTTCTATGCCCTCACCTGGCAGACTCACCTGCTCGCCCTCATCTGTGCCCTGTTCTGT                   GCATACATGGAAGCAGCCATCTCCAACATCATGTCAGTGGTAGGCGTGCCACCAGGCACCTGGGCCT                   TCTGCCTTGCCACCATCATCTTCCTGCTCCTGACGACAAACAACCCAGCCATCTTCAGACTCCCACT                   CAGCAAAGTCACCTACCCCGAGGCCAACCGCATCTACTACCTGACAGTGAAAAGCGGTGAAGAAGAG                   AAGGCCCCCAGCCGTGAA TAG   CCATGTTCGGGGAAGAAACGCTCTTT                                               ORF Start: ATG at 3       ORF Stop: TAG at 1359               SEQ ID NO:106   452 aa   MW at 49740.4 kD                         NOV22a,   MSDPHSSPLLPEPLSSRYKLYEAEFTSPSWPSTSPDTHPALPLLEMPEEKDLRSSNEDSHIVKIEKL           CG140335-01       Protein Sequence   NERSKRKDDGVAHRDSAGQRCICLSKAVGYLTGDMKEYRIWLPDKPVVLQFTDWILRGISQVVFVNN                   PVSGILILVGLLVQNPWWALTGWLGTVVSTLMALLLSQDRSAIASGLHGYNGMLVGLLMAVFSEKLD                   YYWWLLFPVTFTAMSGPVLSSALNSIFSKWDLPVFTLPFNIAVTLYLAATGHYNLEFPTTLVEPVSS                   VPNITWTEMEMPLLLQAIPVGVGQVYGCDNPWTGGVFLVALFISSPLICLHAAIGSIVGLLAALSVA                   TPFETIYTGLWSYNCVLSCIAICGMFYALTWQTHLLALICALFCAYMEAAISNIMSVVGVPPGTWAF                   CLATIIFLLLTTNNPAIFRLPLSKVTYPEANRIYYLTVKSGEEEKAPSGE                  
 
     [0467] Further analysis of the NOV22a protein yielded the following properties shown in Table 22B.  
               TABLE 22B                       Protein Sequence Properties NOV22a                                                PSort   0.6000 probability located in plasma membrane;           analysis:   0.4000 probability located in Golgi body; 0.3000               probability located in endoplasmic reticulum               (membrane); 0.0300 probability located in mito-               chondrial inner membrane           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0468] A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22C.  
               TABLE 22C                          Geneseq Results for NOV22a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV22a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAE22853   Human transporter protein -   1 . . . 452   431/452 (95%)   0.0              Homo sapiens , 452 aa.   1 . . . 452   441/452 (97%)           [WO200220763-A2, 14 MAR. 2002]       AAW13742   Urea transporter polypeptide -   57 . . . 439    271/383 (70%)        e−164             Oryctolagus cuniculus , 397 aa.   2 . . . 378   329/383 (85%)           [US5441875-A, 15 AUG. 1995]       ABP40193   Staphylococcus epidermidis ORF   114 . . . 419     82/312 (26%)       3e−24           amino acid sequence SEQ ID   4 . . . 305   150/312 (47%)           NO: 5038 -  Staphylococcus               epidermidis , 305 aa.           [US6380370-B1, 30 APR. 2002]       AAU32094   Novel human secreted protein   352 . . . 391     21/40 (52%)       3e−04           #2585 -  Homo sapiens , 70 aa.   6 . . . 45     28/40 (69%)           [WO200179449-A2, 25 OCT. 2001]       ABB48958   Listeria monocytogenes protein   121 . . . 197     24/78 (30%)   0.29           #1662 -  Listeria monocytogenes ,   26 . . . 98     43/78 (54%)           357 aa. [WO200177335-A2,           18 OCT. 2001]                  
 
     [0469] In a BLAST search of public sequence datbases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22D.  
               TABLE 22D                          Public BLASTP Results for NOV22a                                             Identities/           Protein           Similarities for       Accession       NOV22a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         Q96PH5   Urea transporter UT-A1 -   1 . . . 451   429/451 (95%)   0.0             Homo sapiens  (Human), 920 aa.   1 . . . 451   439/451 (97%)       Q9ES04   Urea transporter isoform   1 . . . 452   362/452 (80%)   0.0           UTA-3 -  Mus musculus  (Mouse),   10 . . . 461    413/452 (91%)           461 aa.       Q8R4T9   Urea transporter isoform   1 . . . 451   362/451 (80%)   0.0           UT-A1 -  Mus musculus  (Mouse),   10 . . . 460    412/451 (91%)           930 aa.       Q9R1Y7   Urea transporter UT-A3 -   1 . . . 452   360/452 (79%)   0.0             Rattus norvegicus  (Rat),   9 . . . 460   410/452 (90%)           460 aa.       Q9Z2R3   Urea transporter UT4 -  Rattus     1 . . . 452   359/452 (79%)   0.0             norvegicus  (Rat), 460 aa.   9 . . . 460   409/452 (90%)                  
 
     [0470] PFam analysis predicts that the NOV22a protein contains the domains shown in the Table 22E.  
               TABLE 22E                          Domain Analysis of NOV22a                                     Identities/                   Similarities for       Pfam   NOV22a   the Matched   Expect       Domain   Match Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 23  
     [0471] The NOV23 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 23A.  
               TABLE 23A                       NOV23 Sequence Analysis                                                    SEQ ID NO:107   534 bp                             NOV23a,     GCCTCCAGGGGCCCCATACTATCAGCT   ATG GTCAACCCCACCAAGTTCTTCAATGAGCCCTGGGGCC           CG140355-01       DNA Sequence   GCATCTCCATCCAGCTGTTTGCAGACAAGTTTCCAAAGACAGCAGAAAATGTTTGTGCTCTGAGCAT                   TCGAGAGAAAGGATTTGGTTATAACGGTTCCTGCTTTCACAGAATTATTCCGGGGTTTATGTGTCAC                   GGTGGTGACTTCACACACCATAATGGCAGTGGTGGCAAGTACATCTATGCGGAGAAATTTGATGATG                   AGAACTTCATCCTGAAGCAGACAGGTTCTGGCATCTTGTCCAAGGAAAATGCTGGACCCAACACAAA                   CGGTTCCCAGTTTTTCATCTGCAGTGCCAAGAGTGAGTGGTTCGATCGTGAGCATGTGTTCTTTGGC                   AAGGTGAAAGAAGGCATGAATATTGTGGAGGCCATGGAGGGTTTTGGGTCCAGGAATGGCAAGACCA                   GCAAGAAGATCACCATTGCTGACTGT TGA   CAACTCTAATAAGCTTGACTTGTGTTCGTTTTGTTT                                               ORE Start: ATG at 28       ORE Stop: TGA at 496               SEQ ID NO: 108   156 aa   MW at 17164.3 kD                         NOV23a,   MVNPTKFFNEPWGRISIQLFADKFPKTAENVCALSIGEKGFGYKGSCFHRIIPGFMCNGGDFTHHNG           CG140355-01       Protein Sequence   SGGKYIYGEKFDDENFILKQTGSGILSKENAGPNTNGSQFFICSAKSEWLDGEHVFFGKVXEGNNIV                   EAMEGFGSRNGKTSKKITIADC                  
 
     [0472] Further analysis of the NOV23a protein yielded the following properties shown in Table 23B.  
               TABLE 23B                       Protein Sequence Properties NOV23a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.4500 probability located in cytoplasm; 0.1000           probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0473] A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23C.  
               TABLE 23C                          Geneseq Results for NOV23a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV23a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               ABG29319   Novel human diagnostic protein   1 . . . 156    156/156 (100%)   2e−92           #29310 -  Homo sapiens , 407 aa.   252 . . . 407     156/156 (100%)           [WO200175067-A2, 11 OCT. 2001]       ABG27276   Novel human diagnostic protein   1 . . . 156    156/156 (100%)   2e−92           #27267 -  Homo sapiens , 407 aa.   252 . . . 407     156/156 (100%)           [WO200175067-A2, 11 OCT. 2001]       AAU01195   Human cyclophilin A protein -   1 . . . 156   132/161 (81%)   5e−74             Homo sapiens , 165 aa.   1 . . . 161   140/161 (85%)           [WO200132876-A2, 10 MAY 2001]       AAW56028   Calcineurin protein - Mammalia,   1 . . . 156   132/161 (81%)   5e−74           165 aa. [WO9808956-A2,   1 . . . 161   140/161 (85%)           05 MAR. 1998]       AAR13726   Bovine cyclophilin -  Bos taurus ,   2 . . . 156   132/160 (82%)   6e−74           163 aa. [US5047512-A,   1 . . . 160   139/160 (86%)           10 SEP. 1991]                  
 
     [0474] In a BLAST search of public sequence datbases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23D.  
               TABLE 23D                          Public BLASTP Results for NOV23a                                             Identities/           Protein           Similarities for       Accession       NOV23a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               CAC39529   Sequence 26 from Patent   1 . . . 156   132/161 (81%)   1e−73           WO0132876 -  Homo sapiens     1 . . . 161   140/161 (85%)           (Human), 165 aa.       P04374   Peptidyl-prolyl cis-trans   2 . . . 156   132/160 (82%)   2e−73           isomerase A (EC 5.2.1.8)   1 . . . 160   139/160 (86%)           (PPIase) (Rotamase)           (Cyclophilin A) (Cyclo-           sporin A-binding protein) -             Bos taurus  (Bovine), and,           163 aa.       Q9BRU4   Peptidylprolyl isomerase A   1 . . . 156   131/161 (81%)   5e−73           (cyclophilin A) -  Homo     1 . . . 161   139/161 (85%)             sapiens  (Human), 165 aa.       P05092   Peptidyl-prolyl cis-trans   2 . . . 156   131/160 (81%)   5e−73           isomerase A (EC 5.2.1.8)   1 . . . 160   139/160 (86%)           (PPIase) (Rotamase)           (Cyclophilin A) (Cyclo-           sporin A-binding protein) -             Homo sapiens  (Human),, 164 aa.       Q96IX3   Peptidylprolyl isomerase A   1 . . . 156   131/161 (81%)   2e−72           (cyclophilin A) -  Homo     1 . . . 161   139/161 (85%)             sapiens  (Human), 165 aa.                  
 
     [0475] PFam analysis predicts that the NOV23a protein contains the domains shown in the Table 23E.  
               TABLE 23E                          Domain Analysis of NOV23a                                     Identities/                   Similarities for       Pfam   NOV23a   the Matched   Expect       Domain   Match Region   Region   Value               pro_isomerase   10 . . . 156   95/166 (57%)   1.2e−75               128/166 (77%)                   
 
     Example 24  
     [0476] The NOV24 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 24A.  
               TABLE 24A                       NOV24 Sequence Analysis                                                    SEQ ID NO:109   900 bp                             NOV24a,     GCTAAGATTGCTACCTGGACTTTCGTTGACC   ATG CTGTCCCGGGTGGTACTTTCCGCCGCCGCCACA           CG140612-01       DNA Sequence   GCGGCCCCCTCTCTGAAGAATGCAGCCTTCCTAGGTCCAGGGGTATTGCACGCAACAAGGACCTTTC                   ATACAGGGCAGCCACACCTTGTCCCTGTACCACCTCTTCCTGAATACGGAGGAAAAGTTCGTTATGG                   ACTGATCCCTGAGGAATTCTTCCAGTTTCTTTATCCTAAAACTGGTGTAACAGGGCCCTATGTACTC                   GGAACTGGGCTTATCTTGTACGCTTTATCCAAAGAAATATATGTGATTAGCGCAGAGACCTTCACTG                   CCCTATCAGTACTAGGTGTAATGGTCTATGGAATTAAAAAATATGGTCCCTTTGTTGCAGACTTTGC                   TGATAAACTCAATGAGCAAAAACTTGCCCAACTAGAAGAGGCGAACCAGGCTTCCATCCAACACATC                   CGGAATGCAATTGATACGGAGAAGTCACAACAGGCACTGGTTCAGAAGCGCCATTACCTTTTTGATG                   TGCAAAGGAATAACATTGCTATGGCTTTGGAAGTTACTTACCGGGAACGACTGTATAGAGTATATAA                   GGAAGTAAAGAATCGCCTGGACTATCATATATCTGTGCAGAACATGATGCGTCGAAAGGAACAAGAA                   CACATGATAAATTGGGTGGAGAAGCACGTGGTGCAAAGCATCACCACACAGCAGGAAAAGGAGACAA                   TTGCCGAGTGCATTGCGGACCTAAAGCTGCTGGCAAAGAAGGCCCAAGCACAGCCAGTTATG TAA AT                     GTATCTATCCCAATTGAGACAGCTAGAAACAGTTGACTGACTAAATGGAAACTAGTCTATTTGACAA                       AGTCTTTCTGTGTTGGTGTCTACTGAAGT                                               ORF Start: ATG at 32       ORF Stop: TAA at 800               SEQ ID NO:110   256 aa   MW at 28951.4 kD                             NOV24a, MLSRVVLSAAATAAPSLKNAAFLGPGVLQATRTFHTGQPHLVPVPPLPEYGGKVRYGLIPEEFFQFL               CG140612-01           Protein Sequence   YPKTGVTGPYVLGTGLILYALSKEIYVISAETFTALSVLGVMVYGIKKYGPFVADFADKLNEQKLAQ                           LEEAKQASIQHIRNAIDTEKSQQALVQKRHYLFDVQRNNIAMALEVTYRERLYRVYKEVKNRLDYHI                           SVQNMMRRKEQEHMINWVEKHVVQSTTTQQEKETIAECIADLKLLAKKAQAQPVM                                             SEQ ID NO:111   894 bp                             NOV24b,     GCTAAGATTGCTACCTGGACTTTCGTTGACC   ATG CTGTCCCGGGTGGTACTTTCCGCCGCCGCCACA           CG140612-02       DNA Sequence   GCGGCCCCCTCTCTGAAGAATGCAGCCTTCCTAGGTCCAGCGGTATTGCAGGCAACAAGGACCTTTC                   ATACAGGGCAGCCACACCTTGTCCCTGTACCACCTCTTCCTGAATACGGAGGAAAAGTTCGTTATGG                   ACTGATCCCTGAGGAATTCTTCCAGTTTCTTTATCCTAAAACTGGTGTAACAGGACCCTATGTACTC                   GGAACTGGGCTTATCTTGTACGCTTTATCCAAAGAAATATATGTGATTAGCGCAGAGACCTTCACTG                   CCCTATCAGTACTAGGTGTAATGGTCTATGGAATTAAAAAATATGGTCCCTTTGTTGCAGACTTTGC                   TGATAAACTCAATGAGCAAAAACTTGCCCAACTAGAAGAGGCGAAGCAGGCTTCCATCCAACACATC                   CAGAATGCAATTGATACGGAGAAGTCACAACAGGCACTGGTTCAGAAGCGCCATTACCTTTTTGATG                   TGCAAAGGAATAACATTGCTATGGCTTTGGAAGTTACTTACCGGGAACGACTGTATAGAGTATATAA                   GGAAGTAAAGAATCGCCTGGACTATCATATATCTGTGCAGAACATGATGCGTCGAAAGGAACACATG                   ATAAATTGGGTGGAGAAGCACGTGGTGCAAAGCATCTCCACACAGCAGGAAAAGGAGACAATTGCCA                   AGTGCATTGCGGACCTAAAGCTGCTGGCAAAGAAGGCTCAAGCACAGCCAGTTATG TAA   ATGTATCT                       ATCCCAATTGAGACAGCTAGAAACAGTTGACTGACTAAATGGAAACTAGTCTATTTGACAAAGTCTT                       TCTGTGTTGGTGTCTACTGAAGT                                               ORE Start: ATG at 32       ORF Stop: TAA at 794               SEQ ID NO:112   254 aa   MW at 28651.1 kD                         NOV24b,   MLSRVVLSAAATAAPSLKNAAFLGPGVLQATRTFHTGQPHLVPVPPLPEYGGKVRYGLIPEEFFQFL           CG140612-02       Protein Sequence   YPKTGVTGPYVLGTGLILYALSKEIYVISAETFTALSVLGVMVYGIKKYGPFVADFADKLNEQKLAQ                   LEEAKQASIQHIQNAIDTEKSQQALVQKRHYLFDVQRNNIAMALEVTYRERLYRVYKEVKNRLDYHI                   SVQNMMRRKEHMINWVEKHVVQSISTQQEKETIAKCIADLKLLAKKAQAQPVM                  
 
     [0477] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 24B.  
               TABLE 24B                          Comparison of NOV24a against NOV24b.                                         Identities/                   Similarities for           Protein   NOV24a Residues/   the Matched           Sequence   Match Residues   Region                       NOV24b   1 . . . 256   240/256 (93%)               1 . . . 254   243/256 (94%)                      
 
     [0478] Further analysis of the NOV24a protein yielded the following properties shown in Table 24C.  
               TABLE 24C                       Protein Sequence Properties NOV24a                                                PSort   0.5326 probability located in outside; 0.1000           analysis:   probability located in endoplasmic reticulum               (membrane); 0.1000 probability located in               endoplasmic reticulum (lumen); 0.1000               probability located in lysosome (lumen)           SignalP   Cleavage site between residues 14 and 15           analysis:                      
 
     [0479] A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24D.  
               TABLE 24D                          Geneseq Results for NOV24a                                         NOV24a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG03729   Human secreted protein, SEQ   1 . . . 132   126/132 (95%)   4e−67           ID NO: 7810 -  Homo     1 . . . 132   127/132 (95%)             sapiens , 134 aa.           [EP1033401-A2,           06 SEP. 2000]       AAU32833   Novel human secreted   1 . . . 253   169/282 (59%)   1e−66           protein #3324 -  Homo     10 . . . 290    188/282(65%)             sapiens , 292 aa.           [WO200179449-A2,           25 OCT. 2001]       ABG17750   Novel human diagnostic   72 . . . 230    117/159 (73%)   3e−59           protein #17741 -  Homo     206 . . . 360    134/159 (83%)             sapiens , 360 aa.           [WO200175067-A2,           11 OCT. 2001]       AAU32832   Novel human secreted   2 . . . 104   102/103 (99%)   4e−53           protein #3323 -  Homo     1 . . . 103   103/103 (99%)             sapiens , 114 aa.           [WO200179449-A2,           25 OCT. 2001]       ABB63734     Drosophila melanogaster     48 . . . 252     94/206 (45%)   1e−47           polypeptide SEQ ID NO   38 . . . 242    138/206 (66%)           17994 -  Drosophila               melanogaster , 243 aa.           [WO200171042-A2,           27 SEP. 2001]                  
 
     [0480] In a BLAST search of public sequence datbases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24E.  
               TABLE 24E                          Public BLASTP Results for NOV24a                                         NOV24a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               P24539   ATP synthase B chain,   1 . . . 256   253/256 (98%)   e−142           mitochondrial precursor (EC   1 . . . 256   256/256 (99%)           3.6.3.14) -  Homo sapiens             (Human), 256 aa.       JQ1144   H+-transporting ATP   1 . . . 256   252/256 (98%)   e−142           synthase (EC 3.6.1.34) chain   1 . . . 256   256/256 (99%)           b precursor, mitochondrial -           human, 256 aa.       Q9CQQ7   ATP synthase B chain,   1 . . . 256   209/256 (81%)   e−118           mitochondrial precursor (EC   1 . . . 256   234/256 (90%)           3.6.3.14) -  Mus musculus             (Mouse), 256 aa.       P19511   ATP synthase B chain,   1 . . . 256   207/256 (80%)   e−118           mitochondrial precursor (EC   1 . . . 256   234/256 (90%)           3.6.3.14) -  Rattus norvegicus             (Rat), 256 aa.       P13619   ATP synthase B chain,   43 . . . 256    182/214 (85%)   e−102           mitochondrial (EC 3.6.3.14) -   1 . . . 214   201/214 (93%)             Bos taurus  (Bovine), 214 aa.                  
 
     [0481] PFam analysis predicts that the NOV24a protein contains the domains shown in the Table 24F.  
               TABLE 24F                          Domain Analysis of NOV24a                                     Identities/               NOV24a   Similarities       Pfam   Match   for the Matched   Expect       Domain   Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 25  
     [0482] The NOV25 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 25A.  
               TABLE 25A                       NOV25 Sequence Analysis                                                    SEQ ID NO:113   1316 bp                             NOV25a,     TCCTACCAC   AGT GTCTGATGGAGCTTTCCTACCAGACCCTGAAATTCACCCATCACGCGCGGGAAGC           CG140696-01       DNA Sequence   GAGCGAGATGAGGACAGAAGCACGACGAAAAAATCTTCTCATTTTGATTTCGCATTATTTAACACAA                   GAAGGGTATCTCGATACAGCAAATGCTTTGGAGCAAGAAACTAAACTGGGGTTACGACGGTTTGAAG                   TTTCTGACAACATTGATCTTGAAACTATTTTGATGGAATATGAGAGTTATTATTTTGTAAAATTTCA                   GAAATACCCCAAAATTGTCAAAAAGTCATCAGACACAGCAGAAAATAATTTACCGCAAAGAAGTAGA                   GGGAAGACCAGAAGGATGATGAACGACAGTTGTCAAAATCTTCCCAAGATCAATCAGCAGAGGCCCC                   GGTCCAAAACCACAGCGGGGAAGACAGCGGACACCAAATCGCTCAAAAAGCATCTATTGCAGGTCTT                   AGAGTCAGTCTCTAACACTCGCCTGGAAAGTGCCAACTTCGGCCTACATATATCAAGAATCCGTAAA                   GACAGTGGAGAGGAAAATGCCCACCCACGAAGACGCCAAATCATTGACTTCCAAGGGCTGCTCACAG                   ATGCCATCAAGGGAGCAACCAGTGAACTTGCCTTGAACACCTTCGACCATAATCCAGACCCCTCAGA                   ACGACTCCTGAAACCTCTGAGTGCATTTATTGGCATGAACAGTGAGATGCGAGAATTGGCAGCCGTG                   GTGAGCCGGGACATTTATCTCCATAATCCAAACATAAAGTGGAATGACATTATTGGACTTGATGCAG                   CCAAGCAGTTAGTCAAAGAAGCTGTTGTGTATCCTATAAGGTATCCACAGCTATTTACAGGAATTCT                   TTCTCCCTGGAAAGGACTACTGCTGTACGGCCCTCCAGGTACAGGAAAGACTTTACTGGCCAAAGCT                   CTGGCCACTGAATGTAAAACAACCTTCTTTAACATTTCTGCATCCACCATTGTCAGCAAATGGAGAG                   GGGATTCAGAAAAACTCGTTCGGGTGTTATTTGAGCTTGCCCGCTACCACGCCCCATCCACGATCTT                   CCTGGACGAGCTGGAGTCGGTGATGAGTCAGAGAGGCACAGCTTCTGGGGGAGAACATGAACGAAGC                   CTGCGGATGAAGACAGAGTTACTGGTGCAGATGGATGGGCTGGCACGCTCAGAAGATCTCGTATTTG                   TCTTAGCAGCTTCTAACCTGCCGTGG TAA   GAGACCAAGAGAGTAAATTTTGAATACATTTTCAGGAG                       TCACTAAGTGCAAATAAAAATTTTATATTGACCACTTCAAAAA                                               ORF Start: ATG at 18       ORF Stop: TAA at 1233               SEQ ID NO:114   405 aa   MW at 45796.9 kD                         NOV25a,   MELSYQTLKFTHQAREASEMRTEARRKNLLILISHYLTQEGYLDTANALEQETKLGLRRFEVCDNID           CG140696-01       Protein Sequence   LETILMEYESYYFVKFQKYPKIVKKSSDTAENNLPQRSRGKTRRMMNDSCQNLPKINQQRPRSKTTA                   GKTGDTKSLKKHLLQVLESVSNTRLESANFGLHISRIRKDSGEENANPRRGQIIDFQGLLTDAIKGA                   TSELALNTFDHNPDPSERLLKPLSAFIGMNSEMRELAAVVSRDTYLHNPNIKWNDIIGLDAAKQLVK                   EAVVYPIRYPQLFTGILSPWKGLLLYGPPGTGKTLLAKAVATECKTTFFNISASTIVSKWRGDSEKL                   VRVLFELARYHAPSTIFLDELESVMSQRGTASGGEHEGSLRMKTELLVQMDGLARSEDLVFVLAASN                   LPW                                         SEQ ID NO:115   1035 bp                             NOV25b,     TCCTAGCACAGTGTCTGATGGAGCTTTCCTACCAGACCCTGAAATTCACGCATCAGGCGCGGGAAGC             CG140696-02       DNA Sequence     GACTG   ATG AACGACAGTTGTCAAAATCTTCCCAAGATCAATCAGCAGAGGCCCCGGTCCAAAACCAC                   AGCCGGGGCAAGACACGGGGACACCAAATCGCTCAATAAGGAGCATCCTAATCAGGAGGTAGTTGAT                   AACACTCGCCTGCAAAGTGCCAACTTCGGCCTACATATATCAAGAATCCGTAAAGACAGTGGAGAGG                   AAAATGCCCACCCACGAAGAGGCCAAATCATTGACTTCCAAGGGCTGCTCACAGATGCCATCAAGGG                   AGCAACCAGTGAACTTGCCTTGAACACCTTCGACCATAATCCAGACCCCTCAGAACGACTGCTGAAA                   CCTCTGAGTGCATTTATTGGCATGAACAGTGAGATGCGAGAATTGGCAGCCGTGGTGAGCCGGGACA                   TTTATCTCCATAATCCAAACATAAAGTGGAATGACATTATTGGACTTGATGCAGCCAAGCAGTTAGT                   CAAAGAAGCTGTTGTGTATCCTATAAGGTATCCACAGCTATTTACAGGAATTCTTTCTCCCTGGAAA                   GGACTACTGCTGTACGGCCCTCCAGGTACAGGAAAGACTTTACTGGCCAAAGCTGTGCCCACTGAAT                   GTAAAACAACCTTCTTTAACATTTCTGCATCCACCATTGTCAGCAAATGGAGAGGGGATTCAGAAAA                   ACTCGTTCGGGTGTTATTTGAGCTTGCCCGCTACCACGCCCCATCCACGATCTTCCTGGACGAGCTG                   GAGTCGGTGATGAGTCAGAGAGGCACAGCTTCTGGGGGAGAACATGAAGGAAGCCTGCGGATGAAGA                   CAGAGTTACTGGTGCAGATGGATGGGCTGGCACCCTCAGAAGATCTCGTATTTGTCTTAGCAGCTTC                   TAACCTGCCCTGG TAA   CAGACCAACAGAGTAAATTTTGAATACATTTTCAGGAGTCACTAAGTGCAA                       ATAAAAATTTTATATTGACCACTTCAAAAA                                               ORF Start: ATG at 73       ORF Stop: TAA at 952               SEQ ID NO:116   293 aa   MW at 32516.6 kD                         NOV2Sb,   MNDSCQNLPKINQQRPRSKTTAGARHGDTKSLNKEHPNQEVVDNTRLESANFGLHISRIRKDSGEEN           CG140696-02       Protein Sequence   AHPRRGQIIDFQGLLTDAIKGATSELALNTFDHNPDPSERLLKPLSAFIGMNSEMRELAAVVSRDIY                   LHNPNIKWNDIIGLDAAKQLVKEAVVYPTRYPQLFTGILSPWKGLLLYGPPGTGKTLLAKAVATECK                   TTFFNISASTIVSKWRGDSEKLVRVLFELARYHAPSTIFLDELESVMSQRGTASGGEHEGSLRNKTE                   LLVQMDGLARSEDLVFVLAASNLPW                                         SEQ ID NO:117   1215 bp                             NOV25c,     ATG GAGCTTPCCTACCAGACCCTGAAATTCACGCATCAGGCGCGGGAAGCGTGCGAGATGAGGACAG           CG140696-03       DNA Sequence   AAGCACGACGAAAAAATCTTCTCATTTTGATTTCCCATTATTTAACACAAGAAGGGTATATCGATAC                   AGCAAATGCTTTGGAGCAAOAAACTAAACTGGGGTTACGACGGTTTGAAGTTTGTGACAACATTGAT                   CTTGAAACTATTTTGATGGAATATGAGAGTTATTATTTTGTAAAATTTCAGAAATACCCCAAAATTG                   TCAAAAAGTCATCAGACACAGCAGAAAATAATTTACCGCAAAGAAGTAGAGGGAAGACCAGAAGGAT                   GATGAACGACAGTTGTCAAAATCTTCCCAAGATCAATCAGCAGAGGCCCCGGTCCAAAACCACAGCG                   GGGAAGACAGGGGACACCAAATCGCTCAATAAGGAGCATCCTAATCACGAGGTAGTTGATAACACTC                   GCCTCGAAAGTGCCAACTTCGGCCTACATATATCAAGAATCCGTAAAGACAGTGGAGACGAAAATGC                   CCACCCACGAAGAGGCCAAATCATTGACTTCCAAGGGCTGCTCACAGATGCCATCAAGGGAGCAACC                   AGTGAACTTGCCTTGAACACCTTCGACCATAATCCAGACCCCTCAGAACGACTGCTGAAACCTCTGA                   GTGCATTTATTGGCATGAACAGTGAGATGCGAGAATTGGCAGCCGTGGTGAGCCGGGACATTTATCT                   CCATAATCCAAACATAAAGTGGAATGACATTATTGGACTTGATGCAGCCAAGCAGTTAGTCAAAGAA                   GCTGTTGTGTATCCTATAAGGTATCCACAGCTATTTACAGGAATTCTTTCTCCCTGGAAAGGACTAC                   TGCTGTACGGCCCTCCAGGTACAGGAAAGACTTTACTGGCCAAAGCTGTGGCCACTGAATGTAAAAC                   AACCTTCTTTAACATTTCTGCATCCACCATTGTCAGCAAATGGAGAGGGGATTCAGAAAAACTCGTT                   CGGGTGTTATTTGAGCTTGCCCCCTACCACGCCCCATCCACGATCTTCCTGGACGAGCTGGAGTCGG                   TGATGAGTCAGAGAGGCACAGCTTCTGGFGGAGAACATGAAGGAAGCCTGCGGATGAAGACAGAGTT                   ACTGGTGCAGATGGATGGGCTGGCACGCTCAGAAGATCTCGTATTTGTCTTAGCAGCTTCTAACCTG                   CCGTGG TAA                                               ORF Start: ATG at 1       ORF Stop: TAA at 1213               SEQ ID NO:118   404 aa   MW at 45740.7 kD                         NOV25c,   MELSYQTLKFTHQAREACEMRTEARRKNLLILISHYLTQEGYIDTANALEQETKLGLRRFEVCDNID           CG140696-03       Protein Sequence   LETILMEYESYYFVKFQKYPKIVKKSSDTAENNLPQRSRGKTRRMMNDSCQNLPKINQQRPRSKTTA                   GKTGDTKSLNKEHPNQEVVDNTRLESANFGLHISRIRKDSGEENAHPRRGQIIDFQGLLTDAIKGAT                   SELALNTFDHNPDPSERLLKPLSAFIGMNSEMRELAAVVSRDIYLHNPNIKWNDIIGLDAAKQLVKE                   AVVYPIRYPOLFTGILSPWKGLLLYGPPGTGKTLLAKAVATECKTTFFNISASTIVSKWRGDSEKLV                   RVLFELARYHAPSTIFLDELESVMSQRGTASGGEHEGSLRMXTELLVQNDGLARSEDLVFVLAASNL                   PW                  
 
     [0483] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 25B.  
               TABLE 25C                       Protein Sequence Properties NOV25a                                                PSort   0.6500 probability located in cytoplasm; 0.1000           analysis:   probability located in mitochondrial matrix               space; 0.1000 probability located in lysosome               (lumen); 0.0000 probability located in               endoplasmic reticulum (membrane)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0484] Further analysis of the NOV25a protein yielded the following properties shown in Table 25C.  
               TABLE 25D                          Geneseq Results for NOV25a                                         NOV25a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAG67151   Amino acid sequence of a   1 . . . 405   394/406 (97%)   0.0           human enzyme -  Homo     1 . . . 403   396/406 (97%)             sapiens , 403 aa.           [WO200164896-A2,           07 SEP. 2001]       AAB69399   Human retinoid receptor   230 . . . 405    176/176 (100%)   4e−97           interacting protein #2 -   1 . . . 176    176/176 (100%)             Homo sapiens , 176 aa.           [WO200112786-A1,           22 FEB. 2001]       AAG48014     Arabidopsis thaliana  protein   231 . . . 405   122/175 (69%)   5e−69           fragment SEQ ID NO: 60587 -   7 . . . 181   150/175 (85%)             Arabidopsis thaliana , 312           aa. [EP1033405-A2,           06 SEP. 2000]       AAG48013     Arabidopsis thaliana  protein   231 . . . 405   122/175 (69%)   5e−69           fragment SEQ ID NO: 60586 -   88 . . . 262   150/175 (85%)             Arabidopsis thaliana , 393           aa. [EP1033405-A2,           06 SEP. 2000]       AAG31755     Arabidopsis thaliana  protein   231 . . . 405   122/175 (69%)   5e−69           fragment SEQ ID NO: 38188 -   7 . . . 181   150/175 (85%)             Arabidopsis thaliana , 312           aa. [EP1033405-A2,           06 SEP. 2000]                  
 
     [0485] A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25D.  
     [0486] In a BLAST search of public sequence datbases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25E.  
               TABLE 25E                          Public BLASTP Results for NOV25a                                         NOV25a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9D3R6   4933439B08Rik protein -    1 . . . 405   354/405 (87%)   0.0             Mus musculus (Mouse), 409    1 . . . 405   374/405 (91%)           aa.       Q9GNC3   Probable AAA ATPase    8 . . . 405   184/427 (43%)   9e−82           (Probable katanin-like    22 . . . 429   256/427 (59%)           protein) -  Leishmania major ,           565 aa.       Q8S0S5   Katanin p60 subunit A 1-like -   211 . . . 405   131/195 (67%)   8e−70             Oryza saliva  (japonica   104 . . . 293   161/195 (82%)           cultivar-group), 428 aa.       B84758   probable katanin [imported] -   231 . . . 405   122/175 (69%)   2e−68             Arabidopsis thaliana , 393 aa.    88 . . . 262   150/175 (85%)       O64691   Putative katanin -  Arabidopsis     231 . . . 405   122/175 (69%)   2e−68             thaliana (Mouse-ear cress),    79 . . . 253   150/175 (85%)           384 aa.                  
 
     [0487] PFam analysis predicts that the NOV25a protein contains the domains shown in the Table 25F.  
               TABLE 25F                          Domain Analysis of NOV25a                                             Identities/                       Similarities               NOV25a   for the               Match   Matched   Expect           Pfam Domain   Region   Region   Value                       Sigma54_activat   291 . . . 308   10/18 (56%)   0.94                   16/18 (89%)           AAA   290 . . . 405   59/220 (27%)    6.8e−13                   99/220 (45%)                       
 
     Example 26  
     [0488] The NOV26 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 26A.  
               TABLE 26A                       NOV26 Sequence Analysis                                                    SEQ ID NO:119   3915 bp                             NOV26a,     ATACCTACTGAACGTGAACGAACAGAAAGGCTAATTAAAACCAAATTAAGGGAGATC   ATG ATGCAGA           CG140747-01       DNA Sequence   AGGATTTCGAGAATATTACATCCAAAGAGATAAGAACAGAGTTGGAAATGCAAATGGTGTGCAACTT                   GCGGGAATTCAACGAATTTATAGACAATGAAATGATAGTGATCCTTGGTCAAATGGATAGCCCTACA                   CAGATATTTGACCATGTGTTCCTGGGCTCAGAATGGAATGCCTCCAACTTAGAGGACTTACAGAACC                   GAGGGGTACGGTATATCTTGAATGTCACTCGAGAGATAGATAACTTCTTCCCAGGAGTCTTTGAGTA                   TCATAACATTCGGGTATATGATGAAGAGGCAACGGATCTCCTGGCGTACTGGAATGACACTTACAAA                   TTCATCTCTAAAGCAAAGAAACATGGATCTAAATGCCTTGTGCACTGCAAAATGGGGGTGAGTCGCT                   CAGCCTCCACCGTGATTGCCTATGCAATGAAGGAATATGGCTGGAATCTGGACCGAGCCTATGACTA                   TGTGAAACAAAGACGAACGGTAACCAAGCCCAACCCAAGCTTCATGAGACAACTGGAAGAGTATCAG                   GGGATCTTGCTGGCAAGCAAACAGCGGCATAACAAACTATGGAGATCTCATTCAGATAGTGACCTCT                   CAGACCACCACGAACCCATCTGCAAACCTGGGCTAGAACTCAACAAGAAGGATATCACCACCTCAGC                   AGACCAGATTGCTGAGGTGAAGACCATGGAGAGTCACCCACCCATACCTCCTGTCTTTGTGCAACAT                   ATGGTCCCACAAGATGCAAATCAGAAAGGCCTGTGTACCAAAGAAAGAATGATCTGCTTGGAGTTTA                   CTTCTAGGGAATTTCATGCTGGACAGATTGAGGATGAATTAAACTTAAATGACATCAATGGATGCTC                   ATCAGGGTGTTGTCTGAATGAATCAAAATTTCCTCTTGACAATTGCCATGCATCCAAAGCCTTAATT                   CAGCCTGGACATGTCCCAGAAATGGCCAACAAGTTTCCAGACTTAACAGTGGAAGATTTGGAGACAG                   ATGCACTGAAAGCAGACATGAATGTCCACCTACTGCCTATGGAAGAATTGACATCTCCACTGAAAGA                   CCCCCCCCATGTCCCCTGATCCTGAGTCACCAAGCCCCCAACCAGTTGCCAGACTGAAATCTCAGAT                   TTCAGTACAGATCGCATTGACTTTTTTAGTGCCCTAGAGAAGTTTGTGGAGCTCTCCCAAGAAACCC                   GGTCACGATCTTTTTCCCATTCAAGGATGGAGGAACTGGGTGGAGGAAGGAATGAGAGCTGTCGACT                   GTCAGTGGTAGAAGTAGCCCCTTCCAAAGTGACAGCTGATGACCAGAGAAGCAGCTCTTTGAGTAAT                   ACTCCCCATGCATCAGAAGAATCTTCAATGGATGAGGAACAGTCAAAGGCAATTTCAGAACTGGTCA                   GCCCAGACATCTTCATGCAGTCTCACTCGGAAAATGCAATTTCAGTCAAAGAAATTGTCACTGAAAT                   TGAGTCCATCAGTCAAGGAGTTGCGCAGATTCAACTGAAAGGAGACATCTTACCCAACCCATGCCAT                   ACACCAAAGAAGAACAGCATCCATGAGCTGCTCCTTGAGAGGGCCCAGACTCCAGAGAACAAACCTG                   GACATATGGAGCAAGATGAGGACTCCTGCACAGCCCAGCCTGAACTAGCCAAAGACTCAGGGATGTG                   CAACCCAGAAGGCTGCCTAACCACACACTCATCTATAGCAGACTTCGAAGAAGGGGAACCAGCTGAG                   GGGGAACAAGAGCTCCAGGGCTCAGCGATGCACCCAGGTGCCAAGTGGTACCCTGGGTCTGTGAGGC                   GAGCCACCTTGGAGTTCGAAGAGCGCTTACGGCAGGAGCAAGAGCATCATGGTGCTGCCCCAACATG                   TACCTCATTGTCCACTCGTAAGAATTCAAAGAATGATTCTTCTGTGGCAGACCTAGCACCAAAAGGG                   AAAAGTGATGAAGCCCCCCCAGAACATTCATTTGTCCTCAAGGAACCAGAAATGAGCAAAGGCAAAG                   GGAAATACAGTGGGTCTGAGGCTGGCTCACTGTCCCATTCTGAGCAGAATGCCACTGTTCCAGCTCC                   CAGGGTGCTGGAGTTTGACCACTTGCCAGATCCTCAGGAGGGCCCAGGGTCAGATACTGGAACACAG                   CAGGAAGGAGTCCTGAAGGATCTGAGGACTGTGATTCCATACCACGAGTCTGAAACACAAGCAGTCC                   CTCTTCCCCTTCCCAAGAGGGTAGAAATCATTGAATATACCCACATAGTTACATCACCCAATCACAC                   TGGGCCAGGGAGTGAAATAGCCACCAGTGAGAAGACCGGAGAGCAAGGGCTGAGGAAAGTGAACATG                   GAAAAATCTGTCACTGTGCTCTGCACACTGGATGAAAATCTAAACAGGACTCTGGACCCCAACCAGG                   TTTCTCTGCACCCCCAAGTGCTACCTCTGCCTCATTCTTCCTCCCCTGAGCACAACAGACCCACTCA                   CCATCCAACCTCCATCCTGAGTAGCCCTGAAGACAGAGGCAGCAGCCTGTCCACAGCCCTGGAGACA                   GCAGCACCTTTTGTCAGTCATACAACCCATTTACTGTCTGCCAGTTTGGATTACCTGCATCCCCAGA                   CTATGGTTCACCTGGAGAGGGCTTCACAGAGCAGAGCAGCACTACAGATGAGCCCTCTGCAGCAGGT                   TAGCTGCGAAGAAAGTCAGGAGAGCCCTCTCTCCAGTGGCAGTGAGGTGCCATATAAGGACTCCCAG                   CTAAGTAGCGCAGACCTAAGTTTAATTAGCAAACTTCGTGACAACACTGGGCAGTTACAGGAGAAAA                   TGGACCCATTGCCTGTAGCCTGTCGACTCCCACATAGCTCTAGTAGTGAAACATAAAAGAGTCTCAG                   CCACAGCCCCCGTGTGGTGAAGGAGCGTGCTAAAGAAATCGAGTCTCGAGTGGTTTTCCAGGCAGGG                   CTCACCAAACCATCCCAAATGAGGCGCTCAGCTTCTCTCGCCAAATTAGGTTACTTGGACCTCTGTA                   AAGACTGCTTACCAGAGAGGGAGCCTGCCTCCTGTGAATCCCCTCATCTCAAACTGCTTCAGCCTTT                   CCTCAGAACAGACTCAGGCATGCACGCGATGGAGGACCAAGAGTCCCTAGAAAACCCAGGTGCCCCC                   CACAACCCAGAGCCCACCAAGTCTTTTGTAGAACAACTCACAACAACAGAGTGTATTGTGCAGAGCA                   AGCCAGTGGAGAGGCCCCTTGTGCAGTATGCCAAAGAATTTGGTTCTAGTCAGCAGTATTTGCTCCC                   CAGGGCAGGACTTGAATTGACTAGTTCTGAAGGAGGCCTTCCCGTGCTACAGACCCAGGGACTGCAG                   TGTGCATGCCCAGCTCCAGGGCTGGCCGTGGCACCCCGTCACCAACGGCCAGAAACTCACCCCCTTA                   GGAGACTGAAAAAGGCAAATGACAAAAAACGGACAACCAACCCCTTCTATAATACCATG TGA   TTCTG                       AGCCTACACATGTGACTTTCTAGAAGAAAATGTTTGTAAAGGGGCAGGTGTAATATGTAAGGAACAT                       GCACTTTATTGGTTAATTTTATAATATTTTGGTCATTTTACTGTTTCTGGTGCATGCAGGGTTTGGG                       TGTTTTTCAGTGTGTATGTGTGTGTATATGTAAGGGGAAAGAGAGATTGATCTGGATGGCAAGACCC                       TTTATCATTTTTTATTTAAAAAAATCAAACCTCAAAAAAGTCATTTTCAGAGAACACCTTTATCAAA                       GGCAATTGCTGTTTTTCAGTCAGCTGCCACCTGCTTCTCATTTTGCCCTCTGAGAAAAAGGCATGGT                       TTCTTAATTGAGGGAAGGAAGCAGATTCG                                               ORF Start: ATG at 58       ORF Stop: TGA at 3544               SEQ ID NO:120   1162 aa   MW at 128957.7 kD                         NOV26a,   MMQKDLENITSKEIRTELEMQMVCNLREFKEFIDNEMIVILGQMDSPTQIFEHVFLGSEWNASNLED           CG140747-01       Protein Sequence   LQNRGVRYILNVTREIDNFFPGVFEYHNIRVYDEEATDLLAYWNDTYKFISKAKKHGSKCLVHCKMG                   VSRSASTVIAYAMKEYGWNLDRAYDYVKERRTVTKPNPSFMRQLEEYQGILLASKQRHNKLWRSHSD                   SDLSDHHEPICKPGLELNKKDITTSADQIAEVKTMESHPPIPPVFVEHMVPQDANQKGLCTKERMIC                   LEFTSREFHAGQIEDELNLNDINGCSSGCCLNESKFPLDNCHASKALIQPGHVPEMANKFPDLTVED                   LETDALKADMNVHLLPMEELTSPLKDPPMSPDPESPSPQPSCQTEISDFSTDRIDFFSALEKFVELS                   QETRSRSFSHSRMEELGGGRNESCRLSVVEVAPSKVTADDQRSSSLSNTPHASEESSMDEEQSKAIS                   ELVSPDIFMQSHSENAISVXEIVTEIESISQGVGQIQLKGDILPNPCHTPKKNSIHELLLERAQTPE                   NKPGHMEQDEDSCTAQPELAKDSGMCNPEGCLTTHSSIADLEEGEPAEGEQELQGSGMHPGAKWYPG                   SVRRATLEFEERLRQEQEHHGAAPTCTSLSTRKNSKNDSSVADLAPKGKSDEAPPEHSFVLKEPEMS                   KGKGKYSGSEAGSLSHSEQNATVPAPRVLEFDHLPDPQEGPGSDTGTQQEGVLKDLRTVIPYQESET                   QAVPLPLPKRVEIIEYTHTVTSPNHTGPGSEIATSEKSGEQGLRKVNMEKSVTVLCTLDENLNRTLD                   PNQVSLHPQVLPLPHSSSPEHNRPTDHPTSILSSPEDRGSSLSTALETAAPFVSHTTHLLSASLDYL                   HPQTMVHLEGFTEQSSTTDEPSAEQVSWEESQESPLSSGSEVPYKDSQLSSADLSLISKLGDNTGEL                   QEKMDPLPVACRLPHSSSSENIKSLSHSPGVVKERAKEIESRVVFQAGLTKPSQMRRSASLAKLGYL                   DLCKDCLPEREPASCESPHLKLLQPFLRTDSGMHAMEDQESLENPGAPHNPEPTKSFVEQLTTTECI                   VQSKPVERPLVQYAKEFGSSQQYLLPRAGLELTSSEGGLPVLQTQGLQCACPAPGLAVAPRQQHGRT                   HPLRRLKKANDKKRTTNPFYNTM                  
 
     [0489] Further analysis of the NOV26a protein yielded the following properties shown in Table 26B.  
               TABLE 26B                       Protein Sequence Properties NOV26a                                                PSort   0.4500 probability located in cytoplasm; 0.3000           analysis:   probability located in microbody (peroxisome);               0.1000 probability located in mitochondrial               matrix space; 0.1000 probability located in               lysosome (lumen)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0490] A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26C.  
               TABLE 26C                          Geneseq Results for NOV26a                                         NOV26a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAE06776   Human dual-specificity   1 . . . 188    188/188 (100%)   e−107           phosphatase (DSP)-13 splice   1 . . . 188    188/188 (100%)           variant protein -  Homo               sapiens , 241 aa.           [WO200157221-A2,           09 AUG. 2001]       AAE06775   Human dual-specificity   1 . . . 188    188/188 (100%)   e−107           phosphatase (DSP)-13   269 . . . 456     188/188 (100%)           protein -  Homo sapiens , 509           aa. [WO200157221-A2,           09 AUG. 2001]       AAE07044   Human dual-specificity   1 . . . 188   187/188 (99%)   e−106           phosphatase (DSP)-13   269 . . . 456    187/188 (99%)           mutant protein, D368A -             Homo sapiens , 509 aa.           [WO200157221-A2,           09 AUG. 2001]       AAE07045   Human dual-specificity   1 . . . 188   187/188 (99%)   e−106           phosphatase (DSP)-13   269 . . . 456    187/188 (99%)           mutant protein, C399S -             Homo sapiens , 509 aa.           [WO200157221-A2,           09 AUG. 2001]       AAE04835   Human SGP001 phosphatase   1 . . . 188   184/188 (97%)   e−102           polypeptide -  Homo sapiens ,   262 . . . 445    184/188 (97%)           498 aa. [WO200146394-A2,           28 JUN. 2001]                  
 
     [0491] In a BLAST search of public sequence datbases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26D.  
               TABLE 26D                          Public BLASTP Results for NOV26a                                         NOV26a               Protein       Residues/   Identities/       Accession       Match   Similarities for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9C0D8   KIAA1725 protein -  Homo      121 . . . 1162   1042/1042 (100%)    0.0             sapiens  (Human), 1042 aa     1 . . . 1042   1042/1042 (100%)            (fragment).       Q8WYL2   HSSH-2 -  Homo sapiens      1 . . . 187    187/187 (100%)    e−106           (Human), 449 aa.   262 . . . 448    187/187 (100%)       BAC04546   CDNA FLJ38102 fis, clone    1 . . . 246   163/249 (65%)   7e−91           D3OST2000618,   274 . . . 522   195/249 (77%)           moderately similar to             Drosophila melanogaster             slingshot mRNA -  Homo               sapiens  (Human), 703 aa.       Q8WYL4   HSSH-1S -  Homo sapiens      1 . . . 246   163/249 (65%)   7e−91           (Human), 692 aa.   263 . . . 511   195/249 (77%)       Q8WYL5   HSSH-1L -  Homo sapiens      1 . . . 246   163/249 (65%)   7e−91           (Human), 1049 aa.   263 . . . 511   195/249 (77%)                  
 
     [0492] PFam analysis predicts that the NOV26a protein contains the domains shown in the Table 26E.  
               TABLE 26E                          Domain Analysis of NOV26a                                             Identities/                   NOV26a   Similarities           Pfam   Match   for the   Expect           Domain   Region   Matched Region   Value                       DSPc   46 . . . 184   62/172 (36%)   1.5e−45                   116/172 (67%)                       
 
     Example 27  
     [0493] The NOV27 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 27A.  
               TABLE 27A                       NOV27 Sequence Analysis                                                    SEQ ID NO: 121   1290bp                             NOV27a,     GACCTTAAGATTCCCCGCTCCAGCTCCGAG   ATG TCAGCAACGCTGATCCTGGAGCCCGCGGGCCGCG           CG141137-01       DNA Sequence   GCTGCCGAGACAAGCCGGTGCGCATCACCATGCGCGGCCTGGCTTCGGAGCCGCTGGACACGCTGCG                   CGCGTCCCTGCGCGGCGAGAAGGCTGGGCTCTTCCGCTACTGCGCCGACGCCCGCGGCGAGCTGGAC                   CTGGAGCGCGCGCCCGTGCTGGGCGGCAGCTTTAGGGGGCTAGAGTCCATGGGGCTGCTCTGGGCCC                   TGGAATCCAAGAAACCTTTTTGGCGCTTTCTGAAGCGGGACGTACAGATTCCCTTTATCGTGGAGTT                   GGAGGTGCTGGACGGCCACGACCCCGAGCCTGGAGAGCGCGACTTCCTCCCACAAGGGGTGCGGAGC                   GATTCGGTGCGCGCGGGCCGGGTACGCGCCACGCTCTTCCTGCCGCCAGGACCTGGACCCTTCCTAG                   GGATCATTGGCATCTTTGGTATTGGAGGGAGCCTGTTGGAATATCGAGCCAGCCTCCTTGCTGGCCA                   TGGCTTTGCCACGTTCGCTCTAGCTTGTTATAACTTTGAAGATCTCCCCAAGAACGTGGACAACATA                   CCCCTGGAGTACTTCGAAGAAGCCCTATGCTACATGCTTCAACATCCCCAGGTAAAAGGCCCAGGCA                   CTGGGCTTTGGGGCATTTCTCTAGGAGCTGATATTTGTCTCTCAATGGCCTCATTCTTGAAGAATGA                   CTCAGACACAGTTTCCATCAATGGATCCGGGATCAGTGGGAACAGAGGCATAAACTGTAAGCAGAAT                   AGCATTCCACCATTGGGCTATGACCTGAGGAGAATCAAGGTAGCTTTCTCAGGCCTCGTGGACGTCG                   TGGATATAAAGAATGATCTTGTAGGAGGGTATAAGAACCCCAGCATGATTTCAATGGAGAAGGCCCA                   GGGCCCCATCATTTTCATTGTTGGTCAGGATGACCATAACTGGAGGAGTGAGTTGTATGCCGAACGG                   TTACGGGCCCATGGAAAGGGAAAACCCCAGATCATCTGTTACCCTGGGACTGGGCTTTACACTGAGC                   CTCCTTACTTCCCCCTGTGCCCAGCTTCCCTTCACAAATTACTGAACAAACACGTGATATGGGTTGG                   GGAGCCAAGGGCTCATTCTAAGGCCCAGGTAGATGCCTGGAAGCAAATTCTAGCCGCCTTCTCCAAA                   CACCTGGGAGGTACCCAGAAAACAGCTTTCCCTAAATTG TAA   TGCCTTTGTCTGTTGTTGACATGAG                       AGAGTCAAGATCACATT                                           ORF Start: ATG at 31   ORF Stop: TAA at 1246                                         SEQ ID NO: 122   405 aa   MW at 44471.8kD                             NOV27a,   MSATLILEPAGRGCRDKPVRITNRGLASEPLDTLRASLRGEKAGLFRYCADARGELDLERAPVLGGS           CG141137-01       Protein Sequence   FRGLESMGLLWALESKKPFWRFLKRDVQIPFIVELEVLDGHDPEPGERDFLPQGVRSDSVPAGRVRA                   TLFLPPGPGPFLGIIGIFGIGGSLLEYRASLLAGHGFATFALACYNFEDLPKNVDNIPLEYFEEALC                   YMLQHPQVKGPGTGLWGISLGADICLSMASFLKNDSDTVSINGSGISGNRGINCKQNSIPPLGYDLR                   RIKVAFSGLVDVVDIKNDLVGGYKNPSMISMEKAQGPIIFIVGQDDHNWRSELYAERLRAHGKEKPQ                   IICYPGTGLYTEPPYFPLCPASLHKLLNXMVINVGEPRAHSKAQVDAWKQILAAFCKHLGGTQKTAF                   PKL                  
 
     [0494] Further analysis of the NOV27a protein yielded the following properties shown in Table 27B.  
               TABLE 27B                       Protein Sequence Properties NOV27a                                                PSort   0.4500 probability located in cytoplasm; 0.3164           analysis:   probability located in microbody (peroxisome);               0.1984 probability located in lysosome (lumen);               0.1000 probability located in mitochondrial               matrix space           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0495] A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27C.  
               TABLE 27C                          Geneseq Results for NOV27a                                         NOV27a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU76350   Human Acyl-CoA   1 . . . 405   347/421 (82%)   0.0           thioesterase 56939 -  Homo     1 . . . 421   361/421 (85%)             sapiens , 421 aa.           [WO200208274-A2,           31 JAN. 2002]       AAM41490   Human polypeptide SEQ ID   1 . . . 400   256/416 (61%)   e−141           NO 6421 -  Homo sapiens ,   74 . . . 489    299/416 (71%)           494 aa. [WO200153312-A1,           26 JUL. 2001]       AAM39704   Human polypeptide SEQ ID   1 . . . 400   256/416 (61%)   e−141           NO 2849 -  Homo sapiens ,   63 . . . 478    299/416 (71%)           483 aa. [WO200153312-A1,           26 JUL. 2001]       AAY71112   Human Hydrolase protein-10   1 . . . 400   256/416 (61%)   e−141           (HYDRL-10) - Homo   63 . . . 478    299/416 (71%)           sapiens, 483 aa.           [WO200028045-A2,           18 MAY 2000]       AAB93479   Human protein sequence   1 . . . 400   255/416 (61%)   e−141           SEQ ID NO: 12766 -  Homo     63 . . . 478    298/416 (71%)             sapiens , 483 aa.           [EP1074617-A2,           07 FEB. 2001]                  
 
     [0496] In a BLAST search of public sequence datbases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27D.  
               TABLE 27D                          Public BLASTP Results for NOV27a                                         NOV27a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               BAC04313   CDNA FLJ36904 fis, clone   1 . . . 405   345/421 (81%)   0.0           BRACE2002762, moderately   1 . . . 421   359/421 (84%)           similar to CYTOSOLIC           ACYL COENZYME A           THIOESTER HYDROLASE,           INDUCEBLE (EC 3.1.2.2) -             Homo sapiens (Human), 421           aa.       Q9QYR8   Peroxisomal long chain   1 . . . 405   275/421 (65%)   e−158           acyl-CoA thioesterase Ib -   1 . . . 421   327/421 (77%)             Mus musculus  (Mouse), 421           aa.       P49753   Peroxisomal acyl-coenzyme   1 . . . 400   256/416 (61%)   e−141           A thioester hydrolase 2 (EC   1 . . . 416   299/416 (71%)           3.1.2.2) (Peroxisomal           long-chain acyl-coA           thioesterase 2) (ZAP128) -             Homo sapiens  (Human), 421           aa.       Q9QYR7   Peroxisomal acyl-coenzyme   1 . . . 405   245/423 (57%)   e−130           A thioester hydrolase 2 (EC   12 . . . 432    296/423 (69%)           3.1.2.2) (Peroxisomal           long-chain acyl-coA           thioesterase 2) (PTE-Ia) -             Mus musculus  (Mouse), 432           aa.       O88267   Cytosolic acyl coenzyme A   1 . . . 405   239/422 (56%)   e−128           thioester hydrolase, inducible   1 . . . 419   295/422 (69%)           (EC 3.1.2.2) (Long chain           acyl-CoA thioester           hydrolase) (Long chain           acyl-CoA hydrolase) (CTE-I)           (LACH2) (ACH2) -  Rattus               norvegicus  (Rat), 419 aa.                  
 
     [0497] PFam analysis predicts that the NOV27a protein contains the domains shown in the Table 27E.  
               TABLE 27E                          Domain Analysis of NOV27a                                     Identities/               NOV27a   Similarities       Pfam   Match   for the Matched   Expect       Domain   Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 28  
     [0498] The NOV28 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 28A.  
               TABLE 28A                       NOV28 Sequence Analysis                                                    SEQ ID NO: 123   384 bp                             NOV28a,     TTGTGCAACGGCAGTCCAGCCCGGGCAAAAGAGTGAGACTATGTCTCTAAAAAAACCAAG   ATG GAGT           CG141240-01       DNA Sequence   CAGTTGTACCAGTGAAGGACAAGAAACTTCTGGAGGTCAAACTAGGGGAGCTGCCAAGCTGGATCTT                   GATGTGCGACTTCAGCCCTAGTGGCCTTGATGGAGCGTTTCAAAGAGGTTACTACTGGTACTACAAC                   AAGTACATCAACGTCAAGAAGGGGAGCATCTCGGGGTTTACCATGGTGCTGGCAGGGTACATGCTCT                   TCATCTACTGCCTTTCCTACAAGAGCTCAAGCACGAGCGGCTATGCAAGTACCAC TGA   AGAAGACA                       TGCTCTGCACTCCCCCAGCAACCTTCTTGGCTGCAACCCCTCCATAAGC                                           ORF Start: ATG at 61   ORF Stop: TGA at 325                                         SEQ ID NO: 124   88 aa   MW at 10416.2kD                             NOV28a,   MESVVPVKDKKLLEVKLGELPSWILMWDFSPSGLDGAFQRGYYWYYNKYINVKKGSISGFTMVLAGY           CG141240-01       Protein Sequence   MLFIYCLSYKELKHERLCKYH                  
 
     [0499] Further analysis of the NOV28a protein yielded the following properties shown in Table 28B.  
               TABLE 28B                       Protein Sequence Properties NOV28a                                                PSort   0.6400 probability located in microbody           analysis:   (peroxisome); 0.4500 probability located               in cytoplasm; 0.1000 probability located               in mitochondrial matrix space; 0.1000               probability located in lysosome (lumen)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0500] A search of the NOV28a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 28C.  
               TABLE 28C                          Geneseq Results for NOV28a                                         NOV28a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG89150   Human secreted protein, SEQ   1 . . . 88   75/88 (85%)   4e−37           ID NO: 270 -  Homo sapiens ,   1 . . . 88   77/88 (87%)           88 aa. [WO200142451-A2,           14 JUN. 2001]       AAY66171   Human bladder tumour EST   1 . . . 88   75/88 (85%)   4e−37           encoded protein 29 -  Homo     17 . . . 104   77/88 (87%)             sapiens , 104 aa.           [DE19818619-A1,           28 OCT. 1999]       AAB65990   Human secreted protein   3 . . . 88   74/86 (86%)   1e−36           BLAST search protein SEQ   2 . . . 87   76/86 (88%)           ID NO: 130 -  Homo sapiens ,           87 aa. [WO200077023-A1,           21 DEC. 2000]       AAB65989   Human secreted protein   3 . . . 88   74/86 (86%)   1e−36           BLAST search protein SEQ   2 . . . 87   76/86 (88%)           ID NO: 129 -  Homo sapiens ,           87 aa. [WO200077023-A1,           21 DEC. 2000]       AAY29462   Human CBMAJC02 protein -   5 . . . 88   72/84 (85%)   1e−35             Homo sapiens , 94 aa.   11 . . . 94    74/84 (87%)           [WO9936526-A1,           22 JUL. 1999]                  
 
     [0501] In a BLAST search of public sequence datbases, the NOV28a protein was found to have homology to the proteins shown in the BLASTP data in Table 28D.  
               TABLE 28D                          Public BLASTP Results for NOV28a                                         NOV28a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               A54211   H+-transporting ATP synthase   1 . . . 88   69/88 (78%)   3e−35           (EC 3.6.1.34) chain f - bovine, 88   1 . . . 88   77/88 (87%)           aa.       P56134   ATP synthase f chain,   5 . . . 88   72/84 (85%)   3e−35           mitochondrial (EC 3.6.3.14) -   10 . . . 93    74/84 (87%)             Homo sapiens  (Human), 93 aa.       Q28851   ATP synthase f chain,   3 . . . 88   68/86 (79%)   8e−35           mitochondrial (EC 3.6.3.14) -   2 . . . 87   76/86 (88%)             Bos taurus  (Bovine), 87 aa.       Q95339   ATP synthase f chain,   3 . . . 88   66/86 (76%)   4e−34           mitochondrial (EC 3.6.3.14) -   2 . . . 87   76/86 (87%)             Sus scrofa  (Pig), 87 aa.       AAH29226   ATP synthase, H+ transporting,   1 . . . 88   65/88 (73%)   1e−33           mitochondrial F0 complex,   1 . . . 88   78/88 (87%)           subunit f, isoform 2 -  Mus               musculus  (Mouse), 88 aa.                  
 
     [0502] PFam analysis predicts that the NOV28a protein contains the domains shown in the Table 28E.  
               TABLE 28E                          Domain Analysis of NOV28a                                     Identities/               NOV28a   Similarities       Pfam   Match   for the Matched   Expect       Domain   Region   Region   Value                         No Significant Matches Found to Publically Available Domains                  
 
     Example 29  
     [0503] The NOV29 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 29A.  
               TABLE 29A                       NOV29 Sequence Analysis                                                    SEQ ID NO: 125   789 bp                             NOV29a,     GGCCGTTCCTGCGCTCTCCTTCGCCTGCGGGCCGGCACTGCTCACCTCTCGTCCAGGGAC   ATG ACGG           CG141355-01       DNA Sequence   GCACGCCAGGCGCCGTTGCCACCCGGGATGGCGAGGCCCCCGAGCGCTCCCCGCCCTGCAGTCCGAG                   CTACGACCTCACGGGCAAGGTGATGCTTCTGGGAGACACAGGCGTCGGCAAAACATGTTTCCTGATC                   CAATTCAAAGACGGGGCCTTCCTGTCCGGAACCTTCATAGCCACCGTCGGCATAGACTTCAGGAACA                   AGGTGGTGACTCTCGATGGCGTGAGAGTGAAGCTGCAGATCTGGGACACCGCTGGGCAGGAACGGTT                   CCGAAGCGTCACCCATGCTTATTACAGAGATGCTCAGGCCTTGCTTCTGCTGTATGACATC~CCAAC                   AAATCTTCTTTCGACAACATCAGGGCCTGGCTCACTGAGATTCATGAGTATGCCCAGAGGGACGTGG                   TGATCATGCTGCTAGGCAACAAGGCGGATATGAGCAGCGAAAGAGTGATCCGTTCCGAAGACGGAGA                   GACCTTGGCCAGGGAGTACGGTGTTCCCTTCCTGGAGACCAGCGCCAAGACTGGCATGAATGTGGAG                   TTAGCCTTTCTGGCCATCGCCAAGGAACTGAAATACCGGGCCGGGCATCAGGCGGATGAGCCCAGCT                   TCCAGATCCCAGACTATGTAGAGTCCCAGAAGAAGCGCTCCAGCTGCTGCTCCTTCATGTGAATCCC                   AGGGGGCAGAGAGGAGGCTCTGGAGGCACACAGGATGCAGCCTTCCCCCTCC                                         ORF Start: ATG at 61   ORF Stop: TGA at 730                                         SEQ ID NO: 126   223aa   MW at 248 14.9kD                         NOV29a,   MTGTPGAVATRDGEAPERSPPCSPSYDLTGKVMLLGDTGVGKTCFLIQFKDGAFLSGTFIATVGIDF       CG141355-01       Protein Sequence   RNKVVTVDGVRVKLQIWDTAGQERFRSVTHAYYRDAQALLLLYDITNXSSFDNIRAWLTEIHEYAQR                   DVVIMLLGNKADMSSERVIRSEDGETLAREYGVPFLETSAKTGMNVELAFLAIAKELKYRAGHQADE                   PSFQIRDYVESQKKRSSCCSFM                                         SEQ ID NO: 127   686 bp                             NOV29b,     TCCAGGAAC   ATG ACGGGCACGCCAGGCGCCGTTGCCACCCGGGATCGCGAGGCCCCCGAGCGCTCCC           CG141355-02       DNA Sequence   CGCCCTGCAGTCCGAGCTACGACCTCACGGGCAAGGTGATGCTTCTGGGAGACACAGGCGTCGGCAA                   AACATGTTTCCTGATCCAATTCAAAGACGGGGCCTTCCTGTCCGGAACCTTCATAGCCACCGTCGGC                   ATAGACTTCAGGAACAAGGTGGTGACTGTGGATGGCGTGAGAGTGAAGCTGCAGATCTGGGACACCG                   CTGGGCAGGAACGGTTCCGAAGCGTCACCCATGCTTATTACAGAGATGCTCAGGCCTTGCTTCTGCT                   GTATGACATCACCAACAAATCTTCTTTCGACAACATCAGGGCCTGGCTCACTGAGATTCATGAGTAT                   GCCCAGAGGGACGTGGTGATCATGCTGCTAGGCAACAAGGCGGATATGAGCAGCGAAAGAGTGATCC                   GTTCCGAAGACGGAGAGACCTTGGCCAGGGAGTACGGTGTTCCCTTCCTGGAGACCAGCGCCAAGAC                   TGGCATGAATGTGGAGTTAGCCTTTCTGGCCATCGCCAAGGAACTGAAATACCGCGCCCGOCATCAG                   GCGGATGAGCCCAGCTTCCAGATCCGAGACTATGTAGAGTCCCAGAAGAAGCGCTCCAGCTGCTGCT                   CCTTCATG TGA   ATCCC                                           ORF Start: ATG at 10   ORF Stop: TGA at 679                                         SEQ ID NO: 128   223 aa   MW at 24814.9kD                             NOV29b,   MTGTPGAVATRDGEAPERSPPCSPSYDLTGKVMLLGDTGVGKTCFLTQFKDGAFLSGTFIATVGIDF           CG141355-02       Protein Sequence   RNRVVTVDGVRVKLQIWDTAGQERFRSVTHAYYRDAQALLLLYDITNKSSFDNIRAWLTEIHEYAQR                   DVVIMLLGNKADMSSERVIRSEDGETLAREYGVPFLETSAKTGMNVELAFLAIAKELKYRAGHQADE                   PSFQIRDYVESQKKRSSCCSFM                  
 
     [0504] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 29B.  
               TABLE 29B                          Comparison of NOV29a against NOV29b.                                         Identities/Similarities           Protein   NOV29a Residues/   for the           Sequence   Match Residues   Matched Region                       NOV29b   1 . . . 223   223/223 (100%)               1 . . . 223   223/223 (100%)                      
 
     [0505] Further analysis of the NOV29a protein yielded the following properties shown in Table 29C.  
               TABLE 29C                       Protein Sequence Properties NOV29a                                                PSort   0.4500 probability located in cytoplasm; 0.3020           analysis:   probabilitylocated in microbody (peroxisome);               0.1000 probability locatedin mitochondrial matrix               space; 0.1000 probability located in               lysosome (lumen)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0506] A search of the NOV29a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 29D.  
               TABLE 29D                          Geneseq Results for NOV29a                                         NOV29a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent#, Date]   Residues   Matched Region   Value               AAM41696   Human polypeptide SEQ ID   1 . . . 223   223/223 (100%)   e−127           NO 6627 -  Homo sapiens ,   10 . . . 232    223/223 (100%)           232 aa. [WO200153312-A1,           26 JUL. 2001]       AAU17119   Novel signal transduction   1 . . . 223   222/223 (99%)    e−126           pathway protein, Seq ID 684 -   4 . . . 226   222/223 (99%)              Homo sapiens ,226 aa.           [WO200154733-A1,           02 AUG.2001]       AAU17541   Novel signal transduction   2 . . . 223   220/222 (99%)    e−125           pathway protein, Seq ID 1106 -   1 . . . 222   220/222 (99%)              Homo sapiens ,222 aa.           [WO200154733-A1,           02 AUG.2001]       AAM39910   Human polypeptide SEQ ID   33 . . . 223    191/191 (100%)   e−106           NO 3055 -  Homo sapiens ,   1 . . . 191   191/191 (100%)           191 aa. [WO200153312-A1,           26 JUL. 2001]       AAG67156   Amino acid sequence of   33 . . . 223    191/191 (100%)   e−106           human 32712 G-protein -   1 . . . 191   191/191 (100%)             Homo sapiens , 191 aa.           [W0200164887-A2,           07 SEP. 2001]                  
 
     [0507] In a BLAST search of public sequence datbases, the NOV29a protein was found to have homology to the proteins shown in the BLASTP data in Table 29E.  
               TABLE 29E                          Public BLASTP Results for NOV29a                                         NOV29a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q96AX2   Ras-related protein Rab-37 -   1 . . . 223    223/223 (100%)   e−126             Homo sapiens  (Human),   1 . . . 223    223/223 (100%)           223 aa.       Q9JKM7   Ras-related protein Rab-37 -   1 . . . 223   209/223 (93%)   e−118             Mus musculus  (Mouse), 223 aa.   1 . . . 223   215/223 (95%)       CAC88255   Sequence 13 from Patent   33 . . . 223     191/191 (100%)   e−106           WO0164887 -   1 . . . 191    191/191 (100%)             Homo sapiens  (Human),           191 aa.       Q9ULW5   Ras-related protein Rab-26 -   33 . . . 220    138/188 (73%)   9e−80              Homo sapiens  (Human),   1 . . . 188   166/188 (87%)           190 aa.       P51156   Ras-related protein Rab-26 -   33 . . . 220    138/188 (73%)   8e−79              Rattus norvegicus  (Rat),   1 . . . 188   165/188 (87%)           190 aa.                  
 
     [0508] PFam analysis predicts that the NOV29a protein contains the domains shown in the Table 29F.  
               TABLE 29F                          Domain Analysis of NOV29a                                             Identities/                       Similarities           Pfam   NOV29a Match   for the   Expect           Domain   Region   Matched Region   Value                       arf   21 . . . 194   42/197 (21%)   1.9e−05                   104/197 (53%)            ras   31 . . . 223   93/206 (45%)   6.2e−89                   164/206 (80%)                       
 
     Example 30  
     [0509] The NOV30 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 30A.  
               TABLE 30A                       NOV30 Sequence Analysis                                                    SEQ ID NO: 129   1078 bp                             NOV30a,     CAGATCCTCATTTCTTTTCCCTTCCTAGGTTTTAAAAC   ATG AATCCTACACTCATCCTTGCTGCCTT           CG142072-01       DNA Sequence   TTGCCTGGGAATTGCCTCAGCTACTCTAACATTTGATCACAGTTTAGAGGCACAGTGGACCAAGTGG                   AAGGCGATGCACAACAGATTATACGGCATGAATGAAGAAGGATGGAGGAGAGCAGTGTGCGAGAAGA                   ACATGAAGATGATTGAACTGCACAATCAGGAATACACGGAAGGGAAACACAGCTTCACAATGGCCAT                   GAACGCCTTTGGAGACATGACCAGTGAAGAATTCAGGCAGGTGATGAATGGCTTTCAAAACCGTAAG                   CCCACGAAGGGGAAAGTGTTCCAGGAACCTCTGTTTTATGAGGCCCCCAGATCTGTGGATTGGAGAG                   AGAAACGCTACGTGACTCCTGTGAAGAATCAGGGTCAGTGTGGTTCTTGTTGGGCTTTTAGTGCTAC                   TGGTGCTCTTGAAGGACAGATGTTCCGGAAAACTCGGAGGCTTATCTCACTGAGTGAGCAGAATCTG                   GTAGACTGCTCTGGGCCTCAAGGCAATGAAGGCTCCAATGGTGGCCTAATGGATTATGCTTTCCAGT                   ATGTTCAGGATAATGGAGGCCTGGACTCTGAGGAATCCTATCCATATGAGGCAACAGAAGAATCCTG                   TAAGTACAATCCCAAGTACTCTGTTGCTAATGACACCGGCTTTGTGGACATCCCTAAGCAGGAGAAG                   GCCCTGATGAAGGCAGTTGCAACTGTGGGGCCCATTTCTGTTGCTATTGATGCAGGTCATGAGTCCT                   TCCTGTTCTATAAAGAAGGCATTTATTTTGAGCCAGACTGTAGCAGTGAAGACATGGATCATGGTGT                   GCTGGTGGTTGGCTACGGATTTGAAAGCACAGAATCAGATAACAATAAATATTGGCTGGTGAAGAAC                   AGCTGGGGTGAAGAATGGGGCATGGGTGGCTACGTAAAGATGGCCAAAGACCGGAGAAACCATTGTG                   GAATTGCCTCAGCAGCCAGCTACCCCACTGTG TGA   GCTGGTGGACGGTGATGAGGAAGGACTTGACT                       GGGGAT                                           ORF Start: ATO at 39   ORF Stop: TGA at 1038                                         SEQ ID NO: 130   333 aa   MW at 37563.9kD                             NOV3Oa,   MNPTLILAAFCLGIASATLTFDHSLEAQWTKWKAMHNRLYGMNEEGWRRAVWEKNMKMIELHNQEYR           CG142072-01       Protein Sequence   EGKHSFTNAHNAFGDMTSEEFRQVMNGFQNRKPRKGKVFQEPLFYEAPRSVDWREKGYVTPVKNQGQ                   CGSCWAFSATGALEGQMFRKTGRLTSLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEES                   YPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGFISVAIDAGHESFLFYKEGIYFEPD                   CSSEDMDHGVLVVGYGPESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV                                         SEQ ID NO: 131   870 bp                             NOV3Ob,     C   CTG GGAATTGCCTCAGCTACTCTAACATTTGATCACAGTTTAGAGGCACAGTGGACCGAGTGGAAG           CG142072-02       DNA Sequence   GCGATGCACAACAGATTATACGGCATGAATGAAGAAGGATGGAGGAGAGCAGTGTGGGAGAAGAACA                   TGAAGATGATTGAACTGCACAATCAGGAATACAGGGAAGGGAAACACAGCTTCACAATGGCCATGAA                   CGCCTTTGGAGACATCACCAGTGAAGAATTCAGGCAGGTGATGAATGGCTTTCAAAACCGTAAGCCC                   AGGAAGGGGAAAGTGTTCCGGAAAACTGGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACT                   GCTCTGGGCCTCAAGGCAATGAAGGCTGCAATGGTGGCCTAATGGATTATGCTTTCCAGTATGTTCA                   GGATAATGGAGGCCTGGACTCTGAGGAATCCTATCCATATGAGGCAACAGAAGAATCCTGTAAGTAC                   AATCCCAAGTATTCTGTTGCTAATGACACCGGCTTTGTGGACATCCCTAAGCACGAGAAGGCCCTGA                   TGAAGGCAGTTGCAACTGTGGGGCCCATTTCTGTTGCTATTGATGCAGGTCATGAGTCCTTCCTGTT                   CTATAAAGAAGGCATTTATTTTGAGCCAGACTGTAGCAGTGAAGACATGGATCATGGTGTGCTGGTG                   GTTGGCTACGGATTTGAAAGCACAGAATCAGATAACAATAAATATTGGCTGGTGAAGAACAGCTGGG                   GTGAAGAATGCGGCATGGGTGGCTACGTAAAGATGGCCAAAGACCGGAGAAACCATTGTGGAATTGC                   CTCAGCAGCCAGCTACCCCACTGTGTGAGCTGGTGGACGGTCATGAGGAAGGACTTGACTGGGGAT                                         ORF Start: at 2   ORF Stop: TGA at 830                                         SEQ ID NO: 132   1276 aa   MW at 31236.6kD                             NOV30b,   LGIASATLTFDHSLEAQWTEWKAMHNRLYGMNEEGWRRAVWEKNMKMIELHNQEYREGKHSFTMAMN           CG142072-02       Protein Sequence   AFGDMTSEEFRQVMNGFQNRKPRKGKVFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQ                   DNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLF                   YKECIYFEPDCSSEDMDHGVLVVCYGFESTESDNNXYWLVKNSWGEEWGMGGYVKNAXDRRNHCGIA                   SAASYPTV                  
 
     [0510] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 30B.  
               TABLE 30B                          Comparison of NOV30a against NOV30b.                                         Identities/                   Similarities               NOV30a Residues/   for the           Protein Sequence   Match Residues   Matched Region                       NOV30b   12 . . . 333   275/322 (85%)                1 . . . 276   276/322 (85%)                      
 
     [0511] Further analysis of the NOV30a protein yielded the following properties shown in Table 30C.  
               TABLE 30C                       Protein Sequence Properties NOV30a                                        PSort   0.8200 probability located in outside; 0.1679 probability       analysis:   located inmicrobody (peroxisome); 0.1000 probability           located in endoplasmic reticulum(membrane); 0.1000           probability located in endoplasmic reticulum (lumen)       SignalP   Cleavage site between residues 18 and 19       analysis:                  
 
     [0512] A search of the NOV30a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 30D.  
               TABLE 30D                          Geneseq Results for NOV30a                                         NOV30a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Matched Region   Value               ABB77396   Human cathepsin L -  Homo     1 . . . 333    333/333 (100%)   0.0             sapiens , 333 aa.   1 . . . 333    333/333 (100%)           [DE10050274-A1,           18 APR. 2002]       AAW47031   Human procathepsin L -  Homo     1 . . . 333    333/333 (100%)   0.0             sapiens , 333 aa.   1 . . . 333    333/333 (100%)           [US5710014-A,           20 JAN.1998]       AAM93531   Human polypeptide, SEQ   1 . . . 333   332/333 (99%)   0.0           ID NO: 3271 -  Homo     1 . . . 333   332/333 (99%)             sapiens , 333 aa.           [EP1130094-A2,           05 SEP. 2001]       AAR28829   Human procathepsin L -   1 . . . 333   332/333 (99%)   0.0             Homo sapiens ,   1 . . . 333   332/333 (99%)           333 aa. [WO9219756-A,           12 NOV.1992]       AAP82094   pHu-16 sequence encoded   1 . . . 333   327/333 (98%)   0.0           human procathepsin L -   1 . . . 333   332/333 (99%)             Homo sapiens , 333 aa.           [USN7154692-N,           11 FEB. 1988]                  
 
     [0513] In a BLAST search of public sequence datbases, the NOV30a protein was found to have homology to the proteins shown in the BLASTP data in Table 30E.  
               TABLE 30E                          Public BLASTP Results for NOV30a                                         NOV30a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               P07711   Cathepsin L precursor   1 . . . 333    333/333 (100%)   0.0           (EC 3.4.22.15)(Major   1 . . . 333    333/333 (100%)           excreted protein) (MEP) -  Homo               sapiens  (Human), 333 aa.       Q9GKL8   Cysteine protease -   1 . . . 333   320/333 (96%)   0.0             Cercopithecus aethiops     1 . . . 333   328/333 (98%)           (Green monkey) (Grivet),           333 aa.       Q9GL24   Cathepsin L (EC 3.4.22.15) -   1 . . . 333   270/334 (80%)   e−166             Canis familiaris  (Dog),   1 . . . 333   299/334 (88%)           333 aa.       Q28944   Cathepsin L precursor   1 . . . 333   263/334 (78%)   e−162           (EC 3.4.22.15) -   1 . . . 334   293/334 (86%)             Sus scrofa  (Pig), 334 aa.       P25975   Cathepsin L precursor   1 . . . 333   257/334 (76%)   e−160           (EC 3.4.22.15)-   1 . . . 334   291/334 (86%)             Bos taurus  (Bovine), 334 aa.                  
 
     [0514] PFam analysis predicts that the NOV30a protein contains the domains shown in the Table 30F.  
               TABLE 30F                          Domain Analysis of NOV30a                                     Identities/               NOV30a   Similarities           Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               Peptidase_C1   114 . . . 332   129/337 (38%)   1.8e−132               201/337 (60%)                  
 
     Example 31  
     [0515] The NOV31 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 31A.  
               TABLE 31A                       NOV31 Sequence Analysis                                                    SEQ ID NO: 133   639 bp                             NOV31 a,     CCTGTTTAATAAACAGATCTTGGCTTTGCAGATGCTGCCAGGAACCCCATACTATCAGCC   ATG GTCA           CG142102-01       DNA Sequence   ACCCCACCGTGTTCTTCAACATGGCTGTCAATGATGAGCCCTTGTGCCACGTCTCCTTTGAGCTGTA                   TGCAGACAAGTTTCCAAAGACAGCAGAAAACTTTCGTCCTCTGAGCACTGGAOAGAAAGGATTTCGT                   TACAAGGGTTTCTGCTTTTACAGAATTATTCCAGGOTTTATGTGGTTTATGTGTCAGGGCAGTGACT                   TCACACACCATAATGGCACTGGTGGCAAGTCCATCTATGGAGAGAAATTTGATGACGAGAACTTCAT                   CCTGAAGCATACAGGTCCTGAACCCTCACATTCCCAAACCAATTACTTATCCATGGCAAATGCTGGA                   CCCAACACAAATGGTTCCCAGTTTTTCCTCTGCACTGCCAAGACTGAGTGGTTGGATGGCACACATG                   TGGTCTTTGGCAAGGTGAAAGAAGGCATCAATATTGTGGAGGCCATGGAGCGCTTTGGATCTAGGAA                   TGGCAAGACCAGcAGATCACCATTGTTGACTGTGGACAACTCTAATGAATTTAACTTGTGTTTTTT                   CTTTTTAAGATGGAGTTTCACTCTTGTTTCCCAGGC                                         ORF Start: ATG at 61   ORF Stop: TAA at 580                                         SEQ ID NO: 134   173 aa   MW at 19324.7kD                             NOV31 a,   MVNPTVFFNMAVNDEPLCHVSFELYADKFPKTAENFRALSTGEKGFGYKGFCFYRIIPGFMWFMCQG           CG142102-01       Protein Sequence   SDFTHHNGTGGKSIYGEKFDDENFILKHTGPEPSHSQTNYLSHANAGPNTNGSQFFLCTAKTEWLDG                   THVVFGKVKEGINIVEAMERFGSRNGKTSKITIVDCGQL                  
 
     [0516] Further analysis of the NOV31a protein yielded the following properties shown in Table 31B.  
               TABLE 31B                       Protein Sequence Properties NOV31a                                        PSort   0.6400 probability located in microbody (peroxisome); 0.6000       analysis:   probability located in plasma membrane; 0.4500 probability           located in cytoplasm; 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0517] A search of the NOV31 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 31C.  
               TABLE 31C                          Geneseq Results for NOV31a                                         NOV31a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU01195   Human cyclophilin A   1 . . . 173   144/174 (82%)   2e−78           protein -  Homo sapiens , 165   1 . . . 164   152/174 (86%)           aa. [WO200132876-A2,           10 MAY 2001]       AAW56028   Calcineurin protein -   1 . . . 173   144/174 (82%)   2e−78           Mammalia, 165 aa.   1 . . . 164   152/174 (86%)           [WO9808956-A2,           05 MAR. 1998]       AAG03831   Human secreted protein, SEQ   1 . . . 173   144/174 (82%)   3e−78           ID NO: 7912 -  Homo     1 . . . 164   152/174 (86%)             sapiens , 165 aa.           [EP1033401-A2,           06 SEP. 2000]       AAR13726   Bovine cyclophilin -  Bos     2 . . . 173   143/173 (82%)   4e−78             taurus , 163 aa.   1 . . . 163   151/173 (86%)           [US5047512-A,           10 SEP. 1991]       AAG65275   Haematopoietic stem cell   2 . . . 173   143/173 (82%)   7e−78           proliferation agent related   1 . . . 163   151/173 (86%)           human protein #2 -  Homo               sapiens , 164 aa.           [JP2001163798-A,           19 JUN. 2001]                  
 
     [0518] In a BLAST search of public sequence datbases, the NOV31a protein was found to have homology to the proteins shown in the BLASTP data in Table 31D.  
               TABLE 31D                          Public BLASTP Results for NOV31a                                         NOV31a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               CAC39529   Sequence 26 from Patent   1 . . . 173   144/174 (82%)   5e−78           WO0132876 -  Homo sapiens     1 . . . 164   152/174 (86%)           (Human), 165 aa.       P04374   Peptidyl-prolyl cis-trans   2 . . . 173   143/173 (82%)   1e−77           isomerase A (EC 5.2.1.8)   1 . . . 163   151/173 (86%)           (PPIase) (Rotamase)           (Cyclophilin A) (Cyclosporin           A-binding protein) -  Bos               taurus  (Bovine), and, 163 aa.       Q9BRU4   Peptidylprolyl isomerase A   1 . . . 173   143/174 (82%)   2e−77           (cyclophilin A) -  Homo     1 . . . 164   151/174 (86%)             sapiens  (Human), 165 aa.       P05092   Peptidyl-prolyl cis-trans   2 . . . 173   143/173 (82%)   2e−77           isomerase A (EC 5.2.1.8)   1 . . . 163   151/173 (86%)           (PPIase) (Rotamase)           (Cyclophilin A) (Cyclosporin           A-binding protein) -  Homo               sapiens  (Human),, 164 aa.       Q96IX3   Peptidylprolyl isomerase A   1 . . . 173   143/174 (82%)   6e−77           (cyclophilin A) -  Homo     1 . . . 164   151/174 (86%)             sapiens  (Human), 165 aa.                  
 
     [0519] PFam analysis predicts that the NOV31a protein contains the domains shown in the Table 31E.  
               TABLE 31E                          Domain Analysis of NOV31a                                             Identities/                   NOV31a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       pro_isomerase   5 . . . 173   101/187 (54%)   2.7e−84                   147/187 (79%)                      
 
     Example 32  
     [0520] The NOV32 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 32A.  
               TABLE 32A                       NOV32 Sequence Analysis                                                    SEQ ID NO:135   651 bp                             NOV32a,     CTTCCCTACCCTCCTCTCTCCCACACCACTGGCACCAGGCCCCGGACACCCGCTCTGCTGCAGGAGA             CG57760-01       DNA Sequence     ATG GCTACTCATCACACGCTGTGGATGGGACTGGCCCTGCTGGGGGTGCTGGGCGACCTGCAGGCAG                   CACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTCCAGCAGGACAAGTTCCTGGGGCGCTGGTTCAG                   CGCGGGCCTCGCCTCCAACTCGAGCTGGCTCCGGGAGAAGAAGGCGGCGTTGTCCATGTGCAAGTCT                   GTGGTGGCCCCTGCCACGGATGGTGGCCTCAACCTGACCTCCACCTTCCTCAGGAAAAACCAGTGTG                   AGACCCGAACCATGCTGCTGCAGCCCGCGGGGTCCCTCGGCTCCTACAGCTACCCGAGTCCCCACTG                   GGGCAGCACCTACTCCGTGTCAGTGGTGGAGACCGACTACGACCAGTACGCGCTGCTGTACAGCCAG                   GGCAGCAAGGGCCCTGGCGAGGACTTCCGCATGGCCACCCTCTACAGCCGAACCCAGACCCCCAGGG                   CTGAGTTAAAGGAGAAATTCACCGCCTTCTGCAAGGCCCAGGGCTTCACAGAGGATACCATTGTCTT                   CCTGCCCCAAACCGATAAGTGCATGACGGAACAA TAG   AAGGGCGAATT                                           ORf Start: ATG at 68   ORF Stop: TAG at 638                                         SEQ ID NO: 136   190 aa   MW at 21028.6kD                             NOV32a,   MATHHTLWMGLALLGVLGDLQAAPEAQVSVQPNFQQDKFLGRWFSAGLASNSSWLREKKAALSMCKS           CG57760-01       Protein Sequence   VVAPATDGGLNLTSTFLRKNQCETRTMLLQPAGSLGSYSYRSPHWGSTYSVSVVETDYDQYALLYSQ                   GSKGPGEDFRMATLYSRTQTPRAELKEKFTAFCKAQGFTEDTIVFLPQTDKCMTEQ                                         SEQ ID NO: 137   487 bp                             NOV32b,     CCGGACACCCGCTCTGCTGCAGGAGA   ATG GCTACTCATCACACGCTGTGGATGGGACTGGCCCTGCT           CG57760-02       DNA Sequence   GGGGGTGCTGGGCGACCTGCAGGCAGCACCGGAGGCCCAGGTCTCCGTGCAGCCCAACTTACAGCAG                   CGCGTACTGGTGGAGACCGACTACGACCAGTACGCGCTGCTGTACAGCCAGGGCAGCAAGGGCCCTG                   GCGAGGACTTCCGCATGGCCACCCTCTACAGCCGAACCCAGACCCCCAGGGCTGAGTTAAAGGAGAA                   ATTCACCGCCTTCTGCAAGGCCCAGGGCTTCACAGAGGATACCATTGTCTTCCTGCCCCAAACCGAT                   AAGTGCATGACGGAACAA TAG   GACTCCCCAGGGCTGAAGCTCGGATCCCGGCCAGCCAGGTGACCCC                       CACGCTCTGGATGTCTCTGCTCCAACTCGAGCTGGCTCCGGGAGAAGAAGGCGGCGTTGTCCATGTG                       CAAGTCTGTGGTGGCCCC                                           ORF Start: ATG at 27   ORF Stop: TAG at 354                                         SEQ ID NO: 138   109 aa   MW at 12216.8kD                             NOV32b,   MATHHTLWMGLALLGVLGDLQAAPEAQVSVQPNLQQRVLVETDYDQYALLYSQGSKGPGEDFRMATL           CG57760-02       Protein Sequence   YSRTQTPRAELKEKFTAFCKAQGFTEDTIVFLPQTDKCMTEQ                  
 
     [0521] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 32B.  
               TABLE 32B                          Comparison of NOV32a against NOV32b.                                     NOV32a   Identities/               Residues/   Similarities for           Protein   Match   the Matched           Sequence   Residues   Region                       NOV32b   120 . . . 190   70/71 (98%)                39 . . . 109   71/71 (99%)                      
 
     [0522] Further analysis of the NOV32a protein yielded the following properties shown in Table 32C.  
               TABLE 32C                       Protein Sequence Properties NOV32a                                                PSort   0.3700 probability located in outside; 0.1900           analysis:   probability located in lysosome (lumen); 0.1507               probability located in microbody (peroxisome);               0.1000 probability located in endoplasmic               reticulum (membrane)           SignalP   Cleavage site between residues 23 and 24           analysis:                      
 
     [0523] A search of the NOV32a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 32D.  
               TABLE 32D                          Geneseq Results for NOV32a                                         NOV32a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU31028   Novel human secreted   5 . . . 190   156/191 (81%)   7e−81           protein #1519 -  Homo     32 . . . 222    159/191 (82%)             sapiens , 222 aa.           [WO200179449-A2,           25 OCT. 2001]       ABB57144   Mouse ischaemic condition   1 . . . 189   137/189 (72%)   2e−76           related protein sequence SEQ   1 . . . 189   158/189 (83%)           ID NO: 348 -  Mus musculus ,           189 aa. [WO200188188-A2,           22 NOV. 2001]       AAY71471   Human prostaglandin D2   1 . . . 137    137/137 (100%)   6e−76           synthase (PD2 synthase) -   1 . . . 137    137/137 (100%)             Homo sapiens , 137 aa.           [WO200029576-A1,           25 MAY 2000]       ABG60136   Human DITHP polypeptide   1 . . . 188   131/188 (69%)   8e−74           #194 -  Homo sapiens , 212   19 . . . 206    152/188 (80%)           aa. [WO200220754-A2,           14 MAR. 2002]       AAB90661   Xenopus cpl-1 protein, SEQ   26 . . . 189     70/164 (42%)   3e−39           ID NO: 204 - Xenopus sp,   21 . . . 183    113/164 (68%)           184 aa. [WO200121658-A1,           29 MAR. 2001]                  
 
     [0524] In a BLAST search of public sequence datbases, the NOV32a protein was found to have homology to the proteins shown in the BLASTP data in Table 32E.  
               TABLE 32E                          Public BLASTP Results for NOV32a                                         NOV32a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               P41222   Prostaglandin-H2 D-isomerase   1 . . . 190    190/190 (100%)   e−108           precursor (EC 5.3.99.2)   1 . . . 190    190/190 (100%)           (Prostaglandin-D synthase)           (Glutathione-independent PGD           synthetase) (Prostaglandin D2           synthase) (PGD2 synthase)           (PGDS2) (PGDS) (Beta-trace           protein) -  Homo sapiens             (Human), 190 aa.       Q8WNM0   Prostaglandin D2 synthase -   1 . . . 190   188/190 (98%)   e−107             Pongo pygmaeus  (Orangutan),   1 . . . 190   188/190 (98%)           190 aa.       Q8WNM1   Prostaglandin D2 synthase -   1 . . . 190   187/190 (98%)   e−106             Gorilla gorilla  (gorilla), 190 aa.   1 . . . 190   188/190 (98%)       Q9TUI1   Prostaglandin D synthase -   1 . . . 190   179/190 (94%)   e−102             Macaca fuscata  (Japanese   1 . . . 190   183/190 (96%)           macaque), 190 aa.       Q29562   Prostaglandin-H2 D-isomerase   1 . . . 189   146/189 (77%)   7e−83           precursor (EC 5.3.99.2)   1 . . . 189   160/189 (84%)           (Prostaglandin-D synthase)           (Glutathione-independent PGD           synthetase) (Prostaglandin D2           synthase) (PGD2 synthase)           (PGDS2) -  Ursus arctos  (Brown           bear) (Grizzly bear), 191 aa.                  
 
     [0525] PFam analysis predicts that the NOV32a protein contains the domains shown in the Table 32F.  
               TABLE 32F                          Domain Analysis of NOV32a                                             Identities/                   NOV32a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       lipocalin   38 . . . 186   49/157 (31%)   4.9e−42                   125/157 (80%)                       
 
     Example 33  
     [0526] The NOV33 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 33A.  
               TABLE 33A                       NOV33 Sequence Analysis                                                    SEQ ID NO: 139   4620 bp                             NOV33a,     TTTGGGAGATGTCTAAGTGATTTTTTTTTTTTTCCCGGAAGGCAAATGGCTGGCGTGGAAGCACAAC             CG59361-01       DNA Sequence     CCGCTTTCACTCTTCGAATTTGTGCTTAGCTCTTTTCTTGTACCTTGCCACTCGTGACCAACATGCT                       GTGATGCGACTCGTGACCIACATGCTGTGATGTGTGCCGAGGGAGGAATTGGTCAGCTACACAACCT                       GGATCTTACCACAGTTTGGAT   ATG ACTGAGGCTCTCCAATGGGCCAGATATCACTGGCGACGGCTGA                   TCAGAGGTGCAACCAGGGATGATGATTCAGGGCCATACAACTATTCCTCGTTGCTCGCCTGTGGGCG                   CAAGTCCTCTCAGATCCCTAAACTGTCAGGAAGGCACCGGATTGTTGTTCCCCACATCCAGCCCTTC                   AAGGATGAGTATGAGAAGTTCTCCGGAGCCTATGTGAACAATCGAATACGAACAACAAAGTACACAC                   TTCTGAATTTTGTGCCAAGAAATTTATTTGAACAATTTCACACAGCTCCCAATTTATATTTCCTGTT                   CCTAGTTGTCCTGAACTGGGTACCTTTGGTAGAAGCCTTCCAAAAGGAAATCACCATGTTGCCTCTG                   GTGGTGGTCCTTACAATTATCGCAATTAAAGATGGCCTGGAAGATTATCCGAAATACAAAATTGACA                   AACAGATCAATAATTTAATAACTAAAGTTTATAGTAGGAAAGAGAAAAAATACATTGACCGACGCTG                   GAAAGACGTTACTOTTGCGGACTTTATTCGCCTCTCCTGCAACCAGGTCATCCCTGCAGACATGGTA                   CTACTCTTTTCCACTGATCCAGATGGAATCTGTCACATTGAGACTTCTGGTCTTGATGGAGAGAGCA                   ATTTAAAACAGAGGCAGGTGGTTCGGGGATATGCAGAACAGGACTCTGAAGTTGATCCTGAGAAGTT                   TTCCAGTAGGATAGAATGTGAAAGCCCAAACAATGACCTCAGCAGATTCCGAGGCTTCCTAGAACAT                   TCCAACAAAGAACGCGTGGGTCTCAGTAAAGAAAATTTGTTGCTTAGAGGATGCACCATTAGAAACA                   CAGAGGCTGTTGTGGGCATTGTGGTTTATGCAGGCCATGAAACCAAAGCAATGCTGAACAACAGTGG                   GCCACGGTATAAGCGCAGCAAATTAGAAAGAAGAGCAAACACAGATGTCCTCTGGTGTGTCATGCTT                   CTGGTCATAATGTGCTTAACTGGCGCAGTACGTCATGGAATCTGGCTGAGCAGGTATGAAAAGATGC                   ATTTTTTCAATGTTCCCGAGCCTGATGGACATATCATATCACCACTGTTGGCACGATTTTATATGTT                   TTGGACCATGATCATTTTGTTACAGGTCTTGATTCCTATTTCTCTCTATGTTTCCATCGAAATTGTG                   AAGCTTGGACAAATATATTTCATTCAAAGTGATGTGGATTTCTACAATGAAAAAATGGATTCTATTG                   TTCAGTGCCGAGCCCTGAACATCGCCGAGGATCTGGGACAGATTCAGTACCTCTTTTCCGATAAGAC                   AGGAACCCTCACTGAGAATAAGATGGTTTTTCGAAGATGTAGTGTGGCAGGATTTGATTACTGCCAT                   GAAGAAAATGCCAGGAGGTTGGAGTCCTATCAGGAAGCTGTCTCTGAAGATGAAGATTTTATAGACA                   CAGTCAGTGGTTCCCTCAGCAATATGGCAAAACCGAGAGCCCCCAGCTGCAGGACAGTTCATAATGG                   GCCTTTGGGAAATAAGCCCTCAAATCATCTTGCTGGGAGCTCTTTTACTCTACGAAGTGGAGAAGGA                   GCCAGTGAAGTGCCTCATTCCAGACAGGCTGCTTTCAGTAGCCCCATTGAAACAGACGTGGTACCAG                   ACACCAGGCTTTTAGACAAATTTAGTCAGATTACACCTCGGCTCTTTATGCCACTAGATGAGACCAT                   CCAAAATCCACCAATGGAAACTTTGTACATTATCGACTTTTTCATTGCATTGGCAATTTGCAACACA                   GTAGTGGTTTCTGCTCCTAACCAACCCCGACAAAAGATCAGACACCCTTCACTGGGGGGGTTGCCCA                   TTAAGTCTTTGGAAGAGATTAAAAGTCTTTTCCAGAGATGGTCTGTCCGAAGATCAAGTTCTCCATC                   GCTTAACAGTGGGAAAGAGCCATCTTCTGGAGTTCCAAACGCCTTTGTGAGCAGACTCCCTCTCTTT                   AGTCGAATGAAACCAGCTTCACCTGTGGAGGAAGAGGTCTCCCAGGTGTGTGAGAGCCCCCAGTGCT                   CCAGTAGCTCAGCTTGCTGCACAGAGACAGAGAAACAACACGGTGATGCAGGCCTCCTGAATGGCAA                   GGCAGAGTCCCTCCCTGGACAGCCATTGGCCTGCAACCTGTGTTATGAGGCCGAGAGCCCAGACGAA                   GCGGCCTTAGTGTATGCCGCCAGCGCTTACCAATGCACTTTACGGTCTCGGACACCAGAGCAGGTCA                   TGGTCGACTTTNCTGCTTTGGGACCATTAACATTTCAACTCCTACACATCCTGCCCTTTGACTCAGT                   AAGAAAAAGAATGTCTGTTGTGGTCCGACACCCTCTTTCCAATCAAGTTGTGGTGTATACGAAAGGC                   GCTGATTCTGTCATCATGGAGTTACTGTCGGTGGCTTCCCCACATGGAGCAAGTCTGGAGAAACAAC                   AGATGATAGTAAGGGAGAAAACCCAGAAGCACTTGGATGACTATGCCAAACAAGGCCTTCGTACTTT                   ATGTATAGCAAAGAAGGTCATGAGTGACACTGAATATGCAGAGTGGCTCAGGAATCATTTTTTAGCT                   GAAACCAGCATTGACAACAGGGAAGAATTACTACTTGAATCTGCCATGAGGTTGGAGAACAAACTTA                   CATTACTTGGTGCTACTGGCATTGAAGACCGTCTGCAGGAGGGAGTCCCTGAATCTATAGAAGCTCT                   TCACAAAGCGGGCATCAAGATCTGGATGCTGACAGGGGACAAGCAGGAGACAGCTGTCAACATACCT                   TATGCATGCAAACTACTGGAGCCAGATGACAACCTTTTTATCCTCAATACCCAAAGTAAAGATGCCT                   GTGGGATGCTGATGAGCACAATTTTGAAAGAACTTCAGAAGAAAACTCAAGCCCTGCCAGAGCAAGT                   GTCATTAAGTGAAGATTTACTTCAGCCTCCTGTCCCCCGGGACTCAGGGTTACGAGCTGGACTCATT                   ATCACTGGGAAGACCCTGGAGTTTGCCCTGCAAGAAAGTCTGCAAAAGCAGTTCCTGGAACTGACAT                   CTTGGTGTCAAGCTGTGGTCTGCTGCCGAGCCACACCGCTGCAGAAAAGTGAAGTGGTGAAATTGGT                   CCGCAGCCATCTCCAGGTGATGACCCTTGCTATTGGTGATGGTGCCAATGATGTTAGCATGATACAA                   GTGGCAGACATTGGGATAGGGGTCTCAGGTCAAGAAGGCATGCAGGCTGTGATGGCCAGTGACTTTG                   CCGTTTCTCAGTTCAAACATCTCAGCAAGCTCCTTCTTGTCCATGGACACTGGTGTTATACACGGCT                   TTCCAACATGATTCTCTATTTTTTCTATAAGAATGTGGCCTATGTGAACCTCCTTTTCTGGTACCAG                   TTCTTTTGTGGATTTTCAGGAACATCCATGACTGATTACTGGGTTTTGATCTTCTTCAACCTCCTCT                   TCACATCTGCCCCTCCTGTCATTTATGGTGTTTTGGAGAAAGATGPGTCTGCAGAGACCCTCATGCA                   ACTGCCTGAACTTTACAGAAGTGGTCAGAAATCAGAGGCATACTTACCCCATACCTTCTGGATCACC                   TTATTGGATGCTTTTTATCAAAGCCTGGTCTGCTTCTTTGTGCCTTATTTTACCTACCAGGGCTCAG                   ATACTGACATCTTTGCATTTGGAAACCCCCTGAACACAGCCGCTCTGTTCATCGTTCTCCTCCATCT                   GGTCATTGAAAGCAAGAGTTTGACTTGGATTCACTTGCTGGTCATCATTGGTAGCATCTTGTCTTAT                   TTTTTATTTGCCATAGTTTTTGGAGCCATGTGTGTAACTTGCAACCCACCATCCAACCCTTACTGGA                   TTATGCAGGAGCACATGCTGGATCCAGTATTCTACTTAGTTTGTATCCTCACGACGTCCATTGCTCT                   TCTGCCCAGGTTTGTATACAGAGTTCTTCAGGGATCCCTGTTTCCATCTCCAATTCTGAGAGCTAAG                   CACTTTGACAGACTAACTCCAGAGGAGAGGACTAAAGCTCTCAAGAAGTGGAGAGGGGCTGGAAAGA                   TGAATCAAGTGACATCAAAGTATGCTAACCAATCAGCTGGCAAGTCAGGAAGAAGACCCATGCCTGG                   CCCTTCTGCTGTATTTGCAATGAAGTCAGCAAGTTCCTGTGCTATTGAGCAAGGAAACTTATCTCTG                   TGTGAAACTGCTTTACATCAAGGCTACTCTGAAACTAAGGCCTTTGAGATGGCTGGACCCTCCAAAG                   GTAAAGAAAGC TAG   ATACCCTCCTTGGAGTTGCAAGTATTCTTTCAAGGTTGGAAGAGGGATTTTGA                       AGAGGTATCTCTCCAAGCAAGAATGACTTGTTTTTCCATAAGGGACATGAGCATTTTACTAGGC                                               ORF Start: ATG at 223       ORF Stop: TAG at 4501               SEQ ID NO: 140   1426 aa   MW at 160265.91W                         NOV33a,   MTEALQWARYHWRRLIRGATRDDDSGPYNYSSLLACGRKSSQIPKLSGRHRIVVPHIQPFKDEYEKF           CG59361-01       Protein Sequence   SGAYVNNRIRTTKYTLLNFVPRNLFEQFHRAANLYFLFLVVLNWVPLVEAFQKEITMLPLVVVLTII                   AIKDGLEDYRKYKIDKQINNLITKVYSRKEKKYIDRRWKDVTVGDFIRLSCNEVIPADMVLLFSTDP                   DGICHIETSGLDGESNLKQRQVVRGYAEQDSEVDPEKFSSRIECESPNNDLSRFRGFLEHSNKERVG                   LSKENLLLRGCTIRNTEAVVGIVVYAGHETKAMLNNSGPRYKRSKLERRANTDVLWCVMLLVIMCLT                   GAVGHGIWLSRYEKMHFFNVPEPDGHIISFLLAGFYMFWTMIILLQVLIPISLYVSIEIVKLGQIYF                   IQSDVDFYNEKMDSIVQCRALNIAEDLGQIQYLFSDKTGTLTENKMVFRRCSVAGFDYCHEENARRL                   ESYQEAVSEDEDFIDTVSGSLSNMAKPRAPSCRTVHNGPLGNKPSNHLAGSSFTLGSGEGASEVPHS                   RQAAFSSPIETDVVPDTRLLDKFSQITPRLFMPLDETIQNPPMETLYIIDFFIALAICNTVVVSAPN                   QPRQKIRHPSLGGLPIKSLEEIKSLFQRWSVRRSSSPSLNSGKEPSSGVPNAFVSRLPLFSRMKPAS                   PVEEEVSQVCESPQCSSSSACCTETEKQHGDAGLLNGKAESLPGQPLACNLCYEAESPDEAALVYAA                   RAYQCTLRSRTPEQVMVDFXALGPLTFQLLHILPFDSVRKRMSVVVRHPLSNQVVVYTKGADSVIME                   LLSVASPDGASLEKQQMIVREKTQKHLDDYAKQGLRTLCIAKKVMSDTEYAEWLRNHFLAETSIDNR                   EELLLESAMRLENKLTLLGATGIEDRLQEGVPESIEALHKAGIKIWMLTGDKQETAVNIAYACKLLE                   PDDKLFILNTQSKDACGMLMSTILKELQKKTQALPEQVSLSEDLLQPPVPRDSGLRAGLIITGKTLE                   FALQESLQKQFLELTSWCQAVVCCRATPLQKSEVVKLVRSHLQVMTLAIGDGANDVSMIQVADIGIG                   VSGQEGMQAVMASDFAVSQFKHLSKLLLVHGHWCYTRLSNNILYFFYKNVAYVNLLFWYQFFCGFSG                   TSMTDYWVLIFFNLLFTSAPPVIYGVLEKDVSAETLMQLPELYRSGQKSEAYLPHTFWITLLDAFYQ                   SLVCFFVPYFTYQCSDTDIFAFGNPLNTAALFIVLLHLVIESKSLTWIHLLVIIGSILSYFLFAIVF                   GAMCVTCNPPSNPYWIMQEHMLDPVFYLVCILTTSIALLPRFVYRVLQGSLFPSPILRAKHFDRLTP                   EERTKALKKWRGAGKMNQVTSKYANQSAGKSGRRPMPGPSAVFAMKSASSCAIEQGNLSLCETALDQ                   GYSETKAFEMAGPSKGKES                  
 
     [0527]               TABLE 33B                       Protein Sequence Properties NOV33a                                        PSort   0.6471 probability located in mitochondrial inner membrane;       analysis:   0.6000 probability located in plasma membrane; 0.4000           probability located in Golgi body; 0.3377 probability           located in mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                    
     [0528] A search of the NOV33a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 33C.  
               TABLE 33C                          Geneseq Results for NOV33a                                         NOV33a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                         AAE01984   Human ATPase-related   1 . . . 1426   1422/1426 (99%)   0.0           protein #7 -  Homo sapiens ,   1 . . . 1426   1423/1426 (99%)           1426 aa.           [WO200134778-A2,           17 MAY 2001]       AAE01982   Human ATPase-related   1 . . . 1252   1249/1252 (99%)   0.0           protein #5 -  Homo sapiens ,   1 . . . 1252   1249/1252 (99%)           1270 aa.           [WO200134778-A2,           17 MAY 2001]       AAE01980   Human ATPase-related   1 . . . 1056   1053/1056 (99%)   0.0           protein #3 -  Homo sapiens ,   1 . . . 1056   1054/1056 (99%)           1056 aa.           [WO200134778-A2,           17 MAY 2001]       AAE01978   Human ATPase-related   1 . . . 951     949/951 (99%)   0.0           protein #1 -  Homo sapiens ,   1 . . . 951     949/951 (99%)           972 aa. [WO200134778-A2,           17 MAY 2001]       AAB95253   Human protein sequence   753 . . . 1426     673/674 (99%)   0.0           SEQ ID NO: 17421 -  Homo     1 . . . 674     673/674 (99%)             sapiens , 674 aa.           [EP1074617-A2,           07 FEB. 2001]                  
 
     [0529] In a BLAST search of public sequence datbases, the NOV33a protein was found to have homology to the proteins shown in the BLASTP data in Table 33D.  
               TABLE 33D                          Public BLASTP Results for NOV33a                                         NOV33a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         Q96SR3   CDNA FLJ14692 fis, clone   753 . . . 1426     673/674 (99%)   0.0           NT2RP2005344, weakly   1 . . . 674    673/674 (99%)           similar to probable           calcium-transporting ATPase           5 (EC 3.6.1.38) -  Homo               sapiens  (Human), 674 aa.       O54827   Potential   73 . . . 1329   692/1274 (54%)   0.0           phospholipid-transporting   65 . . . 1318   907/1274 (70%)           ATPase VA (EC 3.6.3.1) -             Mus musculus  (Mouse),           1508 aa.       O60312   Potential   73 . . . 1377   706/1315 (53%)   0.0           phospholipid-transporting   61 . . . 1349   922/1315 (69%)           ATPase VC (EC 3.6.3.1)           (ATPVC)           (Aminophospholipid           translocase VC) -  Homo               sapiens  (Human), 1499 aa.       Q9P241   Potential   777 . . . 1426     649/650 (99%)   0.0           phospholipid-transporting   1 . . . 650    650/650 (99%)           ATPase VD (EC 3.6.3.1)           (ATPVD) -  Homo sapiens             (Human), 650 aa (fragment).       AAM20894   P locus fat-associated   163 . . . 1329    649/1194 (54%)   0.0           ATPase -  Mus musculus      1 . . . 1164   842/1194 (70%)           (Mouse), 1354 aa           (fragment).                  
 
     [0530] PFam analysis predicts that the NOV33a protein contains the domains shown in the Table 33E.  
               TABLE 33E                          Domain Analysis of NOV33a                                             Identities/                       Similarities for           Pfam   NOV33a Match   the Matched   Expect           Domain   Region   Region   Value                                                 Hydrolase   432 . . . 1077   38/653 (6%)   0.17                   377/653 (58%)                      
 
     Example 34  
     [0531] The NOV34 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 34A.  
               TABLE 34A                       NOV34 Sequence Analysis                                                    SEQ ID NO: 141   3198bp                             NOV34a,     TTTGGGGCTGAAGTTCCCTGTGGGAGGCTGTTTTCTGAGGCAGCTGAGTGTTTACAGCCACTCAGCC             CG59444-01       DNA Sequence     CTGCTCTGCTCAGCTGAAGCAGAAAACAGAGACCTTTTGCATTACTTTGGTTCAAGAGCAAGACAGG                       ACGCGACTGC   ATG AGACCATGGCTGAGACACCTACTCCTCCAGGCACTGAGGAACTCCAGGGCATTC                   TGTGGGTCTCATCGGAAGCCAGCACCTCTACCTGTTCCTCAGAAGATCGTGGCCACCTGGGAAGCCA                   TCAGCCTGGGAAGGCAGCTGGTGCCTGAGTACTTCAACTTCGCCCATGATGTGTTGGATGTGTGGAG                   CGGCTGGAAGAGGCTGGACACCCCCCCCCAAATCCTGCCTTCTGGTGGGTCAATGGCACAGGAGCA                   GAGATCJAGTGGACATTTGAGGAGCTGGGGAAGCAGTCCAGGAAGGCAGCCAATGTGCTGGGGGGTG                   CATGCGGCCTCCAGCCTCGGGACAGAATGATGCTGGTACTCCCACGGCTCCCGGAGTGGTGGCTGGT                   CAGTGTGGCTTGCATGCGGACAGGGACTGTGATGATTCCGGGTGTGACTCAGCTGACAGAGAAGGAC                   CTCAAGTACCGGCTGCACGCGTCCAGGGCCAAGTCCATTATCACCAGTGACTCCCTAGCTCCAAGGG                   TGGATGCCATCAGTGCCGAATGCCCCTCCCTCCAGACCAAGCTGCTGGTGTCAGACAGCAGTCGGCC                   AGGCTGGTTGAACTTCAGGGAACTCCTCCGGGAGGCTTCTACAGAGCACAACTGCATGAGGACAAAG                   AGTCGAGACCCGCTGGCCATCTACTTTACCAAGCGGGAACCACCGGGGGCCCCCAAGATGGTCGAGC                   ACTCCCAGAGCAGCTACGGACTGGGTTTTGTGGCCAGCGGAAGACGGTGGGTGGCCTTGACCGAATC                   TGACATCTTCTGGAACACGACTGACACTGGCTGGGTGAAGGCAGCCTGGACTCTCTTCTCTGCCTGG                   CCTAATGGATCTTGCATTTTTGTGCATGAGCTGCCCCGAGTTGATGCCAAAGTTATCCTGAATACTC                   TCTCCAAATTCCCGATAACCACCCTCTGCTGTGTCCCAACCATCTTTCGGCTGCTTGTGCAGGAGGA                   TCTGACCAGGTACCAGTTTCAGAGCTTCAGGCACTGTCTGACCGGAGGAGAGGCCCTCAACCCTGAC                   GTGAGGGAGAAGTGGAAACACCAGACTGGTGTGGAGCTGTACGAAGGCTATGGCCAGTCTGAAACGG                   TTGTCATCTGTGCCAATCCAAAAGGCATGAAAATCAAGTCTGGATCCATGGGGAAGGCGTCCCCACC                   CTACGATGTGCAGATTGTGGATGATGAGGGCAACGTCCTGCCTCCTGGAGAAGAGGGGAATGTTGCC                   GTCCGTATCAGACCCACTCGGCCCTTCTGTTTCTTCAATTGCTATTTGGACAATCCTGAGAAGACAG                   CTGCATCAGAACAAGGGGACTTTTACATCACAGGGGACCGAGCTCGCATGGACAAGGATGGCTACTT                   TTGGTTCATGCGAAGAAACGACGATGTGATCAATTCTTCAAGCTACCGGATCGGGCCTGTTGAAGTG                   GAAAGTGCCCTGGCAGAGCATCCTGCTGTCCTGGAGTCGGCTGTGGTCAGCAGCCCAGACCCCATCA                   GGGGAGAGGTGGTAAAGGCATTTATAGTCCTTACTCCAGCCTACTCCTCTCATGACCCAGAGGCACT                   AACGCGGGAACTCCAGGAGCATGTGAAAAGGGTGACTGCTCCATACAAATACCCCAGGAAGGTGGCC                   TTTGTTTCAGAACTTGCCAAAGACGGTTTCTGGAAAGATCCAAAGGAG TAA   ATTGCCAAGTCAGGAG                       TGGGGGAAATGAGGTGCACCCCAGGAAGGCCCCGTAGACCTCCGAAGACTCCACAAGAAACTAATGG                       ATCACTGGTCAGTCCCCATGGGGAGCATCATCTCTTCGACCCTAAAGATGTCAAAGGTGTGCAGCTT                       CCAAACGGCATCCCCAGGATCACTGGGCAATGCTGGAAAGAGCAAAAGAATATCATTGGCCCTGATC                       ACATAGATGCTGCGCCGCCTAGCAAATGCTTGGTGGTTCGACATCTCCCTCTGTCTGGGGGCAGGCT                       CAGCATCTGCCCACTGGTCTCACTAAGAGCTTTCAGATTTCCCTCCATAGGACAGGTTACCATAGAC                       TTCGGGCACTTGTGGGTACTCATTCTCTGCCAGTGGGAATGTAAAGGCTTCATCCTTTGTATGTAAC                       CATPTGGCAAAAGTATGCAGGAACATAAAATAAAATATCCTTTAGCTCAGAAATTCTATCTTCGGGA                       GTCACCACAAAAGAAAAAAATCAAAATGCAGAAAATGTGTGATGCACTAAGATGATCACACAGCATT                       AAAACTAAAAAAAAAAAAGAAAAAATTAACAATTAACATCCAAACAACAAGGAAATGATTAACAAAA                       TTGTAGTAGATTAACTCAATTACATATGATGTAGCCACTAAAATATTTGAGAGCAGTTTAGTATGTC                       TTGGGAAAAGTGTAAGCTATATTAATTTTAAAAATCAGAGCAAAAATATTCATACTGGAGAATCCCA                       ACTCTGAAAAATAAAGGGAAAACTCTGGTTAATTGTAATCCTCCTGGAGATTGAGGAGGGAGGGAGA                       GAAAATAATGGATGGPAGTTTTTCTTCTTCCTTTTTCCATTACATTTCTGTATTTTCCAAGTTTTTG                       TACGAAGCACATATAACTATTTTAATGAAAAAGTTATGTTAAAGAAAGCATACTCTGCTTCATGTCT                       AGTTCTTCCTCCACATACTCATACATCAACCCCAAAGACTGCTGTATTATGTCTGTATTAGTCAGCA                       TTCTCCAGAGAAGGAGAAGCAATAGGACATATATAGACATAGGAGAGGGGATTTATGATGGGAATTG                       GCTCACTCGATTTTGGA~GCTGAGAAGTTCCACAATCTACCATCTGCATGCTGGAGATCCAGGAAAC                       CCCGTGGTATAATTCCATCTGAGTCCAAAGGCCTGGTATTTGTCATATGCCTCGGCTCCTCAAACTG                       CAGCAAACAAACTCTATGGAAGAGAAAAAAATGGGACTCCAGAGACTTGAAATCACAGCCACTTGTC                       AGATGCAGCCCCCAACTCAGCTGCACGAGCTTAGCCAAATTTCTAGTCC                                               ORF Start: ATG at 145       ORF Stop: TAA at 1858               SEQ ID NO: 142   571 aa   MW at 64041.6kD                         NOV34a,   MRPWLRHLVLQALRNSRAFCGSHGKPAPLPVPQKIVATWEAISLGRQLVPEYFNFAHDVLDVWSRLE           C059444-01       Protein Sequence   EAGHRPPNPAFWWVNGTGAEIKWTFEELGKQSRKAANVLGGACGLQPGDRIHLVLPRLPEWWLVSVA                   CMRTGTVMIPGVTQLTEKDLKYRLQASRAKSIITSDSLAPRVDAISAECPSLQTKLLVSDSSRPGWL                   NFRELLREASTEHNCMRTKSRDPLAIYFTKREPPGAPKMVEHSQSSYGLGFVASCRRWVALTESDIF                   WNTTDTGWVKAAWTLFSAWPNGSCIFVHELPRVDAKVILNTLSKFPITTLCCVPTIFRLLVQEDLTR                   YQFQSLRHCLTGGEALNPDVREHWKNQTGVELYEGYGQSETVVICANPKGMKTKSGSMGKASPPYDV                   QIVDDEGNVLPPGEEGNVAVRIRPTRPFCFFNCYLDNPEKTAASEQGDFYITGDRARMDKDGYFWFM                   GRNDDVINSSSYRIGPVEVESALAEHPAVLESAVVSSPDPIRGEVVKAFIVLTPAYSSHDPEALTRE                   LQEHVKRVTAPYKYPRKVAFVSELAKDGFWKDPKE                                         SEQ ID NO: 143   1875 bp                             NOV34b,     AGCTGAAGCAGAAAACAGAGACCTTTTGCATTACTTTGGTTCAAGAGCAAGACAGGAGGCGACTGC   A             CG59444-02       DNA Sequence     TG AGACCATGGCTGAGACACCTAGTCCTCCAGGCACTGAGGAACTCCAGGGCATTCTGTGGGTCTCA                   TGGGAAGCCAGCACCTCTACCTGTTCCTCAGAAGATCGTGGCCACCTGGGAAGCCATCAGCCTGGGA                   AGGCAGCTGGTGCCTGAGTACTTCAACTTCGCCCATGATGTGCTGGATGTGTGGAGTCAGCTCGAAG                   AGGCTGGACACCGCCCCCCAAATCCTGCCTTCTGGTGGGTCAATGGCACAGGAGCAGAGATCAAGTG                   GAGCTTTGAGGAGCTGGGGAAGCAGTCCAGGAAGGCAACCAATGTGCTGGGGGGTGCATGCGGCCTG                   CAGCCTGGGGACAGAATGATGCTGGTACTCCCACGGCTCCCGGAGTGGTGGCTGGTCAGTGTGGCTT                   CCATGCGGACAGGGACTGTGATGATTCCGGGTGTGACTCAGCTGACAGAGAAGGACCTCAAGTACCG                   GCTGCAGGCGTCCAGCGCCAAGTCCATTATCACCAGTGACTCCCTAGCTCCAAGGGTGGATGCCATC                   AGTGCCGAATGCCCCTCCCTCCAGACCAAACTGCTGGTGTCAGACAGCAGTCGGCCACCCTGGTTGA                   ACTTCAGGGAACTCCTCCGCGAGGCTTCTACAGAGCACAACTGCGTGAGGACAAAGAGTCGAGACCC                   GCTGGCCATCTACTTTACCAGCGGAACCACCGGGGCCCCCAAGATGGTCGAGCACTCCCAGAGCAGC                   TACGGTCTGGGTTTTGTGCCCAGCGGAAGACGGTGGGTGGCCTTGACCGAATCTGACATCTTCTAGA                   ACACGACTGACACTGGCTGGGTGAAGGCAGCCTGGACTCTCTTCTCTCCCTGGCCTAATGGATCTTG                   CATTTTTGTACATCAGCTGCCCCGAGTTGATGCCAAACTTATCCTGAATACTCTCTCCAAATTCCCG                   ATAACCACCCTCTGCTGTGTCCCAACCATCTTTCGGCTGCTTGTGCAGGAGGATCTGACCAAATACC                   AGTTTCAGAGCCTGAGGCACTGTCTGACCGGACGAGAGGCCCTCAACCCTGACGTGACCGAGAGATG                   GAAACACCAGACTGGTGTGGAGCTGTACGAACGCTATGGCCAGTCTGAACGCATTGTCATCTCTGCC                   AATCCAAAAGGCATGAAAATCAAGTCTGGATCCATGGGGAAGGCGTCCCCACCCTACGATGTGCAGA                   TTGTGGATGATGAGGGCAACGTCCTGCCTCCTGGAGAAGAGGGGAATGTTGCCGTCCGTATCACACC                   CACTCGGCCCTTCTGTTTCTTCAATTGCTATTTGGACAATCCTGAGAAGACAGCTGCATCAGAACAA                   GGGGACTTTTACATCACAGGGGACCGAGCTCGCATGGACAAGGATGGCTACTTTTGGTTCATCGGAA                   GAAACGACGATGTGATCAATTCTTCAAGCTACCGGATCGGGCCTGTTGAAGTGGAAAGTGCCCTGGC                   AGAGCATCCTGCTGTCCTGGAGTCGGCTGTGGTCAGCAGCCCAGACCCCATCAGGGGACACGTCGTA                   AAGGCATTTATAGTCCTTACTCCAGCCTACTCCTCTCATGACCCAGAGGCACTAACGCGGGAACTCC                   AGGAGCATGTGAAAAGGGTGACTGCTCCATACAAATACCCCAGGAAGGTGGCCTTTGTTTCAGAACT                   GCCAAAGACGGTTTCTGGAAAGATCCAAAGGAGTAAATTGCGAAGTCAGGAGTGGGGGAAATGAGAT                   AACACCCCAGGAAGGCCCCGTAGACCTCCGAAGACTCCACAAGAAACTAATGGATCACTGGTCAGTC                                             ORF Start: ATG at 67       ORF Stop: TGA at 1804               SEQ ID NO: 144   579 aa   MW at 64699.3kD                         NOV34b,   MRPWLRHLVLQALRNSRAFCGSHGKPAPLPVPQKIVATWEAISLGRQLVPEYFNFAHDVLDVWSQLE           CG59444-02       Protein Sequence   EAGHRPPNPAFWWVNGTGAEIKWSFEELGKQSRKAANVLGGACGLQPGDRMMLVLPRLPEWWLVSVA                   CMRTGTVMIPGVTQLTEKDLKYRLQASRAKSIITSDSLAPRVDAISAECPSLQTKLLVSDSSRPGWL                   NFRELLREASTEHNCVRTKSRDPLAIYFTSGTTGAPKMVEHSQSSYGLGFVASGRRWVALTESDIFW                   NTTDTGWVKAAWTLFSAWPNGSCIFVHELPRVDAKVILNTLSKFPITTLCCVPTIFRLLVQEDLTRY                   QFQSLRHCLTGGEALNPDVREKWXHQTGVELYEGYGQSETVVICANPKGMKIKSGSMGKASPPYDVQ                   IVDDEGNVLPPGEEGNVAVRIRPTRPFCFFNCYLDNPEKTAASEQGDFYITGDRAPMDKDGYFWFMG                   RNDDVINSSSYRIGPVEVESALAEHPAVLESAVVSSPDPIRGEVVKAFIVLTPAYSSHDPEALTREL                   QEHVKRVTAPYKYPRKVAFVSELPKTVSGKIQRSKLRSQEWGK                  
 
     [0532] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 34B.  
               TABLE 34B                          Comparison of NOV34a against NOV34b.                                 Identities/               Similarities for       Protein   NOV34a Residues/   the Matched       Sequence   Match Residues   Region               NOV34b   1 . . . 562   541/562 (96%)           1 . . . 561   544/562 (96%)                  
 
     [0533] Further analysis of the NOV34a protein yielded the following properties shown in Table 34C.  
               TABLE 34C                       Protein Sequence Properties NOV34a                                        PSort   0.7862 probability located in mitochondrial matrix space;       analysis:   0.5877 probability located in microbody (peroxisome);           0.4642 probability located in mitochondrial inner membrane;           0.4642 probability located in mitochondrial           intermembrane space       SignalP   Cleavage site between residues 21 and 22       analysis:                  
 
     [0534] A search of the NOV34a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 34D.  
               TABLE 34D                          Geneseq Results for NOV34a                                         NOV34a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE22093   Human kidney specific renal   41 . . . 562   287/523 (54%)   e−174           cell carcinoma (KSRCC)   32 . . . 552   378/523 (71%)           protein -  Homo sapiens , 577           aa. [WO200216595-A2,           28 FEB. 2002]       AAB43245   Human ORFX ORF3009   50 . . . 562   284/514 (55%)   e−173           polypeptide sequence SEQ    1 . . . 512   373/514 (72%)           ID NO: 6018 -  Homo sapiens ,           537 aa. [WO200058473-A2,           05 OCT. 2000]       AAU23054   Novel human enzyme   336 . . . 562    224/227 (98%)   e−130           polypeptide #140 -  Homo      2 . . . 228   224/227 (98%)             sapiens , 246 aa.           [WO200155301-A2,           02 AUG. 2001]       ABB53263   Human polypeptide #3 -   47 . . . 562   235/521 (45%)   e−129             Homo sapiens , 583 aa.   43 . . . 559   337/521 (64%)           [WO200181363-A1,           01 NOV. 2001]       ABB53262   Human polypeptide #2 -   47 . . . 483   198/439 (45%)   e−114             Homo sapiens , 480 aa.   43 . . . 480   295/439 (67%)           [WO200181363-A1,           01 NOV. 2001]                  
 
     [0535] In a BLAST search of public sequence datbases, the NOV34a protein was found to have homology to the proteins shown in the BLASTP data in Table 34E.  
               TABLE 34E                          Public BLASTP Results for NOV34a                                         NOV34a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         Q9NWV3   CDNA FLJ20581 fis, clone    1 . . . 571   570/571 (99%)   0.0           REC00491 -  Homo sapiens      1 . . . 571   571/571 (99%)           (Human), 571 aa.       O60363   SA gene -  Homo sapiens     49 . . . 562   317/515 (61%)   0.0           (Human), 578 aa.   46 . . . 559   407/515 (78%)       Q13732   SA SA gene product   49 . . . 562   317/515 (61%)   0.0           precursor -  Homo sapiens     46 . . . 559   407/515 (78%)           (Human), 578 aa.       Q91WI1   SA rat   49 . . . 562   313/515 (60%)   0.0           hypertension-associated   46 . . . 559   405/515 (77%)           homolog (SA protein) -  Mus               musculus  (Mouse), 578 aa.       Q9Z2F3   SA protein -  Mus musculus     49 . . . 562   312/515 (60%)   0.0           (Mouse), 578 aa.   46 . . . 559   404/515 (77%)                  
 
     [0536] PFam analysis predicts that the NOV34a protein contains the domains shown in the Table 34F.  
               TABLE 34F                          Domain Analysis of NOV34a                                     Identities/                   Similarities for       Pfam   NOV34a Match   the Matched   Expect       Domain   Region   Region   Value               AMP-binding   91 . . . 230   28/140 (20%)   4.6e−17               92/140 (66%)       AMP-binding   236 . . . 503    88/277 (32%)   1.4e−67               209/277 (75%)                   
 
     Example 35  
     [0537] The NOV35 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 35A.  
               TABLE 35A                       NOV35 Sequence Analysis                                                    SEQ ID NO: 145   846bp                             NOV35a,   ACCACCATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGATG           CG59482-01       DNA Sequence   ATGACAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCACGTGTGCCCTGAATTC                   TGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCAGCAGGCCACTGCTAC                   AGTCCCGCATCCAGGTGAGACTGGAGAGCACAACATCGAAGTCCTGGAGGGGAATATGAGCAGTTCA                   TCAATGCAGCCAGATCATCCGCCACCCCCAATACGACAGGAAGACTCTGAACAAATCACATCATCTT                   AATCAAGCTCTCCTCACGTGCAGTAATCAACGCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCT                   CCAGCCACTGGCACGAAGTGCCTCATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACC                   CAGACGAGCTGCAGTGCCTGGACGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCATGG                   AAAGATTACCAGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGAT                   TCTGGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGTGCCC                   AGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAGAACACCATAGC                   TGCCAACAGC TAA   ACCCCCCAGTATCTCTTCAGTCTCTATACCAATAAAGTGACGCTCGAGCCCTAT                       AGTGAGTCGTATTAGGATGTGCCTTCACGTCGTCAGCATCGT                                               ORF Start: ATG at 7       ORF Stop: TAA at 748               SEQ ID NO: 146   247 aa   MW at 26557.8kD                         NOV35a,   MNPLLILTFVAAALAAPFDDDDKIVGCYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYXS           CG59482-01       Protein Sequence   RIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPA                   TGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSG                   GPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS                                         SEQ ID NO: 147   506 bp                             NOV35b,     C   ATG AATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTAATCAACGCCCGCGTGTCCACCATC           CG59482-02       DNA Sequence   TCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTCATCTCTGGCTGGGGCAACACTGCGA                   GCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGCCTGGATGCTCCTGTGCTGAGCCAGCCTAAGTG                   TGAAGCCTCCTACCCTGGAAAGATTACCAGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAG                   GATTCATGTCAGGGTGATTCTGGTGGCCCTGTGGTCTGCAATGGACAGCTCCAACGAGTTGTCTCCT                   GGGGTGATGGCTGTGCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTATGTGAAATG                   GATTAAGAACACCATAGCTGCCAATAGC TAA   AGCCCCCAGTATCTCTTCAGTCTCTATACCAATAAA                       GTGACCCTGTTCTCACAAAAAAAAAAAAAAAAAAACCC                                               ORF Start: ATG at 2       ORF Stop: TAA at 431               SEQ ID NO: 148   143 aa   MW at 14865.8kD                         NOV35b,   MNPLLILTFVAAALINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKC           CG59482-02       Protein Sequence   EASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNRPCVYTKVYNYVKW                   IKNTIAANS                                         SEQ ID NO 149   837 bp                             NOV35c,     GCAAQTGTGAATCGCCCTTC   ATG AATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTCC           CG59482-03       DNA Sequence   CCCCTTTGATGATGATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTCTCCCCTACCAG                   GTGTCCCTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCAG                   CAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTCCTGGAGCG                   GAATGAGCAGTTCATCATGCAGCCAAGATCATCCGCCACCCCCAATACGACAGGAAGGACTCTGAAC                   AATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAACGCCCGCGTGTCCACCATCTCTC                   TGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTCATCTCTGGCTGGGGCAACACTGCGAGCTC                   TGGCGCCGACTACCCAGACGAGCTGCAGTGCCTGGACGCTCCTGTGCTGAGCCAGGCTAAGTGTGAA                   GCCTCCTACCCTGGAAAGATTACCAGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAG~ATT                   CATCTCAGGGTGATTCTGGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTCGGG                   TGATGGCTGTGCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTATGTGAAATGGATT                   AAGAACACCATAGCTGCCAATAGC TAA   AGCCCCCAGTATCTCTTCAGTCTCTATACCAATAAAGTGA                       CCCTGTTCCTCACAAAAAAAGGGCGATTCCAGA                                               ORF Start: ATG at 21       ORF Stop: TAA at 762               SEQ ID NO: 150   247 aa   MW at 26557.8kD                         NOV35c,   MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVSAGHCYKS           CG59482-03       Protein Sequence   RIQVRLGEHNIEVLECNEQFINAAXIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPA                   TGTKCLTSGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSG                   GPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTTAANS                  
 
     [0538] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 35B.  
               TABLE 35B                          Comparison of NOV35a against NOV35b and NOV35c.                                         Identities/                   Similarities for           Protein   NOV35a Residues/   the Matched           Sequence   Match Residues   Region                       NOV35b   106 . . . 247    131/142 (92%)               2 . . . 143   137/142 (96%)           NOV35c   1 . . . 247   235/247 (95%)               1 . . . 247   235/247 (95%)                      
 
     [0539] Further analysis of the NOV35a protein yielded the following properties shown in Table 35C.  
               TABLE 35C                       Protein Sequence Properties NOV35a                                                PSort   0.5708 probability located in outside; 0.1000           analysis:   probability located in endoplasmic reticulum               (membrane); 0.1000 probability located in               endoplasmic reticulum (lumen); 0.1000               probability located in lysosome (lumen)           SignalP   Cleavage site between residues 16 and 17           analysis:                      
 
     [0540] A search of the NOV35a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 35D.  
               TABLE 35D                          Geneseq Results for NOV35a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV35a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAB21321   Human trypsinogen -  Homo     1 . . . 247   247/247 (100%)   e−147             sapiens , 247 aa.   1 . . . 247   247/247 (100%)           [WO200053776-A2,           14 SEP. 2000]       AAB21316   Human trypsinogen -  Homo     1 . . . 241   241/241 (100%)   e−143             sapiens , 241 aa.   1 . . . 241   241/241 (100%)           [WO200053776-A2,           14 SEP. 2000]       AAW93488   Human TRYI trypsinogen   19 . . . 247   229/229 (100%)   e−137           variant protein -  Homo     2 . . . 230   229/229 (100%)             sapiens , 230 aa.           [WO9910503-A1,           04 MAR. 1999]       AAB98503   Human trypsin serine   23 . . . 247   225/225 (100%)   e−134           protease catalytic domain -   1 . . . 225   225/225 (100%)             Homo sapiens , 225 aa.           [WO200129056-A1,           26 APR. 2001]       AAY31160   Human trypsin serine   24 . . . 247   224/224 (100%)   e−133           protease protein domain -   1 . . . 224   224/224 (100%)             Homo sapiens , 224 aa.           [US5948892-A,           07 SEP. 1999]                  
 
     [0541] In a BLAST search of public sequence datbases, the NOV35a protein was found to have homology to the proteins shown in the BLASTP data in Table 35E.  
               TABLE 35E                          Public BLASTP Results for NOV35a                                             Identities/           Protein           Similarities for       Accession       NOV35a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               P07477   Trypsin I precursor (EC   1 . . . 247    247/247 (100%)   e−146           3.4.21.4) (Cationic   1 . . . 247    247/247 (100%)           trypsinogen) -  Homo sapiens             (Human), 247 aa.       P07478   Trypsin II precursor (EC   1 . . . 247   221/247 (89%)   e−130           3.4.21.4) (Anionic   1 . . . 247   236/247 (95%)           trypsinogen) -  Homo sapiens             (Human), 247 aa.       AAC80208   TRYPSINOGEN C -  Homo     1 . . . 247   219/247 (88%)   e−129             sapiens  (Human), 247 aa.   1 . . . 247   230/247 (92%)       AAC13322   MESOTRYPSINOGEN -   1 . . . 247   214/247 (86%)   e−127             Homo sapiens  (Human), 247   1 . . . 247   231/247 (92%)           aa.       AAH30260   Protease, serine, 2 (trypsin 2) -   1 . . . 239   214/239 (89%)   e−126             Homo sapiens  (Human),   1 . . . 239   228/239 (94%)           239 aa.                  
 
     [0542] PFam analysis predicts that the NOV35a protein contains the domains shown in the Table 35F.  
               TABLE 35F                          Domain Analysis of NOV35a                                             Identities/                   NOV35a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       trypsin   24 . . . 239   113/262 (43%)   1.5e−111                   198/262 (76%)                      
 
     Example 36  
     [0543] The NOV36 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 36A.  
               TABLE 36A                       NOV36 Sequence Analysis                                                    SEQ ID NO: 151   3080 bp                             NOV36a,     TTCCAGCCGGCAGG   ATG GAGGACGAGGAAGGCCCTGAGTATGGCAAACCTGACTTTGTGCTTTTGGA           CG59522-01       DNA Sequence   CCAAGTGACCATGGACGACTTCATGAGGAACCTGCAGCTCAGGTTCGAGAAGGGCCGCATCTACACC                   TACATCGGTGAGGTGCTGGTGTCCGTGAACCCCTACCAGGAGCTGCCCCTGTATGGGCCTGAAGCCA                   TCGCCAGGTACCAGGGCCGTGAGCTCTATGAGCGGCCACCCCATCTCTATGCTGTGGCCGAACGCGC                   CTACAAGGCAATGAAGCACCGGTCCAGGGACACCTGCATCGTCATCTCAGGGGAGAGTGGGGCAGGG                   AAGACAGAAGCCAGTAAGCACATCATGCAGTACATCGCTGCTGTCACCAATCCTAGCCAGAGGGCTG                   AGGTGGAGAGGGTCAAGGACGTGCTGCTCAAGTCCACCTGTGTGCTGGAGGCCTTTGGCAATGCCCG                   CACCAACCGCAATCACAACTCCAGCCGCTTTGGCAAGTACATGGACATCAACTTTGACTTCAAGGGG                   GACCCGATCGGAGGACACATCCACAGCTACCTACTGGAGAAGTCTCGGGTCCTCAAGCAGCACGTGG                   GTGAAAGAAACTTCCACGCCTTCTACCAATTGCTGAGAGGCAGTGAGGACAAGCAGCTGCATGAACT                   GCACTTGGAGAGAAACCCTGCTGTATACAATTTCACACACCAGGGAGCAGGACTCAACATGACTGTC                   AGTGATGAGCAGAGCCACCAGGCAGTGACCGAGGCCATGAGGGTCATCGGCTTCAGTCCTGAAGAGG                   TGGAGTCTGTGCATCGCATCCTGGCTGCCATATTGCACCTGGGAAACATCGAGTTTGTGGAGACCGA                   GGAGGGTGGGCTGCAGAAGGAGGGCCTGGCAGTGGCCGAGGAGGCACTGGTGGACCATGTGGCTGAG                   CTGACGGCCACACCCCGGGACCTCGTGCTCCGCTCCCTGCTGGCTCGCACAGTTGCCTCGGGAGGCA                   GGGAACTCATAGAGAAGGGCCACACTGCACCTGAGGCCAGCTATGCCCGGGATGCCTGTGCCAAGGC                   AGTGTACCAGCGGCTGTTTGAGTGGGTGGTGAACAGGATCAACAGTGTCATGGAACCCCGGGGCCGG                   GATCCTCGGCGTGATGGCAAGGACACAGTCATTGGCGTGCTGGACATCTATGGCTTCGAGGTGTTTC                   CCGTCAACAGTTTCGAGCAGTTCTGCATCAACTACTGCAACGAGAAGCTCCAGCAGCTATTCATCCA                   GCTCATCCTGAAGCAGGAACAGGAAGAGTACGAGCGCGAGGGCATCACCTGGCAGAGCGTTGAGTAT                   TTCAACAACGCCACCATTGTGGATCTGGTGGAGCGGCCCCACCGTGGCATCCTGCCCGTGCTGGACG                   AGGCCTGCAGCTCTGCTGGCACCATCACTGACCGAATCTTCCTGCAGACCCTCGACATGCACCACCG                   CCATCACCTACACTACACCAGCCGCCAGCTCTGCCCCACAGACAAGACCATGGAGTTTGGCCGAGAC                   TTCCGGATCAAGCACTATGCAGCGGACGTCACGTACTCCGTGCAAGGCTTCATCGACAGAAACAGAG                   ATTTCCTCTTCCAGGACTTCAAGCGGCTGCTGTACAACAGCACGGACCCCACTCTACGGGCCATGTG                   GCCGGACGGGCAGCAGGACATCACAGAGGTCACCAAGCGCCCCCTGACGGCTGGCACACTCTTCAAG                   ACTCCATGGTGGCCCTGGTGGAGAACCTTGCCTCCAAGGAGCCCTTCTACGTCCGCTGCATCAAAGC                   CCAATGAGGACAAGGTAGCTGGGAAGCTGGATGAGAACCACTGTCGCCACCAGGTCGCATACCTAAG                   GCTGCTGCAGAATGTGAGGGTCCGCAGGGCTGGCTTCGCTTCCCGCCAGCCCTACTCTCGATTCCTG                   CTCAGGTACAAGATGACCTGTGAATACACATGGCCCAACCACCTGCTGGGCTCCGACAAGGCAGCCG                   TGAGCGCTCTCCTGCAGCAGCACGGGCTGCAGGGGGACGTCCACCTTTGGCCACAGCAGCTGTTCAT                   CCGCTCACCCCGGACACTGGTCACACTGGAGCAGAGCCGAGCCCGCCTCATCCCCATCATTGTGCTG                   CTATTGCAGAAGGCATGGCGGGGCACCTTGGCGAGGTGGCGCTGCCGGAGGCTGAGGGCTATCTACA                   CCATCATGCGCTGGTTCCGGAGACACAAGGTGCGGGCTCACCTAACTGAGCTGCAGCGGCGATTCCA                   GGCTGCAAGGCAGCCGCCACTCTACGGGCGTGACCTTGTGTGCCCGCTGCCCCCTGCTGTGCTGCAG                   CCCTTCCAGGACACCTGCCACGCACTCTTCTGCAGGTGGCGGCCCCCGCAGCTGGTGAAAGACATCC                   CCCCTTCAGACATGCCCCAGATCAAGGCCAAGGTGGCCGCCATCGGGGCCCTCCAAGGGCTTCGTCA                   GGACTGGGGCTGCCGACGGGCCTGGGCCCGAGACTACCTGTCCTCTGCCACTGACATTCCCACAGCA                   TCAAGCCTGTTTGCTCAGCGACTAAAGACACTTCAGGACAAAGATGGCTTCGGATCTGTGCTCTTTT                   CAAGCCATGTCCGCAAGGTGAACCGCTTCCACAAGATCCGGAACCGGGCCCTCCTGCTCACAGACCA                   GCACCTCTACAAGCTGGACCCTGACCGGCAGTACCGGGTCATGCGGGCCGTGCCCCTTGAGGCGGTG                   ACGGGGCTGAGCGTGACCAGCCGACGAGACCAGCTGGTGGTGCTGCACGCCCGCGCCCAGGACGACC                   TCGTGGTGTGCCTGCACCGCTCCCGGCCGCCATTGGACAACCGCGTTAAGGAGCTGGTGGGCGTGCT                   GGCCGCACACTGCCGCAGGGAGGGCCGCACCCTGGAGGTTCGCGTCTCCGACTGCATCCCACTAAGC                   CATCGCGGGGTCCGGCGCCTCATCTCCGTGGAGCCCAGGCCGGAGCAGCCAGAGCCCGATTTCCGCT                   GCGCTCGCGGCTCCTTCACCCTGCTCTGGCCCAGCCGC TGA   GCGCCCCCACCCGCCGCACCCCGA                                               ORF Start: ATG at 15       ORF Stop: TGA at 3054               SEQ ID NO: 152   1013 aa   MW at 116O44.5kD                         NOV36a,   MEDEEGPEYGKPDFVLLDQVTMEDFMRNLQLRFEKGRIYTYIGEVLVSVNPYQELPLYGPEAIARYQ           CG59522-01       Protein Sequence   GRELYERPPHLYAVANAAYXA(HRSRDTCIVISGESGAGKTEASKHIMQYIAAVTNPSPQRAEVERV                   KDVLLKSTCVLEAFGNARTNRNHNSSRFGKYMDINFDFKGDPIGGHIHSYLLEKSRVLKQHVGERNF                   HAFYQLLRGSEDKQLHELHLERNPAVYNFTHQGAGLNMTVSDEQSHQAVTEAMRVIGFSPEEVESVH                   RILAAILHLGNIEFVETEEGGLQKEGLAVAEEALVDHVAELTATPRDLVLRSLLARTVASGGRELIE                   KGHTAAEASYARDACAKAVYQRLFEWVVNRINSVMEPRGRDPRRDGKDTVIGVLDIYGFEVFPVNSF                   EQFCINYCNEKLQQLFIQLILKQEQEEYEREGITWQSVEYFNNATIVDLVERPHRGILAVLDEACSS                   AGTITDRIFLQTLDMHHRHHLHYTSRQLCPTDKTMEFGRDFRIKHYAGDVTYSVEGFIDFGEDFLFQ                   DFKRLLYNSTDPTLRAMWPDGQQDITEVTKRPLTAGTLFKNSMVALVENLASKEPFYVRCIKPNEDK                   VAGKLDENHCRHQVAYLGLLENVRVRRAGFASRQPYSRFLLRYKMTCEYTWPNHLLGSDKAAVSALL                   EQHGLQGDVAFGHSKLFIRSPRTLVTLEQSRARLIPIIVLLLQKAWRGTLARWRCRRLRAIYTIMRW                   FRRHKVRAHLAELQRRFQAARQPPLYGRDLVWPLPPAVLQPFQDTCHALFCRWRARQLVKNIPPSDM                   PQIKAKVAAMGALQGLRQDWGCRRAWARDYLSSATDNPTASSLFAQRLKTLQDKDGFGAVLFSSHIR                   KVNRFHKIRNRALLLTDQHLYXLDPDRQYRVAVPLEAVTGLSVTSCGDQLVVLIJARGQDDLKSJCL                   HRSRPPLDNRVGELVGVLAAHCRREGRTLEVRVSDCIPLSHRGVRRLISVEPRPEQPEPDFRCARGS                   FTLLWPSR                                         SEQ ID NO: 153   3071 bp                             NOV36b,     TTCCAGCCGGCAGG   ATG GAGGACGAGGAAGGCCCTGAGTATGGCGAACCTGACTTTGTGCTTTTGGA           CG59522-02       DNA Sequence   CCAGTGACCATGGAGGACTTCATGAGGAACCTGCAGCTCAGGTTCGAGAAAGGGCCGCATCTACACC                   TACATCGGTGAGGTGCTGGTGTCCGTGAACCCCTACCAGGAGCTGCCCCTGTATGGGCCTGAACACA                   TCGCCAGGTACCAGGGCCGTGAGCTCTATGAGCGGCCACCCCATCTCTATGCTGTGGCCAACGCCGC                   CTACAAGGCAATGAAGTACCGGTCCAGGGACACCTGCATCGTCATCTCAGGGGAGAGTAGAACAGGG                   AAGACAGAAGCCAGTAAGCACATCATGCAGTACATCGCTGCTGTCACCAATCCAAGCCAGAGGGCTG                   AGGTGGAGAGGTCAAGGACGTGCTGCTCAAGTCCACCTGTGTGCTGGAGGCCTTTGGCAAGTGCCCG                   CACCAACCGCAATCACAACTCCAGCCGCTTTGGCAAGTACATGGACATCAACTTTGACTTCAAGGGG                   GACCCGATCGGAGGACGCATCCACAGCTACCTACTGGAGAAGTCTCGGGTCCTCAAGCAGCACGTGG                   GTGAAAGAAACTTCCACGCCTTCTACCAATTGCTGAGAGGCAGTGAGGACAAGCAGCTGCATGAACT                   GCACTTGGAGAGAAACCCTGCTGTATACAATTTCACACACCAGGGAGCAGGACTCAACATGACTGTG                   CACAGTGCCTTGGACAGTGATGAGCAGAGCCACCAGGCAGTGACCGAGGCCATGAGGGTCATCAACT                   TCAGTCCTGAAGAGGTGGAGTCTGTGCATCGCATCCTGGCTGCCATATTGCACCTGGGAAACATCGA                   GTTTGTGGAGACGGAGGAGGGTGGGCTGCAGAAGGAGCGCCTGGCACTGGCCGAGCAGGCACTGGTG                   GACCATGTGGCTGAGCTGACGGCCACACCCCGGGACCTCGTGCTCCGCTCCCTGCTGGCTCGCACAG                   TTGCCTCCGGACGCAGGGAACTCATAGAGAAGGGCCACACTGCAGCTGAGGCCAGCTATGCCCGAAA                   TGCCTGTGCCAAGGCAGTGTACCAGCGGCTGTTTGAGTGGGTGGTGAACAGGATCAACAGTGTCATG                   GAACCCCGGGGCCGGGATCCTCGGCGTGATGGCAACGACACAGTCATTGGCGTGCTGGACATCTATG                   GCTTCGAGGTGTTTCCCGTCAACAGTTTCGAGCAGTTCTGCATCAACTACTGCAATGAGAAGCTGCA                   GCAGCTATTCATCCAGCTCATCCTGAAGCAGGAACAGGAAGAGTACGAGCGCGAGCGCATCACCTGG                   CAGAGCGTTGAGTATTTCAACAACGCCACCATTGTGGATCTGGTGGAGCGGCCCCACCGTGGCATCC                   TGGCCGTGCTGGACGAGGCCTGCAGCTCTGCTGGCACCATCACTGACCGAATCTTCCTGCAGACCCT                   GGACACGCACCACCGCCATCACCTACACTACACCAGCCGCCAGCTCTGCCCCACAGACAAGACCATG                   GAGTTTGGCCGAGACTTCCGGATCAAGCACTATGCAGGGCACGTCACGTACTCCGTGGAAGGCTTCA                   TCGACAAGAACAGAGATTTCCTCTTCCAGGACTTCAAGCGGCTGCTGTACAACAGCACGGACCCCAC                   TCTACGCGCCATGTGGCCGGACGGGCAGCAGGACATCACAGAGGTGACCAAGCGCCCCCTGACGGCT                   GGCACACTCTTCAAGAACTCCATGGTGGCCCTGGTGGAGAACCTTGCCTCCAAGGAGCCCTTCTACG                   TCCGCTGCATCAAGCCCAATGAGGACAAGGTAGCTGGGAAGCTGGATGAGAACCACTGTCGCCACCA                   GGTCGCATACCTGGGGCTGCTGGAGAATOTGAGGGTCCGCAGGGCTGGCTTCGCTTCCCGCCAGCCC                   TACTCTCGATTCCTGCTCAGGTACAAGATGACCTGTGAATACACATGGCCCAACCACCTCCTGGGCT                   CCGACAAGGCAGCCGTGAGCGCTCTCCTGGAGCACCACGGGCTGCAGGOGGACGTGGCCTTTGGCCA                   CAGCAAGCTGTTCATCCGCTCACCCCGGACACTGGTCACACTGGAGCAGAGCCCAGCCCGCCTCATC                   CCCATCATTGTGCTGCTATTGCAGAAGGCATGGCGGGGCACCTTGGCGAGGTGGCGCTGCCGGAGGC                   TGAGGGCTATCTACACCATCATGCGCTGGTTCCGGAGACACAAGGTGCGGGCTCACCTGGCTGAGCT                   GCAGCGGCGATTCCAGACTGCAAGGCAGCCGCCACTCTACGGGCGTGACCTTCTGTGGCCGCTGCCC                   CCTGCTGTGCTGCAGCCCTTCCAGGACACCTGCCACGCACTCTTCTGCAGGTGGCGGGCCCGGCAGC                   TGGTGAAAAACATCCCCCCTTCAGACATCCCCCAGATCAAGGCCAAGCTGGCCGCCATGGGGCCCCT                   CCAAGGGCTTCGTCAGGACTGGGGCTGCCGACGGGCCTGGGCCCGAGACTACCTGTCCTCTGCCACT                   GACAATCCCACAGCATCAAGCCTGTTTGCTCAGCGACTAAAGACACTTCGGGACAAAGATGGCTTCG                   GGGCTGTGCTCTTTTCAAGCCATGTCCGCAAGGTGAACCGCTTCCACAAGATCCGGAACCGGGCCCT                   CCTGCTCACAGACCAGCACCTCTACAAGCTGGACCCTGACCGGCAGTACCGGGTGATGCGGGCCGTG                   CCCCTTGAGGCGGTGACGGGGCTGAGCGTGACCAGCGGAGGAGACCAGCTGGTGGTGCTGCACGCCC                   GCGGCCAGGACGACCTCGTGGTGTGCCTGCACCGCTCCCGGCCGCCATTGGACAACCGCGTTGGGGA                   CCTGGTGGGCGTGCTGGCCGCACACTGCCAGGGGGAGGGCCGCACCCTGGAGGTTCGCGTCTCCGAC                   TGCATCCCACTAAGCCATCGCGGGGTCCGGCGCCTCATCTCCGTGGACCCCAGGCCGGAGCAGCCAG                   AGCCCGATTTCCGCTGCGCTCGCGGCTCCTTCACCCTGCTCTGGCCCAGCCGC TGA                                               ORE Start: ATG at 15       ORF Stop: TGA at 3069               SEQ ID NO: 154   1018 aa   MW at 116483.8kD                         NOV36b,   MEDEEGPEYGKPDFVLLDQVTMEDFMRNLQLRFEKGRIYTYIGEVLVSVNPYQELPLYGPEAIARYQ           CG59522-02       Protein Sequence   GRELYERPPHLYAVANAAYKAMKYRSRDTCIVISGESGAGKTEASKHIMQYIAAVTNPSQRAEVERV                   KDVLLKSTCVLEAFGNARTNRNHNSSRFGKYNDINFDFKGDPTGGRIHSYLLEKSRVLKQHVGERNF                   HAFYQLLRGSEDKQLHELHLERNPAVYNFTHQGAGLNMTVHSALDSDEQSHQAVTEAMRVIGFSPEE                   VESVHRILAAILHLGNIEFVETEEGGLQKEGLAVAEEALVDHVAELTATPRDLVLRSLLARTVASGG                   RELIEKGHTAAEASYARDACAKAVYQRLFEWVVNRINSVMEPRGRDPRRDGKDTVIGVLDIYGFEVF                   PVNSFEQFCINYCNEKLQQLFIQLILKQEQEEYEREGITWQSVEYFNNATIVDLVERPHRGILAVLD                   EACSSAGTITDRIFLQTLDTHHRHHLHYTSRQLCPTDKTMEFGRDFRIKHYAGDVTYSVEGFIDKNR                   DFLFQDFKRLLYNSTDPTLRAHWPDGQQDITEVTKRPLTAGTLFKNSMVALVENLASKEPFYVRCIK                   PNEDKVAGKLDENHCRHQVAYLGLLENVRVRRAGFASRQFYSRFLLRYKMTCEYTWPNHLLGSDKAA                   VSALLEQHOLQGDVAFGHSKLFIRSPRTLVTLEQSRARLIPITVLLLQKAWRGTLARWRCRRLRAIY                   TIMRWTRRHKVRAHLAELQRRFQAARQPPLYGRDLVWPLPPAVLQPFQDTCHALFCRWRARQLVKNI                   PPSDMPQIKAKVAAMGALQGLRQDWGCRRAWARDYLSSATDNPTASSLFAQRLKTLRDKDGRGAVLF                   SSHVRKVNRFHKIRNRALLLTDQHLYKLDPDRQYRVMRAVPLEAVTGLSVTSGGDQLVVLHARGQDD                   LVVCLHRSRPPLDNRVGELVGVLAAHCQGEGRTLEVRVSDCIPLSHRGVRRLISVEPRPEQPEPDFR                   CARGSFTLLWPSR                  
 
     [0544] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 36B.  
               TABLE 36B                          Comparison of NOV36a against NOV36b.                                         Identities/                   Similarities for           Protein   NOV36a Residues/   the Matched           Sequence   Match Residues   Region                       NOV36b   1 . . . 1013   979/1018 (96%)               1 . . . 1018   982/1018 (96%)                      
 
     [0545] Further analysis of the NOV36a protein yielded the following properties shown in Table 36C.  
               TABLE 36C                       Protein Sequence Properties NOV36a                                        PSort   0.8800 probability located in nucleus; 0.3902       analysis:   probability located in microbody (peroxisome);           0.2210 probability located in lysosome (lumen);           0.1000 probability located in mitochondrial           matrix space       SignalP analysis:   No Known Signal Sequence Predicted                  
 
     [0546] A search of the NOV36a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 36D.  
               TABLE 36D                          Geneseq Results for NOV36a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV36a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value                                         AAU23125   Novel human enzyme   1 . . . 1013   1009/1018 (99%)    0.0           polypeptide #211 -  Homo     9 . . . 1026   1011/1018 (99%)              sapiens , 1026 aa.           [WO200155301-A2,           02 AUG. 2001]       AAU23128   Novel human enzyme   1 . . . 853    851/858 (99%)   0.0           polypeptide #214 -  Homo     9 . . . 866    851/858 (99%)             sapiens , 909 aa.           [WO200155301-A2,           02 AUG. 2001]       ABB71113     Drosophila melanogaster     8 . . . 1012   503/1017 (49%)    0.0           polypeptide SEQ ID NO   6 . . . 1007   686/1017 (66%)            40131 - Drosophila               melanogaster , 1011 aa.           [WO200171042-A2,           27 SEP. 2001]       AAM80123   Human protein SEQ ID NO   243 . . . 1011    438/769 (56%)   0.0           3769 -  Homo sapiens , 764   1 . . . 762    570/769 (73%)           aa. [WO200157190-A2,           09 AUG. 2001]       AAM79139   Human protein SEQ ID NO   254 . . . 1011    434/758 (57%)   0.0           1801 -  Homo sapiens , 753   1 . . . 751    564/758 (74%)           aa. [WO200157190-A2,           09 AUG. 2001]                  
 
     [0547] In a BLAST search of public sequence datbases, the NOV36a protein was found to have homology to the proteins shown in the BLASTP data in Table 36E.  
               TABLE 36E                          Public BLASTP Results for NOV36a                                             Identities/           Protein           Similarities for       Accession       NOV36a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         Q63357   Myosin I -  Rattus norvegicus     1 . . . 1011   606/1011 (59%)   0.0           (Rat), 1006 aa.   1 . . . 1004   780/1011 (76%)       A53933   myosin I myr 4 - rat, 1006 aa.   1 . . . 1011   604/1011 (59%)   0.0               1 . . . 1004   778/1011 (76%)       Q96RI6   Unconventional myosin 1G   33 . . . 646     612/619 (98%)   0.0           valine form -  Homo sapiens     1 . . . 619     612/619 (98%)           (Human), 633 aa (fragment).       Q96RI5   Unconventional myosin 1G   33 . . . 646     611/619 (98%)   0.0           methonine form -  Homo     1 . . . 619     612/619 (98%)             sapiens  (Human), 633 aa           (fragment).       Q23978   Myosin IA (MIA) (Brush   8 . . . 1012   503/1017 (49%)   0.0           border myosin IA) (BBMIA) -   6 . . . 1007   686/1017 (66%)             Drosophila melanogaster             (Fruit fly), 1011 aa.                  
 
     [0548] PFam analysis predicts that the NOV36a protein contains the domains shown in the Table 36F.  
               TABLE 36F                          Domain Analysis of NOV36a                                 NOV36a   Identities/           Pfam   Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               myosin_head   11 . . . 689   305/747 (41%)   8.1e−288               531/747 (71%)                  
 
     Example 37  
     [0549] The NOV37 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 37A.  
               TABLE 37A                       NOV37 Sequence Analysis                                                    SEQ ID NO: 155   3807 bp                             NOV37a,   ATGGCGGCGGCGGCGGCGAGCGGAGCTGGCGGGGCTGCCCGGCCCGGGACTGGGGGAGCCGGGCCCG           CG89709-01       DNA Sequence   CGGGCCGCCTGCTGCCTCCGCCCGCGCCGGGGTCCCCAGCCGCCCCCGCTGCCGTGTCCCCTGCGGC                   CGGCCAGCCGCGTCCCCCAGCCCCGGCCTCCCGCGGACCCATGCCCGCCCGTATCGGCTACTACGAG                   ATCGACCGCACCATCGGCAAGGGCAACTTCGCGGTGGTCAAGCGGGCCACGCCCTCGTACACCAAGG                   CCAAGGTTGCTATCAAGATCATAGATAAGACCCAGCTGGATGAAGAAAACTTGAAGAAGATTTTCCG                   GGAAGTTCAAATTATGAAGATGCTTTGCCACCCCCATATCATCAGGCTCTACCACGTTATGGAGACA                   GAACGGATGATTTATCTGGTGACAGAATATGCTAGTGGAGGGGAAATATTTGACCACCTGGTGGCCC                   ATGGTAGAATGGCAGAAAAGGAGGCACGTCGGAAGTTCAAACAGATCGTCACAGCTGTCTATTTTTG                   TCACTGTCGGAACATTGTTCATCGTGATTTAAAAGCTGAAAATTTACTTCTGGATGCCAATCTGAAT                   ATCAAAATAGCAGATTTTGGTTTCAGTAACCTCTTCACTCCTGGCCAGCTCCTGAAGACCTGGTGTG                   GCAGCCCTCCCTATGCTGCACCTGAACTCTTTGAAGGAAAAGAATATGATGGGCCCAAAGTGGACAT                   CTGGAGCCTTGGAGTTGTCCTCTACGTGCTTGTGTGCGGTGCCCTGCCATTTGATGGAAGCACACTG                   CAGAATCTGCGGGCCCGCGTGCTCAGTGGAAAGTTCCGCATCCCATTTTTTATGTCCACAGAATGTG                   AGCATTTGATCCGCCATATGTTGGTGTTAGATCCCAATAAGCGCCTCTCCATGGAGCAGATCTGCAA                   GCACAAGTGGATGAAGCTAGGGGACGCCGATCCCAACTTTGACAGGTTAATAGCTGAATGcCAAcAA                   CTAAAGGAAGAAAGACAGGTCGACCCCCTGAATGAGGATGTCCTCTrGGCCATGGAGGACATGGGAC                   TGCACAAAGAACAGACACTGCAGGCGGAGCAGGCAGGTACTGCTATGAACATCAGCGTTCCCCAGGT                   GCACCTGATCAACCCAGAGAACCAAATTGTGGACCCCGATGGGACACTGAATTTGGACAGTGATGAG                   GGTGAAGAGCCTTCCCCTGAAGCATTGGTGCGCTATTTGTCAATGAGGAGGCACACAGTGGGTGTGG                   CTGACCCACGCACGGAAGTTATGGAAGATCTGCAGAAGCTCCTACCTGGCTTTCCTGGAGTCAACCC                   CCAGGCTCCATTCCTGCAGGTGGCCCCTAATGTGAACTTCATGCACAACCTGTTGCCTATGCAAAAC                   TTGCAACCAACCGGGCAACTTGAGTACAAGGAGCAGTCTCTCCTACAGCCGCCCACGCTACAGcTGT                   TGAATGGAATGGGCCCCCTTGGCCGGAGGCATCAGATGGAGGACCCAACATCCAACTGCATGCCCA                   GCAGCTGCTGAAGCGCCCACGGGGACCCPCTCCGCTTGTCACCATGACACCAOCAGTGCCAGCAGTT                   ACCCCTGTGGACGAGGAGAGCTCAGACGGGGAGCCAGACCAGGAAGCTGTGCAGAGCTCACCTACA                   AGGACTCCAACACTCTGCACCTCCCTACGGAGCGTTTCTCCCCTGTGCGCcGGTTcTcAGATGGGGC                   TGCGAGCATCCAGGCCTTCAAAGCTCACCTCGAAAAAATGGGCAACAACAGCAGCATCAAACAGCTG                   CAGCAGGAGTGTGAGCAGCTGCAGAAGATGTACGGGGGGCAGATTGATGAAAGAACCCTGGAGAAGA                   CCCAGCAGCAGCATATGTTATACCAGCAGGAGCAGCACCATCAAATTCTCCAGCAACAAATTCAAGA                   CTCTATCTGTCCTCCTCAGCCATCTCCACCTCTTCAGGCTGCATGTGAAAATCAGCCAGCCCTCCTT                   ACCCATCAGCTCCAGACGTTAGGATTCAGCCTTCAAGCCCACCCCCCAACCACCCCAACAACCCATC                   TCTTCAGGCAGCCCAGTAATAGTCCTCCCCCCATGAGCAGTGCCATGATCCAGCCTCACGGGGCTGC                   ATCTTCTTCCCAGTTTCAAGGCTTACCTTCCCGCAGTGCAATCTTTCAGCAGCAACCTCAGAACTGT                   TCCTCTCCTCCCAACGTGGCACTAACCTGCTTGGGTATGCAGCAGCCTGCTCAGTCACAGCAGGTCA                   CCATCCAAGTCCAAGAGCCTGTTGACATGCTCAGCAACATGCCAGGCACAGCTGCAGGCTCCAGTGG                   GCGCGGCATCTCCATCAGCCCCAGTGCTGGTCAGATGCAGATGCAGCACCGTACCAACCTGATGGCC                   ACCCTCAGCTATGGGCACCGTCCCTTGTCCAAGCAGCTGAGTGCTGACAGTGCAGAGGCTCACAGTG                   CACATCAGCAGCCGCCACACTATACCACGTCGGCACTACAGCAGGCCCTGCTGTCTCCCACGCCGCC                   AGACTATACAAGACACCAGCAGGTACCCCACATCCTTCAAGGACTGCTTTCTCCCCGGCATTCGCTC                   ACCGGCCACTCGGACATCCGGCTGCCCCCAACAGAGTTTGCACAGCTCATTAAAAGGCAGCAGCAAC                   AACGGCAGCAGCAGCAGCAACAGCAGCAACAGCAAGAATACCAGGAACTGTTCAGGCACATGAACCA                   AGGGGATGCGGGGAGTCTGGCTCCCAGCCTTGGGGGACAGAGCATGACAGAGCGCCAGGCTTTATCT                   TATCAAAATGCTGACTCTTATCACCACACGATCCACAACAGCCACGATGCTTATGTACAGCTGGATA                   ACTTGCCAGGAATGAGTCTCGTGGCTGGGAAAGCACTTAGCTCTGCCCGGATGTCGGATGCAGTTCT                   CAGTCAGTCTTCGCTCATGGGCAGCCAGCAGTTTCAGGATGGGGAAAATGAGGAATGTGGGGCAAGC                   CTGGGAGGTCATGAGCACCCAGACCTGAGTGATGGCAGCCAGCATTTAAACTCCTCTTGCTATCCAT                   CTACGTGTATTACAGACATTCTGCTCAGCTACAAGCACCCCGAAGTCTCCTTCAGCATGGAGCAGGC                   AGGCGTG TAA   CAAGAAACAGAGAGAGAGCAAGAGGTCCCGAGTCCCCTCCTAGTCTTTCATCCTCAA                       TTTGCACAGAGGAAAGCGGGTGCCCGGCATGGCCATCCTGATGTTGCTGGCGGGATCCCCATGCACC                       TTGTCCTTCTCCACTGATACTCGCAGCTCGGCTCCTGGACCCAAGATCCCTTGAGTGGAATTCTGCA                       GTGCAAGAGCCCTTCGTGGGAGCTGTCCCATGTTTCCATGGTCCCCAGTCTCCCCTCCACTTGGTCG                       GGTCACCAACTACTCACCAGAAGGGGGCTTACCAAGAAAGCCCTAAAAAGCTGTTGACTTATCTGCG                       CTTGTTCCAACTCTTATGCCCCCAACCTGCCCTACCACCACCACGCGCTCAGCCTGATGTGTTTACA                       TGGTACTGTATGTATGGGAGAGCAGACTGCACCCTCCAGCAACAACAGATGAAAGCCAGTGAGCCTA                       CTAACCGTGCCATCTTGCACAACTACACTTTAAAAAAACTCATTGCTTTGTATTGTAGTAACCAATA                       TGTCCAGTATACGTTGAATGTATATGAACATACTTTCCTATTTCTGTTCTPTGAAAATGTCAGAAAT                       ATTTTTTTCTTTCTCATTTTATGTTGAACTAAAAAGGATTAAAAAAAAATCTCC                                               ORF Start: ATG at 1       ORF Stop: TAA at 3157               SEQ ID NO: 156   1052 aa   MW at 115587.7kD                         NOV37a,   MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYE           CG89709-01       Protein Sequence   IDRTIGKGNFAVVKRATHLVTKAXVAIKIIDKTQLDEENLKRIFREVQIMKMLCHPHIIRLYQVMET                   ERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNIVHRDLKAENLLLDANLN                   IKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTL                   QNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQ                   LKEERQVDPLNEDVLLAMEDMGLDKEQTLQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDE                   GEEPSPEALVRYLSMRRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQN                   LQPTGQLEYKEQSLLQPPTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTPAVPAV                   TPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQL                   QQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQIQDSICPPQPSPPLQAACENQPALL                   THQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENC                   SSPPNVALTCLGMQQPAQSQQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSACQMQMQHRTNLMA                   TLSYGHRPLSKQLSADSAEAHSAHQQPPNYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSL                   TGIISDIRLPPTEFAQLIKRQQQQRQQQQQQQQQQEYQELFRHMNQGDAGSLAPSLGGQSMTERQALS                   YQNADSYHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQSSLMGSQQFQDGENEEcGAs                   LGGHEHFDLSDGSQHLNSSCYPSTC ITDILLSYKHPEVSFSMEQAGV                                         SEQ ID NO: 157   3987 bp                             NOV37b,     ATG GCGGCGGCGGCGGCGAGCGGAGCTGGCGGGGCTGCCGGGGCCGGGACTGGGGGAGCCGGGCCCG           CG89709-02       DNA Sequence   CGGGCCGCCTGCTGCCTCCGCCCGCGCCGGGGTCCCCAGCCGCCCCCGCTGCCGTGTCCCCTGCGGC                   CGGCCAGCCGCGTCCCCCACCCCCGGCCTCCCGCGGACCCATGCCCGCCCGTATCGGCTACTACGAG                   ATCGACCGCACCATCGGCAAGGGCAACTTCGCGGTGGTCAAGCGGGCCACGCACCTCGTCACCAAGG                   CCAAGGTTGCTATCAAGATCATAGATAAGACCCAGCTGGATGAAGAAAACTTGAAGAAGATTTTCCG                   GGAAGTTCAAATTATGAAGATGCTTTGCCACCCCCATATCATCAGGCTCTACCAGGTTATGGAGACA                   GAACGGATGATTTATCTGGTGACAGAATATGCTAGTGGAGGGGAAATATTTGACCACCTGGTGGCCC                   ATGGTACAATGGCACAAAAGGAGGCACGTCGGAAGTTCAAACAGATCGTCACAGCTGTCTATTTTTG                   TCACTGTCCGAACATTGTTCATCGTGATTTAAAAGCTGAAAATTTACTTCTGGATGCCAATCTGAAT                   ATCAAAATAGCAGATTTTGGTTTCAGTAACCTCTTCACTCCTCGGCAGCTGCTGAAGACCTGGTGTG                   GCAGCCCTCCCTATGCTGCACCTGAACTCTTTGAAGGAAAAGAATATGATGGGCCCAAAGTGGACAT                   CTGGAGCCTTGGAGTTGTCCTCTACGTGCTTGTGTGCGGTGCCCTGCCATTTGATGGAAGCACAcTG                   CAGAATCTGCGGGCCCGCGTGCTGAGTGGAAAGTTCCGCATCCCATTTTTTATGTCCACAGAATGTG                   AGCATTTGATCCGCCATATGTTGGTGTTAGATCCCAATAAGCGCCTCTCCATGGAGCAGATcTGc~                   GCACAAGTCGATGAACCTAGCGGACGCCGATCCCAACTTTGACAGGTTAATAGCTGAATGCCAACAA                   CTAAAGGAAGAAAGACAGGTGGACCCCCTGAATGAGGATGTCCTCTTGOCCATGGAGGACATGGGAC                   TCGACAAAGAACAGACACTGCAGGCGGAGCACGCAGGTACTGCTATGAACATCAGCGTTCCCCAGGT                   GCAGCTGATCAACCCAGAGAACCAAATTGTGGAGCCGGATCGGACACTGAATTTGGACAGTGATGAC                   CGTGAAGAGCCTTCCCCTGAAGCATTCCTGCGCTATTTGTCAATGAGGAGGCACACAGTGGGTGTGG                   CTGACCCACGCACGGAAGTTATGGAAGATCTGCAGAAGCTCCTACCTGGCTTTCCTGGAGTCAACCc                   CCAGGCTCCATTCCTGCAGGTGGCCCCTAATGTGAACTTCATGCACAACCTGTTGCCTATGCAAAAC                   TTGCAACCAACCGGGCAACTTGAGTACAAGGACCAGTCTCTCCTACAGCCGCCCACGCTACAGCTGT                   TGAATGGAATGGGCCCCCTTGGCCGGAGGGCATCAGATGGAGGAGCCAACATCCAACTGCATGCCCA                   GCAGCTGCTGAAGCGCCCACGCGGACCCTCTCCGCTTGTCACCATGACACCA~CAGTGCCAGCAGTT                   ACCCCTGTGGACGAGGAGAGCTCAGACCGGGAGCCAGACCAGGAAGCTGTGCAGAGCTCTACCTAcA                   AGGACTCCAACACTCTGCACCTCCCTACGGAGCGTTTCTCCCCTGTGCGCCGGTTCTCAGATGGGGC                   TGCGAGCATCCAGGCCTTCAAAGCTCACCTGCAAAAAATGGGCAACAACAGCAGCATCAAACAGCTG                   CAGCAGGAGTGTGAGCAGCTGCAGAAGATGTACGGGGGGCAGATTGATGAAAGAACCCTGGAGAAGA                   CCCAGCAGCAGCATATGTTATACCAGCAGGAGCAGCACCATCAAATTCTCCAGCAACAAATTC~GA                   CTCTATCTGTCCTCCTCAGCCATCTCCACCTCTTCAGGCTGCATGTGAAAATCAGCCAGCCCTCCTT                   ACCCATCAGCTCCAGAGGTTAAGGATTCAGCCTTCAAGCCCACCCCCCAACCACCCCAACAACCATC                   TCTTCAGGCAGCCCAGTAATAGTCCTCCCCCCATGAGCAGTGCCATGATCCAGCCTCACOGGGCTGC                   ATCTTCTTCCCAGTTTCAAGGCTTACCTTCCCGCAGTGCAATCTTTCAGCAGCAACCTGAGAACTGT                   TCCTCTCCTCCCAACGTGGCACTAACCTGCTTGGGTATGCAGCAGCCTGCTCAGTCACAGCAGGTCA                   CCATCCAAGTCCAAGAGCCTGTTGACATGCTCAGCAACATGCCAGGCACAGCTGCAGGCTCCAGTGG                   GCGCGGCATCTCCATCAGCCCCAGTGCTGGTCAGATGCAGATGCAGCACCGTACCAACCTGATGGCC                   ACCCTCAGCTATGGGCACCGTCCCTTGTCCAAGCAGCTGAGTGCTGACAGTGCAGACGCTCACAGCT                   TGAACGTGAATCGGTTCTCCCCTGCTAACTACGACCAGGCGCATTTACACCCCCATCTGTTTTCGGA                   CCAGTCCCGGGGTTCCCCCAGCAGCTACAGCCCTTCAACAGGAGTGGGGTTCTCTCCAACCCAAGCC                   CTGAAAGTCCCTCCACTTGACCAATTCCCCACCTTCCCTCCCACTGCACATCAGCAGCCGCCACACT                   ATACCACGTCGGCACTACAGCAGGCCCTGCTGTCTCCCACGCCGCCAGACTATACAAGACACcAGCA                   GGTACCCCACATCCTTCAAGGACTGCTTTCTCCCCGGCATTCGCTCACCGGCCACTCGGACATCCGG                   CTGCCCCCAACAGAGTTTGCACAGCTCATTAAAAGGCAGCAGCAACAACGGCAGCAGCAGCAGCAAC                   AGCAGCAACAGCAAGAATACCAGGAACTGTTCAGGCACATGAACCAAGGGGATGCGGGGAGTCTGGC                   TCCCAGCCTTGGGGGACAGAGCATGACAGAGCGCCAGGCTTTATCTTATCAAAGTGCTGACTCTTAT                   CACCACACGATCCAGAACAGCGACGATGCTTATGTACAGCTGGATAACTTCCCAGGAATGAGTCTCG                   TGGCTGGGAAAGCACTTAGCTCTCCCCGGATGTCGGATGCAGTTCTCAGTCAGTCTTCGCTCATGGG                   CAGCCAGCAGTTTCAGGATGGGGAAAATGAGGAATGTGGGGCAAGCCTGGGAGGTCATGAGCACCCA                   GACCTGAGTGATCGCAGCCAGCATTTAAACTCCTCTTGCTATCCATCTACGTGTATTACAGACATTC                   TGCTCAGCTACAAGCACCCCGAAGTCTCCTTCAGCATGGAGCAGGCAGGCGTG TAA   CAAGAAACAGA                       GAGAGAGCAAGAGGTCCCGAGTCCCCTCCTAGTCTTTCATCCTGAATTTGCACAGAGGAAAGCGGGT                       GCCCGGCATGGCCATCCTGATGTTGCTGGCGGGATCCCCATGCACCTTGTCCTTCTCCACTGATACT                       GGCAGCTCGGCTCCTGGACCCAAGATCCCTTGAGTGCAATTCTGCAGTGCAAGAGCCCTTCGTGAGA                       GCTGTCCCATGTTTCCATGGTCCCCAGTCTCCCCTCCACTTGGTGGGGTCACCAACTACTCACCAGA                       AGGGGGCTTACCAAGAAAGCCCTAAAAAGCTGTTGACTTATCTGCGCTTGTTCCAACTCTTATGCCC                       CCAACTGCCCTTACCACCACCACGCGCTCAGCCTGATGTGTTTACATGGTACTGTATGTATGGGAGA                       GCAGACTGCACCCTCCAGCAACAACAGATGAAAGCCAGTGAGCCTACTAACCGTGCCATCTTGCAAA                       CTACACTTTAAAAAAAACTCATTGCTTTGTATTGTAGTAACCAATATGTGCAGTATACGTTGAATGT                       ATATGAACATACTTTCCTATTTCTGTTCTTTGAAAATGTCAGAAATATTTTTTTCTTTCTCATTTTA                       TGTTGAACTAAAAAGGATTAAAAAAAAAATCTCC                                               ORF Start: ATG at 1       ORF Stop: TAA at 3337               SEQ ID NO: 158   1112 aa   MW at 122094.8kD                         NOV37b,   MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYE           CG89709-02       Protein Sequence   IDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIFREVQIMKMLCHPHIIRLYQVMET                   ERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNIVHRDLKAENLLLDANLN                   IKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTL                   QNLRARVLSGKFRIFFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQ                   LKEERQVDPLNEDVLLAMEDMGLDKEQTLQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLSKDE                   GEEPSPEALVRYLSMRRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQU                   DLSDGSQHLNSSCYPSTCITDILLSYKHPEVSFSMEQAGV                                         SEQ ID NO: 159   4889 bp                             NOV37c,     TTGAACTGGGACAGAGGTCACAGCAGAGGTCACATTGGCGATTCGAGCGGCGGTCGGGGGTTGGCTT             CG89709-03       DNA Sequence     TCGGTCGGGCATCCTGCGCCCCCCACTCGGGAAACGTGGCGGAGACTTCCAGGTTGGGGGCCCATCG                       AACGTTCCCACCGCCAGCTCCCGGAGGGGGGCACCCGGGAGCCAGCGCCTCAGGAACCGGGGCCCAC                       GCGGGAAGGTCGAGCCCGCCGGTGAGGTCACGGTTGCCATGGCTCCGGGCAGTGACGCGCGTCGGCA                       CGTGACCCGCGGTTGCCATGGAGCCGGGCGCCGGTCGGCGAAAGCGCCCCGCCTCCCCGAGTGACGT                       CCGCGGCCCCCCCTTTCCCGCCCCCCCTTGCCCCCTCCCCCGAGCCGGCTCCCCGCGGCCCCGGAGC                       TTTCACTGCACAACAAG   ATG GCGGCGGCGGCGGCGAGCGGAGCTGGCQGGGCTGCCGGGGCCGGGAC                   TGGGGGAGCCGGGCCCGCGGGCCCCCTGCTGCCTCCGCCCGCGCCGGGGTCCCCAGCCGCCCCCGCT                   GCCGTGTCCCCTGCGGCCGGCCAGCCGCGTCCCCCAGCCCCGGCCTCCCGCCGACCCATGCCCGCCC                   GTATCGGCTACTACGAGATCGACCGCACCATCGGCAAGGGCAACTTCGCGGTGGTCAAGCGGGCCAC                   GCACCTCGTCACCAAGGCCAAGGTTGCTATCAAGATCATAGATAAGACCCAGCTCGATGAAGAAAAC                   TTGAAGAAGATTTTCCGGGAAGTTCAAATTATGAAGATGCTTTGCCACCCCCATATCATCACGCTCT                   ACCAGGTTATGGAGACAGAACGGATGATTTATCTCGTGACAGAATATGCTAGTGGAGGGGAAATATT                   TGACCACCTGGTGGCCCATGGTAGAATGGCAGAAAAGGAGGCACGTCGGAAGTTCAAACAGATCGTC                   ACAGCTGTCTATTTTTGTCACTGTCGGAACATTGTTCATCGTGATTTAAAAGCTGAAAATTTACTTC                   TGGATGCCAATCTGAATATCAAAATAGCAGATTTTGGTTTCAGTAACCTCTTCACTCCTGGGCAGCT                   GCTGAAGACCTGGTGTGGCAGCCCTCCCTATGCTGCACCTGAACTCTTTGAAGGAAAAGAATATGAT                   GGGCCCAAAGTGGACATCTGGAGCCTTGGAGTTGTCCTCTACGTGCTTGTCTGCGGTGCCCTGCCAT                   TTGATGGAAGCACACTGCAGAATCTGCGGGCCCGCGTGCTGAGTGGAAAGTTCCGCATCCCATTTTT                   TATGTCCACAGAATGTGAGCATTTGATCCGCCATATGTTGGTGTTAGATCCCAATAAGCGCCTCTCC                   ATGGAGCAGATCTGCAAGCACAAGTGGATTAAGCTAGGGGACGCCCATCCCAACTTTGACAGGTTAA                   TAGCTGAATGCCAACAACTAAACGAAGAAAGACACGTCGACCCCCTGAATGAGGATGTCCTCTTGGC                   CATGGAGGACATGGGACTGGACAAAGAACAGACACTCCAGGCGGAGCAGGCAGGTACTGCTATGAAC                   ATCAGCGTTCCCCAGGTGCAGCTGATCAACCCAGAGAACCAAATTGTGGAGCCCGATGGGACACTGA                   ATTTGGACAGTGATGAGGGTGAAGAGCCTTCCCCTGAAGCATTGGTGCGCTATTTGTCAATGAGGAG                   GCACACAGTGGGTGTGGCTGACCCACCCACGGAAGTTATGGAAGATCTGCAGAAGCTCCTACCTGGC                   TTTCCTGGAGTCAACCCCCAGGCTCCATTCCTGCAGGTGGCCCCTAATGTGAACTTCATGCACAACC                   TGTTGCCTATGCAAAACTTGCAACCAACCGGGCAACTTGAGTACAAGGAGCAGTCTCTCCTACAGCC                   GCCCACGCTACAGCTGTTGAATGGAATGGGCCCCCTTGGCCGGAGCGCATCAGATGGAGGAGCCAAC                   ATCCAACTGCATGCCCAGCAGCTGCTGAAGCGCCCACGGGGACCCTCTCCGCTTGTCACCATGACAC                   CAGCAGTGCCAGCAGTTACCCCTGTGGACGAGGAGAGCTCAGACGGGGAGCCAGACCAGGAAGCTGT                   GCAGAGCTCTACCTACAAGGACTCCAACACTCTGCACCTCCCTACGGAGCGTTTCTCCCCTGTGCGC                   CGGTTCTCAGATGGGGCTGCGAGCATCCAGGCCTTCAAAGCTCACCTGGAAAAAATGGGCAACAACA                   GCAGCATCAAACAGCTGCAGCAGGAGTGTGAGCAGCTGCAGAAGATGTACGGGGGGCAGATTGATGA                   AAGAACCCTGGAGAAGACCCAGCAGCAGCATATGTTATACCAGCAGGAGCAGCACCATCAAATTCTC                   CAGCAACAAATTCAAGACTCTATCTGTCCTCCTCAGCCATCTCCACCTCTTCAGGCTGCATGTGAAA                   ATCAGCCAGCCCTCCTTACCCATCAGCTCCAGAGGTTAAGGATTCAGCCTTCAAGCCCACCCCCCAT                   CCACCCCAACAACCATCTCTTCAGGCAGCCCAGTAATAGTCCTCCCCCCATGAGCAGTGCCATGATC                   CAGCCTCACGGGGCTGCATCTTCTTCCCAGTTTCAAGGCTTACCTTCCCGCAGTGCAATCTTTCAGC                   AGCAACCTGAGAACTGTTCCTCTCCTCCCAACGTGGCACTAACCTGCTTGGGTATGCAGCAGCCTGC                   TCAGTCACAGCAGGTCACCATCCAAGTCCAAGACCCTGTTGACATGCTCAGCAACATGCCAGGCACA                   GCTGCACGCTCCAGTGGGCGCGGCATCTCCATCAGCCCCAGTGCTGGTCAGATGCAGATGCAGCACC                   GTACCAACCTGATGGCCACCCTCAGCTATGGGCACCGTCCCTTGTCCAAGCAGCTGAGTGCTGACAG                   TGCAGAGGCTCACAGCTTGAACGTGAATCGGTTCTCCCCTGCTAACTACGACCAGGCGCATTTACAC                   CCCCATCTGTTTTCGGACCAGTCCCGCGGTTCCCCCAGCAGCTACAGCCCTTCAACAGGAGTGGGGT                   TCTCTCCAACCCAAGCCCTGAAAGTCCCTCCACTTGACCAATTCCCCACCTTCCCTCCCAGTGCACA                   TCAGCAGCCGCCACACTATACCACGTCGGCACTACAGCAGGCCCTGCTGTCTCCCACGCCGCCAGAC                   TATACAAGACACCAGCAGGTACCCCACATCCTTCAAGGACTGCTTTCTCCCCGGCATTCGCTCACCG                   GCCACTCGGACATCCGGCTGCCCCCAACAGAGTTTGCACAGCTCATTAAAAGGCAGCAGCAACAACG                   GCAGCAGCAGCAGCAACAGCAGCAACAGCAAGAATACCAGGAACTCTTCAGGCACATGAACCAAGGG                   GATGCGGGGAGTCTGGCTCCCAGCCTTGGGGGACAGAGCATGACAGAGCGCCAGGCTTTATCTTATC                   AAAATGCTGACTCTTATCACCATCACACCAGCCCCCAGCATCTGCTACAAATCAGGGCACAAGAATG                   TGTCTCACAGGCTTCCTCACCCACCCCGCCCCACGGGTATGCTCACCAGCCGGCACTGATGCATTCA                   GAGAGCATGGAGGAGGACTGCTCGTGTGAGGGGGCCAAGGATGGCTTCCAAGACAGTAAGAGTTCAA                   GTACATTGACCAAAGGTTGCCATGACAGCCCTCTGCTCTTGAGTACCGGTGGACCTGGGGACCCTGA                   ATCTTTGCTAGGAACTGTGAGTCATGCCCAAGAATTGGGGATACATCCCTATGGTCATCAGCCAACT                   GCTGCATTCAGTAAAAATAAGGTGCCCAGCAGAGAGCCTGTCATACGGAACTGCATGGATAGAAGTT                   CTCCAGGACAAGCAGTGGAGCTGCCGGATCACAATGGGCTCGGGTACCCAGCACGCCCCTCCGTCCA                   TCAGCACCACAGGCCCCGGGCCCTCCAGAGACACCACACGATCCAGAACAGCGACGATGCTTATGTA                   CAGCTGGATAACTTGCCAGGAATGAGTCTCGTGGCTGGGAAAGCACTTACCTCTGCCCGGATGTCGG                   ATGCAGTTCTCAGTCAGTCTTCGCTCATGGGCAGCCAGCAGTTTCAGGATGGGGAAAATGAGGAATG                   TGGGGCAAGCCTGGGAGGTCATGAGCACCCAGACCTGAGTGATGGCAGCCAGCATTTAAACTCCTCT                   TGCTATCCATCTACGTGTATTACAGACATTCTGCTCAGCTACAAGCACCCCGAAGTCTCCTTCAGCA                   TGGAGCAGCCAGGCGTG TAA   CAAGAAACAGAGAGAGAGCAAGAGGTCCCGAGTCCCCTCCTAGTCTT                       TCATCCTGAATTTGCACAGAGGAAAGCGGGTGCCCGGCATGOCCATCCTGATGTTGCTGGCGGGATC                       GCCATGCACCTTGTCCTTCTCCACTGATACTGGCACCTCGGCTCCTGGACCCAAGATCCCTTGAGTC                       GAATTCTGCAGTGCAAGAGCCCTTCGTGGGAGCTGTCCCATGTTTCCATGGTCCCCAGTCTCCCCTC                       CACTTGGTGGGGTCACCAACTACTCACCAGAAGGGGGCTTACCAAGAAAGCCCTAAAAAGCTGTTGA                       CTTATCTGCGCTTGTTCCAACTCTTATGCCCCCAACCTGCCCTACCACCACCACGCGCTCAGCCTGT                       TGTGTTTACATGGTACTGTATGTATGGGAGAGCAGACTGCACCCTCCAGCAACAACAGATGAAAGCC                       AGTGAGCCTACTAACCGTGCCATCTTGCAAACTACACTTTAAAAAAAACTCATTGCTTTGTATTGTA                       GTAACCAATATGTGCAGTATACGTTGAATGTATATGAACATACTTTCCTATTTCTGTTCTTTGAAAG                       TGTCAGAAATATTTTTTTCTTTCTCATTTTATGTTGAACTAAAAAGGATTAAAAAAAAAATCTCC                                               ORF Start: ATG at 420       ORF Stop: TAA at 4239               SEQ ID NO: 160   1273 aa   MW at 139385.7kD                         NOV37c,   MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYE           CG89709-03       Protein Sequence   IDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIFREvQIMKMLCHPHIERLYQVMET                   ERMIYLVTEYASGGEIFDHLVAHGRNAEKEARRKFKQIVTAVYFCNCRNIVHRDLKAENLLLDANLN                   IKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPEDGSTL                   QNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKTHKLGDADPNFDRLIAECQQ                   LKEERQVDPLNEDVLLAMEDMGLDKEQTLQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDE                   GEEPSPEALVRYLSMRRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQN                   LQPTGQLEYKEQSLLQPPTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTNTPAVPAV                   TPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQL                   QQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQIQDSICPPQFSPFLQAACENQPALL                   TEQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENC                   SSPPNVALTCLGMQQPAQSQQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSAGQMQMQHRTNLMA                   TLSYGHRPLSKQLSADSAEAHSLNVNRFSPANYDQAHLHPHLFSDQSRGSPSSYSPSTGVGFSPTQA                   LKVPPLDQFPTFPPSAHQQPPHYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSLTGHSDIR                   LPPTEFAQLIKRQQQQRQQQQQQQQQQEYQELFRBMNQGDAGSLAPSLGGQSMTERQALSYQNADSY                   HHHTSPQHLLQIRAQECVSQASSPTPPHGYAHQPALMHSESMEEDCSCEGAKDGFQDSKSSSTLTKG                   CHDSPLLLSTGGPGDPESLLGTVSHAQELGIHPYGHQPTAAFSKNXVPSREPVIGNCMDRSSPGQAV                   ELPDHNGLGYPARPSVHEHHRPRALQRHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQ                   SSLMGSQQFQDGENEECGASLGGHEHPDLSDGSQHLNSSCYPSTCITDILLSYKUPEVSFSMEQAGV                                         SEQ ID NO: 161   5033 bp                             NOV37d,     TTGAACTGGGACACAGGTCACACCAGAGGTCACATTGGCGATTCGACCGGCGGTGCGGGGTTGGCTT             CG89709-04       DNA Sequence     TGGGTCGGGCATCCTGCGCCCCCCACTCGGGAAAGGTGGCGGAGACTTCGAGGTTGGGGGCCCATCG                       AAGGTTCCCACCGCCAGCTCCCGGAGGGGGGCACCCGGGAGCCAGCGCCTCAGGAACCGGGGCCCAC                       GCGGGAAGGTCGAGCCCGCCGGTGAGGTCACCGTTGCCATGGCTCCGGGCAGTGACGCGCGTCGGCA                       CGTGACCCGCGGTTGCCATGGAGCCGGGCGCCGGTCGGCGAAAGCGCCCCGCCTCCCCGAGTGACGT                       CCGCGGCCCCCCCTTTCCCGCCCCCCCTTGCCCCCTCCCCCGAGCCGGCTCCCCGCGGCCCCGGAGG                       TTTCACTGCACAACAAG   ATG GCGGCGGCGGCGGCGAGCGGAGCTGGCGGGGCTGCCGGGGCCGGGAC                   TGGGGGAGCCGGGCCCGCGGGCCGCCTGCTGCCTCCGCCCGCGCCGGGGTCCCCAGCCGCCCCCGCT                   GCCGTGTCCCCTGCGGCCGGCCAGCCGCGTCCCCCAGCCCCGGCCTCCCGCGGACCCATGCCCGCCC                   GTATCGGCTACTACGAGATCGACCGCACCATCGGCAAGGGCAACTTCGCGGTGGTCAAGCGGGCCAC                   GCACCTCGTCACCAAGGCCAAGGTTGCTATCAAGATCATAGATAAGACCCAGCTGGATGAAGAAAAC                   TTGAAGAAGATTTTCCGGGAAGTTCAAATTATGAAGATGCTTTGCCACCCCCATATCATCAGGCTCT                   ACCAGGTTATGGAGACAGAACGGATGATTTATCTGGTGACAGAATATGCTAGTGGAGGGGAAATATT                   TGACCACCTGGTGGCCCATGGTAGAATGGCAGAAAAGGAGGCACGTCGGAAGTTCAAACAGATCGTC                   ACAGCTGTCTATTTTTGTCACTGTCGGAACATTGTTCATCGTGATTTAAAACCTGAAAATTTACTTC                   TGGATGCCAATCTGAATATCAAAATAGCAGATTTTGGTTTCAGTAACCTCTTCACTCCTCGGCAGCT                   GCTGAAGACCTGGTGTGGCAGCCCTCCCTATGCTCCACCTGAACTCTTTGAAGGAAAAGAATATGAT                   GGGCCCAAAGTGGACATCTGGACCCTTGGAGTTGTCCTCTACGTGCTTGTGTGCGGTGCCCTGCCAT                   TTGATGGAAGCACACTGCAGAATCTGCGGGCCCGCGTGCTGAGTGGAAAGTTCCGCATCCCATTTTT                   TATGTCCACAGAATGTGAGCATTTGATCCGCCATATGTTGGTGTTAGATCCCAATAAGCGCCTCTCC                   ATGGAGCAGATCTGCAAGCACAAGTGGATGAAGCTAGGGGACGCCGATCCCAACTTTGACAGGTTAA                   TAGCTGAATGCCAACAACTAAAGGAAGAAAGACAGGTGGACCCCCTGAATGAGGATGTCCTCTTGGC                   CATGGAGGACATGGGACTGGACAAAGAACAGACACTGCAGTCATTAAGATCAOATGCCTATGATCAC                   TATAGTGCAATCTACAGCCTGCTGTGTGATCGACATAAGAGACATAAAACCCTGCGTCTCGGAGCAC                   TTCCTAGCATGCCCCOAGCCCTGGCCTTTCAAGCACCAGTCAATATCCAGGCGGAGCAGGCAGGTAC                   TGCTATGAACATCAGCGTTCCCCAGGTGCAGCTGATCAACCCAGAGAACCAAATTGTGGAGCCGGAT                   GGGACACTGAATTTGGACAGTGATGAGGGTGAAGAGCCTTCCCCTGAAGCATTGGTGCGCTATTTGT                   CAATGAGGAGCCACACAGTGGGTGTGGCTGACCCACGCACGGAAGTTATGGAAGATCTGCAGAAGCT                   CCTACCTGGCTTTCCTGGAGTCAACCCCCAGGCTCCATTCCTGCAGGTGGCCCCTAATGTGAACTTC                   ATGCACAACCTGTTGCCTATGCAAAACTTGCAACCAACCGGGCAACTTGAGTACAAGGAGCAGTCTC                   TCCTACAGCCGCCCACGCTACAGCTGTTGAATGGAATGGGCCCCCTTGGCCGGAGGGCATCAGATGG                   AGGAGCCAACATCCAACTGCATGCCCAGCAGCTGCTGAAGCGCCCACGGGGACCCTCTCCGCTTGTC                   ACCATGACACCAGCAGTGCCAGCAGTTACCCCTGTGGACGAGGAGAGCTCAGACGGGGAGCCAGACC                   AGGAAGCTGTGCAGAGCTCTACCTACAAGGACTCCAACACTCTGCACCTCCCTACGGAGCGTTTCTC                   CCCTGTGCGCCGGTTCTCAGATGGGGCTGCGAGCATCCAGGCCTTCAAAGCTCACCTGGAAAAAATG                   GGCAACAACAGCAGCATCAAACAGCTGCAGCAGGAGTGTGAGCAGCTGCAGAAGATGTACGGGGGGC                   AGATTGATGAAAGAACCCTGGAGAAGACCCAGCAGCAGCATATGTTATACCAGCAGGAGCAGCACCA                   TCAAATTCTCCAGCAACAAATTCAAGACTCTATCTGTCCTCCTCAGCCATCTCCACCTCTTCAGGCT                   GCATGTGAAAATCAGCCAGCCCTCCTTACCCATCAGCTCCAGAGGTTAAGGATTCAGCCTTCAAGCC                   CACCCCCCAACCACCCCAACAACCATCTCTTCAGGCAGCCCAGTAATAGTCCTCCCCCCATGAGCAG                   TGCCATGATCCAGCCTCACGGGGCTGCATCTTCTTCCCAGTTTCAAGGCTTACCTTCCCGCACTCCA                   ATCTTTCAGCAGCAACCTGAGAACTGTTCCTCTCCTCCCAACGTGGCACTAACCTGCTTGGGTATGC                   AGCAGCCTGCTCAGTCACAGCAGGTCACCATCCAAGTCCAAGAGCCTGTTGACATGCTCAGCAACAT                   GCCAGGCACAGCTGCAGGCTCCAGTGGGCGCGGCATCTCCATCAGCCCCAGTGCTGGTCAGATGCAG                   ATGCAGCACCGTACCAACCTGATGGCCACCCTCAGCTATGGGCACCGTCCCTTGTCCAAGCAGCTGA                   GTGCTGACAGTGCAGAGGCTCACAGCTTGAACGTGAATCGGTTCTCCCCTGCTAACTACGACCAGGC                   GCATTTACACCCCCATCTGTTTTCCGACCAGTCCCGGGGTTCCCCCAGCAGCTACAGCCCTTCAACA                   GGAGTGGGGTTCTCTCCAACCCAAGCCCTGAAAGTCCCTCCACTTGACCAATTCCCCACCTTCCCTC                   CCAGTGCACATCAGCAGCCGCCACACTATACCACGTCGGCACTACAGCAGGCCCTGCTGTCTCCCAC                   GCCGCCAGACTATACAAGACACCAGCAGGTACCCCACATCCTTCAAGGACTGCTTTCTCCCCGGCAT                   TCGCTCACCGGCCACTCGGACATCCGGCTGCCCCCAACAGAGTTTGCACAGCTCATTAAAAGGCAGC                   AGCAACAACGGCAGCAGCAGCAGCAACAGCAGCAACAGCAAGAATACCAGGAACTGTTCACGCACAT                   GAACCAAGGGGATGCCGGGAGTCTGGCTCCCAGCCTTGGGGGACAGAGCATGACAGAGCGCCAGGCT                   TTATCTTATCAAAATGCTGACTCTTATCACCATCACACCAGCCCCCAGCATCTGCTACAAATCAGGG                   CACAAGAATGTGTCTCACAGGCTTCCTCACCCACCCCGCCCCACGGGTATGCTCACCAGCCGGCACT                   GATGCATTCAGAGAGCATGGAGGAGGACTGCTCGTGTGAGGGGGCCAAGGATCGCTTCCAAGACAGT                   AAGAGTTCAAGTACATTGACCAAAGGTTGCCATGACAGCCCTCTGCTCTTGAGTACCGGTGGACCTG                   GGGACCCTGAATCTTTGCTAGGAACTGTGAGTCATGCCCAAGAATTGGGGATACATCCCTATGGTCA                   TCAGCCAACTGCTGCATTCAGTAAAAATAAGGTGCCCAGCAGAGAGCCTGTCATAGGGAACTGCATG                   GATAGAAGTTCTCCAGGACAAGCAGTGGAGCTGCCGGATCACAATGGGCTCGGGTACCCAGCACGCC                   CCTCCGTCCATGAGCACCACAGGCCCCGGGCCCTCCAGAGACACCACACGATCCAGAACAGCGACGA                   TGCTTATGTACAGCTGGATAACTTGCCAGGAATGAGTCTCGTGGCTGGGAAAGCACTTAGCTCTGCC                   CGGATGTCGGATGCAGTTCTCAGTCAGTCTTCGCTCATGGGCAGCCAGCAGTTTCAGGATGGGGAAA                   ATGAGGAATGTGGGGCAAGCCTGGGAGGTCATGAGCACCCAGACCTGAGTGATGGCAGCCAGCATTT                   AAACTCCTCTTGCTATCCATCTACGTGTATTACAGACATTCTGCTCAGCTACAAGCACCCCGAAGTC                   TCCTTCAGCATGGAGCAGGCAGGCGTG TAA   CAAGAAACAGAGAGAGAGCAAGAGGTCCCGAGTCCCC                       TCCTAGTCTTTCATCCTGAATTTGCACACAGGAAAGCGTGTGCCCGGCATGGCCATCCTGATGTTGC                       TGCCGGGATCCCCATGCACCTTGTCCTTCTCCACTGATACTGGCAGCTCGGCTCCTGCACCCAAGAT                       ACCTTGAGTGGAATTCTGCAGTGCAAGAGCCCTTCGTGGGAGCTGTCCCATGTTTCCATGGTCCCCA                       GTCTCCCCTCCACTTGGTGGGGTCACCAACTACTCACCACAAGGGGGCTTACCAACAAAGCCCTAAA                       AAGCTGTTGACTTATCTGCGCTTGTTCCAACTCTTATGCCCCCAACCTGCCCTACCACCACCACGCC                       CTCAGCCTGATGTGTTTACATGGTACTGTATGTATGGGAGAGCAGACTGCACCCTCCAGCAACAACA                       AATGAAAGCCAGTGAGCCTACTAACCGTGCCATCTTGCAAACTACACTTTAAAAAAAACTCATTGCT                       TTGTATTGTAGTAACCAATATGTGCAGTATACGTTGAATGTATATGAACATACTTTCCTATTTCTGT                       TCTTTGAAAATGTCAGAAATATTTTTTTCTTTCTCATTTTATGTTGAACTAAAAAGGATTAAAAAAA                       AAATCTCC                                               ORF Start: ATG at 420       ORF Stop: TAA at 4383               SEQ ID NO: 162   1321 aa   MW at 144850.0kD                         NOV37d,   MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPAPASRGPMPARIGYYE           CG89709-04       Protein Sequence   IDRTIGKGNFAXTVKRATHLVTKAKVAIKHDKTQLDEENLKKIFREVQIMKMLCHPHIIRLYQVMET                   ERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNTVHRDLKAENLLLDANLN                   IKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLCVVLYVLVCGALPFDGSTL                   QNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQ                   LKEERQVDPLNEDVLLAMEDMGLDKEQTLQSLRSDAYDHYSAIYSLLCDRHKRHKTLRLGALPSMPR                   ALAFQAPVNIQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDEGEEPSPEALVRYLSMRRHT                   VGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQNLQPTGQLEYKEQSLLQPPT                   LQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTPAVPAVTPVDEESSDGEPDQEAVQS                   STYKDSNTLHLFTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQLQQECEQLQKMYGGQIDERT                   LEKTQQQHMLYQQEQHHQILQQQIQDSICPPQPSPPLQAACENQPALLTHQLQRLRIQPSSPPPNHP                   NNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENCSSPPNVALTCLGMQQPAQS                   QQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSAGQMQMQHRTNLMATLSYGHRPLSKQLSADSAE                   AHSLNVNRFSPANYDQAHLHPHLFSDQSRGSPSSYSPSTGVGBSPTQALKVPPLDQFPTFPPSAHQQ                   PPHYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSLTGHSDIRLPPTEFAQLIKRQQQQRQQ                   QQQQQQQQEYQELFRHMNQGDAGSLAPSLGGQSMTERQALSYQNADSYHHHTSPQHLLQIRAQECVS                   QASSPTPPHGYAHQPALMHSESMEEDCSCEGAKDGFQDSKSSSTLTKGCHDSPLLLSTGGPGDPESL                   LGTVSHAQELGIHPYGHQPTAAFSKNKVPSREPVIGNCMDRSSPGQAVELPDHNCLGYPARFSVHEH                   HRPRALQRHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQSSLMCSQQFQDGENEECGA                   SLGGHEHPDLSDGSQHLNSSCYPSTCITDILLSYXHPEVSFSMEQAGV                                         SEQ ID NO: 163   3807 bp                             NOV37e,   ATGGCGGCGGCGGCGGCGAGCGGAGCTGGCGGGGCTGCCGGGGCCGGGACTGGGGGAGCCGGGCCCG           CG89709-01       DNA Sequence   CGGGCCGCCTGCTGCCTCCGCCCGCGCCGGGGTCCCCAGCCGCCCCCGCTGCCGTGTCCCCTGCGGC                   CGGCCAGCCGCGTCCCCCAGCCCCGGCCTCCCGCGGACCCATGCCCGCCCCTATCGGCTACTACGAG                   ATCGACCGCACCATCGGCAAGGGCAACTTCGCGGTGGTCAAGCGGGCCACGCACCTCGTCACCAAGG                   CCAAGGTTGCTATCAAGATCATAGATAAGACCCAGCTGGATGAAQAAAACTTGAAGAAGATTTTCCG                   GGAAGTTCAAATTATGAAGATGCTTTGCCACCCCCATATCATCAGGCTCTACCAGGTTATGGAGACA                   GAACGGATGATTTATCTGGTCACAGAATATGCTAGTGGAGGCGAAATATTTCACCACCTGGTGGCCC                   ATGGTAGAATGGCAGAAAAGGAGGCACGTCGGAAGTTCAAACAGATCGTCACAGCTGTCTATTTTTG                   TCACTGTCCGAACATTGTTCATCGTGATTTAAAAGCTGAAAATTTACTTCTGGATGCCAATCTGAAT                   ATCAAAATAGCAGATTTTGGTTTCAGTAACCTCTTCACTCCTGGGCAGCTACTGAAGACCTGGTGTG                   GCAGCCCTCCCTATGCTGCACCTGAACTCTTTGAAGGAAAAGAATATGATGGGCCCAAAGTGGACAT                   CTGGAGCCTTGGAGTTGTCCTCTACGTGCTTGTGTGCGGTGCCCTGCCATTTCATGGAAGCACACTG                   CAGAATCTGCGGGCCCGCGTGCTGAGTGGAAAGTTCCGCATCCCATTTTTTATGTCCACAGAATGTG                   AGCATTTGATCCGCCATATGTTGGTGTTAGATCCCAATAAGCGCCTCTCCATGGAGCAGATCTGCAA                   GCACAAGTGGATGAGCTAGGGGACGCCGATCCCAACTTTGACAGGTTAATTAGCTGAATGCCAACAA                   CTAAAGGAAGAAAGACAGGTGGACCCCCTGAATGAGGATGTCCTCTTGGCCATGGAGGACATGGGAC                   TGGACAAAGAACAGACACTGCAGGCGGAGCAGGCAGGTACTGCTATGAACATCAGCGTTCCCCAGGT                   GCAGCTGATCAACCCAGAGAACCAAATTGTCGAGCCGGATGGGACACTGAATTTGGACAGTGATGAG                   GGTGAAGAGCCTTCCCCTGAAGCATTGGTGCGCTATTTGTCAATGAGGAGGCACACAGTGGGTGTGG                   CTGACCCACGCACGGAAGTTATGGAAGATCTGCAGAAGCTCCTACCTGGCTTTCCTGGAGTCAACCC                   CCAGGCTCCATTCCTGCAGGTGGCCCCTAATGTGAACTTCATGCACAACCTGTTGCCTATGCAAAAC                   TTGCAACCAACCGGGCAACTTGAGTACAAGGAGCAGTCTCTCCTACAGCCGCCCACGCTACAGCTGT                   TGAATCCAATGGCCCCCCTTGGCCGGAGGGCATCAGATGGAGGAGCCAACATCCAACTCCATGCCCA                   GCAGCTGCTGAAGCGCCCACGGGGACCCTCTCCGCTTGTCACCATGACACCAGCAGTGCCAGCAGTT                   ACCCCTGTGGACGAGGAGAGCTCAGACGGGGACCCAGACCACGAAGCTGTGCAGAGCTCTACCTACA                   AGGACTCCAACACTCTGCACCTCCCTACGGAGCGTTTCTCCCCTGTGCGCCGGTTCTCAGATGGGGC                   TGCGAGCATCCAGGCCTTCAAAGCTCACCTGGAAAAAATGCGCAACAACAGCAGCATCAAACAGCTG                   CAGCAGGAGTGTGAGCAGCTGCAGAAGATGTACGGGGGGCAGATTGATGAAAGAACCCTGGAGAAGA                   CCCAGCAGCAGCATATGTTATACCAGCAGGAGCAGCACCATCAAATTCTCCAGCAACAAATTCAAGA                   CTCTATCTGTCCTCCTCAGCCATCTCCACCTCTTCAGGCTGCATGTGAAAATCAGCCAGCCCTCCTT                   ACCCATCAGCTCCAGAGGTTAAGGATTCAGCCTTCAAGCCCACCCCCCAACCACCCCAACAACCATc                   TCTTCAGOCAGCCCAGTAATAGTCCTCCCCCCATGAGCAGTGCCATGATCCAGCCTCACGGGGCTGC                   ATCTTCTTCCCAGTTTCAAGGCTTACCTTCCCCCAGTGCTTCTTTCAGCAGCACCTGAGTAGTCTGT                   TCCTCTCCTCCCAACGTGGCACTAACCTGCTTGGGTATGCAGCAGCCTGCTCAGTCACAGCAGGTCA                   CCATCCAAGTCCAAGAGCCTGTTGACATGCTCAGCAACATGCCAGCCACAGCTGCAGGCTCCAGTGG                   GCGCGGCATCTCCATCAGCCCCAGTGCTGGTCAGATGCAGATGCAGCACCGTACCAACCTGATGGCC                   ACCCTCAGCTATGGGCACCGTCCCTTGTCCAAGCAGCTGAGTGCTGACTAAGTCCAGACTCACAGTG                   CACATCAGCAGCCGCCACACTATACCACGTCGGCACTACAGCAGGCCCTGCTGTCTCCCACGCCGCC                   AGACTATACAAGACACCAGCAGGTACCCCACATCCTTCAAGGACTCCTTTCTCCCCGGCATTCGCTC                   ACCGGCCACTCGGACATCCGGCTGCCCCCAACAGAGTTTGCACAGCTCATTAACGCAGCAGCAAGAC                   AACGGCAGCAGCAGCAGCAACAGCAGCAACAGCAAGAATACCAGGAACTGTTCAGGCACATGAACCA                   AGGGCATGCGGGGAGTCTGGCTCCCAGCCTTGGGGGACAGAGCATGACAGAGCGCCAGGCTTTATCT                   TATCAAAATGCTGACTCTTATCACCACACGATCCAGAACAGCGACGATGCTTATGTACAGCTAAATA                   ACTTGCCAGGAATGAGTCTCGTGGCTGGGAAAGCACTTAGCTCTGCCCGGATGTCGGATGCAGTTCT                   CAGTCAGTCTTCGCTCATGGGCAGCCAGCAGTTTCAGGATGGGGAAAATGAGGAATGTGGGGCAAGC                   CTGGGAGGTCATGAGCACCCAGACCTGAGTGATGGCAGCCAGCATTTAAACTCCTCTTGCTATCCAT                   CTACGTGTATTACAGACATTCTGCTCAGCTACAAGCACCCCGAAGTCTCCTTCAGCATAAAGCAGGC                   AGGCGTG TAA   CAGAAACAGAGAGACAGCAIXGAGGTCCCGAGTCCCCTCCTAGTCTTTCATCCTGGG                       TTTGCACAGAGGAAAGCGGGTGCCCGGCATGGCCATCCTGATGTTGCTGGCGGGATCCCCATGCACC                       TTGTCCTTCTCCACTGATACTGCCAGCTCGGCTCCTGGACCCAAGATCCCTTGAGTGGAGTTCTGCA                       GTGCAAGAGCCCTTCGTGGGAGCTGTCCCATGTTTCCATGGTCCCCAGTCTCCCCTCCACTTGGTGC                       GGTCACCAACTACTCACCAGAACGGGGCTTACCAAGAAAGCCCTAAAAAGCTGTTGACTTATCTGCG                       CTTGTTCCAACTCTTATGCCCCCAACCTGCCCTACCACCACCACGCGCTCAGCCTGATGTGTTTACA                       TGGTACTGTATGTATGGGAGAGCAGACTGCACCCTCCAGCAACAACAGATGAAGCCAGTGAGCCTAA                       CTAACCGTGCCATCTTGCAAACTACACTTTAAAAAAAACTCATTGCTTTGTATTGTAGTAACCAATA                       TGTGCAGTATACGTTGAATGTATATGAACATACTTTCCTATTTCTGTTCTTTGAAAATGTCAGAAAT                       ATTTTTTTCTTTCTCATTTTATGTTGAACTAAAAGCATTAAAAAAAAAAAATCTCC                                               ORF Start: ATG at 1       ORF Stop: TAA at 3157               SEQ ID NO: 164   1052 aa   MW at 115587.7kD                         NOV37e,   MAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQRPRPPAPASRGPMPARIGYYE           CG89709-01       Protein Sequence   IDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIFREVQIMKMLCHPHIIRLYQVMET                   ERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFKQIVTAVYFCHCRNIVHRDLKAENLLLDANLN                   IKIADFGFSNLFTPGQLLKTWCGSPPYAAPELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTL                   QNLRARVLSGKFRIPFFMSTECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQ                   LKEERQVDPLNEDVLLAMEDMGLDKEQTLQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDE                   GEEPSPEALVRYLSMRRHTVGVADFRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFNTDLLPMQN                   LQPTGQLEYKEQSLLQPFTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTTAVPAV                   TPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKMGNNSSIKQL                   QQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQTQDSICPPQPSPPLQAACENQPALL                   THQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPHGAASSSQFQGLPSRSAIFQQQPENC                   SSPPNVALTCLGMQQPAQSQQVTIQVQEPVDMLSNMPGTAAGSSGRGISISPSAGQMQMQHRTNLMA                   TLSYGHRPLSKQLSADSAEAHSAHQQPPHYTTSALQQALLSPTPPDYTRHQQVPHILQGLLSPRHSL                   TGHSDIRLPPTEFAQLIKRQQQQRQQQQQQQQQQEYQELFRHMNQGDAGSLAPSLGGQSMTERQALS                   YQNADSYHHTIQNSDDAYVQLDNLPGMSLVAGKALSSARMSDAVLSQSSLMGSQQFQDGENEECGAS                   LGGHEHPDLSDGSQHLNSSCYPSTCITDILLSYKHPEVSFSMEQAGV                  
 
     [0550] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 37B.  
               TABLE 37B                          Comparison of NOV37a against NOV37b through NOV37e.                                         Identities/                   Similarities for           Protein   NOV37a Residues/   the Matched           Sequence   Match Residues   Region                       NOV37b   62 . . . 1052   886/1051 (84%)                62 . . . 1112   887/1051 (84%)            NOV37c   62 . . . 947    781/946 (82%)               62 . . . 1007   782/946 (82%)           NOV37d   62 . . . 947    781/994 (78%)               62 . . . 1055   782/994 (78%)           NOV37e   62 . . . 1052   892/991 (90%)               62 . . . 1052   892/991 (90%)                      
 
     [0551] Further analysis of the NOV37a protein yielded the following properties shown in Table 37C.  
               TABLE 37C                       Protein Sequence Properties NOV37a                                        PSort   0.6000 probability located in endoplasmic reticulum       analysis:   (membrane); 0.3000 probability located in microbody           (peroxisome); 0.1000 probability located in mitochondrial           inner membrane; 0.1000 probability located in plasma           membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0552] A search of the NOV37a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 37D.  
               TABLE 37D                          Geneseq Results for NOV37a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV37a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAB43286   Human ORFX ORF3050   11 . . . 1052   1022/1102 (92%)    0.0           polypeptide sequence SEQ    1 . . . 1102   1026/1102 (92%)            ID NO: 6100 -  Homo               sapiens , 1102 aa.           [WO200058473-A2,           05 OCT. 2000]       AAE21712   Human PKIN-7 protein -   1 . . . 947   940/1103 (85%)    0.0             Homo sapiens , 1369 aa.    1 . . . 1103   941/1103 (85%)            [WO200218557-A2,           07 MAR. 2002]       AAB65626   Novel protein kinase, SEQ   59 . . . 947    821/996 (82%)   0.0           ID NO: 152 -  Homo sapiens ,   1 . . . 985   831/996 (83%)           1251 aa.           [WO200073469-A2,           07 DEC. 2000]       ABG08443   Novel human diagnostic   204 . . . 830    597/776 (76%)   0.0           protein #8434 -  Homo     43 . . . 818    603/776 (76%)             sapiens , 1265 aa.           [WO200175067-A2,           11 OCT. 2001]       AAB65631   Novel protein kinase, SEQ   51 . . . 368    202/318 (63%)   e−115           ID NO: 158 -  Homo sapiens ,   7 . . . 319   251/318 (78%)           926 aa. [WO200073469-A2,           07 DEC. 2000]                  
 
     [0553] In a BLAST search of public sequence datbases, the NOV37a protein was found to have homology to the proteins shown in the BLASTP data in Table 37E.  
               TABLE 37E                          Public BLASTP Results for NOV37a                                             Identities/           Protein           Similarities for       Accession       NOV37a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value               Q9Y2K2   KIAA0999 protein -  Homo     6 . . . 947   935/1050 (89%)    0.0             sapiens  (Human), 1371 aa   56 . . . 1105   937/1050 (89%)            (fragment).       Q9CYD5   5730525O22Rik protein -   117 . . . 554    425/486 (87%)   0.0             Mus musculus  (Mouse), 487   1 . . . 486   433/486 (88%)           aa.       BAA34501   KIAA0781 protein -  Homo     22 . . . 368    210/347 (60%)   e−117             sapiens  (Human), 950 aa   2 . . . 343   261/347 (74%)           (fragment).       BAB91442   KIAA0781 protein -  Homo     51 . . . 368    203/318 (63%)   e−116             sapiens  (Human), 346 aa   5 . . . 317   252/318 (78%)           (fragment).       Q9H0K1   Hypothetical 103.9 kDa   51 . . . 368    203/318 (63%)   e−116           protein (KIAA0781 protein) -   7 . . . 319   252/318 (78%)             Homo sapiens  (Human),           926 aa.                  
 
     [0554] PFam analysis predicts that the NOV37a protein contains the domains shown in the Table 37F.  
               TABLE 37F                          Domain Analysis of NOV37a                                             Identities/                   NOV37a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       pkinase   66 . . . 317   106/291 (36%)   4.7e−97                   219/291 (75%)                      
 
     Example 38  
     [0555] The NOV38 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 38A.  
               TABLE 38A                       NOV38 Sequence Analysis                                                    SEQ ID NO: 165   2927 bp                             NOV38a,     CCGGGTGGGCTCCAGGCGGCCGGTCCCCGGCCTCCCCCC   ATG GCCACCGCCCCCTCTTATCCCGCCG           CG90879-01       DNA Sequence   GGCTCCCTGGCTCTCCCGGGCCGGGGTCTCCTCCGCCCCCCGGCGGCCTAGAGCTGCAGTCGCCGCC                   ACCGCTACTGCCCCAGATCCCGGCCCCGGGTTCCGGGGTCTCCTTTCACATCCAGATCGGGCTGACC                   CGCGAGTTCGTGCTGTTGCCCGCCGCCTCCGAGCTGGCTCATGTGCGCAGCTGGCCTGGTTCCATCG                   TGGACCAGAAGTTCCCTGAGTGTGGCTTCTACGGCCTTTACCACAAGATCCTGCTTTTACAGCATGA                   CCCCACCTCGGCCAACCTCCTGCAGCTGGTGCGCTCGTCCGGAGACATCCACGAGGGCGTACCTGTG                   GAGGTGGTGCTGTCGGCCTCGGCCACCTTCGAGGACTTCCAGATCCGCCCGCACGCCCTCACGGTGC                   ACTCCTATCGGGCGCCTGCCTTCTGTGATCACTGCGGGGAGATGCTCTTCGGCCTAGTGCGCCAGGG                   CCTCAAGTGCGATGGCTGCGGGCTGAACTACCACAAGCGCTGTGCCTTCAGCATCCCCAACAACTGT                   AGTGGGGCCCGCAAACGGCGCCTGTCATCCACGTCTCTGGCCAGTGGCCACTCGGTGCGCCTCGGCA                   CCTCCGAGTCCCTGCCCTGCACGGCTGAAGAGCTCAGCCGTAGCACCACCGATCTCCTGCCTCGCCG                   TCCCCCGTCATCCTCTTCCTCCTCTTCTGCCTCATCGTATACGGGCCGCCCCATTGAGCTGGACTAG                   ATGCTGCTCTCCAAGGTCAAGGTGCCGCACACCTTCCTCATCCACAGCTATACACGGCCCACCGTTT                   GCCAGGCTTGCAAGAAACTCCTCAAGGGCCTCTTCCGGCAGGGCCTGCAATGCAAAGACTGCAAGTT                   TAACTGTCACAAACGCTGCGCCACCCGCGTCCCTAATGACTGCCTGGGGGAGGCCCTTATCAATGGA                   GACCCCTCTGATGCCTCCGTCCCCACAGATGTGCCGATGGAGGAGGCCACCGATTTCAGCGAGGCTG                   ACAAGAGCGCCCTCATGGATGAGTCAGAGGACTCCGGTGTCATCCCTGGCTCCCACTCAGAGAATGC                   GCTCCACGCCAGTCAGGAGGAGGAAGGCGAGGGAGGCTAGGCCCAGAGCTCCCTGGGGTACATCCCC                   CTAATGAGGGTGGTGCAATCGGTGCGACACACGACGCGGAAATCCAGCACCACGCTGCGGGAGGGTT                   GGGTGGTTCATTACAGCAACAAGGACACGCTGAGAAAGCGGCACTATTGGCGCCTGGACTGCAAGTG                   TATCACGCTCTTCCAGAACAACACCACCAACAGATACTATAAGGAATTCCGCTGTCAGATTCATCTC                   ACGGTGCAGTCCGCCCAGAACTTCAGCCTTGTGCCGCCGGGCACCAACCCACACTGCTTTGAGATCG                   TCACTGCCAATGCCACCTACTTCGTGGGCGAGATGCCTGGCGGGACTCCGGGTGGGCCAAGTGGGCA                   GGGGGCTGAGGCCGCCCGGGGCTGGGAGACAGCCATCCGCCAGGCCCTGATGCCCGTCATCCTTCAG                   GACGCACCCAGCGCCCCAGGCCACGCGCCCCACAGACAAGCTTCTCTGAGCATCTCTGTGTCCGTCA                   GTCAGATCCAAGAGAATGTGGACATTGCCACTGTCTACCAGATCTTCCCTGACGACGTGCTGGGCTC                   AGGGCAGTTTGGAGTGGTCTATGGAGGGAAACACCGGAAGACAGGCCGGGACGTGGCAGTTAAGGTC                   ATTGACAAACTGCGCTTCCCTACCAAGCAGGAGAGCCAGCTCCGGAATGAAGTGGCCATTCTGCAGA                   GCCTGCGGCATCCCGGGATCGTGAACCTGGAGTGCATGTTCGAGACGCCTGAGTGACTGTTTGTGGT                   GATGGAGAAGCTGCATGGGGACATGTTGGAGATGATCCTGTCCAGTGAGTAGGGCCGGCTGCCTGAG                   CGCCTCACCAAGTTCCTCATCACCCAGATCCTGGTGGCTTTCAGACACCTTCACTTCTAGTACATTG                   TCCACTGTGACTTGAAACCAGAAAACGTGTTGCTGGCATCAGCAGACCCATTTCCTCAGGTGAAGCT                   GTGTGACTTTGGCTTTGCTCGCATCATCGGCGAGAAGTCGTTCCGCCGCTCAGTGGTGGGCACGCCG                   GCCTACCTGGCACCCGAGCTGCTGCTCAACCAGGGCTACTACCGCTCGCTGGACATGTGGTCAGTGG                   GCGTGATCATGTACGTCAGCCTCAGCGGCACCTTCCCTTTCAACGAGGATGAGGACATCAATGACCA                   GATCCAGAACGCCGCCTTCATGTACCCCGCCAGCCCCTGGAGCCACATCTCAGCTTAAGCCATTGAC                   CTCATCAACAACCTGCTGCAGGTGAAGATGCGCAAACGCTACAGCGTGGACAAATCTCTCAGCCACC                   CCTGGTTACAGGAGTACCAGACGTGGCTGGACCTCCGAOAGCTGGAGGGGAAGATGGGAGAGCGATA                   CATCACGCATGAGAGTGACGACGCGCGCTGCGAGCAGTTTGCAGCAGAGCATCCGCTGCCTGGGTCT                   GGGCTGCCCACGGACAGGGATCTCGGTGGGGCCTGTCCACCACAGGACCACGACATGCAGGGGCTTA                   CGGAGCGCATCAGTGTTCTCTGAGGTCCTGTGCCCTCGTCCAGCTGCTGCCCTCCACAGCGGTTCTT                   CACAGGATCCCAGCAATGAACTGTTCTAGGGAAAGTOGCTTCCTGCCCAAACTGGATTAGACACGTG                   GGGAGTGGGGTGGGGGGAGCTATTTCCAAGGCCCCTCCCTGTTTCCCCAGCAATTAAAACGGACTCA                   TCTCTGGCCCCATGGCCTTGATCTCAAAAAAAAAAAAAAAAAAAAA                                             ORF Start: ATG at 40       ORF Stop: TGA at 2701               SEQ ID NO: 166   887 aa   MW at 97590.9kD                         NOV38a,   MATAPSYPAGLPGSPGPGSPPPGGLELQSPPPLLPQIPAPGSGVSFHIQIGLTREFVLRLPAASELA           CG90879-01       Protein Sequence   HVKQLACSIVDQKFPECGFYGLYDKILLFKHDPTSANLLQLVRSSGDIQEGDLVEVVLSASATFEDF                   QTRPHALTVHSYRAPAFCDHCGEMLFGLVRQGLKCDGCGLNYHKRCAYSIPNNCSGARKRRLSSTSL                   ASGHSVRLGTSESLPCTAEELSRSTTELLPRRPPSSSSSSSASSYTGRPIELDKMLLSKVKVFHTFL                   IHSYTRPTVCQACKKLLKGLFRQGLQCKDCKFNCHKRCATRVPNDCLGKRAINGDPSDASVPTDVPM                   EEATDFSEADKSALMDESEDSGVIPGSHSENALHASEEEEGEGGKAQSSLGYIPLMRVVQSVRHTTR                   RSSTTLREGWVVHYSNKDTLRKRHYWRLDCKCITLFQNNTTNRYYKEIPLSEILTVESAQNFSLVPP                   GTNPHCFEIVTANATYFVGEMPGGTPGGPSCQGAEAARGWETAIRQALMPVILQDAPSAPGKGPHRQ                   ASLSISVSNSQIQENVDIATVYQIFPDEVLGSGQFGVVYGGKHRKTGRDVATKVIDKLRFPTKQESQ                   LRNEVAILQSLRHPGIVNLECMFETPEKVFVVMEKLHGDMLEMILSSEKGRLPERLTKULITQILVA                   LRHLHFKNIVHCDLKPENVLLASALPFPQVKLCDFGFKHIGEKSFRRSVVGTPAYLAPEJVLLNQGY                   NRSLDMWSVGVINYVSLSGTFPFNEDEDINDQTQNAAFNYPASPWSHISAGAIDLIARLLQVKMRKR                   YSVDKSLSHPWLQEYQTWLDLRELEGKMGERYITHESDDARWEQFKGEHPLPGSGLPTDRDLGGACP                   PQDHDMQGLAERISVL                  
 
     [0556] Further analysis of the NOV38a protein yielded the following properties shown in Table 38B.  
               TABLE 38B                       Protein Sequence Properties NOV38a                                        PSort   0.9600 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located           in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0557] A search of the NOV38a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 38C.  
               TABLE 38C                          Geneseq Results for NOV38a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV38a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value                                         AAE22768   Human protein kinase D2   1 . . . 887   878/887 (98%)   0.0           (PKD2) -  Homo sapiens , 878   1 . . . 878   878/887 (98%)           aa. [WO200224947-A2,           28 MAR. 2002]       AAE22719   Human kinase protein -   1 . . . 887   878/887 (98%)   0.0             Homo sapiens , 878 aa.   1 . . . 878   878/887 (98%)           [WO200222795-A2,           21 MAR. 2002]       AAE11771   Human kinase (PKIN)-5   1 . . . 887   878/887 (98%)   0.0           protein -  Homo sapiens , 878   1 . . . 878   878/887 (98%)           aa. [WO200181555-A2,           01 NOV. 2001]       AAB65604   Novel protein kinase, SEQ   5 . . . 887   872/884 (98%)   0.0           ID NO: 130 -  Homo sapiens ,   104 . . . 978    872/884 (98%)           978 aa. [WO200073469-A2,           07 DEC. 2000]       AAU17318   Novel signal transduction   58 . . . 887    820/830 (98%)   0.0           pathway protein, Seq ID 883 -   1 . . . 821   820/830 (98%)             Homo sapiens , 821 aa.           [WO200154733-A1,           02 AUG. 2001]                  
 
     [0558] In a BLAST search of public sequence datbases, the NOV38a protein was found to have homology to the proteins shown in the BLASTP data in Table 38D.  
               TABLE 38D                          Public BLASTP Results for NOV38a                                             Identities/           Protein           Similarities for       Accession       NOV38a Residues/   the Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         Q9BZL6   Protein kinase C, D2 type (EC   1 . . . 887   878/887 (98%)   0.0           2.7.1.-) (nPKC-D2) (Protein   1 . . . 878   878/887 (98%)           kinase D2) (Protein           HSPC187) -  Homo sapiens             (Human), 878 aa.       Q15139   Protein kinase C, mu type   2 . . .887    626/918 (68%)   0.0           (EC 2.7.1.-) (nPKC-mu)   19 . . . 912    719/918 (78%)           (Protein kinase D) -             Homo sapiens  (Human), 912 aa.       Q62101   Protein kinase C, mu type   2 . . . 887   621/918 (67%)   0.0           (EC 2.7.1.-) (nPKC-mu)   19 . . . 918    719/918 (77%)           (Protein kinase D) -  Mus               musculus  (Mouse), 918 aa.       O94806   Protein kinase C, nu type (EC   8 . . . 855   573/861 (66%)   0.0           2.7.1.-) (nPKC-nu) (Protein   20 . . . 871    665/861 (76%)           kinase EPK2) -  Homo sapiens             (Human), 890 aa.       T08777   probable protein kinase C (EC   346 . . . 887     542/542 (100%)   0.0           2.7.1.-) mu - human, 542 aa   1 . . . 542    542/542 (100%)           (fragment).                  
 
     [0559] PFam analysis predicts that the NOV38a protein contains the domains shown in the Table 38E.  
               TABLE 38E                          Domain Analysis of NOV38a                                             Identities/                   NOV38a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       DAG_PE-bind   139 . . . 188   28/51 (55%)   1.4e−16                   41/51 (80%)           DAG_PE-bind   265 . . . 314   23/51 (45%)   3.3e−20                   45/51 (88%)           PH   407 . . . 487   19/81 (23%)   2.2e−08                   58/81 (72%)           pkinase   560 . . . 816   96/297 (32%)    3.4e−75                   200/297 (67%)                       
 
     Example 39  
     [0560] The NOV39 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 39A.  
               TABLE 39A                       NOV39 Sequence Analysis                                                    SEQ ID NO: 167   2292 bp                             NOV39a,   ATGCATACAGGAGGAGAGACTTCAGCATGCAAACCTTCATCTGTCCGGCTTGCACCGTCGTTCTCAT           CG96334-01       DNA Sequence   TCCATGCTGCTGGCCTTCAGATGGCTGCACAGATGCCCCACTCACACCAGTACAGTGACCGTCGCCA                   GCCGAGCATAAGTGACCAGCAGGTGTCTGCCTTACCATATTCTGACCAGATTCAGCAACCTCTAACT                   AACCAGGTGATGCCTGACATTGTCATGTTACAGAGGCGGATGCCCCAAACCTTCCGTGATCCAGCAA                   CTGCTCCTCTGAGAAAACTCTCTGTGGACTTGATCAAAACATACAAGCATATTAATGAGGTTTACTA                   TGCAAAAAAGAAGCGAAGACACCAACAGGGCCGGGGGGACGATTCCAGTCATAAGAAGGAGCGGAAG                   GTTTACAATGATGGTTACGATGATGATAACTATGATTATATTGTAAAAAACGGCOAAAAGTGGATGG                   ATCGGTATGAAATCGACTCCTTAATAGGCAAAGGTTCATTTGGACAGGTTGTGAAAGCTTATGACAG                   AGTGGAGCAAGAATGGGTCCCCATTAAAATCATCAAGAACAAGAAAGCGTTTCTGAATCAAGCCCAG                   ATAGAAGTGCGGCTGCTTGAGCTCATGAACAAACACGACACTGAAATGAAGTACTACATAGTGCATT                   TGAAACGCCACTTTATGTTTCGAAACCATCTCTGTTTAGTGTTTGAAATGCTGTCCTATAATCTCTA                   TGATTTGTTGAGAAACACCAACTTCCGAOCGGTCTCTTTGAACCTAACACGAAAGTTTGCGCAACAG                   ATGTGCACAGCATTGCTTTTTCTTGCGACTCCAGAACTTAGTATCATTCACTGTGACTTAAAGCCTG                   AGAACATCCTTCTTTGTAACCCCAAACGCAGTGCAATCAAGATAGTTGACTTTGGCAGTTCTTGTCA                   GTTGGGGCAGAGGATATACCAGTATATTCAGAGTCGCTTTTATCGGTCTCCAGAGGTGCTACTGGGA                   ATGCCTTATGACCTTGCCATTOATATGTGGTCCCTCGGGTGTATTTTGGTTGAAATGCACACTGGAG                   AACCTCTGTTCAGTGGTGCCAATGAGGTAGATCAGATGAATAAAATACTGGAAGTTCTGGGTATTCC                   ACCTGCTCATATTCTTGACCAAGCACCAAAAGCAAGAAAGTTCTTTGAGAATTTGCCAGATGGCACT                   TGGAACTPAAAGAAGACCAAAGATGGAAAACGGGAGTACAAACCACCAGGAACCCGTAAACTTCATA                   ACATTCTTGGAGTGGAAACAGGAGGACCTGGTGGGCGACGTGCTGGGGAGTCAGGTCATACGGTCGC                   TGACTACTTGAAGTTCAAAGACCTCATTTTAAGGATGCTTGATTATGACCCCAAAACTCGAATTCAA                   CCTTATTATGCTCTGCAGCACAGTTTCTTCAAGAAAACAGCTGATGAAGGTACAAATACAACTAATA                   GTCTATCTACAAGCCCCGCCATGGACCAGTCTCAGTCTTCGCGCACCACCTCCAGTACATCGTCAAG                   CTCAGGTGGCTCATCGGGGACAAGCAACAGTGGGAGAGCCCGGTCGGATCCGACGCACCAGCATCGG                   CACAGTGGTCGGCACTTCACAGCTGCCGTGCAGGCCATGGACTGCGAGACACACAGTCCCCAGGTGC                   GTCAGCAATTTCCTGCTCCTCTTGGTTGGTCAGGCACTGAAGCTCCTACACAGGTCACTGTTGAAAC                   TCATCCTGTTCAAGAAACAACCTTTCATGTAGGCCCTCAACAGAATGCATTGCATCATCACCATGGT                   AACAGTTCCCATCACCATCACCACCACCACCACCATCACCACCACCATGGACAACAAGCCTTGGGTA                   ACCGGACCACGCCAAGCGTCTACAATTCTCCAACGAATAGCTCCTCTACCCAAGATTCTATGGAGGT                   TGGCCACAGTCACCACTCCATGACATCCCTGTCTTCCTCAACGACTTCTTCCTCGACATCTTCCTCC                   TCTACTGGTAACCAAGGCAATCAGCCCTACCAGAATCGCCCAGTGGCTGCTAATACCTTGGACTTTG                   GACAGAATGGAGCTATGGACGTTAATTTGACCGTCTACTCCAATCCCCGCCAAGAGACTGGCATAGC                   TGGACATCCAACATACCAATTTTCTGCTAATACAGGTCCTGCACATTACATGACTGAAGGACATCTG                   ACAATGAGGCAAGGGGCTGATAGAGAAGAGTCCCCCATGACAGGAGTTTGTGTGCAACAGAGTCCTG                   TAGCTAGCTCG TGA                                               ORF Start: ATG at 1       ORF Stop: TGA at 2290               SEQ ID NO: 168   763 aa   MW at 85606.2kD                         NOV39a,   MHTGGETSACKPSSVRLAPSFSFHAAGLQMAAQMPHSHQYSDRRQPSISDQQVSALPYSDQIQQPLT           CG96334-01       Protein Sequence   NQVMPDIVMLQRRMPQTFRDPATAPLRKLSVDLIKTYKHINEVYYAXKKRRHQQGRGDDSSHKKERK                   VYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQ                   IEVRLLELMNKHDTEMXYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQ                   MCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRTYRSPEVLLG                   MPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFENLPDGT                   WNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQ                   PYYALQHSFFKKTADEGThTSNSVSTSPAMEQSQSSGTTSSTSSSSGGSSGTSNSGRARSDPTHQHR                   HSGGHFTAAVQAMDCETHSPQVRQQFPAPLGWSGTEAPTQVTVETHPVQETTFHVGPQQNALHHHHG                   NSSHHHHHHHHHHHHHGQQALGNRTRPRVYNSPTNSSSTQDSMEVGHSHHSMTSLSSSTTSSSTSSS                   STGNQGNQPYQNRPVAANTLDFGQNGAMDVNLTVYSNPRQETGIAGHPTYQFSANTGPAHYMTEGHL                   TMRQGADREESPMTGVCVQQSPVASS                                         SEQ ID NO: 169   1369 bp                             NOV39b,     GACTTGAAAGAAGACG   ATG CATACAGGAGGAGACACTTCAGCATGCAAACCTTCATCTGTTCGGCTT           CG96334-02       DNA Sequence   GCACCGTCATTTTCATTCCATGCTGCTCGCCTTCAGATCGCTGGACAGATGCCCCATTCACATCAGT                   ACAGTGACCGTCGCCAGCCAAACATAAGTGACCAACAGGTTTCTGCCTTATCATATTCTGACCAGAT                   TCAGCAACCTCTAACTAACCAGAGGCGGATGCCCCAAACCTTCCGTGACCCAGCAACTGCTCCCCTG                   AGAAAACTTTCTGTTGACTTGATCAAAACATACAAGCATATTAATGAOGAGTACAAACCACCAGGAA                   CCCGTAAACTTCATAACATTCTTGGAGTGGAAACAGGAGGACCTGGTGGGCGACGTGCTGGGGAGTC                   AGGTCATACGGTCGCTCACTACTTGAAGTTCAAAGACCTCATTTTAAGGATGCTTGATTAPGACCCC                   AAAACTCGAATTCAACCTTATTATGCTCTGCAGCACAGTTTCTTCAAGAAAACAGCTGATGAAGGTA                   CAAATACAAGTAATAGTGTATCTACAAGCCCCGCCATGGAGCAGTCTCAGTCTTCGGGCACCACCTC                   CAGTACATCGTCAAGCTCAGGTGGCTCATCGGGGACAAGCAACAGTGGGAGAGCCCGGTCCGATCCG                   ACGCACCAGCATCGGCACAGTGGTGGGCACTTCACAGCTGCCGTGCAGGCCATGGACTGCCAGACAC                   ACAGTCCCCAGGTGCGTCAGCAATTTCCTGCTCCTCTTGGTTGGTCAGGCACTGAAGCTCCTACACA                   GGTCACTGTTGAAACTCATCCTGTTCAAGAAACAACCTTTCATGTAGGCCCTCAACAGAATGCATTG                   CATCATCACCATGGTAACAGTTCCCATCACCATCACCACCACCACCACCATCACCACCACCATGGAC                   AACAAGCCTTGGGTAACCGGACCAGGCCAAGGGTCTACAATTCTCCAACGAATAGCTCCTCTACCCA                   AGATTCTATGGAGGTTGGCCACAGTCACCACTCCATGACATCCCTGTCTTCCTCAACGACTTCTTCC                   TCGACATCTTCCTCCTCTACTGGTAACCAAGGCAATCAGCCCTACCAGAATCGCCCAGTGGCTGCTA                   ATACCTTGGACTTTGGACAGAATGGAGCTATGGACGTTAATTTGACCGTCTACTCCAATCCCCGCCA                   AGAGACTGGCATAGCTGGACATCCAACATACCAATTTTCTGCTAATACAGGTCCTGCACATTACATG                   ACTGAAGGACATCTGACAATGAGGCAAGGGGCTGATAGAGAAGAGTCCCCCATGACAGGAGTTTGTG                   TGCAACAGAGTCCTGTAGCTAGCTCG TGA                                               ORF Start: ATG at 17       ORF Stop: TGA at 1367               SEQ ID NO: 170   450 aa   MW at 48984.0kD                         NOV39b,   MHTGGETSACKPSSVRLAPSFSFHAAGLQMAGQMPHSHQYSDRRQPNISDQQVSALSYSDQIQQPLT           CG96334-02       Protein Sequence   NQRPMPQTFRDPATAPLRKLSVDLIKTYKHINEEYKPPGTRKLHNILGVETGGPGGRRAGESGHTVA                   DYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTSNSVSTSPAMEQSQSSGTTSSTSSS                   SGGSSGTSNSGRARSDPTHQHRHSGGHFTAAVQAMDCETHSPQVRQQFPAPLGWSGTEAPTQVTVET                   HPVQETTFHVGFQQNALHHHHGNSSHHHHHHHHHHHHHGQQALGNRTRPRVYNSPTNSSSTQDSMEV                   GHSHHSMTSLSSSTTSSSTSSSSTGNQGNQPYQNRPVAANTLDFGQNGAMDVNLTVYSNPRQETGIA                   GHPTYQFSANTGPAHYMTEGHLTMRQGADREESPMTGVCVQQSPVASS                  
 
     [0561] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 39B.  
               TABLE 39B                          Comparison of NOV39a against NOV39b.                                         Identities/                   Similarities for           Protein   NOV39a Residues/   the Matched           Sequence   Match Residues   Region                       NOV39b   405 . . . 763   267/359 (74%)                92 . . . 450   268/359 (74%)                      
 
     [0562] Further analysis of the NOV39a protein yielded the following properties shown in Table 39C.  
               TABLE 39C                       Protein Sequence Properties NOV39a                                        PSort   0.9600 probability located in nucleus; 0.1736 probability       analysis:   located in lysosome (lumen); 0.1198 probability located           in microbody (peroxisome); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0563] A search of the NOV39a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 39D.  
               TABLE 39D                          Geneseq Results for NOV39a                                             Identities/                       Similarities for       Geneseq   Protein/Organism/Length   NOV39a Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value                                         ABB57155   Mouse ischaemic condition   1 . . . 763   756/763 (99%)   0.0           related protein sequence SEQ   1 . . . 763   758/763 (99%)           ID NO: 377 -  Mus musculus ,           763 aa. [WO200188188-A2,           22 NOV. 2001]       AAW41734   Human TRAF-2 kinase -   1 . . . 763   756/763 (99%)   0.0             Homo sapiens , 763 aa.   1 . . . 763   758/763 (99%)           [WO9801541-A1,           15 JAN. 1998]       AAU02221   Human MNB, homologue of   1 . . . 763   755/763 (98%)   0.0           Drosphila minibrain mnb -   1 . . . 763   757/763 (98%)             Homo sapiens , 763 aa.           [US6251664-B1,           26 JUN. 2001]       AAU02222   Rat Dyrk, a homologue of   1 . . . 763   753/763 (98%)   0.0           Drosphila minibrain mnb -   1 . . . 763   756/763 (98%)           Rattus sp, 763 aa.           [US6251664-B1,           26 JUN. 2001]       AAM93441   Human polypeptide, SEQ ID   69 . . . 574    376/509 (73%)   0.0           NO: 3082 -  Homo sapiens ,   21 . . . 522    429/509 (83%)           629 aa. [EP1130094-A2,           05 SEP. 2001]                  
 
     [0564] In a BLAST search of public sequence datbases, the NOV39a protein was found to have homology to the proteins shown in the BLASTP data in Table 39E.  
               TABLE 39E                          Public BLASTP Results for NOV39a                                             Identities/                   NOV39a   Similarities           Protein       Residues/   for the           Accession       Match   Matched           Number   Protein/Organism/Length   Residues   Portion   Expect Value                                         Q61214   Dual-specificity   1 . . . 763   756/763   0.0           tyrosine-phosphorylation       (99%)           regulated kinase 1A (EC   1 . . . 763   758/763           2.7.1.-) (Protein kinase       (99%)           minibrain homolog) (MNBH)           (MP86) (Dual specificity           YAK 1-related kinase) -  Mus               musculus  (Mouse); 763 aa.       Q13627   Dual-specificity   1 . . . 763   756/763   0.0           tyrosine-phosphorylation       (99%)           regulated kinase 1A (EC   1 . . . 763   758/763           2.7.1.-) (Protein kinase       (99%)           minibrain homolog) (MNBH)           (HP86) (Dual specificity           YAK 1-related kinase) -             Homo sapiens  (Human),           763 aa.       Q63470   Dual-specificity   1 . . . 763   755/763   0.0           tyrosine-phosphorylation       (98%)           regulated kinase 1A (EC   1 . . . 763   758/763           2.7.1.-) (Protein kinase       (98%)           minibrain homolog) (MNBH)           (RP86) (Dual specificity           YAK 1-related kinase) -             Rattus norvegicus  (Rat),           763 aa.       JC4898   Down-syndrome-critical-   1 . . . 763   747/763   0.0           region protein - human, 754 aa.       (97%)               1 . . . 754   749/763                   (97%)       CAD30635   Minibrain protein kinase -   1 . . . 763   729/766   0.0                   (95%)             Gallus gallus  (Chicken),   1 . . . 756   739/766           756 aa.       (96%)                  
 
     [0565] PFam analysis predicts that the NOV39a protein contains the domains shown in the Table 39F.  
               TABLE 39F                          Domain Analysis of NOV39a                             Pfam   NOV39a   Identities/Similarities   Expect       Domain   Match Region   for the Matched Region   Value               pkinase   159 . . . 380   84/235 (36%)    2.8e−51               170/235 (72%)        pkinase   452 . . . 479   10/31 (32%)   2.7e−05               22/31 (71%)                  
 
     Example 40  
     [0566] The NOV40 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 40A.  
               TABLE 40A                       NOV40 Sequence Analysis                                                    SEQ ID NO: 171   1186 bp                             NOV4a,     GATGTCCGGCTGGAGCTGTCGCCTCCGCCGCCGCTGCTGCCGGTGCCGGTTGTGAGCGGGTCTCCAG             CG96714-01       DNA Sequence     TCGGCTCCTCTGGGCGTCTC   ATG GCCTCTAGCAGCTCCCTGGTGCCCGACCGGCTGCGCCTGCCGCT                   CTGCTTCCTGGGTGTCTTTGTCTGCTATTTTTACTATCGGATCCTGCAGGAAAAGATAACAAGAGGA                   AAGTATGGGGAAGGAGCCAAGCAGGAGACGTTCACCTTTGCCTTAACTTTGGTCTTCATTCAATGTG                   TGATCAATGCTGTGTTTGCCAAGATCTTGATCCAGTTTTTTGACACTGCCACGGTGGATCGTACCCG                   GAGCTGGCTCTATGCTGCCTGTTCTATCTCCTATCTGGGTGCCATGGTCTCCAGCAATTCAGCACTA                   CAGTTTGTCAACTACCCAACTCAGGTCCTTCGTAAATCCTGCAAGCCAATCCCAGTCATGCTCCTTG                   GGGTGACCCTCTTGAAGAAGAAGTACCCGTTGGCCAAGTACCTGTGTGTGCTGTTAATTGTGGCTGG                   AGTGGCCCTTTTCATGTACAAACCCAAGAAAGTTGTTGGGATAGAAGAACACACAGTCGGCTATGGA                   GAGCTACTCTTGCTATTATCGCTGACCCTCGATGGACTGACTGGTGTTTCCCAGGACCACATGCGGG                   CTCATTACCAAACAGGCTCCAACCACATGATGCTGAACATCAACCTTTGGTCGACATTGCTGCTGCG                   AATGGGAATCCTGTTCACTGGGGAGCTCTGGGAGTTCTTGAGCTTTGCTGAAAGGTACCCTGCCATC                   ATCTATAACATCCTGCTCTTTGGGCTGACCAGTGCCCTGGGTCAGAGCTTCATCTTTATGACGCTTG                   TGTATTTTGGTCCCCTGACCTGCTCCATCATCACTACAACTCGAAAGTTCTTCACAATTTTGGCCTC                   TGTGATCCTCTTCGCCAATCCCATCAGCCCCATGCAGTGGGTGGGCACTGTGCTTGTGTTCCTGGGT                   CTTGGTCTTGATGCCAAGTTTGGGAAAGGACCTAAGAAGACATCCCAC TAG   GAAGAGAGAGACTACC                       TCCACATCAAGAATATTTAAGTTATTATCTCAAACAGTGACATCTCTTGGGAAAATGGACTTAATAG                       GAATATGGGACTGAGTTCCAGTCTTTTTTAATAAAATAAAATCAAGC                                               ORF Start: ATG at 88       ORF Stop: TAG at 1054               SEQ ID NO: 172   322 aa   MW at 35759.2kD                         NOV40a,   MASSSSLVPDRLRLPLCFLGVFVCYFYYGILQEKITRGKYGEGAKQETFTFALTLVFIQCVINAVFA           CG96714-01       Protein Sequence   KILIQFFDTARVDRTRSWLYAACSISYLGAMVSSNSALQFVNYPTQVLGKSCKPIPVMLLGVTLLKX                   KYPLAKYLCVLLIVAGVALFMYKPKKVVGIEEHTVGYGELLLLLSLTLDGLTGVSQDHMRAHYQTGS                   NHMMLNINLWSTLLLGMGILFTGELWEFLSFAERYPAIIYNILLFGLTSALGQSFIFMTVVYFGPLT                   CSIITTTRKFFTILASVILFANPISPMQWVGTVLVFLGLGLDAKFGKGAKKTSH                                         SEQ ID NO: 173   1340 bp                             NOV40b,   ATTNNAAGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAAC           212778987 DNA       Sequence   TAGAGAACCCACTGCTTACTCGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGC                   TAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGCATCCACTAGTCCAGTGTGGTGGAATTCCACCAT                   CGCCTCTAGCAGCTCCCTGGTGCCCGACCGGCTGCGCCTCCCCCTCTGCTTCCTGGGTGTCTTTGTC                   TGCTATTTTTACTATGGGATCCTGCAGGAAAAGATAACAAGAGGAAAGTATGCGGAAGGAGCCAAGC                   AGGAGACGTTCACCTTTGCCTTAACTTTGGTCTTCATTCAATGTGTGATCAATGCTGTGTTTGCCAA                   GATCTTGATCCAGTTTTTTGACACTGCCAGGGTGGATCGTACCCGGAGCTGGCTCTATGCTGCCTGT                   TCTATCTCCTATCTGGGTGCCATOGTCTCCAGCAATTCAGCACTACAGTTTGTCAACTACCCAACTC                   AGGTCCTTGGTAAATCCTGCAAGCCAATCCCAGTCATGCTCCTTGGGGTGACCCTCTTGAAGAAGAA                   GTACCCGTTCGCCAAGTACCTGTGTGTGCTGTTAATTGTGGCTGGAGTGGCCCTTTTCATGTACAAA                   CCCAAGAAAGTTGTTGGGATAGAAGAACACACAGTCGGCTATGGACAGCTACTCTTGCTATTATCGC                   TGACCCTGGATGGACTGACTGGTGTTTCCCAGGACCACATGCGGGCTCATTACCAAACAGGCTCCAA                   CCACATGATGCTGAACATCAACCTTTCCTCGACATTGCTGCTGGGAATGGGAATCCTGTTCACTGGG                   GAGCTCTGGGAGTTCTTGAGCTTTGCTGAAAGGTACCCTGCCATCATCTATAACATCCTGCTCTTTG                   GGCTGACCAGTGCCCTGGGTCAGAGCTTCATCTTTATGACGGTTGTGTATTTTGGTCCCCTGACCTG                   CTCCATCATCACTACAACTCGAAAGTTCTTCACAATTTTGGCCTCTGTGATCCTCTTCGCCAATCCC                   ATCAGCCCCATGCAGTGGGTGGGCACTGTGCTTGTGTTCCTGGGTCTTGGTCTTGATGCCAAGTTTG                   GGAAAGGAGCTAAGAAGACATCCCACTAGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCT                   GATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTT                   GACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTG                                             ORF Start: at 119       ORF Stop: TAG at 1166               SEQ ID NO: 174   349 aa   MW at 38719.5kD                         NOV40b,   GDPSWLAFKLKLGTELGSTSPVWWNSTMASSSSLVPDRLRLPLCFLGVFVCYFYYGILQEKITRGKY           212778987       Protein Sequence   GEGAKQETFTFALTLVFIQCVINAVFAKILIQFFDTARVDRTRSWLYAACSISYLGAMVSSNSALQF                   VNYPTQVLGKSCKPIPVMLLGVTLLKKKYPLAKYLCVLLIVAGVALFMYKPKKVVGIEEHTVGYGEL                   LLLLSLTLDGLTGVSQDHMRAHYQTGSNHMMLNINLWSTLLLGMGILFTGELWEFLSFAERYPAIIY                   NILLFGLTSALGQSFIFMTVVYFGPLTCSIITTTRKFFTILASVILFANPISPMQWVGTVLVFLGLG                   LDAKFGKGAKKTSH                                         SEQ ID NO: 175   1025 bp                             NOV40c,     GGTCTCCAGTCGGCTCCTCTGGGCGTCTC   ATG GCCTCTAGCAGCTCCCTGGTGCCCGACCGGCTGCC           CG96714-02       DNA Sequence   CCTGCCGCTCTGCTTCCTGGGTGTCTTTGTCTGCTATTTTTACTATGGGATCCTGCAGGAAAAGATA                   ACAAGAGGAAAGTATGGGGAAGGAGCCAAGCAGGAGACGTTCACCTTTGCCTTAACTTTGGTCTTCA                   TTCAATGTGTGATCAATGCTGTGTTTGCCAAGATCTTGATCCAGTTTTTTGACACTGCCAGGGTGGA                   TCGTACCCGGAGCTGGCTCTATGCTGCCTGTTCTATCTCCTATCTGGGTCCCATGGTCTCCAGCAAT                   TCAGCACTACAGTTTGTCACTACCCAACTCAGGTCCTTGGTAAATCCTGCAAGCCAATCCCATGTCA                   TGCTCCTTGGGGTGACCCTCTTGAAGAAGAAGTACCCGTTGGCCAAGTACCTGTGTGTGCTGTTAAT                   TGTGGCTGGAGTGGCCCTTTTCATGTACAAACCCAAGAAAGTTGTTGGGATAGAAGAACACACAGTC                   GGCTATGGAGAGCTACTCTTGCTATTATCGCTGACCCTGGATGGACTGACTGGTGTTTCCCAGGACC                   ACATGCGGGCTCATTACCAAACAGCCTCCAACCACATGATGCTGAACATCAACCTTTGGTCGACATT                   GCTGCTGGGAATGGGAATCCTGTTCACTGGGGAGCTCTGGGAGTTCTTGAGCTTTGCTGAAAGGTAC                   CCTGCCATCATCTATAACATCCTGCTCTTTCGGCTGACCAGTGCCCTGGGTCAGAGCTTCATCTTTA                   TGACGGTTGTGTATTTTGGTCCCCTGACCTGCTCCATCATCACTACAACTCGAAAGTTCTTCACAAT                   TTTGGCCTCTGTGATCCTCTTCGCCAATCCCATCAGCCCCATGCAGTGGGTGGGCACTGTGCTTGTG                   TTCCTGGGTCTTGGTCTTGATGCCAAGTTTGGGAAAGGAGCTAAGAAGACATCCCAC TAG   GAAGAGA                       GAGACTACCTCCACATCAAG                                               ORF Start: ATG at 30       ORF Stop: TAG at 996               SEQ ID NO: 176   322 aa   MW at 35759.2kD                         NOV4Oc,   MASSSSLVPDRLRLPLCFLGVFVCYFYYGILQEKITRGKYGEGAKQETFTFALTLVFIQCVINAVFA           CG96714-02       Protein Sequence   KILIQFFDTARVDRTRSWLYAACSISYLGAMVSSNSALQFVNYPTQVLGKSCKPIPVMLLGVTLLKK                   KYPLAKYLCVLLIVAGVALFMYKPKKVVGIEEHTVGYGELLLSLTLDGLTGVSQDHHYERAHYQTGS                   NHMMLNINLWSTLLLGMGILFTGELWEFLSFAERYPAIIYNILLFGLTSALGQSFIFMTVVYFGPLT                   CSIITTTRKFFTILASVILFANPISPMQWVGTVLVFLGLGLDAXFGKGAKKTSH                                         SEQ ID NO: 177   975 bp                             NOV4Od,   CCAGAATTCCACCATGGCCTCTAGCACCTCCCTGGTGCCCGACCGGCTGCGCCTGCCGCTCTGCTTC           190235426 DNA       Sequence   CTGGGTGTCTTTGTCTGCTATTTTTACTATGGGATCCTGCAGGAAAAGATAACAAGAGGAAAGTATG                   GGGAAGGAGCCAAGCAGGAGACGTTCACCTTTGCCTTAACTTTGGTCTTCATTCAATGTGTGATCAA                   TGCTGTGTTTGCCAAGATCTGGTGGATCGTACCCGGAGCTGGCTCTATGCTGCCTGTTCTATCTCCT                   ATCTGGGTGCCATGGTCTCCAGCAATTCAGCACTACAGTTTGTCAACTACCCAACTCAGGTCCTTGG                   TAAATCCTGCAAGCCAATCCCAGTCATGCTCCTTGGGGTGACCCTCTTGAAGAAGAAGTACCCGTTG                   GCCAAGTACCTGTGTGTGCTGTTAATTGTGCCTGGAGTGGCCCTTTTCATGTACAAACCCAAGAAAG                   TTGTTGGGATAGAAGAACACACAGTCGGCTATGGAGAGCTACTCTTGCTATTATCGCTGACCCTGGA                   TGGACTGACTAGTGTTTCCCAGGACCACATGCGGGCTCATTACCAAACAGGCTCCAACCACATGATG                   CTGAACATCAACCTTTGGTCGACATTGCTGCTGGGAATGGGAATCCTGTTCACTGCGGAGCTCTGGG                   AGTTCTTGAGCTTTGCTGAAAGGTACCCTGCCATCATCTATAACATCCTGCTCTTTGGGCTGACCAG                   TGCCCTGGGTCAGAGCTTCATCTTTATGACGGTTGTGTATTTTGGTCCCCTGACCTGCTCCATCATC                   ACTACAACTCGAAAGTTCTTCACAATTTTGGCCTCTGTGATCCTCTTCGCCAATCCCATCAGCCCCA                   TGCAGTGGGTGGGCACTGTGCTTGTGTTCCTTGGTCTTGGTCTTGATGCCAAGTTTGGGAAAGGAGC                   TAAGAAGACATCCCAC TAG   GCGCCCCCTTTTTTCCTT                                               ORF Start: at 25       ORF Stop: TAG at 955               SEQ ID NO: 178   310 aa   MW at 34026.1kD                         NOV4Od,   QLPGARPAAPAALLPGCLCLLFLLWDPAGKDNXRKVWGRSQAGDVELCLNFGLHSMCDQCCVCQDLV           190235426       Protein Sequence   DRTRSWLYAACSISYLGAMVSSNSALQFVNYPTQVLGKSCKPIPVMLLGVTLLKKKYFLAKYLCVLL                   IVAGVALFNYKPKKVVGTEEHTVGYGELLLLLSLTLDGLTGVSQDHMRAHYQTGSNHMMLNTNLWST                   LLLGMGILFTGELWEFLAFAERYPAIIYNILLFGLTSALGQSFIFMTVVYFGPLTCSIITTTRKFFT                   ILASVILFANPISPMQWVGTVLVFLGLGLDAKFGKGAIKKTSH                                         SEQ ID NO: 179   1025 bp                             NOV40e,     GGTCTCCAGTCGGCTCCTCTGGGCGTCTC   ATG GCCTCTAGCAGCTCCCTGGTGCCCGACCGGCTGCG           CG96714-03       DNA Sequence   CCTGCCGCTCTGCTTCCTGGGTGTCTTTGTCTGCTATTTTTACTATGGGATCCTGCAGGAAAAGATA                   ACAAGAGGAAAGTATGGGGAAGGAGCCAAGCAGGAGACGTTCACCTTTGCCTTAACTTTGGTCTTCA                   TTCAATGTGTGATCAATGCTGTGTTTGCCAAGATCTTGATCCAGTTTTTTGACACTGCCACGGTGGA                   TCGTACCCGGAGCTGGCTCTATGCTGCCTGTTCTATCTCCTATCTGGGTGCCATGGTCTCCAGCAAT                   TCAGCACTACAGTTTGTCAACTACCCAACTCAGGTCCTTGGTAAATCCTGCAAGCCAATCCCAGTCA                   TGCTCCTTGGGGTGACCCTCTTGAAGAAGAAGTACCCGTTGGCCAAGTACCTGTGTGTGCTGTTAAT                   TGTGGCTGGAGTGGCCCTTTTCATGTACAAACCCAAGAAAGTTGTTGGGATAGAAGAACACACAGTC                   GGCTATGGAGAGCTACTCTTGCTATTATCGCTGACCCTGGATGGACTGACTGGTGTTTCCCAGGACC                   ACATGCGGGCTCATTACCAAACAGGCTCCAACCACATGATGCTGAACATCAACCTTTGGTCGACATT                   GCTGCTGGGAATGGGAATCCTGTTCACTGGCGAGCTCTGGGAGTTCTTGAGCTTTGCTGAAAGGTAC                   CCTGCCATCATCTATAACATCCTGCTCTTTGGGCTGACCAGTGCCCTGGGTCAGAGCTTCATCTTTA                   TGACGGTTGTGTATTTTGGTCCCCTGACCTGCTCCATCATCACTACAACTCGAAAGTTCTTCACAAT                   TTTGGCCTCTGTGATCCTCTTCGCCAATCCCATCAGCCCCATGCAGTCGGTGGGCACTGTGCTTGTG                   TTCCTGGGTCTTGGTCTTGATGCCAAGTTTCGGAAAGGAGCTAAGAAGACATCCCAC TAG   GAAGAGA                       GAGACTACCTCCACATCAAG                                               ORF Start: ATG at 30       ORF Stop: TAG at 996               SEQ ID NO: 180   322 aa   MW at 35759.2kD                         NOV40e,   MASSSSLVPDRLRLPLCFLGVFVCYFYYGILQEKITRGKYGEGAKQETFTFALTLVFIQCVINAVFA           CG96714-03       Protein Sequence   KILIQFFDTARVDRTRSWLYAACSISYLGAMVSSNSALQFVNYPTQVLGKSCKPIPVMLLGVTLLKK                   KYPLAKYLCVLLIVALVALFMYKPKKVVGIEEHTVGYGELLLLLSLTLDGLTGVSQDHMRAHYQTGS                   NHMMLNINLWSTLLLGMGILFTGELWEFLSFAERYPAIIYNILLFGLTSALGQSFIFMTVVYFGPLT                   CSIITTTRKFFTILASVILFANPISPMQWVGTVLVFLGLGLDAKFGKGAKKTSH                  
 
     [0567] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 40B.  
               TABLE 40B                          Comparison of NOV40a against NOV40b through NOV40e.                                 Protein   NOV40a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV40b   1 . . . 322   284/322 (88%)               28 . . . 349    284/322 (88%)           NOV40c   1 . . . 322   284/322 (88%)               1 . . . 322   284/322 (88%)           NOV40d   81 . . . 322    204/242 (84%)               69 . . . 310    204/242 (84%)           NOV40e   1 . . . 322   284/322 (88%)               1 . . . 322   284/322 (88%)                      
 
     [0568] Further analysis of the NOV40a protein yielded the following properties shown in Table 40C.  
               TABLE 40C                       Protein Sequence Properties NOV40a                                        PSort   0.6850 probability located in endoplasmic reticulum       analysis:   (membrane); 0.6400 probability located in plasma           membrane; 0.4600 probability located in Golgi body;           0.1000 probability located in endoplasmic reticulum (lumen)       SignalP   Cleavage site between residues 68 and 69       analysis:                  
 
     [0569] A search of the NOV40a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 40D.  
               TABLE 40D                          Geneseq Results for NOV40a                                         NOV40a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAB43476   Human cancer associated   1 . . . 322    322/322 (100%)   0.0           protein sequence SEQ ID   51 . . . 372     322/322 (100%)           NO:921 -  Homo sapiens , 372           aa. [WO200055350-A1,           21 SEP. 2000]       ABG25333   Novel human diagnostic   30 . . . 220    184/191 (96%)    e−103           protein #25324 -  Homo     114 . . . 304    187/191 (97%)             sapiens , 846 aa.           [WO200175067-A2,           11 OCT. 2001]       ABB61815     Drosophila melanogaster     8 . . . 317   159/315 (50%)   1e−84           polypeptide SEQ ID NO   3 . . . 316   212/315 (66%)           12237 -  Drosophila               melanogaster , 338 aa.           [WO200171042-A2,           27 SEP. 2001]       AAG04835     Arabidopsis thaliana  protein   1 . . . 307   114/315 (36%)   3e−44           fragment SEQ ID NO: 1012 -   1 . . . 311   171/315 (54%)             Arabidopsis thaliana , 329 aa.           [EP1033405-A2,           06 SEP. 2000]       AAG07182     Arabidopsis thaliana  protein   12 . . . 307    101/302 (33%)   5e−41           fragment SEQ ID NO: 4238 -   12 . . . 311    161/302 (52%)             Arabidopsis thaliana , 332 aa.           [EP1033405-A2,           06 SEP 2000]                  
 
     [0570] In a BLAST search of public sequence datbases, the NOV40a protein was found to have homology to the proteins shown in the BLASTP data in Table 40E.  
               TABLE 40E                          Public BLASTP Results for NOV40a                                         NOV40a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               P78383   UGTrel1 -  Homo sapiens     1 . . . 322    322/322 (100%)   0.0           (Human), 322 aa.   1 . . . 322    322/322 (100%)       Q96EW7   Similar to UDP-galactose   1 . . . 322   321/322 (99%)   0.0           transporter related -  Homo     1 . . . 322   321/322 (99%)             sapiens  (Human), 322 aa.       CAD33236   Putative endoplasmic   1 . . . 322   314/322 (97%)   0.0           reticulum nucleotide sugar   34 . . . 355    320/322 (98%)           transporter -  Bos taurus             (Bovine), 355 aa.       P70639   UGTrel1 -  Rattus rattus     1 . . . 322   309/322 (95%)   e−179           (Black rat), 322 aa.   1 . . . 322   316/322 (97%)       P97858   UGTREL1 (Solute carrier   1 . . . 322   308/322 (95%)   e−178           family 35 (UDP-galactose   1 . . . 322   315/322 (97%)           transporter), member 2) -             Mus musculus  (Mouse), 322           aa.                  
 
     [0571] PFam analysis predicts that the NOV40a protein contains the domains shown in the Table 40F.  
               TABLE 40F                          Domain Analysis of NOV40a                             Pfam   NOV40a   Identities/Similarities   Expect       Domain   Match Region   for the Matched Region   Value               DUF6   23 . . . 156   25/140 (18%)   0.049               97/140 (69%)       DUF6   181 . . . 312    29/135 (21%)   0.006               91/135 (67%)                  
 
     Example 41  
     [0572] The NOV41 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 41A.  
               TABLE 41A                       NOV41 Sequence Analysis                                                    SEQ ID NO: 181   1650 bp                             NOV41a,   CCTTCACACAGCTCTTTCACCATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAAAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAACATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGCGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCACAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAACGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTCGATGAAAAGCAC                   AGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGAACCTGAAGCAGCTGTCATTAGTAATGGGGAACATTAAGATACTCTGTGAGGTGCAAGACTT                   CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                             ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 182520 aa   MW at 57293.0kD                         NOV41a,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAXMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHA                   YDFYXPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFMSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNWITSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENIKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSMIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 183   1650 bp                             NOV41b,     CCTTCACACAGCTCTTTCACC   ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGCCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGGCAGAAAGAGCGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTCGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTTTATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCACAACCTGAAGCAGCTGTCATTAGTAATGCGGAACATTATGATACTCTCTGAGGTGCAAGACTT                   CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGCAACAGTTGG                                             ORE Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 184   520 aa   MW at 57293.0kD                         NOV41b,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHNQHA                   YDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMTKHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 185   1650 bp                             NOV41c,   CCTTCACACAOCTCTTTCACCATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTCGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTCCCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTCGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTACGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTCCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGAACCTGAAGCAGCTGTCATTAGTAATGGGGAACATTAGGATACTCTGTGAGGTGCAAGACTT                   CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                             ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 186   520 aa   MW at 57293.0kD                         NOV41c,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHA                   YDFYKPDNLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDHNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYCSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENMXLREDTHHLTNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHI PSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 187   1593 bp                             NOV41d,     CCT GGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGAATTGTTGCCCTTGAGA           254869578 DNA       Sequence   TCTATTTTCCTTCTCAATATGTTGATCAAGCAGACTTGGAAAAATATGATGGTGTAGATGCTGGAAA                   GTATACCATTCGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAGAGAAGATATTAACTCTCTT                   TGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATTGCATTGGGCGGCTGG                   AAGTTGGAACAGACACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGTTTGA                   AGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATGCTATGGAGGCACAGCTGCT                   GTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGGTATGCCCTGGTAGTTGCAG                   GAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAGTTGGAGCAGTAGCTCTGCT                   AATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGACACATATGCAACATGCCTAT                   GATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAACTCTCCATACAGTGCT                   ACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCCATGCCCAGTGGCAGAAAGA                   GGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCACTCACCATATTGTAAA                   CTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACCAGAATAGAGATAAaxA                   ATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAGACACCTACTTTGATAGAGA                   TGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACAAAGGCATCTTTACTT                   GTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCCCTTGCATCTGTTCTAGCAC                   AGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGCAGTGTTTTCTTATGGTTCTGGTTTGGCTGC                   CACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGCTCTTGATAAAATAACAGCA                   AGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTCGCACCAGATGTCTTCGCTGAAA                   ACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATTCACT                   CTTTGAAGGAACGTCGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCGTCCC                   ACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCAAACATAGCAACTGAGCATA                   TTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAGAACCTGAAGCAGCTGTCAT                   TAGTAATGGGGAACAT TAA   GCGGCCGCACTCGAGCACCACCACCACCACCAC                                               ORF Start: at 1       ORF Stop: TAA at 1558               SEQ ID NO: 188   519 aa   MW at 57161.8kD                         NOV41d,   PGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINSL           254869578       Protein Sequence   CMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIECIDTTNACYGGTAA                   VFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHAY                   DFYXPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYCK                   LVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASLL                   VSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKITA                   SLCDLKSRLDSRTGVAPDVFAENNKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARRP                   TPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 189   1650 bp                             NOV41e,     CCTTCACACAGCTCTTTCACC   ATG CCTGGATCACTTCCTTTGAATGCACAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAACTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGCCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTCTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGCAGTTGGAGCAGTAGCTCTGCTAATTCGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCACTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGCCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTOAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACGCTCCGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGAACCTCAAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GATACTCTGTGAGGTGCAAGACTT                       CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                               ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 190   520 aa   MW at 57293.OkD                         NOV41e,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHA                   YDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQHRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 191   1601 bp                             NOV41f,     CAC CGGTCTCACATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGAA           253174237 DNA       Sequence   TTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATGATGG                   TGTAGATGCTGGAAAATATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAGAGAA                   GATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATT                   GCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTT                   GATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATGCTAT                   GGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGGTATG                   CCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAGTTGG                   AGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGACACAT                   ATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAAC                   TCTCCATACAGTCCTACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCCATGC                   CCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCAC                   TCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACC                   AGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAGACAC                   CTACTTTGATAGAGATGTGGAGAACGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACA                   AAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCCCTTG                   CATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTCGAGTGTTTTCTTATGG                   TTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTCCTCTT                   GATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCACCAG                   ATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGG                   TTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACT                   TACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCAAACA                   TAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAGAACC                   TGAAGCAGCTGTCATTAGTAATGGGGAACATCATCACCACCATCACTAAGCGCCCGCAAG                                             ORF Start: at 1       ORF Stop: TAA at 1588               SEQ ID NO: 192   529 aa   MW at 58496.2kD                         NOV41f,   HRSHMPGSLPLNAEACWPKDVGIVALETYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDRE           253174237       Protein   DINSLCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACY       Sequence           CGTAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTH                   MQHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKECNDKDFTLNDFGFMIFH                   SPYCKLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKT                   KASLLVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSAL                   DKITASLCDLKSRLDSRTGVAPDVFAENHKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRT                   YARRPTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEHHHHHH                                         SEQ ID NO: 193   1650 bp                             NOV41g,     CCTTCACACAGCTCTTTCACC   ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGTGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAA                   GACTAATTTGATGCAGCTGTTIGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTCGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACCCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGAACCTGAAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GATACTCTGTGAGGTGCAAGACTT                       CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTCG                                               ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 194   520 aa   MW at 57293.0kD                         NOV41g,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRCTHMQHA                   YDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFHKASSELFSQKTKASL                   LVSNQMGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENHKLREDTHHLVNYIPQGSIDSLFEGTWYLTRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHI PSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 195   1608 bp                             NOV41h,     CCT CGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGAATTGTTGCCCTTGAGA           256420363 DNA       Sequence   TCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATGATGGTGTAGATGCTGGAAA                   GTATACCATTGGCTTGGGCCAGGCCAAGATGGCCTTCTGCACAGATAGAGAAGATATTAACTCTCTT                   TGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATTGCATTGGGCGGCTGG                   AAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGTTTGA                   AGAGTCTCGGAATACAGATATAGAAGGAATCGACACAACTAATGCATGCTATGGAGGCACAGCTGCT                   GTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGGTATCCCCTGGTAGTTGCAG                   GAGATATTGCTGTATATGCCACAGCAAATGCTAGACCTACAGGTGGAGTTGGAGCAGTAGCTCTGCT                   AATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGACACATATGCAACATGCCTAT                   GATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAACTCTCCATACAGTGCT                   ACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCCATGCCCAGTGGCAGAAAGA                   GGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCACTCACCATATTGTAAA                   CTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACCAGAATAGAGATAAAA                   ATAGTATCTATAGTGGCCTGGAAGCCTTTCGGGATGTTAAATTAGAAGACACCTACTTTGATAGAGA                   TGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACAAAGGCATCTTTACTT                   GTATCAAATCAAAATCGAAATATGTACACATCTTCAGTATATGGTTCCCTTCCATCTGTTCTAGCAC                   AGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTTTTCTTATGGTTCTGGTTTGGCTGC                   CACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGCTCTTGATAAAATAACAGCA                   AGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCACCAGATGTCTTCGCTGAAT                   ACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATTCACT                   CTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCGTCCC                   ACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTCCATTCAAACATAGCAACTGAGCATA                   TTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAGAACCTGAAGCAGCTGTCAT                   TAGTAATGGGGAACATCATCACCACCATCACTAAGCGGCCGCACTCGAGCACCACCACCACCACCAC                                             ORF Start: at 1       ORF Stop: TAA at 1573               SEQ ID NO: 196   524 aa   MW at 57847.5kD                         NOV41h,   PGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINSL           256420363       Protein Sequence   CMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTAA                   VFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHAY                   DFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNKKDFTLNDFGFMIFHSPYCK                   LVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMXASSELFSQKTKASLL                   VSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKITA                   SLCDLKSRLDSRTGVAPDVFAENHKLREDTHHLVNYIPQGSDSLFEGTWYLVRXTDEKHRRTYARRP                   TPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEHHHHGH                                         SEQ ID NO: 197   1650 bp                             NOV41j,   CCTTCACACAGCTCTTTCACCATGCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGCAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTCTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGCGAATACAGATATAGAAGGAATCGACACAACTAAT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGG                   TGGAGTTGGAGCACTAGCTCTCCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGGCAGAAAGAGGGAAATGATAAGATTTTACCTTGAATCAATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCCGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAATAATGGAAATTGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCTAGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGACCTGAAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GATACTCTGGTGACGTCCAAGACTT                       CAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                               ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 198   520aa   MW at 57293.0kD                         NOV41i,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAXMGFCTDREDINS           CG97025-01       Protein   LCNTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYCGTA       Sequence           AVFNAWIEWSSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGTLRGTHMQHA                   YDFYKPDNLSEYPTVDGKLSTQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAWYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 199   1612 bp                             NOV41j,     A   CAT CATCACCACCATCACCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTG           255667064 DNA       Sequence   GGAATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATG                   ATGGTGTAGATGCTGGAAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAG                   AGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTAT                   GATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTA                   ATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATG                   CTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGOACGG                   TATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAG                   TTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGACGGCTTCGTGGGAC                   ACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGA                   AAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCC                   ATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTT                   TCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAAT                   GACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAG                   ACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATCAAGGCTAGCTCTGAACTCTTCAGTCAGAA                   AACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCC                   CTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTTTTCTT                   ATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGC                   TCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCA                   CCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCC                   AGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAG                   AACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCA                   AACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAG                   AACCTGAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GCGGCCGCACTCGAGCACCACCACCACCA                       CCAC                                               ORF Start: at 2       ORF Stop: TAA at 1577               SEQ ID NO: 200   525 aa   MW at 57984.6kD                         NOV41j,   HHHHHHPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLCQAXMGFCTDR           255667064       Protein   EDINSLCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNAC       Sequence           YGGTAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGT                   HMQHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIF                   HSPYCKLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQK                   TKASLLVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATFGSA                   LDKITASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRR                   TYARRPTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 201   1650 bp                             NOV41k,     CCTTCACACAGCTCTTTCACC   ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAG           CG97025-01       DNA Sequence   ATGTTGGGATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAA                   ATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACA                   GATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTT                   CCTATGATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAATGTCTGTGAA                   GACTAATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGATCGACACAACTAAGT                   GCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATG                   GACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGC                   TGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGT                   GGGACACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAG                   ATGGGAAACTCTCCATACAGTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTCTACTGCAAAAA                   GATCCATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATG                   ATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCC                   TTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATT                   AGAAGACACCTACTTTGATAGAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGT                   CAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATG                   GTTCCCTTGCATCTGTTCTAGCACACTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTT                   TTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGG                   TCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTG                   TGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATAT                   TCCCCAGCGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCAC                   AGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATCACACTTTGGATGAAGGAGTAGGACTTGTGC                   ATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGC                   AGCAGAACCTGAAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GATACTCTGTGAGGTGCAAGACTT                     CAGCGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                             ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 202   520 aa   MW at 57293.0kD                         NOV41k,   MPGSLPLNAFiACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-01       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMSQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTNNMQHA                   YDFYKPDMLSEYPIVDGGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNFKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSGQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPKGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENMHREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEGKKHRRTYARR                   PTPNDDTLDEGVGLVHSNVTATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 203   1564 bp                             NOV41L,     C   ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGAATTGTTGCCCTT           228832739 DNA       Sequence   GAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATGATGGTGTAGATGCTG                   GAAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAGAGAAGATATTAACTC                   TCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATTGCATTGGGCGG                   CTGGAAGTTGCAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGT                   TTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATGCTATGGACGCACAGC                   TGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGGTATGCCCTGGTAGTT                   GCAGGAGATATTGCTGTATATGCCACAOGAAATGCTAGACCTACAGGTGGAGTTGGAGCAGTAGCTC                   TGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGACACATATGCAACATGC                   CTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAACTCTCCATACAG                   TGCTACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCCATGCCCAGTGGCAGA                   AAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCACTCACCATATTG                   TAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACCAGAATAGAGAT                   AAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAGACACCTACTTTGATA                   GAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACAAAGGCATCTTT                   ACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCCCTTGCATCTGTTCTA                   GCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTTTTCTTATGGTTCTGGTTTGG                   CTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGCTCTTGATAAAATAAC                   AGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCACCAGATGTCTTCGCT                   GAAAACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATT                   CACTCTTTGAAOGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCG                   TCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCAAACATAGCAACTGAG                   CATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAGAACCTGAAGCAGCTG                   TCATTAGTAATGGGGAACAT TAA                                               ORF Start: ATG at 2       ORF Stop: TAA at 1562               SEQ ID NO: 204   520 aa   MW at 57293.0kD                         NOV41l,   NPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           228832739       Protein   LCMTVVQNLMERTTHTHSYDCIGRLEVGTETDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA       Sequence           AVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHA                   YDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMXASSELFSQKTKASL                   ASLCDLKSRLDSRTGVAPDVFAENNKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 205   1650 bp                             NOV41m,   +E,unc CCTTCACACAGCTCTTTCACC ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAA           CG97025-02       DNA Sequence   AAATATGATGGTGTAGATGCTGGGAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGC                   ACAGATAGAGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAAC                   CTTTCCTATGATTGCATTGGGCGGCTGGAAOTTGGAACAGAGACAATCATCGACAAATCAAAGTCT                   GTGAAGACTAATTTGATGCAGCTGTTTGAAGAGTCTCGGAATACAGATATAGAAGGAATCGACACA                   ACTAATGCATGCTATGGAGGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCT                   TGGCATGGACGGTATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGA                   CCTACAGGTGGAGTTGGAGCAGTAGCTCTGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGA                   GGGCTTCGTGGGACACATATGCAACATCCCTATGATTTTTACAAGCCTGATATGCTATCTGAATAT                   CCTATAGTAGATGGGAAACTCTCCATACACTGCTACCTCAGTGCATTAGACCGCTGCTATTCTGTC                   TACTGCAAAAAGATCCATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGAT                   TTTGGCTTCATGATCTTTCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCGGATGTTG                   CTGAATGACTTCCTTAATGACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTT                   GGGGATGTTAAATTAGAAGACACCTACTTTGATAGAGATTTCGAGAAGGCATTTATGAAGOCTAGC                   TCTGAACTCTTCAGTCAGAAAACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTAC                   ACATCTTCAGTATATGGTTCCCTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGG                   AAGAGAATTGGAGTGTTTTCTTATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACA                   CAAGATGCTACACCGGGGTCTGCTCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGG                   CTTGATTCAAGAACTGGTGTGGCACCAGATGTCTTCGCTGAAAACATGAAGCTCAGAGACGACACC                   CATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTA                   GTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTG                   GATGAAGGAGTAGGACTTGTGCATTCAAACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAA                   GTACCAAGACTCCCTGCCACAGCAGCAGAACCTGAAGCAGCTGTCATTAGTAATGGGGAACATTAA                   GATACTCTGTGAGGTGCAAGACTTCAGGGTGGGGTGGGCATGGGGTGGGGGTATGGGAACAGTTGG                                             ORF Start: ATG at 22       ORF Stop: TAA at 1582               SEQ ID NO: 206   520 aa   MW at 57293.0kD                         NOV41m,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAXMGFCTDREDIN           CG97025-02       Protein Sequence   SLCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGG                   TAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHM                   QHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFH                   SPYCKLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQK                   TKASLLVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPCS                   ALDKITASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKH                   RRTYARRPTPNDDTLDEGVGLXTHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 207   1564 bp                             NOV41n,     C   ATG CCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAACATGTGGGAATTGTTGCCCTT           CG97025-03       DNA Sequence   GAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATGATGGTGTAGATGCTG                   GAAAGTATACCATTGGCTTCGGCCAGGCCAAGATGGGCTTCTGCACAGATAGAGAAGATATTAACTC                   TCTTTGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATTGCATTGGGCGC                   CTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGT                   TTGAAGAGTCTGGGAATACAGATATAGAGGAATCGACACAACTAATGCATGCTATGGAaGGCACAGC                   TGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGGTATGCCCTGGTAGTT                   GCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAGTTGCAGCAGTAGCTC                   TGCTAATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGACACATATGCAACATGC                   CTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAACTCTCCATACAG                   TGCTACCTCAGTGCATTAGACCGCTGCTACTCTGTCTACTGCAAAAAGATCCATGCCCAGTGGCAGA                   AAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCACTCACCATATTG                   TAAACTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACCAGAATAGAGAT                   AAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGCATGTTAAATTAGAAGACACCTACTTTGATA                   GAGATGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACAAACGCATCTTT                   ACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCCCTTGCATCTGTTCTA                   GCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTCTTTTCTTATCGTTCTCGTTTGG                   CTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGCTCTTGATAAAATAAC                   AGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCACCAGATGTCTTCGCT                   GAAAACATGAAGCTCACAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATT                   CACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCG                   TCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCAAACATAGCAACTGAG                   CATATTCCAAGCCCTGCCAAGAAAGTACCAACACTCCCTGCCACAGCAGCAGAACCTGAAGCAGCTG                   TCATTAGTAATGGGGAACATTAA                                             ORF Start: ATG at 2       ORF Stop: TAA at 1562               SEQ ID NO: 208   520 aa   MW at 57293.0kD                         NOV41n,   MPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINS           CG97025-03       Protein Sequence   LCMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTA                   AVFNAVNWTESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHA                   YDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYC                   KLVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVXLEDTYFDRDVEKAFMKASSELFSQKTKASL                   LVSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKIT                   ASLCDLKSRLDSRTGVAPDVFAENNKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARR                   PTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO: 209   1612 bp                             NOV41o,     A   CAT CATCACCACCATCACCCTGGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTG           CG97025-04       DNA Sequence   GGAATTGTTGCCCTTGAGATCTATTTTCCTTCTCAATATGTTGATCAAGCAGAGTTGGAAAAATATG                   ATGGTGTAGATGCTGCAAAGTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAG                   AGAAGATATTAACTCTCTTTGCATGACTGTGGTTCAGAATCTTATOGAGAGAAATAACCTTTCCTAT                   GATTGCATTGGGCGGCTGGAAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAACACTA                   ATTTGATGCAGCTGTTTGAAGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATG                   CTATGGATGCACAGCTGCTGTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTGGGATGGACGG                   TATGCCCTGGTAGTTGCAGGAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAG                   TTGGAGCAGTAGCTCTGCTAATTGGCCCAAATGCTCCTTTAATTTTTGAACGAGGGCTTCGTGGGAC                   ACATATGCAACATGCCTATGATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGA                   AAACTCTCCATACAGTGCTACCTCAGTGCATTACACCGCTGCTACTCTGTCTACTGCAAAAAGATCC                   ATGCCCAGTGGCAGAAAGAGGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTT                   TCACTCACCATATTGTAAACTGGTTCAGAAATCTCTAGCTCCGATGTTCCTGAATGACTTCCTTAAT                   GACCAGAATAGAGATAAAAATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAG                   ACACCTACTTTGATAGAGATGTGGAGAACGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAA                   AACAAAGGCATCTTTACTTGTATCAAATCAAAATGGAAATATGTACACATCTTCAGTATATGGTTCC                   CTTGCATCTGTTCTAGCACAGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTCGAGTGTTTTCTT                   ATGGTTCTGGTTTGGCTGCCACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGGGTCTGC                   TCTTGATAAAATAACAGCAAGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCA                   CCAGATGTCTTCGCTGAAAACATTAAGCTCAOAGAGGACACCCATCATTTGGTCAACTATATTCCCC                   AGGGTTCAATAGATTCACTCTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAG                   AACTTACGCTCGGCGTCCCACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCA                   AACATAGCAACTGAGCATATTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCAG                   AACCTGAAGCAGCTGTCATTAGTAATGGGGAACAT TAA   GCGGCCGCACTCGAGCACCACCACCACCA                       CCAC                                               ORE Start: at 2       ORF Stop: TAA at 1577               SEQ ID NO: 210   525 aa   MW at 57984.6kD                         NOV41o,   HHHHHHPGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDR           CG97025-04       Protein Sequence   EDINSLCMTVVQNLMERNIThSYDCIGRLEVGTETHDKSKSVKTNLMQLFEESGNTDIEGIDTTNAC                   YGGTAAVFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTCGVGAVALLIGPNAPLIFERGLRGT                   HMQHAYDFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDHDFTLNDFGFMIF                   HSPYCKLVQKSLARHLLNDFLNDQNRDKNSIYSCLEAFGDVKLEDTYFDRDVEKAFMKASSELFSQK                   TKASLLVSNQNONMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSA                   LDKITASLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRR                   TYARRPTPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEH                                         SEQ ID NO:211   1608 bp                             NOV41p,     CCT GGATCACTTCCTTTGAATGCAGAAGCTTGCTGGCCAAAAGATGTGGGAATTGTTGCCCTTGAGA           CG97025-05       DNA Sequence   GTATACCATTGGCTTGGGCCAGGCCAAGATGGGCTTCTGCACAGATAGAGAAGATATTAACTCTCTT                   TGCATGACTGTGGTTCAGAATCTTATGGAGAGAAATAACCTTTCCTATGATTGCATTGGGCGGCTGG                   AAGTTGGAACAGAGACAATCATCGACAAATCAAAGTCTGTGAAGACTAATTTGATGCAGCTGTTTGA                   AGAGTCTGGGAATACAGATATAGAAGGAATCGACACAACTAATGCATGCTATGGAGGCACAGCTGCT                   GTCTTCAATGCTGTTAACTGGATTGAGTCCAGCTCTTCGCATGCACGGTATGCCCTGGTAGTTGCAG                   GAGATATTGCTGTATATGCCACAGGAAATGCTAGACCTACAGGTGGAGTTGGAGCAGTAGCTCTGCT                   AATTGGGCCAAATGCTCCTTTAATTTTTGAACGAGGCCTTCGTGGGACACATATGCAACATGCCTAT                   GATTTTTACAAGCCTGATATGCTATCTGAATATCCTATAGTAGATGGAAAACTCTCCATACAGTGCT                   ACCTCAGTGCATTAGACCGCTGCTACTCTCTCTACTGCAAAAAGATCCATGCCCAGTGGCAGAAAGA                   GGGAAATGATAAAGATTTTACCTTGAATGATTTTGGCTTCATGATCTTTCACTCACCATATTGTAAA                   CTGGTTCAGAAATCTCTAGCTCGGATGTTGCTGAATGACTTCCTTAATGACCAGAATAGAGATAAAA                   ATAGTATCTATAGTGGCCTGGAAGCCTTTGGGGATGTTAAATTAGAAGACACCTACTTTGATAGAGA                   TGTGGAGAAGGCATTTATGAAGGCTAGCTCTGAACTCTTCAGTCAGAAAACAAAGGCATCTTTACTT                   GTATCAAATCAAAATGGAAATATGPACACATCTTCAGTATATGGTTCCCTTGCATCTGTTCTAGCAC                   AGTACTCACCTCAGCAATTAGCAGGGAAGAGAATTGGAGTGTTTTCTTATGGTTCTGGTTTGGCTGC                   CACTCTGTACTCTCTTAAAGTCACACAAGATGCTACACCGGCTTCTGCTCTTGATAAAATAACAGCA                   AGTTTATGTGATCTTAAATCAAGGCTTGATTCAAGAACTGGTGTGGCACCAGATGTCTTCGCTGAAA                   ACATGAAGCTCAGAGAGGACACCCATCATTTGGTCAACTATATTCCCCAGGGTTCAATAGATTCACT                   CTTTGAAGGAACGTGGTACTTAGTTAGGGTGGATGAAAAGCACAGAAGAACTTACGCTCGGCGTCCC                   ACTCCAAATGATGACACTTTGGATGAAGGAGTAGGACTTGTGCATTCAAACATAGCAACTGAGCATA                   TTCCAAGCCCTGCCAAGAAAGTACCAAGACTCCCTGCCACAGCAGCACAACCTGAAGCAGCTGTCAT                   TAGTAATGGGGAACATCATCACCACCATCACTAAGCGGCCGCACTCGAGCACCACCACCACCACCAC                                             ORF Start: at 1       ORF Stop: TAA at 1573               SEQ ID NO: 212   524 aa   MW at 57847.5kD                         NOV41p,   PGSLPLNAEACWPKDVGIVALEIYFPSQYVDQAELEKYDGVDAGKYTIGLGQAKMGFCTDREDINSL           CG97025-05       Protein Sequence   CMTVVQNLMERNNLSYDCIGRLEVGTETIIDKSKSVKTNLMQLFEESGNTDIEGIDTTNACYGGTAA                   VFNAVNWIESSSWDGRYALVVAGDIAVYATGNARPTGGVGAVALLIGPNAPLIFERGLRGTHMQHAY                   DFYKPDMLSEYPIVDGKLSIQCYLSALDRCYSVYCKKIHAQWQKEGNDKDFTLNDFGFMIFHSPYCK                   LVQKSLARMLLNDFLNDQNRDKNSIYSGLEAFGDVKLEDTYFDRDVEKAFGKASSELFSQKTKASLL                   VSNQNGNMYTSSVYGSLASVLAQYSPQQLAGKRIGVFSYGSGLAATLYSLKVTQDATPGSALDKITA                   SLCDLKSRLDSRTGVAPDVFAENMKLREDTHHLVNYIPQGSIDSLFEGTWYLVRVDEKHRRTYARRP                   TPNDDTLDEGVGLVHSNIATEHIPSPAKKVPRLPATAAEPEAAVISNGEHHHHHH                  
 
     [0573] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 41B.  
               TABLE 41B                          Comparison of NOV41a against NOV41b through NOV41p.                                 Protein   NOV41a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV41b   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41c   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41d   2 . . . 520   519/519 (100%)               1 . . . 519   519/519 (100%)           NOV41e   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41f   1 . . . 520   520/520 (100%)               5 . . . 524   520/520 (100%)           NOV41g   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41h   2 . . . 520   519/519 (100%)               1 . . . 519   519/519 (100%)           NOV41i   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41j   2 . . . 520   519/519 (100%)               7 . . . 525   519/519 (100%)           NOV41k   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41l   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41m   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41n   1 . . . 520   520/520 (100%)               1 . . . 520   520/520 (100%)           NOV41o   2 . . . 520   519/519 (100%)               7 . . . 525   519/519 (100%)           NOV41p   2 . . . 520   519/519 (100%)               1 . . . 519   519/519 (100%)                      
 
     [0574] Further analysis of the NOV41a protein yielded the following properties shown in Table 41C.  
               TABLE 41C                       Protein Sequence Properties NOV41a                                        PSort   0.3000 probability located in microbody (peroxisome); 0.3000       analysis:   probability located in nucleus; 0.1000 probability located in           mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0575] A search of the NOV41a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 41D.  
               TABLE 41D                          Geneseq Results for NOV41a                                         NOV41a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent#, Date]   Residues   Matched Region   Value               AAW32222   Avian   1 . . . 520   438/522 (83%)   0.0           3-hydroxy-2-methylglutaryl-   1 . . . 522   476/522 (90%)           CoA synthase - Aves, 522 aa.           [US5668001-A,           16 SEP. 1997]       AAM79853   Human protein SEQ ID NO   4 . . . 470   315/467 (67%)   0.0           3499 -  Homo sapiens , 518 aa.   51 . . . 517    387/467 (82%)           [WO200157190-A2,           09 AUG. 2001]       AAM78869   Human protein SEQ ID NO   4 . . . 470   315/467 (67%)   0.0           1531 -  Homo sapiens , 508 aa.   41 . . . 507    387/467 (82%)           [WO200157190-A2,           09 AUG. 2001]       ABB66034     Drosophila melanogaster     13 . . . 471    294/459 (64%)   e−170           polypeptide SEQ ID NO   5 . . . 459   353/459 (76%)           24894 -  Drosophila               melanogaster , 465 aa.           [WO200171042-A2,           27 SEP. 2001]       ABB60545     Drosophila melanogaster     13 . . . 471    294/459 (64%)   e−170           polypeptide SEQ ID NO   5 . . . 459   353/459 (76%)           8427 -  Drosophila               melanogaster , 465 aa.           [WO200171042-A2,           27 SEP. 2001]                  
 
     [0576] In a BLAST search of public sequence datbases, the NOV41 a protein was found to have homology to the proteins shown in the BLASTP data in Table 41E.  
               TABLE 41E                          Public BLASTP Results for NOV41a                                         NOV41a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q01581   Hydroxymethylglutaryl-CoA   1 . . . 520    520/520 (100%)   0.0           synthase, cytoplasmic (EC   1 . . . 520    520/520 (100%)           4.1.3.5) (HMG-CoA synthase)           (3-hydroxy-3-methylglutaryl           coenzyme A synthase) -             Homo sapiens  (Human), 520           aa.       S27197   hydroxymethylglutaryl-CoA   1 . . . 518   513/518 (99%)   0.0           synthase (EC 4.1.3.5),   1 . . . 518   514/518 (99%)           cytosolic, fibroblast isoform -           human, 520 aa.       BAC04559   CDNA FLJ38173 fis, clone   1 . . . 520   509/520 (97%)   0.0           FCBBF1000053, highly   1 . . . 509   509/520 (97%)           similar to           HYDROXYMETHYLGLUTARYL-           COA SYNTHASE,CYTOPLASMIC           (EC 4.1.3.5) -  Homo               sapiens  (Human), 509 aa.       P17425   Hydroxymethylglutaryl-CoA   1 . . . 520   493/520 (94%)   0.0           synthase, cytoplasmic (EC   1 . . . 520   508/520 (96%)           4.1.3.5) (HMG-CoA synthase)           (3-hydroxy-3-methylglutaryl           coenzyme A synthase) -             Rattus norvegicus  (Rat), 520           aa.       P13704   Hydroxymethylglutaryl-CoA   1 . . . 520   495/520 (95%)   0.0           synthase, cytoplasmic (EC   1 . . . 520   506/520 (97%)           4.1.3.5) (HMG-CoA synthase)           (3-hydroxy-3-methylglutaryl           coenzyme A synthase) -             Cricetulus griseus  (Chinese           hamster), 520 aa.                  
 
     [0577] PFam analysis predicts that the NOV41a protein contains the domains shown in the Table 41F.  
               TABLE 41F                          Domain Analysis of NOV41a                                     Identities/                   Similarities           NOV41a   for the       Pfam Domain   Match Region   Matched Region   Expect Value                                     HMG_CoA_synt   13 . . . 469   334/461 (72%)   0               434/461 (94%)                  
 
     Example 42  
     [0578] The NOV42 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 42A.  
               TABLE 42A                       NOV42 Sequence Analysis                                                    SEQ ID NO: 213   1380 bp                             NOV42a,     CAGCAGC   ATG CGGGGGTTGCTGGTGTTGAGTGTCCTGTTGGGGGCTGTCTTTGGCAAGGAGGACTTT           CG97955-01       DNA Sequence   GTGGGGCATCAGGTGCTCCGAATCTCTGTAGCCGATGAGGCCGACAGGTACAGAATGAAGGAGCTGG                   AGGACCTGGAGCACCTGCAGCTGGACTTCTGGCGGGGGCCTGCCCACCCTGGCTCCCCCATCGACGT                   CCGAGTGCCCTTCCCCAGCATCCAGGCGGTCAAGATCTTTCTGGAGTCCCACGGCATCAGCTATGAC                   ACCATGATCGAGGACGTGCAGTCGCTGCTGGACGAGGAGCAGGAGCAGATGTTCGCCTTCCGGTCCC                   GGGCGCGCTCCACCGACACTTTTAACTACGCCACCTACCACACCCTGGAGGAGATCTATGACTTCCT                   CGACCTGCTGGTGGCGGAGAACCCGCACCTTGTCAGCAAGATCCAGATTGGCAACACCTATGAAGGG                   CGTCCCATTTATGTGCTGAAGTTCAGCACGGGGGGCAGTAAGCGTCCAGCCATCTGGATCGACACGG                   GCATCCATTCCCGGGAGTGGGTCACCCAGGCCAGTGGGGTCTGGTTTGCAAAGAAGATCACTCAAGA                   CTATGGGCAGGATGCAGCTTTCACCGCCATTCTCGACACCTTGGACATCTTCCTGGAGATCGTCACC                   AACCCTGATGGCTTTGCCTTCACGCACAGCACGAATCGCATGTGGCGCAAGACTCGGTCCCACACAG                   CAGGCTCCCTCTGTATTGGCGTGGACCCCAACAGGAACTGGGACGCTGGCTTTGGGTTGTCCGGAGC                   CAGCAGTAACCCCTGCTCGGAGACTTACCACGGCAAGTTTGCCAATTCCGAAGTGGAGGTCAAGTCC                   ATTGTAGACTTTGTGAAGGACCATGGGAACATCAAGGCCTTCATCTCCATCCACAGCTACTCCCAGC                   TCCTCATGTATCCCTATGGCTACAAAACAGAACCAGTCCCTGACCAGGATGAGCTGGATCAGCTTTC                   CAAGGCTGCTGTGACAGCCCTGGCCTCTCTCTACGGGACCAAGTTCAACTATGGCAGCATCATCAAG                   GCAATTTATCAAGCCAGTGGAAGCACTATTGACTGGACCTACAGCCAGGGCATCAAGTACTCCTTCA                   CCTTCGACCTCCGGGACACTGGCCGCTATGGCTTCCTGCTGCCAGCCTCCCAGATCATCCCCACAGC                   CAAGGAGACGTGGCTGGCGCTTCTGACCATCATGGAGCACACCCTGAATCACCCCTAC TGA   GCTGAC                       CCTTTGACACCCTTCTTGTCCTCCTCTCTGGCCCCATCCAGGCAACCAAATAAAGTTTGACTGTACC                       AGGAACAGAATCCTGGGGCTTGCAAAAAAAAAAAAAAAAA                                               ORF Start: ATG at 8       ORF Stop: TGA at 1265               SEQ ID NO: 214   419 aa   MW at 47139.7kD                         NOV42a,   MRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRCPAHPGSPIDVRV           CG97955-01       Protein Sequence   PFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDTFNYATYHTLEEIYDFLDL                   LVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIDTGIHSREWVTQASGVWFAKKITQDYG                   QDAAFTAILDTLDIFLEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLSGASS                   NPCSETYHGKFANSEVEVKSTVDFVKDHGNIKAFISIHSYSOLLMYPYGYKTEPVPDODELDOLSKA                   AVTALASLYGTKFNYGSIIKAIYQASGSTIDWTYSQGIKYSFTFELRDTGRYGFLLPASQTIPTAKE                   TWLALLTIMEHTLNHPY                                         SEQ ID NO: 215   821 bp                             NOV42b,     GACCTTCCCTCCCGGCAGCAGC   ATG CGCGGGTTGCTGGTGTTGAGTGTCCTGTTGGGGGCTGTCTTT           CG97955-03       DNA Sequence   GGCAAGGAGGACTTTGTGGGGCATCAGGTGCTCCGAATCTCTGTAGCCGATGAGCCCCAGGTACAGA                   AGGTGAAGGAGCTGGAGGACCTGGAGCACCTGCAGCTGGACTTCTGGCGGGGGCCTGCCCACCCTGC                   CTCCCCCATCGACGTCCGAGTGCCCTTCCCCAGCATCCAGGCGGTCAAGATCTTTCTGGAGTCCCAC                   GGCATCAGCTATCAGACCATGATCGAGGACGTGCAGTCGCTTCTGGACGAGGAGCAGGAGCACATGT                   TCGCCTTCCGGTCCCGGGCGCGCTCCACCGACACTTTTAACTACGCCACCTACCACACCCTGGAGGA                   GATCTATGACTTCCTGGACCTGCTGGTGGCGGAGAACCCGCACCTTGTCAGCAAGATCCAGATTGGC                   AACACCTATGAAGGGCGTCCCATTTATGTGCTGAAGATCAAGCCAGTGGAAGCACTATTGACTGGAC                   CTACAGCCAGGGCATCAAGTACTCCTTCACCTTCGAGCTCCGGGACACTGOGCGCTATGGCTTCCTG                   CTGCCAGCCTCCCAGATCATCCCCACAGCCAAGGAGACGTGGCTGGCGCTTC TGA   CCATCATGGAGC                       ACACCCTGAATCACCCCTACTGACCTGACCCTTTGACACCCTTCTTGTCCTCCTCTCTGGCCCCATC                       CAGGCAACCAAATATAGTTTGAGTGTACCAGGAACAGAATCCTGGGGCTTGCAGGAAAAAAAAAAAGA                       AAAAAAAAAAAAAAA                                               ORF Start: ATG at 23       ORF Stop: TGA at 656               SEQ ID NO: 216   211 aa   MW at 23626.7kD                         NOV42b,   MRGLLVLSVLLGAVEGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRGPAHPGSPIDVRV           CG97955-03       Protein Sequence   PFPSIQAVRIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDTFNYATYHTLEEIYDFLDL                   LVAENPHLVSKIQIGNTYEGRPIYVLKIKPVEALLTGPTARASSTPSPSSSGTLGAMASCCQPPRSS                   PQPRRRGWRF                                         SEQ ID NO:217   1279 bp                             NOV42c,   CACCGGATCCACCATGCGGGGGTTGCTGGTGTTGAGTGTCCTGTTGGGGGCTGTCTTTGGCAAGGAG           308559628 DNA       Sequence   GACTTTGTGGGGCATCAGGTGCTCCGAATCTCTGTAGCCGATGAGGCCCAGGTACAGAAGGTGAAGG                   AGCTGGAGGACCTGGAGCACCTGCAGCTGGACTTCTGGCGGGGGCCTGCCCACCCTGGCTCCCCCAT                   CGACGTCCGAGTGCCCTTCCCCAGCATCCAGGCGGTCAAGATCTTTCTGGAGTCCCACGGCATCAGC                   TATGAGACCATGATCGAGGACGTGCAGTCGCTGCTGGACGACGAGCAGGAGCAGATGTTCGCCTTCC                   GGTCCCGGGCGCGCTCCACCGACACTTTTAACTACGCCACCTACCACACCCTGGAGGAGATCTATGA                   CTTCCTGGACCTGCTGGTGGCGGAGAACCCGCACCTTGTCAGCAAGATCCAGATTGGCAACACCTAT                   GAAGGGCGTCCCATTTACGTGCTCAAGTTCAGCACCCCGGGCAGTAAGCGTCCAGCCATCTGGATCG                   ACACGGGCATCCATTCCCGGGAGTGGGTCACCCAGGCCAGTGGGGTCTGGTTTGCAAAGAACATCAC                   TCAAGACTACGGGCAGGATGCAGCTTTCACCGCCATTCTCGACACCTTGGACATCTTCCTGGAGATC                   GTCACCAACCCTGATGQCTTTGCCTTCACGCACAGCACGAATCGCATGTGGCGCAAGACTCGGTCCC                   ACACAGCAGGCTCCCTCTGTATTGGCGTGGACCCCAACAGGAACTGGGACGCTGGCTTTGGGTTGTC                   CGGAGCCAGCAGTAACCCCTGCTCGGAGACTTACCACGGCAAGTTTGCCATTTCCGAAGTGGAGGTC                   AAGTCCATTGTAGACTTTGTGAAGGACCATGGGAACATCAAGGCCTTCATCTCCATCCACAGCTACT                   CCCAGCTCCTCATGTATCCCTATGGCTACAAAACAGAACCAGTCCCTGACCACGATGAGCTGCATCA                   GCTTTCCAAGGCTGCTGTGACAGCCCTGGCCTCTCTCTACGGGACCAAGTTCAACTATGGCAGCATC                   ATCAAGGCAATTTATCAAGCCAGTGGAAGCACTATTGACTGGACCTACAGCCAGGGCATCAAGTACT                   CCTTCACCTTCGAGCTCCGGGACACTGGGCGCTATGGCTTCCTGCTGCCAGCCTCCCAGATCATCCC                   CACAGCCAACGAGACGTGGCTGGCGCTTCTGACCATCATGGAGCACACCCTGAATCACCCCTACCTC                   GAGGGC                                             ORF Start: at 2       ORF Stop: end of sequence               SEQ ID NO: 218   426 aa   MW at 47785.4kD                         NOV42c,   TGSTNRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKXTKELEDLEHLQLDFWRGPAHPGSPI           308559628       Protein Sequence   DVRVPFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQIGFAFRSRAGSTDTFNYATYHTLEEIYD                   FLDLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIKDTGIHSREWVTQASGVWFAKKIT                   QDYGQDAAFTAILDTLDIFLEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDRPNRNWDAGFGLS                   GASSNPCSETYHGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYGSQLLMYPYGYKTEPVPDQDELDQ                   LSKAAVTALASLYGTKFWYGSIIKAIYQASGSTIDWTYSQGTKYSFTFELRDTGRYGFLLPASQIHIP                   TAKETWLALLTIMEHTLNHPYLEG                                         SEQ ID NO: 219   1290 bp                             NOV42d,     CTCATGAACACGAAGGCAGCAGC   ATG CGGGGGTTGCTGGTGTTGAGTGTCCTGTTGGGGGCTGTCTT           CG97955-02       DNA Sequence   TGGCAAGGAGGACTTTGTGGCGCATCAGGTGCTCCGAATCTCTGTAGCCGATGAGGCCCAGGTACAG                   AAGGTGAAGGAGCTGGAGGACCTGGAGCACCTGCAGCTGGACTTCTGGCGGGGGCCTGCCCACCCCG                   GCTCCCCCATCGACGTCCGAGTGCCCTTCCCCAGCATCCAGGCGGTCAAGATCTTTCTGGAGTCCCA                   CGGCATCAGCTATGAGACCATGATCGAGGACGTGCAGTCGCTGCTGGACGAGGAGCAGGAGCAGATG                   TTCGCCTTCCGGTCCCGGGCGCGCTCCACCGACACTTTTAACTACGCCACCTACCACACCCTGGAGG                   AGATCTATGACTTCCTGGACCTGCTGGTGGCGGAGAACCCGCACCTTGTCAGCAAGATCCAGATTGG                   CAACACCTATGAACGGCGTCCCATTTACGTGCTGAAGTTCAGCACGGGGGGCAGTATGCGTCCAGCC                   ATCTGGATCGACACGGGCATCCATTCCCGGGAGTGGGTCACCCAGGCCAGTGGGGTCTGGTTTGCAT                   AGAAGATCACTCAAGACTACGGGCAGGATGCAGCTTTCACCGCCATTCTCGACACCTTGGACATCTT                   CCTGAGATCGTCACCACCCTGATGGCTTTGCCTTCACGCACAGCACGTATCGCATGTCTGCGCAATG                   ACTCGGTCCCACACAGCAGGCTCCCTCTGTATTGGCGTGGACCCCAACAGGAACTGGGACGCTGGCT                   TTGGGTTGTCCGGAGCCAGCAGTAACCCCTGCTCGGAGACTTACCACGGCAAGTTTGCCAYTTCCGA                   AGTGGAGGTCAAGTCCATTGTAGACTTTGTGAAGGACCATGGGAACATCAAGGCCTTCATCTCCATC                   CACAGCTACTCCCAGCTCCTCATGTATCCCTATGGCTACAAAACAGAACCAGTCCCTGACCAGGATG                   AGCTGGATCAGCTTTCCAAGGCTGCTGTGACAGCCCTGGCCTCTCTCTACGGGACCAAGTTCGACTA                   TGGCAGCATCATCAAGGCAATTTATCAAGCCAGTGGAAGCACTATTGACTGGACCTACAGCCAGGGC                   ATCAAGTACTCCTTCACCTTCGAGCTCCGGGACACTGGGCGCTATGGCTTCCTGCTGCCAGCCTCCC                   AGATCATCCCCACAGCCAAGGAGACCTGGCTGGCGCTTCTGACCATCATGGAGCACACCCTGAATCA                   CCCCTAC TAG   CCGCACT                                               ORF Start: ATG at 24       ORF Stop: TAG at 1281               SEQ ID NO: 220   419 aa   MW at 47139.7kD                         NOV42d,   MRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDGFWRGPAHPSPIDRVR           CG97955-02       Protein Sequence   VPFPSIQAXTKIFLESHGISYETMIEDVQSLLDEEQEQMEAFRSRARSTDTFNYATYHTLEIYGDFL                   DLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIDTGIHSREWVTQASGVWFAKKIPTQ                   DYGQDAAFTAILDTLDIFLEIVTNPDGFAFTIiSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLS                   GASSNPCSETYIIGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYSQLLMYPYGYKTEPVPDQDELD                   QLSKAAVTALASLYGTKFNYGSIIKAIGYQASGSTIDWTYSQGIKYSFTFELRDTGRYGFLLPASQI                   IPTAKETWLALLTIMEHTLNHPY                  
 
     [0579] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 42B.  
               TABLE 42B                          Comparison of NOV42a against NOV42b through NOV42d.                                 Identities/           NOV42a Residues/   Similarities       Protein Sequence   Match Residues   for the Matched Region               NOV42b   17 . . . 161   145/145 (100%)           17 . . . 161   145/145 (100%)       NOV42c   17 . . . 419   403/403 (100%)           21 . . . 423   403/403 (100%)       NOV42d   17 . . . 419   403/403 (100%)           17 . . . 419   403/403 (100%)                  
 
     [0580] Further analysis of the NOV42a protein yielded the following properties shown in Table 42C.  
               TABLE 42C                       Protein Sequence Properties NOV42a                                                PSort analysis:   0.4323 probability located in outside;               0.2367 probability located in microbody               (peroxisome); 0.1000 probability located in               endoplasmic reticulum (membrane); 0.1000               probability located in endoplasmic reticulum               (lumen)           SignalP analysis:   Cleavage site between residues 17 and 18                      
 
     [0581] A search of the NOV42a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 42D.  
               TABLE 42D                          Geneseq Results for NOV42a                                         NOV42a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                         AAY28915   Human regulatory protein   1 . . . 419    419/419 (100%)   0.0           HRGP-1 -  Homo sapiens , 419 aa.   1 . . . 419    419/419 (100%)           [WO9933870-A2, 08 JUL. 1999]       AAR97618   Human carboxypeptidase A1 -   1 . . . 419    419/419 (100%)   0.0             Homo sapiens , 419 aa.   1 . . . 419    419/419 (100%)           [WO9616179-A1, 30 MAY 1996]       AAW01504   Wild-type human pancreatic   1 . . . 419   418/419 (99%)   0.0           carboxypeptidase 1 -  Homo sapiens ,   1 . . . 419   419/419 (99%)           419 aa. [WO9513095-A2, 18 MAY 1995]       AAW01509   Human pancreatic carboxypeptidase   1 . . . 419   417/419 (99%)   0.0           1 variant (T268G,A) - Synthetic,   1 . . . 419   418/419 (99%)           419 aa. [WO9513095-A2,           18 MAY 1995]       AAW01508   Human pancreatic carboxypeptidase   1 . . . 419   417/419 (99%)   0.0           1 variant (I255A) - Synthetic,   1 . . . 419   418/419 (99%)           419 aa. [WO9513095-A2,           18 MAY 1995]                  
 
     [0582] In a BLAST search of public sequence datbases, the NOV42a protein was found to have homology to the proteins shown in the BLASTP data in Table 42E.  
               TABLE 42E                          Public BLASTP Results for NOV42a                                             NOV42a   Identities/               Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             P15085   Carboxypeptidase A1   1 . . . 419    419/419 (100%)   0.0               precursor (EC 3.4.17.1) -   1 . . . 419    419/419 (100%)             Homo sapiens  (Human), 419 aa.       CAA02810   SEQUENCE 1 FROM   1 . . . 419   418/419 (99%)   0.0           PATENT WO9513095 -   1 . . . 419   419/419 (99%)           unidentified, 419 aa           (fragment).       Q9TV85   Carboxypeptidase A1   1 . . . 419   362/419 (86%)   0.0           (EC 3.4.17.1) -  Sus     1 . . . 419   385/419 (91%)             scrofa  (Pig), 419 aa.                                 P00731   Carboxypeptidase A1   1 . . . 419   350/419 (83%)   0.0           precursor (EC 3.4.17.1) -   1 . . . 419   382/419 (90%)             Rattus norvegicus  (Rat),           419 aa.       P00730   Carboxypeptidase A   1 . . . 419   343/419 (81%)   0.0           precursor (EC 3.4.17.1) -   1 . . . 419   385/419 (91%)             Bos taurus  (Bovine), 419 aa.                  
 
     [0583] PFam analysis predicts that the NOV42a protein contains the domains shown in the Table 42F.  
               TABLE 42F                          Domain Analysis of NOV42a                                     Identities/                   Similarities           NOV42a   for the       Pfam Domain   Match Region   Matched Region   Expect Value               Propep_M14   24 . . . 101   48/82 (59%)   8e-42               74/82 (90%)       Zn_carbOpept   122 . . . 402    156/304 (51%)     5e-166               271/304 (89%)                   
 
     Example B  
     [0584] Sequencing Methodology and Identification of NOVX Clones  
     [0585] 1. GeneCalling™ Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.  
     [0586] 2. SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen&#39;s proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [0587] 3. PathCalling™ Technology: The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation&#39;s proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.  
     [0588] The laboratory screening was performed using the methods summarized below:  
     [0589] cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, Calif.) were then transferred from  E.coli  into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).  
     [0590] Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [0591] Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106′ and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).  
     [0592] 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.  
     [0593] 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain—amygdala, brain—cerebellum, brain—hippocampus, brain—substantia nigra, brain—thalamus, brain—whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma—Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation&#39;s database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least,95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.  
     [0594] 6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.  
     [0595] The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.  
     Example C  
     [0596] Quantitative Expression Analysis of Clones in Various Cells and Tissues  
     [0597] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM®  7700  or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune/autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer&#39;s diseased brains).  
     [0598] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.  
     [0599] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer&#39;s instructions.  
     [0600] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer&#39;s instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42 ° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions.  
     [0601] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer&#39;s Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.  
     [0602] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer&#39;s instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 90° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.  
     [0603] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.  
     [0604] Panels 1, 1.1, 1.2, and 1.3D  
     [0605] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.  
     [0606] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:  
     [0607] ca.=carcinoma,  
     [0608] *=established from metastasis,  
     [0609] met=metastasis,  
     [0610] s cell var=small cell variant,  
     [0611] non-s=non-sm=non-small,  
     [0612] squam=squamous,  
     [0613] pl. eff=pl effusion=pleural effusion,  
     [0614] glio=glioma,  
     [0615] astro=astrocytoma, and  
     [0616] neuro=neuroblastoma.  
     [0617] General_Screening_panel_v1.4, v1.5 and v1.6  
     [0618] The plates for Panels 1.4, v1.5 and v1.6 include two control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panels 1.4, v1.5 and v1.6 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, v1.5 and v1.6 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, v1.5 and v1.6 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.  
     [0619] Panels 2D, 2.2, 2.3 and 2.4  
     [0620] The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include two control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute&#39;s Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics. The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen. General oncology screening panel_v — 2.4 is an updated version of Panel 2D.  
     [0621] HASS Panel v 1.0  
     [0622] The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls. Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, Md.) and were grown in the media and conditions recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.  
     [0623] ARDAIS Panel v 1.0  
     [0624] The plates for ARDAIS panel v 1.0 generally include 2 control wells and 22 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human lung malignancies (lung adenocarcinoma or lung squamous cell carcinoma) and in cases where indicated many malignant samples have “matched margins” obtained from noncancerous lung tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). Unmatched malignant and non-malignant RNA samples from lungs were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.  
     [0625] Panels 3D and 3.1  
     [0626] The plates of Panels 3D and 3.1 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature. Oncology_cell_line_screening_panel_v3.2 is an updated version of Panel 3. The cell lines in panel 3D, 3.1, 1.3D and oncology_cell_line_screening_panel_v3.2 are of the most common cell lines used in the scientific literature.  
     [0627] Panels 4D, 4R, and 4.1D  
     [0628] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn&#39;s disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).  
     [0629] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/mi. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.  
     [0630] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10 6  cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10  5 M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.  
     [0631] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer&#39;s instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 5 M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.  
     [0632] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer&#39;s instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and plated at 10 6  cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.  
     [0633] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 10 6  cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.  
     [0634] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 10 5 -10 6 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/mi). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.  
     [0635] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10 5  cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10 5  cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco). CCD1 106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.  
     [0636] For these cell lines and blood cells, RNA was prepared by lysing approximately 10 7  cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20° C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8μl DNAse were added. The tube was incubated at 37° C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80° C.  
     [0637] AI_comprehensive Panel_v1.0  
     [0638] The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.  
     [0639] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.  
     [0640] Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.  
     [0641] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn&#39;s patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.  
     [0642] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-lanti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.  
     [0643] In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:  
     [0644] Al=Autoimmunity  
     [0645] Syn=Synovial  
     [0646] Normal=No apparent disease  
     [0647] Rep22 /Rep20=individual patients  
     [0648] RA=Rheumatoid arthritis  
     [0649] Backus=From Backus Hospital  
     [0650] OA=Osteoarthritis  
     [0651] (SS) (BA) (MF)=Individual patients  
     [0652] Adj=Adjacent tissue  
     [0653] Match control=adjacent tissues  
     [0654] −M=Male  
     [0655] −F=Female  
     [0656] COPD=Chronic obstructive pulmonary disease  
     [0657] Panels 5D and 51  
     [0658] The plates for Panel SD and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.  
     [0659] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (&lt;1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:  
     [0660] Patient 2 Diabetic Hispanic, overweight, not on insulin  
     [0661] Patient 7-9 Nondiabetic Caucasian and obese (BMI&gt;30)  
     [0662] Patient 10 Diabetic Hispanic, overweight, on insulin  
     [0663] Patient 11 Nondiabetic African American and overweight  
     [0664] Patient 12 Diabetic Hispanic on insulin  
     [0665] Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr.  2, 1999: 143-147 . Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:  
     [0666] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose  
     [0667] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated  
     [0668] Donor 2 and 3 AD: Adipose, Adipose Differentiated  
     [0669] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.  
     [0670] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.  
     [0671] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:  
     [0672] GO Adipose=Greater Omentum Adipose  
     [0673] SK=Skeletal Muscle  
     [0674] UT=Uterus  
     [0675] PL=Placenta  
     [0676] AD=Adipose Differentiated  
     [0677] AM=Adipose Midway Differentiated  
     [0678] U=Undifferentiated Stem Cells  
     [0679] Panel CNSD.01  
     [0680] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [0681] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer&#39;s disease, Parkinson&#39;s disease, Huntington&#39;s disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington&#39;s disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington&#39;s cases. Likewise Parkinson&#39;s disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.  
     [0682] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:  
     [0683] PSP=Progressive supranuclear palsy  
     [0684] Sub Nigra=Substantia nigra  
     [0685] Glob Palladus=Globus palladus  
     [0686] Temp Pole=Temporal pole  
     [0687] Cing Gyr=Cingulate gyrus  
     [0688] BA 4=Brodman Area 4  
     [0689] Panel CNS_Neurodegeneration_V1.0  
     [0690] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [0691] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer&#39;s disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer&#39;s like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer&#39;s like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.  
     [0692] In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:  
     [0693] AD=Alzheimer&#39;s disease brain; patient was demented and showed AD-like pathology upon autopsy  
     [0694] Control=Control brains; patient not demented, showing no neuropathology  
     [0695] Control (Path)=Control brains; pateint not demented but showing sever AD-like pathology  
     [0696] SupTemporal Ctx=Superior Temporal Cortex  
     [0697] Inf Temporal Ctx=Inferior Temporal Cortex  
     [0698] A. CG105324-01: Human Nuclear Orphan Receptor LXR-Alpha Like Gene  
     [0699] Expression of gene CG105324-01 was assessed using the primer-probe set Ag4284, described in Table AA. Results of the RTQ-PCR runs are shown in Tables AB, AC and AD.  
               TABLE AA                          Probe Name Ag4284                                             Start   SEQ       Primers   Sequences   Length   Position   ID No                                             Forward   5&#39;-ccttctcagtc   22   260   221               tgttccacttc-3&#39;       Probe   TET-5&#39;-agccatc   23   304   222           cggccaagaaaacaga-3&#39;           -TAMRA       Reverse   5&#39;-tgactgttct   22   327   223           gtccccatattt-3&#39;                  
 
     [0700]               TABLE AB                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4284,           Tissue Name   Run 222181958                                         Adipose   4.2           Melanoma* Hs688(A).T   1.4           Melanoma* Hs688(B).T   0.9           Melanoma* M14   1.7           Melanoma* LOXIMVI   0.9           Melanoma* SK-MEL-5   0.1           Squamous cell carcinoma SCC-4   1.2           Testis Pool   2.8           Prostate ca.* (bone met) PC-3   4.4           Prostate Pool   1.3           Placenta   2.1           Uterus Pool   0.8           Ovarian ca. OVCAR-3   3.0           Ovarian ca. SK-OV-3   2.6           Ovarian ca. OVCAR-4   1.2           Ovarian ca. OVCAR-5   36.3           Ovarian ca. IGROV-1   5.3           Ovarian ca. OVCAR-8   2.2           Ovary   1.4           Breast ca. MCF-7   2.1           Breast ca. MDA-MB-231   3.8           Breast ca. BT 549   1.1           Breast ca. T47D   100.0           Breast ca. MDA-N   1.0           Breast Pool   3.4           Trachea   1.5           Lung   3.1           Fetal Lung   5.7           Lung ca. NCI-N417   0.7           Lung ca. LX-1   7.6           Lung ca. NCI-H146   1.0           Lung ca. SHP-77   2.6           Lung ca. A549   7.4           Lung ca. NCI-H526   1.6           Lung ca. NCI-H23   1.3           Lung ca. NCI-H460   3.0           Lung ca. HOP-62   2.1           Lung ca. NCI-H522   2.8           Liver   2.0           Fetal Liver   4.8           Liver ca. HepG2   5.1           Kidney Pool   4.1           Fetal Kidney   4.0           Renal ca. 786-0   1.4           Renal ca. A498   1.6           Renal ca. ACHN   3.4           Renal ca. UO-31   4.7           Renal ca. TK-10   4.9           Bladder   4.8           Gastric ca. (liver met.) NCI-N87   18.7           Gastric ca. KATO III   4.5           Colon ca. SW-948   3.4           Colon ca. SW480   9.5           Colon ca.* (SW480 met) SW620   6.6           Colon ca. HT29   19.6           Colon ca. HCT-116   7.8           Colon ca. CaCo-2   17.8           Colon cancer tissue   8.4           Colon ca. SW1116   1.9           Colon ca. Colo-205   4.4           Colon ca. SW-48   6.7           Colon Pool   2.8           Small Intestine Pool   2.8           Stomach Pool   3.1           Bone Marrow Pool   1.4           Fetal Heart   1.2           Heart Pool   1.0           Lymph Node Pool   2.8           Fetal Skeletal Muscle   1.6           Skeletal Muscle Pool   1.4           Spleen Pool   7.0           Thymus Pool   5.3           CNS cancer (glio/astro) U87-MG   4.7           CNS cancer (glio/astro) U-118-MG   2.7           CNS cancer (neuro; met) SK-N-AS   2.3           CNS cancer (astro) SF-539   1.1           CNS cancer (astro) SNB-75   2.2           CNS cancer (glio) SNB-19   3.6           CNS cancer (glio) SF-295   3.7           Brain (Amygdala) Pool   1.2           Brain (cerebellum)   2.0           Brain (fetal)   2.1           Brain (Hippocampus) Pool   1.9           Cerebral Cortex Pool   2.7           Brain (Substantia nigra) Pool   2.8           Brain (Thalamus) Pool   2.9           Brain (whole)   1.2           Spinal Cord Pool   2.7           Adrenal Gland   3.3           Pituitary gland Pool   0.3           Salivary Gland   0.6           Thyroid (female)   1.7           Pancreatic ca. CAPAN2   12.5           Pancreas Pool   4.5                        
     [0701]               TABLE AC                          Panel 5 Islet                                 Rel. Exp. (%)               Ag4284,           Tissue Name   Run 181325887                                         97457_Patient-02go_adipose   99.3           97476_Patient-07sk_skeletal muscle   35.1           97477_Patient-07ut_uterus   12.2           97478_Patient-07pl_placenta   43.2           99167_Bayer Patient 1   94.6           97482_Patient-08ut_uterus   8.0           97483_Patient-08pl_placenta   8.5           97486_Patient-09sk_skeletal muscle   3.5           97487_Patient-09ut_uterus   18.0           97488_Patient-09pl_placenta   51.4           97492_Patient-10ut_uterus   22.4           97493_Patient-10pl_placenta   45.4           97495_Patient-11go_adipose   24.5           97496_Patient-11sk_skeletal muscle   8.1           97497_Patient-11ut_uterus   11.9           97498_Patient-11pl_placenta   14.9           97500_Patient-12go_adipose   100.0           97501_Patient-12sk_skeletal muscle   17.3           97502_Patient-12ut_uterus   12.3           97503_Patient-12pl_placenta   43.8           94721_Donor 2 U - A_Mesenchymal   0.0           Stem Cells           94722_Donor 2 U - B_Mesenchymal   0.0           Stem Cells           94723_Donor 2 U - C_Mesenchymal   7.8           Stem Cells           94709_Donor 2 AM - A_adipose   12.8           94710_Donor 2 AM - B_adipose   20.9           94711_Donor 2 AM - C_adipose   3.5           94712_Donor 2 AD - A_adipose   39.5           94713_Donor 2 AD - B_adipose   23.0           94714_Donor 2 AD - C_adipose   33.9           94742_Donor 3 U - A_Mesenchymal   0.0           Stem Cells           94743_Donor 3 U - B_Mesenchymal   11.3           Stem Cells           94730_Donor 3 AM - A_adipose   17.2           94731_Donor 3 AM - B_adipose   8.4           94732_Donor 3 AM - C_adipose   11.7           94733_Donor 3 AD - A_adipose   21.6           94734_Donor 3 AD - B_adipose   4.2           94735_Donor 3 AD - C_adipose   15.6           77138_Liver_HepG2untreated   58.6           73556_Heart_Cardiac stromal cells   3.1           (primary)           81735_Small Intestine   50.3           72409_Kidney_Proximal Convoluted   3.5           Tubule           82685_Small intestine_Duodenum   13.6           90650_Adrenal_Adrenocortical   7.1           adenoma           72410_Kidney_HRCE   26.8           72411_Kidney_HRE   16.8           73139_Uterus_Uterine smooth   8.5           muscle cells                        
     [0702]               TABLE AD                          Panel 5D                                 Rel. Exp. (%)               Ag4284,           Tissue Name   Run 181457563                                         97457_Patient-02go_adipose   10.4           97476_Patient-07sk_skeletal muscle   5.1           97477_Patient-07ut_uterus   2.1           97478_Patient-07pl_placenta   8.4           97481_Patient-08sk_skeletal muscle   23.0           97482_Patient-08ut_uterus   0.8           97483_Patient-08pl_placenta   3.3           97486_Patient-09sk_skeletal muscle   0.5           97487_Patient-09ut_uterus   1.5           97488_Patient-09pl_placenta   9.9           97492_Patient-10ut_uterus   2.1           97493_Patient-10pl_placenta   12.7           97495_Patient-11go_adipose   3.2           97496_Patient-11sk_skeletal muscle   2.1           97497_Patient-11ut_uterus   1.8           97498_Patient-11pl_placenta   10.8           97500_Patient-12go_adipose   14.3           97501_Patient-12sk_skeletal muscle   4.5           97502_Patient-12ut_uterus   1.6           97503_Patient-12pl_placenta   3.3           94721_Donor 2 U - A_Mesenchymal   3.0           Stem Cells           94722_Donor 2 U - B_Mesenchymal   2.0           Stem Cells           94723_Donor 2 U - C_Mesenchymal   1.3           Stem Cells           94709_Donor 2 AM - A_adipose   5.5           94710_Donor 2 AM - B_adipose   3.7           94711_Donor 2 AM - C_adipose   2.1           94712_Donor 2 AD - A_adipose   5.1           94713_Donor 2 AD - B_adipose   7.8           94714_Donor 2 AD - C_adipose   9.7           94742_Donor 3 U - A_Mesenchymal   0.8           Stem Cells           94743_Donor 3 U - B_Mesenchymal   1.0           Stem Cells           94730_Donor 3 AM - A_adipose   5.1           94731_Donor 3 AM - B_adipose   3.1           94732_Donor 3 AM - C_adipose   4.1           94733_Donor 3 AD - A_adipose   7.3           94734_Donor 3 AD - B_adipose   7.3           94735_Donor 3 AD - C_adipose   3.7           77138_Liver_HepG2untreated   7.7           73556_Heart_Cardiac stromal cells   2.0           (primary)           81735_Small Intestine   8.7           72409_Kidney_Proximal Convoluted   1.7           Tubule           82685_Small intestine_Duodenum   100.0           90650_Adrenal_Adrenocortical adenoma   6.5           72410_Kidney_HRCE   4.2           72411_Kidney_HRE   23.3           73139_Uterus_Uterine smooth muscle   1.9           cells                        
     [0703] General_screening_panel_v1.4 Summary: Ag4284 Highest expression of this gene is detected in a breast cancer T47D cell line (CT=29.9). Moderate to low levels of expression of this gene is also seen in some cell lines derived from pancreatic, brain, colon, liver, lung, breast and ovarian cancers. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of these cancers.  
     [0704] In addition, moderate to low levels of expression of this gene is also seen in pancrease, adipose and stomach. This gene codes for a nuclear orphan receptor LXR-alpha. LXRalpha is thought to play a major role in the control of cholesterol catabolism by regulating the expression of cholesterol 7alpha-hydroxylase, the rate- limiting enzyme of bile acid synthesis. LXR is part of networks that include other nuclear hormone such as FXR, PPAR, and RXR proteins and play critical roles in lipid metabolism by virtue of their transcriptional regulation of the genes that control sterol metabolic pathways. Some of the major downstream targets of these regulatory networks involve members of the ABC transporter family, including ABCA1, ABCG1, ABCG5, ABCG8, MDR3/Mdr2, and SPGP/BSEP. (Niesor et al., 2001, Curr Pharm Des 7(4):231-59, PMID: 1125-4888; Fitzgerald et al., J Mol Med May 2002;80(5):271-81, PMID: 12021839). In GeneCalling studies done at Curagen, it was found that LXRA is up-regulated in obese and/or diabetic patients and the SHR model of Syndrome X. Reduction in LXRA activity would limit lipid production and thus improve obesity and/or diabetes. Therefore, therapeutic modulation of the LXR encoded by this gene may be useful in the treatment of metabolic related diseases such as obesity and diabetes.  
     [0705] Panel 5 Islet Summary: Ag4284 Low but significant levels of expression of this gene is seen only in adipose sample derived from a Hispanic diabetic patient on insulin (CT=34.5). Therefore, expression of this gene may be used to distinguish this sample from other samples used in this panel.  
     [0706] LXR alpha has several important roles in adipocyte function. New studies show that this nuclear receptor increases basal glucose uptake and glycogen synthesis in 3T3-L1 adipocytes. In addition, LXR alpha increases cholesterol synthesis and release of nonesterified fatty acids. Finally, treatment of mice with an LXR alpha agonist results in increased serum levels of glycerol and nonesterified fatty acids (NEFA), consistent with increased lipolysis within adipose tissue. High serum levels of NEFA are believed to contribute to the pathogenesis of Type 2 diabetes (Ross et al., 2002, Mol Cell Biol. 22(16):5989-99, PMID: 12138207; Boden G, Shulman GI, 2002, Eur J Clin Invest. 32 Suppl 3:14-23, PMID: 12028371). These findings demonstrate new metabolic roles for LXR alpha. 5 Thus, an antagonist of LXR alpha may decrease circulating levels of NEFA and therefore could be beneficial in the treatment of Type 2 diabetes.  
     [0707] Panel 5D Summary: Ag4284 Highest expression of this gene is detected in small intestine (CT=30.4). Moderate to low levels of expression of this gene is also seen in adipose, skeletal muscle, small intestine, and placenta of both diabetic and non-diabetic patients. In addition, moderate levels of expression of this gene are also seen in kidney. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0708] B. CG105355-01: Human Aryl Hydrocarbon Receptor Like Gene  
     [0709] Expression of gene CG105355-01 was assessed using the primer-probe set Ag4285, described in Table BA. Results of the RTQ-PCR runs are shown in Tables BB, BC, BD, BE, BF, BG and BH.  
               TABLE BA                          Probe Name Ag4285                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-caggatttcatccgttaagtca-3′   22   3505   224       Probe   TET-5′-tgtctctgaagtcaacctcaccagaa-   26   3528   225           3′-TAMRA       Reverse   5′-acatcagacacatgcagaatga-3′   22   3575   226                  
 
     [0710]               TABLE BB                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4285, Run           Tissue Name   222182745                                         Adipose   11.7           Melanoma* Hs688(A).T   4.2           Melanoma* Hs688(B).T   8.5           Melanoma* M14   16.0           Melanoma* LOXIMVI   2.8           Melanoma* SK-MEL-5   14.1           Squamous cell carcinoma SCC-4   13.5           Testis Pool   1.7           Prostate ca.* (bone met) PC-3   17.1           Prostate Pool   2.6           Placenta   4.6           Uterus Pool   3.8           Ovarian ca. OVCAR-3   2.3           Ovarian ca. SK-OV-3   4.2           Ovarian ca. OVCAR-4   1.5           Ovarian ca. OVCAR-5   26.8           Ovarian ca. IGROV-1   2.6           Ovarian ca. OVCAR-8   0.5           Ovary   3.9           Breast ca. MCF-7   7.5           Breast ca. MDA-MB-231   17.1           Breast ca. BT 549   55.9           Breast ca. T47D   37.6           Breast ca. MDA-N   7.6           Breast Pool   5.4           Trachea   9.0           Lung   1.6           Fetal Lung   45.1           Lung ca. NCI-N417   0.0           Lung ca. LX-1   7.3           Lung ca. NCI-H146   0.8           Lung ca. SHP-77   4.1           Lung ca. A549   10.4           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   26.4           Lung ca. NCI-H460   7.6           Lung ca. HOP-62   10.4           Lung ca. NCI-H522   0.1           Liver   0.2           Fetal Liver   5.0           Liver ca. HepG2   7.9           Kidney Pool   6.1           Fetal Kidney   10.6           Renal ca. 786-0   8.5           Renal ca. A498   3.9           Renal ca. ACHN   2.7           Renal ca. UO-31   11.5           Renal ca. TK-10   12.2           Bladder   11.8           Gastric ca. (liver met.) NCI-N87   38.4           Gastric ca. KATO III   87.7           Colon ca. SW-948   5.1           Colon ca. SW480   6.0           Colon ca.* (SW480 met) SW620   4.5           Colon ca. HT29   5.4           Colon ca. HCT-116   6.4           Colon ca. CaCo-2   12.6           Colon cancer tissue   16.8           Colon ca. SW1116   0.7           Colon ca. Colo-205   0.7           Colon ca. SW-48   2.6           Colon Pool   6.2           Small Intestine Pool   3.3           Stomach Pool   3.9           Bone Marrow Pool   3.3           Fetal Heart   3.0           Heart Pool   3.1           Lymph Node Pool   4.8           Fetal Skeletal Muscle   2.8           Skeletal Muscle Pool   0.8           Spleen Pool   4.7           Thymus Pool   3.3           CNS cancer (glio/astro) U87-MG   24.8           CNS cancer (glio/astro) U-118-MG   40.1           CNS cancer (neuro; met) SK-N-AS   4.7           CNS cancer (astro) SF-539   2.0           CNS cancer (astro) SNB-75   13.4           CNS cancer (glio) SNB-19   2.5           CNS cancer (glio) SF-295   100.0           Brain (Amygdala) Pool   1.1           Brain (cerebellum)   0.7           Brain (fetal)   0.7           Brain (Hippocampus) Pool   1.3           Cerebral Cortex Pool   1.4           Brain (Substantia nigra) Pool   0.8           Brain (Thalamus) Pool   1.8           Brain (whole)   0.7           Spinal Cord Pool   1.4           Adrenal Gland   2.5           Pituitary gland Pool   0.4           Salivary Gland   0.4           Thyroid (female)   2.8           Pancreatic ca. CAPAN2   7.6           Pancreas Pool   6.2                        
     [0711] Table BC. General Screening Panel v1.5  
               TABLE BD                          Oncology_cell_line_screening_panel_v3.2                         Rel. Exp. (%)           Ag4285, Run       Tissue Name   259180693                             94905_Daoy_Medulloblastoma/   3.0       Cerebellum_sscDNA       94906_TE671_Medulloblastom/   0.0       Cerebellum_sscDNA       94907_D283 Med_Medulloblastoma/   2.6       Cerebellum_sscDNA       94908_PFSK-1_Primitive Neuroectodermal/   1.8       Cerebellum_sscDNA       94909_XF-498_CNS_sscDNA   33.2       94910_SNB-78_CNS/glioma_sscDNA   0.0       94911_SF-268_CNS/glioblastoma_sscDNA   2.2       94912_T98G_Glioblastoma_sscDNA   45.7       96776_SK-N-SH_Neuroblastoma   0.0       (metastasis)_sscDNA       94913_SF-295_CNS/glioblastoma_sscDNA   44.1       132565_NT2 pool_sscDNA   0.4       94914_Cerebellum_sscDNA   3.4       96777_Cerebellum_sscDNA   0.3       94916_NCI-H292_Mucoepidermoid   18.7       lung carcinoma_sscDNA       94917_DMS-114_Small cell lung cancer —     0.1       sscDNA       94918_DMS-79_Small cell lung cancer/   17.9       neuroendocrine_sscDNA       94919_NCI-H146_Small cell lung cancer/   5.0       neuroendocrine_sscDNA       94920_NCI-H526_Small cell lung cancer/   0.3       neuroendocrine_sscDNA       94921_NCI-N417_Small cell lung cancer/   0.3       neuroendocrine_sscDNA       94923_NCI-H82_Small cell lung cancer/   1.1       neuroendocrine_sscDNA       94924_NCI-H157_Squamous cell lung   37.4       cancer (metastasis)_sscDNA       94925_NCI-H1155_Large cell lung   3.2       cancer/neuroendocrine_sscDNA       94926_NCI-H1299_Large cell lung   4.4       cancer/neuroendocrine_sscDNA       94927_NCI-H727_Lung carcinoid_sscDNA   32.8       94928_NCI-UMC-11_Lung carcinoid_sscDNA   5.1       94929_LX-1_Small cell lung cancer_sscDNA   8.0       94930_Colo-205_Colon cancer_sscDNA   4.7       94931_KM12_Colon cancer_sscDNA   51.4       94932_KM20L2_Colon cancer_sscDNA   4.8       94933_NCI-H716_Colon cancer_sscDNA   35.4       94935_SW-48_Colon adenocarcinoma_sscDNA   20.3       94936_SW1116_Colon adenocarcinoma_sscDNA   2.3       94937_LS 174T_Colon adenocarcinoma_sscDNA   20.3       94938_SW-948_Colon adenocarcinoma_sscDNA   7.7       94939_SW-480_Colon adenocarcinoma_sscDNA   15.2       94940_NCI-SNU-5_Gastric carcinoma_sscDNA   4.3       112197_KATO III_Stomach_sscDNA   66.0       94943_NCI-SNU-16_Gastric carcinoma_sscDNA   3.6       94944_NCI-SNU-1_Gastric carcinoma_sscDNA   17.2       94946_RF-1_Gastric adenocarcinoma_sscDNA   0.5       94947_RF-48_Gastric adenocarcinoma_sscDNA   0.3       96778_MKN-45_Gastric carcinoma_sscDNA   100.0       94949_NCI-N87_Gastric carcinoma_sscDNA   13.3       94951_OVCAR-5_Ovarian carcinoma_sscDNA   3.9       94952_RL95-2_Uterine carcinoma_sscDNA   17.2       94953_HelaS3_Cervical adenocarcinoma —     6.7       sscDNA       94954_Ca Ski_Cervical epidermoid   6.7       carcinoma (metastasis)_sscDNA       94955_ES-2_Ovarian clear cell   3.0       carcinoma_sscDNA       94957_Ramos/6 h stim_Stimulated with   3.7       PMA/ionomycin 6 h_sscDNA       94958_Ramos/14 h stim_Stimulated with   2.6       PMA/ionomycin 14 h_sscDNA       94962_MEG-01_Chronic myelogenous   10.7       leukemia (megokaryoblast)_sscDNA       94963_Raji_Burkitt&#39;s lymphoma_sscDNA   0.0       94964_Daudi_Burkitt&#39;s lymphoma —     0.0       sscDNA       94965_U266_B-cell plasmacytoma/   0.0       myeloma_sscDNA       94968_CA46_Burkitt&#39;s lymphoma_sscDNA   0.0       94970_RL_non-Hodgkin&#39;s B-cell   0.5       lymphoma_sscDNA       94972_JM1_pre-B-cell lymphoma/   0.0       leukemia_sscDNA       94973_Jurkat_T cell leukemia_sscDNA   0.0       94974_TF-1_Erythroleukemia_sscDNA   12.2       94975_HUT 78_T-cell lymphoma_sscDNA   10.6       94977_U937_Histiocytic lymphoma —     6.3       sscDNA       94980_KU-812_Myelogenous leukemia —     2.5       sscDNA       94981_769-P_Clear cell renal   2.7       carcinoma_sscDNA       94983_Caki-2_Clear cell renal   11.0       carcinoma_sscDNA       94984_SW 839_Clear cell renal   10.5       carcinoma_sscDNA       94986_G401_Wilms&#39; tumor_sscDNA   0.0       126768_293 cells_sscDNA   2.0       94987_Hs766T_Pancreatic carcinoma   9.2       (LN metastasis)_sscDNA       94988_CAPAN-1_Pancreatic   18.6       adenocarcinoma (liver metastasis) —         sscDNA       94989_SU86.86_Pancreatic carcinoma   47.0       (liver metastasis)_sscDNA       94990_BxPC-3_Pancreatic   19.6       adenocarcinoma_sscDNA       94991_HPAC_Pancreatic   17.6       adenocarcinoma_sscDNA       94992_MIA PaCa-2_Pancreatic   0.8       carcinoma_sscDNA       94993_CFPAC-1_Pancreatic ductal   40.3       adenocarcinoma_sscDNA       94994_PANC-1_Pancreatic epithelioid   15.2       ductal carcinoma_sscDNA       94996_T24_Bladder carcinma   3.8       transitional cell)_sscDNA       94997_5637_Bladder carcinoma_sscDNA   37.1       94998_HT-1197_Bladder   7.5       carcinoma_sscDNA       94999_UM-UC-3_Bladder carcinma   0.3       (transitional cell)_sscDNA       95000_A204_Rhabdomyosarcoma_sscDNA   20.2       95001_HT-1080_Fibrosarcoma_sscDNA   19.3       95002_MG-63_Osteosarcoma   15.9       (bone)_sscDNA       95003_SK-LMS-1_Leiomyosarcoma   25.7       (vulva)_sscDNA       95004_SJRH30_Rhabdomyosarcoma   0.0       (met to bone marrow)_sscDNA       95005_A431_Epidermoid   19.8       carcinoma_sscDNA       95007_WM266-4_Melanoma_sscDNA   10.1       112195_DU145_Prostate_sscDNA   3.7       95012_MDA-MB-468_Breast   11.6       adenocarcinoma_sscDNA       112196_SSC-4_Tongue_sscDNA   14.7       112194_SSC-9_Tongue_sscDNA   12.4       112191_SSC-15_Tongue_sscDNA   36.1       95017_CAL 27_Squamous cell carcinoma   48.6       of tongue_sscDNA                  
 
     [0712]               TABLE BE                          Panel 4.1D                         Rel. Exp. (%)           Ag4285, Run       Tissue Name   223211035                             Secondary Th1 act   10.6       Secondary Th2 act   14.9       Secondary Tr1 act   17.1       Secondary Th1 rest   2.1       Secondary Th2 rest   6.0       Secondary Tr1 rest   4.1       Primary Th1 act   14.4       Primary Th2 act   21.6       Primary Tr1 act   23.5       Primary Th1 rest   4.3       Primary Th2 rest   3.3       Primary Tr1 rest   11.5       CD45RA CD4 lymphocyte act   21.2       CD45RO CD4 lymphocyte act   21.0       CD8 lymphocyte act   13.0       Secondary CD8 lymphocyte rest   12.6       Secondary CD8 lymphocyte act   6.0       CD4 lymphocyte none   6.9       2ry Th1/Th2/Tr1_anti-CD95 CH11   7.1       LAK cells rest   27.2       LAK cells IL-2   2.8       LAK cells IL-2 + IL-12   7.1       LAK cells IL-2 + IFN gamma   8.1       LAK cells IL-2 + IL-18   11.1       LAK cells PMA/ionomycin   100.0       NK Cells IL-2 rest   12.4       Two Way MLR 3 day   17.3       Two Way MLR 5 day   14.1       Two Way MLR 7 day   12.2       PBMC rest   13.7       PBMC PWM   27.9       PBMC PHA-L   18.3       Ramos (B cell) none   2.9       Ramos (B cell) ionomycin   4.2       B lymphocytes PWM   38.7       B lymphocytes CD40L and IL-4   61.6       EOL-1 dbcAMP   35.8       EOL-1 dbcAMP PMA/ionomycin   60.3       Dendritic cells none   29.7       Dendritic cells LPS   71.2       Dendritic cells anti-CD40   54.7       Monocytes rest   50.0       Monocytes LPS   54.7       Macrophages rest   28.1       Macrophages LPS   16.2       HUVEC none   5.7       HUVEC starved   11.1       HUVEC IL-1beta   8.0       HUVEC IFN gamma   29.7       HUVEC TNF alpha + IFN gamma   8.5       HUVEC TNF alpha + IL4   4.4       HUVEC IL-11   7.9       Lung Microvascular EC none   7.0       Lung Microvascular EC TNFalpha + IL-1beta   3.2       Microvascular Dermal EC none   10.5       Microsvasular Dermal EC TNFalpha + IL-1beta   3.7       Bronchial epithelium TNFalpha + IL1beta   14.8       Small airway epithelium none   8.4       Small airway epithelium TNFalpha + IL-1beta   18.0       Coronery artery SMC rest   12.2       Coronery artery SMC TNFalpha + IL-1beta   14.7       Astrocytes rest   16.5       Astrocytes TNFalpha + IL-1beta   23.0       KU-812 (Basophil) rest   1.4       KU-812 (Basophil) PMA/ionomycin   26.1       CCD1106 (Keratinocytes) none   16.0       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   16.5       Liver cirrhosis   10.4       NCI-H292 none   14.7       NCI-H292 IL-4   22.5       NCI-H292 IL-9   31.4       NCI-H292 IL-13   22.2       NCI-H292 IFN gamma   29.5       HPAEC none   7.6       HPAEC TNF alpha + IL-1 beta   9.6       Lung fibroblast none   9.2       Lung fibroblast TNF alpha + IL-1 beta   21.9       Lung fibroblast IL-4   16.0       Lung fibroblast IL-9   10.9       Lung fibroblast IL-13   8.9       Lung fibroblast IFN gamma   16.5       Dermal fibroblast CCD1070 rest   14.8       Dermal fibroblast CCD1070 TNF alpha   32.5       Dermal fibroblast CCD1070 IL-1 beta   15.6       Dermal fibroblast IFN gamma   9.2       Dermal fibroblast IL-4   89.5       Dermal Fibroblasts rest   13.7       Neutrophils TNFa + LPS   1.8       Neutrophils rest   3.9       Colon   2.9       Lung   27.5       Thymus   14.0       Kidney   6.0                    
     [0713]               TABLE BF                          Panel 5 Islet                         Rel. Exp. (%)           Ag4285, Run       Tissue Name   182400679                             97457_Patient-02go_adipose   1.8       97476_Patient-07sk_skeletal muscle   15.9       97477_Patient-07ut_uterus   3.3       97478_Patient-07pl_placenta   87.7       99167_Bayer Patient 1   2.9       97482_Patient-08ut_uterus   5.4       97483_Patient-08pl_placenta   72.2       97486_Patient-09sk_skeletal muscle   2.4       97487_Patient-09ut_uterus   13.6       97488_Patient-09pl_placenta   46.0       97492_Patient-10ut_uterus   11.0       97493_Patient-10pl_placenta   100.0       97495_Patient-11go_adipose   21.8       97496_Patient-11sk_skeletal muscle   4.7       97497_Patient-11ut_uterus   13.8       97498_Patient-11pl_placenta   14.1       97500_Patient-12go_adipose   21.6       97501_Patient-12sk_skeletal muscle   7.3       97502_Patient-12ut_uterus   10.6       97503_Patient-12pl_placenta   41.5       94721_Donor 2 U - A_Mesenchymal Stem Cells   12.6       94722_Donor 2 U - B_Mesenchymal Stem Cells   5.7       94723_Donor 2 U - C_Mesenchymal Stem Cells   12.3       94709_Donor 2 AM - A_adipose   14.7       94710_Donor 2 AM - B_adipose   10.7       94711_Donor 2 AM - C_adipose   6.5       94712_Donor 2 AD - A_adipose   29.9       94713_Donor 2 AD - B_adipose   29.3       94714_Donor 2 AD - C_adipose   38.2       94742_Donor 3 U - A_Mesenchymal Stem Cells   7.2       94743_Donor 3 U - B_Mesenchymal Stem Cells   12.7       94730_Donor 3 AM - A_adipose   26.1       94731_Donor 3 AM - B_adipose   13.3       94732_Donor 3 AM - C_adipose   13.8       94733_Donor 3 AD - A_adipose   50.3       94734_Donor 3 AD - B_adipose   12.0       94735_Donor 3 AD - C_adipose   39.8       77138_Liver_HepG2untreated   66.0       73556_Heart_Cardiac stromal cells (primary)   0.0       81735_Small Intestine   17.3       72409_Kidney_Proximal Convoluted Tubule   19.5       82685_Small intestine_Duodenum   1.2       90650_Adrenal_Adrenocortical adenoma   4.5       72410_Kidney_HRCE   28.7       72411_Kidney_HRE   10.0       73139_Uterus_Uterine smooth muscle cells   5.3                    
     [0714]               TABLE BG                          Panel 5D                         Rel. Exp. (%)           Ag4285, Run       Tissue Name   181457564                             97457_Patient-02go_adipose   14.5       97476_Patient-07sk_skeletal muscle   10.6       97477_Patient-07ut_uterus   3.1       97478_Patient-07pl_placenta   61.6       97481_Patient-08sk_skeletal muscle   12.7       97482_Patient-08ut_uterus   5.1       97483_Patient-08pl_placenta   62.9       97486_Patient-09sk_skeletal muscle   2.1       97487_Patient-09ut_uterus   7.1       97488_Patient-09pl_placenta   34.9       97492_Patient-10ut_uterus   5.7       97493_Patient-10pl_placenta   100.0       97495_Patient-11go_adipose   13.9       97496_Patient-11sk_skeletal muscle   2.4       97497_Patient-11ut_uterus   8.5       97498_Patient-11pl_placenta   32.3       97500_Patient-12go_adipose   12.1       97501 _Patient-12sk_skeletal muscle   6.3       97502_Patient-12ut_uterus   6.5       97503_Patient-12pl_placenta   25.9       94721_Donor 2 U - A_Mesenchymal Stem Cells   8.8       94722_Donor 2 U - B_Mesenchymal Stem Cells   7.6       94723_Donor 2 U - C_Mesenchymal Stem Cells   7.6       94709_Donor 2 AM - A_adipose   9.9       94710_Donor 2 AM - B_adipose   9.5       94711_Donor 2 AM - C_adipose   7.3       94712_Donor 2 AD - A_adipose   22.1       94713_Donor 2 AD - B_adipose   28.9       94714_Donor 2 AD - C_adipose   37.9       94742_Donor 3 U - A_Mesenchymal Stem Cells   7.5       94743_Donor 3 U - B_Mesenchymal Stem Cells   8.7       94730_Donor 3 AM - A_adipose   22.7       94731_Donor 3 AM - B_adipose   9.8       94732_Donor 3 AM - C_adipose   14.2       94733_Donor 3 AD - A_adipose   34.4       94734_Donor 3 AD - B_adipose   19.3       94735_Donor 3 AD - C_adipose   32.8       77138_Liver_HepG2untreated   46.0       73556_Heart_Cardiac stromal cells (primary)   8.3       81735_Small Intestine   9.7       72409_Kidney_Proximal Convoluted Tubule   18.0       82685_Small intestine_Duodenum   5.1       90650_Adrenal_Adrenocortical adenoma   2.4       72410_Kidney_HRCE   16.2       72411_Kidney_HRE   11.3       73139_Uterus_Uterine smooth muscle cells   4.2                    
     [0715]               TABLE BH                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag4285, Run           Tissue Name   260280467                                         Colon cancer 1   12.7           Colon cancer NAT 1   6.0           Colon cancer 2   63.3           Colon cancer NAT 2   8.6           Colon cancer 3   59.5           Colon cancer NAT 3   25.3           Colon malignant cancer 4   59.9           Colon normal adjacent tissue 4   6.7           Lung cancer 1   84.7           Lung NAT 1   5.3           Lung cancer 2   43.2           Lung NAT 2   14.0           Squamous cell carcinoma 3   51.4           Lung NAT 3   5.5           metastatic melanoma 1   27.5           Melanoma 2   6.4           Melanoma 3   8.4           metastatic melanoma 4   43.5           metastatic melanoma 5   49.0           Bladder cancer 1   3.2           Bladder cancer NAT 1   0.0           Bladder cancer 2   17.7           Bladder cancer NAT 2   0.5           Bladder cancer NAT 3   0.8           Bladder cancer NAT 4   3.1           Prostate adenocarcinoma 1   20.4           Prostate adenocarcinoma 2   2.0           Prostate adenocarcinoma 3   4.8           Prostate adenocarcinoma 4   24.5           Prostate cancer NAT 5   5.8           Prostate adenocarcinoma 6   1.6           Prostate adenocarcinoma 7   5.2           Prostate adenocarcinoma 8   1.5           Prostate adenocarcinoma 9   13.2           Prostate cancer NAT 10   0.6           Kidney cancer 1   15.4           Kidney NAT 1   7.6           Kidney cancer 2   100.0           Kidney NAT 2   7.0           Kidney cancer 3   21.0           Kidney NAT 3   2.5           Kidney cancer 4   8.9           Kidney NAT 4   2.0                        
     [0716] General_screening_panel − v1.4 Summary: Ag4285 Highest expression of this gene is detected in brain cancer SF-295 cell line (CT=23). High levels of expression of this gene is also seen in number of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers.  
     [0717] This gene codes for aryl hydrocarbon receptor (AhR). AhR is a ligand-activated nuclear transcription factor that mediates responses to toxic halogenated aromatic toxins such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polynuclear aromatic hydrocarbons, combustion products, and numerous phytochemicals such as flavonoids and indole-3-carbinol (13C). The nuclear AhR complex is a heterodimer containing the AhR and AhR nuclear translocator (Arnt) proteins, and the molecular mechanism of AhR action is associated with binding of the heterodimer to dioxin responsive elements (DREs) in regulatory regions of Ah-responsive genes. TCDD, a ‘xenodioxin’, is a multi-site carcinogen in several species and possibly in humans, whereas natural AhR ligands including I3C and flavonoids tend to protect against cancer. Both TCDD and phytochemicals inhibit estrogen-induced breast and endometrial cancers (Safe S., 2001, Toxicol Lett 120(1-3):1-7, PMID: 11323156). Thus, therapeutic modulation of the expression or function of AhR may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0718] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. AhR is a member of the PAS (Per-Ahr-Sim) superfamily of transcription factors having functions in development and detoxification (Wilson C L, Safe S., 1998, Toxicol Pathol 26(5):657-71, PMID: 9789953). It forms an active complex with ARNT (a nuclear translocator) that crosses the nuclear membrane and binds DNA. In addition, TCDD is a known activating ligand for AhR that initiates expression of multiple genes, including CYP1B1 and glutathione S-transferase. Studies using AhR −/− MEFs have indicated that constitutive AhR activity is required for basal expression of CYP1B1 and suppression of lipogenesis in subconfluent cultures. Activation of AhR suppresses PPAR gamma and adipogenesis. AhR is a constitutive inhibitor of triglyceride synthesis, and as an early regulator of adipocyte differentiation (Alexander et al., 1998, J Cell Sci 111 (Pt 22):3311-22, PMID: 9788873). Furthermore, using CuraGen&#39;s GeneCalling™ method of differential gene expression, this gene was found to be up-regulated by 1.9 fold in the adipose tissues of human gestational diabetics relative to normal pregnant females. Furthermore, the mouse ortholog of this gene was found to have altered expression in a mouse model of dietary-induced obesity. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0719] Interestingly, this gene is expressed at much higher levels in fetal (CTs=24-27) when compared to adult lung and liver (CTs=29-31). This observation suggests that expression of this gene can be used to distinguish fetal from adult lung and liver. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance growth or development of these tissues in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung and liver related diseases.  
     [0720] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0721] General_screening_panel_v1.5 Summary: Ag4285 Highest expression of this gene is detected in brain cancer SF-295 cell line (CT=22.6). Consistent with expression pattern seen in panel 1.4, high levels of expression of this gene is seen in number of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. In addition, moderate levels of expression of this gene are also seen in tissues with endocrine/metabolic functions and also in all the regions of central nervous system. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0722] Oncology_cell_line_screening_panel_v3.2 Summary: Ag4285 Highest expression of this gene is detected in gastric cancer MKN-45 cell line (CT=25.8). In addition, high to moderate levels of expression of this gene is seen in number of cell lines derived from tongue, prostate, vulva, epidermoid, bone, fibrosarcoma, rhabdomyosarcoma, bladder, pancreatic, Wilm tumor, renal, B- and T-cell lymphomas and leukemia, cervical, gastric, colon, lung and brain. Therefore, therapeutic modulation of this gene may be useful in the treatment of these cancers. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0723] Panel 4.1D Summary: Ag4285 Highest expression of this gene is detected PMA/ionomycin treated LAK cells (CT=27.5). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0724] Panel 5 Islet Summary: Ag4285 Highest expression of this gene is detected in placenta (CTs=28). In addition, significant expression of this gene is also seen in all the tissues with metabolic/endocrine functions. These results are consistent with the expression pattern seen in panel 1.4 and 1.5. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0725] Panel 5D Summary: Ag4285 Highest expression of this gene is detected in placenta (CTs=28). In addition, significant expression of this gene is also seen in all the tissues with metabolic/endocrine functions. These results are consistent with the expression pattern seen in panels 5 Islet, 1.4 and 1.5. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0726] general oncology screening panel_v — 2.4 Summary: Ag4285 Highest expression of this gene is detected in kidney cancer 2 (CT=24.4). High expression of this gene is also seen 5 in melanoma and normal and cancer samples derived from colon, lung, bladder, prostate and kidney. Interestingly, expression of this gene is higher in cancer samples as compared to corresponding normal adjacent samples. Therefore, expression of this gene may be used as diagnostic marker for the detection of melanoma, colon, lung, bladder, prostate and kidney cancers. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0727] C. CG105521-01: Stearoyl CoA Desaturase-Like Gene  
     [0728] Expression of gene CG105521-01 was assessed using the primer-probe set Ag4290, described in Table CA. Results of the RTQ-PCR runs are shown in Tables CB, CC, CD, CE, CF and CG.  
               TABLE CA                          Probe Name Ag4290                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-tctgctgagtaaggaacacgat-   22   4112   227           3′       Probe   TET-5′-tcaagattctaaagctcaa   30   4136   228           ttcaagtgaca-3′-TAMRA       Reverse   5′-tccggactcttgatcagatct-3′   21   4182   229                  
 
     [0729]               TABLE CB                          AI_comprehensive panel_v1.0                                 Rel. Exp. (%)               Ag4290, Run           Tissue Name   248389291                                         110967 COPD-F   0.3           110980 COPD-F   0.3           110968 COPD-M   0.3           110977 COPD-M   0.7           110989 Emphysema-F   2.1           110992 Emphysema-F   0.7           110993 Emphysema-F   0.6           110994 Emphysema-F   0.1           110995 Emphysema-F   2.5           110996 Emphysema-F   0.4           110997 Asthma-M   0.7           111001 Asthma-F   0.4           111002 Asthma-F   1.0           111003 Atopic Asthma-F   2.2           111004 Atopic Asthma-F   1.8           111005 Atopic Asthma-F   1.2           111006 Atopic Asthma-F   0.3           111417 Allergy-M   0.8           112347 Allergy-M   0.0           112349 Normal Lung-F   0.0           112357 Normal Lung-F   10.9           112354 Normal Lung-M   2.8           112374 Crohns-F   0.7           112389 Match Control Crohns-F   2.3           112375 Crohns-F   0.5           112732 Match Control Crohns-F   3.2           112725 Crohns-M   0.5           112387 Match Control Crohns-M   0.2           112378 Crohns-M   0.0           112390 Match Control Crohns-M   2.7           112726 Crohns-M   1.9           112731 Match Control Crohns-M   1.7           112380 Ulcer Col-F   0.8           112734 Match Control Ulcer Col-F   4.8           112384 Ulcer Col-F   1.6           112737 Match Control Ulcer Col-F   0.8           112386 Ulcer Col-F   0.0           112738 Match Control Ulcer Col-F   4.3           112381 Ulcer Col-M   0.0           112735 Match Control Ulcer Col-M   0.7           112382 Ulcer Col-M   2.0           112394 Match Control Ulcer Col-M   0.0           112383 Ulcer Col-M   0.7           112736 Match Control Ulcer Col-M   2.8           112423 Psoriasis-F   1.3           112427 Match Control Psoriasis-F   2.2           112418 Psoriasis-M   0.1           112723 Match Control Psoriasis-M   1.0           112419 Psoriasis-M   0.4           112424 Match Control Psoriasis-M   1.0           112420 Psoriasis-M   1.4           112425 Match Control Psoriasis-M   1.5           104689 (MF) OA Bone-Backus   39.2           104690 (MF) Adj “Normal” Bone-Backus   14.8           104691 (MF) OA Synovium-Backus   5.6           104692 (BA) OA Cartilage-Backus   3.3           104694 (BA) OA Bone-Backus   27.0           104695 (BA) Adj “Normal” Bone-Backus   100.0           104696 (BA) OA Synovium-Backus   31.2           104700 (SS) OA Bone-Backus   10.8           104701 (SS) Adj “Normal” Bone-Backus   20.9           104702 (SS) OA Synovium-Backus   50.3           117093 OA Cartilage Rep7   0.5           112672 OA Bone5   3.4           112673 OA Synovium5   1.2           112674 OA Synovial Fluid cells5   0.6           117100 OA Cartilage Rep14   0.1           112756 OA Bone9   6.4           112757 OA Synovium9   0.5           112758 OA Synovial Fluid Cells9   0.4           117125 RA Cartilage Rep2   0.0           113492 Bone2 RA   2.3           113493 Synovium2 RA   1.0           113494 Syn Fluid Cells RA   2.7           113499 Cartilage4 RA   2.9           113500 Bone4 RA   4.5           113501 Synovium4 RA   3.7           113502 Syn Fluid Cells4 RA   1.7           113495 Cartilage3 RA   2.9           113496 Bone3 RA   3.7           113497 Synovium3 RA   1.2           113498 Syn Fluid Cells3 RA   4.5           117106 Normal Cartilage Rep20   0.1           113663 Bone3 Normal   0.0           113664 Synovium3 Normal   0.0           113665 Syn Fluid Cells3 Normal   0.1           117107 Normal Cartilage Rep22   0.0           113667 Bone4 Normal   0.2           113668 Synovium4 Normal   0.2           113669 Syn Fluid Cells4 Normal   0.5                        
     [0730]               TABLE CC                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag4290, Run           Tissue Name   249266040                                         AD 1 Hippo   12.8           AD 2 Hippo   23.3           AD 3 Hippo   8.1           AD 4 Hippo   7.1           AD 5 Hippo   22.8           AD 6 Hippo   68.3           Control 2 Hippo   28.1           Control 4 Hippo   18.6           Control (Path) 3 Hippo   8.2           AD 1 Temporal Ctx   15.3           AD 2 Temporal Ctx   27.5           AD 3 Temporal Ctx   4.6           AD 4 Temporal Ctx   20.7           AD 5 Inf Temporal Ctx   100.0           AD 5 Sup Temporal Ctx   34.4           AD 6 Inf Temporal Ctx   55.9           AD 6 Sup Temporal Ctx   46.3           Control 1 Temporal Ctx   4.3           Control 2 Temporal Ctx   20.0           Control 3 Temporal Ctx   14.2           Control 3 Temporal Ctx   10.5           Control (Path) 1 Temporal Ctx   20.4           Control (Path) 2 Temporal Ctx   24.1           Control (Path) 3 Temporal Ctx   5.1           Control (Path) 4 Temporal Ctx   17.7           AD 1 Occipital Ctx   12.5           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   6.7           AD 4 Occipital Ctx   25.3           AD 5 Occipital Ctx   17.0           AD 6 Occipital Ctx   24.7           Control 1 Occipital Ctx   3.7           Control 2 Occipital Ctx   30.8           Control 3 Occipital Ctx   18.3           Control 4 Occipital Ctx   17.7           Control (Path) 1 Occipital Ctx   37.4           Control (Path) 2 Occipital Ctx   12.6           Control (Path) 3 Occipital Ctx   7.8           Control (Path) 4 Occipital Ctx   8.7           Control 1 Parietal Ctx   6.7           Control 2 Parietal Ctx   27.0           Control 3 Parietal Ctx   16.7           Control (Path) 1 Parietal Ctx   25.7           Control (Path) 2 Parietal Ctx   25.2           Control (Path) 3 Parietal Ctx   7.5           Control (Path) 4 Parietal Ctx   22.5                        
     [0731]               TABLE CD                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4290, Run           Tissue Name   222183058                                         Adipose   1.9           Melanoma* Hs688(A).T   0.4           Melanoma* Hs688(B).T   0.7           Melanoma* M14   5.8           Melanoma* LOXIMVI   0.8           Melanoma* SK-MEL-5   38.7           Squamous cell carcinoma SCC-4   6.0           Testis Pool   0.6           Prostate ca.* (bone met) PC-3   3.3           Prostate Pool   2.3           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   10.2           Ovarian ca. SK-OV-3   0.7           Ovarian ca. OVCAR-4   0.4           Ovarian ca. OVCAR-5   23.8           Ovarian ca. IGROV-1   11.8           Ovarian ca. OVCAR-8   3.6           Ovary   1.1           Breast ca. MCF-7   14.0           Breast ca. MDA-MB-231   4.0           Breast ca. BT 549   100.0           Breast ca. T47D   47.6           Breast ca. MDA-N   6.8           Breast Pool   0.1           Trachea   0.7           Lung   0.2           Fetal Lung   0.7           Lung ca. NCI-N417   0.3           Lung ca. LX-1   12.4           Lung ca. NCI-H146   1.7           Lung ca. SHP-77   4.8           Lung ca. A549   12.6           Lung ca. NCI-H526   1.3           Lung ca. NCI-H23   24.0           Lung ca. NCI-H460   6.4           Lung ca. HOP-62   3.9           Lung ca. NCI-H522   2.9           Liver   1.5           Fetal Liver   15.0           Liver ca. HepG2   25.7           Kidney Pool   0.1           Fetal Kidney   0.2           Renal ca. 786-0   9.2           Renal ca. A498   13.3           Renal ca. ACHN   11.7           Renal ca. UO-31   5.2           Renal ca. TK-10   15.8           Bladder   0.4           Gastric ca. (liver met.) NCI-N87   3.9           Gastric ca. KATO III   1.7           Colon ca. SW-948   0.8           Colon ca. SW480   4.6           Colon ca.* (SW480 met) SW620   5.0           Colon ca. HT29   10.4           Colon ca. HCT-116   15.7           Colon ca. CaCo-2   11.7           Colon cancer tissue   3.3           Colon ca. SW1116   1.4           Colon ca. Colo-205   9.7           Colon ca. SW-48   6.6           Colon Pool   0.1           Small Intestine Pool   0.1           Stomach Pool   0.2           Bone Marrow Pool   0.1           Fetal Heart   0.1           Heart Pool   0.0           Lymph Node Pool   0.2           Fetal Skeletal Muscle   1.3           Skeletal Muscle Pool   0.0           Spleen Pool   0.2           Thymus Pool   0.3           CNS cancer (glio/astro) U87-MG   27.9           CNS cancer (glio/astro) U-118-MG   0.5           CNS cancer (neuro; met) SK-N-AS   4.2           CNS cancer (astro) SF-539   3.7           CNS cancer (astro) SNB-75   0.9           CNS cancer (glio) SNB-19   9.4           CNS cancer (glio) SF-295   5.8           Brain (Amygdala) Pool   7.2           Brain (cerebellum)   4.8           Brain (fetal)   2.8           Brain (Hippocampus) Pool   7.3           Cerebral Cortex Pool   8.4           Brain (Substantia nigra) Pool   9.0           Brain (Thalamus) Pool   11.9           Brain (whole)   5.2           Spinal Cord Pool   12.6           Adrenal Gland   3.0           Pituitary gland Pool   0.1           Salivary Gland   0.2           Thyroid (female)   0.0           Pancreatic ca. CAPAN2   31.2           Pancreas Pool   0.2                        
     [0732]               TABLE CE                          Panel 4.1D                         Rel. Exp. (%)           Ag4290, Run       Tissue Name   248386497                             Secondary Th1 act   9.8       Secondary Th2 act   10.5       Secondary Tr1 act   3.0       Secondary Th1 rest   1.0       Secondary Th2 rest   0.6       Secondary Tr1 rest   1.0       Primary Th1 act   3.5       Primary Th2 act   21.5       Primary Tr1 act   19.9       Primary Th1 rest   0.3       Primary Th2 rest   0.5       Primary Tr1 rest   1.1       CD45RA CD4 lymphocyte act   3.6       CD45RO CD4 lymphocyte act   7.4       CD8 lymphocyte act   4.2       Secondary CD8 lymphocyte rest   5.4       Secondary CD8 lymphocyte act   2.2       CD4 lymphocyte none   0.0       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.2       LAK cells rest   18.9       LAK cells IL-2   5.1       LAK cells IL-2 + IL-12   0.6       LAK cells IL-2 + IFN gamma   0.5       LAK cells IL-2 + IL-18   0.5       LAK cells PMA/ionomycin   22.2       NK Cells IL-2 rest   6.2       Two Way MLR 3 day   1.2       Two Way MLR 5 day   0.9       Two Way MLR 7 day   1.1       PBMC rest   0.1       PBMC PWM   2.5       PBMC PHA-L   7.9       Ramos (B cell) none   8.8       Ramos (B cell) ionomycin   24.3       B lymphocytes PWM   4.1       B lymphocytes CD40L and IL-4   4.8       EOL-1 dbcAMP   16.5       EOL-1 dbcAMP PMA/ionomycin   0.9       Dendritic cells none   44.1       Dendritic cells LPS   9.5       Dendritic cells anti-CD40   4.4       Monocytes rest   0.1       Monocytes LPS   1.3       Macrophages rest   4.9       Macrophages LPS   0.4       HUVEC none   19.6       HUVEC starved   29.1       HUVEC IL-1beta   27.5       HUVEC IFN gamma   9.9       HUVEC TNF alpha + IFN gamma   8.5       HUVEC TNF alpha + IL4   7.8       HUVEC IL-11   14.7       Lung Microvascular EC none   10.4       Lung Microvascular EC TNFalpha + IL-1beta   2.5       Microvascular Dermal EC none   1.5       Microsvasular Dermal EC TNFalpha + IL-1beta   2.8       Bronchial epithelium TNFalpha + IL1beta   25.0       Small airway epithelium none   14.6       Small airway epithelium TNFalpha + IL-1beta   100.0       Coronery artery SMC rest   11.8       Coronery artery SMC TNFalpha + IL-1beta   11.9       Astrocytes rest   4.9       Astrocytes TNFalpha + IL-1beta   1.6       KU-812 (Basophil) rest   18.6       KU-812 (Basophil) PMA/ionomycin   22.2       CCD1106 (Keratinocytes) none   50.0       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   11.5       Liver cirrhosis   7.0       NCI-H292 none   45.7       NCI-H292 IL-4   24.7       NCI-H292 IL-9   31.9       NCI-H292 IL-13   43.5       NCI-H292 IFN gamma   15.0       HPAEC none   5.6       HPAEC TNF alpha + IL-1 beta   17.4       Lung fibroblast none   47.0       Lung fibroblast TNF alpha + IL-1 beta   10.3       Lung fibroblast IL-4   12.7       Lung fibroblast IL-9   22.5       Lung fibroblast IL-13   6.0       Lung fibroblast IFN gamma   21.2       Dermal fibroblast CCD1070 rest   2.3       Dermal fibroblast CCD1070 TNF alpha   6.3       Dermal fibroblast CCD1070 IL-1 beta   2.2       Dermal fibroblast IFN gamma   17.8       Dermal fibroblast IL-4   37.1       Dermal Fibroblasts rest   21.6       Neutrophils TNFa + LPS   0.0       Neutrophils rest   0.0       Colon   0.1       Lung   1.0       Thymus   0.4       Kidney   1.2                    
     [0733]               TABLE CF                          Panel 5 Islet                         Rel. Exp. (%)           Ag4290, Run       Tissue Name   271406443                             97457_Patient-02go_adipose   6.3       97476_Patient-07sk_skeletal muscle   0.9       97477_Patient-07ut_uterus   0.1       97478_Patient-07pl_placenta   0.3       99167_Bayer Patient 1   7.2       97482_Patient-08ut_uterus   0.1       97483_Patient-08pl_placenta   0.4       97486_Patient-09sk_skeletal muscle   0.3       97487_Patient-09ut_uterus   0.2       97488_Patient-09pl_placenta   0.1       97492_Patient-10ut_uterus   0.2       97493_Patient-10pl_placenta   0.3       97495_Patient-11go_adipose   0.7       97496_Patient-11sk_skeletal muscle   0.0       97497_Patient-11ut_uterus   0.3       97498_Patient-11pl_placenta   0.3       97500_Patient-12go_adipose   2.6       97501_Patient-12sk_skeletal muscle   0.2       97502_Patient-12ut_uterus   0.4       97503_Patient-12pl_placenta   0.3       94721_Donor 2 U - A_Mesenchymal Stem Cells   7.0       94722_Donor 2 U - B_Mesenchymal Stem Cells   4.7       94723_Donor 2 U - C_Mesenchymal Stem Cells   3.8       94709_Donor 2 AM - A_adipose   11.3       94710_Donor 2 AM - B_adipose   9.9       94711_Donor 2 AM - C_adipose   7.0       94712_Donor 2 AD - A_adipose   39.0       94713_Donor 2 AD - B_adipose   54.7       94714_Donor 2 AD - C_adipose   51.4       94742_Donor 3 U - A_Mesenchymal Stem Cells   0.0       94743_Donor 3 U - B_Mesenchymal Stem Cells   5.5       94730_Donor 3 AM - A_adipose   11.8       94731_Donor 3 AM - B_adipose   5.7       94732_Donor 3 AM - C_adipose   6.4       94733_Donor 3 AD - A_adipose   51.1       94734_Donor 3 AD - B_adipose   33.9       94735_Donor 3 AD - C_adipose   48.0       77138_Liver_HepG2untreated   100.0       73556_Heart_Cardiac stromal cells (primary)   1.2       81735_Small Intestine   0.7       72409_Kidney_Proximal Convoluted Tubule   6.0       82685_Small intestine_Duodenum   0.4       90650_Adrenal_Adrenocortical adenoma   4.7       72410_Kidney_HRCE   25.2       72411_Kidney_HRE   17.4       73139_Uterus_Uterine smooth muscle cells   8.5                    
     [0734]               TABLE CG                          Panel 5D                         Rel. Exp. (%)           Ag4290, Run       Tissue Name   182304009                             97457_Patient-02go_adipose   8.5       97476_Patient-07sk_skeletal muscle   0.9       97477_Patient-07ut_uterus   0.1       97478_Patient-07pl_placenta   0.5       97481_Patient-08sk_skeletal muscle   2.2       97482_Patient-08ut_uterus   0.1       97483_Patient-08pl_placenta   0.3       97486_Patient-09sk_skeletal muscle   0.1       97487_Patient-09ut_uterus   0.1       97488_Patient-09pl_placenta   0.1       97492_Patient-10ut_uterus   0.3       97493_Patient-10pl_placenta   0.3       97495_Patient-11go_adipose   0.7       97496_Patient-11sk_skeletal muscle   0.0       97497_Patient-11ut_uterus   0.3       97498_Patient-11pl_placenta   0.4       97500_Patient-12go_adipose   3.4       97501_Patient-12sk_skeletal muscle   0.6       97502_Patient-12ut_uterus   0.4       97503_Patient-12pl_placenta   0.2       94721_Donor 2 U - A_Mesenchymal Stem Cells   7.3       94722_Donor 2 U - B_Mesenchymal Stem Cells   5.0       94723_Donor 2 U - C_Mesenchymal Stem Cells   5.4       94709_Donor 2 AM - A_adipose   14.8       94710_Donor 2 AM - B_adipose   7.1       94711_Donor 2 AM - C_adipose   5.4       94712_Donor 2 AD - A_adipose   41.8       94713_Donor 2 AD - B_adipose   48.6       94714_Donor 2 AD - C_adipose   52.9       94742_Donor 3 U - A_Mesenchymal Stem Cells   4.7       94743_Donor 3 U - B_Mesenchymal Stem Cells   6.6       94730_Donor 3 AM - A_adipose   11.8       94731_Donor 3 AM - B_adipose   6.1       94732_Donor 3 AM - C_adipose   6.5       94733_Donor 3 AD - A_adipose   54.3       94734_Donor 3 AD - B_adipose   36.9       94735_Donor 3 AD - C_adipose   51.8       77138_Liver_HepG2untreated   100.0       73556_Heart_Cardiac stromal cells (primary)   0.9       81735_Small Intestine   0.8       72409_Kidney_Proximal Convoluted Tubule   5.4       82685_Small intestine_Duodenum   0.5       90650_Adrenal_Adrenocortical adenoma   4.3       72410_Kidney_HRCE   23.2       72411_Kidney_HRE   21.6       73139_Uterus_Uterine smooth muscle cells   5.4                    
     [0735] AI_comprehensive panel_v1.0 Summary: Ag4290 Highest expression of this gene is detected in normal bone (CT=27). Moderate levels of expression of this gene are also seen in samples derived from osteoarthritic (OA) bone and adjacent bone as well as OA cartilage, and OA synovium samples. Moderate to low levels of expression of this gene is also seen in cartilage, bone, synovium and synovial fluid samples from rheumatoid arthritis patients. Low level expression is also detected in samples derived from normal lung samples, emphysema, atopic asthma, asthma, Crohn&#39;s disease (normal matched control and diseased), ulcerative colitis(normal matched control and diseased), and psoriasis (normal matched control and diseased). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis  
     [0736] CNS_neurodegeneration_v1.0 Summary: Ag4290 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene is found to be slightly upregulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.  
     [0737] General_screening_panel_v1.4 Summary: Ag4290 Highest expression of this gene is detected in breast cancer BT 549 cell line (CT=22). High levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0738] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, fetal skeletal muscle, heart, liver and the gastrointestinal tract. This gene codes for Stearoyl-CoA desaturase (SCD). SCD is an iron-containing enzyme that catalyzes a rate-limiting step in the synthesis of unsaturated fatty acids by insertion of a cis-double bond in the Delta9 position of fatty acid substrates. It is regulated by both SREBP and C/EBPalpha, which are transcription factors that have been shown to be essential in adipose differentiation and lipogenesis. SCD is a key enzyme in the synthesis of unsaturated fatty acids that are being stored as triglycerides (TG), and the induction of TG synthesis is highly dependent on the expression of SCD. Using CuraGen&#39;s GeneCalling method of differential gene expression, SCD is found to be up-regulated in two genetic models of obesity. In addition, recently, SCD1 is shown to play a role in leptin-mediated weight loss. Obese mice treated with leptin lose weight and have decreased levels of SCD1 in their livers. Therefore, an antagonist for SCD to inhibit SCD directly may be an effective therapeutic for obesity and diabetes.  
     [0739] Interestingly, this gene is expressed at much higher levels in fetal (CTs=25-29) when compared to adult liver, lung and skeletal muscle (CTs=28-35). This observation suggests that expression of this gene can be used to distinguish these fetal from adult tissues. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance growth or development of these tissues in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver, lung and skeletal muscle related diseases.  
     [0740] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0741] References:  
     [0742] 1. Miyazaki et al., 2001, J Lipid Res. 42(7):1018-24. PMID: 11441127.  
     [0743] 2. Kim et al., 2000, J Lipid Res. 41(8):1310-6. PMID: 10946019  
     [0744] 3. Kim et al., 1998, Cell. 93(5):693-704. PMID: 9630215.  
     [0745] 4. Miyazaki et al., 2000, J Biol Chem. 275(39):30132-8. PMID: 10899171.  
     [0746] 5. Kim Y C, Ntambi J M., 1999, Biochem Biophys Res Commun. 266(1):1-4. Review. PMID: 10581155.  
     [0747] 6. Miyazaki et al., 2001, J Biol Chem. 276(42):39455-61. PMFD: 11500518.  
     [0748] 7. Cohen et al., 2002, Science. 297(5579):240-3. PMID: 12114623  
     [0749] Panel 4.1D Summary: Ag4290 Highest expression of this gene is detected in TNFalpha+IL-1beta treated small airway epithelium (CT=27). Expression of this gene is higher in cytokine stimulated than in resting small airway epithelium. Therefore, expression of this gene may be used to distinguish between these two samples.  
     [0750] In addition, moderate to low levels of expression of this gene is also seen in activated polarized, naive and memory T cells, LAK cells, NK cells, PWM/PHA-L stimulated PBMC, Ramos B cells, B lymphocytes, eosinophils, monocytes, macrophages, endothelial cells, bronchial epithelium, coronery artery SMC, astrocytes, basophils, mucoepidermoid cells, lung and dermal fibroblasts and normal tissues represented by kidney and lung. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0751] Panel 5 Islet Summary: Ag4290 Highest expression of this gene is detected in liver HepG2 cell line (CT=28.3). Moderate to low levels of expression of this gene is also seen in adipose, islet cells, mesenchymal stem cells and kidney. Interestingly, expression of this gene is induced in differentiated adipose cells. Therefore, expression of this gene may be used as a marker for differentiation. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0752] Panel 5D Summary: Ag4290 Highest expression of this gene is detected in liver HepG2 cell line (CT=28.3). Moderate to low levels of expression of this gene is also seen in 5 adipose, islet cells, mesenchymal stem cells and kidney. Interestingly, expression of this gene is induced in differentiated adipose. This expression pattern is in agreement with expression seen in panel 5 Islet. Please see panels 1.4 and 5 Islet for further discussion on the utility of this gene.  
     [0753] D. CG107234-02 and CG107234-03: HYDROLASE Like Gene  
     [0754] Expression of full-length physical clone CG107234-02 and full-length physical clone CG107234-03 was assessed using the primer-probe set Ag6935, described in Table DA. Results of the RTQ-PCR runs are shown in Table DB.  
               TABLE DA                          Probe Name Ag6935                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-tactgactcgacctcccaaaat-3′   22   685   230       Probe   TET-5′-cgagcctctggtctctgt   26   712   321           tcagaacc-3′-TAMRA       Reverse   5′-ctgatgaagtcaatgctgttct   24   745   232           ct-3′                  
 
     [0755]               TABLE DB                          General_screening_panel_v1.6                                 Rel. Exp. (%)               Ag6935, Run           Tissue Name   278388839                                         Adipose   4.4           Melanoma* Hs688(A).T   2.8           Melanoma* Hs688(B).T   5.4           Melanoma* M14   1.6           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   2.7           Squamous cell carcinoma SCC-4   10.2           Testis Pool   4.7           Prostate ca.* (bone met) PC-3   8.0           Prostate Pool   6.2           Placenta   1.2           Uterus Pool   0.9           Ovarian ca. OVCAR-3   2.2           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   8.2           Ovarian ca. OVCAR-5   10.3           Ovarian ca. IGROV-1   1.4           Ovarian ca. OVCAR-8   2.9           Ovary   18.6           Breast ca. MCF-7   22.8           Breast ca. MDA-MB-231   10.9           Breast ca. BT 549   12.8           Breast ca. T47D   2.4           Breast ca. MDA-N   0.0           Breast Pool   1.5           Trachea   6.0           Lung   8.7           Fetal Lung   0.0           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   1.1           Lung ca. A549   0.0           Lung ca. NCI-H526   1.1           Lung ca. NCI-H23   100.0           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   3.2           Lung ca. NCI-H522   4.8           Liver   1.2           Fetal Liver   1.0           Liver ca. HepG2   2.1           Kidney Pool   12.0           Fetal Kidney   3.1           Renal ca. 786-0   0.0           Renal ca. A498   6.3           Renal ca. ACHN   1.2           Renal ca. UO-31   4.3           Renal ca. TK-10   2.1           Bladder   0.9           Gastric ca. (liver met.) NCI-N87   2.1           Gastric ca. KATO III   2.5           Colon ca. SW-948   0.0           Colon ca. SW480   6.6           Colon ca.* (SW480 met) SW620   1.0           Colon ca. HT29   0.0           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   0.0           Colon cancer tissue   1.3           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.6           Colon Pool   2.1           Small Intestine Pool   8.0           Stomach Pool   2.7           Bone Marrow Pool   0.6           Fetal Heart   5.5           Heart Pool   5.2           Lymph Node Pool   2.2           Fetal Skeletal Muscle   3.2           Skeletal Muscle Pool   2.3           Spleen Pool   5.9           Thymus Pool   2.0           CNS cancer (glio/astro) U87-MG   11.5           CNS cancer (glio/astro) U-118-MG   3.3           CNS cancer (neuro; met) SK-N-AS   1.0           CNS cancer (astro) SF-539   1.0           CNS cancer (astro) SNB-75   6.8           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   3.4           Brain (Amygdala) Pool   7.1           Brain (cerebellum)   20.2           Brain (fetal)   5.5           Brain (Hippocampus) Pool   7.2           Cerebral Cortex Pool   6.1           Brain (Substantia nigra) Pool   4.0           Brain (Thalamus) Pool   15.4           Brain (whole)   10.3           Spinal Cord Pool   5.1           Adrenal Gland   1.0           Pituitary gland Pool   0.0           Salivary Gland   6.1           Thyroid (female)   9.0           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   0.0                        
     [0756] General_screening_panel_v1.6 Summary: Ag6935 Expression of this gene is highest to a sample derived from a lung cancer cell line (CT=32). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.  
     [0757] E. CG113144-02: CtBP (D-Isomer Specific 2-Hydroxyacid Dehydrogenase)-Like Gene  
     [0758] Expression of gene CG1 13144-02 was assessed using the primer-probe sets Ag5052 and Ag5078, described in Tables EA and EB. Results of the RTQ-PCR runs are shown in Tables EC, ED and EE.  
               TABLE EA                          Probe Name Ag5052                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-cagggaggacctggagaag-3′   19   222   233       Probe   TET-5′-ttcaaagccctccgcat   23   241   234           catcgt-3′-TAMRA       Reverse   5′-cttgatgtcgatgttgtcaaa   22   279   235           a-3′                  
 
     [0759]               TABLE EB                          Probe Name Ag5078                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-catgagaaggtcctgaacga-3′   20   163   236       Probe   TET-5′-gccctgatgtaccacacc   26   193   237           atcactct-3′-TAMRA       Reverse   5′-aacttctccaggtcctccct-3′   20   223   238                    
     [0760]               TABLE EC                          Oncology_cell_line_screening_panel_v3.1                             Rel. Exp. (%)   Rel. Exp. (%)           Ag5052, Run   Ag5078,       Tissue Name   225138920   Run 225061085                                 Daoy Medulloblastoma/Cerebellum   11.5   8.2       TE671 Medulloblastom/Cerebellum   19.5   14.1       D283 Med Medulloblastoma/   76.8   74.7       Cerebellum       PFSK-1 Primitive   47.0   38.7       Neuroectodermal/Cerebellum       XF-498_CNS   39.8   26.1       SNB-78_CNS/glioma   28.1   30.8       SF-268_CNS/glioblastoma   15.2   16.4       T98G_Glioblastoma   32.1   33.9       SK-N-SH_Neuroblastoma   45.1   55.1       (metastasis)       SF-295_CNS/glioblastoma   35.6   31.2       Cerebellum   37.1   39.5       Cerebellum   37.1   73.2       NCI-H292_Mucoepidermoid   56.6   60.7       lung ca.       DMS-114_Small cell lung   16.7   18.9       cancer       DMS-79_Small cell lung   31.9   34.6       cancer/neuroendocrine       NCI-H146_Small cell lung   39.8   54.3       cancer/neuroendocrine       NCI-H526_Small cell lung   93.3   90.8       cancer/neuroendocrine       NCI-N417_Small cell lung   13.5   14.3       cancer/neuroendocrine       NCI-H82_Small cell lung   20.0   24.1       cancer/neuroendocrine       NCI-H157_Squamous cell lung   28.7   33.4       cancer (metastasis)       NCI-H1155_Large cell lung   55.5   85.3       cancer/neuroendocrine       NCI-H1299_Large cell lung   51.4   72.7       cancer/neuroendocrine       NCI-H727_Lung carcinoid   40.6   34.4       NCI-UMC-11_Lung carcinoid   42.0   46.7       LX-1_Small cell lung cancer   38.7   42.6       Colo-205_Colon cancer   35.8   44.4       KM12_Colon cancer   52.1   73.7       KM20L2_Colon cancer   28.7   36.9       NCI-H716_Colon cancer   73.7   100.0       SW-48_Colon adenocarcinoma   30.6   37.1       SW1116_Colon adenocarcinoma   15.9   16.8       LS 174T_Colon adenocarcinoma   46.7   65.1       SW-948_Colon adenocarcinoma   16.8   22.2       SW-480_Colon adenocarcinoma   21.5   29.9       NCI-SNU-5_Gastric ca.   40.3   36.1       KATO III_Stomach   37.4   33.2       NCI-SNU-16_Gastric ca.   29.3   32.8       NCI-SNU-1_Gastric ca.   28.9   34.9       RF-1_Gastric adenocarcinoma   19.2   27.7       RF-48_Gastric adenocarcinoma   24.5   31.2       MKN-45_Gastric ca.   20.6   25.9       NCI-N87_Gastric ca.   21.9   21.0       OVCAR-5_Ovarian ca.   16.3   17.6       RL95-2_Uterine carcinoma   18.3   22.5       HelaS3_Cervical adenocarcinoma   21.3   28.9       Ca Ski_Cervical epidermoid   46.3   64.2       carcinoma (metastasis)       ES-2_Ovarian clear cell   17.4   23.0       carcinoma       Ramos/6 h stim_Stimulated   27.2   36.9       with PMA/ionomycin 6 h       Ramos/14 h stim_Stimulated   23.0   19.6       with PMA/ionomycin 14 h       MEG-01_Chronic myelogenous   29.9   30.6       leukemia (megokaryoblast)       Raji_Burkitt&#39;s lymphoma   10.9   12.9       Daudi_Burkitt&#39;s lymphoma   26.4   39.0       U266_B-cell plasmacytoma/   24.3   34.2       myeloma       CA46_Burkitt&#39;s lymphoma   24.3   30.1       RL_non-Hodgkin&#39;s B-cell   19.5   17.9       lymphoma       JM1_pre-B-cell lymphoma/   23.7   33.7       leukemia       Jurkat_T cell leukemia   54.0   55.9       TF-1_Erythroleukemia   46.3   62.4       HUT 78_T-cell lymphoma   52.9   76.8       U937_Histiocytic lymphoma   64.2   50.3       KU-812_Myelogenous leukemia   30.1   26.8       769-P_Clear cell renal ca.   33.0   30.8       Caki-2_Clear cell renal ca.   20.6   25.9       SW 839_Clear cell renal ca.   26.2   32.1       G401_Wilms&#39; tumor   16.0   24.7       Hs766T_Pancreatic ca. (LN   35.4   46.0       metastasis)       CAPAN-1_Pancreatic   11.0   15.1       adenocarcinoma       (liver metastasis)       SU86.86_Pancreatic carcinoma   49.7   49.0       (liver metastasis)       BxPC-3_Pancreatic   24.3   28.7       adenocarcinoma       HPAC_Pancreatic adenocarcinoma   55.5   66.0       MIA PaCa-2_Pancreatic ca.   10.8   6.3       CFPAC-1_Pancreatic ductal   100.0   94.6       adenocarcinoma       PANC-1_Pancreatic epithelioid   37.6   30.8       ductal ca.       T24_Bladder ca. (transitional   18.7   17.0       cell)       5637_Bladder ca.   9.5   10.9       HT-1197_Bladder ca.   18.7   15.7       UM-UC-3_Bladder ca.   10.9   10.0       (transitional cell)       A204_Rhabdomyosarcoma   21.2   18.0       HT-1080_Fibrosarcoma   21.9   20.3       MG-63_Osteosarcoma (bone)   22.7   20.3       SK-LMS-1_Leiomyosarcoma (vulva)   36.3   31.6       SJRH30_Rhabdomyosarcoma   32.1   34.2       (met to bone marrow)       A431_Epidermoid ca.   22.5   22.5       WM266-4_Melanoma   16.0   19.1       DU 145_Prostate   40.9   36.1       MDA-MB-468_Breast   15.0   12.0       adenocarcinoma       SSC-4_Tongue   21.8   25.3       SSC-9_Tongue   26.6   31.4       SSC-15_Tongue   18.2   28.1       CAL 27_Squamous cell ca. of   22.2   20.6       tongue                    
     [0761]               TABLE ED                          Panel 4.1D                         Rel. Exp. (%)           Ag5052, Run       Tissue Name   223784810                             Secondary Th1 act   71.2       Secondary Th2 act   81.8       Secondary Tr1 act   54.7       Secondary Th1 rest   25.3       Secondary Th2 rest   48.0       Secondary Tr1 rest   27.0       Primary Th1 act   0.0       Primary Th2 act   71.7       Primary Tr1 act   81.8       Primary Th1 rest   27.7       Primary Th2 rest   28.5       Primary Tr1 rest   48.6       CD45RA CD4 lymphocyte act   43.5       CD45RO CD4 lymphocyte act   69.7       CD8 lymphocyte act   55.1       Secondary CD8 lymphocyte rest   82.9       Secondary CD8 lymphocyte act   28.9       CD4 lymphocyte none   19.6       2ry Th1/Th2/Tr1_anti-CD95 CH11   62.0       LAK cells rest   54.0       LAK cells IL-2   54.7       LAK cells IL-2 + IL-12   24.0       LAK cells IL-2 + IFN gamma   38.7       LAK cells IL-2 + IL-18   37.1       LAK cells PMA/ionomycin   27.0       NK Cells IL-2 rest   95.9       Two Way MLR 3 day   47.6       Two Way MLR 5 day   56.6       Two Way MLR 7 day   38.2       PBMC rest   24.1       PBMC PWM   62.0       PBMC PHA-L   45.7       Ramos (B cell) none   77.9       Ramos (B cell) ionomycin   98.6       B lymphocytes PWM   45.4       B lymphocytes CD40L and IL-4   57.0       EOL-1 dbcAMP   62.0       EOL-1 dbcAMP PMA/ionomycin   64.6       Dendritic cells none   44.4       Dendritic cells LPS   33.9       Dendritic cells anti-CD40   59.5       Monocytes rest   45.1       Monocytes LPS   56.6       Macrophages rest   51.4       Macrophages LPS   10.7       HUVEC none   34.4       HUVEC starved   56.6       HUVEC IL-1beta   43.8       HUVEC IFN gamma   33.9       HUVEC TNF alpha + IFN gamma   28.3       HUVEC TNF alpha + IL4   34.6       HUVEC IL-11   30.4       Lung Microvascular EC none   72.2       Lung Microvascular EC TNFalpha + IL-1beta   39.0       Microvascular Dermal EC none   31.9       Microsvasular Dermal EC TNFalpha + IL-1beta   27.2       Bronchial epithelium TNFalpha + IL1beta   33.2       Small airway epithelium none   14.5       Small airway epithelium TNFalpha + IL-1beta   36.9       Coronery artery SMC rest   27.4       Coronery artery SMC TNFalpha + IL-1beta   30.1       Astrocytes rest   22.2       Astrocytes TNFalpha + IL-1beta   24.7       KU-812 (Basophil) rest   41.5       KU-812 (Basophil) PMA/ionomycin   46.0       CCD1106 (Keratinocytes) none   51.4       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   43.8       Liver cirrhosis   14.2       NCI-H292 none   56.6       NCI-H292 IL-4   56.3       NCI-H292 IL-9   72.7       NCI-H292 IL-13   57.4       NCI-H292 IFN gamma   49.0       HPAEC none   28.7       HPAEC TNF alpha + IL-1 beta   45.7       Lung fibroblast none   48.6       Lung fibroblast TNF alpha + IL-1 beta   33.0       Lung fibroblast IL-4   64.2       Lung fibroblast IL-9   59.0       Lung fibroblast IL-13   69.7       Lung fibroblast IFN gamma   100.0       Dermal fibroblast CCD1070 rest   52.9       Dermal fibroblast CCD1070 TNF alpha   72.7       Dermal fibroblast CCD1070 IL-1 beta   32.8       Dermal fibroblast IFN gamma   24.7       Dermal fibroblast IL-4   51.1       Dermal Fibroblasts rest   36.3       Neutrophils TNFa + LPS   2.8       Neutrophils rest   12.1       Colon   15.4       Lung   29.9       Thymus   42.6       Kidney   25.9                    
     [0762]               TABLE EE                          Panel 5 Islet                         Rel. Exp. (%)           Ag5052, Run       Tissue Name   306350412                             97457_Patient-02go_adipose   8.3       97476_Patient-07sk_skeletal muscle   0.0       97477_Patient-07ut_uterus   15.8       97478_Patient-07pl_placenta   8.8       99167_Bayer Patient 1   41.2       97482_Patient-08ut_uterus   6.6       97483_Patient-08pl_placenta   5.8       97486_Patient-09sk_skeletal muscle   6.8       97487_Patient-09ut_uterus   5.5       97488_Patient-09pl_placenta   9.9       97492_Patient-10ut_uterus   10.2       97493_Patient-10pl_placenta   36.3       97495_Patient-11go_adipose   7.6       97496_Patient-11sk_skeletal muscle   11.7       97497_Patient-11ut_uterus   21.5       97498_Patient-11pl_placenta   13.9       97500_Patient-12go_adipose   12.9       97501_Patient-12sk_skeletal muscle   46.7       97502_Patient-12ut_uterus   22.2       97503_Patient-12pl_placenta   33.9       94721_Donor 2 U - A_Mesenchymal Stem Cells   51.1       94722_Donor 2 U - B_Mesenchymal Stem Cells   40.6       94723_Donor 2 U - C_Mesenchymal Stem Cells   37.9       94709_Donor 2 AM - A_adipose   63.3       94710_Donor 2 AM - B_adipose   34.2       94711_Donor 2 AM - C_adipose   23.0       94712_Donor 2 AD - A_adipose   67.4       94713_Donor 2 AD - B_adipose   91.4       94714_Donor 2 AD - C_adipose   55.9       94742_Donor 3 U - A_Mesenchymal Stem Cells   26.1       94743_Donor 3 U - B_Mesenchymal Stem Cells   17.1       94730_Donor 3 AM - A_adipose   65.1       94731_Donor 3 AM - B_adipose   86.5       94732_Donor 3 AM - C_adipose   69.7       94733_Donor 3 AD - A_adipose   68.8       94734_Donor 3 AD - B_adipose   100.0       94735_Donor 3 AD - C_adipose   28.9       77138_Liver_HepG2untreated   69.3       73556_Heart_Cardiac stromal cells (primary)   11.0       81735_Small Intestine   24.8       72409_Kidney_Proximal Convoluted Tubule   27.4       82685_Small intestine_Duodenum   17.4       90650_Adrenal_Adrenocortical adenoma   4.4       72410_Kidney_HRCE   41.8       72411_Kidney_HRE   22.5       73139_Uterus_Uterine smooth muscle cells   28.1                    
     [0763] Oncology_cell_line_screening_panel_v3.1 Summary: Ag5052/Ag5078 Two experiments with two different probe primer sets show this gene to be ubiquitously expressed on this panel. Highest expression is seen in a colon and pancreatic cancer cell lines (CTs=26-27).  
     [0764] Panel 4.1D Summary: Ag5052 Highest expression is seen in IFN-gamma treated lung fibroblasts (CT=27). This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in Oncology_cell_line_screening_panel_v3.1 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0765] Panel 5 Islet Summary: Ag5052 Highest expression of this gene is seen in adipose (CT=30). This gene is widely expressed on this panel, with expression in many metabolic samples, including those from adipose, skeletal muscle and placenta. This expression profile suggests that this gene product may be involved in the pathogenesis and/or treatment of metabolic disorders including obesity and diabetes.  
     [0766] F. CG125197-03: LYSOPHOSPHOLIPASE-Like Gene  
     [0767] Expression of gene CG125197-03 was assessed using the primer-probe set Ag5957, described in Table FA. Results of the RTQ-PCR runs are shown in Table FB.  
               TABLE FA                          Probe Name Ag5957                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-agggttttctcagtgccacg-3′   20   366   239       Probe   TET-5′-tggttcccctgatgttt   25   401   240           ggtcctct-3′-TAMRA       Reverse   5′-acattggctggattcaccaat-3′   21   447   241                  
 
     [0768]               TABLE FB                          Panel 5 Islet                         Rel. Exp. (%)           Ag5957, Run       Tissue Name   247937701                             97457_Patient-02go_adipose   22.4       97476_Patient-07sk_skeletal muscle   22.8       97477_Patient-07ut_uterus   24.7       97478_Patient-07pl_placenta   46.7       99167_Bayer Patient 1   12.8       97482_Patient-08ut_uterus   12.2       97483_Patient-08pl_placenta   69.7       97486_Patient-09sk_skeletal muscle   6.8       97487_Patient-09ut_uterus   21.0       97488_Patient-09pl_placenta   47.3       97492_Patient-10ut_uterus   17.1       97493_Patient-10pl_placenta   60.3       97495_Patient-11go_adipose   11.5       97496_Patient-11sk_skeletal muscle   15.8       97497_Patient-11ut_uterus   19.1       97498_Patient-11pl_placenta   50.7       97500_Patient-12go_adipose   11.1       97501_Patient-12sk_skeletal muscle   29.1       97502_Patient-12ut_uterus   10.1       97503_Patient-12pl_placenta   18.7       94721_Donor 2 U - A_Mesenchymal Stem Cells   5.7       94722_Donor 2 U - B_Mesenchymal Stem Cells   4.2       94723_Donor 2 U - C_Mesenchymal Stem Cells   6.3       94709_Donor 2 AM - A_adipose   10.9       94710_Donor 2 AM - B_adipose   5.1       94711_Donor 2 AM - C_adipose   4.7       94712_Donor 2 AD - A_adipose   6.4       94713_Donor 2 AD - B_adipose   10.3       94714_Donor 2 AD - C_adipose   10.8       94742_Donor 3 U - A_Mesenchymal Stem Cells   5.2       94743_Donor 3 U - B_Mesenchymal Stem Cells   3.1       94730_Donor 3 AM - A_adipose   9.4       94731_Donor 3 AM - B_adipose   5.8       94732_Donor 3 AM - C_adipose   8.1       94733_Donor 3 AD - A_adipose   25.7       94734_Donor 3 AD - B_adipose   9.7       94735_Donor 3 AD - C_adipose   13.2       77138_Liver_HepG2untreated   55.9       73556_Heart_Cardiac stromal cells (primary)   22.7       81735_Small Intestine   19.6       72409_Kidney_Proximal Convoluted Tubule   39.0       82685_Small intestine_Duodenum   21.3       90650_Adrenal_Adrenocortical adenoma   10.2       72410_Kidney_HRCE   100.0       72411_Kidney_HRE   53.6       73139_Uterus_Uterine smooth muscle cells   18.6                    
     [0769] Panel 5 Islet Summary: Ag5957 Highest expression of this gene is seen in a kidney cell line (CT=-33).  
     [0770] G. CG134439-01: FLJ20837 FIS, CLONE ADKA02602 Like Gene  
     [0771] Expression of gene CG134439-01 was assessed using the primer-probe set Ag7405, described in Table GA.  
               TABLE GA                          Probe Name Ag7405                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-tgaacccgtatgttcatttcct-3′   22   579   242       Probe   TET-5′-atggagtctctctctgtc   26   632   243           gcccaggc-3′-TAMRA       Reverse   5′-aagatcgtgccactgcact-3′   19   661   244                  
 
     [0772] H. CG137109-01: Phospholipid-Transporting ATPase-Like Gene  
     [0773] Expression of gene CG137109-01 was assessed using the primer-probe set Ag4917, described in Table HA. Results of the RTQ-PCR runs are shown in Table HB.  
               TABLE HA                          Probe Name Ag4917                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-gcagttccagaaacagcattat-3′   22   596   245       Probe   TET-5′-caaacagttgccaatttg   26   620   246           gacactct-3′-TAMRA       Reverse   5′-ctggttgctggcattctattac-3′   22   653   247                  
 
     [0774]               TABLE HB                          Panel 4.1D                         Rel. Exp. (%)           Ag4917, Run       Tissue Name   223458643                             Secondary Th1 act   80.7       Secondary Th2 act   100.0       Secondary Tr1 act   92.7       Secondary Th1 rest   27.9       Secondary Th2 rest   44.1       Secondary Tr1 rest   29.3       Primary Th1 act   38.2       Primary Th2 act   57.8       Primary Tr1 act   53.2       Primary Th1 rest   22.8       Primary Th2 rest   16.2       Primary Tr1 rest   59.9       CD45RA CD4 lymphocyte act   29.5       CD45RO CD4 lymphocyte act   54.3       CD8 lymphocyte act   37.9       Secondary CD8 lymphocyte rest   38.2       Secondary CD8 lymphocyte act   32.8       CD4 lymphocyte none   33.2       2ry Th1/Th2/Tr1_anti-CD95 CH11   44.8       LAK cells rest   29.3       LAK cells IL-2   21.2       LAK cells IL-2 + IL-12   38.4       LAK cells IL-2 + IFN gamma   23.7       LAK cells IL-2 + IL-18   39.2       LAK cells PMA/ionomycin   39.2       NK Cells IL-2 rest   70.7       Two Way MLR 3 day   41.8       Two Way MLR 5 day   34.6       Two Way MLR 7 day   33.0       PBMC rest   24.8       PBMC PWM   32.1       PBMC PHA-L   33.7       Ramos (B cell) none   24.0       Ramos (B cell) ionomycin   41.5       B lymphocytes PWM   33.9       B lymphocytes CD40L and IL-4   41.2       EOL-1 dbcAMP   39.5       EOL-1 dbcAMP PMA/ionomycin   42.6       Dendritic cells none   27.5       Dendritic cells LPS   23.3       Dendritic cells anti-CD40   33.0       Monocytes rest   32.5       Monocytes LPS   40.6       Macrophages rest   32.1       Macrophages LPS   18.9       HUVEC none   17.7       HUVEC starved   20.6       HUVEC IL-1beta   20.3       HUVEC IFN gamma   36.1       HUVEC TNF alpha + IFN gamma   20.6       HUVEC TNF alpha + IL4   17.7       HUVEC IL-11   16.2       Lung Microvascular EC none   49.0       Lung Microvascular EC TNFalpha + IL-1beta   27.0       Microvascular Dermal EC none   24.7       Microsvasular Dermal EC TNFalpha + IL-1beta   16.4       Bronchial epithelium TNFalpha + IL1beta   23.8       Small airway epithelium none   9.7       Small airway epithelium TNFalpha + IL-1beta   34.6       Coronery artery SMC rest   19.9       Coronery artery SMC TNFalpha + IL-1beta   19.5       Astrocytes rest   10.1       Astrocytes TNFalpha + IL-1beta   6.8       KU-812 (Basophil) rest   33.2       KU-812 (Basophil) PMA/ionomycin   85.3       CCD1106 (Keratinocytes) none   28.1       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   18.2       Liver cirrhosis   11.3       NCI-H292 none   17.8       NCI-H292 IL-4   18.9       NCI-H292 IL-9   32.5       NCI-H292 IL-13   24.0       NCI-H292 IFN gamma   12.7       HPAEC none   14.4       HPAEC TNF alpha + IL-1 beta   36.3       Lung fibroblast none   23.2       Lung fibroblast TNF alpha + IL-1 beta   14.9       Lung fibroblast IL-4   17.8       Lung fibroblast IL-9   28.9       Lung fibroblast IL-13   17.7       Lung fibroblast IFN gamma   24.0       Dermal fibroblast CCD1070 rest   24.3       Dermal fibroblast CCD1070 TNF alpha   82.4       Dermal fibroblast CCD1070 IL-1 beta   22.5       Dermal fibroblast IFN gamma   11.8       Dermal fibroblast IL-4   28.5       Dermal Fibroblasts rest   18.9       Neutrophils TNFa + LPS   20.9       Neutrophils rest   45.4       Colon   6.4       Lung   11.7       Thymus   70.2       Kidney   20.3                    
     [0775] Panel 4.1D Summary: Ag4917 Highest expression of this gene is seen in chronically activated Th2 cells (CT=27). This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0776] I. CG137330-01: TGF-BETA Receptor Type I Precursor-Like Gene  
     [0777] Expression of gene CG137330-01 was assessed using the primer-probe set Ag7001, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB and IC.  
               TABLE IA                          Probe Name Ag7001                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-cttccaactactggtttaccat   24   407   248           tg-3′       Probe   TET-5′-agttctcgcaattgttct   26   432   249           ctgaacaa-3′-TAMRA       Reverse   5′-tttgccaatgctttcttgtaac-3′   22   463   250                  
 
     [0778]               TABLE IB                          General_screening_panel_v1.6                                 Rel. Exp. (%)               Ag7001, Run           Tissue Name   283147426                                         Adipose   2.9           Melanoma* Hs688(A).T   45.7           Melanoma* Hs688(B).T   50.0           Melanoma* M14   27.0           Melanoma* LOXIMVI   5.6           Melanoma* SK-MEL-5   85.3           Squamous cell carcinoma SCC-4   7.9           Testis Pool   85.9           Prostate ca.* (bone met) PC-3   26.8           Prostate Pool   5.7           Placenta   44.4           Uterus Pool   3.5           Ovarian ca. OVCAR-3   32.3           Ovarian ca. SK-OV-3   76.3           Ovarian ca. OVCAR-4   21.3           Ovarian ca. OVCAR-5   27.4           Ovarian ca. IGROV-1   20.7           Ovarian ca. OVCAR-8   7.3           Ovary   8.5           Breast ca. MCF-7   8.1           Breast ca. MDA-MB-231   88.3           Breast ca. BT 549   61.1           Breast ca. T47D   22.2           Breast ca. MDA-N   27.2           Breast Pool   12.2           Trachea   8.4           Lung   0.9           Fetal Lung   24.0           Lung ca. NCI-N417   11.3           Lung ca. LX-1   12.8           Lung ca. NCI-H146   23.2           Lung ca. SHP-77   74.7           Lung ca. A549   59.9           Lung ca. NCI-H526   14.8           Lung ca. NCI-H23   25.5           Lung ca. NCI-H460   26.8           Lung ca. HOP-62   14.0           Lung ca. NCI-H522   24.0           Liver   0.0           Fetal Liver   7.9           Liver ca. HepG2   12.7           Kidney Pool   39.8           Fetal Kidney   18.6           Renal ca. 786-0   25.5           Renal ca. A498   5.3           Renal ca. ACHN   6.0           Renal ca. UO-31   14.6           Renal ca. TK-10   34.6           Bladder   27.4           Gastric ca. (liver met.) NCI-N87   27.2           Gastric ca. KATO III   70.7           Colon ca. SW-948   6.6           Colon ca. SW480   96.6           Colon ca.* (SW480 met) SW620   10.2           Colon ca. HT29   5.2           Colon ca. HCT-116   22.7           Colon ca. CaCo-2   29.3           Colon cancer tissue   29.7           Colon ca. SW1116   2.6           Colon ca. Colo-205   3.8           Colon ca. SW-48   0.8           Colon Pool   14.1           Small Intestine Pool   11.1           Stomach Pool   9.5           Bone Marrow Pool   3.1           Fetal Heart   13.7           Heart Pool   11.1           Lymph Node Pool   16.2           Fetal Skeletal Muscle   3.8           Skeletal Muscle Pool   3.1           Spleen Pool   7.8           Thymus Pool   10.9           CNS cancer (glio/astro) U87-MG   79.0           CNS cancer (glio/astro) U-118-MG   54.0           CNS cancer (neuro; met) SK-N-AS   27.0           CNS cancer (astro) SF-539   25.9           CNS cancer (astro) SNB-75   94.6           CNS cancer (glio) SNB-19   7.1           CNS cancer (glio) SF-295   68.8           Brain (Amygdala) Pool   6.4           Brain (cerebellum)   31.2           Brain (fetal)   100.0           Brain (Hippocampus) Pool   13.3           Cerebral Cortex Pool   8.7           Brain (Substantia nigra) Pool   5.6           Brain (Thalamus) Pool   9.4           Brain (whole)   9.5           Spinal Cord Pool   14.3           Adrenal Gland   8.1           Pituitary gland Pool   14.8           Salivary Gland   4.2           Thyroid (female)   2.9           Pancreatic ca. CAPAN2   5.4           Pancreas Pool   1.9                        
     [0779]               TABLE IC                          Panel 4.1D                         Rel. Exp. (%)           Ag7001, Run       Tissue Name   282263186                             Secondary Th1 act   11.2       Secondary Th2 act   22.8       Secondary Tr1 act   3.7       Secondary Th1 rest   4.1       Secondary Th2 rest   0.0       Secondary Tr1 rest   8.5       Primary Th1 act   0.0       Primary Th2 act   6.0       Primary Tr1 act   15.3       Primary Th1 rest   0.0       Primary Th2 rest   0.0       Primary Tr1 rest   0.0       CD45RA CD4 lymphocyte act   17.8       CD45RO CD4 lymphocyte act   21.0       CD8 lymphocyte act   3.4       Secondary CD8 lymphocyte rest   3.8       Secondary CD8 lymphocyte act   0.0       CD4 lymphocyte none   3.5       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0       LAK cells rest   7.6       LAK cells IL-2   12.6       LAK cells IL-2 + IL-12   0.0       LAK cells IL-2 + IFN gamma   0.0       LAK cells IL-2 + IL-18   5.6       LAK cells PMA/ionomycin   18.7       NK Cells IL-2 rest   33.4       Two Way MLR 3 day   0.0       Two Way MLR 5 day   0.0       Two Way MLR 7 day   3.6       PBMC rest   1.5       PBMC PWM   7.2       PBMC PHA-L   5.1       Ramos (B cell) none   7.7       Ramos (B cell) ionomycin   3.4       B lymphocytes PWM   2.2       B lymphocytes CD40L and IL-4   3.3       EOL-1 dbcAMP   0.0       EOL-1 dbcAMP PMA/ionomycin   0.0       Dendritic cells none   8.5       Dendritic cells LPS   3.2       Dendritic cells anti-CD40   6.5       Monocytes rest   0.0       Monocytes LPS   5.8       Macrophages rest   0.0       Macrophages LPS   9.0       HUVEC none   2.9       HUVEC starved   6.9       HUVEC IL-1beta   8.3       HUVEC IFN gamma   8.5       HUVEC TNF alpha + IFN gamma   3.0       HUVEC TNF alpha + IL4   0.0       HUVEC IL-11   0.0       Lung Microvascular EC none   23.5       Lung Microvascular EC TNFalpha + IL-1beta   9.2       Microvascular Dermal EC none   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   0.0       Bronchial epithelium TNFalpha + IL1beta   21.5       Small airway epithelium none   20.3       Small airway epithelium TNFalpha + IL-1beta   100.0       Coronery artery SMC rest   20.0       Coronery artery SMC TNFalpha + IL-1beta   29.9       Astrocytes rest   11.7       Astrocytes TNFalpha + IL-1beta   27.4       KU-812 (Basophil) rest   12.1       KU-812 (Basophil) PMA/ionomycin   8.1       CCD1106 (Keratinocytes) none   24.1       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   8.4       Liver cirrhosis   4.2       NCI-H292 none   4.8       NCI-H292 IL-4   9.0       NCI-H292 IL-9   35.4       NCI-H292 IL-13   3.1       NCI-H292 IFN gamma   6.2       HPAEC none   0.0       HPAEC TNF alpha + IL-1 beta   3.9       Lung fibroblast none   5.1       Lung fibroblast TNF alpha + IL-1 beta   16.6       Lung fibroblast IL-4   7.1       Lung fibroblast IL-9   9.3       Lung fibroblast IL-13   2.6       Lung fibroblast IFN gamma   16.7       Dermal fibroblast CCD1070 rest   37.9       Dermal fibroblast CCD1070 TNF alpha   68.3       Dermal fibroblast CCD1070 IL-1 beta   38.7       Dermal fibroblast IFN gamma   11.9       Dermal fibroblast IL-4   11.6       Dermal Fibroblasts rest   11.2       Neutrophils TNFa + LPS   6.2       Neutrophils rest   44.8       Colon   0.0       Lung   6.3       Thymus   3.3       Kidney   11.1                    
     [0780] General_screening_panel_v1.6 Summary: Ag7001 Highest expression is seen in fetal brain (CT=32.3). This gene is prominently expressed in the cancer cell lines on this panel and may be involved in cellular growth and/or proliferation.  
     [0781] Panel 4.1D Summary: Ag7001 Highest expression is seen in TNF-a and IL-1b treated small airway epithelium (CT=33.8). Therefore, modulation of the expression or activity of the protein encoded by this gene through the application of small molecule therapeutics may be useful in the treatment of asthma, COPD, and emphysema.  
     [0782] J. CG137339-01: Epidermal Growth Factor Receptor Precursor-Like Gene  
     [0783] Expression of gene CG137339-01 was assessed using the primer-probe sets Ag1333 and Ag7280, described in Tables JA and JB. Results of the RTQ-PCR runs are shown in Tables JC, JD, JE, JF, JG, JH, JI, JJ and JK.  
               TABLE JA                          Probe Name Ag1333                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-ggactatgtccgggaacacaa-3′   21   2418   251       Probe   TET-5′-atattggctcccagtacct   30   2444   252           gctcaactggt-3′-TAMRA       Reverse   5′-tcatgccctttgcgatctg-3′   19   2479   253                  
 
     [0784]               TABLE JB                          Probe Name Ag7280                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-ctccataaatgctacgaatatt   28   1233   254           aaacac-3′       Probe   TET-5′-ctccatcagtggcgatct   25   1275   255           ccacatc-3′-TAMRA       Reverse   5′-gaaaactgaccacccctaaatg-3′   22   1310   256                    
     [0785]               TABLE JC                          Ardais Panel v.1.0                                 Rel. Exp. (%)               Ag1333, Run           Tissue Name   263526730                                         136799_Lung cancer(362)   6.3           136800_Lung NAT(363)   3.4           136813_Lung cancer(372)   11.2           136814_Lung NAT(373)   1.7           136815_Lung cancer(374)   0.0           136816_Lung NAT(375)   46.0           136791_Lung cancer(35A)   0.0           136795_Lung cancer(35E)   100.0           136797_Lung cancer(360)   3.9           136794_lung NAT(35D)   0.0           136818_Lung NAT(377)   2.5           136787_lung cancer(356)   1.5           136788_lung NAT(357)   5.3           136804_Lung cancer(369)   13.3           136805_Lung NAT(36A)   2.1           136806_Lung cancer(36B)   8.2           136807_Lung NAT(36C)   1.5           136789_lung cancer(358)   8.7           136802_Lung cancer(365)   12.9           136803_Lung cancer(368)   10.8           136811_Lung cancer(370)   1.8           136810_Lung NAT(36F)   16.2                        
     [0786]               TABLE JD                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag1333, Run           Tissue Name   208579660                                         Adipose   8.7           Melanoma* Hs688(A).T   8.5           Melanoma* Hs688(B).T   9.3           Melanoma* M14   2.5           Melanoma* LOXIMVI   19.3           Melanoma* SK-MEL-5   2.1           Squamous cell carcinoma SCC-4   96.6           Testis Pool   4.4           Prostate ca.* (bone met) PC-3   52.5           Prostate Pool   4.3           Placenta   100.0           Uterus Pool   3.0           Ovarian ca. OVCAR-3   17.4           Ovarian ca. SK-OV-3   38.7           Ovarian ca. OVCAR-4   11.5           Ovarian ca. OVCAR-5   50.0           Ovarian ca. IGROV-1   4.1           Ovarian ca. OVCAR-8   8.2           Ovary   6.4           Breast ca. MCF-7   0.1           Breast ca. MDA-MB-231   25.7           Breast ca. BT 549   36.3           Breast ca. T47D   35.6           Breast ca. MDA-N   0.1           Breast Pool   7.7           Trachea   13.3           Lung   4.5           Fetal Lung   14.9           Lung ca. NCI-N417   0.6           Lung ca. LX-1   2.5           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   2.0           Lung ca. A549   22.4           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   3.5           Lung ca. NCI-H460   11.8           Lung ca. HOP-62   4.7           Lung ca. NCI-H522   1.5           Liver   11.1           Fetal Liver   19.3           Liver ca. HepG2   4.4           Kidney Pool   12.2           Fetal Kidney   4.9           Renal ca. 786-0   45.7           Renal ca. A498   42.0           Renal ca. ACHN   59.0           Renal ca. UO-31   47.3           Renal ca. TK-10   50.7           Bladder   9.4           Gastric ca. (liver met.) NCI-N87   29.1           Gastric ca. KATO III   26.4           Colon ca. SW-948   3.6           Colon ca. SW480   12.0           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   5.2           Colon ca. HCT-116   15.1           Colon ca. CaCo-2   14.5           Colon cancer tissue   5.6           Colon ca. SW1116   13.3           Colon ca. Colo-205   1.4           Colon ca. SW-48   0.5           Colon Pool   11.3           Small Intestine Pool   5.2           Stomach Pool   5.2           Bone Marrow Pool   5.4           Fetal Heart   1.1           Heart Pool   3.8           Lymph Node Pool   10.1           Fetal Skeletal Muscle   3.6           Skeletal Muscle Pool   4.0           Spleen Pool   2.1           Thymus Pool   9.5           CNS cancer (glio/astro) U87-MG   33.2           CNS cancer (glio/astro) U-118-MG   37.6           CNS cancer (neuro; met) SK-N-AS   22.4           CNS cancer (astro) SF-539   7.5           CNS cancer (astro) SNB-75   11.2           CNS cancer (glio) SNB-19   3.9           CNS cancer (glio) SF-295   9.2           Brain (Amygdala) Pool   1.3           Brain (cerebellum)   6.6           Brain (fetal)   6.6           Brain (Hippocampus) Pool   3.3           Cerebral Cortex Pool   3.0           Brain (Substantia nigra) Pool   2.6           Brain (Thalamus) Pool   3.1           Brain (whole)   4.6           Spinal Cord Pool   2.2           Adrenal Gland   6.9           Pituitary gland Pool   0.4           Salivary Gland   8.3           Thyroid (female)   3.5           Pancreatic ca. CAPAN2   27.9           Pancreas Pool   12.9                        
     [0787]               TABLE JE                          HASS Panel v1.0                                     Rel. Exp. (%)   Rel. Exp. (%)               Ag1333, Run   Ag1333, Run           Tissue Name   247736608   248469481                                             MCF-7 C1   0.0   0.0           MCF-7 C2   0.0   0.0           MCF-7 C3   0.0   0.0           MCF-7 C4   0.0   0.0           MCF-7 C5   0.0   0.0           MCF-7 C6   0.1   0.1           MCF-7 C7   0.4   0.4           MCF-7 C9   0.5   0.3           MCF-7 C10   0.0   0.0           MCF-7 C11   0.0   0.0           MCF-7 C12   0.1   0.0           MCF-7 C13   0.4   0.3           MCF-7 C15   0.2   0.1           MCF-7 C16   0.2   0.2           MCF-7 C17   0.1   0.1           T24 D1   0.7   0.6           T24 D2   0.9   0.8           T24 D3   0.8   0.7           T24 D4   1.4   1.3           T24 D5   0.6   0.5           T24 D6   2.4   1.8           T24 D7   3.4   3.3           T24 D9   1.3   1.1           T24 D10   0.6   0.6           T24 D11   0.3   0.3           T24 D12   1.0   1.0           T24 D13   2.0   1.8           T24 D15   0.7   0.8           T24 D16   0.4   0.4           T24 D17   0.6   0.5           CAPaN B1   2.7   2.3           CAPaN B2   1.7   1.6           CAPaN B3   0.5   0.4           CAPaN B4   1.4   1.2           CAPaN B5   1.2   1.0           CAPaN B6   1.9   1.4           CAPaN B7   1.3   1.4           CAPaN B8   1.2   1.1           CAPaN B9   2.2   2.4           CAPaN B10   2.3   2.5           CAPaN B11   1.7   1.4           CAPaN B12   1.8   1.5           CAPaN B13   2.0   1.5           CAPaN B14   1.3   1.4           CAPaN B15   2.8   2.5           CAPaN B16   1.9   1.6           CAPaN B17   2.5   2.0           U87-MG F1 (B)   0.7   0.6           U87-MG F2   0.4   0.4           U87-MG F3   0.4   0.4           U87-MG F4   0.7   0.7           U87-MG F5   2.4   2.3           U87-MG F6   1.2   1.3           U87-MG F7   3.3   3.3           U87-MG F8   2.0   1.9           U87-MG F9   2.3   2.2           U87-MG F10   1.5   1.4           U87-MG F11   0.8   1.0           U87-MG F12   1.9   1.6           U87-MG F13   3.3   3.1           U87-MG F14   2.6   2.6           U87-MG F15   3.4   4.1           U87-MG F16   1.9   1.7           U87-MG F17   2.2   2.2           LnCAP A1   0.9   0.8           LnCAP A2   0.7   0.6           LnCAP A3   0.2   0.2           LnCAP A4   1.3   1.1           LnCAP A5   0.6   0.5           LnCAP A6   0.6   0.5           LnCAP A7   5.2   4.9           LnCAP A8   3.7   4.1           LnCAP A9   3.2   3.2           LnCAP A10   0.4   0.4           LnCAP A11   0.5   0.5           LnCAP A12   0.1   0.1           LnCAP A13   0.6   0.5           LnCAP A14   0.3   0.3           LnCAP A15   0.6   0.5           LnCAP A16   1.2   1.0           LnCAP A17   0.9   0.4           Primary Astrocytes   0.8   0.6           Primary Renal Proximal   0.2   0.2           Tubule Epithelial cell A2           Primary melanocytes A5   0.1   0.1           126443 - 341 medullo   0.0   0.0           126444 - 487 medullo   0.1   0.1           126445 - 425 medullo   0.0   0.0           126446 - 690 medullo   0.2   0.2           126447 - 54 adult glioma   3.8   3.1           126448 - 245 adult glioma   100.0   100.0           126449 - 317 adult glioma   42.0   35.8           126450 - 212 glioma   1.2   0.8           126451 - 456 glioma   61.6   52.9                        
     [0788]               TABLE JF                          Panel 1                                 Rel. Exp. (%)               Ag1333, Run           Tissue Name   132087533                                         Endothelial cells   0.0           Endothelial cells (treated)   0.0           Pancreas   0.2           Pancreatic ca. CAPAN 2   2.1           Adrenal gland   1.0           Thyroid   1.7           Salivary gland   0.9           Pituitary gland   0.0           Brain (fetal)   0.5           Brain (whole)   2.5           Brain (amygdala)   0.0           Brain (cerebellum)   3.8           Brain (hippocampus)   1.6           Brain (substantia nigra)   0.7           Brain (thalamus)   0.3           Brain (hypothalamus)   0.0           Spinal cord   0.3           glio/astro U87-MG   2.6           glio/astro U-118-MG   2.1           astrocytoma SW1783   1.5           neuro*; met SK-N-AS   1.4           astrocytoma SF-539   0.7           astrocytoma SNB-75   0.4           glioma SNB-19   1.5           glioma U251   0.6           glioma SF-295   0.9           Heart   0.0           Skeletal muscle   0.0           Bone marrow   0.0           Thymus   5.4           Spleen   0.1           Lymph node   0.3           Colon (ascending)   0.5           Stomach   1.6           Small intestine   0.5           Colon ca. SW480   0.3           Colon ca.* SW620 (SW480 met)   0.0           Colon ca. HT29   0.7           Colon ca. HCT-116   12.9           Colon ca. CaCo-2   2.5           Colon ca. HCT-15   1.3           Colon ca. HCC-2998   0.6           Gastric ca. * (liver met) NCI-N87   1.3           Bladder   4.8           Trachea   1.6           Kidney   0.3           Kidney (fetal)   0.7           Renal ca. 786-0   6.7           Renal ca. A498   8.0           Renal ca. RXF 393   5.4           Renal ca. ACHN   8.8           Renal ca. UO-31   5.0           Renal ca. TK-10   22.4           Liver   1.7           Liver (fetal)   0.4           Liver ca. (hepatoblast) HepG2   0.1           Lung   5.2           Lung (fetal)   1.9           Lung ca. (small cell) LX-1   0.0           Lung ca. (small cell) NCI-H69   0.0           Lung ca. (s. cell var.) SHP-77   4.0           Lung ca. (large cell)NCI-H460   26.4           Lung ca. (non-sm. cell) A549   2.0           Lung ca. (non-s. cell) NCI-H23   0.1           Lung ca. (non-s. cell) HOP-62   0.0           Lung ca. (non-s. cl) NCI-H522   0.0           Lung ca. (squam.) SW 900   5.4           Lung ca. (squam.) NCI-H596   0.0           Mammary gland   6.5           Breast ca.* (pl. ef) MCF-7   0.0           Breast ca.* (pl. ef) MDA-MB-231   4.2           Breast ca.* (pl. ef) T47D   0.4           Breast ca. BT-549   24.3           Breast ca. MDA-N   0.0           Ovary   1.6           Ovarian ca. OVCAR-3   2.0           Ovarian ca. OVCAR-4   1.7           Ovarian ca. OVCAR-5   5.2           Ovarian ca. OVCAR-8   3.4           Ovarian ca. IGROV-1   0.6           Ovarian ca. (ascites) SK-OV-3   3.2           Uterus   1.6           Placenta   22.7           Prostate   1.4           Prostate ca.* (bone met) PC-3   100.0           Testis   4.9           Melanoma Hs688(A).T   0.3           Melanoma* (met) Hs688(B).T   0.4           Melanoma UACC-62   0.0           Melanoma M14   0.0           Melanoma LOX IMVI   3.5           Melanoma* (met) SK-MEL-5   0.1           Melanoma SK-MEL-28   0.0                        
     [0789]               TABLE JG                          Panel 1.2                             Rel. Exp. (%)   Rel. Exp. (%)           Ag1333, Run   Ag1333, Run       Tissue Name   133088120   133705801                                 Endothelial cells   0.7   0.9       Heart (Fetal)   1.3   1.3       Pancreas   0.7   0.8       Pancreatic ca. CAPAN2   8.8   7.6       Adrenal Gland   8.6   17.8       Thyroid   3.4   2.9       Salivary gland   10.7   11.5       Pituitary gland   1.3   1.3       Brain (fetal)   2.0   2.3       Brain (whole)   3.6   4.3       Brain (amygdala)   2.3   2.9       Brain (cerebellum)   2.4   2.4       Brain (hippocampus)   3.8   3.9       Brain (thalamus)   1.4   1.7       Cerebral Cortex   22.1   24.7       Spinal cord   1.2   2.3       glio/astro U87-MG   12.5   12.0       glio/astro U-118-MG   9.3   10.0       astrocytoma SW1783   5.4   2.6       neuro*; met SK-N-AS   9.9   18.0       astrocytoma SF-539   2.8   2.1       astrocytoma SNB-75   0.7   0.5       glioma SNB-19   7.3   6.0       glioma U251   3.8   3.5       glioma SF-295   3.3   3.1       Heart   9.9   12.7       Skeletal Muscle   3.4   3.5       Bone marrow   0.1   0.1       Thymus   2.5   2.0       Spleen   1.0   1.2       Lymph node   1.5   1.6       Colorectal Tissue   3.1   2.8       Stomach   8.2   8.1       Small intestine   2.4   3.1       Colon ca. SW480   4.8   5.1       Colon ca.* SW620 (SW480 met)   0.0   0.0       Colon ca. HT29   5.1   4.7       Colon ca. HCT-116   2.5   2.9       Colon ca. CaCo-2   2.3   2.9       Colon ca. Tissue (ODO3866)   2.7   3.0       Colon ca. HCC-2998   3.2   3.0       Gastric ca.* (liver met) NCI-N87   10.7   9.6       Bladder   15.1   17.0       Trachea   6.4   7.3       Kidney   2.5   3.4       Kidney (fetal)   5.6   6.3       Renal ca. 786-0   14.6   14.0       Renal ca. A498   40.9   41.5       Renal ca. RXF 393   22.1   16.4       Renal ca. ACHN   29.9   24.5       Renal ca. UO-31   18.4   13.4       Renal ca. TK-10   20.2   17.8       Liver   6.3   7.8       Liver (fetal)   5.2   5.7       Liver ca. (hepatoblast) HepG2   3.0   2.7       Lung   3.5   4.7       Lung (fetal)   4.3   4.9       Lung ca. (small cell) LX-1   1.2   1.1       Lung ca. (small cell) NCI-H69   0.0   0.0       Lung ca. (s. cell var.) SHP-77   0.5   0.4       Lung ca. (large cell)NCI-H460   38.4   25.7       Lung ca. (non-sm. cell) A549   6.9   6.1       Lung ca. (non-s. cell) NCI-H23   1.4   1.1       Lung ca. (non-s. cell) HOP-62   8.2   6.5       Lung ca. (non-s. cl) NCI-H522   2.6   2.7       Lung ca. (squam.) SW 900   12.2   11.4       Lung ca. (squam.) NCI-H596   0.0   0.0       Mammary gland   13.9   13.0       Breast ca.* (pl. ef) MCF-7   0.0   0.0       Breast ca.* (pl. ef) MDA-MB-231   12.3   10.7       Breast ca.* (pl. ef) T47D   1.2   1.5       Breast ca. BT-549   26.2   24.8       Breast ca. MDA-N   0.0   0.1       Ovary   11.3   11.9       Ovarian ca. OVCAR-3   8.5   8.4       Ovarian ca. OVCAR-4   19.3   16.4       Ovarian ca. OVCAR-5   24.3   0.1       Ovarian ca. OVCAR-8   22.7   22.2       Ovarian ca. IGROV-1   6.0   6.7       Ovarian ca. (ascites) SK-OV-3   23.0   20.7       Uterus   3.7   4.8       Placenta   100.0   100.0       Prostate   6.1   5.1       Prostate ca.* (bone met) PC-3   64.6   50.7       Testis   1.5   1.5       Melanoma Hs688(A).T   2.2   2.0       Melanoma* (met) Hs688(B).T   0.9   1.2       Melanoma UACC-62   1.1   1.2       Melanoma M14   0.3   0.4       Melanoma LOX IMVI   2.5   2.0       Melanoma* (met) SK-MEL-5   1.2   1.1                    
     [0790]               TABLE JH                          Panel 1.3D                                 Rel. Exp. (%)               Ag1333, Run           Tissue Name   146087249                                         Liver adenocarcinoma   69.3           Pancreas   1.2           Pancreatic ca. CAPAN 2   22.4           Adrenal gland   3.6           Thyroid   3.8           Salivary gland   3.4           Pituitary gland   0.5           Brain (fetal)   2.0           Brain (whole)   3.3           Brain (amygdala)   3.0           Brain (cerebellum)   1.2           Brain (hippocampus)   3.8           Brain (substantia nigra)   0.5           Brain (thalamus)   1.7           Cerebral Cortex   36.9           Spinal cord   2.5           glio/astro U87-MG   49.0           glio/astro U-118-MG   67.8           astrocytoma SW1783   37.4           neuro*; met SK-N-AS   36.9           astrocytoma SF-539   14.0           astrocytoma SNB-75   34.6           glioma SNB-19   11.3           glioma U251   10.2           glioma SF-295   12.9           Heart (fetal)   7.0           Heart   1.7           Skeletal muscle (fetal)   100.0           Skeletal muscle   2.3           Bone marrow   0.1           Thymus   2.8           Spleen   1.3           Lymph node   2.4           Colorectal   12.8           Stomach   5.5           Small intestine   2.0           Colon ca. SW480   30.6           Colon ca.* SW620(SW480 met)   0.0           Colon ca. HT29   6.9           Colon ca. HCT-116   11.8           Colon ca. CaCo-2   20.7           Colon ca. tissue(ODO3866)   11.0           Colon ca. HCC-2998   7.0           Gastric ca.* (liver met) NCI-N87   52.1           Bladder   9.9           Trachea   9.5           Kidney   1.9           Kidney (fetal)   3.4           Renal ca. 786-0   53.6           Renal ca. A498   84.1           Renal ca. RXF 393   21.3           Renal ca. ACHN   78.5           Renal ca. UO-31   50.3           Renal ca. TK-10   43.5           Liver   1.8           Liver (fetal)   3.6           Liver ca. (hepatoblast) HepG2   5.6           Lung   4.5           Lung (fetal)   6.9           Lung ca. (small cell) LX-1   2.9           Lung ca. (small cell) NCI-H69   0.0           Lung ca. (s. cell var.) SHP-77   3.5           Lung ca. (large cell)NCI-H460   4.7           Lung ca. (non-sm. cell) A549   12.5           Lung ca. (non-s. cell) NCI-H23   3.3           Lung ca. (non-s. cell) HOP-62   5.9           Lung ca. (non-s. cl) NCI-H522   1.8           Lung ca. (squam.) SW 900   15.4           Lung ca. (squam.) NCI-H596   0.0           Mammary gland   15.5           Breast ca.* (pl. ef) MCF-7   0.2           Breast ca.* (pl. ef) MDA-MB-231   89.5           Breast ca.* (pl. ef) T47D   2.6           Breast ca. BT-549   66.0           Breast ca. MDA-N   0.2           Ovary   43.5           Ovarian ca. OVCAR-3   18.3           Ovarian ca. OVCAR-4   7.3           Ovarian ca. OVCAR-5   54.3           Ovarian ca. OVCAR-8   37.1           Ovarian ca. IGROV-1   5.7           Ovarian ca.* (ascites) SK-OV-3   41.2           Uterus   3.8           Placenta   95.3           Prostate   4.7           Prostate ca.* (bone met)PC-3   32.1           Testis   2.5           Melanoma Hs688(A).T   17.8           Melanoma* (met) Hs688(B).T   24.3           Melanoma UACC-62   0.3           Melanoma M14   0.6           Melanoma LOX IMVI   4.4           Melanoma* (met) SK-MEL-5   1.9           Adipose   10.7                        
     [0791]               TABLE JI                          Panel 2.2                             Rel. Exp. (%)   Rel. Exp. (%)           Ag1333, Run   Ag1333, Run       Tissue Name   174923444   184372565                                 Normal Colon   15.2   15.2       Colon cancer (OD06064)   73.2   29.1       Colon Margin (OD06064)   29.7   0.0       Colon cancer (OD06159)   6.7   6.6       Colon Margin (OD06159)   37.1   18.6       Colon cancer (OD06297-04)   7.7   9.5       Colon Margin (OD06297-05)   52.5   23.0       CC Gr.2 ascend colon   11.1   10.3       (ODO3921)       CC Margin (ODO3921)   7.3   5.0       Colon cancer metastasis   2.3   1.7       (OD06104)       Lung Margin (OD06104)   5.1   7.1       Colon mets to lung   9.7   5.3       (OD04451-01)       Lung Margin (OD04451-02)   32.3   10.4       Normal Prostate   14.1   17.7       Prostate Cancer (OD04410)   6.3   11.9       Prostate Margin (OD04410)   11.6   30.6       Normal Ovary   27.4   16.3       Ovarian cancer (OD06283-03)   10.2   7.4       Ovarian Margin (OD06283-07)   6.7   4.1       Ovarian Cancer 064008   17.1   22.4       Ovarian cancer (OD06145)   15.3   9.5       Ovarian Margin (OD06145)   19.5   12.4       Ovarian cancer (OD06455-03)   19.5   15.9       Ovarian Margin (OD06455-07)   20.2   0.0       Normal Lung   12.6   8.8       Invasive poor diff. lung   4.2   3.5       adeno (ODO4945-01       Lung Margin (ODO4945-03)   27.5   11.0       Lung Malignant Cancer   12.8   4.6       (OD03126)       Lung Margin (OD03126)   13.4   38.4       Lung Cancer (OD05014A)   14.1   40.9       Lung Margin (OD05014B)   33.7   15.0       Lung cancer (OD06081)   21.8   14.2       Lung Margin (OD06081)   25.3   12.4       Lung Cancer (OD04237-01)   5.6   2.8       Lung Margin (OD04237-02)   25.9   15.4       Ocular Melanoma Metastasis   0.9   1.4       Ocular Melanoma Margin   29.7   29.1       (Liver)       Melanoma Metastasis   0.0   0.1       Melanoma Margin (Lung)   40.3   27.5       Normal Kidney   9.2   10.4       Kidney Ca, Nuclear   33.4   22.8       grade 2 (OD04338)       Kidney Margin (OD04338)   21.2   74.7       Kidney Ca Nuclear   18.2   12.2       grade 1/2 (OD04339)       Kidney Margin (OD04339)   16.7   13.5       Kidney Ca, Clear cell   45.1   46.3       type (OD04340)       Kidney Margin (OD04340)   17.7   8.7       Kidney Ca, Nuclear   2.1   3.3       grade 3 (OD04348)       Kidney Margin (OD04348)   67.8   14.0       Kidney malignant cancer   13.5   9.5       (OD06204B)       Kidney normal adjacent   13.8   11.3       tissue (OD06204E)       Kidney Cancer (OD04450-01)   72.7   35.8       Kidney Margin (OD04450-03)   21.3   29.5       Kidney Cancer 8120613   10.0   14.9       Kidney Margin 8120614   20.6   12.2       Kidney Cancer 9010320   10.4   12.2       Kidney Margin 9010321   16.2   9.0       Kidney Cancer 8120607   43.5   28.1       Kidney Margin 8120608   4.7   6.3       Normal Uterus   45.4   21.0       Uterine Cancer 064011   7.9   12.5       Normal Thyroid   2.8   6.9       Thyroid Cancer 064010   21.2   38.4       Thyroid Cancer A302152   20.4   24.3       Thyroid Margin A302153   6.9   16.4       Normal Breast   50.7   25.5       Breast Cancer (OD04566)   4.3   0.8       Breast Cancer 1024   17.0   13.4       Breast Cancer (OD04590-01)   5.8   0.0       Breast Cancer Mets (OD04590-03)   12.6   8.5       Breast Cancer Metastasis   2.3   2.6       (OD04655-05)       Breast Cancer 064006   7.7   6.0       Breast Cancer 9100266   5.6   5.6       Breast Margin 9100265   14.2   8.1       Breast Cancer A209073   7.5   6.8       Breast Margin A2090734   27.0   27.4       Breast cancer (OD06083)   19.3   7.6       Breast cancer node   5.0   7.5       metastasis (OD06083)       Normal Liver   55.5   58.2       Liver Cancer 1026   13.3   14.1       Liver Cancer 1025   100.0   100.0       Liver Cancer 6004-T   54.0   49.7       Liver Tissue 6004-N   17.8   14.0       Liver Cancer 6005-T   27.4   16.0       Liver Tissue 6005-N   73.7   39.5       Liver Cancer 064003   35.6   16.0       Normal Bladder   17.3   19.5       Bladder Cancer 1023   4.5   4.1       Bladder Cancer A302173   29.7   19.5       Normal Stomach   36.3   31.0       Gastric Cancer 9060397   5.8   7.3       Stomach Margin 9060396   7.4   6.4       Gastric Cancer 9060395   14.4   11.5       Stomach Margin 9060394   30.1   15.2       Gastric Cancer 064005   9.5   10.8                    
     [0792]               TABLE JJ                          Panel 4.1D                                     Rel. Exp. (%)   Rel. Exp. (%)               Ag1333, Run   Ag7280, Run           Tissue Name   268700632   296559388                                             Secondary Th1 act   0.0   0.0           Secondary Th2 act   0.0   0.0           Secondary Tr1 act   0.0   0.0           Secondary Th1 rest   0.0   0.0           Secondary Th2 rest   0.0   0.0           Secondary Tr1 rest   0.0   0.0           Primary Th1 act   0.0   0.0           Primary Th2 act   0.0   0.0           Primary Tr1 act   0.0   0.0           Primary Th1 rest   0.0   0.0           Primary Th2 rest   0.0   0.0           Primary Tr1 rest   0.0   0.0           CD45RA CD4   19.1   0.0           lymphocyte act           CD45RO CD4   0.0   0.0           lymphocyte act           CD8 lymphocyte act   0.0   0.0           Secondary CD8   0.0   0.0           lymphocyte rest           Secondary CD8   0.0   0.0           lymphocyte act           CD4 lymphocyte none   0.0   0.0           2ry   0.0   0.0           Th1/Th2/Tr1_anti-           CD95 CH11           LAK cells rest   0.0   0.0           LAK cells IL-2   0.0   0.0           LAK cells   0.0   0.0           IL-2 + IL-12           LAK cells IL-2 + IFN   0.0   0.0           gamma           LAK cells IL-2 + IL-18   0.0   0.0           LAK cells   0.0   0.0           PMA/ionomycin           NK Cells IL-2 rest   0.0   0.0           Two Way MLR 3 day   0.0   0.0           Two Way MLR 5 day   0.0   0.0           Two Way MLR 7 day   0.0   0.0           PBMC rest   0.0   0.0           PBMC PWM   0.0   0.0           PBMC PHA-L   0.0   0.0           Ramos (B cell) none   0.2   0.0           Ramos (B cell)   0.9   0.0           ionomycin           B lymphocytes PWM   0.0   0.0           B lymphocytes   0.0   0.0           CD40L and IL-4           EOL-1 dbcAMP   0.0   0.0           EOL-1 dbcAMP   0.0   0.0           PMA/ionomycin           Dendritic cells none   0.0   0.0           Dendritic cells LPS   0.0   0.0           Dendritic cells   0.0   0.0           anti-CD40           Monocytes rest   0.0   0.0           Monocytes LPS   0.0   0.0           Macrophages rest   0.0   0.0           Macrophages LPS   0.0   0.0           HUVEC none   1.5   0.0           HUVEC starved   1.6   0.0           HUVEC IL-1beta   1.7   0.0           HUVEC IFN gamma   1.3   0.0           HUVEC TNF alpha +   0.8   8.2           IFN gamma           HUVEC TNF alpha + IL4   1.3   0.0           HUVEC IL-11   0.5   0.0           Lung Microvascular   5.1   14.5           EC none           Lung Microvascular   4.1   0.0           EC TNFalpha +           IL-1beta           Microvascular Dermal   1.0   0.0           EC none           Microsvasular Dermal   1.5   0.0           EC TNFalpha +           IL-1beta           Bronchial epithelium   80.7   26.6           TNFalpha + IL1beta           Small airway   21.3   0.0           epithelium none           Small airway   80.7   66.0           epithelium TNFalpha +           IL-1beta           Coronery artery SMC   21.8   8.0           rest           Coronery artery SMC   26.4   11.0           TNFalpha + IL-1beta           Astrocytes rest   1.4   0.0           Astrocytes TNFalpha +   3.4   0.0           IL-1beta           KU-812 (Basophil)   0.0   0.0           rest           KU-812 (Basophil)   0.1   0.0           PMA/ionomycin           CCD1106   90.8   100.0           (Keratinocytes) none           CCD1106   54.3   50.0           (Keratinocytes)           TNFalpha + IL-1beta           Liver cirrhosis   10.1   0.0           NCI-H292 none   48.0   46.3           NCI-H292 IL-4   62.4   53.6           NCI-H292 IL-9   100.0   24.7           NCI-H292 IL-13   62.0   47.3           NCI-H292 IFN gamma   23.2   31.2           HPAEC none   0.7   7.6           HPAEC TNF alpha +   6.5   0.0           IL-1 beta           Lung fibroblast none   50.3   11.0           Lung fibroblast TNF   29.9   31.0           alpha + IL-1 beta           Lung fibroblast IL-4   17.6   17.7           Lung fibroblast IL-9   36.9   0.0           Lung fibroblast IL-13   10.9   0.0           Lung fibroblast IFN   28.3   0.0           gamma           Dermal fibroblast   31.6   0.0           CCD1070 rest           Dermal fibroblast   52.9   10.1           CCD1070 TNF alpha           Dermal fibroblast   29.5   18.2           CCD1070 IL-1 beta           Dermal fibroblast IFN   20.2   48.6           gamma           Dermal fibroblast IL-4   95.9   35.4           Dermal Fibroblasts rest   58.2   15.1           Neutrophils   0.0   0.0           TNFa + LPS           Neutrophils rest   0.0   0.0           Colon   1.1   0.0           Lung   1.0   0.0           Thymus   2.1   0.0           Kidney   7.9   0.0                        
     [0793]               TABLE JK                          general oncology screening panel_v_2.4                                     Rel. Exp. (%)   Rel. Exp. (%)               Ag1333, Run   Ag1333, Run           Tissue Name   258052150   258689219                                             Colon cancer 1   6.5   9.4           Colon NAT 1   3.0   2.3           Colon cancer 2   9.6   8.4           Colon NAT 2   4.1   3.8           Colon cancer 3   16.7   16.3           Colon NAT 3   10.3   12.3           Colon malignant cancer 4   11.7   11.0           Colon NAT 4   5.1   4.2           Lung cancer 1   10.5   13.0           Lung NAT 1   1.2   1.1           Lung cancer 2   45.1   45.1           Lung NAT 2   1.8   1.9           Squamous cell carcinoma 3   20.2   20.7           Lung NAT 3   0.6   0.5           Metastatic melanoma 1   8.6   11.1           Melanoma 2   6.7   6.9           Melanoma 3   4.7   6.4           Metastatic melanoma 4   29.1   27.5           Metastatic melanoma 5   32.1   25.9           Bladder cancer 1   0.2   0.5           Bladder NAT 1   0.0   0.0           Bladder cancer 2   2.5   3.1           Bladder NAT 2   0.1   0.2           Bladder NAT 3   0.3   0.7           Bladder NAT 4   3.3   3.1           Prostate adenocarcinoma 1   6.3   11.3           Prostate adenocarcinoma 2   3.1   1.2           Prostate adenocarcinoma 3   10.4   9.4           Prostate adenocarcinoma 4   8.5   8.1           Prostate NAT 5   2.7   2.8           Prostate adenocarcinoma 6   3.9   3.5           Prostate adenocarcinoma 7   2.7   3.9           Prostate adenocarcinoma 8   1.7   1.3           Prostate adenocarcinoma 9   9.2   10.7           Prostate NAT 10   1.1   1.5           Kidney cancer 1   18.4   21.0           Kidney NAT 1   3.8   3.6           Kidney cancer 2   100.0   100.0           Kidney NAT 2   8.5   8.6           Kidney cancer 3   20.0   21.3           Kidney NAT 3   2.2   2.8           Kidney cancer 4   16.8   16.4           Kidney NAT 4   2.9   3.4                        
     [0794] Ardais Panel v.1.0 Summary: Ag1333 Highest expression is seen in a lung cancer sample (CT=20.13). In addition, this gene is overexpressed in lung cancer when compared to expression in the NAT. Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.  
     [0795] General_screening_panel_v1.4 Summary: Ag1333 Highest expression of this gene is seen in placenta (CT=21.4). This gene is widely expressed in this panel, with high levels of expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0796] Among tissues with metabolic function, this gene is expressed at high levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0797] This gene is also expressed at high levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0798] HASS Panel v1.0 Summary: Ag1333 Two experiments with same probe and primer sets are in excellent agreement with highest expression of this gene seen in adult glioma samples (CTs=20.9). In addition, the expression of this gene is induced in LnCAP, T24 and MCF7 cells by a reduction of oxygen concentration compared to the normally low level of gene expression seen in these cell lines. This suggests that expression of this gene may also be increased in hypoxic regions of bladder, breast and prostate cancers.  
     [0799] This gene is also expressed at a low level in medulloblastoma samples and at a moderate level in glioma samples. It may thus be used as marker and modulation of the protein encoded by this gene through the use of antibodies or small molecule drugs may be used for therapy.  
     [0800] Panel 1 Summary: AG1333 Highest expression is seen in a prostate cancer cell line (CT=19). In addition, this gene is expressed in many samples on this panel. Please see Panel 1.4 for discussion of utility of this gene.  
     [0801] Panel 1.2 Summary: Ag1333 Two experiments with the same probe and primer produce results that are in excellent agreement, with highest expression in placenta (CTs=24-25). The results in this panel are consistent with Panel 1.4. Please see that panel for further discussion of utility of this gene.  
     [0802] Panel 1.3D Summary: Ag1333 Highest expression of this gene is seen in skeletal muscle (CT=26). In addition, this gene is expressed at much higher levels in fetal skeletal muscle when compared to adult skeletal muscle (CT=31). This observation suggests that expression of this gene can be used to distinguish fetal from adult skeletal muscle. In addition, the relative overexpression of this gene in fetal skeletal muscle suggests that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.  
     [0803] Overall, expression in this panel is consistent with expression on panel 1.4, with prominenet expression in the cancer cell lines on this panel. Please see Panel 1.4 for discussion of utility of this gene.  
     [0804] Panel 2.2 Summary: Ag1333 Two experiments with the same probe and primer produce results that are in excellent agreement. Highest expression of this gene is seen in a liver cancer (CTs=25-29). This gene is widely expressed in this panel, with higher levels of expression in kidney cancer than in the NAT, consistent with Panel 2.4. Please see that panel for discussion of utility of this gene.  
     [0805] Panel 4.1D Summary: Ag1333 Expression of this gene is highest in IL-9 treated NCI—H292 cells (CT=26.5). Expression of this gene appears to be associated with clusters of samples derived from treated and untreated keratinoyctes, lung and dermal fibroblasts, and HPAECS. Thus, this gene may be involved in inflammatory conditions of the lung and/or skin.  
     [0806] general oncology screening panel_v — 2.4 Summary: Ag1333 Two experiments with the same probe and primer set produce results that are in excellent agreement. Highest expression is seen in a sample derived from kidney cancer (CTs=26). In addition, this gene is overexpressed in kidney and lung cancers when compared to expression in the normal adjacent tissue. Prominent expression is also detected in melanoma. Thus, expression of this gene could be used as a marker of these cancers and modulation of the expression or function may be useful in their treatment.  
     [0807] K. CG138130-01: cGMP-Stimulated 3′,5′-cyclic Nucleotide Phosphodiesterase-Like Gene  
     [0808] Expression of gene CG138130-01 was assessed using the primer-probe set Ag4203, described in Table KA. Results of the RTQ-PCR runs are shown in Table KB.  
               TABLE KA                          Probe Name Ag4203                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No               Forward   5′-caccagatctttgctcctttc-3′   21   3234   257       Probe   TET-5′-accctttgggtctccagg   26   3270   258           atcctcat-3′-TAMRA       Reverse   5′-gctcactcagatgtctcacctt-3′   22   3304   259                  
 
     [0809]               TABLE KB                          Panel 5 Islet                         Rel. Exp. (%)           Ag4203, Run       Tissue Name   174269008                             97457_Patient-02go_adipose   59.0       97476_Patient-07sk_skeletal muscle   33.2       97477_Patient-07ut_uterus   39.0       97478_Patient-07pl_placenta   10.7       99167_Bayer Patient 1   19.1       97482_Patient-08ut_uterus   15.8       97483_Patient-08pl_placenta   4.5       97486_Patient-09sk_skeletal muscle   5.7       97487_Patient-09ut_uterus   23.0       97488_Patient-09pl_placenta   9.4       97492_Patient-10ut_uterus   23.0       97493_Patient-10pl_placenta   25.5       97495_Patient-11go_adipose   17.1       97496_Patient-11sk_skeletal muscle   12.9       97497_Patient-11ut_uterus   42.9       97498_Patient-11pl_placenta   2.1       97500_Patient-12go_adipose   100.0       97501_Patient-12sk_skeletal muscle   46.3       97502_Patient-12ut_uterus   35.6       97503_Patient-12pl_placenta   3.3       94721_Donor 2 U - A_Mesenchymal Stem Cells   0.0       94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0       94723_Donor 2 U - C_Mesenchymal Stem Cells   0.0       94709_Donor 2 AM - A_adipose   0.0       94710_Donor 2 AM - B_adipose   0.0       94711_Donor 2 AM - C_adipose   0.0       94712_Donor 2 AD - A_adipose   0.0       94713_Donor 2 AD - B_adipose   0.0       94714_Donor 2 AD - C_adipose   0.0       94742_Donor 3 U - A_Mesenchymal Stem Cells   1.3       94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0       94730_Donor 3 AM - A_adipose   0.0       94731_Donor 3 AM - B_adipose   0.0       94732_Donor 3 AM - C_adipose   0.9       94733_Donor 3 AD - A_adipose   0.0       94734_Donor 3 AD - B_adipose   0.0       94735_Donor 3 AD - C_adipose   0.0       77138_Liver_HepG2untreated   0.0       73556_Heart_Cardiac stromal cells (primary)   77.9       81735_Small Intestine   22.2       72409_Kidney_Proximal Convoluted Tubule   0.0       82685_Small intestine_Duodenum   1.4       90650_Adrenal_Adrenocortical adenoma   6.4       72410_Kidney_HRCE   1.5       72411_Kidney_HRE   0.0       73139_Uterus_Uterine smooth muscle cells   1.4                    
     [0810] Panel 5 Islet Summary: Ag4203 Highest expression is seen in adipose (CT=32), with low but significant expression seen in other metabolic tissues, including skeletal muscle and placenta. Thus, this gene product may be involved in the pathogenesis and/or treatment of metabolic disease, including obesity and diabetes.  
     [0811] L. CG138372-02: MALEYLACETOACETATE ISOMERASE  
     [0812] 
     [0813] Expression of full-length physical clone CG138372-02 was assessed using the primer-probe set Ag5913, described in Table LA. Results of the RTQ-PCR runs are shown in Tables LB, LC and LD.  
               TABLE LA                          Probe Name Ag5913                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No               Forward   5′-gccaacagttttctaaggactt   23   145   260           c-3′       Probe   TET-5′-attccatcaatcttcagg   26   192   261           gttggcac-3′-TAMRA       Reverse   5′-acagacaggtttgactggtgaa   23   222   262           t-3′                  
 
     [0814]               TABLE LB                          General_screening_panel_v1.5                             Rel. Exp. (%)   Rel. Exp. (%)           Ag5913, Run   Ag5913, Run       Tissue Name   247608924   259048761                                 Adipose   1.8   2.4       Melanoma* Hs688(A).T   3.7   4.6       Melanoma* Hs688(B).T   3.7   3.9       Melanoma* M14   12.6   13.5       Melanoma* LOXIMVI   7.3   4.8       Melanoma* SK-MEL-5   44.8   33.2       Squamous cell carcinoma SCC-4   7.4   6.2       Testis Pool   5.2   6.2       Prostate ca.* (bone met) PC-3   35.6   27.7       Prostate Pool   3.3   4.5       Placenta   2.5   2.5       Uterus Pool   0.7   1.2       Ovarian ca. OVCAR-3   18.8   21.2       Ovarian ca. SK-OV-3   8.1   9.0       Ovarian ca. OVCAR-4   7.2   10.7       Ovarian ca. OVCAR-5   75.3   68.3       Ovarian ca. IGROV-1   8.6   7.5       Ovarian ca. OVCAR-8   13.8   12.3       Ovary   1.1   2.6       Breast ca. MCF-7   40.3   36.9       Breast ca. MDA-MB-231   44.1   33.7       Breast ca. BT 549   13.2   10.4       Breast ca. T47D   14.4   14.7       Breast ca. MDA-N   14.8   14.5       Breast Pool   2.4   2.4       Trachea   4.0   4.2       Lung   0.9   0.2       Fetal Lung   2.0   3.4       Lung ca. NCI-N417   11.6   9.9       Lung ca. LX-1   40.1   45.4       Lung ca. NCI-H146   11.2   10.3       Lung ca. SHP-77   22.2   31.0       Lung ca. A549   27.0   29.1       Lung ca. NCI-H526   5.1   7.3       Lung ca. NCI-H23   13.6   11.2       Lung ca. NCI-H460   4.8   7.5       Lung ca. HOP-62   7.3   7.6       Lung ca. NCI-H522   9.2   11.7       Liver   19.1   21.9       Fetal Liver   16.5   7.3       Liver ca. HepG2   9.9   14.4       Kidney Pool   2.9   3.2       Fetal Kidney   3.4   2.4       Renal ca. 786-0   15.4   9.9       Renal ca. A498   4.1   4.7       Renal ca. ACHN   14.5   22.2       Renal ca. UO-31   9.7   12.9       Renal ca. TK-10   15.6   19.3       Bladder   4.0   4.4       Gastric ca. (liver met.) NCI-N87   13.2   16.8       Gastric ca. KATO III   41.8   41.5       Colon ca. SW-948   8.1   7.5       Colon ca. SW480   56.3   54.7       Colon ca.* (SW480 met) SW620   19.3   31.9       Colon ca. HT29   8.2   10.3       Colon ca. HCT-116   24.0   21.5       Colon ca. CaCo-2   19.6   12.6       Colon cancer tissue   5.8   7.6       Colon ca. SW1116   7.6   11.7       Colon ca. Colo-205   12.2   8.5       Colon ca. SW-48   7.0   9.2       Colon Pool   2.0   1.9       Small Intestine Pool   2.0   1.6       Stomach Pool   1.7   1.5       Bone Marrow Pool   1.4   1.1       Fetal Heart   1.4   1.3       Heart Pool   1.0   1.3       Lymph Node Pool   2.1   0.3       Fetal Skeletal Muscle   2.0   2.3       Skeletal Muscle Pool   13.5   14.9       Spleen Pool   1.9   5.6       Thymus Pool   4.2   3.5       CNS cancer (glio/astro) U87-MG   100.0   100.0       CNS cancer (glio/astro) U-118-MG   16.5   18.7       CNS cancer (neuro; met) SK-N-AS   19.2   19.9       CNS cancer (astro) SF-539   4.9   4.4       CNS cancer (astro) SNB-75   25.9   21.3       CNS cancer (glio) SNB-19   6.9   7.1       CNS cancer (glio) SF-295   8.0   10.4       Brain (Amygdala) Pool   3.2   2.2       Brain (cerebellum)   4.3   4.9       Brain (fetal)   0.8   1.1       Brain (Hippocampus) Pool   2.5   1.8       Cerebral Cortex Pool   1.6   2.8       Brain (Substantia nigra) Pool   3.5   1.7       Brain (Thalamus) Pool   2.3   4.4       Brain (whole)   5.7   3.3       Spinal Cord Pool   5.5   7.9       Adrenal Gland   5.6   4.5       Pituitary gland Pool   1.7   0.9       Salivary Gland   5.3   5.1       Thyroid (female)   4.1   3.4       Pancreatic ca. CAPAN2   28.5   29.5       Pancreas Pool   2.5   4.7                    
     [0815]               TABLE LC                          Panel 5 Islet                             Rel. Exp. (%)   Rel. Exp. (%)           Ag5913, Run   Ag5913, Run       Tissue Name   247624441   259234351                                 97457_Patient-02go_adipose   47.6   23.0       97476_Patient-07sk_skeletal muscle   19.8   3.2       97477_Patient-07ut_uterus   0.0   8.5       97478_Patient-07pl_placenta   11.3   14.7       99167_Bayer Patient 1   90.8   43.2       97482_Patient-08ut_uterus   0.0   6.6       97483_Patient-08pl_placenta   11.0   18.0       97486_Patient-09sk_skeletal muscle   3.6   8.4       97487_Patient-09ut_uterus   12.2   6.3       97488_Patient-09pl_placenta   20.2   7.3       97492_Patient-10ut_uterus   3.4   2.5       97493_Patient-10pl_placenta   74.7   5.1       97495_Patient-11go_adipose   18.4   6.8       97496_Patient-11sk_skeletal muscle   65.5   18.7       97497_Patient-11ut_uterus   57.0   2.6       97498_Patient-11pl_placenta   16.4   10.2       97500_Patient-12go_adipose   59.5   32.1       97501_Patient-12sk_skeletal muscle   100.0   40.6       97502_Patient-12ut_uterus   5.3   8.9       97503_Patient-12pl_placenta   8.8   6.4       94721_Donor 2 U - A_Mesenchymal   37.6   24.8       Stem Cells       94722_Donor 2 U - B_Mesenchymal   11.2   23.3       Stem Cells       94723_Donor 2 U - C_Mesenchymal   33.9   4.8       Stem Cells       94709_Donor 2 AM - A_adipose   27.9   9.3       94710_Donor 2 AM - B_adipose   4.8   30.1       94711_Donor 2 AM - C_adipose   11.8   3.8       94712_Donor 2 AD - A_adipose   23.5   12.8       94713_Donor 2 AD - B_adipose   5.6   38.2       94714_Donor 2 AD - C_adipose   55.9   20.9       94742_Donor 3 U - A_Mesenchymal   12.2   11.2       Stem Cells       94743_Donor 3 U - B_Mesenchymal   23.3   10.3       Stem Cells       94730_Donor 3 AM - A_adipose   40.9   21.2       94731_Donor 3 AM - B_adipose   0.0   13.6       94732_Donor 3 AM - C_adipose   9.1   13.0       94733_Donor 3 AD - A_adipose   25.2   17.4       94734_Donor 3 AD - B_adipose   23.8   0.0       94735_Donor 3 AD - C_adipose   0.0   26.6       77138_Liver_HepG2untreated   65.5   100.0       73556_Heart_Cardiac stromal   40.1   19.3       cells (primary)       81735_Small Intestine   55.5   15.7       72409_Kidney_Proximal Convoluted   26.2   19.1       Tubule       82685_Small intestine_Duodenum   0.0   7.1       90650_Adrenal_Adrenocortical   30.6   16.4       adenoma       72410_Kidney_HRCE   95.9   53.6       72411_Kidney_HRE   26.4   43.8       73139_Uterus_Uterine smooth   0.0   8.5       muscle cells                    
     [0816]               TABLE LD                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag5913, Run           Tissue Name   260316171                                         Colon cancer 1   15.1           Colon NAT 1   11.5           Colon cancer 2   8.7           Colon NAT 2   10.6           Colon cancer 3   21.3           Colon NAT 3   19.9           Colon malignant cancer 4   100.0           Colon NAT 4   10.4           Lung cancer 1   51.4           Lung NAT 1   0.0           Lung cancer 2   25.2           Lung NAT 2   0.0           Squamous cell carcinoma 3   20.6           Lung NAT 3   0.0           Metastatic melanoma 1   7.1           Melanoma 2   2.3           Melanoma 3   2.2           Metastatic melanoma 4   11.9           Metastatic melanoma 5   15.2           Bladder cancer 1   2.1           Bladder NAT 1   0.0           Bladder cancer 2   0.9           Bladder NAT 2   0.0           Bladder NAT 3   0.9           Bladder NAT 4   0.0           Prostate adenocarcinoma 1   3.1           Prostate adenocarcinoma 2   1.5           Prostate adenocarcinoma 3   22.1           Prostate adenocarcinoma 4   14.6           Prostate NAT 5   5.4           Prostate adenocarcinoma 6   4.7           Prostate adenocarcinoma 7   4.8           Prostate adenocarcinoma 8   3.6           Prostate adenocarcinoma 9   13.0           Prostate NAT 10   0.6           Kidney cancer 1   13.9           Kidney NAT 1   6.7           Kidney cancer 2   63.7           Kidney NAT 2   13.4           Kidney cancer 3   16.8           Kidney NAT 3   0.7           Kidney cancer 4   9.7           Kidney NAT 4   5.8                        
     [0817] General_screening_panel_v1.5 Summary: Ag5913 Two experiments with the same probe and primer set produce results that are in excellent agreement. Highest expression is seen in a brain cancer cell line (CTs=30).  
     [0818] This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0819] Among tissues with metabolic function, this gene is expressed at low but significant levels in adrenal gland, skeletal muscle, and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0820] Panel 5 Islet Summary: Ag5913 Low but significant expression is seen in a liver cell line and skeletal muscle.  
     [0821] general oncology screening panel_v — 2.4 Summary: Ag5913 Highest expression is seen in a colon cancer (CT=32.5). In addition, this gene is overexpressed in colon, kidney, and lung cancers when compared to expression in the normal adjacent tissue. Thus, expression of this gene could be used as a marker of these cancers and modulation of the function of this gene product may be useful in the treatment of these cancers.  
     [0822] M. CG138461-01: Novel Intracellular Nitroreductase-Like Gene  
     [0823] Expression of gene CG138461-01 was assessed using the primer-probe set Ag4962, described in Table MA. Results of the RTQ-PCR runs are shown in Tables MB and MC.  
               TABLE MA                          Probe Name Ag4962                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No               Forward   5′-gggtcacagacctcaagaaac-   21   509   263           3′       Probe   TET-5′-tggatactgcccctattt   27   557   264           tgattctca-3′-TAMRA       Reverse   5′-gcgaaaccatgtacttgtttg-   21   588   265           3′                  
 
     [0824]               TABLE MB                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag4962, Run           Tissue Name   228903674                                         Adipose   0.1           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.0           Testis Pool   0.1           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.0           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   0.0           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.2           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   0.0           Ovary   2.5           Breast ca. MCF-7   0.0           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   0.0           Breast ca. T47D   0.0           Breast ca. MDA-N   0.0           Breast Pool   0.0           Trachea   0.6           Lung   0.0           Fetal Lung   0.4           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   0.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.0           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.0           Liver   1.7           Fetal Liver   2.8           Liver ca. HepG2   0.1           Kidney Pool   0.0           Fetal Kidney   0.4           Renal ca. 786-0   0.0           Renal ca. A498   0.0           Renal ca. ACHN   0.0           Renal ca. UO-31   0.0           Renal ca. TK-10   0.0           Bladder   1.7           Gastric ca. (liver met.) NCI-N87   0.2           Gastric ca. KATO III   3.3           Colon ca. SW-948   0.9           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.2           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   6.6           Colon cancer tissue   2.3           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.8           Colon ca. SW-48   3.0           Colon Pool   0.0           Small Intestine Pool   0.0           Stomach Pool   0.1           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   0.0           Lymph Node Pool   0.0           Fetal Skeletal Muscle   0.0           Skeletal Muscle Pool   0.0           Spleen Pool   0.0           Thymus Pool   0.0           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   0.0           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.1           Brain (Amygdala) Pool   0.0           Brain (cerebellum)   0.0           Brain (fetal)   0.0           Brain (Hippocampus) Pool   0.0           Cerebral Cortex Pool   0.0           Brain (Substantia nigra) Pool   0.0           Brain (Thalamus) Pool   0.0           Brain (whole)   0.1           Spinal Cord Pool   0.0           Adrenal Gland   0.0           Pituitary gland Pool   0.0           Salivary Gland   0.2           Thyroid (female)   100.0           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   0.1                        
     [0825]               TABLE MC                          Panel 4.1D                                 Rel. Exp. (%)               Ag4962, Run           Tissue Name   223691582                                         Secondary Th1 act   0.0           Secondary Th2 act   0.0           Secondary Tr1 act   0.0           Secondary Th1 rest   0.0           Secondary Th2 rest   0.0           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   0.0           Primary Tr1 act   0.0           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   0.0           CD45RA CD4 lymphocyte act   0.0           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte rest   0.0           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   0.0           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0           LAK cells rest   0.0           LAK cells IL-2   0.0           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   0.0           LAK cells IL-2 + IL-18   0.0           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   0.0           Two Way MLR 3 day   0.0           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   0.0           PBMC PWM   0.0           PBMC PHA-L   0.0           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   0.0           B lymphocytes CD40L and IL-4   0.0           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   0.0           Dendritic cells LPS   0.0           Dendritic cells anti-CD40   0.0           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   0.0           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.0           HUVEC IFN gamma   0.0           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   0.0           Lung Microvascular EC none   0.0           Lung Microvascular EC TNFalpha +   0.0           IL-1beta           Microvascular Dermal EC none   0.0           Microsvasular Dermal EC   0.0           TNFalpha + IL-1beta           Bronchial epithelium TNFalpha +   0.2           IL1beta           Small airway epithelium none   0.2           Small airway epithelium   0.6           TNFalpha + IL-1beta           Coronery artery SMC rest   0.0           Coronery artery SMC TNFalpha +   0.0           IL-1beta           Astrocytes rest   0.0           Astrocytes TNFalpha + IL-1beta   0.2           KU-812 (Basophil) rest   0.0           KU-812 (Basophil) PMA/ionomycin   0.0           CCD1106 (Keratinocytes) none   0.0           CCD1106 (Keratinocytes)   0.0           TNFalpha + IL-1beta           Liver cirrhosis   1.9           NCI-H292 none   0.4           NCI-H292 IL-4   0.4           NCI-H292 IL-9   0.4           NCI-H292 IL-13   0.0           NCI-H292 IFN gamma   0.1           HPAEC none   0.0           HPAEC TNF alpha + IL-1 beta   0.0           Lung fibroblast none   0.0           Lung fibroblast TNF alpha + IL-1   0.0           beta           Lung fibroblast IL-4   0.0           Lung fibroblast IL-9   0.0           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   0.0           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1   0.0           beta           Dermal fibroblast IFN gamma   0.0           Dermal fibroblast IL-4   0.0           Dermal Fibroblasts rest   0.0           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   13.2           Lung   0.7           Thymus   0.0           Kidney   100.0                        
     [0826] General_screening &#39; panel &#39; v1.5 Summary: Ag4962 Expression of this gene is restricted to the thyroid (CT=26.5). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel, and as a marker of thyroid tissue. Modulation of the expression or function of this protein may be useful in the treatment of thyroidopathies.  
     [0827] Panel 4.1D Summary: Ag4962 This gene is only expressed at detectable levels in the kidney (CT=30. 1). Thus, expression of this gene could be used to differentiate the kidney-derived sample from other samples on this panel and as a marker of kidney tissue. In addition, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.  
     [0828] N. CG138529-01: SA PROTEIN (Medium-Chain Acyl-CoA Synthetase)-Like Gene  
     [0829] Expression of gene CG138529-01 was assessed using the primer-probe set Ag4963, described in Table NA. Results of the RTQ-PCR runs are shown in Tables NB, NC, ND and NE.  
               TABLE NA                          Probe Name Ag4963                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-aagatccaatggccatattctt-   22   757   266           3′       Probe   TET-5′-caagggtacaacaggagc   26   782   267           tcccaaaa-3′-TAMRA       Reverse   5′-cccaaaccatactgggaatact-   22   814   268           3′                  
 
     [0830]               TABLE NB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag4963, Run           Tissue Name   224735225                                         AD 1 Hippo   2.4           AD 2 Hippo   27.0           AD 3 Hippo   7.9           AD 4 Hippo   7.4           AD 5 Hippo   100.0           AD 6 Hippo   50.3           Control 2 Hippo   3.8           Control 4 Hippo   5.8           Control (Path) 3 Hippo   5.0           AD 1 Temporal Ctx   8.2           AD 2 Temporal Ctx   36.1           AD 3 Temporal Ctx   0.0           AD 4 Temporal Ctx   55.9           AD 5 Inf Temporal Ctx   90.1           AD 5 Sup Temporal Ctx   37.9           AD 6 Inf Temporal Ctx   62.0           AD 6 Sup Temporal Ctx   55.5           Control 1 Temporal Ctx   5.5           Control 2 Temporal Ctx   15.8           Control 3 Temporal Ctx   17.1           Control 3 Temporal Ctx   3.9           Control (Path) 1 Temporal Ctx   58.2           Control (Path) 2 Temporal Ctx   55.1           Control (Path) 3 Temporal Ctx   3.7           Control (Path) 4 Temporal Ctx   11.5           AD 1 Occipital Ctx   3.1           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   0.0           AD 4 Occipital Ctx   40.3           AD 5 Occipital Ctx   2.1           AD 6 Occipital Ctx   8.4           Control 1 Occipital Ctx   0.0           Control 2 Occipital Ctx   20.0           Control 3 Occipital Ctx   27.2           Control 4 Occipital Ctx   4.0           Control (Path) 1 Occipital Ctx   46.3           Control (Path) 2 Occipital Ctx   7.4           Control (Path) 3 Occipital Ctx   0.0           Control (Path) 4 Occipital Ctx   3.7           Control 1 Parietal Ctx   6.3           Control 2 Parietal Ctx   24.5           Control 3 Parietal Ctx   19.5           Control (Path) 1 Parietal Ctx   44.4           Control (Path) 2 Parietal Ctx   37.6           Control (Path) 3 Parietal Ctx   4.2           Control (Path) 4 Parietal Ctx   30.6                        
     [0831]               TABLE NC                          General_screening_panel_v1.5                             Rel. Exp. (%)   Rel. Exp. (%)           Ag4963, Run   Ag4963, Run       Tissue Name   228903693   244628523                                 Adipose   46.7   40.6       Melanoma* Hs688(A).T   2.1   1.8       Melanoma* Hs688(B).T   3.3   2.2       Melanoma* M14   0.0   0.0       Melanoma* LOXIMVI   0.0   0.0       Melanoma* SK-MEL-5   0.8   0.0       Squamous cell carcinoma SCC-4   5.6   1.9       Testis Pool   15.0   13.0       Prostate ca.* (bone met) PC-3   2.2   2.3       Prostate Pool   2.3   5.1       Placenta   1.6   0.7       Uterus Pool   3.4   4.0       Ovarian ca. OVCAR-3   5.2   5.3       Ovarian ca. SK-OV-3   3.3   3.3       Ovarian ca. OVCAR-4   3.5   1.6       Ovarian ca. OVCAR-5   3.4   3.2       Ovarian ca. IGROV-1   10.3   4.6       Ovarian ca. OVCAR-8   0.7   0.4       Ovary   9.7   3.3       Breast ca. MCF-7   19.1   11.1       Breast ca. MDA-MB-231   4.7   2.3       Breast ca. BT 549   13.0   7.9       Breast ca. T47D   1.4   0.0       Breast ca. MDA-N   0.0   0.0       Breast Pool   12.7   10.6       Trachea   6.4   4.7       Lung   3.0   1.1       Fetal Lung   46.7   48.0       Lung ca. NCI-N417   0.0   0.8       Lung ca. LX-1   1.0   0.1       Lung ca. NCI-H146   0.0   0.0       Lung ca. SHP-77   24.8   1.1       Lung ca. A549   1.8   2.4       Lung ca. NCI-H526   0.0   0.0       Lung ca. NCI-H23   0.0   0.0       Lung ca. NCI-H460   0.0   11.5       Lung ca. HOP-62   3.3   0.5       Lung ca. NCI-H522   6.9   10.3       Liver   0.0   0.0       Fetal Liver   10.4   7.6       Liver ca. HepG2   9.5   2.3       Kidney Pool   18.0   16.7       Fetal Kidney   100.0   100.0       Renal ca. 786-0   4.5   4.2       Renal ca. A498   5.8   4.8       Renal ca. ACHN   1.0   2.7       Renal ca. UO-31   11.0   8.2       Renal ca. TK-10   6.5   5.3       Bladder   17.3   14.4       Gastric ca. (liver met.) NCI-N87   41.8   26.6       Gastric ca. KATO III   2.9   3.5       Colon ca. SW-948   2.0   0.0       Colon ca. SW480   1.9   0.9       Colon ca.* (SW480 met) SW620   0.0   0.0       Colon ca. HT29   1.6   0.2       Colon ca. HCT-116   16.3   8.4       Colon ca. CaCo-2   24.7   15.0       Colon cancer tissue   0.6   0.0       Colon ca. SW1116   0.0   0.0       Colon ca. Colo-205   0.0   0.0       Colon ca. SW-48   0.0   0.0       Colon Pool   13.5   9.0       Small Intestine Pool   7.0   2.6       Stomach Pool   12.9   7.9       Bone Marrow Pool   6.7   6.7       Fetal Heart   28.3   21.0       Heart Pool   6.5   5.9       Lymph Node Pool   15.7   12.9       Fetal Skeletal Muscle   3.5   1.4       Skeletal Muscle Pool   4.2   6.0       Spleen Pool   9.3   3.6       Thymus Pool   29.9   31.9       CNS cancer (glio/astro) U87-MG   3.1   1.9       CNS cancer (glio/astro) U-118-MG   9.3   4.3       CNS cancer (neuro; met) SK-N-AS   0.0   1.2       CNS cancer (astro) SF-539   2.0   0.8       CNS cancer (astro) SNB-75   6.0   5.3       CNS cancer (glio) SNB-19   9.9   6.7       CNS cancer (glio) SF-295   7.2   8.0       Brain (Amygdala) Pool   10.2   4.3       Brain (cerebellum)   16.5   11.6       Brain (fetal)   17.9   16.6       Brain (Hippocampus) Pool   7.6   4.6       Cerebral Cortex Pool   7.5   3.8       Brain (Substantia nigra) Pool   3.0   5.9       Brain (Thalamus) Pool   11.7   9.2       Brain (whole)   4.6   8.5       Spinal Cord Pool   7.3   4.4       Adrenal Gland   29.9   14.1       Pituitary gland Pool   12.7   6.3       Salivary Gland   0.7   0.6       Thyroid (female)   5.4   4.0       Pancreatic ca. CAPAN2   20.2   23.0       Pancreas Pool   24.0   16.6                    
     [0832]               TABLE ND                          Panel 4.1D                                 Rel. Exp. (%)               Ag4963, Run           Tissue Name   223691584                                         Secondary Th1 act   5.4           Secondary Th2 act   9.6           Secondary Tr1 act   5.1           Secondary Th1 rest   0.0           Secondary Th2 rest   0.0           Secondary Tr1 rest   12.4           Primary Th1 act   13.0           Primary Th2 act   0.0           Primary Tr1 act   8.0           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   5.2           CD45RA CD4 lymphocyte act   15.1           CD45RO CD4 lymphocyte act   10.9           CD8 lymphocyte act   7.0           Secondary CD8 lymphocyte rest   11.2           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   1.7           2ry Th1/Th2/Tr1_anti-CD95 CH11   12.5           LAK cells rest   4.5           LAK cells IL-2   12.1           LAK cells IL-2 + IL-12   4.5           LAK cells IL-2 + IFN gamma   0.0           LAK cells IL-2 + IL-18   19.9           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   15.8           Two Way MLR 3 day   7.1           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   5.2           PBMC PWM   8.2           PBMC PHA-L   15.2           Ramos (B cell) none   7.6           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   12.9           B lymphocytes CD40L and IL-4   32.8           EOL-1 dbcAMP   10.2           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   0.0           Dendritic cells LPS   0.0           Dendritic cells anti-CD40   0.0           Monocytes rest   5.2           Monocytes LPS   0.0           Macrophages rest   4.0           Macrophages LPS   0.0           HUVEC none   3.6           HUVEC starved   0.0           HUVEC IL-1beta   6.9           HUVEC IFN gamma   62.4           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   16.4           Lung Microvascular EC none   0.0           Lung Microvascular EC TNFalpha +   12.5           IL-1beta           Microvascular Dermal EC none   25.5           Microsvasular Dermal EC   41.2           TNFalpha + IL-1beta           Bronchial epithelium TNFalpha +   26.2           IL1beta           Small airway epithelium none   0.0           Small airway epithelium   90.8           TNFalpha + IL-1beta           Coronery artery SMC rest   10.6           Coronery artery SMC TNFalpha +   5.3           IL-1beta           Astrocytes rest   44.1           Astrocytes TNFalpha + IL-1beta   33.7           KU-812 (Basophil) rest   7.5           KU-812 (Basophil) PMA/ionomycin   40.1           CCD1106 (Keratinocytes) none   36.1           CCD1106 (Keratinocytes)   21.5           TNFalpha + IL-1beta           Liver cirrhosis   8.8           NCI-H292 none   15.3           NCI-H292 IL-4   23.5           NCI-H292 IL-9   14.2           NCI-H292 IL-13   31.4           NCI-H292 IFN gamma   5.3           HPAEC none   22.8           HPAEC TNF alpha + IL-1 beta   5.8           Lung fibroblast none   18.4           Lung fibroblast TNF alpha + IL-1   0.0           beta           Lung fibroblast IL-4   14.0           Lung fibroblast IL-9   4.9           Lung fibroblast IL-13   6.3           Lung fibroblast IFN gamma   4.3           Dermal fibroblast CCD1070 rest   4.8           Dermal fibroblast CCD1070 TNF   5.3           alpha           Dermal fibroblast CCD1070 IL-1   5.1           beta           Dermal fibroblast IFN gamma   4.5           Dermal fibroblast IL-4   5.0           Dermal Fibroblasts rest   14.5           Neutrophils TNFa + LPS   0.0           Neutrophils rest   4.2           Colon   16.2           Lung   61.1           Thymus   100.0           Kidney   43.5                        
     [0833]               TABLE NE                          Panel 5 Islet                             Rel. Exp. (%)   Rel. Exp. (%)           Ag4963, Run   Ag4963, Run       Tissue Name   233698024   245232951                                 97457_Patient-02go_adipose   81.8   74.7       97476_Patient-07sk —     39.5   52.1       skeletal muscle       97477_Patient-07ut_uterus   0.0   98.6       97478_Patient-07pl_placenta   0.0   27.4       99167_Bayer Patient 1   42.3   45.7       97482_Patient-08ut_uterus   16.2   20.6       97483_Patient-08pl_placenta   9.8   40.9       97486_Patient-09sk —     0.0   0.0       skeletal muscle       97487_Patient-09ut_uterus   14.6   28.1       97488_Patient-09pl_placenta   0.0   0.0       97492_Patient-10ut_uterus   0.0   36.6       97493_Patient-10pl_placenta   15.2   60.3       97495_Patient-11go_adipose   10.2   23.8       97496_Patient-11sk —     0.0   8.2       skeletal muscle       97497_Patient-11ut_uterus   10.7   23.7       97498_Patient-11pl_placenta   5.5   12.8       97500_Patient-12go_adipose   31.9   100.0       97501_Patient-12sk —     54.3   75.8       skeletal muscle       97502_Patient-12ut_uterus   18.0   55.1       97503_Patient-12pl_placenta   0.0   38.7       94721_Donor 2 U -   0.0   27.9       A_Mesenchymal Stem Cells       94722_Donor 2 U -   0.0   0.0       B_Mesenchymal Stem Cells       94723_Donor 2 U -   0.0   0.0       C_Mesenchymal Stem Cells       94709_Donor 2 AM - A_adipose   13.2   0.0       94710_Donor 2 AM - B_adipose   13.7   0.0       94711_Donor 2 AM - C_adipose   4.5   0.0       94712_Donor 2 AD - A_adipose   16.0   0.0       94713_Donor 2 AD - B_adipose   15.7   0.0       94714_Donor 2 AD - C_adipose   12.4   0.0       94742_Donor 3 U -   11.0   0.0       A_Mesenchymal Stem Cells       94743_Donor 3 U -   16.6   0.0       B_Mesenchymal Stem Cells       94730_Donor 3 AM - A_adipose   14.0   31.6       94731_Donor 3 AM - B_adipose   0.0   0.0       94732_Donor 3 AM - C_adipose   11.0   14.5       94733_Donor 3 AD - A_adipose   16.7   42.6       94734_Donor 3 AD - B_adipose   0.0   0.0       94735_Donor 3 AD - C_adipose   9.7   19.3       77138_Liver_HepG2untreated   61.1   72.2       73556_Heart_Cardiac stromal   11.0   0.0       cells (primary)       81735_Small Intestine   77.9   76.8       72409_Kidney_Proximal   8.2   0.0       Convoluted Tubule       82685_Small intestine_Duodenum   0.0   0.0       90650_Adrenal_Adrenocortical   0.0   0.0       adenoma       72410_Kidney_HRCE   100.0   0.0       72411_Kidney_HRE   0.0   31.6       73139_Uterus_Uterine smooth   0.0   0.0       muscle cells                    
     [0834] CNS_neurodegeneration_v1.0 Summary: Ag4963 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene appears to be slightly upregulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.  
     [0835] General_screening_panel_v — 1.5 Summary: Ag4963 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression in fetal kidney (CT=30). This gene is homologous to the SA protein that is also expressed in human kidney and may play a role in blood pressure regulation in rodent models of genetic hypertension (Samani NJ. Biochem Biophys Res Commun March 15, 1994; 199(2):862-8). In addition, this gene appears to be overexpressed in fetal lung (CTs=30) when compared to expression in the adult counterpart (CT=35). Thus, expression of this gene could be used to differentiate between the fetal and adult source of this tissue. In addition, modulation of the expression or function of this gene may be useful in the treatment of diseases of this organ.  
     [0836] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, fetal liver, skeletal muscle and fetal and adult and fetal skeletal heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0837] This gene is also expressed at low but significant levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0838] Panel 4.1D Summary: Ag4963 Highest expression of this gene is seen in the thymus (CT=32.4). Low but significant expression is also seen in IFN-gamma treated KUVECs, IL-13 and IL-14 treated NCI—H292 cells, untreated IHPAECs and lung fibroblasts, normal lung and kidney. Thus, this gene product may play an important role in T cell development. Therapeutic modulation of the expression or function of this gene may be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.  
     [0839] Panel 5 Islet Summary: Ag4963 Two experiments with the same probe and primer show this gene expressed at low levels in adipose and a kidney cell line (CTs=34.5).  
     [0840] O. CG138563-01: CHOLINE/ETHANOLAMINE KINASE-Like Gene  
     [0841] Expression of gene CG138563-01 was assessed using the primer-probe sets Ag4972 and Ag5937, described in Tables OA and OB. Results of the RTQ-PCR runs are shown in Tables OC, OD and OE.  
               TABLE OA                          Probe Name Ag4972                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-   22   777   269           ggagcggtacctaaaacagatc-           3′       Probe   TET-5′-   25   813   270           aactggcctccctgagatgaacctg-           3′-TAMRA       Reverse   5′-   22   844   271           tctcatccttcaggctgtacat-           3′                  
 
     [0842]               TABLE OB                          Probe Name Ag5937                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-   22   842   272           agatgtacagcctgaaggatga-           3′       Probe   TET-5′-   25   926   273           acatccaggaaggtaggagaaggca-           3′-TAMRA       Reverse   5′-tgaggttctgctcactccaga-   21   989   274           3′                    
     [0843]               TABLE OC                          General_screening_panel_v1.5                             Rel. Exp. (%)   Rel. Exp. (%)           Ag4972, Run   Ag5937, Run       Tissue Name   228926672   247834840                                 Adipose   13.7   11.3       Melanoma* Hs688(A).T   19.5   17.8       Melanoma* Hs688(B).T   18.2   18.2       Melanoma* M14   44.4   57.4       Melanoma* LOXIMVI   15.6   16.6       Melanoma* SK-MEL-5   35.6   25.2       Squamous cell carcinoma SCC-4   9.2   16.4       Testis Pool   20.6   17.8       Prostate ca.* (bone met) PC-3   36.1   49.0       Prostate Pool   21.8   26.6       Placenta   23.0   15.1       Uterus Pool   13.6   10.4       Ovarian ca. OVCAR-3   15.3   14.2       Ovarian ca. SK-OV-3   59.5   55.5       Ovarian ca. OVCAR-4   13.4   7.4       Ovarian ca. OVCAR-5   41.8   64.2       Ovarian ca. IGROV-1   17.6   10.4       Ovarian ca. OVCAR-8   14.4   9.7       Ovary   10.6   11.7       Breast ca. MCF-7   22.1   48.0       Breast ca. MDA-MB-231   28.3   32.3       Breast ca. BT 549   35.1   63.7       Breast ca. T47D   5.3   6.2       Breast ca. MDA-N   11.4   12.3       Breast Pool   24.1   25.2       Trachea   22.8   29.9       Lung   9.0   13.2       Fetal Lung   37.9   37.4       Lung ca. NCI-N417   3.0   3.3       Lung ca. LX-1   25.5   31.0       Lung ca. NCI-H146   6.3   7.4       Lung ca. SHP-77   25.9   50.0       Lung ca. A549   16.4   18.7       Lung ca. NCI-H526   4.3   3.6       Lung ca. NCI-H23   40.1   54.7       Lung ca. NCI-H460   23.3   28.9       Lung ca. HOP-62   25.7   16.0       Lung ca. NCI-H522   47.0   82.4       Liver   2.5   1.9       Fetal Liver   19.9   20.0       Liver ca. HepG2   17.7   23.7       Kidney Pool   32.3   47.6       Fetal Kidney   27.4   37.9       Renal ca. 786-0   32.8   50.0       Renal ca. A498   6.3   6.3       Renal ca. ACHN   19.6   18.0       Renal ca. UO-31   27.2   39.5       Renal ca. TK-10   26.8   31.0       Bladder   54.7   86.5       Gastric ca. (liver met.)   100.0   78.5       NCI-N87       Gastric ca. KATO III   44.8   59.5       Colon ca. SW-948   12.6   9.8       Colon ca. SW480   28.1   32.8       Colon ca.* (SW480 met)   17.4   23.3       SW620       Colon ca. HT29   6.1   8.6       Colon ca. HCT-116   28.5   44.4       Colon ca. CaCo-2   34.2   63.3       Colon cancer tissue   22.1   27.2       Colon ca. SW1116   8.4   7.0       Colon ca. Colo-205   6.9   5.7       Colon ca. SW-48   7.5   5.3       Colon Pool   10.4   27.0       Small Intestine Pool   21.0   27.0       Stomach Pool   13.8   15.5       Bone Marrow Pool   8.8   9.7       Fetal Heart   23.2   23.2       Heart Pool   11.0   11.0       Lymph Node Pool   22.1   38.7       Fetal Skeletal Muscle   9.2   5.5       Skeletal Muscle Pool   22.7   27.7       Spleen Pool   39.5   48.3       Thymus Pool   40.9   61.6       CNS cancer (glio/astro)   46.7   36.9       U87-MG       CNS cancer (glio/astro)   48.0   90.8       U-118-MG       CNS cancer (neuro; met)   23.0   15.3       SK-N-AS       CNS cancer (astro) SF-539   14.6   25.5       CNS cancer (astro) SNB-75   33.0   46.0       CNS cancer (glio) SNB-19   16.0   12.8       CNS cancer (glio) SF-295   56.6   90.8       Brain (Amygdala) Pool   12.7   13.5       Brain (cerebellum)   82.9   100.0       Brain (fetal)   39.5   51.1       Brain (Hippocampus) Pool   11.2   12.9       Cerebral Cortex Pool   9.5   17.1       Brain (Substantia nigra)   12.4   19.1       Pool       Brain (Thalamus) Pool   15.3   16.4       Brain (whole)   11.3   19.2       Spinal Cord Pool   14.3   12.3       Adrenal Gland   28.3   31.6       Pituitary gland Pool   10.5   11.2       Salivary Gland   14.6   15.1       Thyroid (female)   11.4   9.0       Pancreatic ca. CAPAN2   26.2   37.4       Pancreas Pool   34.6   31.9                    
     [0844]               TABLE OD                          Oncology_cell_line_screening_panel_v3.1                                 Rel. Exp. (%)               Ag4972, Run           Tissue Name   225061002                                         Daoy   9.0           Medulloblastoma/Cerebellum           TE671   9.6           Medulloblastom/Cerebellum           D283 Med   31.0           Medulloblastoma/Cerebellum           PFSK-1 Primitive   19.5           Neuroectodermal/Cerebellum           XF-498_CNS   28.9           SNB-78_CNS/glioma   18.6           SF-268_CNS/glioblastoma   10.6           T98G_Glioblastoma   39.2           SK-N-SH_Neuroblastoma   36.9           (metastasis)           SF-295_CNS/glioblastoma   24.7           Cerebellum   100.0           Cerebellum   72.7           NCI-H292_Mucoepidermoid   25.5           lung ca.           DMS-114_Small cell lung   9.7           cancer           DMS-79_Small cell lung   21.2           cancer/neuroendocrine           NCI-H146_Small cell lung   19.3           cancer/neuroendocrine           NCI-H526_Small cell lung   26.6           cancer/neuroendocrine           NCI-N417_Small cell lung   11.0           cancer/neuroendocrine           NCI-H82_Small cell lung   11.0           cancer/neuroendocrine           NCI-H157_Squamous cell lung   19.9           cancer (metastasis)           NCI-H1155_Large cell lung   69.7           cancer/neuroendocrine           NCI-H1299_Large cell lung   20.7           cancer/neuroendocrine           NCI-H727_Lung carcinoid   37.6           NCI-UMC-11_Lung carcinoid   61.6           LX-1_Small cell lung cancer   15.7           Colo-205_Colon cancer   17.8           KM12_Colon cancer   39.8           KM20L2_Colon cancer   6.1           NCI-H716_Colon cancer   80.1           SW-48_Colon adenocarcinoma   24.1           SW1116_Colon adenocarcinoma   14.4           LS 174T_Colon adenocarcinoma   19.8           SW-948_Colon adenocarcinoma   31.2           SW-480_Colon adenocarcinoma   17.6           NCI-SNU-5_Gastric ca.   19.9           KATO III_Stomach   23.5           NCI-SNU-16_Gastric ca.   14.7           NCI-SNU-1_Gastric ca.   30.8           RF-1_Gastric adenocarcinoma   22.5           RF-48_Gastric adenocarcinoma   20.3           MKN-45_Gastric ca.   24.7           NCI-N87_Gastric ca.   21.6           OVCAR-5_Ovarian ca.   9.2           RL95-2_Uterine carcinoma   22.4           HelaS3_Cervical adenocarcinoma   22.2           Ca Ski_Cervical epidermoid carcinoma   71.2           (metastasis)           ES-2_Ovarian clear cell carcinoma   10.3           Ramos/6 h stim_Stimulated with   37.9           PMA/ionomycin 6 h           Ramos/14 h stim_Stimulated with   16.0           PMA/ionomycin 14 h           MEG-01_Chronic myelogenous   18.0           leukemia (megokaryoblast)           Raji_Burkitt&#39;s lymphoma   19.2           Daudi_Burkitt&#39;s lymphoma   40.1           U266_B-cell plasmacytoma/myeloma   10.1           CA46_Burkitt&#39;s lymphoma   9.3           RL_non-Hodgkin&#39;s B-cell lymphoma   6.5           JM1_pre-B-cell lymphoma/leukemia   12.7           Jurkat_T cell leukemia   23.2           TF-1_Erythroleukemia   31.4           HUT 78_T-cell lymphoma   56.6           U937_Histiocytic lymphoma   17.4           KU-812_Myelogenous leukemia   28.3           769-P_Clear cell renal ca.   12.2           Caki-2_Clear cell renal ca.   35.4           SW 839_Clear cell renal ca.   32.1           G401_Wilms&#39; tumor   14.8           Hs766T_Pancreatic ca. (LN metastasis)   29.7           CAPAN-1_Pancreatic adenocarcinoma   21.3           (liver metastasis)           SU86.86_Pancreatic carcinoma (liver   39.5           metastasis)           BxPC-3_Pancreatic adenocarcinoma   26.2           HPAC_Pancreatic adenocarcinoma   83.5           MIA PaCa-2_Pancreatic ca.   5.3           CFPAC-1_Pancreatic ductal   84.1           adenocarcinoma           PANC-1_Pancreatic epithelioid ductal   27.2           ca.           T24_Bladder ca. (transitional cell)   30.1           5637_Bladder ca.   14.4           HT-1197_Bladder ca.   61.6           UM-UC-3_Bladder ca. (transitional   7.4           cell)           A204_Rhabdomyosarcoma   12.6           HT-1080_Fibrosarcoma   24.3           MG-63_Osteosarcoma (bone)   10.1           SK-LMS-1_Leiomyosarcoma (vulva)   27.5           SJRH30_Rhabdomyosarcoma (met to   22.7           bone marrow)           A431_Epidermoid ca.   59.5           WM266-4_Melanoma   20.4           DU 145_Prostate   30.1           MDA-MB-468_Breast adenocarcinoma   17.9           SSC-4_Tongue   12.2           SSC-9_Tongue   12.4           SSC-15_Tongue   19.8           CAL 27_Squamous cell ca. of tongue   33.4                        
     [0845]               TABLE OE                          Panel 5 Islet                             Rel. Exp. (%)   Rel. Exp. (%)           Ag4972, Run   Ag5937, Run       Tissue Name   240188657   247837926                                 97457_Patient-02go_adipose   44.4   56.3       97476_Patient-07sk —     13.2   30.6       skeletal muscle       97477_Patient-07ut_uterus   11.0   12.2       97478_Patient-07pl_placenta   22.5   20.7       99167_Bayer Patient 1   57.8   37.1       97482_Patient-08ut_uterus   10.1   9.7       97483_Patient-08pl_placenta   21.3   12.2       97486_Patient-09sk —     2.6   3.2       skeletal muscle       97487_Patient-09ut_uterus   13.5   27.2       97488_Patient-09pl_placenta   14.2   19.3       97492_Patient-10ut_uterus   16.2   38.7       97493_Patient-10pl_placenta   53.2   42.6       97495_Patient-11go_adipose   20.9   28.5       97496_Patient-11sk —     14.7   14.0       skeletal muscle       97497_Patient-11ut_uterus   18.2   36.9       97498_Patient-11pl_placenta   10.8   23.2       97500_Patient-12go_adipose   49.3   40.3       97501_Patient-12sk —     46.7   38.7       skeletal muscle       97502_Patient-12ut_uterus   21.3   23.7       97503_Patient-12pl_placenta   20.6   18.6       94721_Donor 2 U -   18.0   18.8       A_Mesenchymal Stem Cells       94722_Donor 2 U -   11.7   10.4       B_Mesenchymal Stem Cells       94723_Donor 2 U -   23.8   15.8       C_Mesenchymal Stem Cells       94709_Donor 2 AM - A_adipose   25.5   15.5       94710_Donor 2 AM - B_adipose   11.7   8.5       94711_Donor 2 AM - C_adipose   10.8   5.0       94712_Donor 2 AD - A_adipose   22.5   20.7       94713_Donor 2 AD - B_adipose   17.0   15.2       94714_Donor 2 AD - C_adipose   17.8   18.9       94742_Donor 3 U -   9.6   5.0       A_Mesenchymal Stem Cells       94743_Donor 3 U -   12.5   21.3       B_Mesenchymal Stem Cells       94730_Donor 3 AM - A_adipose   14.1   25.0       94731_Donor 3 AM - B_adipose   9.9   10.4       94732_Donor 3 AM - C_adipose   17.0   8.7       94733_Donor 3 AD - A_adipose   27.5   16.6       94734_Donor 3 AD - B_adipose   4.7   3.0       94735_Donor 3 AD - C_adipose   17.1   11.2       77138_Liver_HepG2untreated   26.2   39.2       73556_Heart_Cardiac stromal   24.3   43.2       cells (primary)       81735_Small Intestine   41.8   59.0       72409_Kidney_Proximal   15.6   25.9       Convoluted Tubule       82685_Small intestine_Duodenum   5.4   21.9       90650_Adrenal_Adrenocortical   12.8   7.0       adenoma       72410_Kidney_HRCE   100.0   100.0       72411_Kidney_HRE   40.3   66.4       73139_Uterus_Uterine smooth   13.5   22.7       muscle cells                    
     [0846] General_screening_panel_v1.5 Summary: Ag4972/Ag5937 Two experiments with two different probe and primer sets produce results that are in very good agreement. Highest expression of this gene is seen in a gastric cancer cell line (CT=26) and the cerebellum (CT=29). This gene encodes a homolog of ethanolaamine kinase that catalyzes the first step of PtdEtn biosynthesis, an abundant phospholipid in eukaryotic cell membranes. This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0847] Among tissues with metabolic function, this gene is expressed at moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, fetal liver and adult and fetal skeletal muscle and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0848] In addition, this gene is expressed at much higher levels in fetal liver tissue (CTs=29-3 1) when compared to expression in the adult counterpart (CTs=32-35). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. In addition, therapeutic modulation of this gene may be useful in the treatment of diseases of this tissue.  
     [0849] This gene is also expressed at high to moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0850] Oncology_cell_line_screening_panel_ — 3.1 Summary: Ag4972 Highest expression of this gene is seen in the cerebellum (CT=29), consistent with expression in Panel 1.5. In addition, this gene is widely expressed in the cancer cell line samples on this panel.  
     [0851] Panel 5 Islet Summary: Ag4972/Ag5937 Two experiments with two different probe and primer sets produce results that are in very good agreement. Highest expression of this gene is seen in kidney (CTs=29-32). This gene is widely expressed on this panel, consistent with expression in the other panels. Moderate levels of expression are seen in metabolic tissues, including adipose, placenta and skeletal muscle. Please see Panel 1.5 for discussion of utility of this gene in metabolic disease.  
     [0852] P. CG140041-01: Pyridoxal-Dependent Decarboxylase-Like Gene  
     [0853] Expression of gene CG140041-01 was assessed using the primer-probe set Ag4979, described in Table PA.  
               TABLE PA                          Probe Name Ag4979                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-   21   1732   275           tgctggactcctgaagaagtt-           3′       Probe   TET-5′-   27   1768   276           tgacctaacctttaaaataggccctga-           3′-TAMRA       Reverse   5′-gacataaaggcagctcttcatg-   22   1804   277           3′                  
 
     [0854] Q. CG140061-01: IMP Dehydrogenase-Like Gene  
     [0855] Expression of gene CG140061-01 was assessed using the primer-probe set Ag4980, described in Table QA. Results of the RTQ-PCR runs are shown in Tables QB and QC.  
               TABLE QA                          Probe Name Ag4980                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-   22   1533   278           gtactcaggggagctcaagttt-           3′       Probe   TET-5′-   23   1562   279           agaccatgtcggcccagatcaag-           3′-TAMRA       Reverse   5′-   22   1609   280           ctcatcacagctgcttctcata-           3′                  
 
     [0856]               TABLE QB                          General screening_panel v1.4                                 Rel. Exp. (%)               Ag4980, Run           Tissue Name   218306194                                         Adipose   0.0           Melanoma* Hs688(A).T   9.8           Melanoma* Hs688(B).T   9.0           Melanoma* M14   2.1           Melanoma* LOXIMVI   4.8           Melanoma* SK-MEL-5   2.7           Squamous cell carcinoma   6.5           SCC-4           Testis Pool   100.0           Prostate ca.* (bone met) PC-3   79.6           Prostate Pool   2.5           Placenta   18.2           Uterus Pool   0.0           Ovarian ca. OVCAR-3   14.1           Ovarian ca. SK-OV-3   27.5           Ovarian ca. OVCAR-4   5.8           Ovarian ca. OVCAR-5   76.3           Ovarian ca. IGROV-1   9.9           Ovarian ca. OVCAR-8   4.3           Ovary   8.0           Breast ca. MCF-7   63.3           Breast ca. MDA-MB-231   14.5           Breast ca. BT 549   23.2           Breast ca. T47D   87.7           Breast ca. MDA-N   1.9           Breast Pool   7.2           Trachea   6.2           Lung   0.0           Fetal Lung   8.3           Lung ca. NCI-N417   1.7           Lung ca. LX-1   29.9           Lung ca. NCI-H146   1.2           Lung ca. SHP-77   3.0           Lung ca. A549   17.1           Lung ca. NCI-H526   1.1           Lung ca. NCI-H23   11.6           Lung ca. NCI-H460   6.2           Lung ca. HOP-62   3.4           Lung ca. NCI-H522   17.9           Liver   0.0           Fetal Liver   1.6           Liver ca. HepG2   8.3           Kidney Pool   23.8           Fetal Kidney   3.4           Renal ca. 786-0   12.6           Renal ca. A498   11.7           Renal ca. ACHN   4.4           Renal ca. UO-31   6.0           Renal ca. TK-10   15.1           Bladder   8.0           Gastric ca. (liver met.) NCI-N87   45.7           Gastric ca. KATO III   14.4           Colon ca. SW-948   3.6           Colon ca. SW480   9.4           Colon ca.* (SW480 met) SW620   9.3           Colon ca. HT29   5.4           Colon ca. HCT-116   19.5           Colon ca. CaCo-2   22.7           Colon cancer tissue   2.1           Colon ca. SW1116   2.6           Colon ca. Colo-205   1.4           Colon ca. SW-48   3.1           Colon Pool   7.1           Small Intestine Pool   5.6           Stomach Pool   4.9           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   4.3           Lymph Node Pool   10.7           Fetal Skeletal Muscle   1.3           Skeletal Muscle Pool   3.3           Spleen Pool   4.6           Thymus Pool   6.2           CNS cancer (glio/astro) U87-MG   7.2           CNS cancer (glio/astro)   11.2           U-118-MG           CNS cancer (neuro; met)   19.8           SK-N-AS           CNS cancer (astro) SF-539   3.6           CNS cancer (astro) SNB-75   15.9           CNS cancer (glio) SNB-19   8.3           CNS cancer (glio) SF-295   7.3           Brain (Amygdala) Pool   0.0           Brain (cerebellum)   0.0           Brain (fetal)   6.2           Brain (Hippocampus) Pool   0.0           Cerebral Cortex Pool   1.1           Brain (Substantia nigra) Pool   0.0           Brain (Thalamus) Pool   1.7           Brain (whole)   2.6           Spinal Cord Pool   0.0           Adrenal Gland   28.1           Pituitary gland Pool   0.0           Salivary Gland   4.7           Thyroid (female)   4.0           Pancreatic ca. CAPAN2   33.9           Pancreas Pool   13.6                        
     [0857]               TABLE QC                          Panel 4.1D                                 Rel. Exp. (%)               Ag4980, Run           Tissue Name   223693388                                         Secondary Th1 act   0.0           Secondary Th2 act   3.0           Secondary Tr1 act   5.7           Secondary Th1 rest   9.2           Secondary Th2 rest   7.6           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   0.0           Primary Tr1 act   4.8           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   3.6           CD45RA CD4 lymphocyte act   3.0           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte   3.1           rest           Secondary CD8 lymphocyte   0.0           act           CD4 lymphocyte none   0.0           2ry Thl/Th2/Trl_anti-CD95   6.3           CH11           LAK cells rest   0.0           LAK cells IL-2   6.7           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   0.0           LAK cells IL-2 + IL-18   0.0           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   17.0           Two Way MLR 3 day   4.0           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   0.0           PBMC PWM   0.0           PBMC PHA-L   3.1           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   4.0           B lymphocytes CD40L and   3.8           IL-4           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP   0.0           PMA/ionomycin           Dendritic cells none   0.0           Dendritic cells LPS   5.4           Dendritic cells anti-CD40   0.0           Monocytes rest   0.0           Monocytes LPS   4.2           Macrophages rest   0.0           Macrophages LPS   0.0           HUVEC none   8.9           HUVEC starved   8.6           HUVEC IL-1beta   5.9           HUVEC IFN gamma   8.1           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   7.1           HUVEC IL-11   6.9           Lung Microvascular EC none   22.8           Lung Microvascular EC TNFalpha +   13.6           IL-1beta           Microvascular Dermal EC none   9.5           Microsvasular Dermal EC TNFalpha +   5.0           IL-1beta           Bronchial epithelium TNFalpha +   37.9           IL1beta           Small airway epithelium none   7.6           Small airway epithelium TNFalpha +   17.8           IL-1beta           Coronery artery SMC rest   0.0           Coronery artery SMC TNFalpha +   9.6           IL-1beta           Astrocytes rest   4.2           Astrocytes TNFalpha + IL-lbeta   10.0           KU-812 (Basophil) rest   0.0           KU-812 (Basophil) PMA/ionomycin   0.0           CCD1106 (Keratinocytes) none   21.9           CCD1106 (Keratinocytes) TNFalpha +   33.9           IL-1beta           Liver cirrhosis   0.0           NCI-H292 none   78.5           NCI-H292 IL-4   100.0           NCI-H292 IL-9   81.2           NCI-H292 IL-13   80.7           NCI-H292 IFN gamma   44.1           HPAEC none   10.2           HPAEC TNF alpha + IL-1 beta   25.5           Lung fibroblast none   18.9           Lung fibroblast TNF alpha + IL-1   7.0           beta           Lung fibroblast IL-4   5.3           Lung fibroblast IL-9   19.1           Lung fibroblast IL-13   7.1           Lung fibroblast IFN gamma   8.6           Dermal fibroblast CCD1070 rest   26.8           Dermal fibroblast CCD1070 TNF   21.2           alpha           Dermal fibroblast CCD1070 IL-1   13.2           beta           Dermal fibroblast IFN gamma   9.9           Dermal fibroblast IL-4   23.5           Dermal Fibroblasts rest   7.3           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   0.0           Lung   0.0           Thymus   8.2           Kidney   25.5                        
     [0858] General_screening_panel_v1.4 Summary: Ag4980 Highest expression of this gene is seen in testis (CT=33). Low but significant levels of expression are seen in cell lines derived from pancreatic, breast, ovarian, lung, and gastric cancer cell lines. This gene encodes a homologue of inosine-5-prime-monophosphate dehydrogenase (IMPD-1) that is the rate-limiting enzyme in the de novo synthesis of guanine nucleotides. Inhibition of this enzyme has been shown to exhibit anticancer activities against tumor cell lines (Jager W. Curr Med Chem April 2002;9(7):781-6). Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [0859] Panel 4.1D Summary: Ag4980 Expression of this transcript is expressed exclusively in NC—-H292 cells stimulated by IL-4 (CT=34.9). This cell line is derived from a human airway epithelial cell line that produces mucins. Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. The expression of the transcript in this mucoepidermoid cell line that is often used as a model for airway epithelium (NCI—H292 cells) suggests that this transcript may be important in the proliferation or activation of airway epithelium. Therefore, therapeutics designed with the protein encoded by the transcript may reduce or eliminate symptoms caused by inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema.  
     [0860] R. CG140335-01: UREA TRANSPORTER ISOFORM UTA-3-Like Gene  
     [0861] Expression of gene CG140335-01 was assessed using the primer-probe set Ag5021, described in Table RA. Results of the RTQ-PCR runs are shown in Tables RB and RC.  
               TABLE RA                          Probe Name Ag5021                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No                                         Forward   5′-ctttctagtgccttgaattcca-3′   22   660   281       Probe   TET-5′-   26   690   282           aagtgggacctcccggtcttcactct-           3′-TAMRA       Reverse   5′-ggtacaaggtgactgcaatgtt-3′   22   723   283                  
 
     [0862]               TABLE RB                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag5021, Run           Tissue Name   228941110                                         Adipose   38.4           Melanoma* Hs688(A).T   22.1           Melanoma* Hs688(B).T   3.7           Melanoma* M14   0.4           Melanoma* LOXIMVI   1.6           Melanoma* SK-MEL-5   1.9           Squamous cell carcinoma   1.1           SCC-4           Testis Pool   30.1           Prostate ca.* (bone met) PC-3   1.4           Prostate Pool   12.7           Placenta   0.9           Uterus Pool   2.6           Ovarian ca. OVCAR-3   4.0           Ovarian ca. SK-OV-3   13.6           Ovarian ca. OVCAR-4   1.7           Ovarian ca. OVCAR-5   1.0           Ovarian ca. IGROV-1   11.7           Ovarian ca. OVCAR-8   1.7           Ovary   1.2           Breast ca. MCF-7   1.5           Breast ca. MDA-MB-231   3.4           Breast ca. BT 549   3.9           Breast ca. T47D   0.0           Breast ca. MDA-N   0.5           Breast Pool   4.3           Trachea   5.7           Lung   0.9           Fetal Lung   5.9           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.5           Lung ca. SHP-77   0.0           Lung ca. A549   0.5           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.5           Lung ca. NCI-H460   0.9           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.7           Liver   0.8           Fetal Liver   2.0           Liver ca. HepG2   0.0           Kidney Pool   4.9           Fetal Kidney   100.0           Renal ca. 786-0   0.0           Renal ca. A498   0.2           Renal ca. ACHN   0.0           Renal ca. UO-31   0.4           Renal ca. TK-10   1.9           Bladder   13.2           Gastric ca. (liver met.) NCI-N87   1.1           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.9           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.0           Colon ca. HCT-116   2.4           Colon ca. CaCo-2   29.9           Colon cancer tissue   1.7           Colon ca. SW1116   0.4           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   6.1           Small Intestine Pool   1.8           Stomach Pool   1.9           Bone Marrow Pool   0.9           Fetal Heart   0.0           Heart Pool   1.4           Lymph Node Pool   1.9           Fetal Skeletal Muscle   0.5           Skeletal Muscle Pool   2.9           Spleen Pool   5.4           Thymus Pool   22.8           CNS cancer (glio/astro) U87-MG   7.7           CNS cancer (glio/astro)   13.7           U-118-MG           CNS cancer (neuro; met)   1.5           SK-N-AS           CNS cancer (astro) SF-539   0.4           CNS cancer (astro) SNB-75   2.7           CNS cancer (glio) SNB-19   20.2           CNS cancer (glio) SF-295   7.7           Brain (Amygdala) Pool   3.5           Brain (cerebellum)   3.2           Brain (fetal)   9.6           Brain (Hippocampus) Pool   2.2           Cerebral Cortex Pool   4.6           Brain (Substantia nigra) Pool   4.5           Brain (Thalamus) Pool   6.5           Brain (whole)   4.7           Spinal Cord Pool   1.0           Adrenal Gland   2.0           Pituitary gland Pool   0.6           Salivary Gland   2.4           Thyroid (female)   1.2           Pancreatic ca. CAPAN2   0.6           Pancreas Pool   2.2                        
     [0863]               TABLE RC                          Panel 4.1D                                 Rel. Exp. (%)               Ag5021, Run           Tissue Name   223740344                                         Secondary Th1 act   2.1           Secondary Th2 act   0.0           Secondary Tr1 act   0.0           Secondary Th1 rest   6.7           Secondary Th2 rest   0.0           Secondary Tr1 rest   2.7           Primary Th1 act   7.9           Primary Th2 act   0.0           Primary Tr1 act   0.0           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   5.3           CD45RA CD4 lymphocyte act   4.7           CD45RO CD4 lymphocyte act   4.6           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte   2.4           rest           Secondary CD8 lymphocyte   1.4           act           CD4 lymphocyte none   0.0           2ry Thl/Th2/Trl_anti-CD95   0.0           CH11           LAK cells rest   4.8           LAK cells IL-2   0.0           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   4.7           LAK cells IL-2 + IL-18   2.6           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   10.6           Two Way MLR 3 day   2.5           Two Way MLR 5 day   2.1           Two Way MLR 7 day   5.4           PBMC rest   0.0           PBMC PWM   2.3           PBMC PHA-L   21.0           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   5.7           B lymphocytes CD40L and   2.6           IL-4           EOL-1 dbcAMP   2.0           EOL-1 dbcAMP   6.1           PMA/ionomycin           Dendritic cells none   0.0           Dendritic cells LPS   1.7           Dendritic cells anti-CD40   2.7           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   4.2           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.0           HUVEC IFN gamma   0.0           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   0.0           Lung Microvascular EC none   2.1           Lung Microvascular EC TNFalpha +   1.4           IL-1beta           Microvascular Dermal EC none   0.0           Microsvasular Dermal EC   0.0           TNFalpha + IL-lbeta           Bronchial epithelium TNFalpha +   2.4           IL1beta           Small airway epithelium none   0.0           Small airway epithelium   0.0           TNFalpha + IL-lbeta           Coronery artery SMC rest   2.9           Coronery artery SMC TNFalpha +   7.5           IL-1beta           Astrocytes rest   2.3           Astrocytes TNFalpha + IL-lbeta   5.1           KU-812 (Basophil) rest   0.0           KU-812 (Basophil) PMA/ionomycin   1.2           CCD1106 (Keratinocytes) none   1.9           CCD1106 (Keratinocytes)   0.0           TNFalpha + IL-lbeta           Liver cirrhosis   6.6           NCI-H292 none   4.6           NCI-H292 IL-4   2.6           NCI-H292 IL-9   2.2           NCI-H292 IL-13   0.0           NCI-H292 IFN gamma   0.0           HPAEC none   0.0           HPAEC TNF alpha + IL-1 beta   0.0           Lung fibroblast none   4.5           Lung fibroblast TNF alpha + IL-1   0.0           beta           Lung fibroblast IL-4   2.2           Lung fibroblast IL-9   0.0           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   0.0           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF   3.9           alpha           Dermal fibroblast CCD1070 IL-1   0.0           beta           Dermal fibroblast IFN gamma   0.0           Dermal fibroblast IL-4   0.4           Dermal Fibroblasts rest   2.7           Neutrophils TNFa + LPS   0.0           Neutrophils rest   3.3           Colon   66.4           Lung   0.0           Thymus   50.7           Kidney   100.0                        
     [0864] General_screening_panel_v1.5 Summary: Ag5021 highest expression of this gene, a Putative Urea Transporter, is seen in Fetal Kidney (CT=29.3). In addition, this gene appears to be overexpressed in fetal kidney when compared to expression in the adult counterpart. Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of diseases of this organ.  
     [0865] Panel 4.1D Summary: Ag5021 Highest expression of this gene is seen in the kidney (CT=31), consistent with Panel 1.5 and the characterization of this protein as a novel urea transporter. Moderate levels of expression are also seen in thymus and colon. Thus, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.  
     [0866] S. CG140355-01: PEPTIDYLPROLYL ISOMERASE A-Like Gene  
     [0867] Expression of gene CG140355-01 was assessed using the primer-probe set Ag5022, described in Table SA.  
               TABLE SA                          Probe Name Ag5022                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No                                         Forward   5′-accccaccaagttcttcaat-3′   20   35   284       Probe   TET-5′-catctccatccagctgtt   26   69   285           tgcagaca-3′-TAMRA       Reverse   5′-ttttctgctgtctttggaaact-   22   95   286           3′                  
 
     [0868] T. CG140696-01 and CG140696-02: AAA ATPase Superfamily-Like Gene  
     [0869] Expression of gene CG140696-01 and variant CG140696-02 was assessed using the primer-probe set Ag5037, described in Table TA. Results of the RTQ-PCR runs are shown in Tables TB and TC.  
               TABLE TA                          Probe Name Ag5037                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No                                         Forward   5′-ttgaacaccttcgaccataatc-   22   636   287           3′       Probe   TET-5′-ccctcagaacgactgctg   26   663   288           aaacctct-3′-TAMRA       Reverse   5′-attctcgcatctcactgttcat-   22   705   289           3′                  
 
     [0870]               TABLE TB                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag5037, Run           Tissue Name   228967211                                         Adipose   9.4           Melanoma* Hs688(A).T   7.4           Melanoma* Hs688(B).T   7.4           Melanoma* M14   3.3           Melanoma* LOXIMVI   1.8           Melanoma* SK-MEL-5   35.6           Squamous cell carcinoma   9.2           SCC-4           Testis Pool   48.0           Prostate ca.* (bone met) PC-3   44.8           Prostate Pool   8.9           Placenta   0.5           Uterus Pool   3.4           Ovarian ca. OVCAR-3   51.8           Ovarian ca. SK-OV-3   3.7           Ovarian ca. OVCAR-4   11.7           Ovarian ca. OVCAR-5   44.4           Ovarian ca. IGROV-1   3.8           Ovarian ca. OVCAR-8   1.4           Ovary   7.5           Breast ca. MCF-7   11.0           Breast ca. MDA-MB-231   1.6           Breast ca. BT 549   58.2           Breast ca. T47D   48.6           Breast ca. MDA-N   3.4           Breast Pool   11.4           Trachea   14.3           Lung   1.8           Fetal Lung   22.8           Lung ca. NCI-N417   6.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   1.6           Lung ca. SHP-77   95.3           Lung ca. A549   10.7           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   50.0           Lung ca. NCI-H460   12.2           Lung ca. HOP-62   1.9           Lung ca. NCI-H522   87.7           Liver   0.2           Fetal Liver   12.1           Liver ca. HepG2   0.0           Kidney Pool   13.0           Fetal Kidney   44.8           Renal ca. 786-0   29.9           Renal ca. A498   6.8           Renal ca. ACHN   13.3           Renal ca. UO-31   10.5           Renal ca. TK-10   44.8           Bladder   4.9           Gastric ca. (liver met.) NCI-N87   15.8           Gastric ca. KATO III   32.5           Colon ca. SW-948   0.9           Colon ca. SW480   10.2           Colon ca.* (SW480 met) SW620   3.8           Colon ca. HT29   0.2           Colon ca. HCT-116   7.0           Colon ca. CaCo-2   1.0           Colon cancer tissue   3.8           Colon ca. SW1116   3.0           Colon ca. Colo-205   0.7           Colon ca. SW-48   0.0           Colon Pool   12.3           Small Intestine Pool   9.7           Stomach Pool   6.6           Bone Marrow Pool   4.3           Fetal Heart   3.5           Heart Pool   4.6           Lymph Node Pool   3.9           Fetal Skeletal Muscle   10.9           Skeletal Muscle Pool   3.1           Spleen Pool   4.6           Thymus Pool   11.3           CNS cancer (glio/astro) U87-MG   15.8           CNS cancer (glio/astro)   83.5           U-118-MG           CNS cancer (neuro; met)   100.0           SK-N-AS           CNS cancer (astro) SF-539   11.7           CNS cancer (astro) SNB-75   46.3           CNS cancer (glio) SNB-19   2.8           CNS cancer (glio) SF-295   20.9           Brain (Amygdala) Pool   21.3           Brain (cerebellum)   54.7           Brain (fetal)   16.2           Brain (Hippocampus) Pool   24.5           Cerebral Cortex Pool   27.7           Brain (Substantia nigra) Pool   24.5           Brain (Thalamus) Pool   31.0           Brain (whole)   17.3           Spinal Cord Pool   29.5           Adrenal Gland   9.2           Pituitary gland Pool   5.2           Salivary Gland   2.2           Thyroid (female)   27.5           Pancreatic ca. CAPAN2   30.1           Pancreas Pool   11.1                        
     [0871]               TABLE TC                          Panel 4.1D                                 Rel. Exp. (%)               Ag5037, Run           Tissue Name   223737388                                         Secondary Th1 act   2.0           Secondary Th2 act   0.0           Secondary Tr1 act   0.0           Secondary Th1 rest   0.6           Secondary Th2 rest   3.6           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   2.1           Primary Tr1 act   2.6           Primary Th1 rest   4.1           Primary Th2 rest   3.0           Primary Tr1 rest   0.0           CD45RA CD4 lymphocyte act   2.8           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   2.1           Secondary CD8 lymphocyte   2.0           rest           Secondary CD8 lymphocyte   0.0           act           CD4 lymphocyte none   1.8           2ry Thl/Th2/Trl_anti-CD95   0.0           CH11           LAK cells rest   9.2           LAK cells IL-2   2.6           LAK cells IL-2 + IL-12   3.8           LAK cells IL-2 + IFN gamma   1.9           LAK cells IL-2 + IL-18   2.1           LAK cells PMA/ionomycin   2.0           NK Cells IL-2 rest   1.1           Two Way MLR 3 day   3.6           Two Way MLR 5 day   5.2           Two Way MLR 7 day   1.9           PBMC rest   0.0           PBMC PWM   1.1           PBMC PHA-L   7.0           Ramos (B cell) none   71.2           Ramos (B cell) ionomycin   100.0           B lymphocytes PWM   2.6           B lymphocytes CD40L and   5.6           IL-4           EOL-1 dbcAMP   2.0           EOL-1 dbcAMP   0.0           PMA/ionomycin           Dendritic cells none   7.4           Dendritic cells LPS   2.4           Dendritic cells anti-CD40   5.6           Monocytes rest   0.5           Monocytes LPS   0.0           Macrophages rest   6.8           Macrophages LPS   1.7           HUVEC none   3.2           HUVEC starved   5.0           HUVEC IL-1beta   7.9           HUVEC IFN gamma   4.7           HUVEC TNF alpha + IFN gamma   1.0           HUVEC TNF alpha + IL4   2.1           HUVEC IL-11   2.1           Lung Microvascular EC none   21.6           Lung Microvascular EC TNFalpha +   4.2           IL-1beta           Microvascular Dermal EC none   1.5           Microsvasular Dermal EC TNFalpha +   0.0           IL-lbeta           Bronchial epithelium TNFalpha +   1.1           IL1beta           Small airway epithelium none   5.3           Small airway epithelium TNFalpha +   3.2           IL-lbeta           (Coronery artery SMC rest   4.3           Coronery artery SMC TNFalpha +   5.4           IL-1beta           Astrocytes rest   5.6           Astrocytes TNFalpha + IL-1beta   3.6           KU-812 (Basophil) rest   3.2           KU-812 (Basophil) PMA/ionomycin   1.2           CCD1106 (Keratinocytes) none   5.4           CCD1106 (Keratinocytes) TNFalpha +   2.7           IL-lbeta           Liver cirrhosis   6.9           NCI-H292 none   39.0           NCI-H292 IL-4   29.3           NCI-H292 IL-9   60.7           NCI-H292 IL-13   36.6           NCI-H292 IFN gamma   28.1           HPAEC none   2.1           HPAEC TNF alpha + IL-1 beta   3.1           Lung fibroblast none   8.8           Lung fibroblast TNF alpha + IL-1   3.7           beta           Lung fibroblast IL-4   0.0           Lung fibroblast IL-9   2.2           Lung fibroblast IL-13   8.4           Lung fibroblast IFN gamma   1.1           Dermal fibroblast CCD1070 rest   2.4           Dermal fibroblast CCD1070 TNF   3.6           alpha           Dermal fibroblast CCD1070 IL-1   3.6           beta           Dermal fibroblast IFN gamma   13.1           Dermal fibroblast IL-4   16.7           Dermal Fibroblasts rest   18.2           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   0.9           Lung   5.9           Thymus   6.6           Kidney   54.3                        
     [0872] General_screening_panel_v1.5 Summary: Ag5037 Highest expression of this gene is seen in a brain cancer cell line (CT=29.4). This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0873] Among tissues with metabolic function, this gene is expressed at low but significant levels in pituitary, adipose, adrenal gland, pancreas, thyroid, fetal heart and adult and fetal skeletal muscle and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0874] In addition, this gene is expressed at much higher levels in fetal lung tissue (CT=31.5) when compared to expression in the adult counterpart (CT=35.2). Thus, expression of this gene may be used to differentiate between the fetal and adult source of these tissue.  
     [0875] This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0876] Panel 4.1D Summary: Ag5037 Highest expression is seen in a sample derived from ionomycin treated Ramos B cells (CT=30). This gene is widely expressed in this panel with prominent expression also seen in untreated Ramos cells and in a cluster of treated and untreated samples derived from the NCI—H292 cell line.  
     [0877] U. CG140747-01: Dual Specificity Phosphatase-Like Gene  
     [0878] Expression of gene CG140747-01 was assessed using the primer-probe set Ag5038, described in Table UA. Results of the RTQ-PCR runs are shown in Tables UB and UC.  
               TABLE UA                          Probe Name Ag5038                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   No                                         Forward   5′-cctggacatatggagcaagat-   21   1672   290           3′       Probe   TET-5′-actcctgcacagcccagc   26   1697   291           ctgaacta-3′-TAMRA       Reverse   5′-gttgcacatccctgagtcttt-   21   1726   292           3′                  
 
     [0879]               TABLE UB                          General_screening_panel_v1.5                                 Rel. Exp (%)               Ag5038, Run           Tissue Name   228966907                                         Adipose   22.2           Melanoma* Hs688(A).T   11.4           Melanoma* Hs688(B).T   10.9           Melanoma* M14   40.6           Melanoma* LOXIMVI   20.2           Melanoma* SK-MEL-5   32.3           Squamous cell carcinoma SCC-4   5.0           Testis Pool   18.3           Prostate ca.* (bone met) PC-3   11.2           Prostate Pool   9.9           Placenta   10.7           Uterus Pool   12.7           Ovarian ca. OVCAR-3   30.8           Ovarian ca. SK-OV-3   54.3           Ovarian ca. OVCAR-4   12.7           Ovarian ca. OVCAR-5   20.3           Ovarian ca. IGROV-1   15.3           Ovarian ca. OVCAR-8   6.7           Ovary   7.9           Breast ca. MCF-7   8.1           Breast ca. MDA-MB-231   28.1           Breast ca. BT 549   31.4           Breast ca. T47D   15.8           Breast ca. MDA-N   8.7           Breast Pool   4.6           Trachea   14.7           Lung   2.4           Fetal Lung   83.5           Lung ca. NCI-N417   2.8           Lung ca. LX-1   24.0           Lung ca. NCI-H146   9.6           Lung ca. SHP-77   13.3           Lung ca. A549   17.4           Lung ca. NCI-H526   11.7           Lung ca. NCI-H23   22.5           Lung ca. NCI-H460   7.3           Lung ca. HOP-62   12.0           Lung ca. NCI-H522   16.8           Liver   1.7           Fetal Liver   12.9           Liver ca. HepG2   8.1           Kidney Pool   17.9           Fetal Kidney   20.4           Renal ca. 786-0   28.7           Renal ca. A498   24.7           Renal ca. ACHN   33.9           Renal ca. UO-31   20.7           Renal ca. TK-10   37.6           Bladder   21.9           Gastric ca. (liver met.) NCI-N87   32.1           Gastric ca. KATO III   29.9           Colon ca. SW-948   4.3           Colon ca. SW480   31.0           Colon ca.* (SW480 met) SW620   21.8           Colon ca. HT29   7.1           Colon ca. HCT-116   23.5           Colon ca. CaCo-2   36.3           Colon cancer tissue   9.7           Colon ca. SW1116   3.7           Colon ca. Colo-205   7.1           Colon ca. SW-48   5.9           Colon Pool   13.9           Small Intestine Pool   10.3           Stomach Pool   6.5           Bone Marrow Pool   7.3           Fetal Heart   39.8           Heart Pool   11.3           Lymph Node Pool   11.5           Fetal Skeletal Muscle   40.3           Skeletal Muscle Pool   100.0           Spleen Pool   33.9           Thymus Pool   42.0           CNS cancer (glio/astro) U87-MG   15.6           CNS cancer (glio/astro) U-118-MG   32.5           CNS cancer (neuro; met) SK-N-AS   64.6           CNS cancer (astro) SF-539   16.6           CNS cancer (astro) SNB-75   34.2           CNS cancer (glio) SNB-19   16.8           CNS cancer (glio) SF-295   49.3           Brain (Amygdala) Pool   12.4           Brain (cerebellum)   46.0           Brain (fetal)   41.2           Brain (Hippocampus) Pool   16.6           Cerebral Cortex Pool   23.3           Brain (Substantia nigra) Pool   14.7           Brain (Thalamus) Pool   22.5           Brain (whole)   19.2           Spinal Cord Pool   15.8           Adrenal Gland   14.8           Pituitary gland Pool   5.0           Salivary Gland   5.9           Thyroid (female)   5.4           Pancreatic ca. CAPAN2   12.0           Pancreas Pool   16.7                        
     [0880]               TABLE UC                          Panel 4.1D                         Rel. Exp. (%)           Ag5038, Run       Tissue Name   223742477                             Secondary Th1 act   5.8       Secondary Th2 act   5.4       Secondary Tr1 act   5.7       Secondary Th1 rest   3.4       Secondary Th2 rest   5.6       Secondary Tr1 rest   3.1       Primary Th1 act   3.2       Primary Th2 act   5.7       Primary Tr1 act   4.4       Primary Th1 rest   3.8       Primary Th2 rest   2.3       Primary Tr1 rest   11.6       CD45RA CD4 lymphocyte act   4.5       CD45RO CD4 lymphocyte act   7.5       CD8 lymphocyte act   4.5       Secondary CD8 lymphocyte rest   6.2       Secondary CD8 lymphocyte act   2.5       CD4 lymphocyte none   6.6       2ry Th1/Th2/Tr1_anti-CD95 CH11   5.4       LAK cells rest   5.8       LAK cells IL-2   7.1       LAK cells IL-2 + IL-12   3.6       LAK cells IL-2 + IFN gamma   4.7       LAK cells IL-2 + IL-18   5.6       LAK cells PMA/ionomycin   1.6       NK Cells IL-2 rest   11.6       Two Way MLR 3 day   8.2       Two Way MLR 5 day   4.6       Two Way MLR 7 day   4.2       PBMC rest   5.7       PBMC PWM   3.5       PBMC PHA-L   5.1       Ramos (B cell) none   4.8       Ramos (B cell) ionomycin   7.7       B lymphocytes PWM   5.3       B lymphocytes CD40L and IL-4   10.4       EOL-1 dbcAMP   10.2       EOL-1 dbcAMP PMA/ionomycin   2.9       Dendritic cells none   3.5       Dendritic cells LPS   3.4       Dendritic cells anti-CD40   4.0       Monocytes rest   26.2       Monocytes LPS   8.2       Macrophages rest   5.6       Macrophages LPS   1.3       HUVEC none   3.7       HUVEC starved   7.2       HUVEC IL-1beta   11.0       HUVEC IFN gamma   5.9       HUVEC TNF alpha + IFN gamma   3.5       HUVEC TNF alpha + IL4   5.1       HUVEC IL-11   5.8       Lung Microvascular EC none   7.7       Lung Microvascular EC TNFalpha + IL-1beta   5.2       Microvascular Dermal EC none   4.4       Microsvasular Dermal EC TNFalpha + IL-1beta   5.3       Bronchial epithelium TNFalpha + IL1beta   3.1       Small airway epithelium none   1.6       Small airway epithelium TNFalpha + IL-1beta   4.2       Coronery artery SMC rest   2.9       Coronery artery SMC TNFalpha + IL-1beta   3.2       Astrocytes rest   1.4       Astrocytes TNFalpha + IL-1beta   1.1       KU-812 (Basophil) rest   1.1       KU-812 (Basophil) PMA/ionomycin   1.0       CCD1106 (Keratinocytes) none   3.8       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   2.6       Liver cirrhosis   2.3       NCI-H292 none   2.7       NCI-H292 IL-4   4.1       NCI-H292 IL-9   5.0       NCI-H292 IL-13   5.0       NCI-H292 IFN gamma   2.7       HPAEC none   4.8       HPAEC TNF alpha + IL-1 beta   19.9       Lung fibroblast none   6.1       Lung fibroblast TNF alpha + IL-1 beta   6.7       Lung fibroblast IL-4   1.4       Lung fibroblast IL-9   2.7       Lung fibroblast IL-13   1.6       Lung fibroblast IFN gamma   2.0       Dermal fibroblast CCD1070 rest   2.4       Dermal fibroblast CCD1070 TNF alpha   8.1       Dermal fibroblast CCD1070 IL-1 beta   1.4       Dermal fibroblast IFN gamma   1.8       Dermal fibroblast IL-4   6.0       Dermal Fibroblasts rest   2.4       Neutrophils TNFa + LPS   13.5       Neutrophils rest   100.0       Colon   0.9       Lung   3.1       Thymus   14.1       Kidney   4.4                    
     [0881] General_screening_panel_v1.5 Summary: Ag5038 Highest expression is seen in skeletal muscle (CT=26). In addition, moderate levels of expression are seen in pancreas, thyroid, adrenal, pituitary, adipose, fetal skeletal muscle and adult and fetal liver and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0882] In addition, this gene is expressed at much higher levels in fetal lung tissue (CT=26.3) when compared to expression in the adult counterpart (CT=31.4). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.  
     [0883] High to moderate levels of expression of this gene are also seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0884] This gene is also expressed at low but significant levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0885] Panel 4.1D Summary: Ag5038 Widespread expression of this gene is seen in this panel with highest expression of this gene seen in resting neutrophils (CT=25). This expression is reduced in neutrophils activated by TNF-alpha+LPS. This expression profile suggests that the protein encoded by this gene is produced by resting neutrophils but not by activated neutrophils. Therefore, the gene product may reduce activation of these inflammatory cells and be useful as a protein therapeutic to reduce or eliminate the symptoms in patients with Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis. In addition, small molecule or antibody antagonistsof this gene product may be effective in increasing the immune response in patients with AIDS or other immunodeficiencies.  
     [0886] V. CG141137-01: Long-Chain Acyl-coA Thioesterase 2-Like Gene  
     [0887] Expression of gene CG141137-01 was assessed using the primer-probe set Ag5044, described in Table VA. Results of the RTQ-PCR runs are shown in Tables VB, VC and VD.  
               TABLE VA                          Probe Name Ag5044                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-cattctaaggcccaggtagatg-   22   1153   293           3′       Probe   TET-5′-caaacacctgggaggtac   26   1203   294           ccagaaaa-3′-TAMRA       Reverse   5′-cgcattacaatttagggaaagc-   22   1231   295           3′                  
 
     [0888]               TABLE VB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag5044, Run           Tissue Name   224757508                                         AD 1 Hippo   17.9           AD 2 Hippo   21.2           AD 3 Hippo   10.3           AD 4 Hippo   3.2           AD 5 hippo   95.9           AD 6 Hippo   38.2           Control 2 Hippo   14.1           Control 4 Hippo   4.8           Control (Path) 3 Hippo   0.0           AD 1 Temporal Ctx   7.7           AD 2 Temporal Ctx   34.2           AD 3 Temporal Ctx   5.1           AD 4 Temporal Ctx   14.4           AD 5 Inf Temporal Ctx   100.0           AD 5 SupTemporal Ctx   38.4           AD 6 Inf Temporal Ctx   55.9           AD 6 Sup Temporal Ctx   77.4           Control 1 Temporal Ctx   3.9           Control 2 Temporal Ctx   30.8           Control 3 Temporal Ctx   18.7           Control 4 Temporal Ctx   10.4           Control (Path) 1 Temporal Ctx   75.3           Control (Path) 2 Temporal Ctx   21.9           Control (Path) 3 Temporal Ctx   4.2           Control (Path) 4 Temporal Ctx   32.3           AD 1 Occipital Ctx   18.0           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   3.3           AD 4 Occipital Ctx   10.0           AD 5 Occipital Ctx   18.8           AD 6 Occipital Ctx   44.1           Control 1 Occipital Ctx   4.2           Control 2 Occipital Ctx   68.8           Control 3 Occipital Ctx   24.3           Control 4 Occipital Ctx   5.1           Control (Path) 1 Occipital Ctx   72.2           Control (Path) 2 Occipital Ctx   19.3           Control (Path) 3 Occipital Ctx   0.0           Control (Path) 4 Occipital Ctx   16.7           Control 1 Parietal Ctx   5.9           Control 2 Parietal Ctx   35.1           Control 3 Parietal Ctx   31.0           Control (Path) 1 Parietal Ctx   88.3           Control (Path) 2 Parietal Ctx   23.7           Control (Path) 3 Parietal Ctx   4.5           Control (Path) 4 Parietal Ctx   38.7                        
     [0889]               TABLE VC                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag5044, Run           Tissue Name   228969278                                         Adipose   0.0           Melanoma* Hs688(A).T   2.4           Melanoma* Hs688(B).T   1.7           Melanoma* M14   0.3           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.2           Squamous cell carcinoma SCC-4   0.7           Testis Pool   1.4           Prostate ca.* (bone met) PC-3   1.5           Prostate Pool   0.8           Placenta   1.8           Uterus Pool   0.3           Ovarian ca. OVCAR-3   6.2           Ovarian ca. SK-OV-3   6.5           Ovarian ca. OVCAR-4   1.0           Ovarian ca. OVCAR-5   23.0           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   100.0           Ovary   1.7           Breast ca. MCF-7   24.5           Breast ca. MDA-MB-231   3.5           Breast ca. BT 549   2.6           Breast ca. T47D   10.4           Breast ca. MDA-N   0.0           Breast Pool   1.7           Trachea   1.2           Lung   0.4           Fetal Lung   1.7           Lung ca. NCI-N417   0.2           Lung ca. LX-1   4.1           Lung ca. NCI-H146   0.8           Lung ca. SHP-77   0.4           Lung ca. A549   1.5           Lung ca. NCI-H526   1.2           Lung ca. NCI-H23   1.5           Lung ca. NCI-H460   2.4           Lung ca. HOP-62   0.8           Lung ca. NCI-H522   3.6           Liver   0.7           Fetal Liver   1.6           Liver ca. HepG2   0.0           Kidney Pool   4.2           Fetal Kidney   1.7           Renal ca. 786-0   0.0           Renal ca. A498   0.7           Renal ca. ACHN   1.1           Renal ca. UO-31   0.7           Renal ca. TK-10   1.1           Bladder   1.2           Gastric ca. (liver met.) NCI-N87   5.6           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   12.1           Colon ca.* (SW480 met) SW620   3.9           Colon ca. HT29   1.5           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   1.8           Colon cancer tissue   0.8           Colon ca. SW1116   0.0           Colon ca. Colo-205   3.6           Colon ca. SW-48   2.1           Colon Pool   1.6           Small Intestine Pool   0.6           Stomach Pool   0.3           Bone Marrow Pool   0.3           Fetal Heart   0.9           Heart Pool   0.9           Lymph Node Pool   1.1           Fetal Skeletal Muscle   0.7           Skeletal Muscle Pool   1.9           Spleen Pool   0.2           Thymus Pool   0.9           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.7           CNS cancer (neuro; met) SK-N-AS   1.3           CNS cancer (astro) SF-539   0.5           CNS cancer (astro) SNB-75   3.1           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.0           Brain (Amygdala) Pool   5.0           Brain (cerebellum)   26.2           Brain (fetal)   5.9           Brain (Hippocampus) Pool   5.3           Cerebral Cortex Pool   6.8           Brain (Substantia nigra) Pool   4.0           Brain (Thalamus) Pool   7.3           Brain (whole)   6.1           Spinal Cord Pool   1.7           Adrenal Gland   1.3           Pituitary gland Pool   0.4           Salivary Gland   0.3           Thyroid (female)   1.2           Pancreatic ca. CAPAN2   12.0           Pancreas Pool   1.8                        
     [0890]               TABLE VD                          Panel 4.1D                         Rel. Exp. (%)           Ag5044, Run       Tissue Name   223785177                             Secondary Th1 act   0.5       Secondary Th2 act   0.7       Secondary Tr1 act   1.0       Secondary Th1 rest   0.3       Secondary Th2 rest   0.0       Secondary Tr1 rest   0.0       Primary Th1 act   0.0       Primary Th2 act   0.4       Primary Tr1 act   2.0       Primary Th1 rest   0.0       Primary Th2 rest   0.0       Primary Tr1 rest   0.7       CD45RA CD4 lymphocyte act   1.2       CD45RO CD4 lymphocyte act   1.8       CD8 lymphocyte act   2.3       Secondary CD8 lymphocyte rest   2.0       Secondary CD8 lymphocyte act   1.6       CD4 lymphocyte none   0.3       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.2       LAK cells rest   0.9       LAK cells IL-2   1.5       LAK cells IL-2 + IL-12   1.0       LAK cells IL-2 + IFN gamma   1.2       LAK cells IL-2 + IL-18   1.1       LAK cells PMA/ionomycin   1.1       NK Cells IL-2 rest   2.1       Two Way MLR 3 day   2.3       Two Way MLR 5 day   1.4       Two Way MLR 7 day   1.7       PBMC rest   0.5       PBMC PWM   0.5       PBMC PHA-L   0.8       Ramos (B cell) none   0.0       Ramos (B cell) ionomycin   0.0       B lymphocytes PWM   1.5       B lymphocytes CD40L and IL-4   0.4       EOL-1 dbcAMP   0.0       EOL-1 dbcAMP PMA/ionomycin   0.0       Dendritic cells none   2.1       Dendritic cells LPS   0.5       Dendritic cells anti-CD40   1.5       Monocytes rest   0.0       Monocytes LPS   0.2       Macrophages rest   5.0       Macrophages LPS   0.6       HUVEC none   0.0       HUVEC starved   0.3       HUVEC IL-1beta   0.2       HUVEC IFN gamma   1.2       HUVEC TNF alpha + IFN gamma   0.3       HUVEC TNF alpha + IL4   0.5       HUVEC IL-11   0.5       Lung Microvascular EC none   0.7       Lung Microvascular EC TNFalpha + IL-1beta   2.1       Microvascular Dermal EC none   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   1.0       Bronchial epithelium TNFalpha + IL1beta   0.0       Small airway epithelium none   0.0       Small airway epithelium TNFalpha + IL-1beta   0.0       Coronery artery SMC rest   0.0       Coronery artery SMC TNFalpha + IL-1beta   0.2       Astrocytes rest   0.6       Astrocytes TNFalpha + IL-1beta   0.8       KU-812 (Basophil) rest   0.2       KU-812 (Basophil) PMA/ionomycin   1.3       CCD1106 (Keratinocytes) none   1.9       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   1.0       Liver cirrhosis   0.2       NCI-H292 none   4.4       NCI-H292 IL-4   5.1       NCI-H292 IL-9   6.4       NCI-H292 IL-13   3.3       NCI-H292 IFN gamma   3.2       HPAEC none   0.4       HPAEC TNF alpha + IL-1 beta   0.0       Lung fibroblast none   0.2       Lung fibroblast TNF alpha + IL-1 beta   0.8       Lung fibroblast IL-4   1.7       Lung fibroblast IL-9   0.4       Lung fibroblast IL-13   0.0       Lung fibroblast IFN gamma   0.7       Dermal fibroblast CCD1070 rest   0.7       Dermal fibroblast CCD1070 TNF alpha   4.0       Dermal fibroblast CCD1070 IL-1 beta   1.1       Dermal fibroblast IFN gamma   3.3       Dermal fibroblast IL-4   0.2       Dermal Fibroblasts rest   2.0       Neutrophils TNFa + LPS   0.3       Neutrophils rest   2.9       Colon   7.3       Lung   8.2       Thymus   25.7       Kidney   100.0                    
     [0891] CNS_neurodegeneration_v1.0 Summary: Ag5044 This panel does not show differential expression of this gene in Alzheimer&#39;s disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.  
     [0892] General_screening_panel_v1.5 Summary: Ag5044 Highest expression of this gene is seen in an ovarian cancer cell line (CT=30). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of ovarian cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian cancer.  
     [0893] This gene is also expressed at low but significant levels in all regions of the CNS examined, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0894] Panel 4.1D Summary: Ag5044 Highest expression of this gene is seen in kidney (CT=30.5). Thus, expression of this gene could be used to differentiate the kidney-derived sample from other samples on this panel and as a marker of kidney tissue. In addition, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.  
     [0895] W. CG141240-01: ATP Synthase F Chain, Mitochondrial-Like Gene  
     [0896] Expression of gene CG141240-01 was assessed using the primer-probe set Ag5045, described in Table WA. Results of the RTQ-PCR runs are shown in Tables WB and WC.  
               TABLE WA                          Probe Name Ag5045                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-gcagggtacatgctcttcatc-   21   253   296           3′       Probe   TET-5′-cctttcctacaaggagct   26   279   297           caagcacg-3′-TAMRA       Reverse   5′-gagtgcagagcatgtcttcttc-   22   326   298           3′                  
 
     [0897]               TABLE WB                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag5045, Run           Tissue Name   228969281                                         Adipose   24.3           Melanoma* Hs688(A).T   1.2           Melanoma* Hs688(B).T   1.9           Melanoma* M14   7.9           Melanoma* LOXIMVI   16.3           Melanoma* SK-MEL-5   33.0           Squamous cell carcinoma SCC-4   6.9           Testis Pool   12.4           Prostate ca.* (bone met) PC-3   40.9           Prostate Pool   10.2           Placenta   0.9           Uterus Pool   5.8           Ovarian ca. OVCAR-3   80.1           Ovarian ca. SK-OV-3   21.8           Ovarian ca. OVCAR-4   1.6           Ovarian ca. OVCAR-5   61.6           Ovarian ca. IGROV-1   11.7           Ovarian ca. OVCAR-8   15.8           Ovary   4.7           Breast ca. MCF-7   59.9           Breast ca. MDA-MB-231   45.4           Breast ca. BT 549   28.3           Breast ca. T47D   5.0           Breast ca. MDA-N   7.1           Breast Pool   13.2           Trachea   10.9           Lung   5.6           Fetal Lung   17.6           Lung ca. NCI-N417   4.0           Lung ca. LX-1   39.2           Lung ca. NCI-H146   5.7           Lung ca. SHP-77   21.5           Lung ca. A549   27.9           Lung ca. NCI-H526   4.1           Lung ca. NCI-H23   32.1           Lung ca. NCI-H460   30.6           Lung ca. HOP-62   24.8           Lung ca. NCI-H522   54.3           Liver   0.0           Fetal Liver   15.9           Liver ca. HepG2   10.5           Kidney Pool   32.3           Fetal Kidney   100.0           Renal ca. 786-0   16.7           Renal ca. A498   4.6           Renal ca. ACHN   18.9           Renal ca. UO-31   9.0           Renal ca. TK-10   23.2           Bladder   24.0           Gastric ca. (liver met.) NCI-N87   30.8           Gastric ca. KATO III   22.8           Colon ca. SW-948   5.6           Colon ca. SW480   21.6           Colon ca.* (SW480 met) SW620   42.3           Colon ca. HT29   9.3           Colon ca. HCT-116   75.3           Colon ca. CaCo-2   28.7           Colon cancer tissue   13.0           Colon ca. SW1116   8.1           Colon ca. Colo-205   5.9           Colon ca. SW-48   4.8           Colon Pool   12.6           Small Intestine Pool   16.8           Stomach Pool   14.2           Bone Marrow Pool   21.0           Fetal Heart   12.9           Heart Pool   5.9           Lymph Node Pool   25.0           Fetal Skeletal Muscle   7.2           Skeletal Muscle Pool   7.2           Spleen Pool   12.9           Thymus Pool   28.5           CNS cancer (glio/astro) U87-MG   33.0           CNS cancer (glio/astro) U-118-MG   29.1           CNS cancer (neuro; met) SK-N-AS   57.0           CNS cancer (astro) SF-539   8.0           CNS cancer (astro) SNB-75   31.0           CNS cancer (glio) SNB-19   15.2           CNS cancer (glio) SF-295   93.3           Brain (Amygdala) Pool   2.6           Brain (cerebellum)   7.9           Brain (fetal)   14.6           Brain (Hippocampus) Pool   2.2           Cerebral Cortex Pool   6.9           Brain (Substantia nigra) Pool   3.3           Brain (Thalamus) Pool   8.0           Brain (whole)   1.3           Spinal Cord Pool   6.7           Adrenal Gland   0.0           Pituitary gland Pool   1.5           Salivary Gland   1.4           Thyroid (female)   2.3           Pancreatic ca. CAPAN2   25.2           Pancreas Pool   28.7                        
     [0898]               TABLE WC                          Panel 4.1D                         Rel. Exp. (%)           Ag5045, Run       Tissue Name   223784809                             Secondary Th1 act   11.2       Secondary Th2 act   11.8       Secondary Tr1 act   15.6       Secondary Th1 rest   9.7       Secondary Th2 rest   8.5       Secondary Tr1 rest   12.2       Primary Th1 act   8.1       Primary Th2 act   12.9       Primary Tr1 act   13.0       Primary Th1 rest   8.5       Primary Th2 rest   9.2       Primary Tr1 rest   5.8       CD45RA CD4 lymphocyte act   11.1       CD45RO CD4 lymphocyte act   12.7       CD8 lymphocyte act   18.7       Secondary CD8 lymphocyte rest   6.4       Secondary CD8 lymphocyte act   11.3       CD4 lymphocyte none   4.0       2ry Th1/Th2/Tr1_anti-CD95 CH11   15.8       LAK cells rest   12.0       LAK cells IL-2   8.4       LAK cells IL-2 + IL-12   5.8       LAK cells IL-2 + IFN gamma   10.7       LAK cells IL-2 + IL-18   21.6       LAK cells PMA/ionomycin   9.2       NK Cells IL-2 rest   22.5       Two Way MLR 3 day   18.6       Two Way MLR 5 day   12.0       Two Way MLR 7 day   7.6       PBMC rest   2.3       PBMC PWM   12.6       PBMC PHA-L   11.7       Ramos (B cell) none   26.4       Ramos (B cell) ionomycin   26.6       B lymphocytes PWM   13.5       B lymphocytes CD40L and IL-4   32.5       EOL-1 dbcAMP   23.7       EOL-1 dbcAMP PMA/ionomycin   20.0       Dendritic cells none   1.6       Dendritic cells LPS   9.1       Dendritic cells anti-CD40   8.5       Monocytes rest   17.2       Monocytes LPS   27.5       Macrophages rest   6.0       Macrophages LPS   2.8       HUVEC none   3.2       HUVEC starved   4.8       HUVEC IL-1beta   2.5       HUVEC IFN gamma   12.3       HUVEC TNF alpha + IFN gamma   6.0       HUVEC TNF alpha + IL4   2.6       HUVEC IL-11   3.3       Lung Microvascular EC none   12.7       Lung Microvascular EC TNFalpha + IL-1beta   5.9       Microvascular Dermal EC none   3.6       Microsvasular Dermal EC TNFalpha + IL-1beta   4.6       Bronchial epithelium TNFalpha + IL1beta   8.7       Small airway epithelium none   1.0       Small airway epithelium TNFalpha + IL-1beta   1.9       Coronery artery SMC rest   5.4       Coronery artery SMC TNFalpha + IL-1beta   4.7       Astrocytes rest   5.5       Astrocytes TNFalpha + IL-1beta   4.5       KU-812 (Basophil) rest   17.6       KU-812 (Basophil) PMA/ionomycin   19.6       CCD1106 (Keratinocytes) none   5.4       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   2.1       Liver cirrhosis   0.6       NCI-H292 none   7.9       NCI-H292 IL-4   14.0       NCI-H292 IL-9   12.5       NCI-H292 IL-13   12.2       NCI-H292 IFN gamma   6.2       HPAEC none   7.3       HPAEC TNF alpha + IL-1 beta   7.4       Lung fibroblast none   5.4       Lung fibroblast TNF alpha + IL-1 beta   2.2       Lung fibroblast IL-4   5.3       Lung fibroblast IL-9   6.0       Lung fibroblast IL-13   3.9       Lung fibroblast IFN gamma   1.4       Dermal fibroblast CCD1070 rest   8.9       Dermal fibroblast CCD1070 TNF alpha   12.9       Dermal fibroblast CCD1070 IL-1 beta   4.0       Dermal fibroblast IFN gamma   7.2       Dermal fibroblast IL-4   6.2       Dermal Fibroblasts rest   3.0       Neutrophils TNFa + LPS   2.5       Neutrophils rest   10.4       Colon   3.1       Lung   5.3       Thymus   30.4       Kidney   100.0                    
     [0899] General_screening_panel_v1.5 Summary: Ag5045 This gene is widely expressed in this panel, with highest expression in kidney (CT=29.4). This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0900] Among tissues with metabolic function, this gene is expressed at moderate to low levels in adipose, pancreas, thyroid, fetal liver and adult and fetal skeletal muscle and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0901] This gene is also expressed at low but significant levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0902] Panel 4.1D Summary: Ag5045 Highest expression of this gene is seen in the kidney (CT=30.1). This gene is widely expressed at low but significant levels in many samples on this panel, including samples derived from B cells, T cells and lung and dermal fibroblasts. Thus, expression of this gene could be used to differentiate the kidney-derived sample from other samples on this panel and as a marker of kidney tissue. In addition, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.  
     [0903] X. CG141355-01 and CG141355-02: GTPASE RAB37-Like Gene  
     [0904] Expression of gene CG141355-01 and full-length physical clone CG141355-02 was assessed using the primer-probe set Ag5048, described in Table XA. Results of the RTQ-PCR runs are shown in Tables XB, XC and XD. Please note that CG141355-02 represents a full-length physical clone of the CG141355-01 gene, validating the prediction of the gene sequence.  
               TABLE XA                          Probe Name Ag5048                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-atcgccaaggaactgaaatac-   21   619   299           3′       Probe   TET-5′-agcccagcttccagatc   24   662   300           cgagact-3′-TAMRA       Reverse   5′-cgcttcttctgggactctaca   22   686   301           t-3′                  
 
     [0905]               TABLE XB                          General_screening panel_v1.5                                 Rel. Exp. (%)               Ag5048, Run           Tissue Name   228969347                                         Adipose   3.5           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   1.5           Squamous cell carcinoma SCC-4   0.4           Testis Pool   0.6           Prostate ca.* (bone met) PC-3   2.7           Prostate Pool   4.6           Placenta   3.1           Uterus Pool   2.0           Ovarian ca. OVCAR-3   0.8           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   52.9           Ovarian ca. IGROV-1   0.9           Ovarian ca. OVCAR-8   0.6           Ovary   2.2           Breast ca. MCF-7   3.5           Breast ca. MDA-MB-231   3.9           Breast ca. BT 549   0.4           Breast ca. T47D   2.4           Breast ca. MDA-N   0.0           Breast Pool   3.8           Trachea   7.6           Lung   0.2           Fetal Lung   12.1           Lung ca. NCI-N417   0.0           Lung ca. LX-1   6.5           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   46.3           Lung ca. NCI-H526   0.5           Lung ca. NCI-H23   6.2           Lung ca. NCI-H460   0.3           Lung ca. HOP-62   6.0           Lung ca. NCI-H522   6.5           Liver   4.5           Fetal Liver   13.2           Liver ca. HepG2   2.7           Kidney Pool   4.8           Fetal Kidney   0.5           Renal ca. 786-0   0.4           Renal ca. A498   2.6           Renal ca. ACHN   0.0           Renal ca. UO-31   0.2           Renal ca. TK-10   3.4           Bladder   2.9           Gastric ca. (liver met.) NCI-N87   5.0           Gastric ca. KATO III   0.8           Colon ca. SW-948   0.2           Colon ca. SW480   2.0           Colon ca.* (SW480 met) SW620   5.2           Colon ca. HT29   2.0           Colon ca. HCT-116   18.3           Colon ca. CaCo-2   100.0           Colon cancer tissue   8.0           Colon ca. SW1116   0.6           Colon ca. Colo-205   2.0           Colon ca. SW-48   4.9           Colon Pool   3.4           Small Intestine Pool   1.4           Stomach Pool   1.6           Bone Marrow Pool   2.5           Fetal Heart   0.8           Heart Pool   2.3           Lymph Node Pool   3.0           Fetal Skeletal Muscle   0.6           Skeletal Muscle Pool   1.7           Spleen Pool   14.6           Thymus Pool   8.4           CNS cancer (glio/astro) U87-MG   0.6           CNS cancer (glio/astro) U-118-MG   1.0           CNS cancer (neuro; met) SK-N-AS   0.2           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   0.3           CNS cancer (glio) SNB-19   0.9           CNS cancer (glio) SF-295   0.2           Brain (Amygdala) Pool   9.0           Brain (cerebellum)   95.3           Brain (fetal)   0.8           Brain (Hippocampus) Pool   6.7           Cerebral Cortex Pool   22.1           Brain (Substantia nigra) Pool   12.0           Brain (Thalamus) Pool   10.8           Brain (whole)   11.6           Spinal Cord Pool   6.2           Adrenal Gland   2.5           Pituitary gland Pool   0.4           Salivary Gland   0.9           Thyroid (female)   0.6           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   3.9                        
     [0906]               TABLE XC                          Panel 4.1D                         Rel. Exp. (%)           Ag5048, Run       Tissue Name   223785397                             Secondary Th1 act   3.2       Secondary Th2 act   5.3       Secondary Tr1 act   7.4       Secondary Th1 rest   68.3       Secondary Th2 rest   73.2       Secondary Tr1 rest   82.9       Primary Th1 act   4.7       Primary Th2 act   6.5       Primary Tr1 act   8.1       Primary Th1 rest   44.4       Primary Th2 rest   82.4       Primary Tr1 rest   47.0       CD45RA CD4 lymphocyte act   6.9       CD45RO CD4 lymphocyte act   9.8       CD8 lymphocyte act   8.4       Secondary CD8 lymphocyte rest   5.8       Secondary CD8 lymphocyte act   32.3       CD4 lymphocyte none   10.4       2ry Th1/Th2/Tr1_anti-CD95 CH11   100.0       LAK cells rest   4.1       LAK cells IL-2   10.2       LAK cells IL-2 + IL-12   2.3       LAK cells IL-2 + IFN gamma   7.2       LAK cells IL-2 + IL-18   8.0       LAK cells PMA/ionomycin   2.0       NK Cells IL-2 rest   54.7       Two Way MLR 3 day   2.8       Two Way MLR 5 day   2.9       Two Way MLR 7 day   15.2       PBMC rest   16.8       PBMC PWM   0.1       PBMC PHA-L   3.0       Ramos (B cell) none   2.0       Ramos (B cell) ionomycin   3.7       B lymphocytes PWM   1.6       B lymphocytes CD40L and IL-4   9.0       EOL-1 dbcAMP   21.6       EOL-1 dbcAMP PMA/ionomycin   0.8       Dendritic cells none   1.3       Dendritic cells LPS   0.6       Dendritic cells anti-CD40   0.6       Monocytes rest   19.1       Monocytes LPS   0.4       Macrophages rest   2.0       Macrophages LPS   0.0       HUVEC none   0.0       HUVEC starved   0.0       HUVEC IL-1beta   0.2       HUVEC IFN gamma   0.1       HUVEC TNF alpha + IFN gamma   0.0       HUVEC TNF alpha + IL4   0.0       HUVEC IL-11   1.0       Lung Microvascular EC none   0.7       Lung Microvascular EC TNFalpha + IL-1beta   0.1       Microvascular Dermal EC none   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   0.0       Bronchial epithelium TNFalpha + IL1beta   0.0       Small airway epithelium none   0.2       Small airway epithelium TNFalpha + IL-1beta   0.0       Coronery artery SMC rest   0.0       Coronery artery SMC TNFalpha + IL-1beta   0.0       Astrocytes rest   0.0       Astrocytes TNFalpha + IL-1beta   0.0       KU-812 (Basophil) rest   10.2       KU-812 (Basophil) PMA/ionomycin   15.6       CCD1106 (Keratinocytes) none   0.1       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0       Liver cirrhosis   0.6       NCI-H292 none   0.2       NCI-H292 IL-4   0.3       NCI-H292 IL-9   0.4       NCI-H292 IL-13   0.6       NCI-H292 IFN gamma   0.3       HPAEC none   0.5       HPAEC TNF alpha + IL-1 beta   0.1       Lung fibroblast none   1.0       Lung fibroblast TNF alpha + IL-1 beta   0.5       Lung fibroblast IL-4   0.1       Lung fibroblast IL-9   0.0       Lung fibroblast IL-13   0.0       Lung fibroblast IFN gamma   0.0       Dermal fibroblast CCD1070 rest   3.4       Dermal fibroblast CCD1070 TNF alpha   65.1       Dermal fibroblast CCD1070 IL-1 beta   0.7       Dermal fibroblast IFN gamma   0.9       Dermal fibroblast IL-4   3.0       Dermal Fibroblasts rest   0.5       Neutrophils TNFa + LPS   10.8       Neutrophils rest   42.3       Colon   3.0       Lung   2.9       Thymus   15.2       Kidney   2.0                    
     [0907]               TABLE XD                          Panel 5 Islet                         Rel. Exp. (%)           Ag5048, Run       Tissue Name   306067452                             97457_Patient-02go_adipose   0.0       97476_Patient-07sk_skeletal muscle   0.0       97477_Patient-07ut_uterus   9.5       97478_Patient-07pl_placenta   12.0       99167_Bayer Patient 1   49.7       97482_Patient-08ut_uterus   11.0       97483_Patient-08pl_placenta   3.0       97486_Patient-09sk_skeletal muscle   15.4       97487_Patient-09ut_uterus   8.3       97488_Patient-09pl_placenta   10.8       97492_Patient-10ut_uterus   3.8       97493_Patient-10pl_placenta   10.7       97495_Patient-11go_adipose   8.7       97496_Patient-11sk_skeletal muscle   19.1       97497_Patient-11ut_uterus   33.7       97498_Patient-11pl_placenta   8.2       97500_Patient-12go_adipose   18.7       97501_Patient-12sk_skeletal muscle   23.7       97502_Patient-12ut_uterus   16.6       97503_Patient-12pl_placenta   19.6       94721_Donor 2 U - A_Mesenchymal Stem Cells   5.0       94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0       94723_Donor 2 U - C_Mesenchymal Stem Cells   7.7       94709_Donor 2 AM - A_adipose   2.5       94710_Donor 2 AM - B_adipose   2.4       94711_Donor 2 AM - C_adipose   100.0       94712_Donor 2 AD - A_adipose   9.2       94713_Donor 2 AD - B_adipose   4.2       94714_Donor 2 AD - C_adipose   6.4       94742_Donor 3 U - A_Mesenchymal Stem Cells   7.4       94743_Donor 3 U - B_Mesenchymal Stem Cells   4.7       94730_Donor 3 AM - A_adipose   7.5       94731_Donor 3 AM - B_adipose   6.2       94732_Donor 3 AM - C_adipose   4.5       94733_Donor 3 AD - A_adipose   0.0       94734_Donor 3 AD - B_adipose   0.0       94735_Donor 3 AD - C_adipose   2.3       77138_Liver_HepG2untreated   18.7       73556_Heart_Cardiac stromal cells (primary)   2.7       81735_Small Intestine   8.3       72409_Kidney_Proximal Convoluted Tubule   13.3       82685_Small intestine_Duodenum   10.9       90650_Adrenal_Adrenocortical adenoma   5.6       72410_Kidney_HRCE   0.0       72411_Kidney_HRE   0.0       73139_Uterus_Uterine smooth muscle cells   2.6                    
     [0908] General_screening_panel_v1.5 Summary: Ag5048 Highest expression is seen in cerebellum and a colon cancer cell line (CTs=27). Prominent expression is also seen in a single ovarian cancer and lung cancer cell line. Thus, expression of this gene could be used to differentiate between the cerebellar and colon cancer cell line sample and other samples on this panel. In addition, this gene may be involved in ovarian, lung, and colon cancers as well as CNS disorders that have the cerebellum as the site of pathology, such as autism and the ataxias.  
     [0909] Panel 4.1D Summary: Ag5048 Prominent levels of expression are seen in resting primary and secondary T cells, resting neutrophils, TNF-a treated dermal fibroblasts, and resting NK cells. This gene encodes a putative Rab37 molecule that may play an important role in mast cell degranulation. (Masuda ES. FEBS Lett Mar. 17, 2000;470(1):61-4). Thus, based on the expression profile of this protein and the homology to Rab37, modulation of the expression or function of this protein may be useful as a therapeutic intervention in the treatment of allergy, asthma, arthritis, psoriasis, IBD, and lupus, as well as any T-cell mediated disease.  
     [0910] Panel 5 Islet Summary: Ag5048 Detectable expression of this gene is limited to a single adipose sample (CT=34) in this panel.  
     [0911] Y. CG142072-02: CATHEPSIN L PRECURSOR  
     [0912] Expression of full-length physical clone CG142072-02 was assessed using the primer-probe set Ag7053, described in Table YA. Results of the RTQ-PCR runs are shown in Table YB.  
               TABLE YA                          Probe Name Ag7053                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-agttttccggaacactttcc-3′   20   576   302       Probe   TET-5′-tttgaaagccattcatca   26   614   303           cctgcctg-3′-TAMRA       Reverse   5′-tttggagacatgaccagtgaa-   21   645   304           3′                  
 
     [0913]               TABLE YB                          General screening panel v1.6                                 Rel. Exp. (%)               Ag7053, Run           Tissue Name   282273864                                         Adipose   1.2           Melanoma* Hs688(A).T   5.1           Melanoma* Hs688(B).T   5.4           Melanoma* M14   1.7           Melanoma* LOXIMVI   6.1           Melanoma* SK-MEL-5   36.3           Squamous cell carcinoma SCC-4   0.7           Testis Pool   1.5           Prostate ca.* (bone met) PC-3   4.3           Prostate Pool   0.9           Placenta   4.9           Uterus Pool   0.4           Ovarian ca. OVCAR-3   2.6           Ovarian ca. SK-OV-3   16.7           Ovarian ca. OVCAR-4   0.7           Ovarian ca. OVCAR-5   3.7           Ovarian ca. IGROV-1   2.8           Ovarian ca. OVCAR-8   2.7           Ovary   1.1           Breast ca. MCF-7   3.3           Breast ca. MDA-MB-231   6.7           Breast ca. BT 549   100.0           Breast ca. T47D   0.4           Breast ca. MDA-N   0.6           Breast Pool   1.6           Trachea   0.8           Lung   0.8           Fetal Lung   1.1           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.1           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.8           Lung ca. A549   19.2           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   10.7           Lung ca. NCI-H460   21.9           Lung ca. HOP-62   0.8           Lung ca. NCI-H522   1.3           Liver   0.6           Fetal Liver   3.4           Liver ca. HepG2   0.8           Kidney Pool   2.7           Fetal Kidney   1.1           Renal ca. 786-0   8.2           Renal ca. A498   6.6           Renal ca. ACHN   1.2           Renal ca. UO-31   2.7           Renal ca. TK-10   5.1           Bladder   2.4           Gastric ca. (liver met.) NCI-N87   3.3           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.3           Colon ca. HT29   0.2           Colon ca. HCT-116   3.3           Colon ca. CaCo-2   1.6           Colon cancer tissue   6.9           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.1           Colon ca. SW-48   0.1           Colon Pool   1.6           Small Intestine Pool   0.7           Stomach Pool   1.2           Bone Marrow Pool   0.3           Fetal Heart   0.8           Heart Pool   0.5           Lymph Node Pool   1.5           Fetal Skeletal Muscle   0.3           Skeletal Muscle Pool   0.3           Spleen Pool   1.4           Thymus Pool   0.9           CNS cancer (glio/astro) U87-MG   21.2           CNS cancer (glio/astro) U-118-MG   25.3           CNS cancer (neuro; met) SK-N-AS   0.5           CNS cancer (astro) SF-539   8.1           CNS cancer (astro) SNB-75   62.9           CNS cancer (glio) SNB-19   2.5           CNS cancer (glio) SF-295   9.1           Brain (Amygdala) Pool   0.8           Brain (cerebellum)   1.3           Brain (fetal)   0.4           Brain (Hippocampus) Pool   1.1           Cerebral Cortex Pool   0.8           Brain (Substantia nigra) Pool   0.8           Brain (Thalamus) Pool   1.1           Brain (whole)   0.8           Spinal Cord Pool   1.0           Adrenal Gland   1.4           Pituitary gland Pool   0.4           Salivary Gland   0.9           Thyroid (female)   0.8           Pancreatic ca. CAPAN2   1.7           Pancreas Pool   0.5                        
     [0914] General_screening_panel_v1.6 Summary: Ag7053 Highest expression of this gene is detected in breast cancer BT 549 cell line (CT=27.2). High to moderate levels of expression of this gene is also seen in number of cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0915] Among tissues with metabolic or endocrine function, this gene is expressed at moderate to low levels in pancreas, adipose, adrenal gland, thyroid, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0916] In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0917] Z. CG142102-01: PEPTIDYLPIROLYL ISOMERASE A-Like Gene  
     [0918] Expression of gene CG142102-01 was assessed using the primer-probe set Ag7410, described in Table ZA.  
               TABLE ZA                          Probe Name Ag7410                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-ctgaaccctcacattcccaa-3′   20   353   305       Probe   TET-5′-ccaattacttatccatgg   26   374   306           caaatgct-3′-TAMRA       Reverse   5′-tcttggcagtgcagaggaa-3′   19   427   307                  
 
     [0919] AA. CG57760-02: Prostaglandin-H12 D-isomerase Precursor  
     [0920] Expression of full-length physical clone CG57760-02 was assessed using the primer-probe set Ag7019, described in Table AAA. Results of the RTQ-PCR runs are shown in Table AAB.  
               TABLE AAA                          Probe Name Ag7019                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-caacttacagcagcgcgta-3′   19   122   308       Probe   TET-5′-agaccgactacgaccag   24   148   309           tacgcgc-3′-TAMRA       Reverse   5′-ttgctgccctggctgta-3′   17   177   310                  
 
     [0921]               TABLE AAB                          General_screening_panel_v1.6                                 Rel.Exp. (%)               Ag7019, Run           Tissue Name   282273670                                         Adipose   0.0           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.0           Testis Pool   0.0           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.0           Placenta   36.6           Uterus Pool   0.0           Ovarian ca. OVCAR-3   0.0           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.0           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   0.0           Ovary   0.0           Breast ca. MCF-7   0.0           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   0.0           Breast ca. T47D   0.0           Breast ca. MDA-N   0.0           Breast Pool   0.0           Trachea   0.0           Lung   0.0           Fetal Lung   0.0           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   0.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.0           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.0           Liver   0.0           Fetal Liver   0.0           Liver ca. HepG2   0.0           Kidney Pool   0.0           Fetal Kidney   0.0           Renal ca. 786-0   0.0           Renal ca. A498   0.0           Renal ca. ACHN   0.0           Renal ca. UO-31   0.0           Renal ca. TK-10   0.0           Bladder   0.0           Gastric ca. (liver met.) NCI-N87   0.0           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   29.3           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.0           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   0.0           Colon cancer tissue   0.0           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   0.0           Small Intestine Pool   0.0           Stomach Pool   0.0           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   0.0           Lymph Node Pool   0.0           Fetal Skeletal Muscle   0.0           Skeletal Muscle Pool   0.0           Spleen Pool   0.0           Thymus Pool   0.0           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   24.8           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.0           Brain (Amygdala) Pool   79.0           Brain (cerebellum)   0.0           Brain (fetal)   0.0           Brain (Hippocampus) Pool   100.0           Cerebral Cortex Pool   0.0           Brain (Substantia nigra) Pool   0.0           Brain (Thalamus) Pool   27.4           Brain (whole)   0.0           Spinal Cord Pool   39.2           Adrenal Gland   0.0           Pituitary gland Pool   0.0           Salivary Gland   0.0           Thyroid (female)   0.0           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   0.0                        
     [0922] General_screening_panel_v1.6 Summary: Ag7410 Highest expression of this gene is seen in brain (hippocampus; CT=100.0) and brain (amygdala; CT=79.0). In addition, this gene is also expressed at moderate levels a colon cancer cell line (CT=29.3); in brain (thalamus; CT=27.4); in spinal cord (CT=39.2); and a CNS cancer line (CT=24.8). Modulation of this gene product may be useful in the treatment of neurological pathologies and cancer.  
     [0923] AB. CG59361-01: POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE VA-Like Gene  
     [0924] Expression of gene CG59361-01 was assessed using the primer-probe set Ag733, described in Table ABA. Results of the RTQ-PCR runs are shown in Table ABB.  
               TABLE ABA                          Probe Name Ag733                                             Start   SEQ       Primers   Sequences   Length   Position   ID No               Forward   5′-ccctgcagacatggtactactc-3′   22   789   311       Probe   TET-5′-tccactgatccagatgga   26   814   312           atctgtca-3′-TAMRA       Reverse   5′-ccatcaagaccagaagtctcaa   22   842   313           -3′                  
 
     [0925]               TABLE ABB                          Panel 1.2                                 Rel. Exp. (%)               Ag733, Run           Tissue Name   115165150                                         Endothelial cells   1.6           Heart (Fetal)   0.2           Pancreas   3.3           Pancreatic ca. CAPAN 2   1.0           Adrenal Gland   2.5           Thyroid   2.5           Salivary gland   5.3           Pituitary gland   3.7           Brain (fetal)   0.9           Brain (whole)   1.0           Brain (amygdala)   0.6           Brain (cerebellum)   0.4           Brain (hippocampus)   1.0           Brain (thalamus)   0.7           Cerebral Cortex   0.9           Spinal cord   1.4           glio/astro U87-MG   1.9           glio/astro U-118-MG   1.6           astrocytoma SW1783   1.0           neuro*; met SK-N-AS   3.3           astrocytoma SF-539   1.4           astrocytoma SNB-75   0.8           glioma SNB-19   0.5           glioma U251   0.6           glioma SF-295   2.2           Heart   2.1           Skeletal Muscle   0.9           Bone marrow   0.5           Thymus   0.4           Spleen   0.9           Lymph node   2.0           Colorectal Tissue   0.2           Stomach   4.5           Small intestine   1.0           Colon ca. SW480   0.0           Colon ca.* SW620 (SW480 met)   0.4           Colon ca. HT29   0.0           Colon ca. HCT-116   0.5           Colon ca. CaCo-2   2.4           Colon ca. Tissue (ODO3866)   0.4           Colon ca. HCC-2998   0.9           Gastric ca.* (liver met) NCI-N87   5.7           Bladder   4.1           Trachea   100.0           Kidney   2.1           Kidney (fetal)   3.2           Renal ca. 786-0   1.1           Renal ca. A498   1.7           Renal ca. RXF 393   0.6           Renal ca. ACHN   0.7           Renal ca. UO-31   2.1           Renal ca. TK-10   0.7           Liver   1.7           Liver (fetal)   0.7           Liver ca. (hepatoblast) HepG2   0.0           Lung   8.2           Lung (fetal)   3.5           Lung ca. (small cell) LX-1   0.8           Lung ca. (small cell) NCI-H69   0.2           Lung ca. (s. cell var.) SHP-77   0.3           Lung ca. (large cell) NCI-H460   1.4           Lung ca. (non-sm. cell) A549   0.9           Lung ca. (non-s. cell) NCI-H23   1.2           Lung ca. (non-s. cell) HOP-62   4.2           Lung ca. (non-s. cl) NCI-H522   1.7           Lung ca. (squam.) SW 900   2.1           Lung ca. (squam.) NCI-H596   0.1           Mammary gland   1.7           Breast ca.* (pl. ef) MCF-7   0.0           Breast ca.* (pl. ef) MDA-MB-231   1.9           Breast ca.* (pl. ef) T47D   1.0           Breast ca. BT-549   0.8           Breast ca. MDA-N   1.1           Ovary   0.5           Ovarian ca. OVCAR-3   0.8           Ovarian ca. OVCAR-4   0.9           Ovarian ca. OVCAR-5   4.4           Ovarian ca. OVCAR-8   0.6           Ovarian ca. IGROV-1   1.1           Ovarian ca. (ascites) SK-OV-3   3.6           Uterus   1.4           Placenta   10.1           Prostate   0.8           Prostate ca.* (bone met) PC-3   0.3           Testis   1.8           Melanoma Hs688(A).T   1.0           Melanoma* (met) Hs688(B).T   2.8           Melanoma UACC-62   1.2           Melanoma M14   0.7           Melanoma LOX IMVI   0.4           Melanoma* (met) SK-MEL-5   2.2                        
     [0926] Panel 1.2 Summary: Ag733 Highest expression is seen in trachea (CT=23.5). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of this tissue.  
     [0927] Moderate to low levels of expression are seen in metabolic tissues, including skeletal muscle, thyroid, adrenal, pancreas, and adult and fetal liver and heart. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0928] This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0929] This gene is widely expressed in this panel, with moderate expression also seen in the cancer cell lines on this panel. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0930] AC. CG59444-01: SA Protein-Like Gene  
     [0931] Expression of gene CG59444-01 was assessed using the primer-probe set Ag3441, described in Table ACA. Results of the RTQ-PCR runs are shown in Tables ACB, ACC and ACD.  
               TABLE ACA                          Probe Name Ag3441                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-caccctacgatgtgcagatt-   20   1337   314           3′       Probe   TET-5′-caacgtcctgcctcctg   25   1371   315           gagaagag-3′-TAMRA       Reverse   5′-gatacggacggcaacattc-3′   19   1398   316                  
 
     [0932]               TABLE ACB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag3441, Run           Tissue Name   210374767                                         AD 1 Hippo   20.3           AD 2 Hippo   52.9           AD 3 Hippo   5.8           AD 4 Hippo   23.3           AD 5 hippo   9.5           AD 6 Hippo   100.0           Control 2 Hippo   26.8           Control 4 Hippo   68.8           Control (Path) 3 Hippo   6.7           AD 1 Temporal Ctx   26.6           AD 2 Temporal Ctx   44.8           AD 3 Temporal Ctx   5.3           AD 4 Temporal Ctx   36.9           AD 5 Inf Temporal Ctx   17.8           AD 5 SupTemporal Ctx   31.4           AD 6 Inf Temporal Ctx   53.2           AD 6 Sup Temporal Ctx   44.8           Control 1 Temporal Ctx   13.7           Control 2 Temporal Ctx   17.0           Control 3 Temporal Ctx   19.5           Control 4 Temporal Ctx   19.6           Control (Path) 1 Temporal Ctx   24.1           Control (Path) 2 Temporal Ctx   21.8           Control (Path) 3 Temporal Ctx   10.0           Control (Path) 4 Temporal Ctx   17.7           AD 1 Occipital Ctx   6.0           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   1.7           AD 4 Occipital Ctx   16.2           AD 5 Occipital Ctx   5.6           AD 6 Occipital Ctx   23.5           Control 1 Occipital Ctx   1.4           Control 2 Occipital Ctx   16.2           Control 3 Occipital Ctx   10.3           Control 4 Occipital Ctx   10.7           Control (Path) 1 Occipital Ctx   29.7           Control (Path) 2 Occipital Ctx   4.4           Control (Path) 3 Occipital Ctx   1.2           Control (Path) 4 Occipital Ctx   8.7           Control 1 Parietal Ctx   10.8           Control 2 Parietal Ctx   16.3           Control 3 Parietal Ctx   8.4           Control (Path) 1 Parietal Ctx   28.3           Control (Path) 2 Parietal Ctx   11.3           Control (Path) 3 Parietal Ctx   3.1           Control (Path) 4 Parietal Ctx   27.0                        
     [0933]               TABLE ACC                          Panel 4D                         Rel. Exp. (%)           Ag3441, Run       Tissue Name   166397101                             Secondary Th1 act   0.0       Secondary Th2 act   0.5       Secondary Tr1 act   0.0       Secondary Th1 rest   0.0       Secondary Th2 rest   0.0       Secondary Tr1 rest   0.0       Primary Th1 act   0.0       Primary Th2 act   0.0       Primary Tr1 act   0.0       Primary Th1 rest   0.0       Primary Th2 rest   0.0       Primary Tr1 rest   0.0       CD45RA CD4 lymphocyte act   0.0       CD45RO CD4 lymphocyte act   0.0       CD8 lymphocyte act   0.0       Secondary CD8 lymphocyte rest   0.0       Secondary CD8 lymphocyte act   0.0       CD4 lymphocyte none   0.1       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0       LAK cells rest   0.2       LAK cells IL-2   0.0       LAK cells IL-2 + IL-12   0.0       LAK cells IL-2 + IFN gamma   0.0       LAK cells IL-2 + IL-18   0.0       LAK cells PMA/ionomycin   0.0       NK Cells IL-2 rest   0.0       Two Way MLR 3 day   0.0       Two Way MLR 5 day   0.0       Two Way MLR 7 day   0.0       PBMC rest   0.0       PBMC PWM   0.0       PBMC PHA-L   0.0       Ramos (B cell) none   0.0       Ramos (B cell) ionomycin   0.0       B lymphocytes PWM   0.0       B lymphocytes CD40L and IL-4   0.3       EOL-1 dbcAMP   0.0       EOL-1 dbcAMP PMA/ionomycin   0.0       Dendritic cells none   3.9       Dendritic cells LPS   0.7       Dendritic cells anti-CD40   5.0       Monocytes rest   0.1       Monocytes LPS   0.2       Macrophages rest   0.8       Macrophages LPS   0.4       HUVEC none   0.0       HUVEC starved   0.0       HUVEC IL-1beta   0.0       HUVEC IFN gamma   0.0       HUVEC TNF alpha + IFN gamma   0.0       HUVEC TNF alpha + IL4   0.0       HUVEC IL-11   0.0       Lung Microvascular EC none   0.0       Lung Microvascular EC TNFalpha + IL-1beta   0.0       Microvascular Dermal EC none   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   0.0       Bronchial epithelium TNFalpha + IL1beta   0.0       Small airway epithelium none   0.0       Small airway epithelium TNFalpha + IL-1beta   0.0       Coronery artery SMC rest   0.0       Coronery artery SMC TNFalpha + IL-1beta   0.0       Astrocytes rest   0.0       Astrocytes TNFalpha + IL-1beta   0.0       KU-812 (Basophil) rest   0.0       KU-812 (Basophil) PMA/ionomycin   0.0       CCD1106 (Keratinocytes) none   0.0       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0       Liver cirrhosis   25.7       Lupus kidney   13.3       NCI-H292 none   0.0       NCI-H292 IL-4   0.0       NCI-H292 IL-9   0.0       NCI-H292 IL-13   0.1       NCI-H292 IFN gamma   0.0       HPAEC none   0.0       HPAEC TNF alpha + IL-1 beta   0.0       Lung fibroblast none   0.1       Lung fibroblast TNF alpha + IL-1 beta   0.0       Lung fibroblast IL-4   0.0       Lung fibroblast IL-9   0.0       Lung fibroblast IL-13   0.0       Lung fibroblast IFN gamma   0.0       Dermal fibroblast CCD1070 rest   0.0       Dermal fibroblast CCD1070 TNF alpha   0.0       Dermal fibroblast CCD1070 IL-1 beta   0.0       Dermal fibroblast IFN gamma   0.0       Dermal fibroblast IL-4   0.0       IBD Colitis 2   0.2       IBD Crohn&#39;s   0.8       Colon   6.7       Lung   1.1       Thymus   100.0       Kidney   0.9                    
     [0934]               TABLE ACD                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag3441, Run           Tissue Name   267143302                                         Colon cancer 1   0.4           Colon cancer NAT 1   0.7           Colon cancer 2   0.0           Colon cancer NAT 2   0.7           Colon cancer 3   0.0           Colon cancer NAT 3   3.1           Colon malignant cancer 4   4.1           Colon normal adjacent tissue 4   0.7           Lung cancer 1   0.8           Lung NAT 1   1.1           Lung cancer 2   1.2           Lung NAT 2   0.8           Squamous cell carcinoma 3   3.0           Lung NAT 3   0.8           metastatic melanoma 1   4.2           Melanoma 2   0.3           Melanoma 3   0.9           metastatic melanoma 4   4.8           metastatic melanoma 5   2.4           Bladder cancer 1   0.4           Bladder cancer NAT 1   0.0           Bladder cancer 2   0.2           Bladder cancer NAT 2   0.0           Bladder cancer NAT 3   0.0           Bladder cancer NAT 4   0.4           Prostate adenocarcinoma 1   15.4           Prostate adenocarcinoma 2   0.8           Prostate adenocarcinoma 3   2.2           Prostate adenocarcinoma 4   1.0           Prostate cancer NAT 5   0.7           Prostate adenocarcinoma 6   0.7           Prostate adenocarcinoma 7   1.1           Prostate adenocarcinoma 8   0.0           Prostate adenocarcinoma 9   6.6           Prostate cancer NAT 10   0.0           Kidney cancer 1   16.7           Kidney NAT 1   3.8           Kidney cancer 2   100.0           Kidney NAT 2   13.0           Kidney cancer 3   70.2           Kidney NAT 3   9.3           Kidney cancer 4   52.9           Kidney NAT 4   21.9                        
     [0935] CNS_neurodegeneration_v1.0 Summary: Ag3441 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene is found to be slightly upregulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.  
     [0936] Panel 4D Summary: Ag3441 Highest expression of this gene is detected in thymus. This gene could therefore play an important role in T cell development. Small molecule therapeutics, or antibody therapeutics designed against the protein encoded for by this gene could be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitiution.  
     [0937] In addition, moderate to low levels of expression of this gene is also detected in dendritic cells, colon, lung, normal and lupus kidney and liver cirrhosis. Therefore, therapeutic modulation of this gene may be useful in the treatment of autoimmune and inflammatory diseases that affect colon, lung and kidney, such as psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis general oncology screening panel_V — 2.4 Summary: Ag3441 Highest expression of this gene is detected in kidney cancer 2 (CT=28.8). Moderate to low levels of expression of this gene is also seen in metastatic melanoma, prostate and kidney cancers. Interestingly, expression of this gene is higher in kidney cancer samples than in the adjacent normal samples. Thus, expression of this gene may be used as marker to detect kidney cancer. In addition, therapeutic modulation of this gene may be useful in the treatment of kidney cancers.  
     [0938] AD. CG59482-02: Trypsin I Precursor  
               TABLE ADA                          Probe Name Ag7118                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-gctaagtgtgaagcctcctacc-   22   194   317           3′       Probe   TET-5′-agcccacacagaacatgtt   29   223   318           gctggtaatc-3′-TAMRA       Reverse   5′-gaatccttgcctccctca-3′   18   256   319                  
 
     [0939]               TABLE ADB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag7118, Run           Tissue Name   296423773                                         AD 1 Hippo   13.1           AD 2 Hippo   13.3           AD 3 Hippo   4.8           AD 4 Hippo   5.0           AD 5 hippo   51.4           AD 6 Hippo   32.5           Control 2 Hippo   34.2           Control 4 Hippo   5.8           Control (Path) 3 Hippo   2.4           AD 1 Temporal Ctx   10.2           AD 2 Temporal Ctx   37.9           AD 3 Temporal Ctx   6.5           AD 4 Temporal Ctx   17.1           AD 5 Inf Temporal Ctx   77.9           AD 5 Sup Temporal Ctx   22.1           AD 6 Inf Temporal Ctx   30.1           AD 6 Sup Temporal Ctx   51.8           Control 1 Temporal Ctx   4.5           Control 2 Temporal Ctx   59.9           Control 3 Temporal Ctx   17.1           Control 4 Temporal Ctx   9.0           Control (Path) 1 Temporal Ctx   65.1           Control (Path) 2 Temporal Ctx   40.9           Control (Path) 3 Temporal Ctx   8.1           Control (Path) 4 Temporal Ctx   24.5           AD 1 Occipital Ctx   11.3           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   6.7           AD 4 Occipital Ctx   12.9           AD 5 Occipital Ctx   17.6           AD 6 Occipital Ctx   39.8           Control 1 Occipital Ctx   2.7           Control 2 Occipital Ctx   100.0           Control 3 Occipital Ctx   12.7           Control 4 Occipital Ctx   2.3           Control (Path) 1 Occipital Ctx   73.7           Control (Path) 2 Occipital Ctx   7.0           Control (Path) 3 Occipital Ctx   2.9           Control (Path) 4 Occipital Ctx   15.5           Control 1 Parietal Ctx   7.4           Control 2 Parietal Ctx   29.3           Control 3 Parietal Ctx   23.5           Control (Path) 1 Parietal Ctx   74.2           Control (Path) 2 Parietal Ctx   15.1           Control (Path) 3 Parietal Ctx   10.6           Control (Path) 4 Parietal Ctx   27.5                        
     [0940]               TABLE ADC                          General_screening_panel_v1.6                                 Rel. Exp. (%)               Ag7118, Run           Tissue Name   296433067                                         Adipose   0.0           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.0           Testis Pool   0.0           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.0           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   0.2           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.0           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   0.0           Ovary   0.0           Breast ca. MCF-7   0.0           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   0.0           Breast ca. T47D   0.0           Breast ca. MDA-N   0.0           Breast Pool   0.0           Trachea   0.0           Lung   0.0           Fetal Lung   0.0           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   0.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.0           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.0           Liver   0.0           Fetal Liver   0.1           Liver ca. HepG2   0.0           Kidney Pool   0.0           Fetal Kidney   0.0           Renal ca. 786-0   0.0           Renal ca. A498   0.0           Renal ca. ACHN   0.0           Renal ca. UO-31   0.0           Renal ca. TK-10   0.0           Bladder   18.4           Gastric ca. (liver met.) NCI-N87   0.0           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.0           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   0.0           Colon cancer tissue   0.0           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   0.0           Small Intestine Pool   0.0           Stomach Pool   0.0           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   0.0           Lymph Node Pool   0.0           Fetal Skeletal Muscle   0.0           Skeletal Muscle Pool   0.0           Spleen Pool   0.0           Thymus Pool   0.0           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   0.0           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.0           Brain (Amygdala) Pool   0.0           Brain (cerebellum)   0.0           Brain (fetal)   0.0           Brain (Hippocampus) Pool   0.0           Cerebral Cortex Pool   0.0           Brain (Substantia nigra) Pool   0.0           Brain (Thalamus) Pool   0.0           Brain (whole)   0.0           Spinal Cord Pool   0.0           Adrenal Gland   0.0           Pituitary gland Pool   0.0           Salivary Gland   0.0           Thyroid (female)   0.0           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   100.0                        
     [0941]               TABLE ADD                          Panel 4.1D                         Rel. Exp. (%)           Ag7118, Run       Tissue Name   296417626                             Secondary Th1 act   0.0       Secondary Th2 act   1.3       Secondary Tr1 act   0.0       Secondary Th1 rest   4.3       Secondary Th2 rest   13.6       Secondary Tr1 rest   4.3       Primary Th1 act   0.0       Primary Th2 act   2.2       Primary Tr1 act   0.8       Primary Th1 rest   1.2       Primary Th2 rest   0.0       Primary Tr1 rest   0.8       CD45RA CD4 lymphocyte act   12.4       CD45RO CD4 lymphocyte act   11.7       CD8 lymphocyte act   2.6       Secondary CD8 lymphocyte rest   0.0       Secondary CD8 lymphocyte act   4.1       CD4 lymphocyte none   2.3       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0       LAK cells rest   0.0       LAK cells IL-2   15.6       LAK cells IL-2 + IL-12   0.0       LAK cells IL-2 + IFN gamma   1.5       LAK cells IL-2 + IL-18   1.6       LAK cells PMA/ionomycin   8.7       NK Cells IL-2 rest   82.9       Two Way MLR 3 day   32.3       Two Way MLR 5 day   4.5       Two Way MLR 7 day   2.9       PBMC rest   2.5       PBMC PWM   0.9       PBMC PHA-L   0.0       Ramos (B cell) none   0.0       Ramos (B cell) ionomycin   0.0       B lymphocytes PWM   0.0       B lymphocytes CD40L and IL-4   10.7       EOL-1 dbcAMP   0.0       EOL-1 dbcAMP PMA/ionomycin   0.0       Dendritic cells none   0.0       Dendritic cells LPS   0.0       Dendritic cells anti-CD40   0.0       Monocytes rest   3.8       Monocytes LPS   1.3       Macrophages rest   0.0       Macrophages LPS   1.2       HUVEC none   31.9       HUVEC starved   36.1       HUVEC IL-1beta   38.4       HUVEC IFN gamma   10.6       HUVEC TNF alpha + IFN gamma   10.8       HUVEC TNF alpha + IL4   16.4       HUVEC IL-11   13.6       Lung Microvascular EC none   21.8       Lung Microvascular EC TNFalpha + IL-1beta   6.0       Microvascular Dermal EC none   1.8       Microsvasular Dermal EC TNFalpha + IL-1beta   0.6       Bronchial epithelium TNFalpha + IL1beta   17.4       Small airway epithelium none   3.0       Small airway epithelium TNFalpha + IL-1beta   11.6       Coronery artery SMC rest   15.2       Coronery artery SMC TNFalpha + IL-1beta   16.7       Astrocytes rest   0.0       Astrocytes TNFalpha + IL-1beta   0.0       KU-812 (Basophil) rest   0.0       KU-812 (Basophil) PMA/ionomycin   0.0       CCD1106 (Keratinocytes) none   100.0       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   16.4       Liver cirrhosis   8.4       NCI-H292 none   0.0       NCI-H292 IL-4   0.0       NCI-H292 IL-9   0.0       NCI-H292 IL-13   0.0       NCI-H292 IFN gamma   1.3       HPAEC none   15.5       HPAEC TNF alpha + IL-1 beta   62.0       Lung fibroblast none   2.4       Lung fibroblast TNF alpha + IL-1 beta   2.2       Lung fibroblast IL-4   3.7       Lung fibroblast IL-9   3.7       Lung fibroblast IL-13   0.0       Lung fibroblast IFN gamma   6.9       Dermal fibroblast CCD1070 rest   47.0       Dermal fibroblast CCD1070 TNF alpha   42.6       Dermal fibroblast CCD1070 IL-1 beta   16.0       Dermal fibroblast IFN gamma   1.1       Dermal fibroblast IL-4   4.4       Dermal Fibroblasts rest   6.3       Neutrophils TNFa + LPS   0.0       Neutrophils rest   1.6       Colon   29.3       Lung   0.0       Thymus   13.6       Kidney   7.5                    
     [0942] CNS_neurodegeneration_v1.0 Summary: Ag7l18 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene appears to be slightly down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor may be of use in reversing the dementia, memory loss, and neuronal death associated with this disease.  
     [0943] General_screening_panel_v1.6 Summary: Ag7118 Highest expression of this gene, a putative trypsin, is seen in the pancreas (CT=17). Thus, expression of this gene could be used to differentiate between this gene and other genes on this panel and as a marker of this organ. In addition, therapeutic modulation of the trypsin encoded by this gene may be useful in the treatment of pancrease related diseases including pancreatitis.  
     [0944] Panel 4.1D Summary: Ag7118 Highest expression is seen in untreated keratinocytes (CT=32.6). Therefore, modulation of the expression or activity of the protein encoded by this transcript through the application of small molecule therapeutics may be useful in the treatment of psoriasis and wound healing.  
     [0945] In addition, low to moderate levels of this gene is also detected in cytokine treated dermal fibroblasts, HPAEC, resting and activated HUVEC cells, IL2-treated resting NK cells, and 2 way MLR. Therefore, therapeutic modulation of the trypsin encoded by this gene may be useful in the treatment of autoimmune and inflammatory diseases that involve endothelial cells, such as lupus erythematosus, asthma, emphysema, Crohn&#39;s disease, ulcerative colitis, rheumatoid arthritis, osteoarthritis, and psoriasis.  
     [0946] AE. CG89709-01 and CG89709-02 and CG89709-03 and CG89709-04: Protein Kinase-Like Gene  
     [0947] Expression of gene CG89709-01 and variants CG89709-02, CG89709-03, and CG89709-04 was assessed using the primer-probe set Ag5763, described in Table AEA. Results of the RTQ-PCR runs are shown in Tables AEB, AEC and AED.  
               TABLE AEA                          Probe Name Ag5763                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-atggcagccagcattaaa-3′   19   3047   320       Probe   TET-5′-tccatctacgtgtattaca   29   3078   321           gacattctgc-3′-TAMRA       Reverse   5′-agacttcggggtgcttgtag-3′   20   3111   322                  
 
     [0948]               TABLE AEB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag5763, Run           Tissue Name   249286625                                         AD 1 Hippo   17.0           AD 2 Hippo   35.8           AD 3 Hippo   6.2           AD 4 Hippo   8.9           AD 5 hippo   71.2           AD 6 Hippo   53.2           Control 2 Hippo   36.3           Control 4 Hippo   16.6           Control (Path) 3 Hippo   8.2           AD 1 Temporal Ctx   28.3           AD 2 Temporal Ctx   41.8           AD 3 Temporal Ctx   8.8           AD 4 Temporal Ctx   43.5           AD 5 Inf Temporal Ctx   84.7           AD 5 Sup Temporal Ctx   45.1           AD 6 Inf Temporal Ctx   58.6           AD 6 Sup Temporal Ctx   58.6           Control 1 Temporal Ctx   6.6           Control 2 Temporal Ctx   40.6           Control 3 Temporal Ctx   18.4           Control 4 Temporal Ctx   10.9           Control (Path) 1 Temporal Ctx   68.8           Control (Path) 2 Temporal Ctx   36.9           Control (Path) 3 Temporal Ctx   5.1           Control (Path) 4 Temporal Ctx   37.1           AD 1 Occipital Ctx   20.0           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   7.9           AD 4 Occipital Ctx   29.7           AD 5 Occipital Ctx   20.6           AD 6 Occipital Ctx   48.6           Control 1 Occipital Ctx   4.4           Control 2 Occipital Ctx   75.3           Control 3 Occipital Ctx   21.3           Control 4 Occipital Ctx   9.5           Control (Path) 1 Occipital Ctx   100.0           Control (Path) 2 Occipital Ctx   14.4           Control (Path) 3 Occipital Ctx   4.1           Control (Path) 4 Occipital Ctx   17.8           Control 1 Parietal Ctx   9.1           Control 2 Parietal Ctx   49.3           Control 3 Parietal Ctx   18.7           Control (Path) 1 Parietal Ctx   85.9           Control (Path) 2 Parietal Ctx   14.3           Control (Path) 3 Parietal Ctx   3.6           Control (Path) 4 Parietal Ctx   54.0                        
     [0949]               TABLE AEC                          General_screening_panel_v1.5                                 Rel. Exp. (%)               Ag5763, Run           Tissue Name   246263911                                         Adipose   7.2           Melanoma* Hs688(A).T   11.3           Melanoma* Hs688(B).T   12.5           Melanoma* M14   8.1           Melanoma* LOXIMVI   8.5           Melanoma* SK-MEL-5   10.9           Squamous cell carcinoma SCC-4   6.9           Testis Pool   13.2           Prostate ca.* (bone met) PC-3   6.6           Prostate Pool   4.8           Placenta   15.9           Uterus Pool   9.3           Ovarian ca. OVCAR-3   8.9           Ovarian ca. SK-OV-3   14.3           Ovarian ca. OVCAR-4   10.3           Ovarian ca. OVCAR-5   18.4           Ovarian ca. IGROV-1   9.5           Ovarian ca. OVCAR-8   5.2           Ovary   7.7           Breast ca. MCF-7   3.6           Breast ca. MDA-MB-231   17.0           Breast ca. BT 549   15.9           Breast ca. T47D   1.1           Breast ca. MDA-N   4.0           Breast Pool   14.5           Trachea   9.2           Lung   3.8           Fetal Lung   18.6           Lung ca. NCI-N417   3.6           Lung ca. LX-1   5.5           Lung ca. NCI-H146   5.7           Lung ca. SHP-77   10.4           Lung ca. A549   9.0           Lung ca. NCI-H526   7.4           Lung ca. NCI-H23   19.2           Lung ca. NCI-H460   7.9           Lung ca. HOP-62   5.3           Lung ca. NCI-H522   8.0           Liver   2.6           Fetal Liver   14.3           Liver ca. HepG2   9.8           Kidney Pool   19.3           Fetal Kidney   8.9           Renal ca. 786-0   7.7           Renal ca. A498   0.9           Renal ca. ACHN   7.6           Renal ca. UO-31   7.3           Renal ca. TK-10   9.1           Bladder   9.8           Gastric ca. (liver met.) NCI-N87   15.5           Gastric ca. KATO III   46.3           Colon ca. SW-948   3.3           Colon ca. SW480   13.0           Colon ca.* (SW480 met) SW620   7.9           Colon ca. HT29   3.2           Colon ca. HCT-116   9.7           Colon ca. CaCo-2   28.9           Colon cancer tissue   4.8           Colon ca. SW1116   1.5           Colon ca. Colo-205   1.9           Colon ca. SW-48   2.0           Colon Pool   13.3           Small Intestine Pool   15.8           Stomach Pool   6.8           Bone Marrow Pool   5.5           Fetal Heart   6.6           Heart Pool   6.0           Lymph Node Pool   15.6           Fetal Skeletal Muscle   5.7           Skeletal Muscle Pool   18.8           Spleen Pool   7.8           Thymus Pool   11.8           CNS cancer (glio/astro) U87-MG   5.1           CNS cancer (glio/astro) U-118-MG   20.7           CNS cancer (neuro; met) SK-N-AS   3.7           CNS cancer (astro) SF-539   6.7           CNS cancer (astro) SNB-75   18.9           CNS cancer (glio) SNB-19   7.9           CNS cancer (glio) SF-295   16.0           Brain (Amygdala) Pool   22.5           Brain (cerebellum)   100.0           Brain (fetal)   20.6           Brain (Hippocampus) Pool   26.1           Cerebral Cortex Pool   25.5           Brain (Substantia nigra) Pool   21.3           Brain (Thalamus) Pool   36.9           Brain (whole)   20.7           Spinal Cord Pool   16.6           Adrenal Gland   10.2           Pituitary gland Pool   5.3           Salivary Gland   4.1           Thyroid (female)   5.4           Pancreatic ca. CAPAN2   12.8           Pancreas Pool   20.2                        
     [0950]               TABLE AED                          Panel 5 Islet                         Rel. Exp. (%)           Ag5763, Run       Tissue Name   243564954                             97457_Patient-02go_adipose   23.3       97476_Patient-07sk_skeletal muscle   27.4       97477_Patient-07ut_uterus   17.2       97478_Patient-07pl_placenta   43.8       99167_Bayer Patient 1   64.6       97482_Patient-08ut_uterus   11.3       97483_Patient-08pl_placenta   56.6       97486_Patient-09sk_skeletal muscle   14.8       97487_Patient-09ut_uterus   36.9       97488_Patient-09pl_placenta   21.0       97492_Patient-10ut_uterus   31.6       97493_Patient-10pl_placenta   100.0       97495_Patient-11go_adipose   24.8       97496_Patient-11sk_skeletal muscle   28.5       97497_Patient-11ut_uterus   43.2       97498_Patient-11pl_placenta   34.4       97500_Patient-12go_adipose   37.6       97501_Patient-12sk_skeletal muscle   57.8       97502_Patient-12ut_uterus   34.4       97503_Patient-12pl_placenta   40.1       94721_Donor 2 U - A_Mesenchymal Stem Cells   17.9       94722_Donor 2 U - B_Mesenchymal Stem Cells   21.6       94723_Donor 2 U - C_Mesenchymal Stem Cells   27.5       94709_Donor 2 AM - A_adipose   19.6       94710_Donor 2 AM - B_adipose   15.4       94711_Donor 2 AM - C_adipose   9.1       94712_Donor 2 AD - A_adipose   37.4       94713_Donor 2 AD - B_adipose   40.9       94714_Donor 2 AD - C_adipose   39.8       94742_Donor 3 U - A_Mesenchymal Stem Cells   11.7       94743_Donor 3 U - B_Mesenchymal Stem Cells   33.0       94730_Donor 3 AM - A_adipose   42.9       94731_Donor 3 AM - B_adipose   11.5       94732_Donor 3 AM - C_adipose   25.5       94733_Donor 3 AD - A_adipose   73.7       94734_Donor 3 AD - B_adipose   20.9       94735_Donor 3 AD - C_adipose   46.3       77138_Liver_HepG2untreated   40.9       73556_Heart_Cardiac stromal cells (primary)   7.9       81735_Small Intestine   40.6       72409_Kidney_Proximal Convoluted Tubule   11.8       82685_Small intestine_Duodenum   15.7       90650_Adrenal_Adrenocortical adenoma   8.1       72410_Kidney_HRCE   40.9       72411_Kidney_HRE   18.4       73139_Uterus_Uterine smooth muscle cells   11.1                    
     [0951] CNS_neurodegeneration_v1.0 Summary: Ag5763 This panel confirms the expression of this gene at significant levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [0952] General_screening_panel_v1.5 Summary: Ag5763 Highest expression of this gene is detected in brain (cerebellum) (CT=26.4). High levels of expression of this gene is also seen in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0953] Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0954] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0955] This gene codes for a novel protein kinase. In PathCalling screening at Curagen, this gene was identified as an interactor of estrogen-related nuclear receptor beta 2 (ERRB2). ERRB2, in turn, interacts with FOXO1A (FKHR), an important transcriptional factor in metabolism. This result suggests that the novel protein kinase may control the phosphorylation state of ERRB2 and FKHR and therefore, their activity. Therefore, inhibition of this gene would impair excessive activities of ERRB2 and FHKR, known to be associated with diabetic condition. Thus, an antagonist of the protein kinase encoded by this gene would be beneficial for the treatment of diabetes.  
     [0956] Panel 5 Islet Summary: Ag5763 Highest expression of this gene is detected in placenta (CT=29.9). In addition, consistent with panel 1.5 this gene is widely expressed in metabolic tissues. Please see panel 1.5 for further discussion on the utility of this gene.  
     [0957] AF. CG90879-01: Protein Kinase D2-Like Gene  
     [0958] Expression of gene CG90879-01 was assessed using the primer-probe sets Ag805 and Ag3770, described in Tables AFA and AFB. Results of the RTQ-PCR runs are shown in Tables AFC, AFD, AFE, AFF and AFG.  
               TABLE AFA                          Probe Name Ag805                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-ccttcgaggacttccagatc-   20   428   323           3′       Probe   TET-5′-acgccctcacggtgcac   23   455   324           tcctat-3′-TAMRA       Reverse   5′-actaggccgaagagcatctc-   20   508   325           3′                  
 
     [0959]               TABLE AFB                          Probe Name Ag3770                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-atccaagagaatgtggacattg-   22   1681   326           3′       Probe   TET-5′-accagatcttccctgacg   26   1712   327           aagtgctg-3′-TAMRA       Reverse   5′-ctccatagaccactccaaactg-   22   1747   328           3′                    
     [0960]               TABLE AFC                          CNS_neurodegeneration_v1.0                             Rel. Exp. (%)   Rel. Exp. (%)           Ag3770, Run   Ag805, Run       Tissue Name   211175147   224758713                                 AD 1 Hippo   41.5   27.4       AD 2 Hippo   32.8   17.0       AD 3 Hippo   29.9   14.1       AD 4 Hippo   24.5   6.8       AD 5 Hippo   54.0   59.5       AD 6 Hippo   100.0   100.0       Control 2 Hippo   27.9   10.9       Control 4 Hippo   57.8   36.1       Control (Path) 3 Hippo   23.2   4.8       AD 1 Temporal Ctx   47.0   24.7       AD 2 Temporal Ctx   22.7   9.1       AD 3 Temporal Ctx   25.5   9.2       AD 4 Temporal Ctx   21.2   4.4       AD 5 Inf Temporal Ctx   94.0   57.8       AD 5 Sup Temporal Ctx   60.7   52.9       AD 6 Inf Temporal Ctx   95.3   67.4       AD 6 Sup Temporal Ctx   96.6   54.0       Control 1 Temporal Ctx   20.2   4.3       Control 2 Temporal Ctx   40.3   22.1       Control 3 Temporal Ctx   28.5   8.6       Control 3 Temporal Ctx   18.3   14.7       Control (Path) 1   61.1   20.3       Temporal Ctx       Control (Path) 2   36.3   17.4       Temporal Ctx       Control (Path) 3   23.3   17.7       Temporal Ctx       Control (Path) 4   26.1   13.8       Temporal Ctx       AD 1 Occipital Ctx   34.2   18.8       AD 2 Occipital Ctx (Missing)   0.0   0.0       AD 3 Occipital Ctx   33.2   19.2       AD 4 Occipital Ctx   23.2   8.6       AD 5 Occipital Ctx   44.1   29.9       AD 6 Occipital Ctx   62.9   13.8       Control 1 Occipital Ctx   25.3   8.3       Control 2 Occipital Ctx   32.1   25.7       Control 3 Occipital Ctx   22.7   12.2       Control 4 Occipital Ctx   22.7   14.8       Control (Path) 1   80.1   54.7       Occipital Ctx       Control (Path) 2   17.8   15.0       Occipital Ctx       Control (Path) 3   18.2   6.0       Occipital Ctx       Control (Path) 4   22.2   15.4       Occipital Ctx       Control 1 Parietal Ctx   33.7   9.1       Control 2 Parietal Ctx   53.2   36.3       Control 3 Parietal Ctx   10.9   12.1       Control (Path) 1 Parietal Ctx   54.3   31.9       Control (Path) 2 Parietal Ctx   24.3   11.3       Control (Path) 3   22.5   6.4       Parietal Ctx       Control (Path) 4   37.4   22.2       Parietal Ctx                    
     [0961]               TABLE AFD                          General screening_panel_v1.4                                 Rel. Exp. (%)               Ag3770, Run           Tissue Name   218982439                                         Adipose   4.5           Melanoma* Hs688(A).T   7.9           Melanoma* Hs688(B).T   8.8           Melanoma* M14   15.7           Melanoma* LOXIMVI   19.1           Melanoma* SK-MEL-5   7.8           Squamous cell carcinoma SCC-4   16.7           Testis Pool   3.3           Prostate ca.* (bone met) PC-3   13.6           Prostate Pool   7.5           Placenta   12.7           Uterus Pool   3.6           Ovarian ca. OVCAR-3   16.2           Ovarian ca. SK-OV-3   37.4           Ovarian ca. OVCAR-4   12.7           Ovarian ca. OVCAR-5   30.6           Ovarian ca. IGROV-1   22.1           Ovarian ca. OVCAR-8   12.1           Ovary   6.0           Breast ca. MCF-7   22.1           Breast ca. MDA-MB-231   20.6           Breast ca. BT 549   24.1           Breast ca. T47D   58.6           Breast ca. MDA-N   4.3           Breast Pool   8.1           Trachea   9.7           Lung   2.2           Fetal Lung   25.7           Lung ca. NCI-N417   2.2           Lung ca. LX-1   16.3           Lung ca. NCI-H146   4.5           Lung ca. SHP-77   10.3           Lung ca. A549   19.2           Lung ca. NCI-H526   4.1           Lung ca. NCI-H23   8.5           Lung ca. NCI-H460   4.2           Lung ca. HOP-62   7.9           Lung ca. NCI-H522   13.3           Liver   1.1           Fetal Liver   5.8           Liver ca. HepG2   6.4           Kidney Pool   13.2           Fetal Kidney   7.8           Renal ca. 786-0   11.9           Renal ca. A498   12.3           Renal ca. ACHN   13.8           Renal ca. UO-31   18.7           Renal ca. TK-10   15.8           Bladder   23.0           Gastric ca. (liver met.) NCI-N87   100.0           Gastric ca. KATO III   42.9           Colon ca. SW-948   13.6           Colon ca. SW480   33.2           Colon ca.* (SW480 met) SW620   13.1           Colon ca. HT29   18.6           Colon ca. HCT-116   48.0           Colon ca. CaCo-2   28.5           Colon cancer tissue   15.5           Colon ca. SW1116   7.4           Colon ca. Colo-205   7.2           Colon ca. SW-48   6.9           Colon Pool   8.7           Small Intestine Pool   9.5           Stomach Pool   7.2           Bone Marrow Pool   2.5           Fetal Heart   5.8           Heart Pool   3.6           Lymph Node Pool   8.1           Fetal Skeletal Muscle   3.9           Skeletal Muscle Pool   3.3           Spleen Pool   12.6           Thymus Pool   16.2           CNS cancer (glio/astro) U87-MG   16.8           CNS cancer (glio/astro) U-118-MG   23.3           CNS cancer (neuro; met) SK-N-AS   26.2           CNS cancer (astro) SF-539   8.5           CNS cancer (astro) SNB-75   15.9           CNS cancer (glio) SNB-19   20.6           CNS cancer (glio) SF-295   50.7           Brain (Amygdala) Pool   1.9           Brain (cerebellum)   2.8           Brain (fetal)   4.1           Brain (Hippocampus) Pool   2.3           Cerebral Cortex Pool   1.9           Brain (Substantia nigra) Pool   2.5           Brain (Thalamus) Pool   2.3           Brain (whole)   2.6           Spinal Cord Pool   1.7           Adrenal Gland   4.8           Pituitary gland Pool   3.1           Salivary Gland   4.4           Thyroid (female)   7.6           Pancreatic ca. CAPAN2   22.1           Pancreas Pool   8.0                        
     [0962]               TABLE AFE                          Panel 1.3D                                 Rel. Exp. (%)               Ag805, Run           Tissue Name   167966906                                         Liver adenocarcinoma   80.1           Pancreas   12.5           Pancreatic ca. CAPAN 2   25.7           Adrenal gland   6.1           Thyroid   14.9           Salivary gland   10.2           Pituitary gland   21.2           Brain (fetal)   11.7           Brain (whole)   6.0           Brain (amygdala)   7.6           Brain (cerebellum)   2.6           Brain (hippocampus)   3.1           Brain (substantia nigra)   6.3           Brain (thalamus)   3.6           Cerebral Cortex   8.1           Spinal cord   7.7           glio/astro U87-MG   19.3           glio/astro U-118-MG   11.2           astrocytoma SW1783   18.4           neuro*; met SK-N-AS   27.4           astrocytoma SF-539   23.5           astrocytoma SNB-75   44.4           glioma SNB-19   55.9           glioma U251   33.0           glioma SF-295   67.8           Heart (fetal)   41.8           Heart   11.9           Skeletal muscle (fetal)   38.4           Skeletal muscle   7.9           Bone marrow   19.6           Thymus   97.9           Spleen   37.4           Lymph node   55.9           Colorectal   9.3           Stomach   13.2           Small intestine   13.9           Colon ca. SW480   48.3           Colon ca.* SW620(SW480 met)   42.6           Colon ca. HT29   33.4           Colon ca. HCT-116   24.1           Colon ca. CaCo-2   42.9           Colon ca. tissue(ODO3866)   21.8           Colon ca. HCC-2998   46.7           Gastric ca.* (liver met) NCI-N87   82.9           Bladder   18.2           Trachea   20.9           Kidney   19.9           Kidney (fetal)   100.0           Renal ca. 786-0   22.5           Renal ca. A498   30.8           Renal ca. RXF 393   72.2           Renal ca. ACHN   41.8           Renal ca. UO-31   26.1           Renal ca. TK-10   25.0           Liver   11.3           Liver (fetal)   9.7           Liver ca. (hepatoblast) HepG2   15.3           Lung   36.6           Lung (fetal)   27.9           Lung ca. (small cell) LX-1   27.5           Lung ca. (small cell) NCI-H69   20.3           Lung ca. (s. cell var.) SHP-77   35.6           Lung ca. (large cell) NCI-H460   3.8           Lung ca. (non-sm. cell) A549   47.3           Lung ca. (non-s. cell) NCI-H23   13.4           Lung ca. (non-s. cell) HOP-62   21.0           Lung ca. (non-s. cl) NCI-H522   24.8           Lung ca. (squam.) SW 900   40.3           Lung ca. (squam.) NCI-H596   16.7           Mammary gland   31.4           Breast ca.* (pl. ef) MCF-7   26.2           Breast ca.* (pl. ef) MDA-MB-231   19.1           Breast ca.* (pl. ef) T47D   34.4           Breast ca. BT-549   13.3           Breast ca. MDA-N   6.7           Ovary   33.9           Ovarian ca. OVCAR-3   17.1           Ovarian ca. OVCAR-4   48.6           Ovarian ca. OVCAR-5   75.8           Ovarian ca. OVCAR-8   10.9           Ovarian ca. IGROV-1   11.7           Ovarian ca.* (ascites) SK-OV-3   52.5           Uterus   20.2           Placenta   4.6           Prostate   14.3           Prostate ca.* (bone met)PC-3   14.7           Testis   6.8           Melanoma Hs688(A).T   7.0           Melanoma* (met) Hs688(B).T   7.3           Melanoma UACC-62   31.6           Melanoma M14   8.5           Melanoma LOX IMVI   46.0           Melanoma* (met) SK-MEL-5   7.2           Adipose   13.6                        
     [0963]               TABLE AFF                          Panel 4.1D                             Rel. Exp. (%)   Rel. Exp. (%)           Ag3770, Run   Ag805, Run       Tissue Name   170069171   169990844                                 Secondary Th1 act   52.1   33.4       Secondary Th2 act   100.0   73.7       Secondary Tr1 act   67.4   40.9       Secondary Th1 rest   41.8   30.1       Secondary Th2 rest   81.2   58.6       Secondary Tr1 rest   57.0   47.3       Primary Th1 act   41.2   19.8       Primary Th2 act   62.0   35.8       Primary Tr1 act   50.0   41.5       Primary Th1 rest   61.1   40.1       Primary Th2 rest   48.0   30.8       Primary Tr1 rest   62.0   33.9       CD45RA CD4 lymphocyte act   28.3   25.3       CD45RO CD4 lymphocyte act   49.3   36.6       CD8 lymphocyte act   55.1   48.6       Secondary CD8 lymphocyte rest   33.2   37.9       Secondary CD8 lymphocyte act   39.5   40.3       CD4 lymphocyte none   24.0   43.8       2ry Th1/Th2/Tr1_anti-CD95 CH11   57.4   45.4       LAK cells rest   30.6   19.5       LAK cells IL-2   52.1   33.7       LAK cells IL-2 + IL-12   42.9   39.2       LAK cells IL-2 + IFN gamma   50.7   45.7       LAK cells IL-2 + IL-18   61.6   34.4       LAK cells PMA/ionomycin   16.8   7.7       NK Cells IL-2 rest   77.4   67.4       Two Way MLR 3 day   54.0   100.0       Two Way MLR 5 day   36.3   35.4       Two Way MLR 7 day   37.9   33.0       PBMC rest   33.7   23.0       PBMC PWM   41.5   32.8       PBMC PHA-L   36.6   33.4       Ramos (B cell) none   47.0   48.0       Ramos (B cell) ionomycin   42.9   39.8       B lymphocytes PWM   14.6   14.2       B lymphocytes CD40L and IL-4   59.5   34.9       EOL-1 dbcAMP   25.2   17.3       EOL-1 dbcAMP PMA/ionomycin   57.0   54.7       Dendritic cells none   12.2   6.9       Dendritic cells LPS   10.2   10.4       Dendritic cells anti-CD40   9.6   8.4       Monocytes rest   22.7   20.3       Monocytes LPS   28.5   24.7       Macrophages rest   11.3   11.5       Macrophages LPS   31.0   31.6       HUVEC none   29.5   30.6       HUVEC starved   37.9   40.9       HUVEC IL-1beta   51.8   52.1       HUVEC IFN gamma   58.2   39.2       HUVEC TNF alpha + IFN gamma   35.8   48.0       HUVEC TNF alpha + IL4   29.7   39.2       HUVEC IL-11   26.8   24.5       Lung Microvascular EC none   75.3   68.8       Lung Microvascular EC   59.0   74.7       TNFalpha + IL-1beta       Microvascular Dermal EC none   28.9   35.6       Microsvasular Dermal EC   57.4   66.9       TNFalpha + IL-1beta       Bronchial epithelium   29.9   33.9       TNFalpha + IL1beta       Small airway epithelium none   10.1   13.5       Small airway epithelium   36.6   30.1       TNFalpha + IL-1beta       Coronery artery SMC rest   17.0   13.8       Coronery artery SMC   13.0   9.6       TNFalpha + IL-1beta       Astrocytes rest   20.3   15.9       Astrocytes TNFalpha + IL-1beta   24.8   14.5       KU-812 (Basophil) rest   24.5   16.6       KU-812 (Basophil) PMA/ionomycin   23.5   42.9       CCD1106 (Keratinocytes) none   28.7   28.1       CCD1106 (Keratinocytes)   56.3   55.5       TNFalpha + IL-1beta       Liver cirrhosis   7.9   8.4       NCI-H292 none   32.3   27.2       NCI-H292 IL-4   34.9   28.9       NCI-H292 IL-9   53.2   23.0       NCI-H292 IL-13   35.6   35.6       NCI-H292 IFN gamma   46.3   47.6       HPAEC none   34.9   31.9       HPAEC TNF alpha + IL-1 beta   57.8   53.6       Lung fibroblast none   10.7   11.5       Lung fibroblast   18.9   18.0       TNF alpha + IL-1 beta       Lung fibroblast IL-4   7.6   7.9       Lung fibroblast IL-9   14.3   12.2       Lung fibroblast IL-13   10.7   5.0       Lung fibroblast IFN gamma   15.0   16.3       Dermal fibroblast CCD1070 rest   12.5   13.6       Dermal fibroblast CCD1070 TNF alpha   42.9   40.1       Dermal fibroblast CCD1070 IL-1 beta   11.5   11.3       Dermal fibroblast IFN gamma   9.4   8.7       Dermal fibroblast IL-4   16.6   13.3       Dermal Fibroblasts rest   11.4   8.5       Neutrophils TNFa + LPS   8.7   13.7       Neutrophils rest   54.0   81.2       Colon   15.2   12.0       Lung   34.2   20.9       Thymus   56.6   56.3       Kidney   15.8   5.6                    
     [0964]               TABLE AFG                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag3770, Run           Tissue Name   267820395                                         Colon cancer 1   33.9           Colon NAT 1   21.2           Colon cancer 2   26.4           Colon NAT 2   12.2           Colon cancer 3   64.6           Colon NAT 3   27.5           Colon malignant cancer 4   39.8           Colon NAT 4   7.4           Lung cancer 1   39.5           Lung NAT 1   6.7           Lung cancer 2   84.7           Lung NAT 2   7.6           Squamous cell carcinoma 3   64.2           Lung NAT 3   2.2           Metastatic melanoma 1   29.3           Melanoma 2   34.2           Melanoma 3   12.9           Metastatic melanoma 4   66.9           Metastatic melanoma 5   59.9           Bladder cancer 1   2.5           Bladder NAT 1   0.0           Bladder cancer 2   7.7           Bladder NAT 2   0.0           Bladder NAT 3   0.9           Bladder NAT 4   4.1           Prostate adenocarcinoma 1   38.7           Prostate adenocarcinoma 2   6.9           Prostate adenocarcinoma 3   13.5           Prostate adenocarcinoma 4   42.3           Prostate NAT 5   12.3           Prostate adenocarcinoma 6   5.0           Prostate adenocarcinoma 7   7.7           Prostate adenocarcinoma 8   2.5           Prostate adenocarcinoma 9   24.3           Prostate NAT 10   4.0           Kidney cancer 1   41.8           Kidney NAT 1   18.6           Kidney cancer 2   100.0           Kidney NAT 2   22.7           Kidney cancer 3   31.2           Kidney NAT 3   13.2           Kidney cancer 4   27.7           Kidney NAT 4   15.4                        
     [0965] CNS_neurodegeneration_v1.0 Summary: Ag805/Ag3770 Two experiments with different probe and primer sets produce results that are in excellent agreement. These panels confirm the expression of this gene at low levels in the brain in an independent group of individuals. This gene appears to be slightly down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor may be of use in reversing the dementia, memory loss, and neuronal death associated with this disease.  
     [0966] General_screening_panel_v1.4 Summary: Ag3770 Highest expression of this gene is seen in a gastric cancer cell line (CT=26.7). This gene is widely expressed in this panel, with high to moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [0967] Among tissues with metabolic function, this gene is expressed at moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [0968] In addition, this gene is expressed at much higher levels in fetal lung tissue (CT=28.5) when compared to expression in the adult counterpart (CT=32). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue.  
     [0969] This gene is also expressed at moderate to low levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0970] Panel 1.3D Summary: Ag805 Highest expression is in fetal kidney (CT=29.2). This gene is widely expressed in this panel, with moderate to low expression in many samples on this panel. Please see Panel 1.4 for further discussion of expression and utility of this gene.  
     [0971] Panel 4.1D Summary: Ag805/Ag3770 Two experiments with different probe and primer sets are in good agreements with highest expression of this gene seen in activated secondary Th2 cells and 2 way MLR (CTs=27.6-28). This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0972] general oncology screening panel_v — 2.4 Summary: Ag3770 Highest expression is seen in a kidney cancer (CT=29.5). In addition, this gene is more highly expressed in lung, colon and kidney cancer than in the corresponding normal adjacent tissue. Prominent expression is seen in prostate cancer and melanoma as well. Thus, expression of this gene could be used as a marker of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of lung, colon, prostate, melanoma and kidney cancer.  
     [0973] AG. CG96334-02: DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION REGULATED KINASE 1A-Like Gene  
     [0974] Expression of gene CG96334-02 was assessed using the primer-probe set Ag7413, described in Table AGA. Results of the RTQ-PCR runs are shown in Tables AGB, AGC and AGD.  
               TABLE AGA                          Probe Name Ag7413                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-aagcatattaatgaggagtacaa   26   302   329           acc-3′       Probe   TET-5′-aggaacccgtaaacttcat   30   331   330           aacattcttgg-3′-TAMRA       Reverse   5′-ccaccaggtcctcctgttt-3′   19   366   331                  
 
     [0975]               TABLE AGB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag7413, Run           Tissue Name   305064633                                         AD 1 Hippo   15.9           AD 2 Hippo   13.1           AD 3 Hippo   6.8           AD 4 Hippo   5.8           AD 5 Hippo   100.0           AD 6 Hippo   36.3           Control 2 Hippo   25.9           Control 4 Hippo   14.0           Control (Path) 3 Hippo   11.7           AD 1 Temporal Ctx   18.8           AD 2 Temporal Ctx   41.5           AD 3 Temporal Ctx   3.6           AD 4 Temporal Ctx   13.9           AD 5 Inf Temporal Ctx   76.8           AD 5 Sup Temporal Ctx   28.5           AD 6 Inf Temporal Ctx   40.3           AD 6 Sup Temporal Ctx   43.2           Control 1 Temporal Ctx   3.8           Control 2 Temporal Ctx   51.8           Control 3 Temporal Ctx   12.5           Control 3 Temporal Ctx   11.3           Control (Path) 1 Temporal Ctx   33.0           Control (Path) 2 Temporal Ctx   31.4           Control (Path) 3 Temporal Ctx   4.8           Control (Path) 4 Temporal Ctx   25.0           AD 1 Occipital Ctx   16.6           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   5.2           AD 4 Occipital Ctx   13.2           AD 5 Occipital Ctx   45.4           AD 6 Occipital Ctx   21.9           Control 1 Occipital Ctx   3.0           Control 2 Occipital Ctx   55.9           Control 3 Occipital Ctx   15.0           Control 4 Occipital Ctx   6.2           Control (Path) 1 Occipital Ctx   73.7           Control (Path) 2 Occipital Ctx   6.4           Control (Path) 3 Occipital Ctx   3.5           Control (Path) 4 Occipital Ctx   12.4           Control 1 Parietal Ctx   5.8           Control 2 Parietal Ctx   26.8           Control 3 Parietal Ctx   23.2           Control (Path) 1 Parietal Ctx   92.0           Control (Path) 2 Parietal Ctx   11.2           Control (Path) 3 Parietal Ctx   1.9           Control (Path) 4 Parietal Ctx   27.5                        
     [0976]               TABLE AGC                          General_screening_panel_v1.6                                 Rel. Exp. (%)               Ag7413, Run           Tissue Name   306067377                                         Adipose   9.3           Melanoma* Hs688(A).T   15.3           Melanoma* Hs688(B).T   22.5           Melanoma* M14   38.2           Melanoma* LOXIMVI   35.6           Melanoma* SK-MEL-5   50.0           Squamous cell carcinoma SCC-4   11.4           Testis Pool   22.2           Prostate ca.* (bone met) PC-3   55.5           Prostate Pool   11.8           Placenta   11.4           Uterus Pool   5.4           Ovarian ca. OVCAR-3   46.0           Ovarian ca. SK-OV-3   42.9           Ovarian ca. OVCAR-4   11.3           Ovarian ca. OVCAR-5   25.2           Ovarian ca. IGROV-1   6.9           Ovarian ca. OVCAR-8   6.7           Ovary   11.9           Breast ca. MCF-7   24.7           Breast ca. MDA-MB-231   22.7           Breast ca. BT 549   55.1           Breast ca. T47D   30.6           Breast ca. MDA-N   12.5           Breast Pool   34.4           Trachea   24.3           Lung   10.4           Fetal Lung   77.9           Lung ca. NCI-N417   6.7           Lung ca. LX-1   34.2           Lung ca. NCI-H146   12.5           Lung ca. SHP-77   29.3           Lung ca. A549   21.2           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   36.9           Lung ca. NCI-H460   27.7           Lung ca. HOP-62   13.2           Lung ca. NCI-H522   37.9           Liver   0.0           Fetal Liver   37.6           Liver ca. HepG2   15.6           Kidney Pool   33.9           Fetal Kidney   48.6           Renal ca. 786-0   24.5           Renal ca. A498   15.2           Renal ca. ACHN   10.7           Renal ca. UO-31   16.8           Renal ca. TK-10   24.1           Bladder   18.7           Gastric ca. (liver met.) NCI-N87   3.1           Gastric ca. KATO III   40.9           Colon ca. SW-948   5.0           Colon ca. SW480   40.9           Colon ca.* (SW480 met) SW620   23.8           Colon ca. HT29   15.9           Colon ca. HCT-116   30.4           Colon ca. CaCo-2   49.7           Colon cancer tissue   12.9           Colon ca. SW1116   6.4           Colon ca. Colo-205   5.8           Colon ca. SW-48   0.0           Colon Pool   27.5           Small Intestine Pool   30.1           Stomach Pool   14.3           Bone Marrow Pool   12.2           Fetal Heart   46.3           Heart Pool   17.0           Lymph Node Pool   35.8           Fetal Skeletal Muscle   28.7           Skeletal Muscle Pool   10.2           Spleen Pool   8.6           Thymus Pool   26.6           CNS cancer (glio/astro) U87-MG   32.8           CNS cancer (glio/astro) U-118-MG   40.3           CNS cancer (neuro; met) SK-N-AS   47.0           CNS cancer (astro) SF-539   32.8           CNS cancer (astro) SNB-75   100.0           CNS cancer (glio) SNB-19   11.9           CNS cancer (glio) SF-295   71.2           Brain (Amygdala) Pool   7.9           Brain (cerebellum)   42.0           Brain (fetal)   36.6           Brain (Hippocampus) Pool   17.2           Cerebral Cortex Pool   20.6           Brain (Substantia nigra) Pool   11.3           Brain (Thalamus) Pool   26.6           Brain (whole)   30.6           Spinal Cord Pool   10.0           Adrenal Gland   24.5           Pituitary gland Pool   7.1           Salivary Gland   6.5           Thyroid (female)   2.4           Pancreatic ca. CAPAN2   15.5           Pancreas Pool   7.6                        
     [0977]               TABLE AGP                          Panel 4.1D                         Rel. Exp. (%)           Ag7413, Run       Tissue Name   305065274                             Secondary Th1 act   71.7       Secondary Th2 act   93.3       Secondary Tr1 act   36.6       Secondary Th1 rest   17.1       Secondary Th2 rest   28.7       Secondary Tr1 rest   12.9       Primary Th1 act   12.9       Primary Th2 act   68.8       Primary Tr1 act   56.3       Primary Th1 rest   6.8       Primary Th2 rest   10.6       Primary Tr1 rest   10.4       CD45RA CD4 lymphocyte act   58.6       CD45RO CD4 lymphocyte act   95.3       CD8 lymphocyte act   8.8       Secondary CD8 lymphocyte rest   47.3       Secondary CD8 lymphocyte act   7.6       CD4 lymphocyte none   28.1       2ry Th1/Th2/Tr1_anti-CD95 CH11   20.3       LAK cells rest   35.4       LAK cells IL-2   19.8       LAK cells IL-2 + IL-12   2.7       LAK cells IL-2 + IFN gamma   18.3       LAK cells IL-2 + IL-18   9.5       LAK cells PMA/ionomycin   65.1       NK Cells IL-2 rest   72.7       Two Way MLR 3 day   60.3       Two Way MLR 5 day   13.2       Two Way MLR 7 day   15.0       PBMC rest   22.8       PBMC PWM   13.4       PBMC PHA-L   21.5       Ramos (B cell) none   23.5       Ramos (B cell) ionomycin   41.8       B lymphocytes PWM   20.2       B lymphocytes CD40L and IL-4   56.3       EOL-1 dbcAMP   56.6       EOL-1 dbcAMP PMA/ionomycin   23.7       Dendritic cells none   28.3       Dendritic cells LPS   18.4       Dendritic cells anti-CD40   5.8       Monocytes rest   16.0       Monocytes LPS   68.3       Macrophages rest   11.8       Macrophages LPS   23.5       HUVEC none   27.9       HUVEC starved   30.6       HUVEC IL-1beta   35.1       HUVEC IFN gamma   31.9       HUVEC TNF alpha + IFN gamma   26.6       HUVEC TNF alpha + IL4   16.6       HUVEC IL-11   36.1       Lung Microvascular EC none   45.4       Lung Microvascular EC TNFalpha + IL-1beta   12.5       Microvascular Dermal EC none   16.0       Microsvasular Dermal EC TNFalpha + IL-1beta   7.8       Bronchial epithelium TNFalpha + IL1beta   17.6       Small airway epithelium none   4.0       Small airway epithelium TNFalpha + IL-1beta   21.3       Coronery artery SMC rest   16.4       Coronery artery SMC TNFalpha + IL-1beta   14.2       Astrocytes rest   9.9       Astrocytes TNFalpha + IL-1beta   22.8       KU-812 (Basophil) rest   60.3       KU-812 (Basophil) PMA/ionomycin   96.6       CCD1106 (Keratinocytes) none   32.3       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   16.0       Liver cirrhosis   27.2       NCI-H292 none   36.1       NCI-H292 IL-4   46.3       NCI-H292 IL-9   51.4       NCI-H292 IL-13   46.7       NCI-H292 IFN gamma   44.8       HPAEC none   15.7       HPAEC TNF alpha + IL-1 beta   34.2       Lung fibroblast none   37.6       Lung fibroblast TNF alpha + IL-1 beta   31.0       Lung fibroblast IL-4   19.1       Lung fibroblast IL-9   57.4       Lung fibroblast IL-13   9.2       Lung fibroblast IFN gamma   22.8       Dermal fibroblast CCD1070 rest   52.5       Dermal fibroblast CCD1070 TNF alpha   94.0       Dermal fibroblast CCD1070 IL-1 beta   21.8       Dermal fibroblast IFN gamma   25.9       Dermal fibroblast IL-4   36.1       Dermal Fibroblasts rest   25.7       Neutrophils TNFa + LPS   41.2       Neutrophils rest   100.0       Colon   14.6       Lung   8.4       Thymus   39.2       Kidney   49.3                    
     [0978] CNS_neurodegeneration_v1.0 Summary: Ag7413 This gene is expressed at low levels in the CNS. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [0979] General_screening_panel_v1.6 Summary: Ag7413 Detectable expression of this gene is limited to two brain cancer cell line samples. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of brain cancer.  
     [0980] Panel 4.1D Summary: Ag7413 Highest expression of this gene is seen in resting neutrophils (CT=32.9). Low but significant expression is seen in many samples on this panel, including samples derived from T cells, LAK cells, LPS stimulated monocytes and macrohpages, lung and dermal fibroblasts, and normal kidney and thymus. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of autoimmune and inflammatory diseases such as lupus erythematosus, asthma, emphysema, Crohn&#39;s disease, ulcerative colitis, rheumatoid arthritis, osteoarthritis, and psoriasis. In addition, small molecule or antibody antagonists of this gene product may be effective in increasing the immune response in patients with AIDS or other immunodeficiencies.  
     [0981] AH. CG96714-01: UDP-Galactose Transporter Related Isozyme 1-Like Gene  
     [0982] Expression of gene CG96714-01 was assessed using the primer-probe set Ag4074, described in Table AHA. Results of the RTQ-PCR runs are shown in Tables AHB and AHC.  
               TABLE AHA                          Probe Name Ag4074                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-aaggtaccctgccatcatctat-3′   22   789   332       Probe   TET-5′-acatcctgctctttgggctg   26   812   333           accagt-3′-TAMRA       Reverse   5′-caaccgtcataaagatgaagct-3′   22   850   334                  
 
     [0983]               TABLE AHB                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4074, Run           Tissue Name   218906368                                         Adipose   2.8           Melanoma* Hs688(A).T   13.7           Melanoma* Hs688(B).T   16.5           Melanoma* M14   19.8           Melanoma* LOXIMVI   29.9           Melanoma* SK-MEL-5   27.0           Squamous cell carcinoma SCC-4   18.6           Testis Pool   3.9           Prostate ca.* (bone met) PC-3   82.9           Prostate Pool   2.6           Placenta   5.6           Uterus Pool   1.1           Ovarian ca. OVCAR-3   31.0           Ovarian ca. SK-OV-3   27.4           Ovarian ca. OVCAR-4   11.0           Ovarian ca. OVCAR-5   48.6           Ovarian ca. IGROV-1   28.7           Ovarian ca. OVCAR-8   12.7           Ovary   2.5           Breast ca. MCF-7   23.7           Breast ca. MDA-MB-231   30.6           Breast ca. BT 549   8.0           Breast ca. T47D   100.0           Breast ca. MDA-N   5.6           Breast Pool   0.0           Trachea   7.6           Lung   1.3           Fetal Lung   8.5           Lung ca. NCI-N417   5.2           Lung ca. LX-1   14.2           Lung ca. NCI-H146   9.3           Lung ca. SHP-77   25.9           Lung ca. A549   29.1           Lung ca. NCI-H526   8.4           Lung ca. NCI-H23   18.6           Lung ca. NCI-H460   21.9           Lung ca. HOP-62   15.9           Lung ca. NCI-H522   34.9           Liver   2.7           Fetal Liver   11.7           Liver ca. HepG2   12.2           Kidney Pool   4.8           Fetal Kidney   7.7           Renal ca. 786-0   6.7           Renal ca. A498   5.9           Renal ca. ACHN   9.8           Renal ca. UO-31   10.7           Renal ca. TK-10   20.2           Bladder   10.8           Gastric ca. (liver met.) NCI-N87   38.7           Gastric ca. KATO III   62.9           Colon ca. SW-948   12.2           Colon ca. SW480   16.6           Colon ca.* (SW480 met) SW620   16.0           Colon ca. HT29   9.2           Colon ca. HCT-116   55.5           Colon ca. CaCo-2   71.7           Colon cancer tissue   11.0           Colon ca. SW1116   6.1           Colon ca. Colo-205   11.5           Colon ca. SW-48   6.3           Colon Pool   4.3           Small Intestine Pool   3.1           Stomach Pool   2.6           Bone Marrow Pool   1.9           Fetal Heart   7.5           Heart Pool   3.2           Lymph Node Pool   4.4           Fetal Skeletal Muscle   4.9           Skeletal Muscle Pool   9.0           Spleen Pool   3.1           Thymus Pool   4.3           CNS cancer (glio/astro) U87-MG   43.8           CNS cancer (glio/astro) U-118-MG   25.5           CNS cancer (neuro; met) SK-N-AS   30.6           CNS cancer (astro) SF-539   16.4           CNS cancer (astro) SNB-75   21.3           CNS cancer (glio) SNB-19   25.3           CNS cancer (glio) SF-295   44.1           Brain (Amygdala) Pool   4.9           Brain (cerebellum)   9.4           Brain (fetal)   6.3           Brain (Hippocampus) Pool   4.5           Cerebral Cortex Pool   5.8           Brain (Substantia nigra) Pool   5.4           Brain (Thalamus) Pool   7.2           Brain (whole)   0.0           Spinal Cord Pool   3.8           Adrenal Gland   5.6           Pituitary gland Pool   3.6           Salivary Gland   5.2           Thyroid (female)   6.3           Pancreatic ca. CAPAN2   6.4           Pancreas Pool   3.9                        
     [0984]               TABLE AHC                          Panel 5D                         Rel. Exp. (%)           Ag4074, Run       Tissue Name   172166872                             97457_Patient-02go_adipose   15.4       97476_Patient-07sk_skeletal muscle   9.3       97477_Patient-07ut_uterus   10.7       97478_Patient-07pl_placenta   36.3       97481_Patient-08sk_skeletal muscle   8.8       97482_Patient-08ut_uterus   8.4       97483_Patient-08pl_placenta   43.5       97486_Patient-09sk_skeletal muscle   7.9       97487_Patient-09ut_uterus   8.5       97488_Patient-09pl_placenta   16.5       97492_Patient-10ut_uterus   14.2       97493_Patient-10pl_placenta   58.6       97495_Patient-11go_adipose   8.8       97496_Patient-11sk_skeletal muscle   29.5       97497_Patient-11ut_uterus   17.1       97498_Patient-11pl_placenta   39.5       97500_Patient-12go_adipose   17.9       97501_Patient-12sk_skeletal muscle   72.7       97502_Patient-12ut_uterus   17.6       97503_Patient-12pl_placenta   26.4       94721_Donor 2 U - A_Mesenchymal Stem Cells   36.6       94722_Donor 2 U - B_Mesenchymal Stem Cells   22.5       94723_Donor 2 U - C_Mesenchymal Stem Cells   27.5       94709_Donor 2 AM - A_adipose   100.0       94710_Donor 2 AM - B_adipose   62.4       94711_Donor 2 AM - C_adipose   39.8       94712_Donor 2 AD - A_adipose   37.9       94713_Donor 2 AD - B_adipose   58.2       94714_Donor 2 AD - C adipose   42.9       94742_Donor 3 U - A_Mesenchymal Stem Cells   27.4       94743_Donor 3 U - B_Mesenchymal Stem Cells   24.5       94730_Donor 3 AM - A_adipose   88.3       94731_Donor 3 AM - B_adipose   45.1       94732_Donor 3 AM - C_adipose   60.7       94733_Donor 3 AD - A_adipose   88.3       94734_Donor 3 AD - B_adipose   43.2       94735_Donor 3 AD - C_adipose   79.6       77138_Liver_HepG2untreated   93.3       73556_Heart_Cardiac stromal cells (primary)   40.3       81735_Small Intestine   23.7       72409_Kidney_Proximal Convoluted Tubule   19.2       82685_Small intestine_Duodenum   40.6       90650_Adrenal_Adrenocortical adenoma   10.4       72410_Kidney_HRCE   49.3       72411_Kidney_HRE   49.0       73139_Uterus_Uterine smooth muscle cells   21.9                    
     [0985] General_screening_panel_v1.4 Summary: Ag4074 Highest expression of this gene is detected in breast cancer T47D cell line (CT=26). High levels of expression of this gene is also seen in cluster of cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0986] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0987] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0988] Panel 5D Summary: Ag4074 Highest expression of this gene is detected in adipose (CT-30). Consistent with expression seen in panel 1.4, this gene shows ubiquitous expression in this panel. Please see panel 1.4 for further discussion on the utility of this gene.  
     [0989] AI. CG97025-01: HMG-CoA Synthase-Like Gene  
     [0990] Expression of gene CG97025-01 was assessed using the primer-probe set Ag4087, described in Table AIA. Results of the RTQ-PCR runs are shown in Tables AIB, AIC, AID, AIE, AIF, AIG and AIH.  
               TABLE AIA                          Probe Name Ag4087                                             Start           Primers   Sequences   Length   Position   SEQ ID No               Forward   5′-ttcagtatatggttcccttgca-3′   22   1062   335       Probe   TET-5′-tgttctagcacagtactcac   27   1086   336           ctcagca-3′-TAMRA       Reverse   5′-actccaattctcttccctgcta-3′   22   1115   337                  
 
     [0991]               TABLE AIB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)               Ag4087, Run           Tissue Name   214295439                                         AD 1 Hippo   8.4           AD 2 Hippo   19.2           AD 3 Hippo   2.3           AD 4 Hippo   4.7           AD 5 hippo   38.2           AD 6 Hippo   100.0           Control 2 Hippo   27.2           Control 4 Hippo   8.7           Control (Path) 3 Hippo   2.8           AD 1 Temporal Ctx   5.7           AD 2 Temporal Ctx   27.5           AD 3 Temporal Ctx   2.2           AD 4 Temporal Ctx   17.9           AD 5 Inf Temporal Ctx   54.0           AD 5 Sup Temporal Ctx   13.5           AD 6 Inf Temporal Ctx   72.7           AD 6 Sup Temporal Ctx   87.7           Control 1 Temporal Ctx   3.4           Control 2 Temporal Ctx   25.9           Control 3 Temporal Ctx   10.2           Control 4 Temporal Ctx   5.8           Control (Path) 1 Temporal Ctx   54.0           Control (Path) 2 Temporal Ctx   49.7           Control (Path) 3 Temporal Ctx   2.3           Control (Path) 4 Temporal Ctx   23.0           AD 1 Occipital Ctx   5.5           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   2.5           AD 4 Occipital Ctx   15.6           AD 5 Occipital Ctx   50.7           AD 6 Occipital Ctx   22.5           Control 1 Occipital Ctx   1.4           Control 2 Occipital Ctx   29.9           Control 3 Occipital Ctx   10.0           Control 4 Occipital Ctx   4.2           Control (Path) 1 Occipital Ctx   82.4           Control (Path) 2 Occipital Ctx   10.6           Control (Path) 3 Occipital Ctx   1.1           Control (Path) 4 Occipital Ctx   9.2           Control 1 Parietal Ctx   3.5           Control 2 Parietal Ctx   18.7           Control 3 Parietal Ctx   14.7           Control (Path) 1 Parietal Ctx   72.2           Control (Path) 2 Parietal Ctx   23.2           Control (Path) 3 Parietal Ctx   1.8           Control (Path) 4 Parietal Ctx   23.2                        
     [0992]               TABLE AIC                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4087, Run           Tissue Name   219430028                                         Adipose   2.3           Melanoma* Hs688(A).T   3.2           Melanoma* Hs688(B).T   8.8           Melanoma* M14   18.6           Melanoma* LOXIMVI   4.4           Melanoma* SK-MEL-5   21.6           Squamous cell carcinoma SCC-4   39.5           Testis Pool   6.2           Prostate ca.* (bone met) PC-3   6.8           Prostate Pool   0.6           Placenta   1.3           Uterus Pool   2.0           Ovarian ca. OVCAR-3   80.7           Ovarian ca. SK-OV-3   26.6           Ovarian ca. OVCAR-4   7.1           Ovarian ca. OVCAR-5   31.4           Ovarian ca. IGROV-1   58.6           Ovarian ca. OVCAR-8   3.5           Ovary   11.4           Breast ca. MCF-7   17.9           Breast ca. MDA-MB-231   12.9           Breast ca. BT 549   38.7           Breast ca. T47D   55.9           Breast ca. MDA-N   7.9           Breast Pool   2.4           Trachea   3.8           Lung   1.2           Fetal Lung   9.9           Lung ca. NCI-N417   22.4           Lung ca. LX-1   16.8           Lung ca. NCI-H146   28.5           Lung ca. SHP-77   36.6           Lung ca. A549   25.2           Lung ca. NCI-H526   25.7           Lung ca. NCI-H23   16.7           Lung ca. NCI-H460   4.5           Lung ca. HOP-62   23.0           Lung ca. NCI-H522   9.2           Liver   1.3           Fetal Liver   100.0           Liver ca. HepG2   50.7           Kidney Pool   6.0           Fetal Kidney   8.8           Renal ca. 786-0   31.0           Renal ca. A498   4.1           Renal ca. ACHN   20.9           Renal ca. UO-31   18.6           Renal ca. TK-10   24.7           Bladder   17.6           Gastric ca. (liver met.) NCI-N87   23.3           Gastric ca. KATO III   79.6           Colon ca. SW-948   14.2           Colon ca. SW480   10.7           Colon ca.* (SW480 met) SW620   9.5           Colon ca. HT29   20.4           Colon ca. HCT-116   24.8           Colon ca. CaCo-2   63.3           Colon cancer tissue   5.0           Colon ca. SW1116   3.3           Colon ca. Colo-205   10.2           Colon ca. SW-48   7.9           Colon Pool   2.8           Small Intestine Pool   3.2           Stomach Pool   2.7           Bone Marrow Pool   1.2           Fetal Heart   4.1           Heart Pool   1.5           Lymph Node Pool   2.9           Fetal Skeletal Muscle   0.2           Skeletal Muscle Pool   2.4           Spleen Pool   4.4           Thymus Pool   3.3           CNS cancer (glio/astro) U87-MG   10.4           CNS cancer (glio/astro) U-118-MG   8.7           CNS cancer (neuro; met) SK-N-AS   19.3           CNS cancer (astro) SF-539   42.9           CNS cancer (astro) SNB-75   26.1           CNS cancer (glio) SNB-19   51.8           CNS cancer (glio) SF-295   11.4           Brain (Amygdala) Pool   11.3           Brain (cerebellum)   3.3           Brain (fetal)   52.5           Brain (Hippocampus) Pool   17.7           Cerebral Cortex Pool   17.8           Brain (Substantia nigra) Pool   15.9           Brain (Thalamus) Pool   26.2           Brain (whole)   14.9           Spinal Cord Pool   13.2           Adrenal Gland   23.0           Pituitary gland Pool   1.2           Salivary Gland   0.8           Thyroid (female)   2.1           Pancreatic ca. CAPAN2   56.6           Pancreas Pool   4.9                        
     [0993]               TABLE AID                          Panel 3D                         Rel. Exp. (%)           Ag4087, Run       Tissue Name   184795547                             Daoy- Medulloblastoma   3.3       TE671- Medulloblastoma   8.3       D283 Med- Medulloblastoma   10.4       PFSK-1- Primitive Neuroectodermal   4.9       XF-498- CNS   4.4       SNB-78- Glioma   4.8       SF-268- Glioblastoma   4.1       T98G- Glioblastoma   6.9       SK-N-SH- Neuroblastoma (metastasis)   2.0       SF-295- Glioblastoma   2.1       Cerebellum   5.8       Cerebellum   1.7       NCI-H292- Mucoepidermoid lung carcinoma   13.9       DMS-114- Small cell lung cancer   4.5       DMS-79- Small cell lung cancer   100.0       NCI-H146- Small cell lung cancer   57.0       NCI-H526- Small cell lung cancer   54.3       NCI-N417- Small cell lung cancer   34.9       NCI-H82- Small cell lung cancer   10.9       NCI-H157- Squamous cell lung cancer (metastasis)   2.4       NCI-H1155- Large cell lung cancer   7.9       NCI-H1299- Large cell lung cancer   4.1       NCI-H727- Lung carcinoid   11.2       NCI-UMC-11- Lung carcinoid   76.8       LX-1- Small cell lung cancer   13.0       Colo-205- Colon cancer   17.4       KM12- Colon cancer   9.1       KM20L2- Colon cancer   5.6       NCI-H716- Colon cancer   10.6       SW-48- Colon adenocarcinoma   7.5       SW1116- Colon adenocarcinoma   2.4       LS 174T- Colon adenocarcinoma   11.4       SW-948- Colon adenocarcinoma   1.0       SW-480- Colon adenocarcinoma   6.7       NCI-SNU-5- Gastric carcinoma   1.2       KATO III- Gastric carcinoma   28.3       NCI-SNU-16- Gastric carcinoma   1.7       NCI-SNU-1- Gastric carcinoma   70.2       RF-1- Gastric adenocarcinoma   11.5       RF-48- Gastric adenocarcinoma   8.5       MKN-45- Gastric carcinoma   11.4       NCI-N87- Gastric carcinoma   8.6       OVCAR-5- Ovarian carcinoma   1.5       RL95-2- Uterine carcinoma   2.2       HelaS3- Cervical adenocarcinoma   1.2       Ca Ski- Cervical epidermoid carcinoma   26.2       (metastasis)       ES-2- Ovarian clear cell carcinoma   1.5       Ramos- Stimulated with PMA/ionomycin 6 h   37.9       Ramos- Stimulated with PMA/ionomycin 14 h   24.8       MEG-01- Chronic myelogenous leukemia   10.1       (megokaryoblast)       Raji- Burkitt&#39;s lymphoma   6.7       Daudi- Burkitt&#39;s lymphoma   22.5       U266- B-cell plasmacytoma   9.6       CA46- Burkitt&#39;s lymphoma   10.4       RL- non-Hodgkin&#39;s B-cell lymphoma   7.5       JM1- pre-B-cell lymphoma   7.1       Jurkat- T cell leukemia   37.4       TF-1- Erythroleukemia   31.6       HUT 78- T-cell lymphoma   5.3       U937- Histiocytic lymphoma   5.3       KU-812- Myelogenous leukemia   20.4       769-P- Clear cell renal carcinoma   4.5       Caki-2- Clear cell renal carcinoma   5.7       SW 839- Clear cell renal carcinoma   4.6       G401- Wilms&#39; tumor   5.0       Hs766T- Pancreatic carcinoma (LN metastasis)   2.6       CAPAN-1- Pancreatic adenocarcinoma   17.0       (liver metastasis)       SU86.86- Pancreatic carcinoma (liver metastasis)   20.0       BxPC-3- Pancreatic adenocarcinoma   15.0       HPAC- Pancreatic adenocarcinoma   80.1       MIA PaCa-2- Pancreatic carcinoma   1.2       CFPAC-1- Pancreatic ductal adenocarcinoma   24.7       PANC-1- Pancreatic epithelioid ductal carcinoma   4.2       T24- Bladder carcinma (transitional cell)   4.2       5637- Bladder carcinoma   6.0       HT-1197- Bladder carcinoma   14.8       UM-UC-3- Bladder carcinma (transitional cell)   1.8       A204- Rhabdomyosarcoma   0.9       HT-1080- Fibrosarcoma   9.3       MG-63- Osteosarcoma   2.6       SK-LMS-1- Leiomyosarcoma (vulva)   6.3       SJRH30- Rhabdomyosarcoma (met to bone marrow)   5.1       A431- Epidermoid carcinoma   6.9       WM266-4- Melanoma   1.0       DU 145- Prostate carcinoma (brain metastasis)   0.7       MDA-MB-468- Breast adenocarcinoma   9.8       SCC-4- Squamous cell carcinoma of tongue   1.6       SCC-9- Squamous cell carcinoma of tongue   0.2       SCC-15- Squamous cell carcinoma of tongue   0.5       CAL 27- Squamous cell carcinoma of tongue   7.5                    
     [0994]               TABLE AIE                          Panel 4.1D                         Rel. Exp. (%)           Ag4087, Run       Tissue Name   184793001                             Secondary Th1 act   34.2       Secondary Th2 act   32.8       Secondary Tr1 act   27.0       Secondary Th1 rest   10.0       Secondary Th2 rest   13.4       Secondary Tr1 rest   10.3       Primary Th1 act   26.6       Primary Th2 act   68.8       Primary Tr1 act   66.9       Primary Th1 rest   8.2       Primary Th2 rest   2.7       Primary Tr1 rest   10.7       CD45RA CD4 lymphocyte act   24.1       CD45RO CD4 lymphocyte act   55.5       CD8 lymphocyte act   33.0       Secondary CD8 lymphocyte rest   37.1       Secondary CD8 lymphocyte act   15.6       CD4 lymphocyte none   1.4       2ry Th1/Th2/Tr1_anti-CD95 CH11   8.1       LAK cells rest   32.3       LAK cells IL-2   40.3       LAK cells IL-2 + IL-12   11.7       LAK cells IL-2 + IFN gamma   10.5       LAK cells IL-2 + IL-18   13.3       LAK cells PMA/ionomycin   83.5       NK Cells IL-2 rest   33.7       Two Way MLR 3 day   10.9       Two Way MLR 5 day   10.6       Two Way MLR 7 day   10.7       PBMC rest   2.0       PBMC PWM   27.0       PBMC PHA-L   19.6       Ramos (B cell) none   45.1       Ramos (B cell) ionomycin   68.8       B lymphocytes PWM   25.2       B lymphocytes CD40L and IL-4   22.1       EOL-1 dbcAMP   8.4       EOL-1 dbcAMP PMA/ionomycin   18.4       Dendritic cells none   28.9       Dendritic cells LPS   20.9       Dendritic cells anti-CD40   7.5       Monocytes rest   4.0       Monocytes LPS   26.4       Macrophages rest   13.0       Macrophages LPS   5.8       HUVEC none   19.3       HUVEC starved   34.6       HUVEC IL-1beta   27.0       HUVEC IFN gamma   21.0       HUVEC TNF alpha + IFN gamma   20.2       HUVEC TNF alpha + IL4   17.9       HUVEC IL-11   12.8       Lung Microvascular EC none   23.3       Lung Microvascular EC TNFalpha + IL-1beta   19.9       Microvascular Dermal EC none   5.1       Microsvasular Dermal EC TNFalpha + IL-1beta   11.1       Bronchial epithelium TNFalpha + IL1beta   40.9       Small airway epithelium none   16.0       Small airway epithelium TNFalpha + IL-1beta   100.0       Coronery artery SMC rest   2.5       Coronery artery SMC TNFalpha + IL-1beta   3.7       Astrocytes rest   4.3       Astrocytes TNFalpha + IL-1beta   5.5       KU-812 (Basophil) rest   39.8       KU-812 (Basophil) PMA/ionomycin   95.3       CCD1106 (Keratinocytes) none   79.6       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   59.0       Liver cirrhosis   4.8       NCI-H292 none   10.2       NCI-H292 IL-4   12.5       NCI-H292 IL-9   18.4       NCI-H292 IL-13   14.8       NCI-H292 IFN gamma   9.2       HPAEC none   4.8       HPAEC TNF alpha + IL-1 beta   24.5       Lung fibroblast none   17.7       Lung fibroblast TNF alpha + IL-1 beta   3.9       Lung fibroblast IL-4   18.3       Lung fibroblast IL-9   20.2       Lung fibroblast IL-13   11.7       Lung fibroblast IFN gamma   10.0       Dermal fibroblast CCD1070 rest   4.4       Dermal fibroblast CCD1070 TNF alpha   19.6       Dermal fibroblast CCD1070 IL-1 beta   3.7       Dermal fibroblast IFN gamma   6.7       Dermal fibroblast IL-4   30.4       Dermal Fibroblasts rest   13.9       Neutrophils TNFa + LPS   3.3       Neutrophils rest   1.4       Colon   2.6       Lung   4.0       Thymus   4.0       Kidney   5.3                    
     [0995]               TABLE AIF                          Panel 5 Islet                         Rel.Exp. (%)           Ag4087, Run       Tissue Name   186511156                             97457_Patient-02go_adipose   1.8       97476_Patient-07sk_skeletal muscle   2.3       97477_Patient-07ut_uterus   3.6       97478_Patient-07pl_placenta   5.5       99167_Bayer Patient 1   13.8       97482_Patient-08ut_uterus   1.3       97483_Patient-08pl_placenta   4.5       97486_Patient-09sk_skeletal muscle   0.4       97487_Patient-09ut_uterus   3.0       97488_Patient-09pl_placenta   3.5       97492_Patient-10ut_uterus   2.7       97493_Patient-10pl_placenta   12.6       97495_Patient-11go_adipose   2.2       97496_Patient-11sk_skeletal muscle   2.9       97497_Patient-11ut_uterus   4.5       97498_Patient-11pl_placenta   3.3       97500_Patient-12go_adipose   5.2       97501_Patient-12sk_skeletal muscle   6.2       97502_Patient-12ut_uterus   4.7       97503_Patient-12pl_placenta   6.2       94721_Donor 2 U - A_Mesenchymal Stem Cells   7.9       94722_Donor 2 U - B_Mesenchymal Stem Cells   5.0       94723_Donor 2 U - C_Mesenchymal Stem Cells   9.5       94709_Donor 2 AM - A_adipose   10.6       94710_Donor 2 AM - B_adipose   7.2       94711_Donor 2 AM - C_adipose   2.6       94712_Donor 2 AD - A_adipose   14.0       94713_Donor 2 AD - B_adipose   13.7       94714_Donor 2 AD - C_adipose   14.8       94742_Donor 3 U - A_Mesenchymal Stem Cells   7.2       94743_Donor 3 U - B_Mesenchymal Stem Cells   8.5       94730_Donor 3 AM - A_adipose   12.9       94731_Donor 3 AM - B_adipose   7.9       94732_Donor 3 AM - C_adipose   7.7       94733_Donor 3 AD - A_adipose   28.9       94734_Donor 3 AD - B_adipose   5.6       94735_Donor 3 AD - C_adipose   23.8       77138_Liver_HepG2untreated   100.0       73556_Heart_Cardiac stromal cells (primary)   2.9       81735_Small Intestine   10.3       72409_Kidney_Proximal Convoluted Tubule   8.8       82685_Small intestine_Duodenum   1.8       90650_Adrenal_Adrenocortical adenoma   10.2       72410_Kidney_HRCE   42.6       72411_Kidney_HRE   38.2       73139_Uterus_Uterine smooth muscle cells   4.7                    
     [0996]               TABLE AIG                          Panel 5D                         Rel. Exp. (%)           Ag4087, Run       Tissue Name   172774941                             97457_Patient-02go_adipose   1.7       97476_Patient-07sk_skeletal muscle   2.1       97477_Patient-07ut_uterus   1.2       97478_Patient-07pl_placenta   4.4       97481_Patient-08sk_skeletal muscle   1.9       97482_Patient-08ut_uterus   1.9       97483_Patient-08pl_placenta   2.6       97486_Patient-09sk_skeletal muscle   0.8       97487_Patient-09ut_uterus   2.0       97488_Patient-09pl_placenta   3.1       97492_Patient-10ut_uterus   1.6       97493_Patient-10pl_placenta   8.5       97495_Patient-11go_adipose   2.1       97496_Patient-11sk_skeletal muscle   2.2       97497_Patient-11ut_uterus   3.5       97498_Patient-11pl_placenta   4.4       97500_Patient-12go_adipose   3.3       97501_Patient-12sk_skeletal muscle   3.5       97502_Patient-12ut_uterus   3.6       97503_Patient-12pl_placenta   4.5       94721_Donor 2 U - A_Mesenchymal Stem Cells   7.4       94722_Donor 2 U - B_Mesenchymal Stem Cells   5.5       94723_Donor 2 U - C_Mesenchymal Stem Cells   4.7       94709_Donor 2 AM - A_adipose   11.1       94710_Donor 2 AM - B_adipose   4.7       94711_Donor 2 AM - C_adipose   4.3       94712_Donor 2 AD - A_adipose   9.1       94713_Donor 2 AD - B_adipose   16.0       94714_Donor 2 AD - C_adipose   12.2       94742_Donor 3 U - A_Mesenchymal Stem Cells   5.6       94743_Donor 3 U - B_Mesenchymal Stem Cells   6.0       94730_Donor 3 AM - A_adipose   9.5       94731_Donor 3 AM - B_adipose   5.9       94732_Donor 3 AM - C_adipose   7.0       94733_Donor 3 AD - A_adipose   23.7       94734_Donor 3 AD - B_adipose   11.6       94735_Donor 3 AD - C_adipose   14.7       77138_Liver_HepG2untreated   100.0       73556_Heart_Cardiac stromal cells (primary)   1.3       81735_Small Intestine   4.1       72409_Kidney_Proximal Convoluted Tubule   4.7       82685_Small intestine_Duodenum   9.1       90650_Adrenal_Adrenocortical adenoma   5.7       72410_Kidney_HRCE   22.1       72411_Kidney_HRE   34.9       73139_Uterus_Uterine smooth muscle cells   4.2                    
     [0997]               TABLE AIH                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag4087, Run           Tissue Name   268389980                                         Colon cancer 1   50.0           Colon NAT 1   16.2           Colon cancer 2   26.8           Colon NAT 2   11.3           Colon cancer 3   52.1           Colon NAT 3   31.6           Colon malignant cancer 4   81.8           Colon NAT 4   12.1           Lung cancer 1   12.6           Lung NAT 1   1.2           Lung cancer 2   95.9           Lung NAT 2   2.2           Squamous cell carcinoma 3   66.0           Lung NAT 3   5.4           Metastatic melanoma 1   11.3           Melanoma 2   8.1           Melanoma 3   10.3           Metastatic melanoma 4   40.1           Metastatic melanoma 5   31.0           Bladder cancer 1   1.1           Bladder NAT 1   0.0           Bladder cancer 2   1.6           Bladder NAT 2   0.3           Bladder NAT 3   0.3           Bladder NAT 4   2.2           Prostate adenocarcinoma 1   14.6           Prostate adenocarcinoma 2   2.1           Prostate adenocarcinoma 3   12.1           Prostate adenocarcinoma 4   19.6           Prostate NAT 5   3.7           Prostate adenocarcinoma 6   3.2           Prostate adenocarcinoma 7   4.7           Prostate adenocarcinoma 8   2.7           Prostate adenocarcinoma 9   14.3           Prostate NAT 10   1.8           Kidney cancer 1   15.7           Kidney NAT 1   10.2           Kidney cancer 2   100.0           Kidney NAT 2   23.8           Kidney cancer 3   15.1           Kidney NAT 3   5.1           Kidney cancer 4   14.1           Kidney NAT 4   8.2                        
     [0998] CNS_neurodegeneration_v1.0 Summary: Ag4087 This panel does not show differential expression of this gene in Alzheimer&#39;s disease. However, this profile confirms the expression of this gene at high to moderate levels in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.  
     [0999] General_screening_panel_v1.4 Summary: Ag4087 Highest expression of this gene is seen in fetal liver (CT=22.8). In addition, this gene is expressed at higher levels in fetal lung(CT=26) when compared to expression in the adult counterparts (CTs=29). Conversely, this gene is more highly expressed in skeletal muscle (CT=28) when compared to expression in the fetal tissue (CT=32). Thus, expression of this gene could be used to differentiate between the fetal and adult sources of these tissues.  
     [1000] This gene is widely expressed in this panel, with high levels of expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.  
     [1001] Among tissues with metabolic function, this gene is expressed at high to moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1002] This gene codes for cytosolic HMG CoA synthase. Using CuraGen&#39;s GeneCalling TM method of differential gene expression, expression of this gene was found to be up-regulated in two different rodent models of obesity. HMG CoA synthase is an enzyme in the cholesterol biosynthetic pathway and provides substrate for production of LXR alpha activators (ligands). LXRalpha is a nuclear receptor that is abundantly expressed in tissues associated with lipid metabolism. Under high cholesterol conditions, LXR alpha is activated. It in turn, up-regulates transcription of sterol regulatory element-binding protein 1c, the master regulator of genes involved in fatty acid synthesis. Increased production of LXRalpha ligands may lead to increased fatty acid synthesis and triglyceride formation and an increase in adipose mass. Therefore, therapeutic modulation of this gene may be useful in the treatment of obesity.  
     [1003] This gene is also expressed at high levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1004] Panel 3D Summary: Ag4087 Highest expression is seen in a lung cancer cell line (CT=26) with high to moderate levels of expression in all samples on this panel. This expression is in agreement with expression in 1.4.  
     [1005] Panel 4.1D Summary: Ag4087 Highest expression is seen in TNF-a and IL-1 beta treated small airway epithelium (CT=26). This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1006] Panel 5 Islet Summary: Ag4087 Highest expression is seen in a liver cell line (CT=27.8). In addition this cytosolic HMG CoA synthase has widespread tissue expression including adipose, skeletal muscle, and islets of Langerhans. Recently, it has been shown that upregulation of HMG CoA synthase is associated with the insulin secretory response of islet beta cells to high glucose (Flamez et al., 2002, Diabetes 51(7):2018-24, PMID: 12086928). Thus, pharmacologic activation of this gene may be a treatment to enhance insulin secretion in Type 2 diabetes.  
     [1007] Panel 5D Summary: Ag4087 Highest expression is seen in a liver cell line (CT=27.5). In addition this cytosolic HMG CoA synthase has widespread tissue expression including adipose, skeletal muscle, and islets of Langerhans.  
     [1008] general oncology screening panel_v — 2.4 Summary: AG4087 Highest expression is seen in a kidney cancer (CT=27). ). In addition, this gene is more highly expressed in lung and colon cancer than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of lung, colon and kidney cancer.  
     [1009] 5 AJ. CG97955-03: Carboxypeptidase A1  
     [1010] Expression of full-length physical clone CG97955-03 was assessed using the primer-probe set Ag4135, described in Table AJA. Results of the RTQ-PCR runs are shown in Tables AJB, AJC and AJD.  
               TABLE AJA                          Probe Name Ag4135                                             Start   SEQ       Primers   Sequences   Length   Position   ID No                                         Forward   5&#39;-ccctggaggagat-   22   393   338           ctatgactt-3&#39;       Probe   TET-5&#39;-agaacccgc-   25   435   339           accttgtc           agcaagat-3&#39;-TAMRA       Reverse   5&#39;-cttcataggtgtt-   22   461   340           gccaatctg-3&#39;                  
 
     [1011]               TABLE AJB                          General_screening_panel_v1.4                                 Rel. Exp. (%)               Ag4135, Run           Tissue Name   220967144                                         Adipose   0.0           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.0           Testis Pool   0.0           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.0           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   0.0           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.0           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   0.0           Ovary   0.0           Breast ca. MCF-7   0.0           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   0.0           Breast ca. T47D   0.0           Breast ca. MDA-N   0.0           Breast Pool   0.0           Trachea   0.0           Lung   0.0           Fetal Lung   0.0           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.0           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   0.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.0           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.0           Liver   0.0           Fetal Liver   1.8           Liver ca. HepG2   0.0           Kidney Pool   0.0           Fetal Kidney   0.0           Renal ca. 786-0   0.0           Renal ca. A498   0.0           Renal ca. ACHN   0.0           Renal ca. UO-31   0.0           Renal ca. TK-10   0.0           Bladder   85.3           Gastric ca. (liver met.) NCI-N87   0.0           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.0           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   0.0           Colon cancer tissue   0.0           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   0.0           Small Intestine Pool   0.0           Stomach Pool   0.0           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   0.0           Lymph Node Pool   0.0           Fetal Skeletal Muscle   0.0           Skeletal Muscle Pool   0.0           Spleen Pool   0.0           Thymus Pool   0.0           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   0.0           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.0           Brain (Amygdala) Pool   0.0           Brain (cerebellum)   0.0           Brain (fetal)   0.0           Brain (Hippocampus) Pool   0.0           Cerebral Cortex Pool   0.0           Brain (Substantia nigra) Pool   0.0           Brain (Thalamus) Pool   0.0           Brain (whole)   0.0           Spinal Cord Pool   0.0           Adrenal Gland   0.0           Pituitary gland Pool   0.0           Salivary Gland   0.0           Thyroid (female)   0.0           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   100.0                        
     [1012]               TABLE AJC                          Panel 4.1D                         Rel. Exp. (%)           Ag4135, Run       Tissue Name   172859879                             Secondary Th1 act   0.0       Secondary Th2 act   0.0       Secondary Tr1 act   0.0       Secondary Th1 rest   0.0       Secondary Th2 rest   0.0       Secondary Tr1 rest   0.0       Primary Th1 act   0.0       Primary Th2 act   0.0       Primary Tr1 act   0.0       Primary Th1 rest   3.1       Primary Th2 rest   0.0       Primary Tr1 rest   0.0       CD45RA CD4 lymphocyte act   0.0       CD45RO CD4 lymphocyte act   0.0       CD8 lymphocyte act   0.0       Secondary CD8 lymphocyte rest   0.0       Secondary CD8 lymphocyte act   0.0       CD4 lymphocyte none   0.0       2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0       LAK cells rest   0.0       LAK cells IL-2   0.0       LAK cells IL-2 + IL-12   0.0       LAK cells IL-2 + IFN gamma   0.0       LAK cells IL-2 + IL-18   0.0       LAK cells PMA/ionomycin   0.0       NK Cells IL-2 rest   0.0       Two Way MLR 3 day   0.0       Two Way MLR 5 day   0.0       Two Way MLR 7 day   0.0       PBMC rest   0.0       PBMC PWM   0.0       PBMC PHA-L   0.0       Ramos (B cell) none   0.0       Ramos (B cell) ionomycin   0.0       B lymphocytes PWM   0.0       B lymphocytes CD40L and IL-4   0.0       EOL-1 dbcAMP   0.0       EOL-1 dbcAMP PMA/ionomycin   0.0       Dendritic cells none   0.0       Dendritic cells LPS   0.0       Dendritic cells anti-CD40   0.0       Monocytes rest   0.0       Monocytes LPS   0.0       Macrophages rest   0.0       Macrophages LPS   0.0       HUVEC none   0.0       HUVEC starved   0.0       HUVEC IL-1beta   0.0       HUVEC IFN gamma   0.0       HUVEC TNF alpha + IFN gamma   0.0       HUVEC TNF alpha + IL4   0.0       HUVEC IL-11   0.0       Lung Microvascular EC none   0.0       Lung Microvascular EC TNFalpha + IL-1beta   0.0       Microvascular Dermal EC none   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   0.0       Bronchial epithelium TNFalpha + IL1beta   0.0       Small airway epithelium none   0.0       Small airway epithelium TNFalpha + IL-1beta   0.0       Coronery artery SMC rest   0.0       Coronery artery SMC TNFalpha + IL-1beta   0.0       Astrocytes rest   2.8       Astrocytes TNFalpha + IL-1beta   2.8       KU-812 (Basophil) rest   0.0       KU-812 (Basophil) PMA/ionomycin   0.0       CCD1106 (Keratinocytes) none   0.0       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0       Liver cirrhosis   0.0       NCI-H292 none   0.0       NCI-H292 IL-4   0.0       NCI-H292 IL-9   0.0       NCI-H292 IL-13   0.0       NCI-H292 IFN gamma   0.0       HPAEC none   0.0       HPAEC TNF alpha + IL-1 beta   0.0       Lung fibroblast none   5.7       Lung fibroblast TNF alpha + IL-1 beta   0.0       Lung fibroblast IL-4   3.1       Lung fibroblast IL-9   2.3       Lung fibroblast IL-13   3.0       Lung fibroblast IFN gamma   0.0       Dermal fibroblast CCD1070 rest   0.0       Dermal fibroblast CCD1070 TNF alpha   0.0       Dermal fibroblast CCD1070 IL-1 beta   0.0       Dermal fibroblast IFN gamma   0.0       Dermal fibroblast IL-4   0.0       Dermal Fibroblasts rest   0.0       Neutrophils TNFa + LPS   0.0       Neutrophils rest   0.0       Colon   0.0       Lung   2.8       Thymus   100.0       Kidney   0.0                    
     [1013]               TABLE AJD                          general oncology screening panel_v_2.4                                 Rel. Exp. (%)               Ag4135, Run           Tissue Name   268390081                                         Colon cancer 1   0.0           Colon cancer NAT 1   0.0           Colon cancer 2   1.9           Colon cancer NAT 2   0.0           Colon cancer 3   0.0           Colon cancer NAT 3   0.0           Colon malignant cancer 4   9.5           Colon normal adjacent tissue 4   0.0           Lung cancer 1   0.0           Lung NAT 1   0.0           Lung cancer 2   16.2           Lung NAT 2   0.0           Squamous cell carcinoma 3   0.0           Lung NAT 3   0.0           metastatic melanoma 1   0.0           Melanoma 2   0.0           Melanoma 3   0.0           metastatic melanoma 4   17.9           metastatic melanoma 5   15.7           Bladder cancer 1   1.9           Bladder cancer NAT 1   0.0           Bladder cancer 2   0.0           Bladder cancer NAT 2   0.0           Bladder cancer NAT 3   0.0           Bladder cancer NAT 4   0.0           Prostate adenocarcinoma 1   100.0           Prostate adenocarcinoma 2   11.9           Prostate adenocarcinoma 3   1.8           Prostate adenocarcinoma 4   7.3           Prostate cancer NAT 5   8.4           Prostate adenocarcinoma 6   4.1           Prostate adenocarcinoma 7   6.6           Prostate adenocarcinoma 8   0.0           Prostate adenocarcinoma 9   56.3           Prostate cancer NAT 10   0.0           Kidney cancer 1   0.0           Kidney NAT 1   4.7           Kidney cancer 2   0.0           Kidney NAT 2   17.1           Kidney cancer 3   0.0           Kidney NAT 3   1.7           Kidney cancer 4   0.0           Kidney NAT 4   7.1                        
     [1014] General_screening_panel_v1.4 Summary: Ag4135 Expression of this putative carboxypeptidase is highest in pancreas and bladder (CTs=20). Low but significant levels of expression are seen in adipose, testis, spleen, adult and fetal skeletal muscle, colon cancer tissue, fetal kidney, fetal liver, fetal lung, placenta, and a squamous cell carcinoma cell line. Therefore, therapeutic modulation of this gene may be useful in the treatment of diseases that affect these tissues including pancreatitis.  
     [1015] In addition, this gene is more highly expressed in fetal liver (CT=26) than in the adult counterpart (CT=40). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the carboxypeptidase encoded by this gene could be useful in treatment of liver related diseases.  
     [1016] Panel 4.1D Summary: Ag4135 This gene is expressed at significant levels only in the thymus (CT=33) in both runs. The protein encoded for by this gene could therefore play an important role in T cell development. Small molecule therapeutics, or antibody therapeutics designed against the carboxypeptidase encoded for by this gene could be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.  
     [1017] general oncology screening panel_v — 2.4 Summary: Ag4135 Expression of this gene is restricted to a sample derived from a prostate cancer (CT=32.6). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of prostate cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of prostate cancer.  
     Example D  
     [1018] Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences  
     [1019] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.  
     [1020] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.  
     [1021] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation&#39;s human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.  
     [1022] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderbom et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).  
     [1023] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.  
               TABLE SN1                          PEPTIDYLPROLYL ISOMERASE A -like       Protein. CG142102-01 (NOV31a)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified               13379649   521   G   A   154   Arg   His       13379648   560   T   C   167   Ile   Thr                  
 
     [1024]               TABLE SN2                          SA protein-like Protein CG59444-01 (NOV34a)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380147   338   G   A   65   Arg   Gln       13380148   891   A   T   249   Gly   Gly                    
     [1025]               TABLE SN3                          Potential phospholipid-transporting ATPase       VA -like Protein CG59361-01 (NOV33a)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13377654   733   C   T   171   Arg   Cys       13380152   3845   T   C   1208   Leu   Pro       13380151   3884   C   T   1221   Ser   Leu                    
     [1026]               TABLE SN4                          MYOSIN 1G VALINE FORM-like       protein CG59522-02 (NOV36b)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified               13380146   375   G   T   121   Ala   Ser                    
     [1027]               TABLE SN5                          Protein kinase D2 -like protein CG90879-01 (NOV38a).                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified               13380159   2189   G   T   717   Arg   Leu       13380158   2204   G   A   722   Gly   Asp                    
     [1028]               TABLE SN6                          Carboxypeptidase A1-like protein CG97955-03 (NOV42c).                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380153   311   C   T   97   Leu   Leu       13380154   327   A   G   102   Glu   Gly                    
     [1029]               TABLE SN7                          Novel SNPs for HYDROLASE like-like       Protein CG107234-02 (NOV4b)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380137   150   A   G   46   Asn   Ser       13380139   448   C   A   145   Asn   Lys                    
     [1030]               TABLE SN8                          CtBP (D-isomer specific 2-hydroxyacid dehydrogenase)-like       protein CG113144-02 (NOV5a).                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380136   8   A   G   0                    
     [1031]               TABLE SN9                          cGMF-stimulated 3′,5′-cyclic nucleotide phosphodiesterase-like       protein CG138130-01 (NOV13a).                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380145   2667   A   G   846   Ala   Ala       13380144   2721   C   T   864   Tyr   Tyr                    
     [1032]               TABLE SN10                          MALEYLACETOACETATE ISOMERASE -like       protein CG138372-02 (NOV14a)                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13378194   111   G   A   32   Glu   Lys       13376309   141   G   A   42   Gly   Arg                    
     [1033]               TABLE SN11                          CHOLINE/ETHANOLAMINE KINASE-like       protein CG138563-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380141   733   G   A   216   Glu   Lys                    
     [1034]               TABLE SN12                          Protein-tyrosine kinase ryk - Like -like protein CG138848-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380138   1568   T   C   493   Leu   Ser                    
     [1035]               TABLE SN13                          Pyridoxal-dependent decarboxylase-like protein CG140041-01.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13375791   1193   C   T   366   Arg   Trp       13375803   1285   G   A   396   Gln   Gln       13375802   1318   C   T   407   Ala   Ala                    
     [1036]               TABLE SN14                          ATP SYNTHASE B CHAIN, MITOCHONDRIAL-like       protein CG140612-02.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13380164   858   T   C   0                    
     [1037]               TABLE SN15                          Dual specificity phosphatase -like protein CG140747-01.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13379681   1502   C   T   482   Ser   Leu                    
     [1038]               TABLE SN16                          Human Stearoyl CoA Desaturase L-like protein CG105521-01.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 cgsp:13380102   272   T   C   13   Ser   Pro       cgsp:13380103   463   C   A   76   Ile   Ile       cgsp:13379380   905   A   C   224   Leu   Met       hsnp:rs2958475   1104   C   T   290   Leu   Pro       hsnp:rs1054412   1232   A   G   333   Ala   Thr       cgsp:13380105   2466   G   A   UTR   N/A   N/A       cgsp:13380108   2974   T   C   UTR   N/A   N/A       cgsp:13380109   2981   T   C   UTR   N/A   N/A       cgsp:13380110   3046   T   G   UTR   N/A   N/A       cgsp:13380111   3153   T   C   UTR   N/A   N/A       cgsp:13380112   3338   G   A   UTR   N/A   N/A       cgsp:13380113   3441   T   C   UTR   N/A   N/A       cgsp:13380114   3646   G   A   UTR   N/A   N/A       cgsp:13380116   3791   A   G   UTR   N/A   N/A       cgsp:13380117   3856   C   T   UTR   N/A   N/A       cgsp:13380118   3869   A   C   UTR   N/A   N/A       cgsp:13380119   3915   T   A   UTR   N/A   N/A       cgsp:13380120   3943   A   G   UTR   N/A   N/A       cgsp:13380121   3963   T   C   UTR   N/A   N/A       cgsp:13380122   4023   A   G   UTR   N/A   N/A       cgsp:13380123   4033   T   C   UTR   N/A   N/A       cgsp:13380124   4042   A   G   UTR   N/A   N/A       cgsp:13380099   4061   G   A   UTR   N/A   N/A       cgsp:13380098   4073   G   A   UTR   N/A   N/A       cgsp:13380125   4103   G   A   UTR   N/A   N/A       cgsp:13380127   4174   A   G   UTR   N/A   N/A       cgsp:13380097   4229   G   A   UTR   N/A   N/A       cgsp:13380128   4309   A   T   UTR   N/A   N/A       cgsp:13380071   4574   C   A   UTR   N/A   N/A                    
     [1039]               TABLE 17                          Human aryl hydrocarbon receptor-like protein CG105355-01.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 1   757   A   G   48   Asp   Gly       2   869   T   C   85   Val   Val       3   1132   A   G   173   Gln   Arg       4   2028   G   A   472   Ala   Thr       5   2275   G   A   554   Arg   Lys                    
     Example E  
     [1040] Method of Use for NOVX-Related Polypeptides and Polynucleotides  
     [1041] The present invention is partially based on the identification of biological macromolecules differentially modulated in a pathologic state, disease, or an abnormal condition or state, and/or based on novel associations of proteins and polypeptides and the nucleic acids that encode them, as identified in a yeast 2-hybrid screen using a cDNA library or one-by-one matrix reactions. Among the pathologies or diseases of present interest include metabolic diseases including those related to endocrinologic disorders, cancers, various tumors and neoplasias, inflammatory disorders, central nervous system disorders, and similar abnormal conditions or states. Important metabolic disorders with which the biological macromolecules are associated include obesity and diabetes mellitus, especially obesity and Type II diabetes. It is believed that obesity predisposes a subject to Type II diabetes. In very significant embodiments of the present invention, the biological macromolecules implicated in these pathologies and conditions are proteins and polypeptides, and in such cases the present invention is related as well to the nucleic acids that encode them. Methods that may be employed to identify relevant biological macromolecules include any procedures that detect differential expression of nucleic acids encoding proteins and polypeptides associated with the disorder, as well as procedures that detect the respective proteins and polypeptides themselves. Significant methods that have been employed by the present inventors, include GeneCalling® technology and SeqCalling™ technology, disclosed respectively, in U.S. Pat. No. 5,871,697, and in U.S. Ser. No. 09/417,386, filed Oct. 13, 1999, each of which is incorporated herein by reference in its entirety. GeneCalling® is also described in Shimkets, et al.,  Nature Biotechnology  17:198-803 (1999).  
     [1042] The invention provides polypeptides and nucleotides encoded thereby that have been identified as having novel associations with a disease or pathology, or an abnormal state or condition, in a mammal. Included in the invention are nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to as “obesity and/or diabetes nucleic acids” or “obesity and/or diabetes polynucleotides” and the corresponding encoded polypeptide is referred to as an “obesity and/or diabetes polypeptide” or “obesity and/or diabetes protein”. For example, an obesity and/or diabetes nucleic acid according to the invention is a nucleic acid including an obesity and/or diabetes nucleic acid, and an obesity and/or diabetes polypeptide according to the invention is a polypeptide that includes the amino acid sequence of an obesity and/or diabetes polypeptide. Unless indicated otherwise, “obesity and/or diabetes” is meant to refer to any of the sequences having novel associations disclosed herein.  
     [1043] The present invention identifies a set of proteins and polypeptides, including naturally occurring polypeptides, precursor forms or proproteins, or mature forms of the polypeptides or proteins, which are implicated as targets for therapeutic agents in the treatment of various diseases, pathologies, abnormal states and conditions. A target may be employed in any of a variety of screening methodologies in order to identify candidate therapeutic agents which interact with the target and in so doing exert a desired or favorable effect. The candidate therapeutic agent is identified by screening a large collection of substances or compounds in an important embodiment of the invention. Such a collection may comprise a combinatorial library of substances or compounds in which, in at least one subset of substances or compounds, the individual members are related to each other by simple structural variations based on a particular canonical or basic chemical structure. The variations may include, by way of nonlimiting example, changes in length or identity of a basic framework of bonded atoms; changes in number, composition and disposition of ringed structures, bridge structures, alicyclic rings, and aromatic rings; and changes in pendent or substituents atoms or groups that are bonded at particular positions to the basic framework of bonded atoms or to the ringed structures, the bridge structures, the alicyclic structures, or the aromatic structures.  
     [1044] A polypeptide or protein described herein, and that serves as a target in the screening procedure, includes the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, e.g., the full-length gene product, encoded by the corresponding gene. The naturally occurring polypeptide also includes the polypeptide, precursor or proprotein encoded by an open reading frame described herein. A “mature” form of a polypeptide or protein arises as a result of one or more naturally occurring processing steps as they may occur within the cell, including a host cell. The processing steps occur as the gene product arises, e.g., via cleavage of the amino-terminal methionine residue encoded by the initiation codon of an open reading frame, or the proteolytic cleavage of a signal peptide or leader sequence. Thus, a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an amino-terminal signal sequence from residue 1 to residue M is cleaved, includes the residues from residue M+1 to residue N remaining. A “mature” form of a polypeptide or protein may also arise from non-proteolytic post-translational modification. Such non-proteolytic processes include, e.g., glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or the combination of any of them.  
     [1045] As used herein, “identical” residues correspond to those residues in a comparison between two sequences where the equivalent nucleotide base or amino acid residue in an alignment of two sequences is the same residue. Residues are alternatively described as “similar” or “positive” when the comparisons between two sequences in an alignment show that residues in an equivalent position in a comparison are either the same amino acid or a conserved amino acid as defined below.  
     [1046] As used herein, a “chemical composition” relates to a composition including at least one compound that is either synthesized or extracted from a natural source. A chemical compound may be the product of a defined synthetic procedure. Such a synthesized compound is understood herein to have defined properties in terms of molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as electropherographic or spectroscopic characterizations, and the like. A compound extracted from a natural source is advantageously analyzed by chemical and physical methods in order to provide a representation of its defined properties, including its molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as electropherographic or spectroscopic characterizations, and the like.  
     [1047] As used herein, a “candidate therapeutic agent” is a chemical compound that includes at least one substance shown to bind to a target biopolymer. In important embodiments of the invention, the target biopolymer is a protein or polypeptide, a nucleic acid, a polysaccharide or proteoglycan, or a lipid such as a complex lipid. The method of identifying compounds that bind to the target effectively eliminates compounds with little or no binding affinity, thereby increasing the potential that the identified chemical compound may have beneficial therapeutic applications. In cases where the “candidate therapeutic agent” is a mixture of more than one chemical compound, subsequent screening procedures may be carried out to identify the particular substance in the mixture that is the binding compound, and that is to be identified as a candidate therapeutic agent.  
     [1048] As used herein, a “pharmaceutical agent” is provided by screening a candidate therapeutic agent using models for a disease state or pathology in order to identify a candidate exerting a desired or beneficial therapeutic effect with relation to the disease or pathology. Such a candidate that successfully provides such an effect is termed a pharmaceutical agent herein. Nonlimiting examples of model systems that may be used in such screens include particular cell lines, cultured cells, tissue preparations, whole tissues, organ preparations, intact organs, and nonhuman mammals. Screens employing at least one system, and preferably more than one system, may be employed in order to identify a pharmaceutical agent. Any pharmaceutical agent so identified may be pursued in further investigation using human subjects.  
     [1049] A. NOV 41: Human Cytosolic HMG CoA Synthase-Like Proteins  
     [1050] The following sections describe the study design(s) and the techniques used to identify the Cytosolic HMG CoA synthase—encoded NOV41 protein, and any variants thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for obesity and/or diabetes.  
     [1051] A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.  
     [1052] Cytoplasmic HMG CoA synthase mediates an early step in cholesterol biosynthesis. This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA Reductase. See generally, Carlsson et al., 2001 Am J Physiol Endocrinol Metab. 281(4):E772-81; Lopez et al., 2001 Mol Cell Biochem. 217(1-2):57-66; Olivier et al., 2000 Biochim Biophys Acta. 1529(1-3):89-102; Mascaro et al., 2000 Biochem J. 350 Pt 3:785-90; Sato et al., 2000 J Biol Chem. 275(17):12497-502; Mascaro et al., 2000 Arch Biochem Biophys. 374(2):286-92; Scharnagl et al., 1995 J Lipid Res. 36(3):622-7; and Royo et al., 1993 Biochem J. 289 (Pt 2):557-60.  
     [1053] NOV41 Expression  
     [1054] A gene fragment of the mouse cytosolic HMG CoA synthase was initially found to be up-regulated by 7 fold in the liver of the NZB mouse relative to the SMJ mouse strain using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 312.1 nucleotides in length (FIGS. 1A and 1B.—vertical line) was definitively identified as a component of the mouse Cytosolic HMG CoA synthase cDNA (in the graphs, the abscissa is measured in lengths of nucleotides and the ordinate is measured as signal response). The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the rat Cytosolic HMG CoA synthase are ablated when a gene-specific primer (see below) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 312.1 nt in length are ablated in the sample from both the NZB and SMJ mice. The direct sequence of the 312 nucleotide-long gene fragment and the gene-specific primers used for competitive PC are indicated in italic. The gene-specific primers at the 5′ and 3′ ends of the fragment are in bold. This result was confirmed by competitive PCR.  
     [1055] Biochemistry  
     [1056] Cytosolic HMG CoA synthase condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA Reductase. This condensation reaction occurs above the diversion point to farnesoic acid in the cholesterol biosynthetic pathway.  
     [1057] The reaction proceeds as follows:  
     acetyl- CoA +H 2 O+acetoacetyl- CoA =(S)-3-hydroxy-3-methylglutaryl- CoA+CoA    
     [1058] Rationale for use as a Diagnostic and/or Target for Small Molecule Drugs and Antibody Therapeutics  
     [1059] HMG CoA synthase is up-regulated 7-fold in a genetic model of obesity characterized by apparent LXRα activation (adipose induction of ApoE, malic enzyme, ATP citrate lyase, FAS, SCD), thus HMG CoA synthase provides the substrate for LXRa ligands.  
     [1060] Inhibition of this enzyme may be a treatment for the prevention or treatment of obesity.  
     [1061] Taken in total, the data indicates that an inhibitor of the human Cytosolic HMG CoA synthase enzyme would be beneficial in the treatment of obesity and/or diabetes.  
     [1062] B. NOV 3: Human Stearoyl CoA Desaturase—Like Proteins  
     [1063] The following sections describe the study design(s) and the techniques used to identify the stearoyl CoA desaturase—encoded NOV3 protein, and any variants thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for obesity and/or diabetes.  
     [1064] Stearoyl CoA desaturase (SCD) utilizes O 2  and electrons from reduced cytochrome b5 to catalyze the insertion of a double bond into a spectrum of fatty acyl-CoA substrates, including palmitoyl-CoA and stearoyl-CoA at the position of the 9 th  carbon (“delta-9 desaturase”). Stearoyl CoA desaturase expression is regulated by both SREBP and C/EBPalpha, transcription factors that are essential in adipose differentiation and lipogenesis. SCD is a key enzyme in the synthesis of unsaturated fatty acids that are being stored as triglycerides (TG), and the induction of TG synthesis is highly dependent on the expression of SCD. Recently it was shown that mice lacking SCD1 are lean and hypermetabolic, while ob/ob mice with a mutation in SCD1 are less obese then regular ob/ob mice, indicating that SCD1 is an important component in the metabolic actions of leptin. While in rodents there are two SCD genes, SCD1 and SCD2, there is only one SCD gene in human.  
     [1065] SCD2 is up-regulated in two genetic models of obesity. In adipose tissue of the obese NZB/BINJ mice, SCD2 was up-regulated compared to the lean SM/J mice. In visceral adipose from the Spontaneous Hypertensive Rats (SHR), SCD2 was also up-regulated when compared to subcutaneous adipose from the same strain. Moreover, our data from the diet-induced obesity model showed that for all 4 standard deviations of obese mice (SD1, SD4, SD7 and hyperglycemic SD7) on a high fat diet, SCD1 was down-regulated in brown adipose. In white adipose, SCD1 was up-regulated in the moderately obese SD1 mice, while it was down-regulated in white adipose of severely obese mice (SD7). This suggests that down-regulation of SCD is a compensatory mechanism in response to the high fat diet, which manifests itself earlier in brown adipose and thus, may be protective. Therefore, an antagonist for SCD to inhibit SCD directly may be an effective therapeutic for obesity.  
     [1066] The spontaneously hypertensive rat (SHR) is a strain exhibiting features of the human Metabolic Syndrome X. The phenotypic features include obesity, hyperglycemia, hypertension, dyslipidemia and dysfibrinolysis. Tissues were removed from adult male rats and a control strain (Wistar—Kyoto) to identify the gene expression differences that underlie the pathologic state in the SHR and in animals treated with various anti-hyperglycemic agents such as troglitizone. Tissues included sub-cutaneous adipose, visceral adipose and liver.  
     [1067] A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57L and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver.  
     [1068] Bone marrow-derived human mesenchymal stem cells have the capacity to differentiate into muscle, adipose, cartilage and bone. Culture conditions have been established that permit the differentiation in vitro along the pathway to adipose, cartilage and bone. Understanding the gene expression changes that accompany these distinct differentiation processes would be of considerable biologic value. Regulation of adipocyte differentiation would have importance in the treatment of obesity, diabetes and hypertension. Human mesenchymal stem cells from 3 donors were obtained and differentiated in vitro according to published methods. RNA from samples of the undifferentiated, mid-way differentiated and fully differentiated cells was isolated for analysis of differential gene expression. See generally, Miyazaki et al., 2001 J Lipid Res. 42(7):1018-24; Kim et al. 2000 J Lipid Res. 41(8):1310-6; Kim et al. 1998 Cell. 93(5):693-704; Miyazaki et al. 2000 J Biol Chem. 275(39):30132-8; Kim et al. 1999 Biochem Biophys Res Commun. 266(1):1-4; Miyazaki et al. 2001 J Biol Chem. 276(42):39455-61; Bene et al. 2001 Biochem Biophys Res Commun 284(5):1194-8; and Cohen et al. 2002 Science 297(5579):240-3.  
     [1069] The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design seeks to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights+1 S.D., +4 S.D. and +7 S.D. of the chow-fed controls (See Table E1). In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues should reveal genes and pathways that can be used as therapeutic targets for obesity. 
 
 
     [1070] NOV3 Expression  
     [1071] A fragment of the rat Stearoyl CoA Desaturase 2 gene was initially found to be up-regulated by 1.9 fold in the visceral adipose relative to subcutaneous adipose of the Spntaneous Hypertensive rats (SHR) using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed rat gene fragment migrating, at approximately 373.6 nucleotides in length was definitively identified as a component of the rat Stearoyl CoA Desaturase 2 cDNA. The method of comparative PCR was used for conformation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the rat Stearoyl CoA Desaturase 2 are ablated when a gene-specific primer competes with primers in the linker-adaptors during the PCR amplification. The peaks at 373.6 nt in length are ablated in the sample from both the visceral and subcutaneous adipose. The difference in gene expression in SHR visceral vs subcutaneous adipose is +1.9 fold.  
     [1072] A gene fragment of mouse Stearoyl CoA Desaturase 2 was also found to be up-regulated by 1.9 fold in the adipose tissue of NZB/BINJ obese mice relative to SM/J lean mice using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 94 nucleotides in length was definitively identified as a component of the mouse Stearoyl CoA Desaturase 2 cDNA. The method of comparative PCR was used for conformation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of mouse Stearoyl CoA Desaturase 2 are ablated when a gene-specific primer competes with primers in the linker-adaptors during the PCR amplification. The peaks at 94 nt in length are ablated in the sample from both the NZB/BINJ obese and SM/J lean mice. The difference in gene expression in B/BINJ (obese) vs SM&#39;J (lean) adipose is +1.9 fold.  
     [1073] A gene fragment of human Stearoyl CoA Desaturase was also found to be up-regulated by 2-4 fold in differentiated adipocytes relative to midway differentiated adipocytes using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed human gene fragment migrating, at approximately 443 nucleotides in length was definitively identified as a component of the human Stearoyl CoA Desaturase cDNA. The method of comparative PCR was used for conformation of the gene assessment. The electropherographic peak corresponding to the gene fragment of human Stearoyl CoA Desaturase is ablated when a gene-specific primer competes with primers in the linker-adaptors during the PCR amplification. The peak at 443 nt in length is ablated in the sample from the fully differentiated adipocytes from donor 2. The difference in gene expression in differentiated adipocytes vs midway differentiated adipocytes is +3.9 fold.  
     [1074] A gene fragment of mouse Stearoyl CoA Desaturase 1 was also found to be down-regulated by 2 fold in brown adipose tissue of obese hyperinsulinemic ngsd7 mice relative to normal weight (chow-fed) mice using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 94 nucleotides in length was definitively identified as a component of the mouse Stearoyl CoA Desaturase 1 cDNA. The method of comparative PCR was used for conformation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of mouse Stearoyl CoA Desaturase 1 are ablated when a gene-specific primer competes with primers in the linker-adaptors during the PCR amplification. The peak at 94 nt in length is ablated in the sample from the obese hyperinsulinemic ngsd7 mice. The difference in gene expression in sd7-brown adipose vs chow-brown adipose is −2 fold.  
     [1075] Summary of GeneCalling Results: Up-regulation of stearoyl CoA desaturase is associated with obesity in 2 genetic models of rodent obesity, a diet-induced obesity model, and adipose differentiation.  
     [1076] Biochemistry  
     [1077] Stearoyl CoA desaturase (also known as Delta-9 desaturase) utilizes O 2  and electrons from reduced cytochrome b5 to catalyze the insertion of a double bond into a spectrum of fatty acyl-CoA substrates, including palmitoyl-CoA and stearoyl-CoA. Iron acts as a cofactor for the reaction:  
     Stearoyl- CoA +N AD PH+O 2 →Oleoyl- CoA +N AD P++2 H 2 0  
     [1078] Pathways Relevant to the Etiology and Pathogenesis of Obesity and/or Diabetes  
     [1079] PathCalling screening identified an interaction between SCD and CREB3, a poorly characterized general transcriptional factor. It has been shown in the literature that CREB3 interacts with a cytosolic protein known as HCFC1 (host cell factor C1). This interaction prevents nuclear translocation of CREB3, thus interfering with its transcriptional activity. Similar to HCFC1, SCD may inhibit CREB3 functions by trapping this transcriptional factor in cytoplasm. The significance of this interaction remains to be elucidated.  
     [1080] Rationale for Use of the Human Stearoyl CoA Desaturase Gene as a Diagnostic and/or Target for Small Molecule Drugs and Antibody Therapeutics  
     [1081] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature. Taken in total, the data indicates that an inhibitor/antagonist of the human Stearoyl CoA Desaturase would be beneficial in the treatment of obesity and/or diabetes.  
     [1082] Stearoyl CoA desaturase (SCD) is a key enzyme in the synthesis of unsaturated fatty acids that are being stored as triglyceride molecules and induction of triglyceride synthesis is highly dependent on SCD expression. In our GeneCalling studies, we have found that SCD2 is upregulated in “bad” (i.e. visceral and obese) fat. In addition, SCD1 is upregulated in white adipose of moderately obese mice, whereas it is downregulated in white adipose of extremely obese mice. Furthermore, expression of the SCD gene is downregulated in all stages of obesity in brown adipose tissue, known for a higher level of energy utilization versus storage. This suggests that down-regulation of SCD is a compensatory mechanism in response to a high fat diet, which manifests itself earlier in brown adipose and thus, may be protective.  
     [1083] Mice deficient in SCD1 have very low levels of triglyceride synthesis in the liver, which is reflected in low levels of triglycerides in the VLDL and LDL lipoprotein fractions (Miyazaki et al., 2000; Miyazaki et al., 2001). There are other reports of SCD1 deficient mice that are leaner and have hypermetabolism (Cohen et al., 2002). In addition, transcription of the SCD gene is regulated by SREBP as well as C/EBPalpha, transcription factors that have been shown to be essential in adipose differentiation and lipogenesis (Bene et al., 2001). Moreover, antidiabetic thiazolidinediones downregulate SCD1 in cultured primary adipocytes (Kim et al., 2000). Taken together, these findings suggest that an antagonist for SCD to inhibit SCD directly may be an effective therapeutic for obesity.  
     [1084] C. NOV2: Human Aryl Hydrocarbon Receptor—Like Proteins  
     [1085] The following sections describe the study design(s) and the techniques used to identify the human Aryl Hydrocarbon Receptor—encoded NOV2 protein, and any variants thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for obesity and/or diabetes.  
     [1086] The Aryl Hydrocarbon Receptor (AHR) is a ligand-dependent transcription factor. 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) is a known activating ligand that initiates expression of multiple genes, including CYP1B1 and glutathione S-transferase. The Aryl Hydrocarbon Receptor forms a heterodimer with ARNT, a nuclear translocator, to form an active complex that crosses the nuclear membrane and binds to DNA. As a result of activation of ABR, PPAR-γ can become suppressed and GLUT4 expression becomes down regulated in adipose tissue. These actions are of biological importance in the development of insulin resistance and of diabetes.  
     [1087] The Aryl Hydrocarbon Receptor is a member of the PAS (Per-Ahr-Sim) superfamily of transcription factors having functions in development and detoxification. Only recently has any member of this family been associated with obesity and diabetes.  
     [1088] Gestational diabetes complicates 4% of pregnancies and is a prognostic factor in the development of Type II diabetes. In addition, offspring of women who develop gestational diabetes are at increased risk of becoming obese and developing diabetes. Thus, the differences in gene expression from the metabolic tissues of gestational diabetics and non-diabetic should reveal underlying differences related to the pathophysiology of diabetes. Because many women deliver by C-section this patient population provides an opportunity to examine gene expression changes in surgical material from normals, gestational diabetics treated by diet alone and gestational diabetics treated with insulin. These patients, generally, do not suffer from confounding medical conditions and are not exposed to drugs that may influence gene expression. In this IRB-approved study, clinical information and samples were obtained from sub-cutaneous adipose, skeletal muscle, visceral adipose (omentum) and smooth muscle (uterus) from women giving birth by non-emergency C-section. Maternal and cord blood were also obtained for genotype analysis. The body mass index spanned a wide range in this patient population. Those patients meeting the diagnostic criteria for gestational diabetes were treated with either dietary modification and/or insulin therapy.  
     [1089] See generally, Ma 2001 Curr Drug Metab.: 149-64; Safe 2001 Toxicol Lett. 120(1-3):1-7; Ema 2001 Seikagaku. 73(2):81-8; Delescluse et al. 2000 Toxicology. 153(1-3):73-82; Gu et al 2000 Annu Rev Pharmacol Toxicol. 40:519-61; Schwarz et al. 2000 Toxicol Lett. 112-113:69-77; Okino et al. 2000 Vitam Horm. 59:241-64; Crews et al. 1999 Curr Opin Genet Dev. 9(5):580-7; Safe et al. 1998 Toxicol Lett. 102-103:343-7; Gonzalez et al. 1998 Drug Metab Dispos. 26(12):1194-8; Lahvis et al., 1998 Biochem Pharmacol. 56(7):781-7; Holder et al. 2000 Hum Mol Genet. 9(1):101-8; Seidel et al, 2000 Toxicol.Sci. 55 :107-115 ; and Allen et al. 2001 Drug Metab.Dispos. 29:1074-1079.  
     [1090] The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design seeks to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights +1 S.D., +4 S.D. and +7 S.D. of the chow-fed controls (below). In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues should reveal genes and pathways that can be used as therapeutic targets for obesity.  
     [1091] A gene fragment of the human Aryl Hydrocarbon Receptor was initially found to be up-regulated by 1.9 fold in the adipose tissues of human gestational diabetics relative to normal pregnant females using CuraGen&#39;s GeneCalling™ method of differential gene expression. A differentially expressed human gene fragment migrating, at approximately 131 nucleotides in length was definitively identified as a component of the human Aryl Hydrocarbon Receptor cDNA. The method of competitive PCR was used for conformation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the human Aryl Hydrocarbon Receptor are ablated when a gene-specific primer competes with primers in the linker-adaptors during the PCR amplification. The peaks at 131 nt in length are ablated in the sample from both the gestational diabetics and normal patients.  
     [1092] Additionally, gene fragments corresponding to the mouse orthologue of AHR and two AHR-binding proteins, ARNT (AHR nuclear transporter) and AIP (AHR interacting protein) were found to have altered expression in a mouse model of dietary-induced obesity. The altered expression of these genes in the animal model support the role of the Aryl Hydrocarbon Receptor in the pathogenesis of obesity and/or diabetes.  
     [1093] Pathways Relevant to Obesity and/or Diabetes  
     [1094] Alterations in expression of the human Aryl Hydrocarbon Receptor and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes, based on the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human Aryl Hydrocarbon Receptor would be a reduction of Insulin Resistance, a major problem in obesity and/or diabetes.  
     [1095] In gestational diabetes, a polymeric complex comprising aryl hydrocarbon receptor, a heat shock protein (HSP) such as HSP90 and AHR-interacting protein (AIP) is upregulated. The aryl hydrocarbon receptor and AIP are translocated to the nucleus and interact with ARNT. This complex causes increased gene expression of factors that inhibit GLUT 4 and PPARγ, resulting in insulin resistance.  
     [1096] Rationale for use as a Diagnostic and/or Target for Small Molecule Drugs and Antibody Therapeutics  
     [1097] The following is a summary of the findings from the discovery studies, supplementary investigations and assays that also incorporates knowledge in the scientific literature. Taken in total, the data indicates that an inhibitor/antagonist of the human Aryl Hydrocarbon Receptor would be beneficial in the treatment of obesity and/or diabetes:  
     [1098] a) Aryl Hydrocarbon was upregulated 1.9 fold in sub-cutaneous adipose from gestational diabetics. TCDD, an AHR agonist, suppresses PPAR-γ. Conversely TZDs activate PPAR-γ.  
     [1099] b) AHR activation decreases GLUT4 expression in adipose.  
     [1100] c) The clinical rise may represent a compensatory response.  
     [1101] d) No dysregulation of toxification genes (CYP1A1, CYP1A2, or CYP1B).  
     [1102] e) Upregulated in obese, hyperglycemic mouse liver and adipose. AHR nuclear translocator (ARNT) and AHR interacting protein (AIP) are also upregulated.  
     Example F  
     [1103] NOV35b (CG59482-02 Alignment with Trypsinogen  
     [1104] Table F1 shows a ClustW alignment of the CG59482-02 splice variant with trypsinogen (TRY1_HUMAN). The signal sequence extends from 1-15 and the propeptide sequence extends from 16-23 of SEQ ID NO: 341 (indicated by arrows). These two sequence fragments would normally be cleaved away from the mature protein. The residues in which form the catalytic triad are indicate by a “#” beneath the sequence. 
 
 
     [1105] Crystalographic data is also presented.  
     [1106]FIG. 1 shows the x-ray crystal structure of trypsin 1 at a 2.2 Å resolution (Gaboriaud, C. et. al, Jol. Mol. Biol., 1996, 259:995-1010)(PDB code 1TRN). The sequences absent in the CG59482-02 splice variant are indicated by small arrows. The view in FIG. 1 shows the active site facing outward with a diisopropyl-phosphofluoridate inhibitor in the active site (indicated by large arrows).  
     [1107]FIG. 2 shows the three residues which form the catalytic triad of the active site (indicated by arrowheads).  
     [1108] The mechanism for catalytic triad formation is shown in FIG. 3. The pK a  for the serine hydroxyl is usually about 13, which makes it a poor nucleophile. The aspartate, histidine and serine are arranged in a charge relay system of hydrogen bonds which helps to lower this pK a  which makes the sidechain more reactive. The carboxyl side chain on aspartate attracts a proton from histidine, which in turn, abstracts a proton from the hydroxyl of serine allowing it to react with and then cleave the polypeptide substrate.  
     [1109] Since the CG59482-02 splice variant is missing the Asp107 and His63, the resulting protein cannot form a catalytic triad and therefore would be enzymatically inactive. It is unclear from this stucture what effects the sequence deletion would have upon substrate binding since a small protease inhibitor is shown in the binding site. However, in one embodiment a polypeptide is much larger and has specific interactions with the deleted portions of CG59482-02 (assuming that the protein folded into a similar structure).  
     Other Embodiments  
     [1110] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.